/**
 * Condition Database Store
 *
 * Comprehensive database of medical conditions with simulation data
 * including pathophysiology, progression, and treatment options.
 */

import type {
  ConditionSimulation,
  ConditionSummary,
  ConditionSearchResult,
  ConditionCategory,
} from './types';

import {
  ICD11_CONDITIONS,
  generateConditionTemplate,
} from './condition-generator';
import type { ICD11ConditionEntry } from './condition-generator';

// ============================================
// Condition Database
// ============================================

const conditionDatabase: Map<string, ConditionSimulation> = new Map([
  // ============================================
  // CARDIOVASCULAR CONDITIONS
  // ============================================

  // Hypertension
  [
    'hypertension',
    {
      conditionId: 'hypertension',
      name: 'Hypertension',
      aliases: ['High Blood Pressure', 'HTN', 'Essential Hypertension'],
      icdCode: 'I10',
      category: 'cardiovascular',
      subcategory: 'Vascular',
      description:
        'Chronic elevation of systemic blood pressure that increases risk of heart disease, stroke, and kidney damage',
      pathophysiology: {
        summary:
          'Sustained elevation of arterial blood pressure due to increased peripheral vascular resistance and/or cardiac output',
        mechanisms: [
          {
            name: 'Increased Vascular Resistance',
            description:
              'Arterial wall thickening and vasoconstriction increase resistance to blood flow',
            systemsInvolved: ['Cardiovascular', 'Renal'],
            keyMediators: ['Angiotensin II', 'Endothelin', 'Norepinephrine'],
            contribution: 'Primary driver of elevated blood pressure in most cases',
          },
          {
            name: 'RAAS Overactivation',
            description:
              'Renin-angiotensin-aldosterone system causes vasoconstriction and sodium retention',
            systemsInvolved: ['Cardiovascular', 'Renal', 'Endocrine'],
            keyMediators: ['Renin', 'Angiotensin II', 'Aldosterone'],
            contribution: 'Contributes to both acute and chronic blood pressure elevation',
          },
          {
            name: 'Sympathetic Overactivity',
            description:
              'Increased sympathetic nervous system activity increases heart rate and vasoconstriction',
            systemsInvolved: ['Cardiovascular', 'Nervous'],
            keyMediators: ['Norepinephrine', 'Epinephrine'],
            contribution: 'Contributes to initial and sustained hypertension',
          },
        ],
        riskFactors: [
          {
            name: 'Age',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Blood vessels stiffen with age, increasing systolic pressure',
          },
          {
            name: 'Obesity',
            type: 'modifiable',
            impact: 'major',
            description: 'Increases cardiac output and activates RAAS',
            intervention: 'Weight loss of 5-10% can significantly reduce BP',
          },
          {
            name: 'High Sodium Intake',
            type: 'modifiable',
            impact: 'moderate',
            description: 'Causes fluid retention and increases blood volume',
            intervention: 'Reduce sodium to <2300mg/day (ideally <1500mg)',
          },
          {
            name: 'Family History',
            type: 'non-modifiable',
            impact: 'moderate',
            description: 'Genetic factors influence BP regulation',
          },
          {
            name: 'Physical Inactivity',
            type: 'modifiable',
            impact: 'moderate',
            description: 'Reduces vascular compliance and increases weight',
            intervention: '150 minutes/week moderate aerobic exercise',
          },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Often Asymptomatic',
            prevalence: 'very-common',
            description:
              'Most patients have no symptoms until target organ damage occurs',
            timing: 'Throughout disease course',
          },
          {
            name: 'Headache',
            prevalence: 'common',
            description: 'Particularly morning headaches with severe hypertension',
            location: 'Occipital region',
            timing: 'More common with hypertensive urgency/emergency',
          },
        ],
        associatedSymptoms: [
          {
            name: 'Dizziness',
            prevalence: 'uncommon',
            description: 'May occur with very high or rapidly changing BP',
          },
          {
            name: 'Visual Changes',
            prevalence: 'uncommon',
            description: 'Blurred vision with hypertensive retinopathy',
            timing: 'Advanced disease',
          },
        ],
        labFindings: [
          {
            testName: 'Basic Metabolic Panel',
            abnormality:
              'May show elevated creatinine in advanced cases (kidney damage)',
            significance: 'Assesses renal function as target organ',
          },
          {
            testName: 'Lipid Panel',
            abnormality: 'Often shows dyslipidemia as comorbidity',
            significance: 'Cardiovascular risk stratification',
          },
        ],
      },
      progression: {
        naturalHistory:
          'Without treatment, hypertension progressively damages blood vessels and target organs over years to decades',
        typicalOnsetToDiagnosis: 'Often years (silent disease)',
        timelineSteps: [
          {
            phaseId: 'prehypertension',
            phase: 'preclinical',
            displayName: 'Pre-Hypertension',
            timeframe: 'BP 120-139/80-89',
            description:
              'Elevated blood pressure not yet meeting hypertension criteria',
            symptoms: ['Usually none'],
            anatomicalChanges: [
              {
                structureId: 'arteries',
                structureName: 'Arteries',
                changeType: 'dysfunction',
                description: 'Early endothelial dysfunction',
                severity: 'mild',
                visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Lifestyle modification'],
            goalsOfCare: ['Prevent progression to hypertension'],
          },
          {
            phaseId: 'stage1',
            phase: 'early',
            displayName: 'Stage 1 Hypertension',
            timeframe: 'BP 130-139/80-89',
            description: 'Mild hypertension with minimal target organ damage',
            symptoms: ['Usually asymptomatic', 'Occasional headaches'],
            anatomicalChanges: [
              {
                structureId: 'arteries',
                structureName: 'Arteries',
                changeType: 'hypertrophy',
                description: 'Arterial wall thickening begins',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
              {
                structureId: 'heart',
                structureName: 'Heart',
                changeType: 'hypertrophy',
                description: 'Early left ventricular hypertrophy',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Lifestyle modification', 'Consider medication if high CV risk'],
            goalsOfCare: ['BP <130/80', 'Prevent progression'],
          },
          {
            phaseId: 'stage2',
            phase: 'established',
            displayName: 'Stage 2 Hypertension',
            timeframe: 'BP ≥140/90',
            duration: 'Ongoing without treatment',
            description: 'Moderate to severe hypertension with developing target organ damage',
            symptoms: ['Often asymptomatic', 'Headaches', 'Fatigue'],
            anatomicalChanges: [
              {
                structureId: 'arteries',
                structureName: 'Arteries',
                changeType: 'hypertrophy',
                description: 'Significant arterial wall thickening and stiffening',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 },
                isNewAtPhase: false,
              },
              {
                structureId: 'heart',
                structureName: 'Heart (Left Ventricle)',
                changeType: 'hypertrophy',
                description: 'Left ventricular hypertrophy with diastolic dysfunction',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 },
                isNewAtPhase: false,
              },
              {
                structureId: 'kidney',
                structureName: 'Kidneys',
                changeType: 'dysfunction',
                description: 'Early nephrosclerosis with proteinuria',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            labMarkers: ['Elevated creatinine', 'Microalbuminuria'],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Combination antihypertensives', 'ACE inhibitor/ARB', 'Lifestyle'],
            goalsOfCare: ['BP <130/80', 'Prevent target organ damage'],
          },
          {
            phaseId: 'complicated',
            phase: 'advanced',
            displayName: 'Hypertension with Target Organ Damage',
            timeframe: 'Years of uncontrolled HTN',
            description:
              'Established damage to heart, kidneys, brain, or eyes',
            symptoms: ['Dyspnea on exertion', 'Chest pain', 'Visual changes', 'Edema'],
            anatomicalChanges: [
              {
                structureId: 'heart',
                structureName: 'Heart',
                changeType: 'hypertrophy',
                description: 'Significant LVH with heart failure symptoms',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 },
                isNewAtPhase: false,
              },
              {
                structureId: 'kidney',
                structureName: 'Kidneys',
                changeType: 'fibrosis',
                description: 'Nephrosclerosis with CKD',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.7 },
                isNewAtPhase: false,
              },
              {
                structureId: 'brain',
                structureName: 'Brain',
                changeType: 'ischemia',
                description: 'Small vessel disease with lacunar infarcts',
                severity: 'moderate',
                visualIndicator: { color: '#7c3aed', pulse: false, opacity: 0.6 },
                isNewAtPhase: true,
              },
              {
                structureId: 'eyes',
                structureName: 'Retina',
                changeType: 'ischemia',
                description: 'Hypertensive retinopathy',
                severity: 'moderate',
                visualIndicator: { color: '#7c3aed', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Multiple antihypertensives', 'Treat comorbidities', 'Close monitoring'],
            goalsOfCare: ['Prevent further damage', 'Manage complications'],
          },
        ],
        progressionFactors: [
          'Medication non-adherence',
          'Continued high sodium intake',
          'Obesity',
          'Diabetes',
          'Smoking',
        ],
        prognosis:
          'With good BP control, life expectancy approaches normal. Uncontrolled HTN significantly increases CV mortality.',
      },
      complications: [
        {
          complicationId: 'stroke',
          name: 'Stroke',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'high',
          description: 'Cerebrovascular accident due to ischemia or hemorrhage',
          mechanism:
            'Chronic HTN damages cerebral vessels, leading to rupture or thrombosis',
          affectedStructures: [
            {
              structureId: 'brain',
              structureName: 'Brain',
              effect: 'Ischemic or hemorrhagic damage',
              highlightColor: '#7c3aed',
            },
          ],
          warningSymptoms: [
            'Sudden weakness/numbness',
            'Speech difficulty',
            'Vision loss',
            'Severe headache',
          ],
          prevention: ['BP control', 'Antiplatelet therapy if indicated'],
          preventable: true,
        },
        {
          complicationId: 'heart-failure',
          name: 'Heart Failure',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'high',
          description: 'Heart unable to pump effectively due to chronic pressure overload',
          mechanism: 'LVH progresses to diastolic then systolic dysfunction',
          affectedStructures: [
            {
              structureId: 'heart',
              structureName: 'Heart',
              effect: 'Ventricular dysfunction',
              highlightColor: '#dc2626',
            },
            {
              structureId: 'lungs',
              structureName: 'Lungs',
              effect: 'Pulmonary congestion',
              highlightColor: '#06b6d4',
            },
          ],
          warningSymptoms: ['Dyspnea', 'Orthopnea', 'Peripheral edema', 'Fatigue'],
          prevention: ['Aggressive BP control', 'ACE inhibitors/ARBs'],
          treatment: 'GDMT for heart failure',
          preventable: true,
        },
        {
          complicationId: 'ckd',
          name: 'Chronic Kidney Disease',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Progressive loss of kidney function',
          mechanism: 'Nephrosclerosis from chronic high pressure in renal vasculature',
          affectedStructures: [
            {
              structureId: 'kidney',
              structureName: 'Kidneys',
              effect: 'Glomerular scarring and tubular damage',
              highlightColor: '#ef4444',
            },
          ],
          warningSymptoms: ['Fatigue', 'Swelling', 'Decreased urine output', 'Nausea'],
          prevention: ['BP control', 'ACE inhibitors/ARBs for renoprotection'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'lifestyle-htn',
          name: 'Lifestyle Modification',
          modality: 'lifestyle',
          description:
            'Diet, exercise, weight loss, and sodium restriction',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['preclinical', 'early', 'established', 'advanced'],
          goals: ['Reduce BP by 5-15 mmHg', 'Improve overall CV health'],
          expectedOutcomes: ['BP reduction', 'Weight loss', 'Improved lipids'],
          timeToEffect: '4-12 weeks',
          explanations: {
            level1:
              'Eating less salt, losing weight, and exercising can lower your blood pressure naturally.',
            level2:
              'Lifestyle changes including the DASH diet (rich in fruits, vegetables, low-fat dairy), reducing sodium to less than 2300mg daily, maintaining healthy weight, and regular exercise can significantly reduce blood pressure.',
            level3:
              'First-line treatment for all stages of hypertension. DASH diet reduces BP by 8-14 mmHg. Sodium restriction to <1500mg/day adds 5-6 mmHg reduction. Weight loss of 1kg reduces BP by approximately 1 mmHg.',
            level4:
              'Lifestyle interventions have class IA evidence for hypertension management. DASH diet impacts the renin-angiotensin system and improves endothelial function. Physical activity enhances nitric oxide bioavailability and reduces sympathetic tone.',
            level5:
              'Dietary sodium reduction decreases plasma volume and reduces vascular smooth muscle reactivity. DASH diet provides potassium, magnesium, and calcium which optimize vascular function. Aerobic exercise improves arterial compliance through enhanced NO production and reduced oxidative stress.',
          },
        },
        {
          treatmentId: 'ace-inhibitor-htn',
          name: 'ACE Inhibitors',
          modality: 'pharmacological',
          description: 'Block angiotensin-converting enzyme to reduce BP',
          mechanism:
            'Inhibits ACE, reducing angiotensin II and aldosterone levels, causing vasodilation',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'advanced'],
          goals: ['Reduce BP to target', 'Provide cardio/renoprotection'],
          expectedOutcomes: ['10-15 mmHg systolic reduction', 'Reduced CV events'],
          timeToEffect: '1-2 weeks',
          medicationIds: ['lisinopril'],
          contraindications: ['Pregnancy', 'History of angioedema', 'Bilateral renal artery stenosis'],
          sideEffects: ['Dry cough', 'Hyperkalemia', 'Angioedema (rare)'],
          monitoring: ['Potassium', 'Creatinine', 'Blood pressure'],
          explanations: {
            level1:
              'These medications relax your blood vessels by blocking a chemical that makes them tight.',
            level2:
              'ACE inhibitors like lisinopril block an enzyme that causes blood vessels to constrict, allowing them to relax and lower blood pressure.',
            level3:
              'First-line agents that block the conversion of angiotensin I to angiotensin II. Particularly beneficial in patients with diabetes, CKD, or heart failure due to cardio- and renoprotective effects.',
            level4:
              'ACE inhibitors reduce afterload through decreased angiotensin II-mediated vasoconstriction and reduce preload through decreased aldosterone-mediated sodium retention. They provide end-organ protection beyond BP lowering.',
            level5:
              'Mechanism involves competitive inhibition of ACE, reducing Ang II production and bradykinin degradation. The increased bradykinin contributes to vasodilation via NO and prostacyclin but causes cough. Renoprotection occurs through efferent arteriolar dilation reducing intraglomerular pressure.',
          },
        },
        {
          treatmentId: 'ccb-htn',
          name: 'Calcium Channel Blockers',
          modality: 'pharmacological',
          description: 'Block calcium entry into vascular smooth muscle',
          mechanism:
            'Inhibits L-type calcium channels, causing vasodilation',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'advanced'],
          goals: ['Reduce BP to target'],
          expectedOutcomes: ['10-15 mmHg systolic reduction'],
          timeToEffect: '1-2 weeks',
          medicationIds: ['amlodipine'],
          contraindications: ['Severe aortic stenosis', 'Heart failure with reduced EF (for non-DHP)'],
          sideEffects: ['Peripheral edema', 'Flushing', 'Constipation'],
          monitoring: ['Blood pressure', 'Heart rate', 'Edema'],
          explanations: {
            level1:
              'These medications relax your blood vessels by blocking calcium from entering the vessel walls.',
            level2:
              'Calcium channel blockers like amlodipine prevent calcium from entering blood vessel walls, which relaxes them and lowers blood pressure.',
            level3:
              'Dihydropyridine CCBs (amlodipine, nifedipine) primarily cause vasodilation. Non-dihydropyridines (diltiazem, verapamil) also reduce heart rate. Particularly effective in elderly and African American patients.',
            level4:
              'L-type calcium channel blockade in vascular smooth muscle reduces calcium-dependent contraction, causing arterial vasodilation. DHPs are vascular-selective while non-DHPs also affect cardiac myocytes.',
            level5:
              'DHPs bind to the alpha-1 subunit of L-type calcium channels in vascular smooth muscle, reducing calcium influx during depolarization. This decreases actin-myosin cross-bridge formation. Reflex tachycardia may occur due to baroreceptor response to acute BP drop.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'heart',
            structureName: 'Heart',
            role: 'target-organ',
            involvement: 'Develops left ventricular hypertrophy and eventual failure',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
          {
            structureId: 'arteries',
            structureName: 'Arteries',
            role: 'primary-site',
            involvement: 'Site of increased resistance and vascular damage',
            highlightColor: '#ef4444',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'kidney',
            structureName: 'Kidneys',
            role: 'target-organ',
            involvement: 'Develops nephrosclerosis',
            highlightColor: '#f97316',
            showByDefault: true,
          },
          {
            structureId: 'brain',
            structureName: 'Brain',
            role: 'target-organ',
            involvement: 'Risk of stroke and small vessel disease',
            highlightColor: '#7c3aed',
            showByDefault: false,
          },
          {
            structureId: 'eyes',
            structureName: 'Eyes',
            role: 'target-organ',
            involvement: 'Hypertensive retinopathy',
            highlightColor: '#7c3aed',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Cardiovascular', 'Renal', 'Nervous'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular', 'urinary'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1:
          'High blood pressure means your heart has to work harder than normal to push blood through your body. Over time, this can damage your heart and blood vessels.',
        level2:
          'Hypertension occurs when the force of blood against your artery walls is consistently too high. This extra pressure makes your heart work harder and can damage your arteries, heart, brain, kidneys, and eyes over time.',
        level3:
          'Essential hypertension results from increased peripheral vascular resistance and/or cardiac output. Key mechanisms include RAAS activation, sympathetic overactivity, and endothelial dysfunction. Target organs include the heart (LVH), kidneys (nephrosclerosis), brain (stroke), and eyes (retinopathy).',
        level4:
          'Hypertension pathophysiology involves complex interactions between the RAAS, sympathetic nervous system, endothelium, and kidneys. Vascular remodeling increases peripheral resistance. Target organ damage manifests as left ventricular hypertrophy, nephrosclerosis with proteinuria, cerebral small vessel disease, and hypertensive retinopathy.',
        level5:
          'Essential hypertension represents a polygenic disorder influenced by renal sodium handling, vascular smooth muscle tone, endothelial function, and neurohumoral regulation. Endothelial dysfunction reduces NO bioavailability while increasing endothelin-1 and reactive oxygen species. Arterial stiffening from medial hypertrophy and elastin degradation contributes to systolic hypertension in aging. RAAS-mediated effects include direct vasoconstriction (AT1 receptors), aldosterone-induced sodium retention, and promotion of vascular inflammation and fibrosis.',
      },
      relatedConditions: ['heart-failure', 'coronary-artery-disease', 'stroke', 'ckd'],
      comorbidities: ['diabetes', 'hyperlipidemia', 'obesity'],
      epidemiology: {
        prevalence: '45% of US adults',
        incidence: '~4% annual incidence in adults',
        demographics: 'Increases with age; higher in African Americans',
      },
      clinicalPearls: [
        'Most hypertension is asymptomatic - "silent killer"',
        'Target BP <130/80 for most adults',
        'Always check for secondary causes in resistant or young-onset HTN',
        'RAAS blockade provides renoprotection beyond BP lowering',
      ],
      patientEducation: [
        'Take medications at the same time daily',
        'Monitor your blood pressure at home',
        'Limit sodium to less than 2300mg per day',
        'Maintain a healthy weight through diet and exercise',
        'Limit alcohol consumption',
        'Do not stop medications without consulting your doctor',
      ],
      emergencyWarnings: [
        'Severe headache with vision changes',
        'Chest pain or shortness of breath',
        'Sudden weakness or numbness',
        'Difficulty speaking or understanding',
        'BP >180/120 with symptoms',
      ],
    },
  ],

  // Heart Failure
  [
    'heart-failure',
    {
      conditionId: 'heart-failure',
      name: 'Heart Failure',
      aliases: ['Congestive Heart Failure', 'CHF', 'HF'],
      icdCode: 'I50.9',
      category: 'cardiovascular',
      subcategory: 'Cardiac',
      description:
        'Syndrome where the heart cannot pump blood effectively to meet the body\'s metabolic demands',
      pathophysiology: {
        summary:
          'Cardiac dysfunction leads to inadequate tissue perfusion and fluid accumulation',
        mechanisms: [
          {
            name: 'Neurohormonal Activation',
            description:
              'RAAS and sympathetic activation initially compensate but eventually worsen function',
            systemsInvolved: ['Cardiovascular', 'Renal', 'Endocrine'],
            keyMediators: [
              'Norepinephrine',
              'Angiotensin II',
              'Aldosterone',
              'BNP',
            ],
            contribution:
              'Causes vasoconstriction, fluid retention, and adverse cardiac remodeling',
          },
          {
            name: 'Ventricular Remodeling',
            description:
              'Chamber dilation and wall thinning with altered geometry',
            systemsInvolved: ['Cardiovascular'],
            keyMediators: ['Angiotensin II', 'TGF-beta', 'Matrix metalloproteinases'],
            contribution: 'Progressive decline in cardiac function',
          },
        ],
        riskFactors: [
          {
            name: 'Coronary Artery Disease',
            type: 'partially-modifiable',
            impact: 'major',
            description: 'Leading cause of HF through myocardial damage',
            intervention: 'Revascularization, risk factor control',
          },
          {
            name: 'Hypertension',
            type: 'modifiable',
            impact: 'major',
            description: 'Causes pressure overload and LVH',
            intervention: 'Blood pressure control',
          },
          {
            name: 'Diabetes',
            type: 'partially-modifiable',
            impact: 'moderate',
            description: 'Diabetic cardiomyopathy and accelerated atherosclerosis',
            intervention: 'Glycemic control, SGLT2 inhibitors',
          },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Dyspnea',
            prevalence: 'very-common',
            description: 'Shortness of breath, initially on exertion, progressing to rest',
            quality: 'Air hunger, cannot catch breath',
            timing: 'Worse with activity and lying flat',
          },
          {
            name: 'Fatigue',
            prevalence: 'very-common',
            description: 'Decreased exercise tolerance and persistent tiredness',
          },
          {
            name: 'Peripheral Edema',
            prevalence: 'common',
            description: 'Swelling of ankles, legs, and sometimes abdomen',
            location: 'Lower extremities, sacral area if bedridden',
            timing: 'Worse at end of day',
          },
        ],
        associatedSymptoms: [
          {
            name: 'Orthopnea',
            prevalence: 'common',
            description: 'Difficulty breathing when lying flat',
          },
          {
            name: 'Paroxysmal Nocturnal Dyspnea',
            prevalence: 'common',
            description: 'Waking up at night gasping for air',
          },
        ],
        physicalFindings: [
          {
            name: 'Jugular Venous Distension',
            examType: 'Cardiovascular',
            description: 'Elevated JVP indicating fluid overload',
            diagnosticValue: 'Highly specific for elevated filling pressures',
          },
          {
            name: 'S3 Gallop',
            examType: 'Cardiovascular',
            description: 'Third heart sound indicating volume overload',
            diagnosticValue: 'Specific for decompensated HF',
          },
        ],
        labFindings: [
          {
            testName: 'BNP/NT-proBNP',
            abnormality: 'Elevated (BNP >100, NT-proBNP >300)',
            significance: 'Correlates with wall stress and HF severity',
          },
        ],
      },
      progression: {
        naturalHistory:
          'Progressive syndrome with episodic decompensations and declining function',
        timelineSteps: [
          {
            phaseId: 'stage-a',
            phase: 'preclinical',
            displayName: 'Stage A - At Risk',
            timeframe: 'Risk factors present',
            description: 'High risk for HF but no structural disease or symptoms',
            symptoms: ['None from HF'],
            anatomicalChanges: [],
            reversibility: 'reversible',
            typicalTreatments: ['Risk factor control'],
            goalsOfCare: ['Prevent structural heart disease'],
          },
          {
            phaseId: 'stage-b',
            phase: 'early',
            displayName: 'Stage B - Pre-HF',
            timeframe: 'Structural disease present',
            description: 'Structural heart disease but no HF symptoms',
            symptoms: ['None or minimal'],
            anatomicalChanges: [
              {
                structureId: 'heart',
                structureName: 'Heart',
                changeType: 'hypertrophy',
                description: 'LVH or reduced EF without symptoms',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['ACE inhibitor/ARB', 'Beta-blocker if reduced EF'],
            goalsOfCare: ['Prevent symptoms', 'Prevent progression'],
          },
          {
            phaseId: 'stage-c',
            phase: 'established',
            displayName: 'Stage C - Symptomatic HF',
            timeframe: 'NYHA Class I-III',
            description: 'Structural heart disease with current or prior HF symptoms',
            symptoms: [
              'Dyspnea on exertion',
              'Fatigue',
              'Reduced exercise tolerance',
              'Peripheral edema',
            ],
            anatomicalChanges: [
              {
                structureId: 'heart',
                structureName: 'Heart',
                changeType: 'dilation',
                description: 'Ventricular dilation with reduced function',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 },
                isNewAtPhase: false,
              },
              {
                structureId: 'lungs',
                structureName: 'Lungs',
                changeType: 'edema',
                description: 'Pulmonary congestion',
                severity: 'moderate',
                visualIndicator: { color: '#06b6d4', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: [
              'GDMT: ACEi/ARB/ARNI, Beta-blocker, MRA, SGLT2i',
              'Diuretics for congestion',
            ],
            goalsOfCare: ['Reduce symptoms', 'Prevent hospitalization', 'Improve survival'],
          },
          {
            phaseId: 'stage-d',
            phase: 'advanced',
            displayName: 'Stage D - Advanced HF',
            timeframe: 'NYHA Class IV',
            description: 'Refractory HF requiring specialized interventions',
            symptoms: [
              'Symptoms at rest',
              'Recurrent hospitalizations',
              'Requires IV inotropes',
            ],
            anatomicalChanges: [
              {
                structureId: 'heart',
                structureName: 'Heart',
                changeType: 'dilation',
                description: 'Severely dilated with poor function',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 },
                isNewAtPhase: false,
              },
              {
                structureId: 'lungs',
                structureName: 'Lungs',
                changeType: 'edema',
                description: 'Severe pulmonary congestion',
                severity: 'severe',
                visualIndicator: { color: '#06b6d4', pulse: true, opacity: 0.7 },
                isNewAtPhase: false,
              },
              {
                structureId: 'kidney',
                structureName: 'Kidneys',
                changeType: 'dysfunction',
                description: 'Cardiorenal syndrome',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Advanced therapies', 'Consider transplant/LVAD', 'Palliative care'],
            goalsOfCare: ['Quality of life', 'Symptom management'],
          },
        ],
        prognosis:
          '50% mortality at 5 years. GDMT significantly improves survival.',
      },
      complications: [
        {
          complicationId: 'acute-decompensation',
          name: 'Acute Decompensated Heart Failure',
          category: 'acute',
          severity: 'major',
          riskLevel: 'high',
          description: 'Rapid worsening of HF symptoms requiring hospitalization',
          mechanism: 'Fluid overload, reduced cardiac output',
          affectedStructures: [
            {
              structureId: 'lungs',
              structureName: 'Lungs',
              effect: 'Pulmonary edema',
              highlightColor: '#06b6d4',
            },
          ],
          warningSymptoms: ['Worsening dyspnea', 'Weight gain >2-3 lbs/day', 'Increasing edema'],
          prevention: ['Medication adherence', 'Sodium restriction', 'Daily weights'],
          preventable: true,
        },
        {
          complicationId: 'arrhythmia',
          name: 'Arrhythmia',
          category: 'both',
          severity: 'major',
          riskLevel: 'high',
          description: 'Atrial fibrillation or ventricular arrhythmias',
          mechanism: 'Structural remodeling creates arrhythmogenic substrate',
          affectedStructures: [
            {
              structureId: 'heart',
              structureName: 'Heart',
              effect: 'Electrical instability',
              highlightColor: '#dc2626',
            },
          ],
          warningSymptoms: ['Palpitations', 'Syncope', 'Sudden worsening of symptoms'],
          prevention: ['Beta-blockers', 'ICD if indicated'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'gdmt-hf',
          name: 'Guideline-Directed Medical Therapy',
          modality: 'pharmacological',
          description:
            'Four-pillar therapy: ACEi/ARB/ARNI + Beta-blocker + MRA + SGLT2i',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Improve survival', 'Reduce hospitalizations', 'Improve symptoms'],
          expectedOutcomes: ['30-40% mortality reduction with full GDMT'],
          timeToEffect: 'Weeks to months',
          medicationIds: ['lisinopril', 'metoprolol'],
          explanations: {
            level1:
              'These medications help your heart pump better and live longer.',
            level2:
              'Guideline-directed therapy includes four types of medications that work together to help your heart, reduce fluid buildup, and significantly improve survival.',
            level3:
              'GDMT for HFrEF includes: ACEi/ARB/ARNI (reduce afterload, prevent remodeling), beta-blockers (reduce heart rate, reverse remodeling), MRA (block aldosterone effects), SGLT2i (reduce preload, cardioprotection).',
            level4:
              'Each component of GDMT independently reduces mortality. The combination provides additive benefit. ARNi superior to ACEi alone. Beta-blockers should be titrated to target doses. SGLT2 inhibitors benefit regardless of diabetes status.',
            level5:
              'GDMT targets neurohormonal activation: RAAS inhibition reduces angiotensin II-mediated vasoconstriction, aldosterone-induced sodium retention, and adverse remodeling. Beta-blockade reduces catecholamine toxicity and improves calcium handling. SGLT2 inhibitors have pleiotropic effects including reduced preload, improved energetics, and anti-inflammatory effects.',
          },
        },
        {
          treatmentId: 'diuretics-hf',
          name: 'Diuretics',
          modality: 'pharmacological',
          description: 'Loop diuretics for volume management',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['established', 'advanced'],
          goals: ['Relieve congestion', 'Improve symptoms'],
          timeToEffect: 'Hours to days',
          explanations: {
            level1: 'Water pills help remove extra fluid from your body.',
            level2:
              'Diuretics make you urinate more, removing the excess fluid that causes swelling and breathing problems.',
            level3:
              'Loop diuretics (furosemide, bumetanide) are the cornerstone of decongestion. Dose titrated to achieve euvolemia. No mortality benefit but essential for symptom relief.',
            level4:
              'Loop diuretics inhibit NKCC2 in the thick ascending limb, producing potent diuresis. Diuretic resistance may develop requiring dose escalation or combination therapy with thiazides.',
            level5:
              'Loop diuretics block the Na-K-2Cl cotransporter in the medullary thick ascending limb, disrupting the countercurrent multiplier and producing hypotonic urine. Chronic use leads to nephron remodeling with distal tubule hypertrophy, reducing efficacy over time.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'heart',
            structureName: 'Heart',
            role: 'primary-site',
            involvement: 'Impaired pumping function',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'lungs',
            structureName: 'Lungs',
            role: 'target-organ',
            involvement: 'Pulmonary congestion and edema',
            highlightColor: '#06b6d4',
            showByDefault: true,
          },
          {
            structureId: 'kidney',
            structureName: 'Kidneys',
            role: 'target-organ',
            involvement: 'Cardiorenal syndrome',
            highlightColor: '#f97316',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Cardiovascular', 'Respiratory', 'Renal'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular', 'respiratory'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1:
          'Heart failure means your heart is not pumping blood as well as it should. This causes fluid to build up and makes you feel tired and short of breath.',
        level2:
          'In heart failure, your heart muscle is weakened or stiff and cannot pump enough blood to meet your body\'s needs. This leads to fluid backing up in your lungs and legs, causing shortness of breath and swelling.',
        level3:
          'Heart failure is a clinical syndrome characterized by inadequate cardiac output and/or elevated filling pressures. It may involve systolic dysfunction (reduced ejection fraction) or diastolic dysfunction (preserved ejection fraction). The body compensates through neurohormonal activation, which initially helps but eventually worsens the condition.',
        level4:
          'HF pathophysiology involves a vicious cycle of neurohormonal activation (RAAS, SNS, natriuretic peptides) leading to fluid retention, vasoconstriction, and adverse cardiac remodeling. HFrEF features reduced contractility and chamber dilation. HFpEF features impaired relaxation and elevated filling pressures with relatively normal EF.',
        level5:
          'In HFrEF, myocyte loss (ischemia, toxins, genetic) triggers remodeling with chamber dilation and eccentric hypertrophy. Calcium handling abnormalities reduce contractility. Neurohormonal activation initially maintains output but promotes fibrosis, hypertrophy, and apoptosis. In HFpEF, concentric hypertrophy with increased passive stiffness (titin phosphorylation, collagen deposition) impairs filling. Microvascular inflammation and endothelial dysfunction contribute to both phenotypes.',
      },
      relatedConditions: ['hypertension', 'coronary-artery-disease', 'atrial-fibrillation'],
      comorbidities: ['ckd', 'diabetes', 'anemia'],
      epidemiology: {
        prevalence: '6.2 million US adults',
        demographics: 'Increases with age; equal in men and women',
      },
      patientEducation: [
        'Weigh yourself daily - report gain >2-3 lbs',
        'Limit sodium to <2000mg daily',
        'Take all medications as prescribed',
        'Restrict fluids if advised by your doctor',
        'Report worsening symptoms immediately',
      ],
      emergencyWarnings: [
        'Severe difficulty breathing',
        'Chest pain',
        'Fainting or near-fainting',
        'Coughing up pink/frothy sputum',
        'Unable to lie flat due to breathing',
      ],
    },
  ],

  // Type 2 Diabetes (abbreviated for space)
  [
    'type-2-diabetes',
    {
      conditionId: 'type-2-diabetes',
      name: 'Type 2 Diabetes Mellitus',
      aliases: ['T2DM', 'Diabetes', 'Type 2 Diabetes', 'Adult-onset Diabetes'],
      icdCode: 'E11',
      category: 'metabolic',
      subcategory: 'Endocrine',
      description:
        'Metabolic disorder characterized by chronic hyperglycemia due to insulin resistance and relative insulin deficiency',
      pathophysiology: {
        summary:
          'Insulin resistance combined with progressive beta-cell dysfunction leads to chronic hyperglycemia',
        mechanisms: [
          {
            name: 'Insulin Resistance',
            description:
              'Tissues (muscle, liver, fat) have diminished response to insulin',
            systemsInvolved: ['Endocrine', 'Metabolic'],
            keyMediators: ['Insulin', 'Glucose transporters', 'Inflammatory cytokines'],
            contribution: 'Primary defect requiring compensatory hyperinsulinemia',
          },
          {
            name: 'Beta-Cell Dysfunction',
            description:
              'Pancreatic beta cells fail to produce adequate insulin',
            systemsInvolved: ['Endocrine'],
            keyMediators: ['Insulin', 'Amylin', 'GLP-1'],
            contribution: 'Progressive decline leads to worsening hyperglycemia',
          },
        ],
        riskFactors: [
          {
            name: 'Obesity',
            type: 'modifiable',
            impact: 'major',
            description: 'Particularly visceral adiposity increases insulin resistance',
            intervention: 'Weight loss of 5-10% improves glycemic control',
          },
          {
            name: 'Family History',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Strong genetic component',
          },
          {
            name: 'Physical Inactivity',
            type: 'modifiable',
            impact: 'moderate',
            description: 'Reduces insulin sensitivity',
            intervention: '150 minutes/week moderate exercise',
          },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Polyuria',
            prevalence: 'common',
            description: 'Frequent urination due to osmotic diuresis',
          },
          {
            name: 'Polydipsia',
            prevalence: 'common',
            description: 'Excessive thirst',
          },
          {
            name: 'Often Asymptomatic',
            prevalence: 'very-common',
            description: 'Many diagnosed on routine screening',
          },
        ],
        labFindings: [
          {
            testName: 'Fasting Glucose',
            abnormality: '≥126 mg/dL',
            normalRange: '<100 mg/dL',
            significance: 'Diagnostic criterion',
          },
          {
            testName: 'HbA1c',
            abnormality: '≥6.5%',
            normalRange: '<5.7%',
            significance: 'Reflects 3-month average glucose',
          },
        ],
      },
      progression: {
        naturalHistory:
          'Progressive disease with declining beta-cell function over time',
        timelineSteps: [
          {
            phaseId: 'prediabetes',
            phase: 'preclinical',
            displayName: 'Prediabetes',
            timeframe: 'FPG 100-125 or A1c 5.7-6.4%',
            description: 'Impaired glucose metabolism not yet meeting diabetes criteria',
            symptoms: ['Usually none'],
            anatomicalChanges: [
              {
                structureId: 'pancreas',
                structureName: 'Pancreas',
                changeType: 'dysfunction',
                description: 'Early beta-cell stress',
                severity: 'mild',
                visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Lifestyle modification', 'Consider metformin'],
          },
          {
            phaseId: 'early-diabetes',
            phase: 'early',
            displayName: 'Early Diabetes',
            timeframe: 'A1c 6.5-8%',
            description: 'Newly diagnosed diabetes with preserved beta-cell function',
            symptoms: ['Mild polyuria/polydipsia', 'Fatigue'],
            anatomicalChanges: [
              {
                structureId: 'pancreas',
                structureName: 'Pancreas',
                changeType: 'dysfunction',
                description: 'Reduced insulin secretion',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Lifestyle', 'Metformin', 'Add second agent if needed'],
          },
          {
            phaseId: 'established-diabetes',
            phase: 'established',
            displayName: 'Established Diabetes',
            timeframe: 'Years of disease',
            description: 'Progressive disease requiring multiple medications',
            symptoms: ['May be asymptomatic', 'Early complications developing'],
            anatomicalChanges: [
              {
                structureId: 'pancreas',
                structureName: 'Pancreas',
                changeType: 'dysfunction',
                description: 'Significant beta-cell decline',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 },
                isNewAtPhase: false,
              },
              {
                structureId: 'eyes',
                structureName: 'Retina',
                changeType: 'ischemia',
                description: 'Early diabetic retinopathy',
                severity: 'mild',
                visualIndicator: { color: '#7c3aed', pulse: false, opacity: 0.4 },
                isNewAtPhase: true,
              },
              {
                structureId: 'kidney',
                structureName: 'Kidneys',
                changeType: 'dysfunction',
                description: 'Diabetic nephropathy developing',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Multiple oral agents', 'Consider GLP-1 RA', 'SGLT2 inhibitor'],
          },
          {
            phaseId: 'advanced-diabetes',
            phase: 'advanced',
            displayName: 'Advanced Diabetes with Complications',
            timeframe: 'Long-standing disease',
            description: 'Significant complications and insulin dependence',
            symptoms: ['Complications drive symptoms', 'May require insulin'],
            anatomicalChanges: [
              {
                structureId: 'pancreas',
                structureName: 'Pancreas',
                changeType: 'dysfunction',
                description: 'Near-complete beta-cell failure',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.7 },
                isNewAtPhase: false,
              },
              {
                structureId: 'eyes',
                structureName: 'Retina',
                changeType: 'ischemia',
                description: 'Proliferative diabetic retinopathy',
                severity: 'severe',
                visualIndicator: { color: '#7c3aed', pulse: true, opacity: 0.7 },
                isNewAtPhase: false,
              },
              {
                structureId: 'kidney',
                structureName: 'Kidneys',
                changeType: 'fibrosis',
                description: 'Diabetic nephropathy with CKD',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 },
                isNewAtPhase: false,
              },
              {
                structureId: 'peripheral-nerves',
                structureName: 'Peripheral Nerves',
                changeType: 'degeneration',
                description: 'Diabetic neuropathy',
                severity: 'moderate',
                visualIndicator: { color: '#71717a', pulse: false, opacity: 0.6 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Insulin therapy', 'Manage complications'],
          },
        ],
        prognosis:
          'Life expectancy reduced by 6-7 years without treatment. Good control prevents complications.',
      },
      complications: [
        {
          complicationId: 'diabetic-retinopathy',
          name: 'Diabetic Retinopathy',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'high',
          description: 'Microvascular damage to the retina causing vision loss',
          mechanism: 'Chronic hyperglycemia damages retinal blood vessels',
          affectedStructures: [
            {
              structureId: 'eyes',
              structureName: 'Eyes/Retina',
              effect: 'Hemorrhages, edema, neovascularization',
              highlightColor: '#7c3aed',
            },
          ],
          warningSymptoms: ['Blurred vision', 'Floaters', 'Vision loss'],
          prevention: ['Glycemic control', 'Annual eye exams'],
          preventable: true,
        },
        {
          complicationId: 'diabetic-nephropathy',
          name: 'Diabetic Nephropathy',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'high',
          description: 'Progressive kidney damage leading to CKD',
          mechanism: 'Glomerular hyperfiltration and glycation damage',
          affectedStructures: [
            {
              structureId: 'kidney',
              structureName: 'Kidneys',
              effect: 'Glomerulosclerosis, albuminuria',
              highlightColor: '#ef4444',
            },
          ],
          warningSymptoms: ['Often asymptomatic until advanced', 'Swelling', 'Fatigue'],
          prevention: ['ACE inhibitor/ARB', 'SGLT2 inhibitor', 'BP control'],
          preventable: true,
        },
        {
          complicationId: 'diabetic-neuropathy',
          name: 'Diabetic Neuropathy',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'high',
          description: 'Nerve damage causing pain and numbness',
          mechanism: 'Metabolic damage to nerve fibers',
          affectedStructures: [
            {
              structureId: 'peripheral-nerves',
              structureName: 'Peripheral Nerves',
              effect: 'Demyelination, axonal loss',
              highlightColor: '#71717a',
            },
          ],
          warningSymptoms: ['Numbness', 'Tingling', 'Burning pain', 'Loss of sensation'],
          prevention: ['Glycemic control'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'metformin-dm',
          name: 'Metformin',
          modality: 'pharmacological',
          description: 'First-line medication for type 2 diabetes',
          mechanism: 'Reduces hepatic glucose production and improves insulin sensitivity',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['preclinical', 'early', 'established'],
          goals: ['Lower A1c by 1-1.5%', 'Prevent complications'],
          timeToEffect: '2-4 weeks',
          medicationIds: ['metformin'],
          contraindications: ['eGFR <30', 'Active liver disease'],
          sideEffects: ['GI upset', 'B12 deficiency'],
          explanations: {
            level1: 'This medication helps your body use insulin better and makes less sugar in your liver.',
            level2:
              'Metformin is the first medication most people start for type 2 diabetes. It helps your body respond better to insulin and reduces the amount of sugar your liver makes.',
            level3:
              'Metformin primarily reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity. It has cardiovascular benefits independent of glucose lowering and does not cause hypoglycemia or weight gain.',
            level4:
              'Metformin activates AMPK, suppressing hepatic gluconeogenesis via reduced expression of gluconeogenic enzymes. It also improves insulin sensitivity in skeletal muscle through enhanced GLUT4 translocation.',
            level5:
              'Metformin inhibits mitochondrial complex I, increasing AMP:ATP ratio and activating AMPK. This suppresses mTORC1-mediated lipogenesis, reduces hepatic glucose output through decreased PEPCK and G6Pase expression, and enhances skeletal muscle glucose uptake through AMPK-mediated GLUT4 trafficking.',
          },
        },
        {
          treatmentId: 'lifestyle-dm',
          name: 'Medical Nutrition Therapy & Exercise',
          modality: 'lifestyle',
          description: 'Diet and exercise as foundation of diabetes management',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['preclinical', 'early', 'established', 'advanced'],
          goals: ['Lower A1c by 1-2%', 'Weight management', 'Improve insulin sensitivity'],
          timeToEffect: '3-6 months',
          explanations: {
            level1: 'Eating healthy foods and staying active helps control your blood sugar.',
            level2:
              'A balanced diet low in refined carbohydrates combined with regular exercise can significantly improve blood sugar control, sometimes even reversing prediabetes.',
            level3:
              'Medical nutrition therapy emphasizes carbohydrate counting, glycemic index awareness, and portion control. Exercise improves insulin sensitivity and promotes weight loss.',
            level4:
              'Carbohydrate modification has the greatest impact on postprandial glucose. Exercise increases GLUT4 expression independently of insulin. Weight loss of 5-10% can significantly improve glycemic control.',
            level5:
              'Dietary intervention targets both fasting (hepatic) and postprandial (peripheral) glucose. Exercise acutely increases glucose uptake via AMPK-mediated GLUT4 translocation, with chronic adaptations improving mitochondrial density and insulin signaling.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'pancreas',
            structureName: 'Pancreas',
            role: 'primary-site',
            involvement: 'Beta-cell dysfunction',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'kidney',
            structureName: 'Kidneys',
            role: 'target-organ',
            involvement: 'Diabetic nephropathy',
            highlightColor: '#ef4444',
            showByDefault: true,
          },
          {
            structureId: 'eyes',
            structureName: 'Eyes',
            role: 'target-organ',
            involvement: 'Diabetic retinopathy',
            highlightColor: '#7c3aed',
            showByDefault: true,
          },
          {
            structureId: 'peripheral-nerves',
            structureName: 'Peripheral Nerves',
            role: 'target-organ',
            involvement: 'Diabetic neuropathy',
            highlightColor: '#71717a',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Endocrine', 'Cardiovascular', 'Renal', 'Nervous'],
        recommendedView: 'anterior',
        recommendedLayers: ['endocrine', 'nervous'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1:
          'Diabetes means your body cannot control blood sugar properly. Over time, high blood sugar can damage your heart, kidneys, eyes, and nerves.',
        level2:
          'In type 2 diabetes, your body does not use insulin effectively (insulin resistance), and your pancreas cannot make enough insulin to compensate. This leads to high blood sugar levels that can damage organs over time.',
        level3:
          'Type 2 diabetes involves insulin resistance (primarily in liver, muscle, fat) and progressive beta-cell dysfunction. Chronic hyperglycemia causes microvascular complications (retinopathy, nephropathy, neuropathy) and accelerates macrovascular disease.',
        level4:
          'The pathophysiology involves the "ominous octet": reduced insulin secretion, increased glucagon, increased hepatic glucose production, reduced peripheral glucose uptake, increased lipolysis, reduced incretin effect, increased renal glucose reabsorption, and neurotransmitter dysfunction.',
        level5:
          'Insulin resistance involves defects in insulin receptor substrate phosphorylation, PI3K/Akt signaling, and GLUT4 translocation. Beta-cell failure occurs through glucotoxicity, lipotoxicity, ER stress, and islet amyloid deposition. Microvascular complications arise from polyol pathway activation, AGE formation, PKC activation, and hexosamine pathway flux.',
      },
      relatedConditions: ['hypertension', 'hyperlipidemia', 'obesity', 'metabolic-syndrome'],
      comorbidities: ['cardiovascular-disease', 'ckd', 'depression'],
      epidemiology: {
        prevalence: '11.3% of US adults',
        incidence: '1.5 million new cases/year in US',
        demographics: 'Increasing in all age groups; higher in minorities',
      },
      patientEducation: [
        'Check blood sugar as directed',
        'Learn to count carbohydrates',
        'Check your feet daily for sores',
        'Get annual eye exams',
        'Take all medications as prescribed',
        'Know the symptoms of low blood sugar',
      ],
      emergencyWarnings: [
        'Blood sugar over 300 with symptoms',
        'Fruity breath odor',
        'Severe nausea/vomiting',
        'Confusion or altered consciousness',
        'Very low blood sugar (<70) with symptoms',
      ],
    },
  ],

  // Atrial Fibrillation (abbreviated)
  [
    'atrial-fibrillation',
    {
      conditionId: 'atrial-fibrillation',
      name: 'Atrial Fibrillation',
      aliases: ['AFib', 'AF', 'A-fib'],
      icdCode: 'I48.91',
      category: 'cardiovascular',
      subcategory: 'Arrhythmia',
      description:
        'Irregular rapid heart rhythm originating from chaotic atrial electrical activity',
      pathophysiology: {
        summary:
          'Disorganized atrial electrical activity causes irregular ventricular response and atrial stasis',
        mechanisms: [
          {
            name: 'Atrial Remodeling',
            description: 'Electrical and structural changes in atria create substrate for AF',
            systemsInvolved: ['Cardiovascular'],
            keyMediators: ['Calcium', 'Fibrosis', 'Ion channels'],
            contribution: 'Creates and maintains arrhythmogenic substrate',
          },
        ],
        riskFactors: [
          {
            name: 'Hypertension',
            type: 'modifiable',
            impact: 'major',
            description: 'Leading risk factor for AF',
            intervention: 'Blood pressure control',
          },
          {
            name: 'Age',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Risk increases significantly with age',
          },
          {
            name: 'Obesity',
            type: 'modifiable',
            impact: 'moderate',
            description: 'Increases atrial pressure and inflammation',
            intervention: 'Weight loss',
          },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Palpitations',
            prevalence: 'very-common',
            description: 'Sensation of rapid, irregular heartbeat',
          },
          {
            name: 'Fatigue',
            prevalence: 'very-common',
            description: 'Due to inefficient cardiac output',
          },
        ],
        physicalFindings: [
          {
            name: 'Irregularly Irregular Pulse',
            examType: 'Cardiovascular',
            description: 'Characteristic finding of AF',
            diagnosticValue: 'Highly suggestive',
          },
        ],
      },
      progression: {
        naturalHistory: 'AF begets AF - tends to progress from paroxysmal to persistent to permanent',
        timelineSteps: [
          {
            phaseId: 'paroxysmal',
            phase: 'early',
            displayName: 'Paroxysmal AF',
            timeframe: 'Episodes <7 days, self-terminating',
            description: 'Intermittent AF that converts spontaneously',
            symptoms: ['Episodic palpitations', 'Fatigue during episodes'],
            anatomicalChanges: [
              {
                structureId: 'heart',
                structureName: 'Atria',
                changeType: 'dysfunction',
                description: 'Electrical remodeling beginning',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: true, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Rate control', 'Rhythm control', 'Anticoagulation if indicated'],
          },
          {
            phaseId: 'persistent',
            phase: 'established',
            displayName: 'Persistent AF',
            timeframe: 'Episodes >7 days or requiring cardioversion',
            description: 'AF that does not self-terminate',
            symptoms: ['Continuous symptoms', 'Exercise intolerance'],
            anatomicalChanges: [
              {
                structureId: 'heart',
                structureName: 'Atria',
                changeType: 'fibrosis',
                description: 'Structural remodeling with fibrosis',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Cardioversion', 'Ablation consideration', 'Anticoagulation'],
          },
          {
            phaseId: 'permanent',
            phase: 'chronic',
            displayName: 'Permanent AF',
            timeframe: 'Decision to accept AF',
            description: 'AF accepted as the patient\'s baseline rhythm',
            symptoms: ['Adapted to symptoms', 'Focus on rate control'],
            anatomicalChanges: [
              {
                structureId: 'heart',
                structureName: 'Atria',
                changeType: 'dilation',
                description: 'Dilated atria with significant fibrosis',
                severity: 'moderate',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Rate control', 'Long-term anticoagulation'],
          },
        ],
        prognosis: 'Associated with 5x increased stroke risk. Mortality 1.5-2x higher than general population.',
      },
      complications: [
        {
          complicationId: 'stroke-af',
          name: 'Ischemic Stroke',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'high',
          description: 'Stroke from cardioembolic source',
          mechanism: 'Atrial stasis leads to thrombus formation in LAA',
          affectedStructures: [
            {
              structureId: 'brain',
              structureName: 'Brain',
              effect: 'Ischemic damage',
              highlightColor: '#7c3aed',
            },
          ],
          warningSymptoms: ['Sudden weakness', 'Speech difficulty', 'Face drooping'],
          prevention: ['Anticoagulation based on CHA2DS2-VASc score'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'anticoagulation-af',
          name: 'Anticoagulation',
          modality: 'pharmacological',
          description: 'Blood thinners to prevent stroke',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'chronic'],
          goals: ['Prevent stroke', 'Reduce mortality'],
          explanations: {
            level1: 'Blood thinners prevent blood clots that can cause stroke.',
            level2:
              'Anticoagulants prevent clots from forming in your heart, which can travel to your brain and cause a stroke.',
            level3:
              'DOACs (apixaban, rivaroxaban) or warfarin reduce stroke risk by 65-70% compared to aspirin. Decision based on CHA2DS2-VASc score.',
            level4:
              'DOACs are preferred over warfarin for most patients due to better safety profile and no INR monitoring. Bleeding risk assessed with HAS-BLED score.',
            level5:
              'Factor Xa inhibitors and direct thrombin inhibitors provide predictable anticoagulation. LAA occlusion (Watchman) is an alternative for patients unable to take long-term anticoagulation.',
          },
        },
        {
          treatmentId: 'rate-control-af',
          name: 'Rate Control',
          modality: 'pharmacological',
          description: 'Control ventricular rate without converting to sinus rhythm',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'chronic'],
          goals: ['Heart rate <110 at rest'],
          medicationIds: ['metoprolol'],
          explanations: {
            level1: 'These medications slow your heart rate to a normal speed.',
            level2:
              'Rate control medications like beta-blockers slow your heart rate even though the rhythm stays irregular.',
            level3:
              'Beta-blockers or non-DHP calcium channel blockers are first-line. Target resting HR <110 based on RACE II trial.',
            level4:
              'Lenient rate control (<110) is non-inferior to strict control (<80) for preventing cardiovascular events. AV node agents preferred over digoxin.',
            level5:
              'Beta-blockers slow conduction through the AV node via beta-1 blockade. Calcium channel blockers directly inhibit AV nodal L-type calcium channels.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'heart',
            structureName: 'Heart (Atria)',
            role: 'primary-site',
            involvement: 'Chaotic electrical activity',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'brain',
            structureName: 'Brain',
            role: 'target-organ',
            involvement: 'Stroke risk',
            highlightColor: '#7c3aed',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Cardiovascular', 'Nervous'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1:
          'Your heart has an irregular, often fast rhythm. This increases your risk of stroke, so blood thinners are important.',
        level2:
          'In atrial fibrillation, the upper chambers of your heart beat chaotically instead of rhythmically. This can cause palpitations, fatigue, and increases stroke risk because blood can pool and form clots.',
        level3:
          'AF is characterized by rapid, disorganized atrial electrical activity causing an irregularly irregular ventricular response. The main concerns are symptoms from rapid rate and stroke from left atrial appendage thrombus.',
        level4:
          'AF involves multiple reentrant wavelets in the atria, often triggered from pulmonary vein foci. Electrical and structural remodeling perpetuates the arrhythmia ("AF begets AF"). CHA2DS2-VASc stratifies stroke risk.',
        level5:
          'AF mechanisms include pulmonary vein triggers (ectopic automaticity), atrial substrate (fibrosis, ion channel remodeling shortening APD), and perpetuating factors (electrical dissociation from gap junction disruption). Anticoagulation targets coagulation cascade; DOACs inhibit factor Xa or thrombin.',
      },
      relatedConditions: ['hypertension', 'heart-failure', 'coronary-artery-disease'],
      epidemiology: {
        prevalence: '2.7-6.1 million in US',
        demographics: 'Increases dramatically with age',
      },
      emergencyWarnings: [
        'Signs of stroke (FAST)',
        'Chest pain',
        'Severe shortness of breath',
        'Fainting',
      ],
    },
  ],

  // COPD (abbreviated)
  [
    'copd',
    {
      conditionId: 'copd',
      name: 'Chronic Obstructive Pulmonary Disease',
      aliases: ['COPD', 'Emphysema', 'Chronic Bronchitis'],
      icdCode: 'J44.9',
      category: 'respiratory',
      subcategory: 'Obstructive Lung Disease',
      description:
        'Progressive lung disease characterized by airflow limitation that is not fully reversible',
      pathophysiology: {
        summary:
          'Chronic inflammation causes airway obstruction and parenchymal destruction',
        mechanisms: [
          {
            name: 'Chronic Inflammation',
            description: 'Neutrophilic inflammation in airways and lung parenchyma',
            systemsInvolved: ['Respiratory'],
            keyMediators: ['Neutrophils', 'Macrophages', 'Proteases', 'Oxidants'],
            contribution: 'Drives airway remodeling and alveolar destruction',
          },
          {
            name: 'Protease-Antiprotease Imbalance',
            description: 'Excess proteases destroy alveolar walls',
            systemsInvolved: ['Respiratory'],
            keyMediators: ['Elastase', 'Alpha-1 antitrypsin'],
            contribution: 'Causes emphysematous changes',
          },
        ],
        riskFactors: [
          {
            name: 'Smoking',
            type: 'modifiable',
            impact: 'major',
            description: 'Cause of 85-90% of COPD',
            intervention: 'Smoking cessation',
          },
          {
            name: 'Alpha-1 Antitrypsin Deficiency',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Genetic cause of early-onset emphysema',
          },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Dyspnea',
            prevalence: 'very-common',
            description: 'Progressive breathlessness, initially on exertion',
            quality: 'Air hunger, increased work of breathing',
          },
          {
            name: 'Chronic Cough',
            prevalence: 'very-common',
            description: 'Often productive, worse in morning',
          },
          {
            name: 'Sputum Production',
            prevalence: 'common',
            description: 'Chronic mucus hypersecretion',
          },
        ],
        physicalFindings: [
          {
            name: 'Decreased Breath Sounds',
            examType: 'Pulmonary',
            description: 'Reduced airflow',
            diagnosticValue: 'Suggestive of COPD',
          },
          {
            name: 'Barrel Chest',
            examType: 'Inspection',
            description: 'Increased AP diameter from hyperinflation',
            diagnosticValue: 'Seen in advanced disease',
          },
        ],
      },
      progression: {
        naturalHistory: 'Progressive decline in lung function, accelerated by continued smoking',
        timelineSteps: [
          {
            phaseId: 'gold1',
            phase: 'early',
            displayName: 'GOLD 1 - Mild',
            timeframe: 'FEV1 ≥80% predicted',
            description: 'Mild airflow limitation, often undiagnosed',
            symptoms: ['Mild dyspnea on exertion', 'Occasional cough'],
            anatomicalChanges: [
              {
                structureId: 'lungs',
                structureName: 'Airways',
                changeType: 'inflammation',
                description: 'Early airway inflammation',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Smoking cessation', 'SABA as needed'],
          },
          {
            phaseId: 'gold2',
            phase: 'established',
            displayName: 'GOLD 2 - Moderate',
            timeframe: 'FEV1 50-79% predicted',
            description: 'Worsening airflow limitation with symptoms',
            symptoms: ['Dyspnea with activity', 'Regular cough/sputum'],
            anatomicalChanges: [
              {
                structureId: 'lungs',
                structureName: 'Airways',
                changeType: 'fibrosis',
                description: 'Airway wall thickening and fibrosis',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.5 },
                isNewAtPhase: false,
              },
              {
                structureId: 'lungs',
                structureName: 'Alveoli',
                changeType: 'degeneration',
                description: 'Alveolar destruction (emphysema)',
                severity: 'mild',
                visualIndicator: { color: '#71717a', pulse: false, opacity: 0.4 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['LAMA and/or LABA', 'Pulmonary rehabilitation'],
          },
          {
            phaseId: 'gold34',
            phase: 'advanced',
            displayName: 'GOLD 3-4 - Severe',
            timeframe: 'FEV1 <50% predicted',
            description: 'Severe airflow limitation with significant impact',
            symptoms: ['Dyspnea at rest', 'Frequent exacerbations', 'Exercise intolerance'],
            anatomicalChanges: [
              {
                structureId: 'lungs',
                structureName: 'Lungs',
                changeType: 'degeneration',
                description: 'Extensive emphysema and airway disease',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 },
                isNewAtPhase: false,
              },
              {
                structureId: 'heart',
                structureName: 'Right Ventricle',
                changeType: 'hypertrophy',
                description: 'Cor pulmonale developing',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Triple therapy', 'Oxygen if hypoxic', 'Consider lung volume reduction'],
          },
        ],
        prognosis: 'FEV1 decline is 50-60 mL/year (vs 30 mL/year in non-smokers). Smoking cessation slows decline.',
      },
      complications: [
        {
          complicationId: 'copd-exacerbation',
          name: 'Acute Exacerbation',
          category: 'acute',
          severity: 'major',
          riskLevel: 'high',
          description: 'Acute worsening of symptoms requiring treatment change',
          mechanism: 'Usually triggered by infection or environmental factors',
          affectedStructures: [
            {
              structureId: 'lungs',
              structureName: 'Lungs',
              effect: 'Increased inflammation and mucus',
              highlightColor: '#ef4444',
            },
          ],
          warningSymptoms: ['Increased dyspnea', 'Increased sputum', 'Sputum color change'],
          prevention: ['Inhaler adherence', 'Vaccinations', 'Avoid triggers'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'smoking-cessation-copd',
          name: 'Smoking Cessation',
          modality: 'lifestyle',
          description: 'Only intervention proven to slow disease progression',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'advanced'],
          goals: ['Slow FEV1 decline', 'Reduce exacerbations'],
          explanations: {
            level1: 'Quitting smoking is the most important thing you can do for your lungs.',
            level2:
              'Stopping smoking is the only treatment that slows down the progression of COPD. It\'s never too late to quit.',
            level3:
              'Smoking cessation reduces FEV1 decline to near-normal rates and reduces exacerbation frequency. Use NRT, bupropion, or varenicline.',
            level4:
              'Smoking cessation is a class 1A recommendation. Brief counseling plus pharmacotherapy increases quit rates from 5% to 25-35%.',
            level5:
              'Continued smoking perpetuates inflammation through oxidant burden and impaired host defense. Cessation reduces inflammatory cell recruitment and protease activity, slowing alveolar destruction.',
          },
        },
        {
          treatmentId: 'bronchodilators-copd',
          name: 'Long-acting Bronchodilators',
          modality: 'pharmacological',
          description: 'LAMA and LABA inhalers for maintenance therapy',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'advanced'],
          goals: ['Reduce symptoms', 'Reduce exacerbations'],
          timeToEffect: 'Days to weeks',
          explanations: {
            level1: 'These inhalers open your airways to help you breathe easier.',
            level2:
              'Long-acting bronchodilators relax the muscles around your airways, making it easier to breathe throughout the day.',
            level3:
              'LAMAs (tiotropium) and LABAs (salmeterol) are maintenance bronchodilators. Combination LAMA/LABA is more effective than monotherapy.',
            level4:
              'LAMAs block M3 muscarinic receptors; LABAs stimulate beta-2 receptors. Both cause bronchial smooth muscle relaxation. Dual bronchodilation provides additive benefit.',
            level5:
              'M3 antagonism blocks acetylcholine-mediated bronchoconstriction and mucus secretion. Beta-2 agonism increases cAMP, promoting smooth muscle relaxation and improving mucociliary clearance.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'lungs',
            structureName: 'Lungs',
            role: 'primary-site',
            involvement: 'Airways and alveoli affected',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'heart',
            structureName: 'Heart (Right Side)',
            role: 'secondary-site',
            involvement: 'Cor pulmonale in advanced disease',
            highlightColor: '#ef4444',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Respiratory', 'Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['respiratory'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1:
          'COPD is a lung disease that makes it hard to breathe because your airways are narrowed and damaged. Smoking is the main cause.',
        level2:
          'COPD includes chronic bronchitis (inflamed airways with excess mucus) and emphysema (damaged air sacs). The damage is permanent but progression can be slowed by quitting smoking.',
        level3:
          'COPD involves chronic airway inflammation, mucus hypersecretion, and alveolar destruction (emphysema). Airflow limitation is not fully reversible. FEV1/FVC <0.70 confirms diagnosis.',
        level4:
          'COPD pathophysiology involves neutrophilic airway inflammation, protease-antiprotease imbalance causing alveolar destruction, and small airway fibrosis. Air trapping causes hyperinflation and increased work of breathing.',
        level5:
          'Cigarette smoke activates epithelial cells and alveolar macrophages, releasing chemokines (IL-8, LTB4) recruiting neutrophils. Neutrophil elastase overwhelms alpha-1 antitrypsin, degrading elastin and collagen. Oxidative stress impairs antiprotease function. TGF-beta promotes small airway fibrosis.',
      },
      relatedConditions: ['asthma', 'lung-cancer', 'pulmonary-hypertension'],
      epidemiology: {
        prevalence: '16 million diagnosed in US (many more undiagnosed)',
        demographics: 'Third leading cause of death in US',
      },
      emergencyWarnings: [
        'Severe shortness of breath',
        'Cannot speak in full sentences',
        'Blue lips or fingertips',
        'Confusion or drowsiness',
      ],
    },
  ],

  // Osteoarthritis (abbreviated)
  [
    'osteoarthritis',
    {
      conditionId: 'osteoarthritis',
      name: 'Osteoarthritis',
      aliases: ['OA', 'Degenerative Joint Disease', 'Wear and Tear Arthritis'],
      icdCode: 'M19.90',
      category: 'musculoskeletal',
      subcategory: 'Degenerative Joint Disease',
      description:
        'Most common form of arthritis, characterized by progressive cartilage loss and joint changes',
      pathophysiology: {
        summary:
          'Progressive cartilage degeneration with subchondral bone changes and synovial inflammation',
        mechanisms: [
          {
            name: 'Cartilage Degeneration',
            description: 'Loss of articular cartilage due to mechanical and biological factors',
            systemsInvolved: ['Musculoskeletal'],
            keyMediators: ['MMPs', 'Aggrecanases', 'IL-1', 'TNF'],
            contribution: 'Central feature of OA leading to joint space narrowing',
          },
        ],
        riskFactors: [
          {
            name: 'Age',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Prevalence increases dramatically with age',
          },
          {
            name: 'Obesity',
            type: 'modifiable',
            impact: 'major',
            description: 'Increases mechanical load on weight-bearing joints',
            intervention: 'Weight loss reduces knee OA symptoms',
          },
          {
            name: 'Joint Injury',
            type: 'partially-modifiable',
            impact: 'moderate',
            description: 'Prior trauma increases OA risk',
          },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Joint Pain',
            prevalence: 'very-common',
            description: 'Pain that worsens with activity and improves with rest',
            quality: 'Aching, sometimes sharp with movement',
            location: 'Affected joints - commonly knees, hips, hands, spine',
          },
          {
            name: 'Stiffness',
            prevalence: 'very-common',
            description: 'Morning stiffness lasting <30 minutes',
          },
          {
            name: 'Functional Limitation',
            prevalence: 'common',
            description: 'Difficulty with activities like walking, climbing stairs',
          },
        ],
        physicalFindings: [
          {
            name: 'Crepitus',
            examType: 'Joint Examination',
            description: 'Grinding sensation with joint movement',
            diagnosticValue: 'Suggestive of cartilage loss',
          },
          {
            name: 'Bony Enlargement',
            examType: 'Joint Examination',
            description: 'Osteophytes palpable at joint margins',
            diagnosticValue: 'Specific for OA',
          },
        ],
        imagingFindings: [
          {
            modality: 'X-ray',
            finding: 'Joint space narrowing, osteophytes, subchondral sclerosis',
            significance: 'Diagnostic findings',
            structures: ['Affected joints'],
          },
        ],
      },
      progression: {
        naturalHistory: 'Slowly progressive over years to decades',
        timelineSteps: [
          {
            phaseId: 'early-oa',
            phase: 'early',
            displayName: 'Early OA',
            timeframe: 'Mild symptoms, minimal X-ray changes',
            description: 'Initial cartilage damage with mild symptoms',
            symptoms: ['Intermittent joint aching', 'Minor stiffness'],
            anatomicalChanges: [
              {
                structureId: 'joint-cartilage',
                structureName: 'Articular Cartilage',
                changeType: 'degeneration',
                description: 'Surface fibrillation and softening',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Exercise', 'Weight loss', 'Acetaminophen'],
          },
          {
            phaseId: 'moderate-oa',
            phase: 'established',
            displayName: 'Moderate OA',
            timeframe: 'Clear X-ray changes, regular symptoms',
            description: 'Progressive cartilage loss with frequent symptoms',
            symptoms: ['Regular pain with activity', 'Morning stiffness', 'Reduced mobility'],
            anatomicalChanges: [
              {
                structureId: 'joint-cartilage',
                structureName: 'Articular Cartilage',
                changeType: 'degeneration',
                description: 'Significant cartilage thinning',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 },
                isNewAtPhase: false,
              },
              {
                structureId: 'subchondral-bone',
                structureName: 'Subchondral Bone',
                changeType: 'hypertrophy',
                description: 'Sclerosis and osteophyte formation',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['NSAIDs', 'Physical therapy', 'Injections'],
          },
          {
            phaseId: 'severe-oa',
            phase: 'advanced',
            displayName: 'Severe OA',
            timeframe: 'Bone-on-bone contact',
            description: 'End-stage disease with near-complete cartilage loss',
            symptoms: ['Constant pain', 'Severe functional limitation', 'Deformity'],
            anatomicalChanges: [
              {
                structureId: 'joint-cartilage',
                structureName: 'Articular Cartilage',
                changeType: 'degeneration',
                description: 'Near-complete cartilage loss',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 },
                isNewAtPhase: false,
              },
              {
                structureId: 'subchondral-bone',
                structureName: 'Subchondral Bone',
                changeType: 'degeneration',
                description: 'Bone cysts and deformity',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Joint replacement surgery'],
          },
        ],
        prognosis: 'Variable progression. Some remain stable for years, others progress to joint replacement.',
      },
      complications: [],
      treatmentOptions: [
        {
          treatmentId: 'exercise-oa',
          name: 'Exercise and Physical Therapy',
          modality: 'rehabilitative',
          description: 'Strengthening and low-impact aerobic exercise',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'advanced'],
          goals: ['Reduce pain', 'Improve function', 'Maintain joint mobility'],
          explanations: {
            level1: 'Regular gentle exercise helps reduce pain and keeps your joints moving better.',
            level2:
              'Strengthening the muscles around your joints provides better support and reduces pain. Low-impact activities like swimming and walking are ideal.',
            level3:
              'Exercise is a cornerstone of OA management. Quadriceps strengthening for knee OA reduces pain as effectively as NSAIDs. Aquatic therapy is helpful for those who cannot tolerate land-based exercise.',
            level4:
              'Exercise improves muscle strength, joint stability, and proprioception. The anti-inflammatory effects of muscle contraction may also contribute to pain reduction.',
            level5:
              'Exercise-induced myokine release (IL-6) has anti-inflammatory effects. Mechanical loading promotes cartilage homeostasis through mechanotransduction pathways.',
          },
        },
        {
          treatmentId: 'nsaids-oa',
          name: 'NSAIDs',
          modality: 'pharmacological',
          description: 'Anti-inflammatory pain relievers',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['early', 'established'],
          goals: ['Reduce pain', 'Reduce inflammation'],
          timeToEffect: '1-2 weeks',
          medicationIds: ['ibuprofen', 'naproxen'],
          contraindications: ['Active GI bleeding', 'CKD stage 4-5', 'Uncontrolled HTN'],
          sideEffects: ['GI upset', 'Cardiovascular risk', 'Renal effects'],
          explanations: {
            level1: 'These medications reduce pain and swelling in your joints.',
            level2:
              'NSAIDs like ibuprofen reduce inflammation and pain. They work best for flare-ups but should be used at the lowest effective dose.',
            level3:
              'NSAIDs are more effective than acetaminophen for OA pain, especially with inflammation. Use lowest dose for shortest duration. Topical NSAIDs are safer alternative.',
            level4:
              'COX inhibition reduces prostaglandin synthesis, decreasing inflammation and pain. Topical NSAIDs achieve therapeutic joint concentrations with lower systemic exposure.',
            level5:
              'COX-2 selective inhibitors reduce GI risk but maintain cardiovascular risk. Naproxen may have the most favorable CV profile among NSAIDs.',
          },
        },
        {
          treatmentId: 'joint-replacement',
          name: 'Total Joint Replacement',
          modality: 'surgical',
          description: 'Replacement of damaged joint surfaces with prosthetic components',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: false,
          appropriatePhases: ['advanced'],
          goals: ['Eliminate pain', 'Restore function'],
          timeToEffect: '3-6 months for full recovery',
          explanations: {
            level1: 'Surgery to replace the damaged joint with an artificial one, eliminating pain.',
            level2:
              'Joint replacement is highly effective for end-stage OA when other treatments no longer help. Most people have significant pain relief and improved function.',
            level3:
              'TKA and THA are among the most successful surgeries performed. >90% survivorship at 15 years. Reserved for patients who have failed conservative management.',
            level4:
              'Modern prosthetic designs include bearing surfaces with improved wear characteristics. Patient selection, surgical technique, and rehabilitation protocol all impact outcomes.',
            level5:
              'Polyethylene wear debris drives osteolysis and loosening in older designs. Cross-linked polyethylene and ceramic bearings reduce wear. Bone ingrowth for cementless fixation provides long-term stability.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'joints',
            structureName: 'Affected Joints',
            role: 'primary-site',
            involvement: 'Cartilage degeneration and bone changes',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
        ],
        systemsInvolved: ['Musculoskeletal'],
        recommendedView: 'anterior',
        recommendedLayers: ['musculoskeletal'],
        focusRegion: 'lower-extremity',
      },
      explanations: {
        level1:
          'Osteoarthritis is wear and tear on your joints. The cushioning cartilage wears away, causing pain and stiffness.',
        level2:
          'In osteoarthritis, the protective cartilage that cushions your joints gradually breaks down. This leads to pain, stiffness, and reduced movement. It most commonly affects knees, hips, hands, and spine.',
        level3:
          'OA involves progressive cartilage loss with subchondral bone changes (sclerosis, cysts, osteophytes) and mild synovial inflammation. Mechanical factors (joint malalignment, obesity) and biological factors (aging, genetics) contribute.',
        level4:
          'OA pathophysiology involves chondrocyte dysfunction with imbalance between cartilage synthesis and degradation. MMPs and aggrecanases break down the extracellular matrix. Subchondral bone changes and osteophyte formation reflect attempted repair.',
        level5:
          'Chondrocyte responses to mechanical stress include increased MMP-13 and ADAMTS expression, degrading type II collagen and aggrecan. Subchondral bone thickening alters load distribution. Synovial inflammation (low-grade) releases cytokines perpetuating cartilage damage.',
      },
      epidemiology: {
        prevalence: '32.5 million US adults',
        demographics: 'Most common form of arthritis; increases with age',
      },
      emergencyWarnings: [
        'Sudden severe joint pain with swelling and redness (may indicate infection)',
        'Unable to bear weight',
        'Joint giving way',
      ],
    },
  ],

  // Migraine (abbreviated)
  [
    'migraine',
    {
      conditionId: 'migraine',
      name: 'Migraine',
      aliases: ['Migraine Headache', 'Classic Migraine', 'Migraine with Aura'],
      icdCode: 'G43.909',
      category: 'neurologic',
      subcategory: 'Headache Disorder',
      description:
        'Recurrent headache disorder characterized by moderate to severe pulsating pain, often with nausea and sensitivity to light/sound',
      pathophysiology: {
        summary:
          'Neurovascular disorder involving cortical spreading depression, trigeminal activation, and neurogenic inflammation',
        mechanisms: [
          {
            name: 'Cortical Spreading Depression',
            description: 'Wave of neuronal depolarization causing aura symptoms',
            systemsInvolved: ['Nervous'],
            keyMediators: ['Glutamate', 'Potassium'],
            contribution: 'Triggers aura and activates trigeminal system',
          },
          {
            name: 'Trigeminal Activation',
            description: 'Activation of trigeminal nociceptors around meninges',
            systemsInvolved: ['Nervous'],
            keyMediators: ['CGRP', 'Substance P', 'Serotonin'],
            contribution: 'Produces headache pain and associated symptoms',
          },
        ],
        riskFactors: [
          {
            name: 'Family History',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Strong genetic component',
          },
          {
            name: 'Female Sex',
            type: 'non-modifiable',
            impact: 'major',
            description: '3:1 female predominance',
          },
          {
            name: 'Triggers',
            type: 'modifiable',
            impact: 'moderate',
            description: 'Stress, sleep changes, certain foods, hormones',
            intervention: 'Trigger identification and avoidance',
          },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Headache',
            prevalence: 'very-common',
            description: 'Moderate to severe, often unilateral, pulsating quality',
            location: 'Typically unilateral, may become generalized',
            timing: '4-72 hours duration',
          },
          {
            name: 'Photophobia',
            prevalence: 'very-common',
            description: 'Sensitivity to light',
          },
          {
            name: 'Phonophobia',
            prevalence: 'very-common',
            description: 'Sensitivity to sound',
          },
          {
            name: 'Nausea/Vomiting',
            prevalence: 'common',
            description: 'Often accompanies headache',
          },
        ],
        associatedSymptoms: [
          {
            name: 'Aura',
            prevalence: 'common',
            description: 'Visual, sensory, or speech disturbances preceding headache',
            timing: '5-60 minutes before headache',
          },
        ],
      },
      progression: {
        naturalHistory: 'Episodic disorder that may progress to chronic migraine',
        timelineSteps: [
          {
            phaseId: 'episodic',
            phase: 'established',
            displayName: 'Episodic Migraine',
            timeframe: '<15 headache days/month',
            description: 'Intermittent attacks with normal function between',
            symptoms: ['Periodic attacks', 'Full recovery between'],
            anatomicalChanges: [
              {
                structureId: 'brain',
                structureName: 'Brain',
                changeType: 'dysfunction',
                description: 'Transient neurological changes during attacks',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: true, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Acute treatments (triptans, NSAIDs)', 'Consider prevention if frequent'],
          },
          {
            phaseId: 'chronic',
            phase: 'chronic',
            displayName: 'Chronic Migraine',
            timeframe: '≥15 headache days/month for 3+ months',
            description: 'Frequent attacks with significant disability',
            symptoms: ['Near-daily symptoms', 'Medication overuse common'],
            anatomicalChanges: [
              {
                structureId: 'brain',
                structureName: 'Brain',
                changeType: 'dysfunction',
                description: 'Central sensitization with structural changes',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Preventive medications (CGRP mAbs, etc.)', 'Withdrawal from overused medications'],
          },
        ],
        prognosis: 'Many improve with age, especially women after menopause.',
      },
      complications: [],
      treatmentOptions: [
        {
          treatmentId: 'triptans-migraine',
          name: 'Triptans',
          modality: 'pharmacological',
          description: 'Serotonin receptor agonists for acute migraine',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['established', 'chronic'],
          goals: ['Abort migraine attack', 'Relieve pain within 2 hours'],
          timeToEffect: '30-60 minutes',
          contraindications: ['Cardiovascular disease', 'Uncontrolled hypertension'],
          explanations: {
            level1: 'These medications can stop a migraine headache when it starts.',
            level2:
              'Triptans work by narrowing blood vessels and blocking pain pathways in the brain. They work best if taken early in an attack.',
            level3:
              'Triptans are 5-HT1B/1D agonists that constrict cranial vessels and inhibit trigeminal nociceptor activation. Most effective when taken early. Limit use to <10 days/month to prevent medication overuse.',
            level4:
              '5-HT1B receptors on meningeal vessels cause vasoconstriction. 5-HT1D receptors on trigeminal nerve terminals inhibit CGRP release and reduce neurogenic inflammation.',
            level5:
              'Presynaptic 5-HT1D activation inhibits neuropeptide (CGRP, substance P) release from trigeminal afferents. Central 5-HT1D/1F activation in trigeminal nucleus caudalis reduces central sensitization. Cardiovascular caution due to coronary 5-HT1B receptors.',
          },
        },
        {
          treatmentId: 'cgrp-migraine',
          name: 'CGRP Monoclonal Antibodies',
          modality: 'pharmacological',
          description: 'Preventive therapy targeting CGRP pathway',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established', 'chronic'],
          goals: ['Reduce migraine frequency', 'Reduce migraine days by 50%'],
          timeToEffect: 'Weeks to months',
          explanations: {
            level1: 'Monthly injections that help prevent migraines from happening.',
            level2:
              'CGRP inhibitors are preventive medications that block a chemical involved in migraine. They are given monthly or quarterly by injection.',
            level3:
              'CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) target CGRP or its receptor. Well-tolerated with convenient monthly/quarterly dosing. Effective for both episodic and chronic migraine.',
            level4:
              'CGRP is elevated during migraine attacks and plays a key role in trigeminovascular activation. Blocking CGRP or its receptor prevents these downstream effects without causing vasoconstriction.',
            level5:
              'CGRP released from trigeminal afferents causes vasodilation, mast cell degranulation, and neurogenic inflammation. CGRP receptor antagonism prevents these effects. Unlike triptans, no direct vascular effects make these safe in cardiovascular disease.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'brain',
            structureName: 'Brain',
            role: 'primary-site',
            involvement: 'Cortical and brainstem dysfunction',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'trigeminal-nerve',
            structureName: 'Trigeminal Nerve',
            role: 'primary-site',
            involvement: 'Trigeminal activation produces pain',
            highlightColor: '#ef4444',
            showByDefault: true,
          },
        ],
        systemsInvolved: ['Nervous'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
        focusRegion: 'head',
      },
      explanations: {
        level1:
          'Migraines are severe headaches that can cause throbbing pain, nausea, and sensitivity to light and sound. They can be disabling but are treatable.',
        level2:
          'Migraine is a neurological condition causing intense headaches, often with nausea and sensitivity to light/sound. Some people see visual disturbances (aura) before the headache. Triggers like stress, certain foods, and hormonal changes can set them off.',
        level3:
          'Migraine is a neurovascular disorder involving cortical spreading depression (causing aura), trigeminal nerve activation, and neurogenic inflammation. CGRP plays a central role. Treatment includes acute therapies (triptans) and preventive medications for frequent attacks.',
        level4:
          'Migraine pathophysiology involves genetic susceptibility, cortical hyperexcitability, trigeminovascular system activation with CGRP release, and central sensitization. Modern preventive therapies target the CGRP pathway with excellent efficacy and tolerability.',
        level5:
          'Migraine involves a cascade: cortical spreading depression (K+ and glutamate waves) triggers trigeminal afferent activation via meningeal nociceptors. CGRP release causes vasodilation and neurogenic inflammation. Trigeminal nucleus caudalis sensitization leads to allodynia. Brainstem dysfunction (PAG, LC) modulates descending pain control.',
      },
      epidemiology: {
        prevalence: '12% of adults',
        demographics: '3:1 female predominance; peaks in middle age',
      },
      emergencyWarnings: [
        'Worst headache of life',
        'Headache with fever and stiff neck',
        'New neurological symptoms',
        'Headache after head injury',
      ],
    },
  ],

  // Coronary Artery Disease
  [
    'coronary-artery-disease',
    {
      conditionId: 'coronary-artery-disease',
      name: 'Coronary Artery Disease',
      aliases: ['CAD', 'Coronary Heart Disease', 'Ischemic Heart Disease'],
      icdCode: 'I25.10',
      category: 'cardiovascular',
      subcategory: 'Cardiac',
      description: 'Atherosclerotic plaque buildup in coronary arteries causing reduced blood flow to the heart',
      pathophysiology: {
        summary: 'Atherosclerosis of coronary arteries leads to myocardial ischemia',
        mechanisms: [
          {
            name: 'Atherosclerosis',
            description: 'Lipid deposition and inflammation in arterial walls',
            systemsInvolved: ['Cardiovascular'],
            keyMediators: ['LDL cholesterol', 'Inflammatory cytokines', 'Foam cells'],
            contribution: 'Creates plaques that narrow arteries and may rupture',
          },
        ],
        riskFactors: [
          { name: 'Hyperlipidemia', type: 'modifiable', impact: 'major', description: 'Elevated LDL drives plaque formation', intervention: 'Statins, diet' },
          { name: 'Hypertension', type: 'modifiable', impact: 'major', description: 'Increases shear stress on arteries', intervention: 'BP control' },
          { name: 'Diabetes', type: 'partially-modifiable', impact: 'major', description: 'Accelerates atherosclerosis', intervention: 'Glycemic control' },
          { name: 'Smoking', type: 'modifiable', impact: 'major', description: 'Endothelial damage and inflammation', intervention: 'Cessation' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Angina', prevalence: 'very-common', description: 'Chest pain/pressure with exertion', quality: 'Squeezing, pressure', location: 'Substernal, may radiate to arm/jaw' },
          { name: 'Dyspnea', prevalence: 'common', description: 'Shortness of breath with activity' },
        ],
        labFindings: [
          { testName: 'Lipid Panel', abnormality: 'Elevated LDL', significance: 'Major risk factor' },
          { testName: 'Troponin', abnormality: 'Elevated if MI', significance: 'Indicates myocardial injury' },
        ],
      },
      progression: {
        naturalHistory: 'Progressive plaque buildup; may be stable or present acutely with MI',
        timelineSteps: [
          {
            phaseId: 'subclinical',
            phase: 'preclinical',
            displayName: 'Subclinical Atherosclerosis',
            timeframe: 'Decades',
            description: 'Plaque developing without symptoms',
            symptoms: ['None'],
            anatomicalChanges: [
              { structureId: 'coronary-arteries', structureName: 'Coronary Arteries', changeType: 'inflammation', description: 'Early plaque formation', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Risk factor modification'],
          },
          {
            phaseId: 'stable-cad',
            phase: 'established',
            displayName: 'Stable CAD',
            timeframe: 'Significant stenosis',
            description: 'Stable angina with exertion',
            symptoms: ['Exertional chest pain', 'Predictable pattern'],
            anatomicalChanges: [
              { structureId: 'coronary-arteries', structureName: 'Coronary Arteries', changeType: 'stenosis', description: '>50% stenosis causing ischemia', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Anti-anginal medications', 'Antiplatelet therapy', 'Statins', 'Consider revascularization'],
          },
          {
            phaseId: 'acute-coronary',
            phase: 'acute',
            displayName: 'Acute Coronary Syndrome',
            timeframe: 'Plaque rupture',
            description: 'Unstable angina or myocardial infarction',
            symptoms: ['Rest chest pain', 'Crescendo pattern', 'May be silent in diabetics'],
            anatomicalChanges: [
              { structureId: 'coronary-arteries', structureName: 'Coronary Arteries', changeType: 'ischemia', description: 'Plaque rupture with thrombosis', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: false },
              { structureId: 'heart', structureName: 'Myocardium', changeType: 'ischemia', description: 'Myocardial injury', severity: 'severe', visualIndicator: { color: '#7c3aed', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Emergency revascularization', 'DAPT', 'Intensive medical therapy'],
          },
        ],
        prognosis: 'Variable; aggressive risk factor control improves outcomes',
      },
      complications: [
        { complicationId: 'mi', name: 'Myocardial Infarction', category: 'acute', severity: 'life-threatening', riskLevel: 'high', description: 'Heart attack from complete artery blockage', mechanism: 'Plaque rupture with coronary thrombosis', affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'Myocardial necrosis', highlightColor: '#dc2626' }], warningSymptoms: ['Severe chest pain', 'Shortness of breath', 'Sweating', 'Nausea'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'statin-cad', name: 'Statin Therapy', modality: 'pharmacological', description: 'LDL-lowering therapy', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['preclinical', 'established', 'acute'], goals: ['LDL <70 mg/dL', 'Plaque stabilization'], medicationIds: ['atorvastatin'], explanations: { level1: 'Cholesterol-lowering medication protects your heart.', level2: 'Statins lower LDL cholesterol, which slows plaque buildup and stabilizes existing plaques.', level3: 'High-intensity statins reduce LDL by >50% and have proven mortality benefit in CAD. Pleiotropic effects include plaque stabilization.', level4: 'Statins inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDL receptors. Anti-inflammatory effects reduce plaque vulnerability.', level5: 'Beyond LDL reduction, statins improve endothelial function, reduce inflammation (hsCRP), stabilize plaques by reducing lipid core and matrix metalloproteinase activity.' } },
        { treatmentId: 'antiplatelet-cad', name: 'Antiplatelet Therapy', modality: 'pharmacological', description: 'Aspirin and/or P2Y12 inhibitor', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['established', 'acute'], goals: ['Prevent thrombosis'], medicationIds: ['aspirin'], explanations: { level1: 'Blood thinners prevent clots from forming in your arteries.', level2: 'Aspirin and similar medications prevent platelets from sticking together, reducing the risk of heart attack.', level3: 'Aspirin irreversibly inhibits COX-1, reducing TXA2 production. P2Y12 inhibitors provide additional antiplatelet effect.', level4: 'DAPT (aspirin + P2Y12 inhibitor) is standard after ACS/stent placement. Duration based on ischemic vs bleeding risk balance.', level5: 'Aspirin acetylates COX-1 Ser-530, permanently inhibiting TXA2 synthesis. P2Y12 inhibitors block ADP-mediated platelet activation.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'heart', structureName: 'Heart', role: 'target-organ', involvement: 'Myocardial ischemia', highlightColor: '#dc2626', showByDefault: true },
          { structureId: 'coronary-arteries', structureName: 'Coronary Arteries', role: 'primary-site', involvement: 'Atherosclerotic plaques', highlightColor: '#ef4444', showByDefault: true },
        ],
        systemsInvolved: ['Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1: 'Fatty buildup in the arteries that feed your heart causes reduced blood flow, which can lead to chest pain or heart attacks.',
        level2: 'Coronary artery disease occurs when cholesterol-containing plaques build up in the arteries that supply your heart, reducing blood flow. This can cause chest pain (angina) and may lead to heart attacks.',
        level3: 'CAD is caused by atherosclerosis of the coronary arteries. Risk factors include dyslipidemia, hypertension, diabetes, and smoking. Presentations range from stable angina to acute coronary syndromes.',
        level4: 'Atherosclerotic plaque development involves endothelial dysfunction, lipid accumulation, inflammatory cell recruitment, and fibrous cap formation. Vulnerable plaques with thin caps and large lipid cores are prone to rupture.',
        level5: 'Endothelial injury initiates atherogenesis. Modified LDL triggers foam cell formation via scavenger receptors. Smooth muscle proliferation and matrix deposition create fibrous cap. Plaque rupture exposes tissue factor, triggering coronary thrombosis.',
      },
      relatedConditions: ['hypertension', 'heart-failure', 'hyperlipidemia'],
      epidemiology: { prevalence: '18.2 million US adults', demographics: 'Leading cause of death' },
      emergencyWarnings: ['Chest pain lasting >20 minutes', 'Pain with sweating or nausea', 'New shortness of breath', 'Loss of consciousness'],
    },
  ],

  // Hyperlipidemia
  [
    'hyperlipidemia',
    {
      conditionId: 'hyperlipidemia',
      name: 'Hyperlipidemia',
      aliases: ['High Cholesterol', 'Dyslipidemia', 'Hypercholesterolemia'],
      icdCode: 'E78.5',
      category: 'metabolic',
      subcategory: 'Lipid Disorder',
      description: 'Elevated lipids (cholesterol and/or triglycerides) in the blood increasing cardiovascular risk',
      pathophysiology: {
        summary: 'Elevated LDL promotes atherosclerosis; elevated triglycerides contribute to cardiovascular risk',
        mechanisms: [
          { name: 'LDL Accumulation', description: 'Excess LDL particles deposit in arterial walls', systemsInvolved: ['Cardiovascular', 'Metabolic'], keyMediators: ['LDL', 'Oxidized LDL', 'Inflammatory cells'], contribution: 'Drives atherosclerotic plaque formation' },
        ],
        riskFactors: [
          { name: 'Diet', type: 'modifiable', impact: 'moderate', description: 'High saturated fat intake', intervention: 'Heart-healthy diet' },
          { name: 'Genetics', type: 'non-modifiable', impact: 'major', description: 'Familial hypercholesterolemia' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'Increases triglycerides and LDL', intervention: 'Weight loss' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Asymptomatic', prevalence: 'very-common', description: 'Usually no symptoms until cardiovascular event' },
        ],
        labFindings: [
          { testName: 'LDL Cholesterol', abnormality: '>100 mg/dL (varies by risk)', normalRange: '<100 mg/dL', significance: 'Primary treatment target' },
          { testName: 'HDL Cholesterol', abnormality: '<40 M/<50 F mg/dL', normalRange: '>40 M/>50 F', significance: 'Low HDL increases risk' },
          { testName: 'Triglycerides', abnormality: '>150 mg/dL', normalRange: '<150 mg/dL', significance: 'Independent risk factor' },
        ],
      },
      progression: {
        naturalHistory: 'Silently contributes to atherosclerosis over decades',
        timelineSteps: [
          { phaseId: 'elevated-ldl', phase: 'preclinical', displayName: 'Elevated Lipids', timeframe: 'Ongoing', description: 'Laboratory abnormality without clinical disease', symptoms: ['None'], anatomicalChanges: [{ structureId: 'arteries', structureName: 'Arteries', changeType: 'dysfunction', description: 'Early endothelial dysfunction', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.3 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Lifestyle modification', 'Consider statin'] },
        ],
        prognosis: 'Each 40 mg/dL reduction in LDL reduces major CV events by ~25%',
      },
      complications: [
        { complicationId: 'atherosclerosis', name: 'Atherosclerotic Cardiovascular Disease', category: 'chronic', severity: 'major', riskLevel: 'high', description: 'CAD, stroke, PAD', mechanism: 'LDL deposition in arterial walls', affectedStructures: [{ structureId: 'arteries', structureName: 'Arteries', effect: 'Plaque formation', highlightColor: '#ef4444' }], warningSymptoms: ['Chest pain', 'Stroke symptoms', 'Leg pain with walking'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'statin-lipid', name: 'Statin Therapy', modality: 'pharmacological', description: 'First-line lipid-lowering therapy', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['preclinical'], goals: ['LDL reduction based on CV risk'], medicationIds: ['atorvastatin'], explanations: { level1: 'Medications that lower your cholesterol to protect your heart.', level2: 'Statins are the most effective medications for lowering LDL cholesterol and have been proven to prevent heart attacks and strokes.', level3: 'Statins reduce LDL by 30-50% depending on intensity. Treatment intensity based on 10-year ASCVD risk. LDL goal <70 mg/dL for high-risk patients.', level4: 'HMG-CoA reductase inhibition depletes hepatocyte cholesterol, upregulating LDL receptors and increasing LDL clearance from plasma.', level5: 'Beyond LDL reduction, statins demonstrate pleiotropic effects: improved endothelial function via NO production, anti-inflammatory effects reducing hsCRP, plaque stabilization through reduced MMP activity.' } },
        { treatmentId: 'lifestyle-lipid', name: 'Therapeutic Lifestyle Changes', modality: 'lifestyle', description: 'Diet and exercise', efficacy: 'effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['preclinical'], goals: ['5-15% LDL reduction'], explanations: { level1: 'Healthy eating and exercise can lower your cholesterol.', level2: 'A heart-healthy diet low in saturated fat, combined with regular exercise, can significantly reduce cholesterol levels.', level3: 'TLC includes reducing saturated fat to <7% calories, dietary cholesterol <200mg/day, adding plant stanols/sterols, soluble fiber. Exercise raises HDL.', level4: 'Dietary intervention primarily affects LDL via reduced hepatic cholesterol delivery. Plant stanols compete with cholesterol for absorption.', level5: 'Soluble fiber binds bile acids, increasing fecal excretion and upregulating hepatic LDL receptors for bile acid synthesis. Exercise activates lipoprotein lipase, improving TG clearance.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'arteries', structureName: 'Arteries', role: 'target-organ', involvement: 'Site of atherosclerosis', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'liver', structureName: 'Liver', role: 'primary-site', involvement: 'Cholesterol metabolism', highlightColor: '#f97316', showByDefault: true },
        ],
        systemsInvolved: ['Cardiovascular', 'Metabolic'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1: 'High cholesterol means too much fat in your blood. This can build up in your arteries and cause heart disease over time.',
        level2: 'Hyperlipidemia is when you have too much cholesterol or triglycerides in your blood. LDL (bad cholesterol) contributes to fatty deposits in arteries, while HDL (good cholesterol) helps remove it.',
        level3: 'Dyslipidemia encompasses elevated LDL, low HDL, and/or elevated triglycerides. It is a major modifiable risk factor for ASCVD. Statin therapy is the cornerstone of pharmacologic treatment.',
        level4: 'LDL particles cross the endothelium and are oxidized, triggering inflammatory cascades and foam cell formation. ASCVD risk is determined by cumulative LDL exposure over time (LDL-years).',
        level5: 'ApoB-containing lipoproteins (LDL, VLDL, Lp(a)) are atherogenic. LDL receptor activity determines plasma LDL levels; PCSK9 promotes LDL receptor degradation. Genetic conditions like FH involve LDL receptor mutations.',
      },
      relatedConditions: ['coronary-artery-disease', 'metabolic-syndrome', 'diabetes'],
      epidemiology: { prevalence: '93 million US adults with elevated LDL', demographics: 'Increases with age' },
    },
  ],

  // Asthma
  [
    'asthma',
    {
      conditionId: 'asthma',
      name: 'Asthma',
      aliases: ['Bronchial Asthma', 'Reactive Airway Disease'],
      icdCode: 'J45.909',
      category: 'respiratory',
      subcategory: 'Obstructive Airway Disease',
      description: 'Chronic inflammatory airway disease with reversible bronchoconstriction and airway hyperresponsiveness',
      pathophysiology: {
        summary: 'Chronic airway inflammation leads to bronchoconstriction, mucus production, and airway remodeling',
        mechanisms: [
          { name: 'Airway Inflammation', description: 'Type 2 inflammation with eosinophils and mast cells', systemsInvolved: ['Respiratory', 'Immune'], keyMediators: ['IgE', 'IL-4', 'IL-5', 'IL-13', 'Leukotrienes'], contribution: 'Causes airway hyperresponsiveness and bronchoconstriction' },
          { name: 'Bronchoconstriction', description: 'Smooth muscle contraction narrows airways', systemsInvolved: ['Respiratory'], keyMediators: ['Histamine', 'Acetylcholine', 'Leukotrienes'], contribution: 'Causes acute symptoms' },
        ],
        riskFactors: [
          { name: 'Atopy', type: 'non-modifiable', impact: 'major', description: 'Genetic predisposition to allergic conditions' },
          { name: 'Environmental Allergens', type: 'partially-modifiable', impact: 'moderate', description: 'Dust mites, pollen, mold, pet dander', intervention: 'Allergen avoidance' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'Increases asthma severity', intervention: 'Weight loss' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Wheezing', prevalence: 'very-common', description: 'Musical breathing sound on expiration', timing: 'During exacerbations and with triggers' },
          { name: 'Dyspnea', prevalence: 'very-common', description: 'Shortness of breath', timing: 'Variable, worse at night/early morning' },
          { name: 'Cough', prevalence: 'very-common', description: 'Often dry, worse at night' },
          { name: 'Chest Tightness', prevalence: 'common', description: 'Sensation of constriction' },
        ],
        physicalFindings: [
          { name: 'Wheezes', examType: 'Pulmonary', description: 'Expiratory wheezes on auscultation', diagnosticValue: 'Suggestive but not specific' },
        ],
      },
      progression: {
        naturalHistory: 'Variable course; may improve or persist into adulthood',
        timelineSteps: [
          { phaseId: 'intermittent', phase: 'early', displayName: 'Intermittent Asthma', timeframe: 'Symptoms <2 days/week', description: 'Mild, infrequent symptoms', symptoms: ['Occasional wheeze', 'Rare exacerbations'], anatomicalChanges: [{ structureId: 'lungs', structureName: 'Airways', changeType: 'inflammation', description: 'Intermittent inflammation', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['SABA as needed'] },
          { phaseId: 'persistent', phase: 'established', displayName: 'Persistent Asthma', timeframe: 'Daily symptoms', description: 'Regular symptoms requiring daily controller', symptoms: ['Daily or nightly symptoms', 'Activity limitation'], anatomicalChanges: [{ structureId: 'lungs', structureName: 'Airways', changeType: 'inflammation', description: 'Chronic inflammation with early remodeling', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 }, isNewAtPhase: false }], reversibility: 'partially-reversible', typicalTreatments: ['ICS daily', 'LABA if not controlled'] },
          { phaseId: 'severe', phase: 'advanced', displayName: 'Severe Asthma', timeframe: 'Symptoms throughout day', description: 'Uncontrolled despite high-dose therapy', symptoms: ['Constant symptoms', 'Frequent exacerbations', 'Limited activity'], anatomicalChanges: [{ structureId: 'lungs', structureName: 'Airways', changeType: 'fibrosis', description: 'Significant airway remodeling', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: false }], reversibility: 'partially-reversible', typicalTreatments: ['High-dose ICS/LABA', 'Biologics', 'Oral steroids as needed'] },
        ],
        prognosis: 'Most achieve good control with appropriate therapy. Severe asthma (~5-10%) is difficult to control.',
      },
      complications: [
        { complicationId: 'severe-exacerbation', name: 'Severe Asthma Exacerbation', category: 'acute', severity: 'life-threatening', riskLevel: 'moderate', description: 'Acute severe bronchospasm', mechanism: 'Trigger exposure with severe inflammatory response', affectedStructures: [{ structureId: 'lungs', structureName: 'Lungs', effect: 'Severe bronchoconstriction', highlightColor: '#dc2626' }], warningSymptoms: ['Unable to speak sentences', 'Severe dyspnea', 'Blue lips'], prevention: ['Controller adherence', 'Trigger avoidance', 'Action plan'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'ics-asthma', name: 'Inhaled Corticosteroids', modality: 'pharmacological', description: 'Daily anti-inflammatory controller', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established', 'advanced'], goals: ['Reduce inflammation', 'Prevent exacerbations'], medicationIds: ['fluticasone'], explanations: { level1: 'Daily inhaler that reduces swelling in your airways.', level2: 'Inhaled steroids reduce the inflammation in your airways, making them less likely to react to triggers. They are the most important medications for asthma control.', level3: 'ICS are the cornerstone of persistent asthma management. They reduce airway inflammation, improve symptoms, reduce exacerbations, and may prevent airway remodeling.', level4: 'Corticosteroids suppress multiple inflammatory pathways including cytokine production, eosinophil survival, and mucus secretion. Dose titrated to minimum needed for control.', level5: 'Glucocorticoids translocate to nucleus, activating anti-inflammatory gene transcription (lipocortin-1) and suppressing pro-inflammatory transcription factors (NF-κB, AP-1). Long-term use prevents basement membrane thickening.' } },
        { treatmentId: 'saba-asthma', name: 'Short-Acting Beta Agonists', modality: 'pharmacological', description: 'Rescue inhaler for acute symptoms', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established', 'advanced'], goals: ['Rapid symptom relief'], medicationIds: ['albuterol'], explanations: { level1: 'A rescue inhaler that quickly opens your airways when you have symptoms.', level2: 'Short-acting bronchodilators like albuterol relax the muscles around your airways within minutes, providing quick relief during symptoms or attacks.', level3: 'SABAs are rescue therapy for acute symptoms. Use >2 times/week suggests inadequate control. β2-receptor stimulation relaxes airway smooth muscle.', level4: 'β2-agonists activate adenylyl cyclase, increasing cAMP and promoting smooth muscle relaxation. Onset within 5 minutes, duration 4-6 hours.', level5: 'β2-receptor activation increases cAMP, activating PKA which phosphorylates myosin light chain kinase, reducing its affinity for calcium-calmodulin and promoting bronchodilation.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'lungs', structureName: 'Lungs (Airways)', role: 'primary-site', involvement: 'Inflammation and bronchoconstriction', highlightColor: '#ef4444', showByDefault: true },
        ],
        systemsInvolved: ['Respiratory'],
        recommendedView: 'anterior',
        recommendedLayers: ['respiratory'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1: 'Asthma makes your airways swollen and sensitive. Triggers like allergens or exercise cause them to narrow, making it hard to breathe.',
        level2: 'Asthma is a chronic condition where your airways become inflamed and narrow in response to triggers. This causes wheezing, coughing, and shortness of breath. Daily controller inhalers reduce inflammation, while rescue inhalers provide quick relief.',
        level3: 'Asthma is characterized by reversible airway obstruction, airway hyperresponsiveness, and chronic inflammation. Type 2 inflammation predominates with eosinophilic infiltration. Treatment is stepwise based on control.',
        level4: 'Asthma pathophysiology involves allergen-triggered IgE-mediated mast cell degranulation (early phase) and subsequent eosinophilic inflammation (late phase). Airway remodeling includes smooth muscle hypertrophy and subepithelial fibrosis.',
        level5: 'Type 2 high asthma involves Th2 cells, ILC2s, and eosinophils driven by IL-4, IL-5, IL-13. TSLP, IL-25, IL-33 initiate the response. Type 2 low asthma is neutrophilic or paucigranulocytic. Biologics target specific cytokines (anti-IL-5, anti-IL-4R, anti-IgE).',
      },
      relatedConditions: ['copd', 'seasonal-allergies'],
      epidemiology: { prevalence: '25 million US adults', demographics: 'Often begins in childhood' },
      emergencyWarnings: ['Cannot speak full sentences', 'Blue lips or fingernails', 'No improvement with rescue inhaler', 'Drowsiness or confusion', 'Peak flow <50% personal best'],
    },
  ],

  // Osteoporosis
  [
    'osteoporosis',
    {
      conditionId: 'osteoporosis',
      name: 'Osteoporosis',
      aliases: ['Brittle Bone Disease', 'Low Bone Density'],
      icdCode: 'M81.0',
      category: 'musculoskeletal',
      subcategory: 'Metabolic Bone Disease',
      description: 'Skeletal disorder characterized by low bone mass and microarchitectural deterioration, increasing fracture risk',
      pathophysiology: {
        summary: 'Imbalance between bone resorption and formation leads to decreased bone density and structural weakness',
        mechanisms: [
          { name: 'Increased Resorption', description: 'Osteoclast activity exceeds osteoblast bone formation', systemsInvolved: ['Musculoskeletal', 'Endocrine'], keyMediators: ['RANKL', 'Estrogen deficiency', 'PTH'], contribution: 'Net bone loss over time' },
        ],
        riskFactors: [
          { name: 'Postmenopausal Status', type: 'non-modifiable', impact: 'major', description: 'Estrogen loss accelerates bone resorption' },
          { name: 'Age', type: 'non-modifiable', impact: 'major', description: 'Bone loss accelerates with age' },
          { name: 'Low Calcium/Vitamin D', type: 'modifiable', impact: 'moderate', description: 'Necessary for bone health', intervention: 'Supplementation' },
          { name: 'Sedentary Lifestyle', type: 'modifiable', impact: 'moderate', description: 'Weight-bearing exercise maintains bone', intervention: 'Exercise' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Often Asymptomatic', prevalence: 'very-common', description: 'Silent until fracture occurs' },
          { name: 'Fracture', prevalence: 'common', description: 'Hip, spine, or wrist fracture from minimal trauma', location: 'Hip, vertebrae, distal radius' },
          { name: 'Height Loss', prevalence: 'common', description: 'From vertebral compression fractures' },
        ],
        imagingFindings: [
          { modality: 'DEXA Scan', finding: 'T-score ≤-2.5', significance: 'Diagnostic criterion', structures: ['Spine', 'Hip'] },
        ],
      },
      progression: {
        naturalHistory: 'Progressive bone loss without treatment',
        timelineSteps: [
          { phaseId: 'osteopenia', phase: 'early', displayName: 'Osteopenia', timeframe: 'T-score -1.0 to -2.5', description: 'Low bone mass not yet meeting osteoporosis criteria', symptoms: ['Usually none'], anatomicalChanges: [{ structureId: 'skeleton', structureName: 'Bones', changeType: 'atrophy', description: 'Decreased bone density', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 }, isNewAtPhase: true }], reversibility: 'partially-reversible', typicalTreatments: ['Calcium, vitamin D', 'Weight-bearing exercise', 'Consider medication if high risk'] },
          { phaseId: 'osteoporosis', phase: 'established', displayName: 'Osteoporosis', timeframe: 'T-score ≤-2.5', description: 'Significantly low bone mass', symptoms: ['High fracture risk', 'May have back pain from compression fractures'], anatomicalChanges: [{ structureId: 'skeleton', structureName: 'Bones', changeType: 'atrophy', description: 'Significant bone loss', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: false }], reversibility: 'partially-reversible', typicalTreatments: ['Bisphosphonates', 'Calcium/vitamin D', 'Fall prevention'] },
          { phaseId: 'severe-osteoporosis', phase: 'advanced', displayName: 'Severe Osteoporosis', timeframe: 'T-score ≤-2.5 with fracture', description: 'Osteoporosis with fragility fracture(s)', symptoms: ['History of fracture', 'Chronic pain', 'Disability'], anatomicalChanges: [{ structureId: 'skeleton', structureName: 'Bones', changeType: 'structural-damage', description: 'Fractures present', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: false }], reversibility: 'partially-reversible', typicalTreatments: ['Anabolic therapy (teriparatide)', 'Followed by bisphosphonate'] },
        ],
        prognosis: 'Treatment reduces fracture risk by 50-70%. Hip fracture carries high mortality.',
      },
      complications: [
        { complicationId: 'hip-fracture', name: 'Hip Fracture', category: 'acute', severity: 'major', riskLevel: 'high', description: 'Fracture of proximal femur', mechanism: 'Bone fragility from osteoporosis', affectedStructures: [{ structureId: 'hip', structureName: 'Hip', effect: 'Fracture requiring surgery', highlightColor: '#dc2626' }], warningSymptoms: ['Fall followed by hip pain', 'Unable to bear weight'], prevention: ['Treatment', 'Fall prevention'], preventable: true },
        { complicationId: 'vertebral-fracture', name: 'Vertebral Compression Fracture', category: 'acute', severity: 'moderate', riskLevel: 'high', description: 'Collapse of vertebral body', mechanism: 'Minimal trauma to weakened bone', affectedStructures: [{ structureId: 'spine', structureName: 'Spine', effect: 'Vertebral compression', highlightColor: '#ef4444' }], warningSymptoms: ['Acute back pain', 'Height loss', 'Kyphosis'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'bisphosphonate', name: 'Bisphosphonates', modality: 'pharmacological', description: 'First-line antiresorptive therapy', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established', 'advanced'], goals: ['Reduce fracture risk', 'Maintain/improve BMD'], timeToEffect: '6-12 months for fracture reduction', contraindications: ['Esophageal abnormalities', 'Inability to remain upright'], sideEffects: ['GI upset', 'Osteonecrosis of jaw (rare)', 'Atypical femur fracture (rare)'], explanations: { level1: 'Medications that slow bone loss and reduce fracture risk.', level2: 'Bisphosphonates like alendronate slow down the cells that break down bone, allowing your bones to become stronger over time.', level3: 'Bisphosphonates inhibit osteoclast function, reducing bone resorption. They reduce hip and vertebral fractures by 40-70%. Treatment holiday considered after 3-5 years.', level4: 'Bisphosphonates incorporate into bone matrix and are released during resorption, inducing osteoclast apoptosis. Long skeletal half-life allows drug holiday.', level5: 'Nitrogen-containing bisphosphonates inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, preventing prenylation of GTPases essential for osteoclast function, inducing apoptosis.' } },
        { treatmentId: 'calcium-vitd', name: 'Calcium and Vitamin D', modality: 'supportive', description: 'Essential supplements for bone health', efficacy: 'moderately-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established', 'advanced'], goals: ['Achieve adequate calcium/vitamin D', 'Optimize treatment efficacy'], explanations: { level1: 'Calcium and vitamin D supplements help keep your bones strong.', level2: 'Calcium is the main mineral in bones, and vitamin D helps your body absorb it. Most adults need 1000-1200mg calcium and 800-2000 IU vitamin D daily.', level3: 'Calcium 1000-1200mg/day and vitamin D 800-2000 IU/day are recommended for patients with osteoporosis. Vitamin D levels should be >30 ng/mL for optimal absorption.', level4: 'Adequate calcium maintains calcium-phosphate homeostasis without triggering PTH-mediated bone resorption. Vitamin D promotes intestinal calcium absorption via calbindin expression.', level5: 'Vitamin D undergoes 25-hydroxylation in liver and 1α-hydroxylation in kidney to form calcitriol. Calcitriol binds VDR, inducing TRPV6 and calbindin expression for calcium absorption.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'skeleton', structureName: 'Skeleton', role: 'primary-site', involvement: 'Decreased bone density throughout', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'spine', structureName: 'Spine', role: 'target-organ', involvement: 'Common fracture site', highlightColor: '#dc2626', showByDefault: true },
          { structureId: 'hip', structureName: 'Hip', role: 'target-organ', involvement: 'Common fracture site', highlightColor: '#dc2626', showByDefault: true },
        ],
        systemsInvolved: ['Musculoskeletal'],
        recommendedView: 'anterior',
        recommendedLayers: ['musculoskeletal'],
        focusRegion: 'spine',
      },
      explanations: {
        level1: 'Osteoporosis makes your bones weak and fragile, so they can break easily from a minor fall or bump.',
        level2: 'Osteoporosis is a condition where bones become thin and weak. It often has no symptoms until a fracture occurs. Treatment with medications, calcium, vitamin D, and exercise can strengthen bones and prevent fractures.',
        level3: 'Osteoporosis is defined by T-score ≤-2.5 on DEXA scan. It results from imbalanced bone remodeling with excess resorption. Common fracture sites are hip, spine, and wrist. Bisphosphonates are first-line therapy.',
        level4: 'Bone remodeling involves coupled osteoclast (resorption) and osteoblast (formation) activity. Estrogen deficiency increases RANKL expression, promoting osteoclast differentiation. Treatment targets include resorption inhibition or formation stimulation.',
        level5: 'RANKL-RANK signaling activates NFATc1, the master transcription factor for osteoclast differentiation. OPG acts as decoy receptor. Estrogen suppresses osteoclast formation via OPG upregulation and osteoclast apoptosis. Sclerostin, produced by osteocytes, inhibits Wnt signaling and bone formation.',
      },
      relatedConditions: ['vitamin-d-deficiency', 'menopause'],
      epidemiology: { prevalence: '10 million US adults with osteoporosis', demographics: '80% are women' },
      emergencyWarnings: ['Fall with inability to bear weight', 'Sudden severe back pain', 'Visible deformity after minor trauma'],
    },
  ],

  // Rheumatoid Arthritis
  [
    'rheumatoid-arthritis',
    {
      conditionId: 'rheumatoid-arthritis',
      name: 'Rheumatoid Arthritis',
      aliases: ['RA'],
      icdCode: 'M06.9',
      category: 'musculoskeletal',
      subcategory: 'Autoimmune/Inflammatory',
      description: 'Chronic autoimmune inflammatory disease primarily affecting joints, causing progressive joint destruction',
      pathophysiology: {
        summary: 'Autoimmune inflammation of synovium leads to joint destruction',
        mechanisms: [
          { name: 'Autoimmune Synovitis', description: 'Immune cells infiltrate and inflame the joint lining', systemsInvolved: ['Musculoskeletal', 'Immune'], keyMediators: ['TNF-α', 'IL-6', 'IL-1', 'Autoantibodies (RF, anti-CCP)'], contribution: 'Drives joint inflammation and damage' },
          { name: 'Pannus Formation', description: 'Inflamed synovium grows over cartilage', systemsInvolved: ['Musculoskeletal'], contribution: 'Erodes cartilage and bone' },
        ],
        riskFactors: [
          { name: 'Genetic (HLA-DR4)', type: 'non-modifiable', impact: 'major', description: 'Strong genetic association' },
          { name: 'Female Sex', type: 'non-modifiable', impact: 'moderate', description: '3:1 female predominance' },
          { name: 'Smoking', type: 'modifiable', impact: 'major', description: 'Increases risk and severity', intervention: 'Cessation' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Joint Pain and Swelling', prevalence: 'very-common', description: 'Symmetric polyarthritis', location: 'Small joints (hands, feet) initially', timing: 'Worse in morning with prolonged stiffness' },
          { name: 'Morning Stiffness', prevalence: 'very-common', description: 'Lasting >1 hour', timing: 'Characteristic of inflammatory arthritis' },
          { name: 'Fatigue', prevalence: 'very-common', description: 'Systemic inflammation causes fatigue' },
        ],
        labFindings: [
          { testName: 'Rheumatoid Factor', abnormality: 'Positive in ~70%', significance: 'Diagnostic but not specific' },
          { testName: 'Anti-CCP Antibodies', abnormality: 'Positive in ~70%', significance: 'Highly specific for RA' },
          { testName: 'CRP/ESR', abnormality: 'Elevated', significance: 'Reflects inflammation' },
        ],
      },
      progression: {
        naturalHistory: 'Progressive joint destruction if untreated',
        timelineSteps: [
          { phaseId: 'early-ra', phase: 'early', displayName: 'Early RA', timeframe: 'Symptoms <6 months', description: 'Early inflammatory phase', symptoms: ['Joint pain', 'Swelling', 'Morning stiffness'], anatomicalChanges: [{ structureId: 'joints', structureName: 'Synovium', changeType: 'inflammation', description: 'Synovial inflammation', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Start DMARD (methotrexate)', 'Bridge with steroids'] },
          { phaseId: 'established-ra', phase: 'established', displayName: 'Established RA', timeframe: 'Ongoing disease', description: 'Ongoing inflammation with developing damage', symptoms: ['Persistent polyarthritis', 'Deformities developing'], anatomicalChanges: [{ structureId: 'joints', structureName: 'Joints', changeType: 'degeneration', description: 'Erosions and cartilage loss', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: false }], reversibility: 'partially-reversible', typicalTreatments: ['DMARD combinations', 'Consider biologics'] },
          { phaseId: 'advanced-ra', phase: 'advanced', displayName: 'Advanced RA', timeframe: 'Long-standing disease', description: 'Significant joint destruction and deformity', symptoms: ['Deformities', 'Functional impairment', 'Extra-articular manifestations'], anatomicalChanges: [{ structureId: 'joints', structureName: 'Joints', changeType: 'structural-damage', description: 'Severe erosions and deformity', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: false }], reversibility: 'irreversible', typicalTreatments: ['Biologics', 'Joint replacement if needed'] },
        ],
        prognosis: 'Early aggressive treatment prevents joint damage. Modern biologics have improved outcomes significantly.',
      },
      complications: [],
      treatmentOptions: [
        { treatmentId: 'methotrexate-ra', name: 'Methotrexate', modality: 'pharmacological', description: 'First-line DMARD for RA', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established'], goals: ['Remission or low disease activity', 'Prevent joint damage'], timeToEffect: '6-12 weeks', contraindications: ['Pregnancy', 'Significant liver disease'], sideEffects: ['Nausea', 'Mouth sores', 'Liver toxicity', 'Bone marrow suppression'], monitoring: ['CBC', 'LFTs', 'Creatinine'], explanations: { level1: 'A medication that slows down your overactive immune system to reduce joint inflammation.', level2: 'Methotrexate is the most commonly used medication for RA. It reduces immune system activity, decreasing joint inflammation and preventing damage.', level3: 'Methotrexate is the anchor DMARD in RA. Start within 3 months of diagnosis ("window of opportunity"). Doses for RA (7.5-25mg weekly) are much lower than cancer chemotherapy.', level4: 'At RA doses, methotrexate acts through adenosine release (anti-inflammatory) rather than antifolate effects. Used in combination strategies with biologics.', level5: 'Methotrexate polyglutamates accumulate in cells, inhibiting AICAR transformylase and increasing adenosine release. Adenosine A2A receptor activation suppresses inflammatory cytokine production.' } },
        { treatmentId: 'biologics-ra', name: 'Biologic DMARDs', modality: 'pharmacological', description: 'Targeted immune therapy (TNF inhibitors, IL-6 inhibitors, etc.)', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: false, appropriatePhases: ['early', 'established', 'advanced'], goals: ['Remission when methotrexate insufficient'], explanations: { level1: 'Newer injectable medications that target specific parts of your immune system causing joint damage.', level2: 'Biologic medications like TNF inhibitors target the specific immune chemicals causing joint inflammation. They are often added if methotrexate alone is not controlling your disease.', level3: 'TNF inhibitors (adalimumab, etanercept), IL-6 inhibitors (tocilizumab), and other biologics are highly effective. Used after inadequate response to methotrexate or in combination.', level4: 'TNF-α is a key cytokine driving RA synovitis and bone erosion. TNF inhibitors neutralize soluble and transmembrane TNF. IL-6 drives systemic inflammation and acute phase response.', level5: 'TNF signals through TNFR1 (ubiquitous) and TNFR2 (immune cells), activating NF-κB and MAPK pathways. TNF inhibitors reduce osteoclast activation via RANKL and protect against erosive damage.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'joints', structureName: 'Small Joints (Hands, Feet)', role: 'primary-site', involvement: 'Symmetric inflammatory arthritis', highlightColor: '#dc2626', showByDefault: true },
        ],
        systemsInvolved: ['Musculoskeletal', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['musculoskeletal'],
        focusRegion: 'upper-extremity',
      },
      explanations: {
        level1: 'Rheumatoid arthritis is when your immune system attacks your joints by mistake, causing pain, swelling, and eventually damage.',
        level2: 'RA is an autoimmune disease where your immune system mistakenly attacks your joint lining, causing inflammation. Without treatment, this leads to permanent joint damage. Modern medications can prevent this damage.',
        level3: 'RA is a chronic autoimmune disease causing symmetric inflammatory polyarthritis. Early treatment with DMARDs (especially methotrexate) is critical to prevent erosive joint damage. Treat-to-target strategies aim for remission.',
        level4: 'RA involves autoantibody production (RF, anti-CCP), synovial inflammation with pannus formation, and bone/cartilage destruction via osteoclast activation (RANKL pathway) and matrix metalloproteinases.',
        level5: 'Citrullination of self-proteins (via PAD enzymes) generates neoantigens recognized by anti-CCP antibodies. Immune complexes deposit in synovium, activating complement and recruiting inflammatory cells. Fibroblast-like synoviocytes proliferate, producing MMPs that degrade cartilage matrix.',
      },
      relatedConditions: ['osteoarthritis'],
      epidemiology: { prevalence: '1.3 million US adults', demographics: 'Women 3x more common; typical onset 30-50 years' },
      emergencyWarnings: ['Severe joint pain with fever', 'Red hot swollen joint (may be septic arthritis)'],
    },
  ],

  // Peripheral Neuropathy
  [
    'peripheral-neuropathy',
    {
      conditionId: 'peripheral-neuropathy',
      name: 'Peripheral Neuropathy',
      aliases: ['Neuropathy', 'Polyneuropathy'],
      icdCode: 'G62.9',
      category: 'neurologic',
      subcategory: 'Peripheral Nerve Disorder',
      description: 'Damage to peripheral nerves causing weakness, numbness, and pain, typically in hands and feet',
      pathophysiology: {
        summary: 'Nerve fiber damage from various causes leads to sensory, motor, and autonomic dysfunction',
        mechanisms: [
          { name: 'Axonal Degeneration', description: 'Damage to the nerve fiber itself', systemsInvolved: ['Nervous'], contribution: 'Most common mechanism; length-dependent ("stocking-glove" pattern)' },
          { name: 'Demyelination', description: 'Damage to the myelin sheath', systemsInvolved: ['Nervous'], contribution: 'Slows nerve conduction; seen in inflammatory neuropathies' },
        ],
        riskFactors: [
          { name: 'Diabetes', type: 'modifiable', impact: 'major', description: 'Most common cause; hyperglycemia damages nerves', intervention: 'Glycemic control' },
          { name: 'Alcohol', type: 'modifiable', impact: 'moderate', description: 'Direct toxic effect and nutritional deficiency', intervention: 'Cessation' },
          { name: 'B12 Deficiency', type: 'modifiable', impact: 'moderate', description: 'Necessary for nerve health', intervention: 'Supplementation' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Numbness/Tingling', prevalence: 'very-common', description: 'Starts in feet and spreads proximally', location: 'Distal extremities - stocking-glove distribution' },
          { name: 'Burning Pain', prevalence: 'common', description: 'Neuropathic pain often worse at night' },
          { name: 'Weakness', prevalence: 'common', description: 'Distal weakness affects foot dorsiflexion first' },
        ],
        physicalFindings: [
          { name: 'Decreased Sensation', examType: 'Neurological', description: 'Reduced pin, vibration, or light touch sensation distally', diagnosticValue: 'Confirms sensory neuropathy' },
          { name: 'Absent Ankle Reflexes', examType: 'Neurological', description: 'Often first reflex lost', diagnosticValue: 'Supports neuropathy diagnosis' },
        ],
      },
      progression: {
        naturalHistory: 'Progressive if underlying cause not addressed',
        timelineSteps: [
          { phaseId: 'early-neuropathy', phase: 'early', displayName: 'Early Neuropathy', timeframe: 'Symptoms in feet', description: 'Sensory symptoms in distal feet', symptoms: ['Numbness in toes', 'Tingling', 'Mild discomfort'], anatomicalChanges: [{ structureId: 'peripheral-nerves', structureName: 'Distal Sensory Nerves', changeType: 'degeneration', description: 'Early axonal loss', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 }, isNewAtPhase: true }], reversibility: 'partially-reversible', typicalTreatments: ['Treat underlying cause', 'Pain management'] },
          { phaseId: 'moderate-neuropathy', phase: 'established', displayName: 'Moderate Neuropathy', timeframe: 'Symptoms ascending', description: 'Symptoms spreading proximally, affecting function', symptoms: ['Numbness to mid-calf', 'Hand involvement beginning', 'Balance problems'], anatomicalChanges: [{ structureId: 'peripheral-nerves', structureName: 'Peripheral Nerves', changeType: 'degeneration', description: 'Progressive axonal degeneration', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: false }], reversibility: 'partially-reversible', typicalTreatments: ['Aggressive cause management', 'Neuropathic pain medications', 'Fall prevention'] },
          { phaseId: 'severe-neuropathy', phase: 'advanced', displayName: 'Severe Neuropathy', timeframe: 'Extensive involvement', description: 'Significant sensory loss and weakness', symptoms: ['Sensory loss to knees/elbows', 'Weakness', 'Foot ulcers if diabetic'], anatomicalChanges: [{ structureId: 'peripheral-nerves', structureName: 'Peripheral Nerves', changeType: 'degeneration', description: 'Severe axonal loss with disability', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.7 }, isNewAtPhase: false }], reversibility: 'irreversible', typicalTreatments: ['Symptomatic management', 'Adaptive devices', 'Wound care if ulcers'] },
        ],
        prognosis: 'Depends on cause. Diabetic neuropathy progresses but can stabilize with glycemic control.',
      },
      complications: [
        { complicationId: 'foot-ulcer', name: 'Diabetic Foot Ulcer', category: 'chronic', severity: 'major', riskLevel: 'high', description: 'Ulceration from unrecognized trauma', mechanism: 'Sensory loss leads to unnoticed injury', affectedStructures: [{ structureId: 'feet', structureName: 'Feet', effect: 'Ulceration', highlightColor: '#dc2626' }], warningSymptoms: ['Often painless', 'Skin breakdown', 'Infection'], prevention: ['Daily foot inspection', 'Proper footwear'], preventable: true },
        { complicationId: 'falls', name: 'Falls', category: 'acute', severity: 'moderate', riskLevel: 'high', description: 'Falls due to sensory loss and weakness', mechanism: 'Impaired proprioception and balance', affectedStructures: [], warningSymptoms: ['Unsteady gait', 'Previous falls'], prevention: ['Balance exercises', 'Assistive devices', 'Home safety'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'treat-cause', name: 'Treat Underlying Cause', modality: 'supportive', description: 'Address diabetes, B12 deficiency, alcohol, etc.', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established'], goals: ['Prevent progression', 'Allow nerve recovery'], explanations: { level1: 'Treating the cause of your nerve damage is the most important step.', level2: 'Finding and treating what is causing your neuropathy - like controlling blood sugar in diabetes - is essential to prevent it from getting worse.', level3: 'Identify and treat reversible causes: glycemic control for diabetic neuropathy, B12 supplementation, alcohol cessation. Some neuropathies (inflammatory) require immunotherapy.', level4: 'Tight glycemic control (HbA1c <7%) slows progression of diabetic neuropathy. Inflammatory/demyelinating neuropathies may respond to IVIG or steroids.', level5: 'In diabetic neuropathy, hyperglycemia drives polyol pathway activation (sorbitol accumulation), AGE formation, oxidative stress, and microvascular damage. Normalizing glucose reduces these metabolic insults.' } },
        { treatmentId: 'neuropathic-pain', name: 'Neuropathic Pain Medications', modality: 'pharmacological', description: 'Gabapentin, pregabalin, duloxetine, or TCAs', efficacy: 'effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established', 'advanced'], goals: ['Pain relief'], explanations: { level1: 'Medications that calm overactive nerves and reduce pain.', level2: 'Special medications that work on nerve pain include gabapentin, pregabalin, and certain antidepressants. They work differently than regular pain relievers.', level3: 'First-line agents: gabapentinoids (gabapentin, pregabalin), SNRIs (duloxetine), TCAs (amitriptyline). ~50% of patients achieve 50% pain reduction.', level4: 'Gabapentinoids bind α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. SNRIs enhance descending pain inhibition via norepinephrine and serotonin.', level5: 'Central sensitization in neuropathic pain involves NMDA receptor activation and increased excitability. Gabapentinoids reduce presynaptic calcium influx and glutamate release. TCAs block sodium channels and inhibit norepinephrine/serotonin reuptake.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'peripheral-nerves', structureName: 'Peripheral Nerves', role: 'primary-site', involvement: 'Axonal degeneration', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'feet', structureName: 'Feet', role: 'target-organ', involvement: 'Most affected (longest nerves)', highlightColor: '#f97316', showByDefault: true },
        ],
        systemsInvolved: ['Nervous'],
        recommendedView: 'anterior',
        recommendedLayers: ['nervous'],
        focusRegion: 'lower-extremity',
      },
      explanations: {
        level1: 'Peripheral neuropathy means the nerves in your hands and feet are damaged, causing numbness, tingling, or pain.',
        level2: 'Neuropathy is nerve damage that usually starts in the feet and can spread upward. Common causes include diabetes, vitamin deficiencies, and alcohol. Treatment focuses on the underlying cause and managing symptoms.',
        level3: 'Peripheral neuropathy presents with length-dependent sensory symptoms (stocking-glove distribution), neuropathic pain, and eventual weakness. Workup includes EMG/NCS, metabolic panel, B12, TSH. Diabetic neuropathy is most common.',
        level4: 'Axonal neuropathies show reduced amplitudes on NCS with length-dependent fiber loss. Demyelinating neuropathies show slowed conduction velocities. Small fiber neuropathy may have normal NCS and requires skin biopsy.',
        level5: 'Diabetic neuropathy involves metabolic (polyol, PKC, AGE), vascular (microangiopathy, ischemia), and inflammatory mechanisms. Dying-back axonopathy affects longest fibers first. Small fibers (pain, autonomic) may be affected before large fibers (vibration, proprioception).',
      },
      relatedConditions: ['type-2-diabetes', 'vitamin-deficiency'],
      epidemiology: { prevalence: '3% of general population; >50% of diabetics', demographics: 'Increases with age and diabetes duration' },
      emergencyWarnings: ['Sudden onset with weakness (may be Guillain-Barré)', 'Progressive weakness ascending rapidly', 'Autonomic symptoms (blood pressure changes, urinary retention)'],
    },
  ],

  // ============================================
  // METABOLIC CONDITIONS (continued)
  // ============================================

  // Metabolic Syndrome
  [
    'metabolic-syndrome',
    {
      conditionId: 'metabolic-syndrome',
      name: 'Metabolic Syndrome',
      aliases: ['Syndrome X', 'Insulin Resistance Syndrome', 'Dysmetabolic Syndrome'],
      icdCode: 'E88.81',
      category: 'metabolic',
      subcategory: 'Metabolic',
      description: 'Cluster of metabolic abnormalities including central obesity, insulin resistance, dyslipidemia, and hypertension that dramatically increases cardiovascular disease risk',
      pathophysiology: {
        summary: 'Interconnected metabolic derangements driven by insulin resistance and central adiposity, creating a pro-inflammatory and pro-thrombotic state',
        mechanisms: [
          {
            name: 'Insulin Resistance',
            description: 'Reduced cellular response to insulin leads to compensatory hyperinsulinemia',
            systemsInvolved: ['Endocrine', 'Metabolic', 'Cardiovascular'],
            keyMediators: ['Insulin', 'Free Fatty Acids', 'Adipokines'],
            contribution: 'Central driver linking obesity to metabolic abnormalities',
          },
          {
            name: 'Visceral Adiposity',
            description: 'Excess abdominal fat releases inflammatory cytokines and free fatty acids',
            systemsInvolved: ['Metabolic', 'Cardiovascular'],
            keyMediators: ['TNF-α', 'IL-6', 'Leptin', 'Adiponectin (decreased)'],
            contribution: 'Creates chronic low-grade inflammation and metabolic dysfunction',
          },
          {
            name: 'Dyslipidemia Pattern',
            description: 'Elevated triglycerides, low HDL, and small dense LDL particles',
            systemsInvolved: ['Cardiovascular', 'Metabolic'],
            keyMediators: ['VLDL', 'Apolipoprotein B'],
            contribution: 'Highly atherogenic lipid profile accelerates cardiovascular disease',
          },
        ],
        riskFactors: [
          { name: 'Central Obesity', type: 'modifiable', impact: 'major', description: 'Waist circumference >40 inches (men) or >35 inches (women)', intervention: 'Weight loss, especially visceral fat reduction' },
          { name: 'Sedentary Lifestyle', type: 'modifiable', impact: 'major', description: 'Physical inactivity worsens insulin resistance', intervention: '150+ minutes moderate exercise weekly' },
          { name: 'Genetics', type: 'non-modifiable', impact: 'moderate', description: 'Family history of diabetes and cardiovascular disease' },
          { name: 'Diet', type: 'modifiable', impact: 'major', description: 'High refined carbohydrate and saturated fat intake', intervention: 'Mediterranean or DASH diet' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Central Obesity', prevalence: 'very-common', description: 'Increased waist circumference, "apple-shaped" body', location: 'Abdomen' },
          { name: 'Often Asymptomatic', prevalence: 'very-common', description: 'Many components are silent until complications occur' },
        ],
        associatedSymptoms: [
          { name: 'Fatigue', prevalence: 'common', description: 'May relate to blood sugar fluctuations' },
          { name: 'Acanthosis Nigricans', prevalence: 'common', description: 'Dark, velvety skin patches in body folds indicating insulin resistance' },
        ],
        labFindings: [
          { testName: 'Fasting Glucose', abnormality: '≥100 mg/dL (impaired)', normalRange: '<100 mg/dL', significance: 'Indicates insulin resistance/prediabetes' },
          { testName: 'Triglycerides', abnormality: '≥150 mg/dL', normalRange: '<150 mg/dL', significance: 'Part of atherogenic dyslipidemia' },
          { testName: 'HDL Cholesterol', abnormality: '<40 mg/dL (men) or <50 mg/dL (women)', significance: 'Low protective cholesterol' },
          { testName: 'Blood Pressure', abnormality: '≥130/85 mmHg', significance: 'Contributes to cardiovascular risk' },
        ],
      },
      progression: {
        naturalHistory: 'Without intervention, metabolic syndrome typically progresses to type 2 diabetes and accelerated atherosclerotic cardiovascular disease',
        timelineSteps: [
          { phaseId: 'early-metsyn', phase: 'early', displayName: 'Early Metabolic Dysfunction', timeframe: '1-2 criteria met', description: 'Developing insulin resistance with some metabolic abnormalities', symptoms: ['Weight gain', 'Mild fatigue'], anatomicalChanges: [{ structureId: 'adipose-tissue', structureName: 'Visceral Fat', changeType: 'hypertrophy', description: 'Increasing visceral adiposity', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Lifestyle modification'], goalsOfCare: ['Prevent progression to full syndrome'] },
          { phaseId: 'established-metsyn', phase: 'established', displayName: 'Metabolic Syndrome', timeframe: '3+ criteria met', description: 'Full metabolic syndrome with significantly elevated cardiovascular risk', symptoms: ['Central obesity', 'Possibly asymptomatic'], anatomicalChanges: [{ structureId: 'adipose-tissue', structureName: 'Visceral Fat', changeType: 'hypertrophy', description: 'Significant visceral adiposity', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.5 }, isNewAtPhase: false }, { structureId: 'arteries', structureName: 'Arteries', changeType: 'dysfunction', description: 'Endothelial dysfunction developing', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Intensive lifestyle', 'Consider pharmacotherapy for components'] },
          { phaseId: 'complications', phase: 'advanced', displayName: 'Complications Developing', timeframe: 'Years without intervention', description: 'Progression to diabetes and/or cardiovascular disease', symptoms: ['Diabetes symptoms', 'Cardiovascular symptoms'], anatomicalChanges: [{ structureId: 'pancreas', structureName: 'Pancreas', changeType: 'dysfunction', description: 'Beta cell exhaustion', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.5 }, isNewAtPhase: true }, { structureId: 'arteries', structureName: 'Arteries', changeType: 'structural-damage', description: 'Atherosclerotic plaque formation', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.6 }, isNewAtPhase: false }], reversibility: 'partially-reversible', typicalTreatments: ['Treat diabetes', 'Cardiovascular risk reduction'] },
        ],
        prognosis: 'With aggressive lifestyle intervention, metabolic syndrome can often be reversed. Without treatment, 5-10 year risk of developing diabetes is ~30% and cardiovascular disease risk is doubled.',
      },
      complications: [
        { complicationId: 'metsyn-diabetes', name: 'Type 2 Diabetes', category: 'chronic', severity: 'major', riskLevel: 'high', description: 'Progression to frank diabetes', mechanism: 'Beta cell exhaustion from chronic insulin resistance', affectedStructures: [{ structureId: 'pancreas', structureName: 'Pancreas', effect: 'Beta cell failure', highlightColor: '#dc2626' }], warningSymptoms: ['Increasing fasting glucose', 'Polyuria', 'Polydipsia'], prevention: ['Weight loss', 'Exercise', 'Metformin in high-risk'], preventable: true },
        { complicationId: 'metsyn-cvd', name: 'Cardiovascular Disease', category: 'chronic', severity: 'major', riskLevel: 'high', description: 'Accelerated atherosclerosis', mechanism: 'Atherogenic dyslipidemia, inflammation, and endothelial dysfunction', affectedStructures: [{ structureId: 'coronary-arteries', structureName: 'Coronary Arteries', effect: 'Atherosclerosis', highlightColor: '#dc2626' }], warningSymptoms: ['Chest pain', 'Dyspnea'], prevention: ['Lipid management', 'Blood pressure control', 'Lifestyle changes'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'metsyn-lifestyle', name: 'Intensive Lifestyle Modification', modality: 'lifestyle', description: 'Weight loss, exercise, and dietary changes targeting all metabolic abnormalities', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established'], goals: ['7-10% weight loss', 'Reverse metabolic abnormalities', 'Prevent diabetes and CVD'], expectedOutcomes: ['Improved insulin sensitivity', 'Better lipid profile', 'Lower blood pressure'], timeToEffect: 'Weeks to months', explanations: { level1: 'Losing weight and exercising regularly can reverse metabolic syndrome.', level2: 'Lifestyle changes are the most effective treatment. Losing 7-10% of body weight through diet and exercise can dramatically improve all the metabolic abnormalities.', level3: 'Intensive lifestyle intervention (caloric restriction for 7-10% weight loss + 150 min/week moderate exercise) can resolve metabolic syndrome in 30-50% of patients and reduces diabetes incidence by 58%.', level4: 'Lifestyle intervention improves insulin sensitivity both directly (exercise-mediated GLUT4 translocation) and through weight loss (reduced adipokine dysregulation). Visceral fat reduction is particularly impactful.', level5: 'Exercise increases AMP kinase activity, enhancing glucose uptake independent of insulin. Weight loss reduces IL-6, TNF-α, and leptin while increasing adiponectin, reversing the pro-inflammatory state. Improved endothelial function follows decreased oxidative stress.' } },
        { treatmentId: 'metsyn-metformin', name: 'Metformin', modality: 'pharmacological', description: 'Insulin sensitizer for prediabetes/diabetes prevention', efficacy: 'effective', evidenceLevel: 'level-1b', isFirstLine: false, appropriatePhases: ['established', 'advanced'], goals: ['Improve insulin sensitivity', 'Prevent diabetes'], medicationIds: ['metformin'], explanations: { level1: 'A medication that helps your body use insulin better and can prevent diabetes.', level2: 'Metformin is a medication that helps your body respond better to insulin. It is often used to prevent or delay type 2 diabetes in people with metabolic syndrome.', level3: 'Metformin reduces diabetes incidence by ~30% in high-risk individuals. Also provides modest weight loss and may have cardiovascular benefits independent of glucose lowering.', level4: 'Metformin activates AMPK, suppresses hepatic glucose output, improves peripheral insulin sensitivity. Consider in metabolic syndrome patients with prediabetes, especially if lifestyle alone insufficient.', level5: 'Metformin inhibits mitochondrial complex I, increasing AMP:ATP ratio and activating AMPK. This suppresses gluconeogenesis, enhances fatty acid oxidation, and improves insulin signaling. May also act through gut microbiome alterations.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'adipose-tissue', structureName: 'Visceral Adipose Tissue', role: 'primary-site', involvement: 'Central driver of metabolic dysfunction', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'liver', structureName: 'Liver', role: 'target-organ', involvement: 'Insulin resistance, fatty liver', highlightColor: '#f97316', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'pancreas', structureName: 'Pancreas', role: 'target-organ', involvement: 'Compensatory hyperinsulinemia', highlightColor: '#eab308', showByDefault: false },
          { structureId: 'arteries', structureName: 'Arteries', role: 'target-organ', involvement: 'Endothelial dysfunction', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Endocrine', 'Cardiovascular', 'Metabolic'],
        recommendedView: 'anterior',
        recommendedLayers: ['organs', 'cardiovascular'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: 'Metabolic syndrome means having a combination of health problems - extra belly fat, high blood sugar, high blood pressure, and abnormal cholesterol - that together put you at much higher risk for heart disease and diabetes.',
        level2: 'Metabolic syndrome is when you have at least three of these problems together: large waist size, high triglycerides, low good cholesterol, high blood pressure, or high fasting blood sugar. Having these together is worse than having them separately because they multiply your risk.',
        level3: 'Metabolic syndrome is diagnosed by having ≥3 of 5 criteria: waist >40"(M)/35"(F), TG ≥150, HDL <40(M)/<50(F), BP ≥130/85, fasting glucose ≥100. It confers 2x CVD risk and 5x diabetes risk. First-line treatment is lifestyle modification.',
        level4: 'Metabolic syndrome represents a pro-inflammatory, pro-thrombotic state driven by insulin resistance and visceral adiposity. The atherogenic dyslipidemia (high TG, low HDL, small dense LDL) and hyperglycemia synergistically accelerate atherosclerosis. Pathophysiologically linked by FFA flux, adipokine dysregulation, and hepatic VLDL overproduction.',
        level5: 'Visceral adipocytes release FFA (promoting hepatic insulin resistance and VLDL synthesis), inflammatory cytokines (IL-6, TNF-α reducing insulin receptor signaling), and exhibit reduced adiponectin (losing its anti-inflammatory and insulin-sensitizing effects). This creates systemic insulin resistance, atherogenic dyslipidemia, and a hypercoagulable state (elevated PAI-1, fibrinogen). The liver becomes a nexus of pathology: insulin resistance leads to both impaired glucose suppression and increased VLDL output.',
      },
      relatedConditions: ['type-2-diabetes', 'hypertension', 'hyperlipidemia', 'coronary-artery-disease'],
      comorbidities: ['Non-alcoholic fatty liver disease', 'Polycystic ovary syndrome', 'Sleep apnea'],
      epidemiology: { prevalence: '~35% of US adults', demographics: 'Increases with age; varies by ethnicity' },
      clinicalPearls: ['Waist circumference is often the most clinically useful screening measure', 'Lifestyle intervention can resolve metabolic syndrome in up to 50% of patients', 'Consider early metformin if lifestyle changes insufficient'],
      emergencyWarnings: ['Chest pain (possible MI)', 'Sudden neurological symptoms (possible stroke)', 'Severely elevated blood pressure'],
    },
  ],

  // ============================================
  // NEUROLOGIC CONDITIONS (continued)
  // ============================================

  // Stroke (Ischemic)
  [
    'stroke',
    {
      conditionId: 'stroke',
      name: 'Ischemic Stroke',
      aliases: ['Stroke', 'CVA', 'Cerebrovascular Accident', 'Brain Attack'],
      icdCode: 'I63.9',
      category: 'neurologic',
      subcategory: 'Cerebrovascular',
      description: 'Acute interruption of blood flow to the brain causing neurological deficits; a medical emergency requiring immediate intervention',
      pathophysiology: {
        summary: 'Occlusion of a cerebral artery (by thrombus or embolus) deprives brain tissue of oxygen and glucose, leading to ischemia and infarction within minutes to hours',
        mechanisms: [
          {
            name: 'Large Vessel Atherothrombosis',
            description: 'Atherosclerotic plaque in large arteries (carotid, MCA) ruptures causing thrombosis',
            systemsInvolved: ['Cardiovascular', 'Nervous'],
            keyMediators: ['Platelets', 'Thrombin', 'Fibrin'],
            contribution: 'Accounts for ~20-25% of ischemic strokes',
          },
          {
            name: 'Cardioembolism',
            description: 'Blood clot forms in heart (atrial fibrillation, valve disease) and travels to brain',
            systemsInvolved: ['Cardiovascular', 'Nervous'],
            keyMediators: ['Thrombus', 'Emboli'],
            contribution: 'Accounts for ~20-30% of ischemic strokes; often larger, more disabling',
          },
          {
            name: 'Small Vessel Disease (Lacunar)',
            description: 'Lipohyalinosis of small penetrating arteries from hypertension',
            systemsInvolved: ['Cardiovascular', 'Nervous'],
            keyMediators: ['Fibrinoid necrosis'],
            contribution: 'Accounts for ~25% of strokes; smaller, deeper infarcts',
          },
          {
            name: 'Ischemic Cascade',
            description: 'Glutamate excitotoxicity, calcium influx, and free radicals cause neuronal death',
            systemsInvolved: ['Nervous'],
            keyMediators: ['Glutamate', 'Calcium', 'Reactive Oxygen Species'],
            contribution: 'Core infarct expands into penumbra without reperfusion',
          },
        ],
        riskFactors: [
          { name: 'Hypertension', type: 'modifiable', impact: 'major', description: 'Most important modifiable risk factor', intervention: 'Blood pressure control (<130/80)' },
          { name: 'Atrial Fibrillation', type: 'modifiable', impact: 'major', description: '5x increased stroke risk without anticoagulation', intervention: 'Anticoagulation (DOACs, warfarin)' },
          { name: 'Diabetes', type: 'partially-modifiable', impact: 'moderate', description: '2-4x increased risk', intervention: 'Glycemic control' },
          { name: 'Hyperlipidemia', type: 'modifiable', impact: 'moderate', description: 'Atherosclerosis acceleration', intervention: 'Statin therapy' },
          { name: 'Smoking', type: 'modifiable', impact: 'moderate', description: 'Doubles stroke risk', intervention: 'Smoking cessation' },
          { name: 'Prior Stroke/TIA', type: 'non-modifiable', impact: 'major', description: '10-15% annual recurrence without treatment' },
        ],
        geneticFactors: ['CADASIL (rare hereditary)', 'Sickle cell disease', 'Family history increases risk 2x'],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Sudden Weakness', prevalence: 'very-common', description: 'Unilateral weakness of face, arm, and/or leg', location: 'Contralateral to lesion', timing: 'Sudden onset' },
          { name: 'Speech Difficulty', prevalence: 'very-common', description: 'Aphasia (dominant hemisphere) or dysarthria', timing: 'Sudden onset' },
          { name: 'Facial Droop', prevalence: 'very-common', description: 'Asymmetric facial weakness', location: 'Contralateral lower face', timing: 'Sudden onset' },
        ],
        associatedSymptoms: [
          { name: 'Vision Changes', prevalence: 'common', description: 'Homonymous hemianopia or monocular vision loss' },
          { name: 'Sensory Loss', prevalence: 'common', description: 'Numbness on affected side' },
          { name: 'Ataxia', prevalence: 'uncommon', description: 'Coordination problems (posterior circulation)' },
          { name: 'Severe Headache', prevalence: 'uncommon', description: 'More common in hemorrhagic stroke, but can occur' },
        ],
        physicalFindings: [
          { name: 'NIHSS Score', examType: 'Neurological', description: 'Standardized stroke severity scale (0-42)', diagnosticValue: 'Guides treatment decisions and prognosis' },
          { name: 'Pronator Drift', examType: 'Motor', description: 'Weak arm drifts down and pronates', diagnosticValue: 'Sensitive for mild hemiparesis' },
        ],
        imagingFindings: [
          { modality: 'CT Head', finding: 'Initially normal, then hypodensity evolves over 6-24 hours', significance: 'Rules out hemorrhage; early ischemic changes may be subtle', structures: ['Brain parenchyma'] },
          { modality: 'MRI DWI', finding: 'Restricted diffusion (bright) within minutes', significance: 'Most sensitive for acute ischemia', structures: ['Brain parenchyma'] },
          { modality: 'CT/MR Angiography', finding: 'Vessel occlusion or stenosis', significance: 'Identifies target for thrombectomy', structures: ['Cerebral arteries'] },
        ],
      },
      progression: {
        naturalHistory: 'Without treatment, stroke progresses over hours as ischemic penumbra is recruited into infarct core. Recovery depends on infarct location and size.',
        typicalOnsetToDiagnosis: 'Minutes to hours (time-critical emergency)',
        timelineSteps: [
          { phaseId: 'hyperacute', phase: 'acute', displayName: 'Hyperacute Phase', timeframe: '0-6 hours', description: 'Critical window for reperfusion therapy', symptoms: ['Sudden neurological deficit', 'BE FAST symptoms'], anatomicalChanges: [{ structureId: 'cerebral-artery', structureName: 'Cerebral Artery', changeType: 'stenosis', description: 'Arterial occlusion', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: true }, { structureId: 'brain', structureName: 'Brain', changeType: 'ischemia', description: 'Ischemic penumbra surrounding core', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['IV tPA if <4.5 hours', 'Mechanical thrombectomy if LVO'], goalsOfCare: ['REPERFUSION - Time is brain'] },
          { phaseId: 'acute', phase: 'acute', displayName: 'Acute Phase', timeframe: '6-72 hours', description: 'Infarct evolution, monitoring for complications', symptoms: ['Stable or evolving deficit', 'Risk of brain swelling'], anatomicalChanges: [{ structureId: 'brain', structureName: 'Brain', changeType: 'necrosis', description: 'Infarct core established', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.7 }, isNewAtPhase: false }, { structureId: 'brain', structureName: 'Brain', changeType: 'edema', description: 'Cytotoxic edema develops', severity: 'moderate', visualIndicator: { color: '#06b6d4', pulse: false, opacity: 0.5 }, isNewAtPhase: true }], reversibility: 'irreversible', typicalTreatments: ['Secondary prevention initiated', 'Swallowing evaluation', 'Monitor for hemorrhagic transformation'] },
          { phaseId: 'subacute', phase: 'subacute', displayName: 'Subacute Phase', timeframe: '3 days - 3 months', description: 'Recovery and rehabilitation period', symptoms: ['Some recovery begins', 'Residual deficits become clearer'], anatomicalChanges: [{ structureId: 'brain', structureName: 'Brain', changeType: 'atrophy', description: 'Gliosis replacing infarcted tissue', severity: 'moderate', visualIndicator: { color: '#71717a', pulse: false, opacity: 0.5 }, isNewAtPhase: true }], reversibility: 'partially-reversible', typicalTreatments: ['Intensive rehabilitation', 'Secondary prevention medications'] },
          { phaseId: 'chronic', phase: 'chronic', displayName: 'Chronic Phase', timeframe: '>3 months', description: 'Long-term adaptation and secondary prevention', symptoms: ['Stable residual deficit', 'Ongoing secondary prevention'], anatomicalChanges: [{ structureId: 'brain', structureName: 'Brain', changeType: 'atrophy', description: 'Encephalomalacia (permanent tissue loss)', severity: 'moderate', visualIndicator: { color: '#78716c', pulse: false, opacity: 0.5 }, isNewAtPhase: false }], reversibility: 'irreversible', typicalTreatments: ['Lifelong secondary prevention', 'Adaptive strategies'] },
        ],
        prognosis: 'Variable based on stroke size, location, and time to treatment. ~30% full recovery, ~30% minor disability, ~30% major disability, ~10% mortality at 30 days.',
        outcomes: '50% of patients regain functional independence; early reperfusion dramatically improves outcomes',
      },
      complications: [
        { complicationId: 'hemorrhagic-transformation', name: 'Hemorrhagic Transformation', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Bleeding into infarcted tissue', mechanism: 'Reperfusion injury and damaged blood-brain barrier', affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Hemorrhage into infarct', highlightColor: '#7f1d1d' }], warningSymptoms: ['Sudden neurological worsening', 'Decreasing consciousness'], treatment: 'Supportive; reverse anticoagulation if applicable', timing: '24-48 hours post-stroke', preventable: false },
        { complicationId: 'cerebral-edema', name: 'Malignant Cerebral Edema', category: 'acute', severity: 'life-threatening', riskLevel: 'moderate', description: 'Life-threatening brain swelling with large MCA strokes', mechanism: 'Cytotoxic edema in large infarcts', affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Mass effect and herniation risk', highlightColor: '#dc2626' }], warningSymptoms: ['Declining consciousness', 'New pupil asymmetry'], treatment: 'Decompressive craniectomy in select patients', timing: '2-5 days post-stroke', preventable: false },
        { complicationId: 'stroke-recurrence', name: 'Recurrent Stroke', category: 'chronic', severity: 'major', riskLevel: 'high', description: 'Another stroke without adequate secondary prevention', mechanism: 'Ongoing vascular risk factors', affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'New infarct', highlightColor: '#dc2626' }], warningSymptoms: ['New sudden neurological symptoms'], prevention: ['Antiplatelet/anticoagulation', 'Statin', 'BP control', 'Lifestyle changes'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'tpa', name: 'IV Thrombolysis (tPA/Alteplase)', modality: 'interventional', description: 'Clot-dissolving medication given intravenously within 4.5 hours', mechanism: 'Activates plasminogen to lyse fibrin clot', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute'], goals: ['Restore blood flow', 'Reduce disability'], expectedOutcomes: ['NNT ~7 for improved outcome'], timeToEffect: 'Minutes', contraindications: ['Recent surgery', 'Active bleeding', 'INR >1.7', 'Severe hypertension'], sideEffects: ['Bleeding (6% symptomatic ICH)', 'Angioedema'], explanations: { level1: 'A clot-busting medication given through an IV that can dissolve the blood clot causing your stroke. Must be given within a few hours.', level2: 'tPA is a powerful clot-dissolving medicine. When given quickly after stroke starts (within 4.5 hours), it can dissolve the clot and restore blood flow to save brain tissue. The main risk is bleeding.', level3: 'IV alteplase (0.9 mg/kg, max 90 mg) given within 4.5 hours of symptom onset. Strict inclusion/exclusion criteria. NNT ~7 for improved 3-month outcome. 6% risk of symptomatic intracranial hemorrhage.', level4: 'tPA converts plasminogen to plasmin, degrading fibrin. Door-to-needle time target <60 minutes. NIHSS improvement in first 24 hours predicts good outcome. Screen carefully for contraindications using standardized checklist.', level5: 'Alteplase is a recombinant tissue plasminogen activator with fibrin-specific binding. Therapeutic window based on NINDS, ECASS-III trials. Extended 4.5-hour window with additional exclusions (age >80, severe stroke, diabetes + prior stroke, anticoagulant use). Consider tenecteplase as single-bolus alternative.' } },
        { treatmentId: 'thrombectomy', name: 'Mechanical Thrombectomy', modality: 'surgical', description: 'Catheter-based clot removal for large vessel occlusions', mechanism: 'Mechanical retrieval of clot using stent retriever or aspiration', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute'], goals: ['Remove large clot', 'Restore perfusion'], expectedOutcomes: ['NNT ~3-4 for reduced disability'], timeToEffect: 'Minutes after recanalization', contraindications: ['Small vessel occlusion', 'Large established infarct core', 'Poor baseline function'], explanations: { level1: 'A procedure where doctors thread a thin tube into your brain arteries to physically remove the blood clot.', level2: 'For strokes caused by a clot in a large brain artery, doctors can go in with a catheter and grab the clot to pull it out. This can dramatically improve outcomes, even up to 24 hours in selected patients.', level3: 'Mechanical thrombectomy for LVO (ICA, M1, +/- M2) up to 24 hours in select patients. Based on DAWN/DEFUSE-3 criteria (favorable imaging). NNT ~3-4. Can be done in addition to IV tPA.', level4: 'Endovascular therapy via femoral access. Stent retrievers (Solitaire, Trevo) or aspiration (ADAPT). TICI 2b/3 reperfusion goal. Extended window patients selected by CT perfusion mismatch or DWI-FLAIR mismatch.', level5: 'Seven landmark RCTs (MR CLEAN, ESCAPE, EXTEND-IA, SWIFT-PRIME, REVASCAT, DAWN, DEFUSE-3) established efficacy. Key is patient selection: proximal LVO, small core (ASPECTS ≥6 or core <70mL), and salvageable penumbra. Collateral circulation status influences outcomes.' } },
        { treatmentId: 'secondary-prevention', name: 'Secondary Prevention', modality: 'preventive', description: 'Medications and lifestyle changes to prevent recurrent stroke', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['subacute', 'chronic'], goals: ['Prevent recurrent stroke', 'Reduce cardiovascular events'], medicationIds: ['aspirin', 'clopidogrel', 'atorvastatin'], explanations: { level1: 'Medications and healthy changes to prevent another stroke.', level2: 'After a stroke, taking medications like aspirin and a statin, controlling blood pressure, and making healthy lifestyle changes are essential to prevent it from happening again.', level3: 'Antiplatelet (aspirin +/- clopidogrel for 21-90 days, then monotherapy) or anticoagulation if AFib. High-intensity statin. BP goal <130/80. Address all modifiable risk factors.', level4: 'DAPT (aspirin + clopidogrel) for 21-90 days after minor stroke/TIA per POINT/CHANCE trials. Long-term monotherapy thereafter. Anticoagulation for AFib (CHA2DS2-VASc guided). Target LDL <70 with high-intensity statin.', level5: 'Risk factor management is synergistic. SPARCL trial showed high-dose atorvastatin 80mg reduces recurrent stroke 16%. PROGRESS trial demonstrated BP lowering effective regardless of baseline. Carotid revascularization (CEA/CAS) if symptomatic 50-99% stenosis.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'brain', structureName: 'Brain', role: 'target-organ', involvement: 'Ischemic infarction', highlightColor: '#dc2626', showByDefault: true },
          { structureId: 'cerebral-arteries', structureName: 'Cerebral Arteries', role: 'primary-site', involvement: 'Occlusion site', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'heart', structureName: 'Heart', role: 'secondary-site', involvement: 'Cardioembolic source in AFib', highlightColor: '#f97316', showByDefault: false },
          { structureId: 'carotid-arteries', structureName: 'Carotid Arteries', role: 'secondary-site', involvement: 'Atherosclerotic source', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Nervous', 'Cardiovascular'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous', 'cardiovascular'],
        focusRegion: 'head',
      },
      explanations: {
        level1: 'A stroke happens when blood flow to part of your brain is blocked, causing brain cells to die. It is an emergency - getting treatment fast can save your life and prevent disability.',
        level2: 'An ischemic stroke occurs when a blood clot blocks an artery supplying the brain. The blocked area of brain starts to die within minutes. Acting FAST (Face drooping, Arm weakness, Speech difficulty, Time to call 911) and getting to a hospital quickly can allow doctors to dissolve or remove the clot and save brain tissue.',
        level3: 'Ischemic stroke results from arterial occlusion (thrombotic, embolic, or lacunar). The ischemic penumbra is salvageable tissue surrounding the infarct core. Treatment is IV tPA within 4.5 hours and/or mechanical thrombectomy for large vessel occlusion up to 24 hours. Secondary prevention is critical.',
        level4: 'Stroke subtypes (TOAST classification): large artery atherosclerosis, cardioembolism, small vessel disease, other/undetermined. Workup includes brain imaging (CT/MRI), vascular imaging (CTA/MRA), cardiac evaluation (echo, telemetry). Treatment decisions based on NIHSS, imaging (ASPECTS, perfusion), time from last known well.',
        level5: 'The ischemic cascade involves glutamate-mediated excitotoxicity, calcium overload, mitochondrial dysfunction, and free radical generation expanding the infarct into the penumbra. Collateral circulation (assessed by multiphase CTA or perfusion imaging) determines penumbral viability. Modern endovascular therapy achieves TICI 2b/3 recanalization in >80% of cases. Tissue-based selection (DAWN, DEFUSE-3) extends window to 24 hours using perfusion mismatch or DWI-FLAIR mismatch.',
      },
      relatedConditions: ['hypertension', 'atrial-fibrillation', 'hyperlipidemia', 'type-2-diabetes', 'coronary-artery-disease'],
      comorbidities: ['Atrial fibrillation', 'Carotid stenosis', 'Heart failure'],
      epidemiology: { prevalence: '~7 million stroke survivors in US', incidence: '~795,000 strokes per year in US', demographics: 'Risk doubles each decade after 55; higher in Black and Hispanic populations' },
      clinicalPearls: ['Time is brain - every minute of ischemia kills ~1.9 million neurons', 'BE FAST: Balance, Eyes, Face, Arms, Speech, Time', 'Thrombectomy NNT of ~3 is one of the most powerful interventions in medicine', 'Dont forget to screen for AFib - it changes management'],
      patientEducation: ['Know the signs: sudden weakness, trouble speaking, vision changes, severe headache', 'Call 911 immediately - do not drive yourself', 'Note the time symptoms started - this affects treatment options', 'Take prevention medications as prescribed - they save lives'],
      emergencyWarnings: ['Any sudden neurological symptoms - call 911 immediately', 'This is a true medical emergency', 'Do not wait to see if symptoms improve'],
    },
  ],

  // ============================================
  // GASTROINTESTINAL CONDITIONS
  // ============================================

  // GERD
  [
    'gerd',
    {
      conditionId: 'gerd',
      name: 'Gastroesophageal Reflux Disease',
      aliases: ['GERD', 'Acid Reflux', 'Heartburn Disease'],
      icdCode: 'K21.0',
      category: 'gastrointestinal',
      subcategory: 'Esophageal',
      description: 'Chronic condition where stomach acid frequently flows back into the esophagus, causing symptoms and potential esophageal damage',
      pathophysiology: {
        summary: 'Reflux of gastric contents into the esophagus due to lower esophageal sphincter dysfunction and/or hiatal hernia',
        mechanisms: [
          { name: 'LES Dysfunction', description: 'Lower esophageal sphincter relaxes inappropriately or has reduced tone', systemsInvolved: ['Gastrointestinal'], keyMediators: ['Nitric oxide', 'VIP'], contribution: 'Primary mechanism allowing reflux' },
          { name: 'Hiatal Hernia', description: 'Stomach herniates through diaphragm, disrupting anti-reflux barrier', systemsInvolved: ['Gastrointestinal', 'Musculoskeletal'], contribution: 'Impairs LES function and esophageal acid clearance' },
        ],
        riskFactors: [
          { name: 'Obesity', type: 'modifiable', impact: 'major', description: 'Increases intra-abdominal pressure', intervention: 'Weight loss' },
          { name: 'Smoking', type: 'modifiable', impact: 'moderate', description: 'Reduces LES pressure', intervention: 'Smoking cessation' },
          { name: 'Diet', type: 'modifiable', impact: 'moderate', description: 'Certain foods trigger reflux', intervention: 'Avoid triggers: caffeine, alcohol, fatty foods, chocolate' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Heartburn', prevalence: 'very-common', description: 'Burning sensation behind sternum', location: 'Retrosternal', timing: 'After meals, when lying down' },
          { name: 'Regurgitation', prevalence: 'common', description: 'Sour or bitter taste from stomach contents reaching mouth', timing: 'After meals' },
        ],
        associatedSymptoms: [
          { name: 'Dysphagia', prevalence: 'uncommon', description: 'Difficulty swallowing', timing: 'With stricture development' },
          { name: 'Chronic Cough', prevalence: 'common', description: 'From microaspiration or vagal reflex', timing: 'Nocturnal' },
        ],
        labFindings: [{ testName: 'Upper Endoscopy', abnormality: 'Erosive esophagitis, Barrett esophagus', significance: 'Confirms diagnosis, assesses severity' }],
      },
      progression: {
        naturalHistory: 'Chronic relapsing condition that can progress to complications including stricture and Barrett esophagus',
        timelineSteps: [
          { phaseId: 'nerd', phase: 'early', displayName: 'Non-Erosive Reflux', timeframe: 'Initial presentation', description: 'Symptoms without visible esophageal damage', symptoms: ['Heartburn', 'Regurgitation'], anatomicalChanges: [{ structureId: 'esophagus', structureName: 'Esophagus', changeType: 'dysfunction', description: 'Functional abnormality without visible damage', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Lifestyle modification', 'Antacids', 'H2 blockers'] },
          { phaseId: 'erosive', phase: 'established', displayName: 'Erosive Esophagitis', timeframe: 'Months to years', description: 'Visible mucosal breaks on endoscopy', symptoms: ['Worsening heartburn', 'Odynophagia'], anatomicalChanges: [{ structureId: 'esophagus', structureName: 'Esophageal Mucosa', changeType: 'inflammation', description: 'Erosions and ulcerations', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['PPI therapy'] },
          { phaseId: 'barretts', phase: 'advanced', displayName: 'Barrett Esophagus', timeframe: 'Years of untreated GERD', description: 'Intestinal metaplasia of esophageal epithelium', symptoms: ['May be asymptomatic', 'Dysphagia'], anatomicalChanges: [{ structureId: 'esophagus', structureName: 'Distal Esophagus', changeType: 'structural-damage', description: 'Metaplastic columnar epithelium', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: true }], reversibility: 'irreversible', typicalTreatments: ['PPI', 'Surveillance endoscopy', 'Ablation if dysplasia'] },
        ],
        prognosis: 'Most patients well-controlled with PPIs. Barrett esophagus carries 0.5%/year risk of esophageal adenocarcinoma.',
      },
      complications: [
        { complicationId: 'barretts', name: 'Barrett Esophagus', category: 'chronic', severity: 'major', riskLevel: 'moderate', description: 'Precancerous metaplasia', mechanism: 'Chronic acid exposure causes columnar metaplasia', affectedStructures: [{ structureId: 'esophagus', structureName: 'Distal Esophagus', effect: 'Metaplasia', highlightColor: '#dc2626' }], warningSymptoms: ['May be asymptomatic'], prevention: ['PPI therapy', 'Weight loss'], preventable: true },
        { complicationId: 'stricture', name: 'Esophageal Stricture', category: 'chronic', severity: 'moderate', riskLevel: 'low', description: 'Narrowing from scarring', mechanism: 'Repeated mucosal injury leads to fibrosis', affectedStructures: [{ structureId: 'esophagus', structureName: 'Esophagus', effect: 'Fibrotic narrowing', highlightColor: '#78716c' }], warningSymptoms: ['Progressive dysphagia', 'Food impaction'], prevention: ['Acid suppression'], treatment: 'Endoscopic dilation', preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'ppi-gerd', name: 'Proton Pump Inhibitors', modality: 'pharmacological', description: 'Suppress acid production', mechanism: 'Irreversibly inhibit H+/K+-ATPase', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established', 'advanced'], goals: ['Symptom relief', 'Mucosal healing'], medicationIds: ['omeprazole', 'pantoprazole'], sideEffects: ['Headache', 'C. diff risk with prolonged use'], explanations: { level1: 'These pills greatly reduce stomach acid to let your esophagus heal.', level2: 'PPIs like omeprazole block acid production in the stomach, allowing the esophagus to heal and preventing symptoms.', level3: 'PPIs irreversibly inhibit the proton pump in parietal cells. Most effective when taken 30-60 minutes before meals. Achieve >90% symptom relief in erosive esophagitis.', level4: 'PPIs are prodrugs activated in acidic environment of parietal cell canaliculus. Duration of action exceeds plasma half-life due to irreversible binding. Tachyphylaxis does not occur.', level5: 'Covalent binding to cysteine residues of H+/K+-ATPase alpha subunit. New pump synthesis required for acid secretion to resume. CYP2C19 polymorphisms affect metabolism - poor metabolizers may need lower doses.' } },
        { treatmentId: 'lifestyle-gerd', name: 'Lifestyle Modification', modality: 'lifestyle', description: 'Diet and behavioral changes', efficacy: 'moderately-effective', evidenceLevel: 'level-2b', isFirstLine: true, appropriatePhases: ['preclinical', 'early', 'established'], goals: ['Reduce reflux episodes'], expectedOutcomes: ['Symptom improvement'], explanations: { level1: 'Avoid foods that cause heartburn, dont eat before bed, and raise your head when sleeping.', level2: 'Avoid trigger foods (caffeine, alcohol, spicy foods), elevate head of bed, avoid lying down after meals, lose weight if overweight.', level3: 'Weight loss is the lifestyle intervention with strongest evidence. Head of bed elevation helps nocturnal symptoms. Dietary modifications have limited evidence but may help individual patients.', level4: 'Weight loss reduces intra-abdominal pressure and transient LES relaxations. Head elevation uses gravity to improve acid clearance.', level5: 'Obesity increases gastroesophageal pressure gradient. Studies show 5-10% weight loss reduces GERD symptoms by ~40%.' } },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'esophagus', structureName: 'Esophagus', role: 'primary-site', involvement: 'Target of acid injury', highlightColor: '#dc2626', showByDefault: true }],
        secondaryStructures: [{ structureId: 'stomach', structureName: 'Stomach', role: 'secondary-site', involvement: 'Source of refluxate', highlightColor: '#f97316', showByDefault: true }],
        systemsInvolved: ['Gastrointestinal'],
        recommendedView: 'anterior',
        recommendedLayers: ['gastrointestinal'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1: 'Acid from your stomach keeps coming back up into your food pipe, causing burning and discomfort.',
        level2: 'The valve between your stomach and esophagus doesnt close properly, allowing acid to wash back up and irritate the esophagus lining.',
        level3: 'GERD results from dysfunction of the anti-reflux barrier, primarily the lower esophageal sphincter. Transient LES relaxations and hiatal hernia are key factors.',
        level4: 'Pathogenesis involves transient LES relaxations, reduced LES tone, impaired esophageal clearance, and reduced mucosal resistance. Acid and pepsin cause epithelial damage.',
        level5: 'Transient LES relaxations are mediated by vagal afferents and brainstem pathways via NO and VIP. Hiatal hernia disrupts the crural diaphragm contribution to the high-pressure zone. Duodenal bile reflux may contribute to metaplasia.',
      },
      relatedConditions: ['obesity', 'asthma'],
      clinicalPearls: ['Endoscopy not required for typical symptoms in patients <50 without alarm features', 'Twice-daily PPI is not better than once-daily for uncomplicated GERD', 'Consider H. pylori testing - eradication may worsen GERD'],
      patientEducation: ['Take PPI 30-60 minutes before breakfast', 'Lose weight if overweight', 'Dont eat within 3 hours of bedtime', 'Elevate head of bed 6-8 inches'],
    },
  ],

  // Inflammatory Bowel Disease - Crohn's
  [
    'crohns-disease',
    {
      conditionId: 'crohns-disease',
      name: 'Crohn Disease',
      aliases: ['Crohns', 'Regional Enteritis', 'Granulomatous Ileocolitis'],
      icdCode: 'K50',
      category: 'gastrointestinal',
      subcategory: 'Inflammatory Bowel Disease',
      description: 'Chronic inflammatory bowel disease affecting any part of the GI tract with transmural inflammation and skip lesions',
      pathophysiology: {
        summary: 'Dysregulated immune response to intestinal microbiota in genetically susceptible individuals causing transmural inflammation',
        mechanisms: [
          { name: 'Immune Dysregulation', description: 'Th1/Th17-mediated inflammation in response to gut flora', systemsInvolved: ['Gastrointestinal', 'Immune'], keyMediators: ['TNF-alpha', 'IL-12', 'IL-23', 'IFN-gamma'], contribution: 'Primary driver of inflammation' },
          { name: 'Barrier Dysfunction', description: 'Increased intestinal permeability allows microbial translocation', systemsInvolved: ['Gastrointestinal'], contribution: 'Perpetuates immune activation' },
        ],
        riskFactors: [
          { name: 'Genetics', type: 'non-modifiable', impact: 'major', description: 'NOD2/CARD15 mutations increase risk 20-40x' },
          { name: 'Smoking', type: 'modifiable', impact: 'major', description: 'Doubles risk and worsens disease course', intervention: 'Smoking cessation essential' },
          { name: 'Western Diet', type: 'partially-modifiable', impact: 'moderate', description: 'High fat, low fiber diet associated with increased risk' },
        ],
        geneticFactors: ['NOD2/CARD15', 'ATG16L1', 'IL23R'],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Abdominal Pain', prevalence: 'very-common', description: 'Crampy, often RLQ', location: 'Right lower quadrant (ileocecal)', quality: 'Crampy, colicky' },
          { name: 'Diarrhea', prevalence: 'very-common', description: 'Chronic, may be bloody or non-bloody', quality: 'Watery to loose' },
          { name: 'Weight Loss', prevalence: 'common', description: 'From malabsorption and reduced intake' },
        ],
        physicalFindings: [
          { name: 'RLQ tenderness', examType: 'Abdominal exam', description: 'Tenderness over terminal ileum', diagnosticValue: 'Suggests ileocecal involvement' },
          { name: 'Perianal disease', examType: 'Perianal exam', description: 'Fistulas, fissures, abscesses', diagnosticValue: 'Present in 25-50% of patients' },
        ],
        labFindings: [
          { testName: 'CRP/ESR', abnormality: 'Elevated', significance: 'Indicates active inflammation' },
          { testName: 'Fecal Calprotectin', abnormality: 'Elevated >250 mcg/g', significance: 'Correlates with intestinal inflammation' },
        ],
      },
      progression: {
        naturalHistory: 'Relapsing-remitting course with progressive bowel damage if not treated. Most develop complications within 20 years.',
        timelineSteps: [
          { phaseId: 'inflammatory', phase: 'early', displayName: 'Inflammatory Phenotype', timeframe: 'Initial presentation', description: 'Active inflammation without structural damage', symptoms: ['Diarrhea', 'Abdominal pain', 'Fatigue'], anatomicalChanges: [{ structureId: 'intestine', structureName: 'Terminal Ileum/Colon', changeType: 'inflammation', description: 'Mucosal inflammation with skip lesions', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Corticosteroids', 'Biologics', '5-ASA (colonic)'] },
          { phaseId: 'stricturing', phase: 'advanced', displayName: 'Stricturing Phenotype', timeframe: 'Years of inflammation', description: 'Fibrotic narrowing of bowel', symptoms: ['Obstructive symptoms', 'Bloating', 'Nausea'], anatomicalChanges: [{ structureId: 'intestine', structureName: 'Affected Bowel Segment', changeType: 'fibrosis', description: 'Transmural fibrosis causing stricture', severity: 'severe', visualIndicator: { color: '#78716c', pulse: false, opacity: 0.7 }, isNewAtPhase: true }], reversibility: 'irreversible', typicalTreatments: ['Endoscopic dilation', 'Surgical resection'] },
          { phaseId: 'penetrating', phase: 'severe', displayName: 'Penetrating Phenotype', timeframe: 'Years of inflammation', description: 'Fistulas and abscesses develop', symptoms: ['Feculent drainage', 'Persistent fever', 'Perianal pain'], anatomicalChanges: [{ structureId: 'intestine', structureName: 'Bowel Wall', changeType: 'structural-damage', description: 'Fistula tracts through bowel wall', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: true }], reversibility: 'irreversible', typicalTreatments: ['Biologics', 'Antibiotics', 'Surgery'] },
        ],
        prognosis: 'Chronic lifelong disease. ~50% need surgery within 10 years. Early biologic therapy may prevent complications.',
      },
      complications: [
        { complicationId: 'fistula', name: 'Fistula', category: 'chronic', severity: 'major', riskLevel: 'moderate', description: 'Abnormal connection between bowel and other structures', mechanism: 'Transmural inflammation penetrates through bowel wall', affectedStructures: [{ structureId: 'intestine', structureName: 'Bowel', effect: 'Penetrating tract', highlightColor: '#dc2626' }], warningSymptoms: ['Drainage from perianal area', 'Stool in urine/vagina', 'Skin openings'], treatment: 'Anti-TNF therapy, surgery', preventable: true },
        { complicationId: 'bowel-obstruction', name: 'Bowel Obstruction', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Blockage from stricture', mechanism: 'Fibrotic stricture occludes bowel lumen', affectedStructures: [{ structureId: 'intestine', structureName: 'Strictured Segment', effect: 'Mechanical obstruction', highlightColor: '#f97316' }], warningSymptoms: ['Crampy pain', 'Vomiting', 'Abdominal distension', 'No BMs'], treatment: 'Bowel rest, surgery if refractory', preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'anti-tnf-crohns', name: 'Anti-TNF Therapy', modality: 'pharmacological', description: 'Biologic therapy targeting TNF-alpha', mechanism: 'Neutralizes TNF-alpha, key inflammatory cytokine', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established', 'advanced'], goals: ['Induce and maintain remission', 'Mucosal healing', 'Prevent complications'], medicationIds: ['infliximab', 'adalimumab'], sideEffects: ['Infections', 'Injection site reactions', 'Rare: lymphoma'], monitoring: ['TB screening', 'Hepatitis B screening', 'Drug levels'], explanations: { level1: 'These medications calm your immune system to reduce inflammation in your intestines.', level2: 'Anti-TNF drugs block a protein called TNF that causes inflammation in Crohns disease, allowing the intestines to heal.', level3: 'Anti-TNF biologics induce and maintain remission in moderate-severe Crohns. Early use may prevent disease progression. Monitor drug levels and antibodies to optimize therapy.', level4: 'Infliximab and adalimumab are monoclonal antibodies against TNF-alpha. Induces mucosal healing in 30-50% of patients. Combination with immunomodulator reduces immunogenicity.', level5: 'TNF-alpha is central to the Th1 inflammatory response in Crohns. Anti-TNF induces T cell apoptosis via reverse signaling. Therapeutic drug monitoring guides dose optimization - trough levels >5 mcg/mL for infliximab associated with better outcomes.' } },
        { treatmentId: 'corticosteroids-crohns', name: 'Corticosteroids', modality: 'pharmacological', description: 'For inducing remission in flares', mechanism: 'Broad anti-inflammatory and immunosuppressive effects', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: false, appropriatePhases: ['acute'], goals: ['Induce remission rapidly'], sideEffects: ['Weight gain', 'Hyperglycemia', 'Bone loss', 'Adrenal suppression'], explanations: { level1: 'Strong anti-inflammatory medicine to quickly control a flare-up.', level2: 'Steroids like prednisone rapidly reduce inflammation during flares but shouldnt be used long-term due to side effects.', level3: 'Corticosteroids induce remission in ~70% but do not maintain remission or heal mucosa. Used as bridge to steroid-sparing agents. Budesonide preferred for ileal/right colon disease.', level4: 'Systemic steroids have rapid onset but significant toxicity. Budesonide has high first-pass metabolism, reducing systemic effects. Steroid dependency indicates need for biologic or immunomodulator.', level5: 'Glucocorticoids inhibit NF-kB and AP-1 transcription factors, reducing pro-inflammatory cytokine production. Do not alter natural history of disease - merely suppress symptoms.' } },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'terminal-ileum', structureName: 'Terminal Ileum', role: 'primary-site', involvement: 'Most commonly affected segment', highlightColor: '#dc2626', showByDefault: true }],
        secondaryStructures: [
          { structureId: 'colon', structureName: 'Colon', role: 'secondary-site', involvement: 'Involved in 50% of cases', highlightColor: '#f97316', showByDefault: true },
          { structureId: 'perianal', structureName: 'Perianal Region', role: 'secondary-site', involvement: 'Fistulas and abscesses', highlightColor: '#ef4444', showByDefault: false },
        ],
        systemsInvolved: ['Gastrointestinal', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['gastrointestinal'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: 'An inflammatory condition that attacks your digestive tract, causing pain, diarrhea, and other problems.',
        level2: 'Crohns is a type of inflammatory bowel disease where your immune system mistakenly attacks your intestines, causing inflammation and damage.',
        level3: 'Crohns disease features transmural inflammation affecting any GI segment (mouth to anus), most commonly terminal ileum. Skip lesions and granulomas are characteristic.',
        level4: 'Pathogenesis involves dysregulated mucosal immunity to commensal flora in genetically susceptible hosts. NOD2 mutations impair bacterial sensing. Th1/Th17 responses drive inflammation.',
        level5: 'NOD2 senses muramyl dipeptide from bacterial cell walls. Loss-of-function mutations lead to impaired autophagy and defective Paneth cell antimicrobial peptide secretion, allowing bacterial invasion and chronic immune activation.',
      },
      relatedConditions: ['ulcerative-colitis', 'rheumatoid-arthritis'],
      comorbidities: ['Ankylosing spondylitis', 'Pyoderma gangrenosum', 'Primary sclerosing cholangitis'],
      epidemiology: { prevalence: '200-300 per 100,000 in Western countries', incidence: '6-10 per 100,000 per year', demographics: 'Peak onset 15-35 years; second peak 55-65' },
      clinicalPearls: ['STOP SMOKING - most important modifiable factor', 'Measure fecal calprotectin to assess for active inflammation', 'Early biologic therapy may prevent strictures and fistulas', 'Check vitamin B12 if terminal ileum involved'],
      patientEducation: ['Stop smoking completely - it makes Crohns worse', 'Take medications regularly even when feeling well', 'Report fever, severe pain, or new symptoms promptly', 'See your gastroenterologist regularly for monitoring'],
      emergencyWarnings: ['Severe abdominal pain with fever may indicate abscess', 'Complete inability to pass stool/gas suggests obstruction', 'Heavy rectal bleeding needs immediate evaluation'],
    },
  ],

  // Ulcerative Colitis
  [
    'ulcerative-colitis',
    {
      conditionId: 'ulcerative-colitis',
      name: 'Ulcerative Colitis',
      aliases: ['UC', 'Colitis Ulcerosa'],
      icdCode: 'K51',
      category: 'gastrointestinal',
      subcategory: 'Inflammatory Bowel Disease',
      description: 'Chronic inflammatory bowel disease limited to the colon with continuous mucosal inflammation starting from the rectum',
      pathophysiology: {
        summary: 'Mucosal immune dysregulation causing continuous inflammation of the colonic mucosa',
        mechanisms: [
          { name: 'Th2 Immune Response', description: 'Th2-mediated inflammation with IL-5, IL-13', systemsInvolved: ['Gastrointestinal', 'Immune'], keyMediators: ['IL-5', 'IL-13', 'NKT cells'], contribution: 'Distinct from Crohns Th1 response' },
          { name: 'Epithelial Barrier Defects', description: 'Mucus layer depletion and tight junction dysfunction', systemsInvolved: ['Gastrointestinal'], contribution: 'Allows bacterial contact with epithelium' },
        ],
        riskFactors: [
          { name: 'Genetics', type: 'non-modifiable', impact: 'major', description: 'HLA associations, IL-23R polymorphisms' },
          { name: 'Appendectomy', type: 'non-modifiable', impact: 'moderate', description: 'Paradoxically protective against UC' },
          { name: 'NSAIDs', type: 'modifiable', impact: 'moderate', description: 'May trigger flares', intervention: 'Avoid NSAIDs during flares' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Bloody Diarrhea', prevalence: 'very-common', description: 'Blood and mucus in stool', quality: 'Frequent small stools with urgency' },
          { name: 'Rectal Urgency', prevalence: 'very-common', description: 'Sudden urge to defecate', timing: 'Constant during flares' },
          { name: 'Tenesmus', prevalence: 'common', description: 'Feeling of incomplete evacuation' },
        ],
        physicalFindings: [
          { name: 'Abdominal tenderness', examType: 'Abdominal exam', description: 'Mild tenderness over colon', diagnosticValue: 'Non-specific' },
        ],
        labFindings: [
          { testName: 'Fecal Calprotectin', abnormality: 'Elevated', significance: 'Correlates with endoscopic activity' },
          { testName: 'Hemoglobin', abnormality: 'Low (anemia)', significance: 'From chronic blood loss' },
        ],
      },
      progression: {
        naturalHistory: 'Relapsing-remitting course. Extent may increase over time. Long-standing extensive colitis increases colorectal cancer risk.',
        timelineSteps: [
          { phaseId: 'proctitis', phase: 'early', displayName: 'Ulcerative Proctitis', timeframe: 'Initial presentation (30-50%)', description: 'Inflammation limited to rectum', symptoms: ['Bloody stools', 'Urgency', 'Tenesmus'], anatomicalChanges: [{ structureId: 'rectum', structureName: 'Rectum', changeType: 'inflammation', description: 'Rectal mucosal inflammation', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Topical mesalamine', 'Topical steroids'] },
          { phaseId: 'left-sided', phase: 'established', displayName: 'Left-Sided Colitis', timeframe: 'May progress from proctitis', description: 'Extends to splenic flexure', symptoms: ['Bloody diarrhea', 'LLQ pain', 'Urgency'], anatomicalChanges: [{ structureId: 'descending-colon', structureName: 'Left Colon', changeType: 'inflammation', description: 'Continuous inflammation to splenic flexure', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Oral + topical mesalamine', 'Consider biologics'] },
          { phaseId: 'pancolitis', phase: 'advanced', displayName: 'Pancolitis', timeframe: 'May progress over years', description: 'Entire colon involved', symptoms: ['Severe diarrhea', 'Systemic symptoms', 'Weight loss'], anatomicalChanges: [{ structureId: 'colon', structureName: 'Entire Colon', changeType: 'inflammation', description: 'Continuous inflammation throughout colon', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: false }], reversibility: 'reversible', typicalTreatments: ['Biologics', 'Immunomodulators'] },
        ],
        prognosis: 'Most achieve remission with treatment. 10-15% eventually need colectomy. Increased colorectal cancer risk after 8-10 years of extensive disease.',
      },
      complications: [
        { complicationId: 'toxic-megacolon', name: 'Toxic Megacolon', category: 'acute', severity: 'life-threatening', riskLevel: 'low', description: 'Severe colonic dilation with systemic toxicity', mechanism: 'Transmural inflammation causes colonic atony and dilation', affectedStructures: [{ structureId: 'colon', structureName: 'Colon', effect: 'Severe dilation', highlightColor: '#dc2626' }], warningSymptoms: ['Abdominal distension', 'High fever', 'Tachycardia', 'Decreased bowel sounds'], treatment: 'IV steroids, antibiotics, surgery if no improvement', preventable: true },
        { complicationId: 'colorectal-cancer', name: 'Colorectal Cancer', category: 'chronic', severity: 'life-threatening', riskLevel: 'moderate', description: 'Increased CRC risk with long-standing extensive disease', mechanism: 'Chronic inflammation promotes dysplasia-carcinoma sequence', affectedStructures: [{ structureId: 'colon', structureName: 'Colon', effect: 'Malignant transformation', highlightColor: '#7f1d1d' }], warningSymptoms: ['Often asymptomatic - found on surveillance'], prevention: ['Surveillance colonoscopy', 'Chemoprevention (5-ASA)'], timing: 'Risk increases after 8-10 years of extensive disease', preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: '5-asa-uc', name: '5-Aminosalicylates', modality: 'pharmacological', description: 'First-line for mild-moderate UC', mechanism: 'Topical anti-inflammatory effect on colonic mucosa', efficacy: 'effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established'], goals: ['Induce and maintain remission'], medicationIds: ['mesalamine'], sideEffects: ['Headache', 'Nausea', 'Rare: nephrotoxicity'], explanations: { level1: 'Medicine that reduces inflammation directly in your colon.', level2: '5-ASA drugs like mesalamine work directly on the colon lining to reduce inflammation and can be taken as pills or enemas.', level3: '5-ASA agents are first-line for mild-moderate UC. Combination oral and topical therapy superior to either alone. May reduce colorectal cancer risk.', level4: 'Mesalamine inhibits cyclooxygenase and lipoxygenase pathways locally. Topical formulations (enemas, suppositories) essential for distal disease.', level5: '5-ASA activates PPARγ receptors and inhibits NF-kB signaling. Delivers high concentrations to colonic mucosa with minimal systemic absorption.' } },
        { treatmentId: 'vedolizumab-uc', name: 'Vedolizumab', modality: 'pharmacological', description: 'Gut-selective integrin inhibitor', mechanism: 'Blocks alpha4beta7 integrin, preventing lymphocyte gut homing', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: false, appropriatePhases: ['established', 'advanced'], goals: ['Induce and maintain remission', 'Mucosal healing'], sideEffects: ['Nasopharyngitis', 'Headache', 'Infusion reactions'], monitoring: ['TB screening', 'Hepatitis B screening'], explanations: { level1: 'A targeted medicine that prevents inflammatory cells from entering your intestines.', level2: 'Vedolizumab blocks immune cells from traveling to your intestines, reducing inflammation specifically in the gut.', level3: 'Gut-selective biologic with favorable safety profile compared to anti-TNF. Slower onset but durable responses. No increased infection risk.', level4: 'Alpha4beta7 integrin on lymphocytes binds MAdCAM-1 on gut endothelium. Blocking this interaction prevents lymphocyte gut homing without systemic immunosuppression.', level5: 'Gut-selectivity means vedolizumab doesnt affect alpha4beta1-VCAM-1 interactions important for CNS immune surveillance. No PML risk unlike natalizumab.' } },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'colon', structureName: 'Colon', role: 'primary-site', involvement: 'Site of continuous inflammation', highlightColor: '#dc2626', showByDefault: true }],
        secondaryStructures: [{ structureId: 'rectum', structureName: 'Rectum', role: 'primary-site', involvement: 'Always involved - inflammation extends proximally from rectum', highlightColor: '#ef4444', showByDefault: true }],
        systemsInvolved: ['Gastrointestinal', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['gastrointestinal'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: 'Inflammation in your large intestine that causes bloody diarrhea and urgency.',
        level2: 'Ulcerative colitis is when your immune system attacks the lining of your colon, causing sores (ulcers) and inflammation.',
        level3: 'UC is characterized by continuous mucosal inflammation of the colon, always involving the rectum and extending proximally. Unlike Crohns, its limited to the colon.',
        level4: 'UC features Th2-predominant inflammation confined to mucosa/submucosa. Pathology shows crypt abscesses and goblet cell depletion. Always starts at rectum.',
        level5: 'Atypical NKT cells producing IL-13 drive epithelial apoptosis and barrier dysfunction. Mucus layer depletion allows bacterial contact with epithelium, perpetuating inflammation.',
      },
      relatedConditions: ['crohns-disease', 'primary-sclerosing-cholangitis'],
      comorbidities: ['Primary sclerosing cholangitis', 'Ankylosing spondylitis', 'Erythema nodosum'],
      epidemiology: { prevalence: '200-250 per 100,000 in Western countries', incidence: '8-15 per 100,000 per year', demographics: 'Peak onset 15-30 years; more common in non-smokers' },
      clinicalPearls: ['Unlike Crohns, smoking may be protective in UC', 'Always starts in rectum - if rectum spared, reconsider diagnosis', 'Fecal calprotectin excellent for monitoring disease activity', 'Screen for PSC with LFTs - present in 5% of UC patients'],
      patientEducation: ['Take mesalamine regularly even when well to prevent flares', 'Blood in stool needs prompt evaluation', 'Surveillance colonoscopy is important for cancer prevention', 'Report any new joint pain, skin changes, or eye problems'],
      emergencyWarnings: ['Severe abdominal distension with fever may indicate toxic megacolon', 'Heavy bleeding with dizziness needs immediate care', 'More than 6 bloody stools per day with fever is severe'],
    },
  ],

  // Cirrhosis
  [
    'cirrhosis',
    {
      conditionId: 'cirrhosis',
      name: 'Cirrhosis',
      aliases: ['Liver Cirrhosis', 'Hepatic Cirrhosis', 'End-Stage Liver Disease'],
      icdCode: 'K74',
      category: 'gastrointestinal',
      subcategory: 'Hepatic',
      description: 'End-stage liver disease characterized by replacement of normal liver tissue with fibrosis and regenerative nodules',
      pathophysiology: {
        summary: 'Chronic liver injury leads to hepatic stellate cell activation, fibrosis, and architectural distortion impairing liver function',
        mechanisms: [
          { name: 'Stellate Cell Activation', description: 'Injured hepatocytes release signals activating stellate cells to produce collagen', systemsInvolved: ['Gastrointestinal'], keyMediators: ['TGF-beta', 'PDGF'], contribution: 'Primary fibrogenic mechanism' },
          { name: 'Sinusoidal Capillarization', description: 'Loss of fenestrations impairs exchange between blood and hepatocytes', systemsInvolved: ['Gastrointestinal'], contribution: 'Contributes to portal hypertension and hepatocyte dysfunction' },
        ],
        riskFactors: [
          { name: 'Alcohol Use', type: 'modifiable', impact: 'major', description: 'Heavy drinking causes alcoholic liver disease', intervention: 'Complete alcohol cessation' },
          { name: 'Hepatitis C', type: 'modifiable', impact: 'major', description: 'Chronic HCV leads to fibrosis over 20-30 years', intervention: 'Direct-acting antivirals cure >95%' },
          { name: 'NAFLD/NASH', type: 'partially-modifiable', impact: 'major', description: 'Fatty liver progressing to cirrhosis', intervention: 'Weight loss, metabolic management' },
          { name: 'Hepatitis B', type: 'modifiable', impact: 'major', description: 'Chronic HBV causes inflammation and fibrosis', intervention: 'Antiviral therapy' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Profound tiredness from hepatic dysfunction' },
          { name: 'Ascites', prevalence: 'common', description: 'Abdominal swelling from fluid accumulation', timing: 'Decompensated cirrhosis' },
          { name: 'Jaundice', prevalence: 'common', description: 'Yellow skin/eyes from elevated bilirubin', timing: 'Advanced disease' },
        ],
        physicalFindings: [
          { name: 'Spider angiomata', examType: 'Skin exam', description: 'Red vascular lesions with central arteriole', diagnosticValue: 'Suggests chronic liver disease' },
          { name: 'Palmar erythema', examType: 'Hand exam', description: 'Red palms', diagnosticValue: 'Sign of hyperestrogenism' },
          { name: 'Hepatomegaly/Splenomegaly', examType: 'Abdominal exam', description: 'Enlarged liver (early) or shrunken (late), enlarged spleen', diagnosticValue: 'Splenomegaly from portal hypertension' },
        ],
        labFindings: [
          { testName: 'Albumin', abnormality: 'Low', normalRange: '3.5-5.0 g/dL', significance: 'Reflects synthetic function' },
          { testName: 'INR', abnormality: 'Elevated', significance: 'Reflects synthetic function - cannot make clotting factors' },
          { testName: 'Bilirubin', abnormality: 'Elevated', significance: 'Reflects excretory function' },
          { testName: 'Platelets', abnormality: 'Low', significance: 'From splenomegaly and decreased thrombopoietin' },
        ],
      },
      progression: {
        naturalHistory: 'Progressive fibrosis leads to decompensation. Once decompensated, median survival 2 years without transplant.',
        timelineSteps: [
          { phaseId: 'compensated', phase: 'early', displayName: 'Compensated Cirrhosis', timeframe: 'May persist years', description: 'Cirrhosis present but liver maintaining function', symptoms: ['Often asymptomatic', 'Fatigue', 'Mild cognitive changes'], anatomicalChanges: [{ structureId: 'liver', structureName: 'Liver', changeType: 'fibrosis', description: 'Fibrosis with regenerative nodules', severity: 'moderate', visualIndicator: { color: '#78716c', pulse: false, opacity: 0.6 }, isNewAtPhase: true }], reversibility: 'partially-reversible', typicalTreatments: ['Treat underlying cause', 'Surveillance for HCC', 'Varices screening'] },
          { phaseId: 'decompensated', phase: 'advanced', displayName: 'Decompensated Cirrhosis', timeframe: '5-7% per year progress from compensated', description: 'Liver failing with complications', symptoms: ['Ascites', 'Variceal bleeding', 'Encephalopathy', 'Jaundice'], anatomicalChanges: [{ structureId: 'liver', structureName: 'Liver', changeType: 'fibrosis', description: 'Extensive fibrosis with nodular regeneration', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: false }, { structureId: 'spleen', structureName: 'Spleen', changeType: 'hypertrophy', description: 'Splenomegaly from portal hypertension', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 }, isNewAtPhase: true }], reversibility: 'irreversible', typicalTreatments: ['Diuretics for ascites', 'Beta blockers for varices', 'Lactulose for encephalopathy', 'Transplant evaluation'], labMarkers: ['Low albumin <3.5', 'INR >1.5', 'Bilirubin >2'] },
        ],
        prognosis: 'Compensated cirrhosis: 12+ year median survival. Decompensated: 2-year median survival without transplant.',
      },
      complications: [
        { complicationId: 'variceal-bleeding', name: 'Variceal Bleeding', category: 'acute', severity: 'life-threatening', riskLevel: 'high', description: 'Life-threatening hemorrhage from esophageal/gastric varices', mechanism: 'Portal hypertension causes portosystemic collaterals that can rupture', affectedStructures: [{ structureId: 'esophagus', structureName: 'Esophageal Varices', effect: 'Dilation and rupture', highlightColor: '#dc2626' }], warningSymptoms: ['Vomiting blood', 'Black tarry stools', 'Lightheadedness'], prevention: ['Beta blockers', 'Endoscopic band ligation'], treatment: 'Octreotide, endoscopic therapy, TIPS if refractory', preventable: true },
        { complicationId: 'hepatic-encephalopathy', name: 'Hepatic Encephalopathy', category: 'acute', severity: 'major', riskLevel: 'high', description: 'Brain dysfunction from liver failure', mechanism: 'Ammonia and other toxins cross BBB causing astrocyte swelling', affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Metabolic dysfunction', highlightColor: '#7c3aed' }], warningSymptoms: ['Confusion', 'Asterixis', 'Sleep reversal', 'Personality changes'], prevention: ['Lactulose', 'Rifaximin'], treatment: 'Lactulose, rifaximin, treat precipitants', preventable: true },
        { complicationId: 'hcc', name: 'Hepatocellular Carcinoma', category: 'chronic', severity: 'life-threatening', riskLevel: 'high', description: 'Liver cancer developing in cirrhotic liver', mechanism: 'Chronic inflammation and regeneration promote carcinogenesis', affectedStructures: [{ structureId: 'liver', structureName: 'Liver', effect: 'Malignant nodule', highlightColor: '#7f1d1d' }], warningSymptoms: ['Often asymptomatic - found on surveillance', 'Weight loss', 'RUQ pain'], prevention: ['HCC surveillance with ultrasound +/- AFP every 6 months'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'transplant-cirrhosis', name: 'Liver Transplantation', modality: 'surgical', description: 'Only curative treatment for decompensated cirrhosis', efficacy: 'highly-effective', evidenceLevel: 'level-1b', isFirstLine: false, appropriatePhases: ['advanced', 'severe'], goals: ['Replace failing liver', 'Cure underlying disease'], expectedOutcomes: ['85% 1-year survival', '70% 5-year survival'], contraindications: ['Active substance abuse', 'Extrahepatic malignancy', 'Advanced cardiopulmonary disease'], explanations: { level1: 'Replacing your damaged liver with a healthy one from a donor.', level2: 'Liver transplantation is surgery to remove your failing liver and replace it with a healthy liver from a deceased or living donor.', level3: 'Transplant evaluation considers MELD score, listing criteria, and contraindications. Post-transplant requires lifelong immunosuppression. HCC within Milan criteria may receive exception points.', level4: 'MELD-Na score predicts 3-month mortality and allocates organs. Living donor transplant may reduce waitlist time. Recurrent disease (HCV cured, alcohol requires abstinence) affects outcomes.', level5: 'Allocation based on sickest first within blood type compatibility. ABO-incompatible and LDLT expand donor pool. Post-transplant HCV recurrence now preventable with DAAs. Immunosuppression protocols minimize rejection while reducing infection risk.' } },
        { treatmentId: 'diuretics-ascites', name: 'Diuretics for Ascites', modality: 'pharmacological', description: 'Spironolactone and furosemide for ascites', mechanism: 'Block sodium retention in cirrhosis', efficacy: 'effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['advanced'], goals: ['Reduce ascites', 'Improve comfort'], medicationIds: ['spironolactone', 'furosemide'], sideEffects: ['Hyponatremia', 'Hyperkalemia', 'Renal impairment'], monitoring: ['Creatinine', 'Electrolytes', 'Weight'], explanations: { level1: 'Water pills that help your body get rid of extra fluid in your belly.', level2: 'Diuretics help your kidneys remove excess salt and water to reduce the fluid buildup in your abdomen.', level3: 'Spironolactone is first-line (blocks aldosterone excess in cirrhosis). Add furosemide at 100:40 ratio. Monitor for renal dysfunction and electrolyte abnormalities.', level4: 'Cirrhosis causes secondary hyperaldosteronism via arterial underfilling. Spironolactone antagonizes aldosterone at collecting duct. Ratio with furosemide maintains potassium balance.', level5: 'Effective circulating volume is reduced despite total body sodium excess. RAAS activation and ADH cause avid sodium and water retention. Goal is negative sodium balance with 0.5 kg/day weight loss max.' } },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'liver', structureName: 'Liver', role: 'primary-site', involvement: 'Site of fibrosis and regenerative nodules', highlightColor: '#dc2626', showByDefault: true }],
        secondaryStructures: [
          { structureId: 'spleen', structureName: 'Spleen', role: 'secondary-site', involvement: 'Splenomegaly from portal hypertension', highlightColor: '#f97316', showByDefault: true },
          { structureId: 'portal-vein', structureName: 'Portal Vein', role: 'secondary-site', involvement: 'Portal hypertension', highlightColor: '#ef4444', showByDefault: false },
        ],
        systemsInvolved: ['Gastrointestinal', 'Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['gastrointestinal'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: 'Severe scarring of the liver that prevents it from working properly, often from alcohol or viral hepatitis.',
        level2: 'Cirrhosis is when scar tissue replaces healthy liver tissue, preventing the liver from filtering blood, making proteins, and other important jobs.',
        level3: 'Cirrhosis is the end stage of chronic liver disease characterized by fibrosis and regenerative nodules distorting hepatic architecture. Complications from portal hypertension and hepatic insufficiency.',
        level4: 'Chronic hepatocyte injury activates hepatic stellate cells to myofibroblasts producing collagen. Sinusoidal capillarization increases intrahepatic resistance causing portal hypertension.',
        level5: 'TGF-beta and PDGF from injured hepatocytes and Kupffer cells activate stellate cells. Collagen deposition in space of Disse disrupts exchange. Portal hypertension opens portosystemic shunts, contributing to encephalopathy and varices.',
      },
      relatedConditions: ['hepatitis-c', 'hepatitis-b', 'nafld'],
      comorbidities: ['Hepatorenal syndrome', 'Hepatopulmonary syndrome', 'Coagulopathy'],
      epidemiology: { prevalence: '0.27% of US population', incidence: '~75,000 deaths/year in US from chronic liver disease', demographics: 'Men 2x more than women; increasing due to NAFLD' },
      clinicalPearls: ['Calculate MELD-Na to assess prognosis and transplant priority', 'Every cirrhotic needs HCC surveillance with US +/- AFP every 6 months', 'Screen for varices - large varices need prophylactic beta blockers or banding', 'Cirrhosis is the major risk factor for HCC in Western countries'],
      patientEducation: ['No alcohol - even small amounts can worsen liver damage', 'Get vaccinated for hepatitis A and B if not immune', 'Low-sodium diet helps control fluid retention', 'Take lactulose as prescribed to prevent confusion', 'Report any vomiting blood or confusion immediately'],
      emergencyWarnings: ['Vomiting blood or black stools - call 911 immediately', 'Sudden confusion, sleepiness, or unusual behavior needs immediate evaluation', 'New fever may indicate serious infection - call your doctor'],
    },
  ],

  // Peptic Ulcer Disease
  [
    'peptic-ulcer-disease',
    {
      conditionId: 'peptic-ulcer-disease',
      name: 'Peptic Ulcer Disease',
      aliases: ['PUD', 'Gastric Ulcer', 'Duodenal Ulcer'],
      icdCode: 'K27',
      category: 'gastrointestinal',
      subcategory: 'Gastric/Duodenal',
      description: 'Defect in gastric or duodenal mucosa extending through muscularis mucosae, typically from H. pylori or NSAID use',
      pathophysiology: {
        summary: 'Imbalance between aggressive factors (acid, pepsin, H. pylori, NSAIDs) and protective factors (mucus, bicarbonate, prostaglandins)',
        mechanisms: [
          { name: 'H. pylori Infection', description: 'Bacterium colonizes gastric mucosa, causing inflammation and disrupting mucosal defenses', systemsInvolved: ['Gastrointestinal'], keyMediators: ['Urease', 'CagA', 'VacA'], contribution: 'Causes 70-90% of duodenal ulcers, 50-60% of gastric ulcers' },
          { name: 'NSAID-Induced', description: 'NSAIDs inhibit COX-1, reducing protective prostaglandins', systemsInvolved: ['Gastrointestinal'], keyMediators: ['Prostaglandins (reduced)'], contribution: 'Major cause of H. pylori-negative ulcers' },
        ],
        riskFactors: [
          { name: 'H. pylori infection', type: 'modifiable', impact: 'major', description: 'Bacterial infection acquired in childhood', intervention: 'Eradication therapy' },
          { name: 'NSAID use', type: 'modifiable', impact: 'major', description: 'Especially with chronic use or high doses', intervention: 'Use PPI prophylaxis, minimize use' },
          { name: 'Smoking', type: 'modifiable', impact: 'moderate', description: 'Impairs ulcer healing', intervention: 'Smoking cessation' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Epigastric Pain', prevalence: 'very-common', description: 'Gnawing or burning pain', location: 'Epigastrium', quality: 'Gnawing, burning', timing: 'Duodenal: relieved by food, gastric: worsened by food' },
        ],
        associatedSymptoms: [
          { name: 'Nausea', prevalence: 'common', description: 'May or may not have vomiting' },
          { name: 'Bloating', prevalence: 'common', description: 'Early satiety' },
        ],
        labFindings: [
          { testName: 'H. pylori Testing', abnormality: 'Positive stool antigen, urea breath test, or serology', significance: 'Identifies treatable cause' },
          { testName: 'CBC', abnormality: 'May show anemia from chronic blood loss', significance: 'Suggests bleeding' },
        ],
      },
      progression: {
        naturalHistory: 'Untreated ulcers may heal and recur. H. pylori ulcers tend to recur until bacteria eradicated.',
        timelineSteps: [
          { phaseId: 'active-ulcer', phase: 'acute', displayName: 'Active Ulcer', timeframe: 'Presenting episode', description: 'Open mucosal defect', symptoms: ['Epigastric pain', 'Nausea'], anatomicalChanges: [{ structureId: 'stomach-duodenum', structureName: 'Stomach/Duodenum', changeType: 'structural-damage', description: 'Mucosal ulcer crater', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['PPI therapy', 'H. pylori eradication'] },
          { phaseId: 'healed', phase: 'remission', displayName: 'Healed Ulcer', timeframe: '4-8 weeks with treatment', description: 'Ulcer epithelialized', symptoms: ['Asymptomatic'], anatomicalChanges: [{ structureId: 'stomach-duodenum', structureName: 'Stomach/Duodenum', changeType: 'structural-damage', description: 'Healed scar', severity: 'mild', visualIndicator: { color: '#22c55e', pulse: false, opacity: 0.4 }, isNewAtPhase: false }], reversibility: 'reversible' },
        ],
        prognosis: 'Excellent with H. pylori eradication (>90% cure rate). NSAID ulcers recur if NSAIDs continued without prophylaxis.',
      },
      complications: [
        { complicationId: 'gi-bleeding', name: 'Upper GI Bleeding', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Bleeding from ulcer into GI tract', mechanism: 'Ulcer erodes into blood vessel', affectedStructures: [{ structureId: 'stomach-duodenum', structureName: 'Ulcer Site', effect: 'Hemorrhage', highlightColor: '#dc2626' }], warningSymptoms: ['Vomiting blood', 'Black tarry stools', 'Lightheadedness'], treatment: 'IV PPI, endoscopic therapy', preventable: true },
        { complicationId: 'perforation', name: 'Perforation', category: 'acute', severity: 'life-threatening', riskLevel: 'low', description: 'Ulcer penetrates through bowel wall', mechanism: 'Full thickness ulceration creates free perforation', affectedStructures: [{ structureId: 'stomach-duodenum', structureName: 'Stomach/Duodenum', effect: 'Perforation', highlightColor: '#dc2626' }], warningSymptoms: ['Sudden severe abdominal pain', 'Rigid abdomen'], treatment: 'Surgical repair', preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'h-pylori-eradication', name: 'H. pylori Eradication', modality: 'pharmacological', description: 'Triple or quadruple therapy', mechanism: 'Antibiotics kill H. pylori while PPI heals ulcer', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute'], goals: ['Eradicate infection', 'Heal ulcer', 'Prevent recurrence'], expectedOutcomes: ['>90% eradication with appropriate regimen'], sideEffects: ['GI upset', 'Taste changes', 'C. diff risk'], explanations: { level1: 'Antibiotics to kill the bacteria causing your ulcer, plus medicine to reduce acid.', level2: 'Treatment involves 2 antibiotics plus a PPI for 14 days to kill H. pylori and allow the ulcer to heal.', level3: 'Bismuth quadruple therapy (PPI, bismuth, metronidazole, tetracycline) now preferred due to clarithromycin resistance. Confirm eradication 4 weeks after treatment.', level4: 'Resistance-guided therapy optimal if culture available. CYP2C19 polymorphisms affect PPI efficacy. vonoprazan-based regimens show promise.', level5: 'H. pylori colonizes gastric mucus layer using urease-generated ammonia to neutralize local pH. CagA+ strains more virulent. Eradication eliminates ulcer recurrence risk and may reduce gastric cancer risk.' } },
        { treatmentId: 'ppi-pud', name: 'PPI Therapy', modality: 'pharmacological', description: 'Acid suppression for healing', mechanism: 'Suppress gastric acid secretion', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute', 'chronic'], goals: ['Ulcer healing', 'Symptom relief'], medicationIds: ['omeprazole', 'pantoprazole'], explanations: { level1: 'Medicine that strongly reduces stomach acid so your ulcer can heal.', level2: 'PPIs like omeprazole block acid production, creating a less acidic environment for ulcers to heal.', level3: '4-8 weeks of PPI therapy heals most ulcers. Duodenal ulcers generally heal faster than gastric. Confirm gastric ulcer healing with repeat endoscopy to rule out malignancy.', level4: 'PPIs achieve near-complete acid suppression (intragastric pH >4 for ~16 hours/day). This allows mucosal healing by reducing pepsin activity and improving bicarbonate/mucus barrier function.', level5: 'Ulcer healing requires sustained intragastric pH >3-4. Twice-daily PPI may be needed for refractory ulcers. Higher doses do not significantly increase healing rates but reduce time to healing.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'duodenum', structureName: 'Duodenum', role: 'primary-site', involvement: 'Most common site (duodenal bulb)', highlightColor: '#dc2626', showByDefault: true },
          { structureId: 'stomach', structureName: 'Stomach', role: 'primary-site', involvement: 'Lesser curvature, antrum common sites', highlightColor: '#ef4444', showByDefault: true },
        ],
        systemsInvolved: ['Gastrointestinal'],
        recommendedView: 'anterior',
        recommendedLayers: ['gastrointestinal'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: 'A sore in the lining of your stomach or the first part of your small intestine, often caused by bacteria or pain medications.',
        level2: 'Peptic ulcers are open sores that develop in the stomach or duodenum when the protective mucus layer is damaged, usually by H. pylori bacteria or NSAID medications.',
        level3: 'PUD results from imbalance between aggressive factors (acid, pepsin, H. pylori, NSAIDs) and mucosal defense. H. pylori causes most cases; NSAIDs cause most of the rest.',
        level4: 'H. pylori impairs mucosal defenses through urease-mediated ammonia production and cytotoxins. NSAIDs block COX-1, reducing prostaglandin-mediated mucus and bicarbonate secretion.',
        level5: 'H. pylori-induced gastritis increases gastrin release, leading to increased acid output in duodenal ulcer disease. Gastric ulcers often associated with antral-predominant gastritis and reduced acid secretion.',
      },
      relatedConditions: ['gerd'],
      epidemiology: { prevalence: '5-10% lifetime risk', incidence: 'Declining with H. pylori treatment and PPI use', demographics: 'H. pylori ulcers: lower socioeconomic groups; NSAID ulcers: elderly' },
      clinicalPearls: ['Test all ulcer patients for H. pylori - treat if positive', 'Gastric ulcers require follow-up EGD to confirm healing and rule out cancer', 'NSAID users with ulcer history need PPI prophylaxis', 'Confirm H. pylori eradication 4 weeks after finishing antibiotics'],
      patientEducation: ['Complete the full antibiotic course even if feeling better', 'Avoid NSAIDs - use acetaminophen for pain', 'Dont smoke - it delays ulcer healing', 'Seek immediate care for vomiting blood or sudden severe pain'],
      emergencyWarnings: ['Vomiting blood or coffee-ground material', 'Black, tarry stools', 'Sudden, severe abdominal pain radiating to back', 'Dizziness with rapid heart rate'],
    },
  ],

  // ============================================
  // ENDOCRINE CONDITIONS
  // ============================================

  // Hypothyroidism
  [
    'hypothyroidism',
    {
      conditionId: 'hypothyroidism',
      name: 'Hypothyroidism',
      aliases: ['Underactive Thyroid', 'Low Thyroid', 'Hashimotos Thyroiditis'],
      icdCode: 'E03.9',
      category: 'endocrine',
      subcategory: 'Thyroid',
      description: 'Deficiency of thyroid hormone production causing decreased metabolic rate and multiple systemic effects',
      pathophysiology: {
        summary: 'Inadequate thyroid hormone production leads to decreased cellular metabolism affecting virtually all organ systems',
        mechanisms: [
          { name: 'Autoimmune Destruction', description: 'Hashimotos thyroiditis - antibodies destroy thyroid tissue', systemsInvolved: ['Endocrine', 'Immune'], keyMediators: ['Anti-TPO antibodies', 'Anti-thyroglobulin antibodies'], contribution: 'Most common cause in developed countries' },
          { name: 'Decreased T4/T3', description: 'Reduced hormone production slows cellular metabolism', systemsInvolved: ['Endocrine'], keyMediators: ['T4', 'T3', 'TSH (elevated)'], contribution: 'Primary pathophysiological effect' },
        ],
        riskFactors: [
          { name: 'Female Sex', type: 'non-modifiable', impact: 'major', description: 'Women 5-8x more likely' },
          { name: 'Age >60', type: 'non-modifiable', impact: 'moderate', description: 'Risk increases with age' },
          { name: 'Family History', type: 'non-modifiable', impact: 'moderate', description: 'Autoimmune thyroid disease clusters in families' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Persistent tiredness and low energy' },
          { name: 'Weight Gain', prevalence: 'common', description: 'Usually modest (5-10 lbs) from decreased metabolism' },
          { name: 'Cold Intolerance', prevalence: 'common', description: 'Feeling cold when others are comfortable' },
        ],
        physicalFindings: [
          { name: 'Bradycardia', examType: 'Vital signs', description: 'Heart rate <60 bpm', diagnosticValue: 'Common finding' },
          { name: 'Delayed DTRs', examType: 'Neurological', description: 'Slow relaxation phase of deep tendon reflexes', diagnosticValue: 'Classic finding' },
          { name: 'Dry skin', examType: 'Skin exam', description: 'Coarse, dry skin', diagnosticValue: 'From decreased sweating' },
        ],
        labFindings: [
          { testName: 'TSH', abnormality: 'Elevated (>4.5 mIU/L)', normalRange: '0.4-4.0 mIU/L', significance: 'Most sensitive test for primary hypothyroidism' },
          { testName: 'Free T4', abnormality: 'Low or low-normal', normalRange: '0.8-1.8 ng/dL', significance: 'Confirms diagnosis' },
          { testName: 'Anti-TPO Antibodies', abnormality: 'Positive in Hashimotos', significance: 'Identifies autoimmune etiology' },
        ],
      },
      progression: {
        naturalHistory: 'Progressive decline in thyroid function if untreated. Autoimmune destruction is gradual.',
        timelineSteps: [
          { phaseId: 'subclinical', phase: 'preclinical', displayName: 'Subclinical Hypothyroidism', timeframe: 'May persist for years', description: 'Elevated TSH with normal T4', symptoms: ['Often asymptomatic', 'Mild fatigue'], anatomicalChanges: [{ structureId: 'thyroid', structureName: 'Thyroid Gland', changeType: 'dysfunction', description: 'Early thyroid failure with compensatory TSH increase', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Observation vs treatment depending on TSH level and symptoms'] },
          { phaseId: 'overt', phase: 'established', displayName: 'Overt Hypothyroidism', timeframe: 'Progression from subclinical', description: 'Low T4 with elevated TSH', symptoms: ['Fatigue', 'Weight gain', 'Cold intolerance', 'Constipation', 'Dry skin'], anatomicalChanges: [{ structureId: 'thyroid', structureName: 'Thyroid Gland', changeType: 'atrophy', description: 'Thyroid tissue destruction or atrophy', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: false }], reversibility: 'reversible', typicalTreatments: ['Levothyroxine replacement'] },
          { phaseId: 'myxedema', phase: 'severe', displayName: 'Myxedema Coma', timeframe: 'Severe untreated disease', description: 'Life-threatening severe hypothyroidism', symptoms: ['Altered mental status', 'Hypothermia', 'Hypotension', 'Hypoventilation'], anatomicalChanges: [{ structureId: 'thyroid', structureName: 'Thyroid Gland', changeType: 'atrophy', description: 'Severe thyroid failure', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: false }], reversibility: 'reversible', typicalTreatments: ['IV levothyroxine', 'IV hydrocortisone', 'Supportive care', 'ICU admission'] },
        ],
        prognosis: 'Excellent with proper levothyroxine replacement. Normal life expectancy.',
      },
      complications: [
        { complicationId: 'myxedema-coma', name: 'Myxedema Coma', category: 'acute', severity: 'life-threatening', riskLevel: 'low', description: 'Severe decompensated hypothyroidism', mechanism: 'Extreme thyroid hormone deficiency causes multi-organ failure', affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Altered consciousness', highlightColor: '#dc2626' }], warningSymptoms: ['Confusion', 'Extreme cold', 'Extreme fatigue', 'Slowed breathing'], treatment: 'IV thyroid hormone, supportive care', preventable: true },
        { complicationId: 'cardiovascular', name: 'Cardiovascular Disease', category: 'chronic', severity: 'major', riskLevel: 'moderate', description: 'Accelerated atherosclerosis from dyslipidemia', mechanism: 'Hypothyroidism causes elevated LDL cholesterol', affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'Coronary disease', highlightColor: '#ef4444' }], warningSymptoms: ['Chest pain', 'Dyspnea'], prevention: ['Adequate thyroid replacement'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'levothyroxine', name: 'Levothyroxine', modality: 'pharmacological', description: 'Synthetic T4 hormone replacement', mechanism: 'Replaces deficient thyroid hormone', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['preclinical', 'early', 'established'], goals: ['Normalize TSH', 'Resolve symptoms'], medicationIds: ['levothyroxine'], sideEffects: ['Overtreatment: tachycardia, anxiety, bone loss'], monitoring: ['TSH every 6-8 weeks until stable, then annually'], explanations: { level1: 'A pill that replaces the thyroid hormone your body isnt making enough of.', level2: 'Levothyroxine is the same hormone your thyroid normally makes. Taking it daily brings your hormone levels back to normal.', level3: 'Synthetic T4 replacement. Start low (25-50 mcg) in elderly or cardiac patients. Goal TSH 0.5-2.5 in most adults. Take on empty stomach for best absorption.', level4: 'T4 has 7-day half-life providing stable levels. Peripherally converted to active T3. Avoid calcium, iron, PPIs within 4 hours as they impair absorption.', level5: 'Deiodinase enzymes convert T4 to T3 in target tissues. Most patients do well with T4 monotherapy. Combination T4/T3 controversial - reserve for persistent symptoms despite normal TSH.' } },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'thyroid', structureName: 'Thyroid Gland', role: 'primary-site', involvement: 'Failing to produce adequate hormone', highlightColor: '#dc2626', showByDefault: true }],
        secondaryStructures: [{ structureId: 'pituitary', structureName: 'Pituitary Gland', role: 'compensatory', involvement: 'Produces elevated TSH in response', highlightColor: '#3b82f6', showByDefault: false }],
        systemsInvolved: ['Endocrine'],
        recommendedView: 'anterior',
        recommendedLayers: ['endocrine'],
        focusRegion: 'neck',
      },
      explanations: {
        level1: 'Your thyroid gland isnt making enough hormone, so your body runs slow.',
        level2: 'The thyroid gland in your neck makes hormones that control metabolism. When it makes too little, you feel tired, cold, and gain weight.',
        level3: 'Hypothyroidism results from inadequate thyroid hormone production. Hashimotos (autoimmune) is the most common cause. Diagnosed by elevated TSH, treated with levothyroxine.',
        level4: 'Primary hypothyroidism shows elevated TSH with low/normal T4. TSH is most sensitive marker due to log-linear relationship with T4. Hashimotos characterized by anti-TPO/anti-Tg antibodies.',
        level5: 'Thyroid hormone regulates basal metabolic rate via nuclear receptors affecting gene transcription. T3 binds thyroid hormone receptor complexed with retinoid X receptor on thyroid response elements. Low T3/T4 reduces Na/K-ATPase activity, thermogenesis, and overall cellular metabolism.',
      },
      relatedConditions: ['hyperthyroidism'],
      epidemiology: { prevalence: '4-10% of population has subclinical or overt hypothyroidism', incidence: 'Increases with age, especially women', demographics: 'Women 5-8x more common; increases after age 60' },
      clinicalPearls: ['Check TSH first - most sensitive test', 'Dont treat subclinical hypothyroidism if TSH <10 unless symptomatic or pregnant', 'Start low and go slow in elderly and cardiac patients', 'Takes 6-8 weeks for TSH to stabilize after dose change'],
      patientEducation: ['Take levothyroxine on empty stomach, 30-60 min before food', 'Dont take with calcium, iron, or antacids', 'Symptoms improve gradually over weeks', 'Youll need this medication lifelong'],
    },
  ],

  // Type 1 Diabetes
  [
    'type-1-diabetes',
    {
      conditionId: 'type-1-diabetes',
      name: 'Type 1 Diabetes Mellitus',
      aliases: ['T1DM', 'Juvenile Diabetes', 'Insulin-Dependent Diabetes'],
      icdCode: 'E10',
      category: 'endocrine',
      subcategory: 'Pancreatic',
      description: 'Autoimmune destruction of pancreatic beta cells leading to absolute insulin deficiency requiring lifelong insulin therapy',
      pathophysiology: {
        summary: 'T-cell mediated autoimmune destruction of insulin-producing beta cells in pancreatic islets',
        mechanisms: [
          { name: 'Autoimmune Beta Cell Destruction', description: 'CD4+ and CD8+ T cells attack beta cells', systemsInvolved: ['Endocrine', 'Immune'], keyMediators: ['Anti-GAD65 antibodies', 'Anti-IA2 antibodies', 'Anti-insulin antibodies'], contribution: 'Primary cause - destroys >90% of beta cells before clinical onset' },
          { name: 'Insulin Deficiency', description: 'Absence of insulin prevents glucose uptake and causes hyperglycemia', systemsInvolved: ['Endocrine', 'Metabolic'], contribution: 'Causes all clinical manifestations' },
        ],
        riskFactors: [
          { name: 'HLA Genetics', type: 'non-modifiable', impact: 'major', description: 'HLA-DR3/DR4 associated with increased risk' },
          { name: 'Family History', type: 'non-modifiable', impact: 'moderate', description: '5-6% risk if sibling affected' },
          { name: 'Environmental Triggers', type: 'partially-modifiable', impact: 'moderate', description: 'Viral infections may trigger autoimmunity in susceptible individuals' },
        ],
        geneticFactors: ['HLA-DR3', 'HLA-DR4', 'PTPN22', 'INS gene'],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Polyuria', prevalence: 'very-common', description: 'Frequent urination from osmotic diuresis', timing: 'Early presentation' },
          { name: 'Polydipsia', prevalence: 'very-common', description: 'Excessive thirst from dehydration', timing: 'Early presentation' },
          { name: 'Weight Loss', prevalence: 'very-common', description: 'Despite normal/increased appetite', timing: 'Early presentation' },
        ],
        labFindings: [
          { testName: 'Fasting Glucose', abnormality: '≥126 mg/dL', normalRange: '<100 mg/dL', significance: 'Diagnostic criterion' },
          { testName: 'HbA1c', abnormality: '≥6.5%', normalRange: '<5.7%', significance: 'Reflects 3-month average glucose' },
          { testName: 'C-peptide', abnormality: 'Low or undetectable', significance: 'Distinguishes from T2DM - indicates no endogenous insulin' },
          { testName: 'Autoantibodies', abnormality: 'Positive GAD65, IA2, or insulin antibodies', significance: 'Confirms autoimmune etiology' },
        ],
      },
      progression: {
        naturalHistory: 'Without insulin, progresses rapidly to DKA and death. With treatment, chronic complications develop over decades.',
        timelineSteps: [
          { phaseId: 'prediabetic', phase: 'preclinical', displayName: 'Preclinical Autoimmunity', timeframe: 'Months to years before diagnosis', description: 'Autoimmune destruction occurring silently', symptoms: ['Asymptomatic'], anatomicalChanges: [{ structureId: 'pancreas', structureName: 'Pancreatic Islets', changeType: 'inflammation', description: 'Insulitis - immune infiltration of islets', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.5 }, isNewAtPhase: true }], reversibility: 'irreversible' },
          { phaseId: 'new-onset', phase: 'acute', displayName: 'New Onset T1DM', timeframe: 'At diagnosis', description: '>90% beta cells destroyed, clinical diabetes', symptoms: ['Polyuria', 'Polydipsia', 'Weight loss', 'Fatigue'], anatomicalChanges: [{ structureId: 'pancreas', structureName: 'Pancreatic Beta Cells', changeType: 'necrosis', description: 'Near-complete beta cell destruction', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: false }], reversibility: 'irreversible', typicalTreatments: ['Insulin therapy initiation'] },
          { phaseId: 'established', phase: 'chronic', displayName: 'Established T1DM', timeframe: 'Lifelong after diagnosis', description: 'Requires lifelong insulin, risk of complications', symptoms: ['Depends on glycemic control'], anatomicalChanges: [{ structureId: 'pancreas', structureName: 'Pancreatic Islets', changeType: 'atrophy', description: 'Absent beta cells', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.8 }, isNewAtPhase: false }], reversibility: 'irreversible', typicalTreatments: ['Intensive insulin therapy', 'CGM', 'Pump therapy'] },
        ],
        prognosis: 'Near-normal life expectancy with good glycemic control. Risk of microvascular and macrovascular complications.',
      },
      complications: [
        { complicationId: 'dka', name: 'Diabetic Ketoacidosis', category: 'acute', severity: 'life-threatening', riskLevel: 'moderate', description: 'Metabolic emergency from severe insulin deficiency', mechanism: 'Without insulin, lipolysis increases producing ketone bodies causing acidosis', affectedStructures: [{ structureId: 'blood', structureName: 'Blood', effect: 'Acidosis, dehydration', highlightColor: '#dc2626' }], warningSymptoms: ['Nausea/vomiting', 'Abdominal pain', 'Fruity breath', 'Altered mental status'], treatment: 'IV fluids, IV insulin, electrolyte replacement', preventable: true },
        { complicationId: 'retinopathy', name: 'Diabetic Retinopathy', category: 'chronic', severity: 'major', riskLevel: 'high', description: 'Microvascular damage to retina', mechanism: 'Chronic hyperglycemia damages retinal microvasculature', affectedStructures: [{ structureId: 'eyes', structureName: 'Retina', effect: 'Microaneurysms, hemorrhages, neovascularization', highlightColor: '#ef4444' }], warningSymptoms: ['Often asymptomatic until advanced', 'Floaters', 'Vision changes'], prevention: ['Good glycemic control', 'Annual eye exams'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'basal-bolus-insulin', name: 'Basal-Bolus Insulin Regimen', modality: 'pharmacological', description: 'Long-acting basal insulin plus rapid-acting insulin at meals', mechanism: 'Mimics physiological insulin secretion', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute', 'chronic'], goals: ['HbA1c <7%', 'Minimize hypoglycemia', 'Prevent complications'], expectedOutcomes: ['Near-normal glycemia achievable'], sideEffects: ['Hypoglycemia', 'Weight gain', 'Injection site reactions'], monitoring: ['Self-monitoring BG', 'CGM', 'HbA1c every 3 months'], explanations: { level1: 'Insulin injections that replace what your pancreas cant make anymore.', level2: 'Since your pancreas cant make insulin, you take long-acting insulin once daily for baseline needs and fast-acting insulin at meals to cover the food you eat.', level3: 'Basal-bolus mimics physiological insulin: basal (glargine/detemir/degludec) provides 24-hour coverage, rapid-acting (lispro/aspart/glulisine) covers meals. Doses adjusted based on BG patterns.', level4: 'Basal insulin maintains fasting normoglycemia by suppressing hepatic glucose output. Bolus insulin is calculated using insulin-to-carb ratio and correction factor. CGM with automated insulin delivery approaching closed-loop.', level5: 'Insulin binds tyrosine kinase receptors, activating PI3K-Akt pathway for glucose uptake via GLUT4 translocation. Basal analog modifications (acylation, PEGylation) extend duration. Ultra-rapid analogs use faster absorption kinetics.' } },
        { treatmentId: 'insulin-pump', name: 'Insulin Pump Therapy', modality: 'pharmacological', description: 'Continuous subcutaneous insulin infusion', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: false, appropriatePhases: ['chronic'], goals: ['Improved glycemic control', 'Lifestyle flexibility'], expectedOutcomes: ['Reduced HbA1c', 'Less hypoglycemia', 'Improved quality of life'], explanations: { level1: 'A small device you wear that continuously delivers insulin, replacing daily injections.', level2: 'The pump delivers small amounts of rapid-acting insulin throughout the day and extra doses at meals, closely mimicking a healthy pancreas.', level3: 'CSII delivers rapid-acting insulin at programmed basal rates with patient-activated boluses. Hybrid closed-loop systems adjust basal automatically based on CGM. Reduces hypoglycemia and A1c variability.', level4: 'Automated insulin delivery (AID) systems use algorithms to modulate basal delivery based on CGM trends, predicting and preventing hypo/hyperglycemia. Meal announcement and carb counting still required.', level5: 'Control algorithms use predictive models (PID, MPC) to optimize insulin delivery. Bihormonal pumps adding glucagon may further reduce hypoglycemia. Fully closed-loop systems approaching but not yet available.' } },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'pancreas', structureName: 'Pancreas (Islets)', role: 'primary-site', involvement: 'Beta cells destroyed by autoimmunity', highlightColor: '#dc2626', showByDefault: true }],
        secondaryStructures: [
          { structureId: 'eyes', structureName: 'Eyes', role: 'target-organ', involvement: 'Retinopathy', highlightColor: '#f97316', showByDefault: false },
          { structureId: 'kidneys', structureName: 'Kidneys', role: 'target-organ', involvement: 'Nephropathy', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Endocrine', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['endocrine'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: 'Your body attacks and destroys the cells that make insulin, so you need insulin shots to survive.',
        level2: 'In type 1 diabetes, your immune system mistakenly destroys insulin-producing cells in the pancreas. Without insulin, glucose cant enter cells and builds up in the blood.',
        level3: 'T1DM is autoimmune destruction of pancreatic beta cells leading to absolute insulin deficiency. Presents with hyperglycemia symptoms, often DKA. Requires lifelong insulin.',
        level4: 'CD8+ cytotoxic T cells and CD4+ T helper cells mediate beta cell destruction. Genetic susceptibility (HLA) plus environmental trigger initiates autoimmunity. >90% beta cell mass lost at diagnosis.',
        level5: 'Insulitis involves infiltration by dendritic cells, macrophages, and T cells. GAD65 is a major autoantigen. Beta cell apoptosis occurs via perforin/granzyme and Fas-FasL pathways. C-peptide reflects residual beta cell function.',
      },
      relatedConditions: ['type-2-diabetes', 'hypothyroidism'],
      comorbidities: ['Autoimmune thyroid disease', 'Celiac disease', 'Addisons disease'],
      epidemiology: { prevalence: '~1.6 million in US', incidence: '~15 per 100,000 per year', demographics: 'Usually diagnosed in children/young adults but can occur at any age' },
      clinicalPearls: ['Always rule out T1DM in young adults presenting with diabetes - check C-peptide and antibodies', 'DKA can be the presenting symptom - dont miss it', 'Screen for thyroid disease and celiac disease at diagnosis', 'Target HbA1c <7% but individualize based on hypoglycemia risk'],
      patientEducation: ['Always have fast-acting glucose for hypoglycemia', 'Never skip insulin even when sick - sick day rules are critical', 'Check blood glucose often, especially with CGM if available', 'Learn to count carbohydrates accurately'],
      emergencyWarnings: ['Nausea, vomiting, and high blood sugar may be DKA - go to ER', 'Confusion with low blood sugar needs immediate sugar and may need glucagon', 'If unable to keep fluids down, seek emergency care'],
    },
  ],

  // ============================================
  // PSYCHIATRIC CONDITIONS
  // ============================================

  // Major Depressive Disorder
  [
    'major-depression',
    {
      conditionId: 'major-depression',
      name: 'Major Depressive Disorder',
      aliases: ['MDD', 'Clinical Depression', 'Unipolar Depression'],
      icdCode: 'F32',
      category: 'psychiatric',
      subcategory: 'Mood Disorders',
      description: 'Mood disorder characterized by persistent depressed mood, anhedonia, and neurovegetative symptoms causing significant functional impairment',
      pathophysiology: {
        summary: 'Complex neurobiological disorder involving neurotransmitter imbalances, HPA axis dysregulation, and neural circuit dysfunction',
        mechanisms: [
          { name: 'Monoamine Deficiency', description: 'Reduced serotonin, norepinephrine, and dopamine signaling', systemsInvolved: ['Nervous'], keyMediators: ['Serotonin', 'Norepinephrine', 'Dopamine'], contribution: 'Basis for antidepressant mechanisms' },
          { name: 'HPA Axis Dysregulation', description: 'Chronic stress causes elevated cortisol and hippocampal changes', systemsInvolved: ['Nervous', 'Endocrine'], keyMediators: ['Cortisol', 'CRH'], contribution: 'Stress-depression link' },
          { name: 'Neuroplasticity Deficits', description: 'Reduced BDNF and synaptic plasticity in prefrontal cortex and hippocampus', systemsInvolved: ['Nervous'], keyMediators: ['BDNF'], contribution: 'Explains delayed antidepressant response' },
        ],
        riskFactors: [
          { name: 'Family History', type: 'non-modifiable', impact: 'major', description: '2-3x increased risk with first-degree relative affected' },
          { name: 'Adverse Childhood Events', type: 'non-modifiable', impact: 'major', description: 'Early life stress increases vulnerability' },
          { name: 'Chronic Medical Illness', type: 'partially-modifiable', impact: 'moderate', description: 'Depression common with chronic disease' },
          { name: 'Substance Use', type: 'modifiable', impact: 'moderate', description: 'Alcohol and drugs increase risk', intervention: 'Cessation' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Depressed Mood', prevalence: 'very-common', description: 'Persistent sadness, emptiness, hopelessness', timing: 'Most of the day, nearly every day' },
          { name: 'Anhedonia', prevalence: 'very-common', description: 'Loss of interest or pleasure in activities', timing: 'Persistent' },
          { name: 'Sleep Disturbance', prevalence: 'very-common', description: 'Insomnia or hypersomnia', quality: 'Early morning awakening common' },
        ],
        associatedSymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Loss of energy nearly every day' },
          { name: 'Cognitive Changes', prevalence: 'common', description: 'Poor concentration, indecisiveness' },
          { name: 'Suicidal Ideation', prevalence: 'common', description: 'Thoughts of death or suicide', timing: 'Variable' },
        ],
        labFindings: [
          { testName: 'PHQ-9', abnormality: 'Score ≥10 suggests moderate depression', significance: 'Validated screening and monitoring tool' },
          { testName: 'TSH', abnormality: 'Check to rule out hypothyroidism', significance: 'Organic cause of depression symptoms' },
        ],
      },
      progression: {
        naturalHistory: 'Episodic course. 50% of first episodes recur. Without treatment, episodes last 6-12 months on average.',
        timelineSteps: [
          { phaseId: 'acute', phase: 'acute', displayName: 'Acute Depressive Episode', timeframe: 'Weeks to months', description: 'Active depression with full symptom criteria', symptoms: ['Depressed mood', 'Anhedonia', 'Neurovegetative symptoms'], anatomicalChanges: [{ structureId: 'brain', structureName: 'Prefrontal Cortex/Hippocampus', changeType: 'dysfunction', description: 'Reduced activity and volume in depression circuits', severity: 'moderate', visualIndicator: { color: '#7c3aed', pulse: false, opacity: 0.6 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Antidepressants', 'Psychotherapy', 'Combination'] },
          { phaseId: 'continuation', phase: 'established', displayName: 'Continuation Phase', timeframe: '4-9 months after response', description: 'Continue treatment to prevent relapse', symptoms: ['Symptoms improving or resolved'], anatomicalChanges: [{ structureId: 'brain', structureName: 'Brain', changeType: 'dysfunction', description: 'Normalizing neural function', severity: 'mild', visualIndicator: { color: '#3b82f6', pulse: false, opacity: 0.4 }, isNewAtPhase: false }], reversibility: 'reversible', typicalTreatments: ['Continue acute phase treatment'] },
          { phaseId: 'maintenance', phase: 'chronic', displayName: 'Maintenance Phase', timeframe: 'Indefinite for recurrent depression', description: 'Long-term treatment to prevent recurrence', symptoms: ['In remission'], anatomicalChanges: [], reversibility: 'reversible', typicalTreatments: ['Long-term antidepressant', 'Ongoing psychotherapy as needed'] },
        ],
        prognosis: 'Most episodes remit with treatment. Recurrence risk increases with each episode. 15-20% develop chronic course.',
      },
      complications: [
        { complicationId: 'suicide', name: 'Suicide', category: 'acute', severity: 'life-threatening', riskLevel: 'moderate', description: 'Death by suicide in ~15% of severe cases', mechanism: 'Hopelessness, impulsivity, and neurobiological factors contribute', affectedStructures: [], warningSymptoms: ['Suicidal ideation', 'Plans or means', 'Giving away possessions', 'Sudden calm after severe depression'], prevention: ['Treatment of depression', 'Safety planning', 'Lethal means restriction'], preventable: true },
        { complicationId: 'functional-impairment', name: 'Chronic Functional Impairment', category: 'chronic', severity: 'major', riskLevel: 'high', description: 'Disability from depression', mechanism: 'Untreated depression impairs work, relationships, self-care', affectedStructures: [], warningSymptoms: ['Unable to work', 'Social isolation', 'Self-neglect'], prevention: ['Early and adequate treatment'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'ssri', name: 'SSRIs', modality: 'pharmacological', description: 'Selective serotonin reuptake inhibitors', mechanism: 'Block serotonin transporter, increasing synaptic serotonin', efficacy: 'effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute', 'established', 'chronic'], goals: ['Remission (PHQ-9 <5)', 'Prevent relapse'], medicationIds: ['sertraline', 'escitalopram'], sideEffects: ['Nausea', 'Sexual dysfunction', 'Activation in first weeks'], monitoring: ['PHQ-9 monthly initially', 'Suicidality assessment'], explanations: { level1: 'Medicine that helps your brain make better use of serotonin, a chemical that affects mood.', level2: 'SSRIs increase serotonin levels in the brain by preventing its reabsorption, which improves mood over time.', level3: 'SSRIs are first-line for MDD. Takes 4-6 weeks for full effect. If partial response at 6 weeks, augment or switch. Continue 6-12 months after remission.', level4: 'SSRIs block SERT transporter. Delayed clinical response reflects downstream changes including receptor desensitization and increased neuroplasticity via BDNF. Choose based on side effect profile and interactions.', level5: 'Chronic SSRI increases serotonin signaling, downregulates 5-HT1A autoreceptors (disinhibiting raphe firing), and stimulates neurogenesis in hippocampus. BDNF-TrkB signaling critical for antidepressant effects.' } },
        { treatmentId: 'cbt', name: 'Cognitive Behavioral Therapy', modality: 'lifestyle', description: 'Structured psychotherapy addressing cognitive distortions', mechanism: 'Modifies negative thought patterns and behaviors', efficacy: 'effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute', 'established'], goals: ['Learn skills to manage depression', 'Prevent recurrence'], expectedOutcomes: ['Similar efficacy to medications for mild-moderate MDD'], explanations: { level1: 'Talking therapy that helps you change negative thinking patterns.', level2: 'CBT helps you identify and change unhelpful thought patterns and behaviors that contribute to depression.', level3: 'CBT is first-line psychotherapy for MDD. 12-20 sessions typically. Addresses cognitive distortions (catastrophizing, black-and-white thinking) and behavioral activation. Prevents recurrence.', level4: 'CBT modifies negative automatic thoughts and dysfunctional core beliefs. Behavioral activation counters withdrawal. Comparable to medications acutely; may have more durable effects.', level5: 'CBT produces neural changes including normalized prefrontal-amygdala connectivity and reduced amygdala hyperactivity. Engages cognitive control circuits to regulate emotional responses.' } },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'brain', structureName: 'Brain (Limbic System/PFC)', role: 'primary-site', involvement: 'Altered function in emotion and cognitive circuits', highlightColor: '#7c3aed', showByDefault: true }],
        systemsInvolved: ['Nervous'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
        focusRegion: 'head',
      },
      explanations: {
        level1: 'A medical condition that causes persistent feelings of sadness, hopelessness, and loss of interest in things you used to enjoy.',
        level2: 'Depression is a brain condition where chemical imbalances and changes in brain function cause persistent low mood, loss of pleasure, and other symptoms that affect daily life.',
        level3: 'MDD is diagnosed by ≥5 symptoms including depressed mood or anhedonia for ≥2 weeks. Monoamine hypothesis guides treatment. First-line: SSRIs, SNRIs, or psychotherapy.',
        level4: 'Pathophysiology involves serotonin/norepinephrine deficiency, HPA axis hyperactivity, reduced BDNF/neuroplasticity, and inflammatory dysregulation. Treatment restores monoamine signaling and promotes neuroplasticity.',
        level5: 'Depression involves dysregulated cortico-limbic circuits. Reduced PFC activity fails to inhibit hyperactive amygdala. Hippocampal volume loss from chronic cortisol exposure is reversible with treatment. Inflammation (elevated IL-6, TNF) contributes to subset of patients.',
      },
      relatedConditions: ['anxiety-disorder', 'bipolar-disorder'],
      comorbidities: ['Anxiety disorders', 'Substance use disorders', 'Chronic pain'],
      epidemiology: { prevalence: '7% annual prevalence', incidence: 'Lifetime risk 15-20%', demographics: 'Women 2x more common; onset typically 20s-30s' },
      clinicalPearls: ['Always assess suicide risk', 'Most antidepressants take 4-6 weeks for full effect - counsel patients', 'Dont stop antidepressants early - continue 6-12 months minimum after remission', 'If partial response, augment (lithium, atypical antipsychotic) or switch'],
      patientEducation: ['Depression is a medical illness, not a character flaw', 'Medications take several weeks to work', 'Dont stop medication suddenly - can cause withdrawal', 'Exercise, sleep, and social connection help alongside treatment'],
      emergencyWarnings: ['If you have thoughts of hurting yourself, call 988 (Suicide Hotline) or go to ER', 'New medication can rarely cause increased agitation - report this immediately'],
    },
  ],

  // Generalized Anxiety Disorder
  [
    'anxiety-disorder',
    {
      conditionId: 'anxiety-disorder',
      name: 'Generalized Anxiety Disorder',
      aliases: ['GAD', 'Chronic Anxiety', 'Anxiety Neurosis'],
      icdCode: 'F41.1',
      category: 'psychiatric',
      subcategory: 'Anxiety Disorders',
      description: 'Persistent and excessive worry about various life domains causing significant distress and functional impairment',
      pathophysiology: {
        summary: 'Dysregulation of fear circuits involving amygdala hyperactivity and prefrontal cortex underactivity',
        mechanisms: [
          { name: 'Amygdala Hyperactivity', description: 'Overactive threat detection and fear response', systemsInvolved: ['Nervous'], keyMediators: ['GABA (reduced)', 'Glutamate (increased)'], contribution: 'Generates excessive fear/worry' },
          { name: 'PFC Underactivity', description: 'Reduced top-down cognitive control of emotion', systemsInvolved: ['Nervous'], contribution: 'Fails to inhibit worry' },
        ],
        riskFactors: [
          { name: 'Family History', type: 'non-modifiable', impact: 'major', description: '~30% heritability' },
          { name: 'Temperament', type: 'partially-modifiable', impact: 'moderate', description: 'Behavioral inhibition and neuroticism' },
          { name: 'Chronic Stress', type: 'modifiable', impact: 'moderate', description: 'Life stressors precipitate and maintain anxiety', intervention: 'Stress management' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Excessive Worry', prevalence: 'very-common', description: 'Difficult to control worry about multiple domains', timing: 'More days than not for ≥6 months' },
          { name: 'Restlessness', prevalence: 'very-common', description: 'Feeling keyed up or on edge' },
          { name: 'Muscle Tension', prevalence: 'common', description: 'Chronic muscle tightness', location: 'Shoulders, neck, back' },
        ],
        associatedSymptoms: [
          { name: 'Sleep Disturbance', prevalence: 'very-common', description: 'Difficulty falling asleep, restless sleep' },
          { name: 'Concentration Problems', prevalence: 'common', description: 'Mind going blank, difficulty focusing' },
          { name: 'Fatigue', prevalence: 'common', description: 'From chronic tension and poor sleep' },
        ],
        labFindings: [
          { testName: 'GAD-7', abnormality: '≥10 suggests moderate anxiety', significance: 'Validated screening tool' },
          { testName: 'TSH', abnormality: 'Check to rule out hyperthyroidism', significance: 'Organic cause of anxiety symptoms' },
        ],
      },
      progression: {
        naturalHistory: 'Chronic course with waxing and waning symptoms. Early onset associated with more chronic course.',
        timelineSteps: [
          { phaseId: 'active', phase: 'established', displayName: 'Active GAD', timeframe: 'Chronic', description: 'Persistent excessive worry and somatic symptoms', symptoms: ['Excessive worry', 'Restlessness', 'Muscle tension', 'Sleep problems'], anatomicalChanges: [{ structureId: 'brain', structureName: 'Amygdala/PFC', changeType: 'dysfunction', description: 'Amygdala hyperactivity, reduced PFC control', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['SSRIs/SNRIs', 'CBT', 'Buspirone'] },
        ],
        prognosis: 'Chronic but manageable. ~50% achieve remission with treatment. Relapse common without maintenance treatment.',
      },
      complications: [
        { complicationId: 'depression', name: 'Comorbid Depression', category: 'chronic', severity: 'major', riskLevel: 'high', description: 'MDD develops in 60% of GAD patients', mechanism: 'Shared neurobiological vulnerabilities', affectedStructures: [], warningSymptoms: ['Persistent sadness', 'Anhedonia', 'Hopelessness'], prevention: ['Treat anxiety early and adequately'], preventable: true },
        { complicationId: 'substance-use', name: 'Substance Use Disorder', category: 'chronic', severity: 'major', riskLevel: 'moderate', description: 'Self-medication with alcohol or benzodiazepines', mechanism: 'Temporary anxiolytic effect reinforces use', affectedStructures: [], warningSymptoms: ['Increasing alcohol/drug use', 'Using substances to cope'], prevention: ['Treat anxiety, avoid benzodiazepine dependence'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'ssri-gad', name: 'SSRIs/SNRIs', modality: 'pharmacological', description: 'First-line pharmacotherapy', mechanism: 'Increase serotonin (SSRIs) or serotonin and norepinephrine (SNRIs)', efficacy: 'effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['established'], goals: ['Reduce worry and anxiety', 'Improve function'], medicationIds: ['escitalopram', 'duloxetine'], sideEffects: ['Nausea', 'Activation initially', 'Sexual dysfunction'], explanations: { level1: 'Medicine that helps balance brain chemicals to reduce worry and anxiety.', level2: 'SSRIs and SNRIs increase calming neurotransmitters in the brain, reducing excessive worry over time.', level3: 'SSRIs (escitalopram, sertraline) and SNRIs (duloxetine, venlafaxine) are first-line. Effect in 4-6 weeks. Continue at least 12 months.', level4: 'These medications reduce amygdala hyperactivity and improve prefrontal regulation of emotion. SNRIs may have additional benefit through noradrenergic effects on physical symptoms.', level5: 'Chronic SSRI/SNRI treatment normalizes amygdala-PFC connectivity. Serotonin modulates GABA/glutamate balance. Response correlates with reduced amygdala reactivity on fMRI.' } },
        { treatmentId: 'cbt-gad', name: 'Cognitive Behavioral Therapy', modality: 'lifestyle', description: 'Evidence-based psychotherapy for anxiety', mechanism: 'Addresses worry cognitions and avoidance behaviors', efficacy: 'effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['established'], goals: ['Learn to manage worry', 'Reduce avoidance'], explanations: { level1: 'Therapy that teaches you skills to control worry and reduce anxiety.', level2: 'CBT helps you recognize anxious thoughts and change unhelpful thinking patterns while gradually facing fears.', level3: 'CBT for GAD targets intolerance of uncertainty, metacognitive beliefs about worry, and behavioral avoidance. Includes relaxation training. 12-20 sessions typical.', level4: 'Applied relaxation and cognitive restructuring are core components. Exposure-based techniques address worry domains. Mindfulness-based approaches also effective.', level5: 'CBT increases prefrontal regulation of amygdala via top-down cognitive control mechanisms. Treatment response associated with increased PFC activity and reduced amygdala reactivity.' } },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'brain', structureName: 'Brain (Amygdala/PFC)', role: 'primary-site', involvement: 'Fear circuit dysregulation', highlightColor: '#f97316', showByDefault: true }],
        systemsInvolved: ['Nervous'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
        focusRegion: 'head',
      },
      explanations: {
        level1: "A condition where you worry too much about everyday things and can't seem to stop.",
        level2: "GAD is when your brain's alarm system is overactive, causing you to worry excessively about many things even when there's no real danger.",
        level3: 'GAD is diagnosed by excessive worry about multiple domains, difficult to control, for ≥6 months with ≥3 associated symptoms. First-line: SSRIs/SNRIs and/or CBT.',
        level4: 'Pathophysiology involves amygdala hyperactivity with inadequate PFC top-down regulation. GABA-ergic deficits and glutamate excess in anxiety circuits. 5-HT1A receptor dysfunction.',
        level5: 'GAD involves failure of extinction learning (vmPFC-amygdala circuit), intolerance of uncertainty (insular cortex), and aberrant error monitoring (ACC). Treatment normalizes cortico-limbic connectivity.',
      },
      relatedConditions: ['major-depression', 'panic-disorder'],
      comorbidities: ['Major depression (60%)', 'Other anxiety disorders', 'Substance use'],
      epidemiology: { prevalence: '3-6% lifetime', incidence: 'Gradual onset, often in childhood/adolescence', demographics: 'Women 2x more common; mean onset 30 years' },
      clinicalPearls: ['GAD and depression commonly co-occur - screen for both', 'Avoid long-term benzodiazepines - risk of dependence', 'SSRIs/SNRIs take weeks to work - warn patients', 'CBT has durable effects and should be offered'],
      patientEducation: ['Anxiety is treatable - many people improve significantly', 'Avoid caffeine and alcohol which can worsen anxiety', 'Regular exercise and sleep help reduce anxiety', 'Medication takes several weeks to fully work'],
    },
  ],

  // ============================================
  // INFECTIOUS CONDITIONS
  // ============================================

  // Community-Acquired Pneumonia
  [
    'pneumonia',
    {
      conditionId: 'pneumonia',
      name: 'Community-Acquired Pneumonia',
      aliases: ['CAP', 'Bacterial Pneumonia', 'Lung Infection'],
      icdCode: 'J18.9',
      category: 'infectious',
      subcategory: 'Respiratory Infections',
      description: 'Acute infection of the lung parenchyma acquired outside of healthcare settings, causing alveolar inflammation and consolidation',
      pathophysiology: {
        summary: 'Microbial invasion of lower respiratory tract causes inflammatory response with alveolar exudate and consolidation',
        mechanisms: [
          { name: 'Alveolar Invasion', description: 'Pathogens reach alveoli via aspiration or inhalation', systemsInvolved: ['Respiratory', 'Immune'], contribution: 'Initial infection' },
          { name: 'Inflammatory Response', description: 'Neutrophil infiltration and cytokine release cause exudate', systemsInvolved: ['Respiratory', 'Immune'], keyMediators: ['IL-1', 'IL-6', 'TNF-alpha', 'Neutrophils'], contribution: 'Causes consolidation and symptoms' },
        ],
        riskFactors: [
          { name: 'Age >65', type: 'non-modifiable', impact: 'major', description: 'Impaired immune response' },
          { name: 'Smoking', type: 'modifiable', impact: 'major', description: 'Impairs mucociliary clearance', intervention: 'Smoking cessation' },
          { name: 'COPD/Asthma', type: 'partially-modifiable', impact: 'major', description: 'Impaired lung defenses' },
          { name: 'Immunosuppression', type: 'partially-modifiable', impact: 'major', description: 'Reduced pathogen clearance' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Cough', prevalence: 'very-common', description: 'Productive cough with purulent sputum', quality: 'Productive' },
          { name: 'Fever', prevalence: 'very-common', description: 'Often with chills', timing: 'Acute onset' },
          { name: 'Dyspnea', prevalence: 'common', description: 'Shortness of breath', timing: 'With exertion or at rest in severe cases' },
        ],
        physicalFindings: [
          { name: 'Crackles/Rales', examType: 'Lung auscultation', description: 'Inspiratory crackles over affected area', diagnosticValue: 'Suggests consolidation' },
          { name: 'Dullness to Percussion', examType: 'Lung percussion', description: 'Dull over consolidated lung', diagnosticValue: 'Indicates consolidation or effusion' },
          { name: 'Bronchial Breath Sounds', examType: 'Lung auscultation', description: 'Loud, tubular sounds over consolidation', diagnosticValue: 'Classic for lobar pneumonia' },
        ],
        labFindings: [
          { testName: 'WBC', abnormality: 'Elevated (leukocytosis)', significance: 'Indicates infection' },
          { testName: 'Chest X-ray', abnormality: 'Infiltrate, consolidation, or air bronchograms', significance: 'Confirms pneumonia' },
          { testName: 'Procalcitonin', abnormality: 'Elevated >0.25', significance: 'Suggests bacterial etiology' },
        ],
        imagingFindings: [{ modality: 'Chest X-ray', finding: 'Lobar or patchy consolidation', significance: 'Diagnostic', structures: ['Lung'] }],
      },
      progression: {
        naturalHistory: 'Untreated bacterial pneumonia can progress to respiratory failure, sepsis, and death. With treatment, most resolve in 1-3 weeks.',
        timelineSteps: [
          { phaseId: 'acute', phase: 'acute', displayName: 'Acute Pneumonia', timeframe: 'Hours to days', description: 'Active infection with consolidation', symptoms: ['Cough', 'Fever', 'Dyspnea', 'Pleuritic chest pain'], anatomicalChanges: [{ structureId: 'lungs', structureName: 'Lung (affected lobe)', changeType: 'inflammation', description: 'Alveolar consolidation with exudate', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Antibiotics', 'Supportive care'], labMarkers: ['Elevated WBC', 'Elevated procalcitonin'] },
          { phaseId: 'resolution', phase: 'remission', displayName: 'Resolution', timeframe: '1-3 weeks with treatment', description: 'Healing with clearing of infection', symptoms: ['Improving cough', 'Fatigue may persist'], anatomicalChanges: [{ structureId: 'lungs', structureName: 'Lung', changeType: 'inflammation', description: 'Resolving consolidation', severity: 'mild', visualIndicator: { color: '#22c55e', pulse: false, opacity: 0.4 }, isNewAtPhase: false }], reversibility: 'reversible' },
        ],
        prognosis: 'Mortality 1-5% for outpatients, 5-15% for hospitalized, 20-50% for ICU. Most recover fully.',
      },
      complications: [
        { complicationId: 'parapneumonic-effusion', name: 'Parapneumonic Effusion/Empyema', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Fluid or pus in pleural space', mechanism: 'Inflammation spreads to pleura', affectedStructures: [{ structureId: 'pleura', structureName: 'Pleural Space', effect: 'Effusion', highlightColor: '#f97316' }], warningSymptoms: ['Persistent fever', 'Pleuritic pain', 'Not improving'], treatment: 'Drainage, antibiotics', preventable: true },
        { complicationId: 'respiratory-failure', name: 'Respiratory Failure', category: 'acute', severity: 'life-threatening', riskLevel: 'moderate', description: 'Severe hypoxemia requiring ventilation', mechanism: 'Extensive consolidation impairs gas exchange', affectedStructures: [{ structureId: 'lungs', structureName: 'Lungs', effect: 'Bilateral involvement', highlightColor: '#dc2626' }], warningSymptoms: ['Severe dyspnea', 'Cyanosis', 'Altered mental status'], treatment: 'Oxygen, mechanical ventilation', preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'outpatient-abx', name: 'Outpatient Antibiotic Therapy', modality: 'pharmacological', description: 'Oral antibiotics for non-severe CAP', mechanism: 'Kill or inhibit bacterial pathogens', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute'], goals: ['Eradicate infection', 'Clinical cure'], expectedOutcomes: ['Improvement in 48-72 hours'], medicationIds: ['amoxicillin', 'azithromycin', 'doxycycline'], explanations: { level1: 'Antibiotic pills to kill the bacteria causing your lung infection.', level2: 'Antibiotics fight the bacterial infection in your lungs. For milder pneumonia, you can take pills at home.', level3: 'Healthy outpatients: amoxicillin, doxycycline, or macrolide. With comorbidities: fluoroquinolone or beta-lactam + macrolide. 5-7 days usually sufficient.', level4: 'Coverage targets S. pneumoniae, H. influenzae, atypicals (Mycoplasma, Chlamydia). Local resistance patterns guide empiric choice. De-escalate when culture available.', level5: 'S. pneumoniae remains most common pathogen. Macrolide resistance increasing; consider respiratory fluoroquinolone in high-resistance areas. Procalcitonin can guide duration.' } },
        { treatmentId: 'inpatient-abx', name: 'Inpatient Antibiotic Therapy', modality: 'pharmacological', description: 'IV antibiotics for severe CAP', mechanism: 'Kill or inhibit bacterial pathogens', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute'], goals: ['Eradicate infection', 'Prevent death'], medicationIds: ['ceftriaxone', 'azithromycin', 'levofloxacin'], explanations: { level1: 'Strong antibiotics given through an IV to fight severe lung infection.', level2: 'For more severe pneumonia, you need IV antibiotics in the hospital to ensure the medication reaches your lungs effectively.', level3: 'Beta-lactam (ceftriaxone, ampicillin-sulbactam) + macrolide OR respiratory fluoroquinolone. Add coverage for MRSA/Pseudomonas if risk factors. Switch to oral when stable.', level4: 'Combination therapy covers typical and atypical pathogens and may reduce mortality through immunomodulatory effects of macrolides. Assess CURB-65 or PSI for disposition.', level5: 'Macrolides have anti-inflammatory effects beyond antibacterial activity. IDSA/ATS 2019 guidelines recommend against routine MRSA/Pseudomonas coverage without specific risk factors.' } },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'lungs', structureName: 'Lungs', role: 'primary-site', involvement: 'Site of infection and consolidation', highlightColor: '#ef4444', showByDefault: true }],
        secondaryStructures: [{ structureId: 'pleura', structureName: 'Pleura', role: 'secondary-site', involvement: 'May develop effusion', highlightColor: '#f97316', showByDefault: false }],
        systemsInvolved: ['Respiratory', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['respiratory'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1: 'An infection in your lungs caused by germs that fills the air sacs with fluid and pus.',
        level2: 'Pneumonia is when bacteria or viruses infect your lungs, causing inflammation and fluid buildup in the air sacs, making it hard to breathe.',
        level3: 'CAP is acute infection of lung parenchyma acquired outside healthcare settings. Most common pathogens: S. pneumoniae, H. influenzae, atypicals, respiratory viruses. Diagnose clinically + CXR.',
        level4: 'Severity assessment (CURB-65, PSI) guides disposition. Most common pathogen is S. pneumoniae. Atypical pathogens (Mycoplasma, Legionella) important in younger patients. Consider viral etiology.',
        level5: 'Alveolar macrophages and neutrophils mount initial defense. Inflammatory cascade causes alveolar exudate with neutrophils, fibrin, and bacteria (red hepatization → gray hepatization → resolution stages of lobar pneumonia).',
      },
      relatedConditions: ['copd', 'asthma'],
      comorbidities: ['COPD', 'Heart failure', 'Diabetes', 'CKD'],
      epidemiology: { prevalence: '~4-5 million cases/year in US', incidence: '5-11 per 1000 adults annually', demographics: 'Higher in elderly, smokers, immunocompromised' },
      clinicalPearls: ['Get a chest X-ray - clinical diagnosis alone is inaccurate', 'Use CURB-65 or PSI to guide admission decision', 'Pneumococcal vaccine prevents most severe CAP', 'If not improving in 48-72 hours, reassess and consider complications'],
      patientEducation: ['Complete the full course of antibiotics', 'Rest and drink plenty of fluids', 'You should start feeling better in 2-3 days', 'Cough and fatigue may persist for weeks - this is normal', 'Get pneumonia and flu vaccines when recovered'],
      emergencyWarnings: ['Difficulty breathing at rest', 'Confusion or altered mental status', 'Chest pain', 'Coughing up blood', 'Fever not improving after 2-3 days of antibiotics'],
    },
  ],

  // Urinary Tract Infection
  [
    'uti',
    {
      conditionId: 'uti',
      name: 'Urinary Tract Infection',
      aliases: ['UTI', 'Bladder Infection', 'Cystitis'],
      icdCode: 'N39.0',
      category: 'infectious',
      subcategory: 'Urinary Infections',
      description: 'Bacterial infection of the urinary tract, most commonly affecting the bladder (cystitis) or kidneys (pyelonephritis)',
      pathophysiology: {
        summary: 'Bacterial colonization of normally sterile urinary tract, typically ascending from urethra to bladder',
        mechanisms: [
          { name: 'Ascending Infection', description: 'Bacteria from perineum ascend urethra to bladder', systemsInvolved: ['Urologic'], contribution: 'Most common route of infection' },
          { name: 'Bacterial Virulence', description: 'Uropathogenic E. coli use fimbriae to adhere to urothelium', systemsInvolved: ['Urologic'], keyMediators: ['Type 1 fimbriae', 'P fimbriae'], contribution: 'Allows colonization and invasion' },
        ],
        riskFactors: [
          { name: 'Female Sex', type: 'non-modifiable', impact: 'major', description: 'Short urethra increases risk' },
          { name: 'Sexual Activity', type: 'partially-modifiable', impact: 'moderate', description: 'Introduces bacteria to urethra', intervention: 'Post-coital voiding' },
          { name: 'Menopause', type: 'non-modifiable', impact: 'moderate', description: 'Reduced estrogen changes vaginal flora' },
          { name: 'Urinary Catheter', type: 'modifiable', impact: 'major', description: 'Direct route for bacteria', intervention: 'Remove catheter as soon as possible' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Dysuria', prevalence: 'very-common', description: 'Pain or burning with urination' },
          { name: 'Urinary Frequency', prevalence: 'very-common', description: 'Frequent urge to urinate' },
          { name: 'Urgency', prevalence: 'common', description: 'Sudden strong urge to urinate' },
        ],
        associatedSymptoms: [
          { name: 'Suprapubic Pain', prevalence: 'common', description: 'Lower abdominal discomfort', location: 'Suprapubic' },
          { name: 'Hematuria', prevalence: 'uncommon', description: 'Blood in urine' },
        ],
        labFindings: [
          { testName: 'Urinalysis', abnormality: 'Positive leukocyte esterase, nitrites, pyuria', significance: 'Suggests UTI' },
          { testName: 'Urine Culture', abnormality: '≥10^5 CFU/mL', significance: 'Confirms infection, identifies pathogen' },
        ],
      },
      progression: {
        naturalHistory: 'Uncomplicated cystitis may resolve spontaneously but often requires antibiotics. Can ascend to cause pyelonephritis.',
        timelineSteps: [
          { phaseId: 'cystitis', phase: 'acute', displayName: 'Acute Cystitis', timeframe: 'Hours to days', description: 'Bladder infection', symptoms: ['Dysuria', 'Frequency', 'Urgency', 'Suprapubic pain'], anatomicalChanges: [{ structureId: 'bladder', structureName: 'Bladder', changeType: 'inflammation', description: 'Bladder mucosal inflammation', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Short-course antibiotics'] },
          { phaseId: 'pyelonephritis', phase: 'acute', displayName: 'Pyelonephritis', timeframe: 'If ascending or hematogenous', description: 'Kidney infection', symptoms: ['Fever', 'Flank pain', 'Nausea/vomiting', 'Cystitis symptoms'], anatomicalChanges: [{ structureId: 'kidney', structureName: 'Kidney', changeType: 'inflammation', description: 'Kidney parenchymal infection', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true }], reversibility: 'reversible', typicalTreatments: ['Longer antibiotic course', 'Consider hospitalization'] },
        ],
        prognosis: 'Uncomplicated cystitis resolves quickly with treatment. Pyelonephritis may require hospitalization but usually resolves.',
      },
      complications: [
        { complicationId: 'pyelonephritis', name: 'Pyelonephritis', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Ascending infection to kidney', mechanism: 'Bacteria ascend from bladder via ureters', affectedStructures: [{ structureId: 'kidney', structureName: 'Kidney', effect: 'Parenchymal infection', highlightColor: '#ef4444' }], warningSymptoms: ['Fever', 'Flank pain', 'Nausea/vomiting'], treatment: 'Extended antibiotic course', preventable: true },
        { complicationId: 'urosepsis', name: 'Urosepsis', category: 'acute', severity: 'life-threatening', riskLevel: 'low', description: 'Sepsis from urinary source', mechanism: 'Bacteremia from UTI causes systemic inflammatory response', affectedStructures: [], warningSymptoms: ['High fever', 'Confusion', 'Hypotension', 'Tachycardia'], treatment: 'IV antibiotics, fluids, ICU if severe', preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'nitrofurantoin', name: 'Nitrofurantoin', modality: 'pharmacological', description: 'First-line for uncomplicated cystitis', mechanism: 'Urinary antiseptic concentrated in urine', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute'], goals: ['Cure infection', 'Relieve symptoms'], medicationIds: ['nitrofurantoin'], sideEffects: ['GI upset', 'Avoid if CrCl <30'], monitoring: ['Symptom resolution'], explanations: { level1: 'An antibiotic pill specifically for bladder infections.', level2: 'Nitrofurantoin concentrates in your urine to kill the bacteria causing your bladder infection.', level3: 'First-line for uncomplicated cystitis. 5-day course. High urinary concentration, minimal effect on gut flora. Avoid with significant renal impairment.', level4: 'Nitrofurantoin is reduced intracellularly to reactive intermediates that damage bacterial DNA. Achieves high urinary but low tissue concentrations - not appropriate for pyelonephritis.', level5: 'Minimal resistance development due to multiple mechanisms of action. Preserves vaginal Lactobacillus. 5-day course equals 7-day TMP-SMX efficacy.' } },
        { treatmentId: 'tmp-smx', name: 'Trimethoprim-Sulfamethoxazole', modality: 'pharmacological', description: 'Alternative first-line therapy', mechanism: 'Inhibits folate synthesis', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute'], goals: ['Cure infection'], medicationIds: ['trimethoprim-sulfamethoxazole'], sideEffects: ['Rash', 'GI upset', 'Hyperkalemia'], explanations: { level1: 'An antibiotic that stops bacteria from growing.', level2: 'TMP-SMX kills bacteria by blocking their ability to make essential vitamins (folate) they need to survive.', level3: 'First-line if local E. coli resistance <20%. 3-day course for uncomplicated cystitis. Avoid in elderly on ACE inhibitors (hyperkalemia).', level4: 'Synergistic inhibition of sequential steps in folate synthesis (DHPS by SMX, DHFR by TMP). Achieves high urinary and tissue concentrations.', level5: 'E. coli resistance increasing (20-30% in some areas) - check local antibiogram. If ≥20% resistance, use nitrofurantoin or fluoroquinolone.' } },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'bladder', structureName: 'Bladder', role: 'primary-site', involvement: 'Site of infection in cystitis', highlightColor: '#f97316', showByDefault: true }],
        secondaryStructures: [{ structureId: 'kidney', structureName: 'Kidneys', role: 'target-organ', involvement: 'May be involved in pyelonephritis', highlightColor: '#ef4444', showByDefault: false }],
        systemsInvolved: ['Urologic'],
        recommendedView: 'anterior',
        recommendedLayers: ['urologic'],
        focusRegion: 'pelvis',
      },
      explanations: {
        level1: 'A bacterial infection in your bladder or kidneys that causes burning when you pee.',
        level2: 'UTIs happen when bacteria, usually from your intestines, get into your urinary tract and multiply, causing inflammation and symptoms.',
        level3: 'UTIs are usually ascending infections from periurethral flora. E. coli causes 80%. Uncomplicated cystitis in women treatable with 3-5 day antibiotics.',
        level4: 'Uropathogenic E. coli (UPEC) use type 1 fimbriae to bind mannose on urothelium. P fimbriae associated with pyelonephritis. Host factors (estrogen, pH, Tamm-Horsfall protein) influence susceptibility.',
        level5: 'UPEC invasion of bladder epithelium creates intracellular bacterial communities that can persist and cause recurrent infections. Exfoliation is a host defense but exposes underlying cells. Genomic islands encode virulence factors.',
      },
      relatedConditions: ['bph'],
      epidemiology: { prevalence: '50% of women have at least one UTI', incidence: '~8 million UTIs/year in US', demographics: 'Much more common in women; rare in young men' },
      clinicalPearls: ['In young women with classic symptoms, can treat empirically without culture', 'Always get culture in men, pregnant women, recurrent UTI, or complicated UTI', 'Avoid fluoroquinolones for uncomplicated cystitis - save for resistant infections', 'Asymptomatic bacteriuria does NOT need treatment except in pregnancy'],
      patientEducation: ['Finish all antibiotics even if you feel better', 'Drink plenty of water', 'Urinate when you feel the urge - dont hold it', 'Wipe front to back', 'Consider voiding after intercourse'],
      emergencyWarnings: ['Fever with flank pain suggests kidney infection - seek care promptly', 'Blood in urine with fever needs evaluation', 'Symptoms not improving after 2-3 days of antibiotics'],
    },
  ],
  [
    'migraine',
    {
      conditionId: 'migraine',
      name: 'Migraine',
      aliases: ['Migraine Headache', 'Classic Migraine', 'Common Migraine'],
      icdCode: 'G43.9',
      category: 'neurologic',
      subcategory: 'Headache Disorders',
      description: 'A recurrent headache disorder characterized by moderate to severe pulsating head pain, often with nausea, vomiting, and sensitivity to light and sound.',
      pathophysiology: {
        summary: 'Migraine involves cortical spreading depression triggering trigeminovascular system activation, leading to neurogenic inflammation and pain.',
        mechanisms: [
          { name: 'Cortical Spreading Depression', description: 'Wave of neuronal depolarization spreading across cortex, causing aura and activating pain pathways', systemsInvolved: ['Nervous'], keyMediators: ['Glutamate', 'Potassium'], contribution: 'Triggers the migraine cascade' },
          { name: 'Trigeminovascular Activation', description: 'Trigeminal nerve releases CGRP and substance P causing meningeal vasodilation and inflammation', systemsInvolved: ['Nervous', 'Vascular'], keyMediators: ['CGRP', 'Substance P'], contribution: 'Produces pain and associated symptoms' },
        ],
        riskFactors: [
          { name: 'Family history', type: 'non-modifiable', impact: 'major', description: '70-80% have first-degree relative with migraine' },
          { name: 'Female sex', type: 'non-modifiable', impact: 'major', description: '3x more common in women due to hormonal factors' },
          { name: 'Stress', type: 'modifiable', impact: 'moderate', description: 'Common trigger for attacks' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Unilateral headache', prevalence: 'very-common', description: 'Throbbing pain usually on one side' },
          { name: 'Photophobia', prevalence: 'very-common', description: 'Sensitivity to light' },
          { name: 'Nausea/vomiting', prevalence: 'common', description: 'GI symptoms accompanying headache' },
        ],
        associatedSymptoms: [
          { name: 'Aura', prevalence: 'common', description: 'Visual disturbances preceding headache in ~25%' },
        ],
        physicalFindings: [],
        labFindings: [],
      },
      progression: {
        naturalHistory: 'Episodic attacks that can become chronic if frequent. Most improve with age.',
        timelineSteps: [
          {
            phaseId: 'prodrome',
            phase: 'preclinical',
            displayName: 'Prodrome',
            timeframe: 'Hours to days before',
            description: 'Warning symptoms before headache',
            symptoms: ['Fatigue', 'Mood changes', 'Food cravings'],
            anatomicalChanges: [{ structureId: 'hypothalamus', structureName: 'Hypothalamus', changeType: 'dysfunction', description: 'Hypothalamic activation', severity: 'mild', visualIndicator: { color: '#FFA500', pulse: true, opacity: 0.6 }, isNewAtPhase: true }],
            reversibility: 'reversible',
            typicalTreatments: ['Recognize triggers'],
          },
          {
            phaseId: 'attack',
            phase: 'established',
            displayName: 'Headache Phase',
            timeframe: '4-72 hours',
            description: 'Active migraine attack with severe symptoms',
            symptoms: ['Severe headache', 'Nausea', 'Light sensitivity'],
            anatomicalChanges: [{ structureId: 'trigeminal', structureName: 'Trigeminal Nerve', changeType: 'inflammation', description: 'Neurogenic inflammation', severity: 'moderate', visualIndicator: { color: '#FF0000', pulse: true, opacity: 0.8 }, isNewAtPhase: true }],
            reversibility: 'reversible',
            typicalTreatments: ['Triptans', 'NSAIDs', 'Rest in dark room'],
          },
        ],
        prognosis: 'Good with treatment. Frequency often decreases with age.',
      },
      complications: [
        {
          complicationId: 'chronic-migraine',
          name: 'Chronic Migraine',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: '≥15 headache days/month for ≥3 months',
          mechanism: 'Central sensitization from frequent attacks leading to chronic pain state',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Central sensitization', highlightColor: '#9370DB' }],
          warningSymptoms: ['Increasing headache frequency', 'Reduced triptan effectiveness'],
          preventable: true,
        },
        {
          complicationId: 'medication-overuse-headache',
          name: 'Medication Overuse Headache',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Rebound headaches from frequent acute medication use (>10-15 days/month)',
          mechanism: 'Downregulation of pain inhibition pathways from frequent analgesic use',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Altered pain processing', highlightColor: '#9370DB' }],
          warningSymptoms: ['Daily headaches', 'Needing medication more frequently'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'triptans',
          name: 'Triptans',
          modality: 'pharmacological',
          description: '5-HT1B/1D agonists for acute attacks',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['established'],
          goals: ['Abort acute attack'],
          explanations: {
            level1: 'Medicines that stop migraine attacks by narrowing blood vessels in your brain.',
            level2: 'Triptans work on serotonin receptors to reverse the blood vessel changes and inflammation causing your migraine.',
            level3: 'Selective 5-HT1B/1D agonists that cause vasoconstriction and inhibit trigeminal nerve firing. Take early in attack.',
            level4: 'Triptans activate presynaptic 5-HT1D receptors inhibiting CGRP release, and postsynaptic 5-HT1B receptors causing cranial vasoconstriction.',
            level5: 'Binding to 5-HT1B/1D receptors on trigeminal nerve terminals inhibits release of vasoactive neuropeptides. Central effects on brainstem trigeminal nucleus caudalis also contribute.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'brain', structureName: 'Brain', role: 'primary-site', involvement: 'Site of cortical spreading depression', highlightColor: '#9370DB', showByDefault: true }],
        secondaryStructures: [],
        systemsInvolved: ['Nervous', 'Vascular'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
        focusRegion: 'head',
      },
      explanations: {
        level1: 'A really bad headache that comes with feeling sick and being bothered by light.',
        level2: "Migraines are intense headaches caused by changes in your brain's blood vessels and nerves, often triggered by stress, foods, or hormones.",
        level3: 'Migraine is a neurovascular disorder with cortical spreading depression triggering trigeminovascular activation. Diagnosed clinically with ICHD criteria.',
        level4: 'Pathophysiology involves CSD activating meningeal nociceptors via CGRP release. Central sensitization explains allodynia. Genetic variants affect ion channels.',
        level5: 'CSD causes massive ionic shifts with glutamate release, activating meningeal trigeminal afferents. CGRP and PACAP mediate vasodilation. Thalamic involvement explains sensory hypersensitivity.',
      },
      relatedConditions: ['tension-headache', 'cluster-headache'],
      epidemiology: { prevalence: '12% of population', incidence: 'Peak onset in 20s-30s', demographics: 'Women 3x more than men' },
      clinicalPearls: ['Triptans work best when taken early', 'Limit acute medications to prevent rebound', 'Consider prophylaxis if ≥4 attacks/month'],
      patientEducation: ['Identify and avoid triggers', 'Keep a headache diary', 'Take medications early in attack'],
      emergencyWarnings: ['Worst headache of life - could be aneurysm', 'Headache with fever and stiff neck', 'New headache pattern after age 50'],
    },
  ],
  [
    'epilepsy',
    {
      conditionId: 'epilepsy',
      name: 'Epilepsy',
      aliases: ['Seizure Disorder', 'Convulsive Disorder'],
      icdCode: 'G40.9',
      category: 'neurologic',
      subcategory: 'Seizure Disorders',
      description: 'A chronic brain disorder characterized by recurrent, unprovoked seizures due to abnormal electrical activity.',
      pathophysiology: {
        summary: 'Epilepsy results from imbalance between excitatory and inhibitory neurotransmission, causing synchronized neuronal firing.',
        mechanisms: [
          { name: 'Excitation/Inhibition Imbalance', description: 'Excess glutamate or deficient GABA leads to neuronal hyperexcitability', systemsInvolved: ['Nervous'], keyMediators: ['Glutamate', 'GABA'], contribution: 'Core mechanism of seizure generation' },
          { name: 'Ion Channel Dysfunction', description: 'Mutations in sodium, potassium, or calcium channels alter neuronal excitability', systemsInvolved: ['Nervous'], keyMediators: ['Sodium channels', 'Potassium channels'], contribution: 'Genetic epilepsies often involve channelopathies' },
        ],
        riskFactors: [
          { name: 'Family history', type: 'non-modifiable', impact: 'moderate', description: 'Genetic factors contribute to many epilepsies' },
          { name: 'Prior brain injury', type: 'non-modifiable', impact: 'major', description: 'TBI, stroke, infection can cause structural epilepsy' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Seizures', prevalence: 'very-common', description: 'Recurrent episodes of abnormal movements or behavior' },
          { name: 'Loss of consciousness', prevalence: 'common', description: 'Altered awareness during seizures' },
        ],
        associatedSymptoms: [
          { name: 'Post-ictal confusion', prevalence: 'common', description: 'Confusion after seizure' },
          { name: 'Aura', prevalence: 'common', description: 'Warning sensation before some seizures' },
        ],
        physicalFindings: [],
        labFindings: [],
      },
      progression: {
        naturalHistory: 'Variable - many achieve seizure freedom with medication, some have refractory epilepsy.',
        timelineSteps: [
          {
            phaseId: 'first-seizure',
            phase: 'early',
            displayName: 'First Seizure',
            timeframe: 'Initial presentation',
            description: 'First unprovoked seizure - not yet epilepsy',
            symptoms: ['Single seizure event'],
            anatomicalChanges: [{ structureId: 'cerebral-cortex', structureName: 'Cerebral Cortex', changeType: 'dysfunction', description: 'Focal or generalized abnormal activity', severity: 'moderate', visualIndicator: { color: '#FF6347', pulse: true, opacity: 0.7 }, isNewAtPhase: true }],
            reversibility: 'reversible',
            typicalTreatments: ['Observation', 'Consider starting AED'],
          },
        ],
        prognosis: '60-70% achieve seizure freedom with medication.',
      },
      complications: [
        {
          complicationId: 'status-epilepticus',
          name: 'Status Epilepticus',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Prolonged seizure lasting >5 minutes or repeated seizures without recovery',
          mechanism: 'Failure of seizure termination mechanisms, leading to neuronal injury',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Neuronal injury from prolonged excitotoxicity', highlightColor: '#FF6347' }],
          warningSymptoms: ['Seizure not stopping', 'Confusion between seizures'],
          preventable: true,
        },
        {
          complicationId: 'sudep',
          name: 'SUDEP (Sudden Unexpected Death in Epilepsy)',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'low',
          description: 'Sudden death in person with epilepsy without other cause found',
          mechanism: 'Likely postictal cardiorespiratory dysfunction',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brainstem', effect: 'Autonomic dysfunction', highlightColor: '#FF6347' }],
          warningSymptoms: ['Uncontrolled seizures', 'Frequent nocturnal seizures'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'antiepileptic-drugs',
          name: 'Antiepileptic Drugs',
          modality: 'pharmacological',
          description: 'Medications to prevent seizures',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Seizure freedom', 'Minimize side effects'],
          explanations: {
            level1: 'Medicines that help prevent seizures from happening.',
            level2: 'Anti-seizure medications calm down overactive electrical signals in your brain.',
            level3: 'AEDs work by various mechanisms: sodium channel blockade, GABA enhancement, calcium channel modulation. Choice depends on seizure type.',
            level4: 'Mechanisms include use-dependent sodium channel blockade (carbamazepine), GABA-A receptor modulation (benzodiazepines), SV2A binding (levetiracetam).',
            level5: 'Drug selection based on syndrome, comorbidities, drug interactions. Newer agents (levetiracetam, lamotrigine) often preferred for tolerability. Therapeutic drug monitoring for some agents.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'brain', structureName: 'Brain', role: 'primary-site', involvement: 'Site of seizure generation', highlightColor: '#FF6347', showByDefault: true }],
        secondaryStructures: [],
        systemsInvolved: ['Nervous'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
        focusRegion: 'head',
      },
      explanations: {
        level1: 'A condition where you have seizures because of unusual electrical activity in the brain.',
        level2: 'Epilepsy happens when groups of brain cells fire together abnormally, causing seizures that can affect movement, sensation, or consciousness.',
        level3: 'Epilepsy is diagnosed after 2+ unprovoked seizures or 1 seizure with high recurrence risk. Classified by seizure type (focal vs generalized) and etiology.',
        level4: 'Seizures result from hypersynchronous neuronal firing. Focal seizures arise from discrete cortical regions; generalized involve bilateral networks from onset.',
        level5: 'Epileptogenesis involves molecular changes including altered gene expression, synaptic reorganization, and neuroinflammation. Network-level changes create seizure-prone circuits.',
      },
      relatedConditions: ['stroke', 'brain-tumor'],
      epidemiology: { prevalence: '0.5-1% of population', incidence: 'Bimodal - children and elderly', demographics: 'Slightly more common in males' },
      clinicalPearls: ['EEG may be normal interictally', 'MRI essential to evaluate for structural cause', 'Start with monotherapy, titrate slowly'],
      patientEducation: ['Take medication consistently', 'Avoid triggers like sleep deprivation', 'Know seizure first aid'],
      emergencyWarnings: ['Seizure lasting >5 minutes', 'Repeated seizures without recovery', 'Seizure with injury or in water'],
    },
  ],
  [
    'copd',
    {
      conditionId: 'copd',
      name: 'Chronic Obstructive Pulmonary Disease',
      aliases: ['COPD', 'Emphysema', 'Chronic Bronchitis'],
      icdCode: 'J44.9',
      category: 'respiratory',
      subcategory: 'Obstructive Lung Disease',
      description: 'A progressive lung disease characterized by persistent airflow limitation due to airway and/or alveolar abnormalities.',
      pathophysiology: {
        summary: 'COPD results from chronic inflammatory response to inhaled irritants causing airway remodeling and alveolar destruction.',
        mechanisms: [
          { name: 'Airway Inflammation', description: 'Chronic inflammation leads to mucus hypersecretion and airway remodeling', systemsInvolved: ['Respiratory'], keyMediators: ['Neutrophils', 'IL-8', 'TNF-alpha'], contribution: 'Causes chronic bronchitis phenotype' },
          { name: 'Alveolar Destruction', description: 'Protease-antiprotease imbalance destroys alveolar walls', systemsInvolved: ['Respiratory'], keyMediators: ['Elastase', 'MMPs'], contribution: 'Causes emphysema phenotype' },
        ],
        riskFactors: [
          { name: 'Smoking', type: 'modifiable', impact: 'major', description: 'Primary cause in 80-90% of cases' },
          { name: 'Alpha-1 antitrypsin deficiency', type: 'non-modifiable', impact: 'major', description: 'Genetic cause in ~1% of cases' },
          { name: 'Occupational exposure', type: 'modifiable', impact: 'moderate', description: 'Dust, chemicals, fumes' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Chronic cough', prevalence: 'very-common', description: 'Often productive, worse in morning' },
          { name: 'Dyspnea', prevalence: 'very-common', description: 'Progressive breathlessness, initially on exertion' },
          { name: 'Wheezing', prevalence: 'common', description: 'Expiratory wheezing from airflow obstruction' },
        ],
        associatedSymptoms: [],
        physicalFindings: [{ name: 'Barrel chest', examType: 'Inspection', description: 'Hyperinflation of lungs with increased AP diameter', diagnosticValue: 'Indicates severe emphysema' }],
        labFindings: [{ testName: 'Spirometry', abnormality: 'FEV1/FVC <0.70', normalRange: '>0.70', significance: 'Confirms airflow obstruction' }],
      },
      progression: {
        naturalHistory: 'Progressive decline in lung function over years. Rate of decline can be slowed with smoking cessation.',
        timelineSteps: [
          {
            phaseId: 'mild-copd',
            phase: 'early',
            displayName: 'Mild COPD (GOLD 1)',
            timeframe: 'Years',
            description: 'FEV1 ≥80% predicted. Often undiagnosed.',
            symptoms: ['Chronic cough', 'Mild dyspnea on exertion'],
            anatomicalChanges: [{ structureId: 'lungs', structureName: 'Lungs', changeType: 'inflammation', description: 'Early airway inflammation', severity: 'mild', visualIndicator: { color: '#FFA500', pulse: false, opacity: 0.5 }, isNewAtPhase: true }],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Smoking cessation', 'SABA PRN'],
          },
          {
            phaseId: 'severe-copd',
            phase: 'advanced',
            displayName: 'Severe COPD (GOLD 3-4)',
            timeframe: 'Years',
            description: 'FEV1 <50% predicted. Significant symptoms and exacerbations.',
            symptoms: ['Severe dyspnea', 'Frequent exacerbations', 'Exercise limitation'],
            anatomicalChanges: [{ structureId: 'lungs', structureName: 'Lungs', changeType: 'degeneration', description: 'Extensive alveolar destruction and airway remodeling', severity: 'severe', visualIndicator: { color: '#FF4500', pulse: false, opacity: 0.8 }, isNewAtPhase: false }],
            reversibility: 'irreversible',
            typicalTreatments: ['Triple therapy (ICS/LABA/LAMA)', 'Pulmonary rehab', 'Oxygen therapy'],
          },
        ],
        prognosis: 'Variable. Smoking cessation significantly improves prognosis.',
      },
      complications: [
        {
          complicationId: 'acute-exacerbation',
          name: 'Acute Exacerbation',
          category: 'acute',
          severity: 'major',
          riskLevel: 'high',
          description: 'Acute worsening of respiratory symptoms requiring additional therapy',
          mechanism: 'Viral or bacterial infection triggering increased airway inflammation',
          affectedStructures: [{ structureId: 'lungs', structureName: 'Lungs', effect: 'Increased inflammation and mucus', highlightColor: '#FF4500' }],
          warningSymptoms: ['Increased dyspnea', 'Increased sputum', 'Sputum purulence'],
          preventable: true,
        },
        {
          complicationId: 'respiratory-failure',
          name: 'Respiratory Failure',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Inability to maintain adequate gas exchange',
          mechanism: 'Severe airflow limitation and V/Q mismatch',
          affectedStructures: [{ structureId: 'lungs', structureName: 'Lungs', effect: 'Inadequate ventilation', highlightColor: '#DC143C' }],
          warningSymptoms: ['Severe dyspnea', 'Confusion', 'Cyanosis'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'bronchodilators',
          name: 'Bronchodilators (LABA/LAMA)',
          modality: 'pharmacological',
          description: 'Long-acting inhaled bronchodilators for maintenance',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'advanced'],
          goals: ['Reduce symptoms', 'Prevent exacerbations'],
          explanations: {
            level1: 'Inhalers that open up your airways to make breathing easier.',
            level2: 'These medicines relax the muscles around your airways, allowing more air to flow in and out.',
            level3: 'LABA (beta-2 agonists) and LAMA (anticholinergics) provide sustained bronchodilation. Combination superior to monotherapy.',
            level4: 'LABAs stimulate beta-2 receptors causing smooth muscle relaxation. LAMAs block M3 muscarinic receptors preventing bronchoconstriction.',
            level5: 'Tiotropium (LAMA) has longer receptor dissociation kinetics than ipratropium. Ultra-LABAs (indacaterol, vilanterol) provide 24h bronchodilation.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'lungs', structureName: 'Lungs', role: 'primary-site', involvement: 'Site of airway obstruction and alveolar destruction', highlightColor: '#3B82F6', showByDefault: true }],
        secondaryStructures: [],
        systemsInvolved: ['Respiratory'],
        recommendedView: 'anterior',
        recommendedLayers: ['respiratory'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1: 'A lung disease that makes it hard to breathe, usually from smoking.',
        level2: 'COPD damages your airways and air sacs, making it harder to move air in and out of your lungs.',
        level3: 'COPD encompasses emphysema (alveolar destruction) and chronic bronchitis (airway disease). Diagnosed by spirometry showing fixed airflow obstruction.',
        level4: 'Chronic inflammation driven by innate immune activation. Protease-antiprotease imbalance (elastase vs alpha-1-AT) central to emphysema.',
        level5: 'Small airway disease precedes emphysema. Autoimmune component suggested by lymphoid follicles. Systemic inflammation contributes to comorbidities.',
      },
      relatedConditions: ['asthma', 'lung-cancer'],
      epidemiology: { prevalence: '10% of adults >40', incidence: 'Rising globally', demographics: 'More common in smokers, males historically but equalizing' },
      clinicalPearls: ['COPD is underdiagnosed - consider in any smoker with respiratory symptoms', 'Smoking cessation is the only intervention that slows FEV1 decline', 'Classify by symptoms (CAT/mMRC) AND exacerbation history, not just FEV1'],
      patientEducation: ['Stop smoking - most important step', 'Use inhalers correctly', 'Get flu and pneumonia vaccines', 'Learn to recognize exacerbation signs'],
      emergencyWarnings: ['Severe shortness of breath', 'Blue lips or fingernails', 'Confusion or drowsiness', 'Cannot speak in full sentences'],
    },
  ],
  [
    'atrial-fibrillation',
    {
      conditionId: 'atrial-fibrillation',
      name: 'Atrial Fibrillation',
      aliases: ['AFib', 'AF', 'A-Fib'],
      icdCode: 'I48.91',
      category: 'cardiovascular',
      subcategory: 'Arrhythmia',
      description: 'An irregular and often rapid heart rhythm caused by chaotic electrical signals in the atria.',
      pathophysiology: {
        summary: 'AFib results from multiple reentrant wavelets or focal triggers causing disorganized atrial electrical activity.',
        mechanisms: [
          { name: 'Atrial Remodeling', description: 'Structural and electrical changes in atria promote arrhythmia', systemsInvolved: ['Cardiovascular'], keyMediators: ['Fibrosis', 'Ion channels'], contribution: 'Creates substrate for AFib maintenance' },
          { name: 'Pulmonary Vein Triggers', description: 'Ectopic foci in pulmonary veins initiate AFib', systemsInvolved: ['Cardiovascular'], keyMediators: ['Calcium'], contribution: 'Common trigger site for paroxysmal AFib' },
        ],
        riskFactors: [
          { name: 'Age', type: 'non-modifiable', impact: 'major', description: 'Risk doubles each decade after 55' },
          { name: 'Hypertension', type: 'partially-modifiable', impact: 'major', description: 'Most common modifiable risk factor' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'Increases AFib risk 50%' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Palpitations', prevalence: 'very-common', description: 'Sensation of rapid or irregular heartbeat' },
          { name: 'Fatigue', prevalence: 'common', description: 'Reduced cardiac output causes fatigue' },
          { name: 'Dyspnea', prevalence: 'common', description: 'Shortness of breath, especially on exertion' },
        ],
        associatedSymptoms: [],
        physicalFindings: [{ name: 'Irregularly irregular pulse', examType: 'Cardiovascular', description: 'Completely irregular rhythm with varying intensity', diagnosticValue: 'Hallmark of AFib' }],
        labFindings: [{ testName: 'ECG', abnormality: 'Absent P waves, irregular R-R intervals', normalRange: 'Regular sinus rhythm', significance: 'Diagnostic' }],
      },
      progression: {
        naturalHistory: 'Often progresses from paroxysmal to persistent to permanent over years.',
        timelineSteps: [
          {
            phaseId: 'paroxysmal',
            phase: 'early',
            displayName: 'Paroxysmal AFib',
            timeframe: 'Episodes <7 days',
            description: 'Self-terminating episodes',
            symptoms: ['Intermittent palpitations', 'Episodes of irregularity'],
            anatomicalChanges: [{ structureId: 'heart', structureName: 'Left Atrium', changeType: 'dysfunction', description: 'Electrical instability', severity: 'mild', visualIndicator: { color: '#FF6B6B', pulse: true, opacity: 0.6 }, isNewAtPhase: true }],
            reversibility: 'reversible',
            typicalTreatments: ['Rate or rhythm control', 'Anticoagulation if indicated'],
          },
          {
            phaseId: 'permanent',
            phase: 'established',
            displayName: 'Permanent AFib',
            timeframe: 'Continuous',
            description: 'Decision made to not pursue rhythm control',
            symptoms: ['Persistent irregular heartbeat', 'Chronic symptoms'],
            anatomicalChanges: [{ structureId: 'heart', structureName: 'Left Atrium', changeType: 'dilation', description: 'Left atrial enlargement and fibrosis', severity: 'moderate', visualIndicator: { color: '#DC143C', pulse: true, opacity: 0.8 }, isNewAtPhase: false }],
            reversibility: 'irreversible',
            typicalTreatments: ['Rate control', 'Anticoagulation'],
          },
        ],
        prognosis: 'Variable. Increased risk of stroke and heart failure.',
      },
      complications: [
        {
          complicationId: 'stroke-afib',
          name: 'Stroke',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'high',
          description: 'Thromboembolic stroke from left atrial thrombus',
          mechanism: 'Blood stasis in fibrillating atria leads to thrombus formation, which can embolize to brain',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Embolic infarction', highlightColor: '#7c3aed' }],
          warningSymptoms: ['Sudden weakness', 'Speech difficulty', 'Vision changes'],
          preventable: true,
        },
        {
          complicationId: 'tachycardia-cardiomyopathy',
          name: 'Tachycardia-Induced Cardiomyopathy',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Heart failure from prolonged rapid heart rate',
          mechanism: 'Sustained tachycardia leads to LV dysfunction',
          affectedStructures: [{ structureId: 'heart', structureName: 'Left Ventricle', effect: 'Dilated cardiomyopathy', highlightColor: '#DC143C' }],
          warningSymptoms: ['Progressive dyspnea', 'Leg swelling', 'Exercise intolerance'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'anticoagulation',
          name: 'Anticoagulation',
          modality: 'pharmacological',
          description: 'Blood thinners to prevent stroke',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Prevent stroke'],
          explanations: {
            level1: 'Blood thinners that prevent clots from forming in your heart.',
            level2: 'Because AFib causes blood to pool in your heart, blood thinners reduce the risk of clots forming and causing a stroke.',
            level3: 'DOACs preferred over warfarin for non-valvular AFib. Use CHA2DS2-VASc score to determine need. HAS-BLED for bleeding risk.',
            level4: 'DOACs directly inhibit factor Xa (rivaroxaban, apixaban) or thrombin (dabigatran). More predictable than warfarin, no INR monitoring.',
            level5: 'Apixaban has best safety profile in trials. Left atrial appendage occlusion option for those who cannot anticoagulate. Reversal agents available.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'heart', structureName: 'Heart', role: 'primary-site', involvement: 'Site of arrhythmia', highlightColor: '#DC143C', showByDefault: true }],
        secondaryStructures: [],
        systemsInvolved: ['Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1: 'An irregular heartbeat that can increase your risk of stroke.',
        level2: 'In AFib, the upper chambers of your heart quiver instead of beating normally, which can cause blood clots to form.',
        level3: 'AFib is the most common sustained arrhythmia. Management centers on rate/rhythm control and stroke prevention with anticoagulation.',
        level4: 'Multiple wavelet reentry and focal firing from pulmonary veins. Atrial fibrosis creates conduction heterogeneity maintaining the arrhythmia.',
        level5: 'Electrical and structural remodeling perpetuates AFib ("AFib begets AFib"). Catheter ablation targets pulmonary vein isolation. Substrate modification for persistent AFib.',
      },
      relatedConditions: ['hypertension', 'heart-failure'],
      epidemiology: { prevalence: '1-2% of population, 10% in >80 years', incidence: 'Increasing with aging population', demographics: 'More common with age, male predominance' },
      clinicalPearls: ['Always calculate CHA2DS2-VASc for stroke risk', 'Rate control adequate for most; rhythm control if highly symptomatic', 'Screen for thyroid disease in new AFib'],
      patientEducation: ['Take blood thinner consistently to prevent stroke', 'Check pulse regularly', 'Limit alcohol and caffeine', 'Know stroke warning signs (FAST)'],
      emergencyWarnings: ['Signs of stroke (sudden weakness, speech difficulty)', 'Very rapid heart rate with dizziness', 'Chest pain', 'Severe shortness of breath'],
    },
  ],
  [
    'chronic-kidney-disease',
    {
      conditionId: 'chronic-kidney-disease',
      name: 'Chronic Kidney Disease',
      aliases: ['CKD', 'Chronic Renal Failure', 'Kidney Disease'],
      icdCode: 'N18.9',
      category: 'urologic',
      subcategory: 'Renal Disease',
      description: 'Progressive loss of kidney function over months to years, classified by GFR and albuminuria.',
      pathophysiology: {
        summary: 'CKD results from nephron loss leading to hyperfiltration of remaining nephrons, causing further damage and progressive decline.',
        mechanisms: [
          { name: 'Glomerular Hyperfiltration', description: 'Remaining nephrons compensate by increasing filtration, causing further damage', systemsInvolved: ['Urinary'], keyMediators: ['Angiotensin II', 'TGF-beta'], contribution: 'Maladaptive response accelerates progression' },
          { name: 'Tubulointerstitial Fibrosis', description: 'Progressive scarring of kidney tissue', systemsInvolved: ['Urinary'], keyMediators: ['TGF-beta', 'CTGF'], contribution: 'Final common pathway of CKD' },
        ],
        riskFactors: [
          { name: 'Diabetes', type: 'partially-modifiable', impact: 'major', description: 'Leading cause of ESRD' },
          { name: 'Hypertension', type: 'partially-modifiable', impact: 'major', description: 'Second leading cause' },
          { name: 'Age', type: 'non-modifiable', impact: 'moderate', description: 'GFR declines with age' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'From anemia and uremia' },
          { name: 'Edema', prevalence: 'common', description: 'Fluid retention from reduced kidney function' },
          { name: 'Nocturia', prevalence: 'common', description: 'Impaired concentrating ability' },
        ],
        associatedSymptoms: [],
        physicalFindings: [{ name: 'Peripheral edema', examType: 'Inspection', description: 'Pitting edema in lower extremities', diagnosticValue: 'Indicates fluid overload' }],
        labFindings: [{ testName: 'Serum creatinine/eGFR', abnormality: 'eGFR <60 for >3 months', normalRange: 'eGFR >90', significance: 'Defines CKD' }],
      },
      progression: {
        naturalHistory: 'Progressive decline in GFR over years. Rate varies by cause and management.',
        timelineSteps: [
          {
            phaseId: 'stage-3',
            phase: 'established',
            displayName: 'Stage 3 CKD',
            timeframe: 'Years',
            description: 'eGFR 30-59. Moderate decrease in kidney function.',
            symptoms: ['Mild fatigue', 'Early metabolic changes'],
            anatomicalChanges: [{ structureId: 'kidneys', structureName: 'Kidneys', changeType: 'fibrosis', description: 'Progressive nephron loss and scarring', severity: 'moderate', visualIndicator: { color: '#FFA500', pulse: false, opacity: 0.6 }, isNewAtPhase: true }],
            reversibility: 'partially-reversible',
            typicalTreatments: ['ACEi/ARB', 'BP control', 'Address cause'],
          },
          {
            phaseId: 'stage-5',
            phase: 'end-stage',
            displayName: 'Stage 5 CKD (ESRD)',
            timeframe: 'Variable',
            description: 'eGFR <15. Kidney failure requiring RRT.',
            symptoms: ['Uremic symptoms', 'Severe fatigue', 'Nausea'],
            anatomicalChanges: [{ structureId: 'kidneys', structureName: 'Kidneys', changeType: 'atrophy', description: 'Severely atrophied kidneys with minimal function', severity: 'severe', visualIndicator: { color: '#DC143C', pulse: false, opacity: 0.8 }, isNewAtPhase: false }],
            reversibility: 'irreversible',
            typicalTreatments: ['Dialysis', 'Kidney transplant'],
          },
        ],
        prognosis: 'Variable. Many stabilize with treatment. Some progress to ESRD requiring dialysis/transplant.',
      },
      complications: [
        {
          complicationId: 'ckd-anemia',
          name: 'Anemia of CKD',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'high',
          description: 'Anemia due to reduced erythropoietin production',
          mechanism: 'Damaged kidneys produce less erythropoietin, reducing red blood cell production',
          affectedStructures: [{ structureId: 'bone-marrow', structureName: 'Bone Marrow', effect: 'Reduced RBC production', highlightColor: '#DC143C' }],
          warningSymptoms: ['Fatigue', 'Pallor', 'Dyspnea on exertion'],
          preventable: true,
        },
        {
          complicationId: 'ckd-mbd',
          name: 'CKD-Mineral Bone Disease',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'high',
          description: 'Bone disease from abnormal calcium/phosphorus metabolism',
          mechanism: 'Reduced vitamin D activation and phosphorus retention lead to secondary hyperparathyroidism',
          affectedStructures: [{ structureId: 'bones', structureName: 'Skeleton', effect: 'Bone demineralization', highlightColor: '#FFD700' }],
          warningSymptoms: ['Bone pain', 'Fractures', 'Muscle weakness'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'acei-arb-ckd',
          name: 'ACE Inhibitors/ARBs',
          modality: 'pharmacological',
          description: 'RAAS blockade to slow progression',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Slow progression', 'Reduce proteinuria'],
          explanations: {
            level1: 'Blood pressure medicines that also protect your kidneys.',
            level2: 'These medications reduce pressure in the kidneys and slow down damage, especially if you have protein in your urine.',
            level3: 'ACEi/ARBs reduce intraglomerular pressure and proteinuria. Foundational therapy for CKD, especially with albuminuria.',
            level4: 'Blocking RAAS reduces efferent arteriolar tone, lowering glomerular capillary pressure. Also reduces TGF-beta mediated fibrosis.',
            level5: 'RAAS blockade is renoprotective beyond BP reduction. SGLT2 inhibitors now added for additional renoprotection in diabetic and non-diabetic CKD.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'kidneys', structureName: 'Kidneys', role: 'primary-site', involvement: 'Site of progressive nephron loss', highlightColor: '#8B4513', showByDefault: true }],
        secondaryStructures: [],
        systemsInvolved: ['Urinary'],
        recommendedView: 'posterior',
        recommendedLayers: ['urinary'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: 'When your kidneys slowly stop working properly over time.',
        level2: 'CKD means your kidneys are damaged and cannot filter blood as well as they should, causing waste to build up.',
        level3: 'CKD is staged by eGFR and albuminuria. Focus on treating cause, controlling BP, and using ACEi/ARB. Refer to nephrology by stage 4.',
        level4: 'Nephron loss triggers maladaptive hyperfiltration via RAAS activation. Proteinuria itself is nephrotoxic. SGLT2i provide additional renoprotection.',
        level5: 'Single nephron hyperfiltration drives podocyte injury and proteinuria. Tubulointerstitial fibrosis is the final common pathway. Uremic toxins contribute to systemic complications.',
      },
      relatedConditions: ['diabetes-mellitus', 'hypertension'],
      epidemiology: { prevalence: '~15% of US adults', incidence: 'Increasing with diabetes/hypertension epidemic', demographics: 'Higher in elderly, African Americans, diabetics' },
      clinicalPearls: ['Check urine albumin:creatinine ratio - proteinuria matters for prognosis', 'ACEi/ARB + SGLT2i is now standard of care', 'Avoid nephrotoxins (NSAIDs, contrast)'],
      patientEducation: ['Control blood sugar and blood pressure', 'Avoid NSAIDs and herbal supplements', 'Stay hydrated but follow fluid restrictions if advanced', 'Know your GFR number'],
      emergencyWarnings: ['Severe swelling or shortness of breath', 'Very high potassium symptoms (weakness, palpitations)', 'Unable to urinate', 'Confusion or altered mental status'],
    },
  ],
  [
    'rheumatoid-arthritis',
    {
      conditionId: 'rheumatoid-arthritis',
      name: 'Rheumatoid Arthritis',
      aliases: ['RA', 'Inflammatory Arthritis'],
      icdCode: 'M06.9',
      category: 'musculoskeletal',
      subcategory: 'Inflammatory Arthritis',
      description: 'A chronic autoimmune disease causing symmetric inflammatory arthritis primarily affecting small joints.',
      pathophysiology: {
        summary: 'RA is an autoimmune disease where the immune system attacks the synovium, causing inflammation, pannus formation, and joint destruction.',
        mechanisms: [
          { name: 'Autoimmune Synovitis', description: 'T cells and B cells attack synovial tissue, producing autoantibodies and cytokines', systemsInvolved: ['Musculoskeletal', 'Immune'], keyMediators: ['TNF-alpha', 'IL-6', 'RF', 'Anti-CCP'], contribution: 'Initiates and perpetuates joint inflammation' },
          { name: 'Pannus Formation', description: 'Proliferative synovial tissue invades cartilage and bone', systemsInvolved: ['Musculoskeletal'], keyMediators: ['MMPs', 'RANKL'], contribution: 'Causes irreversible joint destruction' },
        ],
        riskFactors: [
          { name: 'Female sex', type: 'non-modifiable', impact: 'major', description: '2-3x more common in women' },
          { name: 'Genetics (HLA-DR4)', type: 'non-modifiable', impact: 'major', description: 'Strong genetic component' },
          { name: 'Smoking', type: 'modifiable', impact: 'major', description: 'Increases risk, especially in genetically susceptible' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Joint pain and swelling', prevalence: 'very-common', description: 'Symmetric polyarthritis, small joints of hands/feet' },
          { name: 'Morning stiffness', prevalence: 'very-common', description: 'Lasting >1 hour, improves with activity' },
          { name: 'Fatigue', prevalence: 'common', description: 'Systemic inflammatory burden' },
        ],
        associatedSymptoms: [],
        physicalFindings: [{ name: 'Synovial swelling', examType: 'Musculoskeletal', description: 'Boggy swelling of MCP and PIP joints', diagnosticValue: 'Key diagnostic finding' }],
        labFindings: [{ testName: 'RF and Anti-CCP', abnormality: 'Positive in 70-80%', normalRange: 'Negative', significance: 'Anti-CCP more specific for RA' }],
      },
      progression: {
        naturalHistory: 'Without treatment, progressive joint destruction over years. Early aggressive treatment can induce remission.',
        timelineSteps: [
          {
            phaseId: 'early-ra',
            phase: 'early',
            displayName: 'Early RA',
            timeframe: 'First 6-12 months',
            description: 'Window of opportunity for treatment',
            symptoms: ['Joint pain', 'Swelling', 'Morning stiffness'],
            anatomicalChanges: [{ structureId: 'joints', structureName: 'Small Joints', changeType: 'inflammation', description: 'Synovitis without erosions', severity: 'mild', visualIndicator: { color: '#FF6B6B', pulse: true, opacity: 0.6 }, isNewAtPhase: true }],
            reversibility: 'reversible',
            typicalTreatments: ['Methotrexate', 'Bridge steroids'],
          },
          {
            phaseId: 'established-ra',
            phase: 'established',
            displayName: 'Established RA with Erosions',
            timeframe: 'Years',
            description: 'Joint damage present on imaging',
            symptoms: ['Chronic pain', 'Deformity', 'Functional limitation'],
            anatomicalChanges: [{ structureId: 'joints', structureName: 'Small Joints', changeType: 'degeneration', description: 'Erosions and joint space narrowing', severity: 'moderate', visualIndicator: { color: '#DC143C', pulse: false, opacity: 0.8 }, isNewAtPhase: false }],
            reversibility: 'irreversible',
            typicalTreatments: ['DMARDs', 'Biologics', 'PT/OT'],
          },
        ],
        prognosis: 'Variable. Early aggressive treatment improves outcomes. Biologics have transformed prognosis.',
      },
      complications: [
        {
          complicationId: 'ra-cv-disease',
          name: 'Cardiovascular Disease',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'high',
          description: 'Increased risk of heart disease from chronic inflammation',
          mechanism: 'Systemic inflammation accelerates atherosclerosis',
          affectedStructures: [{ structureId: 'heart', structureName: 'Coronary Arteries', effect: 'Accelerated atherosclerosis', highlightColor: '#DC143C' }],
          warningSymptoms: ['Chest pain', 'Shortness of breath', 'Fatigue'],
          preventable: true,
        },
        {
          complicationId: 'ra-deformity',
          name: 'Joint Deformity',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Irreversible joint damage and deformity',
          mechanism: 'Pannus erosion of cartilage and bone',
          affectedStructures: [{ structureId: 'joints', structureName: 'Hand Joints', effect: 'Swan neck, boutonniere deformities', highlightColor: '#FF6B6B' }],
          warningSymptoms: ['Progressive deformity', 'Loss of function'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'methotrexate-ra',
          name: 'Methotrexate',
          modality: 'pharmacological',
          description: 'Anchor DMARD for RA treatment',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Achieve remission', 'Prevent joint damage'],
          explanations: {
            level1: 'A medicine that calms your immune system to reduce joint inflammation.',
            level2: 'Methotrexate is the most effective first-line treatment for RA, taken once weekly to reduce inflammation and prevent joint damage.',
            level3: 'MTX is the anchor DMARD. Start early, titrate to 25mg weekly if tolerated. Add folic acid. Monitor CBC and LFTs.',
            level4: 'MTX has multiple mechanisms including adenosine release (anti-inflammatory) and effects on T cell function. Onset 6-12 weeks.',
            level5: 'MTX inhibits AICAR transformylase increasing adenosine. Also affects JAK/STAT signaling. Combination with biologics synergistic.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'joints', structureName: 'Small Joints', role: 'primary-site', involvement: 'Site of autoimmune synovitis', highlightColor: '#FF6B6B', showByDefault: true }],
        secondaryStructures: [],
        systemsInvolved: ['Musculoskeletal', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['musculoskeletal'],
        focusRegion: 'upper-extremity',
      },
      explanations: {
        level1: 'A disease where your immune system attacks your joints, causing pain and swelling.',
        level2: 'In RA, your immune system mistakenly attacks the lining of your joints, causing inflammation that can damage bones and cartilage.',
        level3: 'RA is a symmetric inflammatory polyarthritis. Treat early and aggressively with DMARDs. Target remission or low disease activity.',
        level4: 'Pathogenesis involves T cell-B cell interaction in HLA-DR4+ individuals. Citrullinated proteins trigger autoantibody formation. TNF and IL-6 drive synovitis.',
        level5: 'Shared epitope hypothesis: HLA-DR4 presents citrullinated peptides. ACPA+ disease has worse prognosis. JAK inhibitors offer targeted synthetic DMARD option.',
      },
      relatedConditions: ['osteoarthritis', 'psoriatic-arthritis'],
      epidemiology: { prevalence: '0.5-1% of population', incidence: 'Peak onset 30-50 years', demographics: 'Women 2-3x more common' },
      clinicalPearls: ['Early treatment (within 3-6 months) improves outcomes - window of opportunity', 'Anti-CCP is highly specific - if positive, likely RA', 'Treat to target: aim for remission or low disease activity'],
      patientEducation: ['Take methotrexate on the same day each week', 'Avoid alcohol while on methotrexate', 'Report any signs of infection', 'Exercise and PT help maintain function'],
      emergencyWarnings: ['Signs of infection (fever, chills) while on immunosuppression', 'Sudden severe joint swelling (could be septic arthritis)', 'Shortness of breath or dry cough (lung involvement)'],
    },
  ],
  [
    'osteoarthritis',
    {
      conditionId: 'osteoarthritis',
      name: 'Osteoarthritis',
      aliases: ['OA', 'Degenerative Joint Disease', 'DJD', 'Wear and Tear Arthritis'],
      icdCode: 'M19.90',
      category: 'musculoskeletal',
      subcategory: 'Degenerative Joint Disease',
      description: 'A degenerative joint disease characterized by cartilage loss, bone remodeling, and joint pain.',
      pathophysiology: {
        summary: 'OA involves progressive cartilage degradation with failed repair, subchondral bone changes, and synovial inflammation.',
        mechanisms: [
          { name: 'Cartilage Degradation', description: 'Chondrocyte dysfunction leads to matrix breakdown exceeding repair', systemsInvolved: ['Musculoskeletal'], keyMediators: ['MMPs', 'Aggrecanases', 'IL-1'], contribution: 'Central feature of OA progression' },
          { name: 'Subchondral Bone Changes', description: 'Bone sclerosis and osteophyte formation', systemsInvolved: ['Musculoskeletal'], keyMediators: ['RANKL', 'OPG'], contribution: 'Contributes to pain and stiffness' },
        ],
        riskFactors: [
          { name: 'Age', type: 'non-modifiable', impact: 'major', description: 'Prevalence increases dramatically with age' },
          { name: 'Obesity', type: 'modifiable', impact: 'major', description: 'Mechanical stress and adipokines' },
          { name: 'Joint injury', type: 'partially-modifiable', impact: 'major', description: 'Prior trauma increases risk' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Joint pain', prevalence: 'very-common', description: 'Pain worse with activity, better with rest' },
          { name: 'Stiffness', prevalence: 'very-common', description: 'Morning stiffness <30 minutes' },
          { name: 'Reduced range of motion', prevalence: 'common', description: 'Progressive loss of joint mobility' },
        ],
        associatedSymptoms: [],
        physicalFindings: [{ name: 'Bony enlargement', examType: 'Musculoskeletal', description: 'Heberden and Bouchard nodes in hands', diagnosticValue: 'Classic for hand OA' }],
        labFindings: [],
      },
      progression: {
        naturalHistory: 'Slowly progressive over years to decades. Variable rate of progression.',
        timelineSteps: [
          {
            phaseId: 'early-oa',
            phase: 'early',
            displayName: 'Early OA',
            timeframe: 'Years',
            description: 'Cartilage thinning, mild symptoms',
            symptoms: ['Occasional pain', 'Mild stiffness'],
            anatomicalChanges: [{ structureId: 'joints', structureName: 'Articular Cartilage', changeType: 'degeneration', description: 'Cartilage thinning and softening', severity: 'mild', visualIndicator: { color: '#FFA500', pulse: false, opacity: 0.5 }, isNewAtPhase: true }],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Exercise', 'Weight loss', 'Topical NSAIDs'],
          },
          {
            phaseId: 'advanced-oa',
            phase: 'advanced',
            displayName: 'Advanced OA',
            timeframe: 'Years-decades',
            description: 'Bone-on-bone changes, severe symptoms',
            symptoms: ['Constant pain', 'Significant disability', 'Night pain'],
            anatomicalChanges: [{ structureId: 'joints', structureName: 'Articular Cartilage', changeType: 'degeneration', description: 'Complete cartilage loss, bone-on-bone', severity: 'severe', visualIndicator: { color: '#DC143C', pulse: false, opacity: 0.8 }, isNewAtPhase: false }],
            reversibility: 'irreversible',
            typicalTreatments: ['Joint replacement surgery'],
          },
        ],
        prognosis: 'Variable. Many manage with conservative treatment. Some require joint replacement.',
      },
      complications: [
        {
          complicationId: 'oa-disability',
          name: 'Functional Disability',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'high',
          description: 'Progressive loss of function affecting daily activities',
          mechanism: 'Pain and mechanical impairment limit mobility',
          affectedStructures: [{ structureId: 'joints', structureName: 'Weight-bearing Joints', effect: 'Loss of mobility', highlightColor: '#FFA500' }],
          warningSymptoms: ['Unable to walk distances', 'Difficulty with stairs', 'Night pain'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'exercise-oa',
          name: 'Exercise and Physical Therapy',
          modality: 'lifestyle',
          description: 'Structured exercise program for joint health',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'advanced'],
          goals: ['Reduce pain', 'Improve function', 'Strengthen muscles'],
          explanations: {
            level1: 'Exercise helps keep your joints working well and reduces pain.',
            level2: 'Regular exercise strengthens the muscles around your joints, reducing stress on the joint and improving function.',
            level3: 'Exercise is first-line for OA. Focus on strengthening (especially quadriceps for knee OA), aerobic exercise, and flexibility.',
            level4: 'Exercise improves proprioception, reduces inflammation, and strengthens periarticular muscles, unloading the joint.',
            level5: 'Exercise has disease-modifying potential through effects on cartilage metabolism and neuromuscular control. Weight loss reduces mechanical stress.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'joints', structureName: 'Synovial Joints', role: 'primary-site', involvement: 'Site of cartilage degeneration', highlightColor: '#FFA500', showByDefault: true }],
        secondaryStructures: [],
        systemsInvolved: ['Musculoskeletal'],
        recommendedView: 'anterior',
        recommendedLayers: ['musculoskeletal'],
        focusRegion: 'lower-extremity',
      },
      explanations: {
        level1: 'Wear and tear on your joints that causes pain and stiffness as you get older.',
        level2: 'OA happens when the protective cartilage in your joints wears down over time, causing bones to rub together.',
        level3: 'OA is the most common arthritis. Diagnose clinically (>50, mechanical pain, <30min stiffness). X-ray shows joint space narrowing, osteophytes, sclerosis.',
        level4: 'OA is not just mechanical wear - involves chondrocyte dysfunction, matrix metalloproteinases, and low-grade inflammation. Subchondral bone changes contribute to pain.',
        level5: 'OA pathogenesis involves failed repair mechanisms, aberrant chondrocyte signaling, and mechanotransduction abnormalities. Synovitis present in many cases.',
      },
      relatedConditions: ['rheumatoid-arthritis', 'gout'],
      epidemiology: { prevalence: '10-15% of adults', incidence: 'Increases with age', demographics: 'Most common in elderly, women slightly more affected' },
      clinicalPearls: ['X-ray findings often do not correlate with symptoms', 'Weight loss is highly effective for knee/hip OA', 'Avoid prolonged NSAID use in elderly'],
      patientEducation: ['Stay active - exercise helps', 'Maintain healthy weight', 'Use assistive devices if needed', 'Heat or ice for symptom relief'],
      emergencyWarnings: ['Hot, red, swollen joint (could be infection or gout)', 'Sudden worsening (could indicate fracture)', 'Joint locking or giving way'],
    },
  ],
  [
    'gout',
    {
      conditionId: 'gout',
      name: 'Gout',
      aliases: ['Gouty Arthritis', 'Crystal Arthritis', 'Uric Acid Arthritis'],
      icdCode: 'M10.9',
      category: 'musculoskeletal',
      subcategory: 'Crystal Arthritis',
      description: 'An inflammatory arthritis caused by deposition of monosodium urate crystals in joints and soft tissues.',
      pathophysiology: {
        summary: 'Gout occurs when hyperuricemia leads to urate crystal deposition, triggering intense inflammatory response.',
        mechanisms: [
          { name: 'Urate Crystal Deposition', description: 'Supersaturation of uric acid leads to crystal formation in joints', systemsInvolved: ['Musculoskeletal'], keyMediators: ['Uric acid', 'MSU crystals'], contribution: 'Initiating event' },
          { name: 'Inflammasome Activation', description: 'Crystals activate NLRP3 inflammasome causing IL-1 release', systemsInvolved: ['Immune'], keyMediators: ['IL-1beta', 'NLRP3'], contribution: 'Drives acute inflammatory response' },
        ],
        riskFactors: [
          { name: 'Hyperuricemia', type: 'partially-modifiable', impact: 'major', description: 'Required but not sufficient' },
          { name: 'Diet', type: 'modifiable', impact: 'moderate', description: 'Red meat, seafood, alcohol, fructose' },
          { name: 'Male sex', type: 'non-modifiable', impact: 'major', description: 'Much more common in men' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Acute joint pain', prevalence: 'very-common', description: 'Severe pain, often nocturnal onset' },
          { name: 'Joint swelling', prevalence: 'very-common', description: 'Red, hot, swollen joint' },
          { name: 'First MTP involvement', prevalence: 'very-common', description: 'Big toe (podagra) classic presentation' },
        ],
        associatedSymptoms: [],
        physicalFindings: [{ name: 'Podagra', examType: 'Musculoskeletal', description: 'Red, hot, swollen first MTP joint', diagnosticValue: 'Highly suggestive of gout' }],
        labFindings: [{ testName: 'Serum uric acid', abnormality: '>6.8 mg/dL', normalRange: '<6.8 mg/dL', significance: 'Supports diagnosis but can be normal during flare' }],
      },
      progression: {
        naturalHistory: 'Acute attacks become more frequent without treatment. Can progress to chronic tophaceous gout.',
        timelineSteps: [
          {
            phaseId: 'acute-gout',
            phase: 'early',
            displayName: 'Acute Gout Flare',
            timeframe: 'Days',
            description: 'Intense acute inflammatory arthritis',
            symptoms: ['Severe pain', 'Swelling', 'Erythema'],
            anatomicalChanges: [{ structureId: 'joints', structureName: 'First MTP Joint', changeType: 'inflammation', description: 'Acute crystal-induced synovitis', severity: 'severe', visualIndicator: { color: '#DC143C', pulse: true, opacity: 0.9 }, isNewAtPhase: true }],
            reversibility: 'reversible',
            typicalTreatments: ['NSAIDs', 'Colchicine', 'Steroids'],
          },
          {
            phaseId: 'chronic-tophaceous',
            phase: 'advanced',
            displayName: 'Chronic Tophaceous Gout',
            timeframe: 'Years',
            description: 'Persistent crystal deposits with joint damage',
            symptoms: ['Chronic joint pain', 'Visible tophi', 'Joint destruction'],
            anatomicalChanges: [{ structureId: 'joints', structureName: 'Multiple Joints', changeType: 'degeneration', description: 'Tophaceous deposits with erosions', severity: 'severe', visualIndicator: { color: '#8B4513', pulse: false, opacity: 0.8 }, isNewAtPhase: false }],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Urate-lowering therapy', 'Surgery for tophi'],
          },
        ],
        prognosis: 'Excellent with treatment. Urate-lowering therapy can dissolve tophi and prevent flares.',
      },
      complications: [
        {
          complicationId: 'gout-nephrolithiasis',
          name: 'Uric Acid Nephrolithiasis',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Kidney stones from uric acid',
          mechanism: 'Supersaturation of urine with uric acid leads to stone formation',
          affectedStructures: [{ structureId: 'kidneys', structureName: 'Kidneys', effect: 'Stone formation', highlightColor: '#8B4513' }],
          warningSymptoms: ['Flank pain', 'Hematuria', 'Dysuria'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'allopurinol',
          name: 'Allopurinol',
          modality: 'pharmacological',
          description: 'Xanthine oxidase inhibitor for urate lowering',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['established', 'advanced'],
          goals: ['Lower serum urate to <6 mg/dL', 'Prevent flares', 'Dissolve tophi'],
          explanations: {
            level1: 'A medicine that lowers the uric acid in your blood to prevent gout attacks.',
            level2: 'Allopurinol blocks the enzyme that makes uric acid, lowering levels to prevent crystal formation and dissolve existing deposits.',
            level3: 'Start low (100mg), titrate to target urate <6 (or <5 with tophi). Provide flare prophylaxis when starting. HLA-B*5801 testing in high-risk groups.',
            level4: 'Allopurinol inhibits xanthine oxidase, reducing uric acid production. Febuxostat is alternative. Target urate <6 mg/dL for crystal dissolution.',
            level5: 'Urate-lowering dissolves tissue deposits over months-years. URAT1 inhibitors (probenecid) increase excretion. Pegloticase for refractory disease.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'joints', structureName: 'First MTP Joint', role: 'primary-site', involvement: 'Classic site of gout', highlightColor: '#DC143C', showByDefault: true }],
        secondaryStructures: [],
        systemsInvolved: ['Musculoskeletal'],
        recommendedView: 'anterior',
        recommendedLayers: ['musculoskeletal'],
        focusRegion: 'lower-extremity',
      },
      explanations: {
        level1: 'A painful type of arthritis caused by too much uric acid that forms crystals in your joints.',
        level2: 'Gout happens when uric acid builds up and forms sharp crystals in your joints, causing sudden severe pain and swelling.',
        level3: 'Gout is crystal arthritis from MSU deposition. Diagnose by crystal analysis. Treat flares with NSAIDs/colchicine/steroids. Start ULT after acute resolves.',
        level4: 'MSU crystals activate NLRP3 inflammasome, releasing IL-1beta. Flares self-resolve via NETs and anti-inflammatory cytokines. Hyperuricemia from underexcretion (90%) or overproduction.',
        level5: 'IL-1 blockade highly effective for acute flares. Chronic gout is metabolic disease - treat comorbidities. Serum urate target based on crystal saturation point.',
      },
      relatedConditions: ['chronic-kidney-disease', 'metabolic-syndrome'],
      epidemiology: { prevalence: '4% of US adults', incidence: 'Increasing with obesity epidemic', demographics: 'Men >> women (until menopause), increases with age' },
      clinicalPearls: ['Uric acid can be normal during acute flare', 'Start allopurinol low and go slow', 'Provide colchicine prophylaxis when starting ULT', 'Treat to target: urate <6 mg/dL'],
      patientEducation: ['Take urate-lowering medication daily even when feeling well', 'Limit alcohol, especially beer', 'Reduce purine-rich foods', 'Stay well hydrated'],
      emergencyWarnings: ['Fever with joint swelling (rule out septic arthritis)', 'Multiple joint involvement', 'Inability to bear weight'],
    },
  ],
  [
    'obstructive-sleep-apnea',
    {
      conditionId: 'obstructive-sleep-apnea',
      name: 'Obstructive Sleep Apnea',
      aliases: ['OSA', 'Sleep Apnea', 'OSAHS'],
      icdCode: 'G47.33',
      category: 'respiratory',
      subcategory: 'Sleep Disorders',
      description: 'A sleep disorder characterized by repeated upper airway collapse during sleep, causing breathing pauses and oxygen desaturation.',
      pathophysiology: {
        summary: 'OSA results from upper airway collapse during sleep due to decreased muscle tone, causing recurrent hypoxia and sleep fragmentation.',
        mechanisms: [
          { name: 'Upper Airway Collapse', description: 'Relaxation of pharyngeal muscles during sleep allows airway obstruction', systemsInvolved: ['Respiratory'], keyMediators: ['Pharyngeal muscles', 'Negative pressure'], contribution: 'Primary mechanism of obstruction' },
          { name: 'Intermittent Hypoxia', description: 'Repeated oxygen desaturation triggers sympathetic activation and inflammation', systemsInvolved: ['Cardiovascular'], keyMediators: ['HIF-1', 'ROS', 'Catecholamines'], contribution: 'Drives cardiovascular complications' },
        ],
        riskFactors: [
          { name: 'Obesity', type: 'modifiable', impact: 'major', description: 'Fat deposition narrows airway' },
          { name: 'Male sex', type: 'non-modifiable', impact: 'moderate', description: '2-3x more common in men' },
          { name: 'Anatomic factors', type: 'partially-modifiable', impact: 'moderate', description: 'Large tonsils, retrognathia' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Snoring', prevalence: 'very-common', description: 'Loud, disruptive snoring' },
          { name: 'Witnessed apneas', prevalence: 'common', description: 'Bed partner reports breathing stops' },
          { name: 'Excessive daytime sleepiness', prevalence: 'very-common', description: 'Unrefreshing sleep, daytime fatigue' },
        ],
        associatedSymptoms: [],
        physicalFindings: [{ name: 'Increased neck circumference', examType: 'Inspection', description: '>17 inches in men, >16 inches in women', diagnosticValue: 'Risk factor for OSA' }],
        labFindings: [{ testName: 'Polysomnography', abnormality: 'AHI ≥5 events/hour', normalRange: 'AHI <5', significance: 'Gold standard for diagnosis' }],
      },
      progression: {
        naturalHistory: 'Chronic condition that worsens with weight gain. Untreated OSA increases cardiovascular risk.',
        timelineSteps: [
          {
            phaseId: 'mild-osa',
            phase: 'early',
            displayName: 'Mild OSA',
            timeframe: 'Chronic',
            description: 'AHI 5-15. Mild symptoms.',
            symptoms: ['Snoring', 'Mild fatigue'],
            anatomicalChanges: [{ structureId: 'pharynx', structureName: 'Upper Airway', changeType: 'dysfunction', description: 'Intermittent airway collapse', severity: 'mild', visualIndicator: { color: '#FFA500', pulse: false, opacity: 0.5 }, isNewAtPhase: true }],
            reversibility: 'reversible',
            typicalTreatments: ['Weight loss', 'Positional therapy'],
          },
          {
            phaseId: 'severe-osa',
            phase: 'established',
            displayName: 'Severe OSA',
            timeframe: 'Chronic',
            description: 'AHI ≥30. Significant symptoms and cardiovascular risk.',
            symptoms: ['Severe sleepiness', 'Cognitive impairment', 'Morning headaches'],
            anatomicalChanges: [{ structureId: 'pharynx', structureName: 'Upper Airway', changeType: 'dysfunction', description: 'Frequent prolonged apneas with desaturation', severity: 'severe', visualIndicator: { color: '#DC143C', pulse: true, opacity: 0.8 }, isNewAtPhase: false }],
            reversibility: 'reversible',
            typicalTreatments: ['CPAP', 'BiPAP'],
          },
        ],
        prognosis: 'Excellent with treatment. CPAP reduces cardiovascular risk and improves quality of life.',
      },
      complications: [
        {
          complicationId: 'osa-hypertension',
          name: 'Resistant Hypertension',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'high',
          description: 'Blood pressure difficult to control',
          mechanism: 'Intermittent hypoxia causes sympathetic activation and endothelial dysfunction',
          affectedStructures: [{ structureId: 'heart', structureName: 'Cardiovascular System', effect: 'Sustained hypertension', highlightColor: '#DC143C' }],
          warningSymptoms: ['Elevated BP despite multiple medications'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'cpap',
          name: 'CPAP (Continuous Positive Airway Pressure)',
          modality: 'interventional',
          description: 'Positive pressure splints airway open during sleep',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Eliminate apneas', 'Improve sleep quality', 'Reduce cardiovascular risk'],
          explanations: {
            level1: 'A machine that gently blows air through a mask to keep your airway open while you sleep.',
            level2: 'CPAP provides constant air pressure that acts like a pneumatic splint, preventing your throat from collapsing.',
            level3: 'CPAP is first-line for moderate-severe OSA. Titrate pressure to eliminate apneas (AHI <5). Auto-titrating devices available.',
            level4: 'CPAP provides pneumatic splinting of upper airway, preventing collapse. Optimal pressure determined by sleep study or auto-PAP.',
            level5: 'CPAP reduces cardiovascular events in severe OSA. Adherence critical - cognitive behavioral interventions improve compliance. Alternatives: oral appliances, surgery.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'pharynx', structureName: 'Upper Airway', role: 'primary-site', involvement: 'Site of obstruction', highlightColor: '#3B82F6', showByDefault: true }],
        secondaryStructures: [],
        systemsInvolved: ['Respiratory'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['respiratory'],
        focusRegion: 'head',
      },
      explanations: {
        level1: 'A condition where your throat closes repeatedly during sleep, stopping your breathing.',
        level2: 'OSA happens when the muscles in your throat relax too much during sleep, blocking your airway and causing you to stop breathing briefly many times.',
        level3: 'OSA is diagnosed by polysomnography showing AHI ≥5 with symptoms. Severity: mild (5-15), moderate (15-30), severe (≥30). CPAP is first-line treatment.',
        level4: 'Pharyngeal collapse occurs at sleep onset when muscle tone decreases. Anatomic (obesity, retrognathia) and neuromuscular factors contribute. Intermittent hypoxia drives cardiovascular consequences.',
        level5: 'Pcrit (critical closing pressure) determines collapsibility. Loop gain affects stability of ventilatory control. Endotypes help predict treatment response.',
      },
      relatedConditions: ['obesity', 'hypertension', 'atrial-fibrillation'],
      epidemiology: { prevalence: '10-30% of adults', incidence: 'Increasing with obesity epidemic', demographics: 'Men > women, increases with age and BMI' },
      clinicalPearls: ['Screen for OSA in resistant hypertension', 'STOP-BANG score helps identify high-risk patients', 'Weight loss can cure mild OSA', 'Check CPAP compliance - aim for >4 hours/night'],
      patientEducation: ['Use CPAP every night for full benefit', 'Weight loss helps significantly', 'Avoid alcohol before bed', 'Sleep on your side if possible'],
      emergencyWarnings: ['Severe sleepiness while driving', 'Waking up gasping or choking', 'Chest pain or palpitations at night'],
    },
  ],
  [
    'pulmonary-embolism',
    {
      conditionId: 'pulmonary-embolism',
      name: 'Pulmonary Embolism',
      aliases: ['PE', 'Blood Clot in Lung'],
      icdCode: 'I26.99',
      category: 'respiratory',
      subcategory: 'Vascular',
      description: 'Obstruction of pulmonary arteries by thromboemboli, usually originating from deep vein thrombosis.',
      pathophysiology: {
        summary: 'PE occurs when thrombus from DVT embolizes to pulmonary circulation, causing V/Q mismatch, hypoxemia, and potentially right heart strain.',
        mechanisms: [
          { name: 'Pulmonary Vascular Obstruction', description: 'Thrombus blocks pulmonary artery branches, increasing pulmonary vascular resistance', systemsInvolved: ['Respiratory', 'Cardiovascular'], keyMediators: ['Thrombin', 'Platelets'], contribution: 'Primary event causing symptoms' },
          { name: 'Right Ventricular Strain', description: 'Increased afterload causes RV dilation and dysfunction', systemsInvolved: ['Cardiovascular'], keyMediators: ['BNP', 'Troponin'], contribution: 'Determines hemodynamic severity' },
        ],
        riskFactors: [
          { name: 'Recent surgery/immobilization', type: 'partially-modifiable', impact: 'major', description: 'Stasis promotes thrombosis' },
          { name: 'Cancer', type: 'partially-modifiable', impact: 'major', description: 'Hypercoagulable state' },
          { name: 'Prior VTE', type: 'non-modifiable', impact: 'major', description: 'Recurrence risk 30% at 10 years' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Dyspnea', prevalence: 'very-common', description: 'Sudden onset shortness of breath' },
          { name: 'Pleuritic chest pain', prevalence: 'common', description: 'Sharp pain worse with breathing' },
          { name: 'Cough', prevalence: 'common', description: 'Sometimes with hemoptysis' },
        ],
        associatedSymptoms: [],
        physicalFindings: [{ name: 'Tachycardia', examType: 'Cardiovascular', description: 'Heart rate >100', diagnosticValue: 'Common but nonspecific' }],
        labFindings: [{ testName: 'D-dimer', abnormality: 'Elevated', normalRange: '<500 ng/mL', significance: 'Sensitive but not specific - useful to rule out PE' }],
      },
      progression: {
        naturalHistory: 'Acute event. Can be life-threatening if massive. Chronic thromboembolic pulmonary hypertension can develop.',
        timelineSteps: [
          {
            phaseId: 'acute-pe',
            phase: 'early',
            displayName: 'Acute PE',
            timeframe: 'Hours to days',
            description: 'Acute pulmonary vascular obstruction',
            symptoms: ['Sudden dyspnea', 'Chest pain', 'Tachycardia'],
            anatomicalChanges: [{ structureId: 'lungs', structureName: 'Pulmonary Arteries', changeType: 'ischemia', description: 'Thrombus occluding pulmonary vessels', severity: 'moderate', visualIndicator: { color: '#DC143C', pulse: true, opacity: 0.8 }, isNewAtPhase: true }],
            reversibility: 'reversible',
            typicalTreatments: ['Anticoagulation', 'Thrombolysis if massive'],
          },
        ],
        prognosis: 'Variable. Most survive with treatment. Massive PE carries high mortality without intervention.',
      },
      complications: [
        {
          complicationId: 'pe-death',
          name: 'Sudden Death',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Cardiovascular collapse from massive PE',
          mechanism: 'Complete or near-complete obstruction of pulmonary circulation',
          affectedStructures: [{ structureId: 'heart', structureName: 'Right Ventricle', effect: 'Acute failure', highlightColor: '#DC143C' }],
          warningSymptoms: ['Severe dyspnea', 'Syncope', 'Hypotension'],
          preventable: true,
        },
        {
          complicationId: 'cteph',
          name: 'Chronic Thromboembolic Pulmonary Hypertension',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'low',
          description: 'Persistent pulmonary hypertension from organized thrombi',
          mechanism: 'Incomplete resolution of thrombi causes chronic vascular obstruction',
          affectedStructures: [{ structureId: 'lungs', structureName: 'Pulmonary Arteries', effect: 'Chronic obstruction and remodeling', highlightColor: '#8B4513' }],
          warningSymptoms: ['Persistent dyspnea', 'Exercise intolerance', 'Right heart failure'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'anticoagulation-pe',
          name: 'Anticoagulation',
          modality: 'pharmacological',
          description: 'Blood thinners to prevent clot extension and recurrence',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early'],
          goals: ['Prevent clot extension', 'Prevent recurrence', 'Allow natural fibrinolysis'],
          explanations: {
            level1: 'Blood thinners that stop the clot from getting bigger and prevent new clots.',
            level2: 'Anticoagulation prevents the clot from growing while your body naturally dissolves it over time.',
            level3: 'Start anticoagulation immediately if PE suspected. DOACs first-line for most. Duration: 3 months for provoked, extended for unprovoked.',
            level4: 'DOACs (apixaban, rivaroxaban) now first-line over LMWH/warfarin for most PE. Thrombolysis reserved for massive PE with hemodynamic instability.',
            level5: 'Risk stratification (PESI, troponin, RV function) guides management intensity. Intermediate-high risk may benefit from thrombolysis. Catheter-directed therapy emerging option.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'lungs', structureName: 'Pulmonary Arteries', role: 'primary-site', involvement: 'Site of embolism', highlightColor: '#DC143C', showByDefault: true }],
        secondaryStructures: [],
        systemsInvolved: ['Respiratory', 'Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular', 'respiratory'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1: 'A blood clot that travels to your lungs and blocks blood flow.',
        level2: 'PE happens when a blood clot, usually from your legs, breaks loose and travels to your lungs, blocking blood flow and making it hard to breathe.',
        level3: 'PE is a clinical diagnosis. Use Wells score/PERC to guide testing. CTA is diagnostic test of choice. Treat with anticoagulation; thrombolysis for massive PE.',
        level4: 'Thrombus from DVT embolizes to pulmonary circulation. V/Q mismatch causes hypoxemia. RV strain from increased afterload determines severity.',
        level5: 'PESI and sPESI stratify mortality risk. Submassive PE (RV strain without hypotension) management controversial. EKOS and other catheter therapies for intermediate-high risk.',
      },
      relatedConditions: ['deep-vein-thrombosis', 'atrial-fibrillation'],
      epidemiology: { prevalence: '~600,000 cases/year in US', incidence: 'Increases with age', demographics: 'Risk increases with age, surgery, immobility, cancer' },
      clinicalPearls: ['PE can present with subtle symptoms - maintain high suspicion', 'D-dimer rules out PE only in low pretest probability', 'Start anticoagulation before imaging if high suspicion'],
      patientEducation: ['Take blood thinner exactly as prescribed', 'Watch for bleeding signs', 'Report leg swelling or pain', 'Wear compression stockings if recommended'],
      emergencyWarnings: ['Severe shortness of breath', 'Chest pain', 'Coughing up blood', 'Fainting or near-fainting', 'Rapid heartbeat'],
    },
  ],
  [
    'deep-vein-thrombosis',
    {
      conditionId: 'deep-vein-thrombosis',
      name: 'Deep Vein Thrombosis',
      aliases: ['DVT', 'Blood Clot in Leg', 'Venous Thrombosis'],
      icdCode: 'I82.40',
      category: 'cardiovascular',
      subcategory: 'Venous Disease',
      description: 'A blood clot in a deep vein, usually in the legs, that can break loose and travel to the lungs.',
      pathophysiology: {
        summary: 'DVT results from Virchow triad: venous stasis, endothelial injury, and hypercoagulability.',
        mechanisms: [
          { name: 'Virchow Triad', description: 'Stasis, endothelial injury, and hypercoagulability promote clot formation', systemsInvolved: ['Cardiovascular'], keyMediators: ['Thrombin', 'Fibrin', 'Platelets'], contribution: 'Core pathophysiology' },
        ],
        riskFactors: [
          { name: 'Immobility', type: 'modifiable', impact: 'major', description: 'Surgery, travel, bed rest' },
          { name: 'Cancer', type: 'partially-modifiable', impact: 'major', description: 'Hypercoagulable state' },
          { name: 'Prior VTE', type: 'non-modifiable', impact: 'major', description: 'Strong predictor of recurrence' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Leg swelling', prevalence: 'very-common', description: 'Unilateral swelling' },
          { name: 'Leg pain', prevalence: 'common', description: 'Calf tenderness' },
          { name: 'Warmth and redness', prevalence: 'common', description: 'Inflammatory signs' },
        ],
        associatedSymptoms: [],
        physicalFindings: [{ name: 'Unilateral edema', examType: 'Inspection', description: 'Asymmetric leg swelling >2cm difference', diagnosticValue: 'Suggestive of DVT' }],
        labFindings: [{ testName: 'D-dimer', abnormality: 'Elevated', normalRange: '<500 ng/mL', significance: 'Sensitive - useful to rule out' }],
      },
      progression: {
        naturalHistory: 'Acute event. Risk of PE if untreated. Post-thrombotic syndrome can develop.',
        timelineSteps: [
          {
            phaseId: 'acute-dvt',
            phase: 'early',
            displayName: 'Acute DVT',
            timeframe: 'Days to weeks',
            description: 'Active thrombus in deep vein',
            symptoms: ['Leg swelling', 'Pain', 'Warmth'],
            anatomicalChanges: [{ structureId: 'veins', structureName: 'Deep Leg Veins', changeType: 'dysfunction', description: 'Thrombus occluding venous flow', severity: 'moderate', visualIndicator: { color: '#8B0000', pulse: false, opacity: 0.8 }, isNewAtPhase: true }],
            reversibility: 'reversible',
            typicalTreatments: ['Anticoagulation'],
          },
        ],
        prognosis: 'Good with treatment. Risk of PE and post-thrombotic syndrome.',
      },
      complications: [
        {
          complicationId: 'dvt-pe',
          name: 'Pulmonary Embolism',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'high',
          description: 'Clot travels to lungs',
          mechanism: 'Thrombus dislodges and embolizes to pulmonary arteries',
          affectedStructures: [{ structureId: 'lungs', structureName: 'Pulmonary Arteries', effect: 'Vascular obstruction', highlightColor: '#DC143C' }],
          warningSymptoms: ['Sudden dyspnea', 'Chest pain', 'Hemoptysis'],
          preventable: true,
        },
        {
          complicationId: 'post-thrombotic-syndrome',
          name: 'Post-Thrombotic Syndrome',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Chronic venous insufficiency after DVT',
          mechanism: 'Valve damage causes chronic venous hypertension',
          affectedStructures: [{ structureId: 'veins', structureName: 'Leg Veins', effect: 'Venous insufficiency', highlightColor: '#8B4513' }],
          warningSymptoms: ['Chronic leg swelling', 'Pain', 'Skin changes'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'anticoagulation-dvt',
          name: 'Anticoagulation',
          modality: 'pharmacological',
          description: 'Blood thinners for 3+ months',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early'],
          goals: ['Prevent PE', 'Prevent clot extension', 'Reduce PTS risk'],
          explanations: {
            level1: 'Blood thinners that prevent the clot from growing and stop new clots from forming.',
            level2: 'Anticoagulation stops the clot from getting bigger while your body slowly dissolves it, and prevents dangerous clots from going to your lungs.',
            level3: 'DOACs first-line for most DVT. Duration: 3 months for provoked, extended for unprovoked or recurrent. Compression stockings reduce PTS.',
            level4: 'DOACs inhibit factor Xa or thrombin directly. Rivaroxaban and apixaban can be given without initial parenteral anticoagulation.',
            level5: 'Extended anticoagulation reduces recurrence but increases bleeding. Individual risk-benefit assessment needed. Low-dose DOACs for extended therapy.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'veins', structureName: 'Deep Leg Veins', role: 'primary-site', involvement: 'Site of thrombus', highlightColor: '#8B0000', showByDefault: true }],
        secondaryStructures: [],
        systemsInvolved: ['Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular'],
        focusRegion: 'lower-extremity',
      },
      explanations: {
        level1: 'A blood clot in a deep vein in your leg that can be dangerous if it travels to your lungs.',
        level2: 'DVT forms when blood pools in your leg veins and clots. The main danger is the clot breaking loose and blocking blood flow in your lungs (PE).',
        level3: 'Diagnose DVT with ultrasound after clinical probability assessment (Wells score). D-dimer useful to rule out in low-probability patients. Treat with anticoagulation.',
        level4: 'Virchow triad explains DVT pathogenesis. Most DVTs arise in calf veins and propagate proximally. Proximal DVT has higher PE risk.',
        level5: 'Thrombus generation involves tissue factor exposure, thrombin generation, and fibrin deposition. Natural anticoagulants (protein C, S, antithrombin) regulate clot formation.',
      },
      relatedConditions: ['pulmonary-embolism'],
      epidemiology: { prevalence: '~1-2 per 1000/year', incidence: 'Increases with age', demographics: 'Risk factors include surgery, cancer, immobility, pregnancy' },
      clinicalPearls: ['Check Wells score before D-dimer', 'Negative D-dimer in low-probability patient rules out DVT', 'Always assess for underlying malignancy in unprovoked DVT'],
      patientEducation: ['Take blood thinner exactly as prescribed', 'Wear compression stockings', 'Stay active and avoid prolonged sitting', 'Report any signs of bleeding'],
      emergencyWarnings: ['Sudden shortness of breath (PE warning)', 'Chest pain', 'Rapidly worsening leg swelling', 'Signs of bleeding'],
    },
  ],
  [
    'iron-deficiency-anemia',
    {
      conditionId: 'iron-deficiency-anemia',
      name: 'Iron Deficiency Anemia',
      aliases: ['IDA', 'Microcytic Anemia'],
      icdCode: 'D50.9',
      category: 'hematologic',
      subcategory: 'Anemia',
      description: 'Anemia caused by insufficient iron for hemoglobin synthesis, the most common cause of anemia worldwide.',
      pathophysiology: {
        summary: 'IDA results from negative iron balance due to blood loss, inadequate intake, or malabsorption, leading to decreased hemoglobin production.',
        mechanisms: [
          { name: 'Iron Depletion', description: 'Progressive loss of iron stores, then transport iron, then functional iron', systemsInvolved: ['Hematologic'], keyMediators: ['Ferritin', 'Transferrin', 'Hepcidin'], contribution: 'Staged depletion leads to anemia' },
        ],
        riskFactors: [
          { name: 'Chronic blood loss', type: 'partially-modifiable', impact: 'major', description: 'GI bleeding, heavy menses' },
          { name: 'Inadequate intake', type: 'modifiable', impact: 'moderate', description: 'Vegetarian diet, food insecurity' },
          { name: 'Malabsorption', type: 'partially-modifiable', impact: 'moderate', description: 'Celiac disease, gastric surgery' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Decreased oxygen delivery to tissues' },
          { name: 'Dyspnea on exertion', prevalence: 'common', description: 'Compensatory response to anemia' },
          { name: 'Pallor', prevalence: 'common', description: 'Reduced hemoglobin' },
        ],
        associatedSymptoms: [{ name: 'Pica', prevalence: 'uncommon', description: 'Craving for ice, dirt' }],
        physicalFindings: [{ name: 'Conjunctival pallor', examType: 'Inspection', description: 'Pale conjunctivae', diagnosticValue: 'Suggests anemia' }],
        labFindings: [{ testName: 'CBC with indices', abnormality: 'Low Hgb, low MCV, low ferritin', normalRange: 'Hgb 12-16 g/dL (women), 14-18 g/dL (men)', significance: 'Microcytic hypochromic anemia with low ferritin diagnostic' }],
      },
      progression: {
        naturalHistory: 'Progressive if cause not addressed. Iron stores deplete before anemia develops.',
        timelineSteps: [
          {
            phaseId: 'iron-depletion',
            phase: 'preclinical',
            displayName: 'Iron Depletion',
            timeframe: 'Weeks to months',
            description: 'Stores depleted, no anemia yet',
            symptoms: ['Possibly asymptomatic'],
            anatomicalChanges: [{ structureId: 'bone-marrow', structureName: 'Bone Marrow', changeType: 'degeneration', description: 'Depleted iron stores', severity: 'mild', visualIndicator: { color: '#FFA500', pulse: false, opacity: 0.5 }, isNewAtPhase: true }],
            reversibility: 'reversible',
            typicalTreatments: ['Oral iron', 'Address cause'],
          },
          {
            phaseId: 'overt-anemia',
            phase: 'established',
            displayName: 'Overt Iron Deficiency Anemia',
            timeframe: 'Months',
            description: 'Hemoglobin falls, symptoms develop',
            symptoms: ['Fatigue', 'Dyspnea', 'Pallor'],
            anatomicalChanges: [{ structureId: 'blood', structureName: 'Red Blood Cells', changeType: 'atrophy', description: 'Microcytic hypochromic red cells', severity: 'moderate', visualIndicator: { color: '#DC143C', pulse: false, opacity: 0.7 }, isNewAtPhase: false }],
            reversibility: 'reversible',
            typicalTreatments: ['Oral or IV iron', 'Find and treat cause'],
          },
        ],
        prognosis: 'Excellent with iron replacement and treatment of underlying cause.',
      },
      complications: [
        {
          complicationId: 'ida-heart-failure',
          name: 'High-Output Heart Failure',
          category: 'acute',
          severity: 'major',
          riskLevel: 'low',
          description: 'Cardiac decompensation from severe anemia',
          mechanism: 'Heart works harder to compensate for reduced oxygen-carrying capacity',
          affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'Volume overload', highlightColor: '#DC143C' }],
          warningSymptoms: ['Severe dyspnea', 'Edema', 'Palpitations'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'oral-iron',
          name: 'Oral Iron Supplementation',
          modality: 'pharmacological',
          description: 'Ferrous sulfate or equivalent',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['preclinical', 'early', 'established'],
          goals: ['Replete iron stores', 'Normalize hemoglobin'],
          explanations: {
            level1: 'Iron pills to replace the iron your body is missing.',
            level2: 'Taking iron supplements rebuilds your iron stores and helps your body make more healthy red blood cells.',
            level3: 'Ferrous sulfate 325mg (65mg elemental) daily or every other day. Take with vitamin C to enhance absorption. Expect reticulocyte response in 1 week, Hgb rise in 2-4 weeks.',
            level4: 'Alternate day dosing may improve absorption due to hepcidin kinetics. IV iron for malabsorption, intolerance, or severe anemia.',
            level5: 'Hepcidin-ferroportin axis regulates iron absorption. High-dose daily iron increases hepcidin, reducing fractional absorption. Every-other-day dosing may improve efficiency.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'bone-marrow', structureName: 'Bone Marrow', role: 'primary-site', involvement: 'Site of RBC production', highlightColor: '#DC143C', showByDefault: true }],
        secondaryStructures: [],
        systemsInvolved: ['Hematologic'],
        recommendedView: 'anterior',
        recommendedLayers: ['hematologic'],
        focusRegion: 'whole-body',
      },
      explanations: {
        level1: 'Not having enough iron in your body, which makes you tired because your blood cannot carry enough oxygen.',
        level2: 'Iron is needed to make hemoglobin in red blood cells. Without enough iron, your body makes fewer red blood cells and they carry less oxygen.',
        level3: 'IDA presents with microcytic hypochromic anemia and low ferritin. Always look for the cause - GI blood loss in men and postmenopausal women.',
        level4: 'Iron deficiency progresses through stages: depleted stores (low ferritin), iron-deficient erythropoiesis (low transferrin sat), then anemia. Ferritin is acute phase reactant.',
        level5: 'Hepcidin regulates iron homeostasis via ferroportin degradation. In IDA, hepcidin is suppressed, maximizing absorption. Functional iron deficiency (inflammation) has normal/high ferritin.',
      },
      relatedConditions: ['chronic-kidney-disease', 'celiac-disease'],
      epidemiology: { prevalence: '~2% in developed countries, higher in developing world', incidence: 'Most common nutritional deficiency worldwide', demographics: 'Women of reproductive age, children, elderly at highest risk' },
      clinicalPearls: ['Low ferritin is diagnostic - no need for other iron studies', 'Always look for GI source in men and postmenopausal women', 'Every-other-day dosing may be as effective as daily with fewer GI side effects'],
      patientEducation: ['Take iron on empty stomach if tolerated', 'Vitamin C enhances absorption', 'Avoid calcium and antacids with iron', 'Expect dark stools'],
      emergencyWarnings: ['Chest pain or severe shortness of breath', 'Signs of GI bleeding (dark stools, vomiting blood)', 'Fainting or severe dizziness'],
    },
  ],

  // ============================================
  // NEUROLOGIC CONDITIONS (Additional)
  // ============================================

  // Parkinson's Disease
  [
    'parkinsons-disease',
    {
      conditionId: 'parkinsons-disease',
      name: "Parkinson's Disease",
      aliases: ['PD', 'Paralysis Agitans', 'Parkinsonism'],
      icdCode: 'G20',
      category: 'neurologic',
      subcategory: 'Movement Disorders',
      description: "A neurodegenerative disorder causing tremor, rigidity, and bradykinesia due to loss of dopamine-producing neurons in the substantia nigra.",
      pathophysiology: {
        summary: "Parkinson's disease results from progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine deficiency in the striatum and motor circuit dysfunction.",
        mechanisms: [
          { name: 'Dopaminergic Neurodegeneration', description: 'Progressive death of dopamine-producing neurons in substantia nigra', systemsInvolved: ['Nervous'], keyMediators: ['Alpha-synuclein', 'Dopamine', 'Mitochondria'], contribution: 'Primary cause of motor symptoms' },
          { name: 'Alpha-Synuclein Aggregation', description: 'Misfolded alpha-synuclein forms Lewy bodies that spread throughout the brain', systemsInvolved: ['Nervous'], keyMediators: ['Alpha-synuclein', 'Ubiquitin'], contribution: 'Key pathological hallmark driving neurodegeneration' },
        ],
        riskFactors: [
          { name: 'Age', type: 'non-modifiable', impact: 'major', description: 'Risk increases significantly after age 60' },
          { name: 'Family history', type: 'non-modifiable', impact: 'moderate', description: '10-15% have genetic component' },
          { name: 'Pesticide exposure', type: 'partially-modifiable', impact: 'moderate', description: 'Rural living and well water associated with increased risk' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Resting Tremor', prevalence: 'very-common', description: '4-6 Hz pill-rolling tremor, worse at rest' },
          { name: 'Bradykinesia', prevalence: 'very-common', description: 'Slowness of movement initiation and execution' },
          { name: 'Rigidity', prevalence: 'very-common', description: 'Cogwheel or lead-pipe muscle stiffness' },
        ],
        associatedSymptoms: [
          { name: 'Postural instability', prevalence: 'common', description: 'Balance problems, typically in later stages' },
          { name: 'Masked facies', prevalence: 'common', description: 'Reduced facial expression' },
        ],
        physicalFindings: [
          { name: 'Pill-rolling tremor', examType: 'Neurological', description: '4-6 Hz tremor at rest, decreases with action', diagnosticValue: 'Highly characteristic' },
          { name: 'Cogwheel rigidity', examType: 'Neurological', description: 'Ratchety resistance to passive movement', diagnosticValue: 'Characteristic finding' },
        ],
        labFindings: [{ testName: 'DaTscan', abnormality: 'Reduced dopamine transporter uptake in striatum', normalRange: 'Symmetric uptake', significance: 'Confirms dopaminergic deficit if diagnosis uncertain' }],
      },
      progression: {
        naturalHistory: "Progressive disease with prodromal non-motor phase, followed by motor symptoms that typically respond well to levodopa initially. Motor fluctuations and dyskinesias develop over years.",
        timelineSteps: [
          {
            phaseId: 'prodromal',
            phase: 'preclinical',
            displayName: 'Prodromal Phase',
            timeframe: 'Years before motor symptoms',
            description: 'Non-motor symptoms precede motor manifestations',
            symptoms: ['Constipation', 'REM sleep behavior disorder', 'Anosmia', 'Depression'],
            anatomicalChanges: [{ structureId: 'brainstem', structureName: 'Brain Stem', changeType: 'degeneration', description: 'Early alpha-synuclein deposits', severity: 'mild', visualIndicator: { color: '#800080', pulse: false, opacity: 0.3 }, isNewAtPhase: true }],
            reversibility: 'irreversible',
            typicalTreatments: ['Monitoring', 'Treat individual symptoms'],
          },
          {
            phaseId: 'early-motor',
            phase: 'early',
            displayName: 'Early Motor Stage',
            timeframe: 'Years 1-5',
            description: 'Unilateral or mildly bilateral symptoms with good medication response',
            symptoms: ['Unilateral tremor', 'Mild bradykinesia', 'Stiffness'],
            anatomicalChanges: [{ structureId: 'substantia-nigra', structureName: 'Substantia Nigra', changeType: 'degeneration', description: 'Significant dopamine neuron loss (60-80%)', severity: 'moderate', visualIndicator: { color: '#800080', pulse: false, opacity: 0.6 }, isNewAtPhase: true }],
            reversibility: 'irreversible',
            typicalTreatments: ['Levodopa', 'Dopamine agonists', 'MAO-B inhibitors'],
          },
          {
            phaseId: 'advanced',
            phase: 'advanced',
            displayName: 'Advanced Stage',
            timeframe: 'Years 5-10+',
            description: 'Motor fluctuations, dyskinesias, and prominent non-motor symptoms',
            symptoms: ['Motor fluctuations', 'Dyskinesias', 'Postural instability', 'Cognitive changes'],
            anatomicalChanges: [{ structureId: 'basal-ganglia', structureName: 'Basal Ganglia', changeType: 'dysfunction', description: 'Widespread dopaminergic dysfunction', severity: 'severe', visualIndicator: { color: '#800080', pulse: false, opacity: 0.8 }, isNewAtPhase: false }],
            reversibility: 'irreversible',
            typicalTreatments: ['Optimized levodopa', 'COMT inhibitors', 'Deep brain stimulation'],
          },
        ],
        prognosis: 'Progressive disease with 10-20 year course. Life expectancy near normal with treatment. Quality of life maintained with proper management.',
      },
      complications: [
        {
          complicationId: 'pd-dementia',
          name: 'Parkinson Disease Dementia',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'high',
          description: 'Cognitive decline occurring in advanced PD',
          mechanism: 'Cortical Lewy body spread and cholinergic deficit',
          affectedStructures: [{ structureId: 'cortex', structureName: 'Cerebral Cortex', effect: 'Diffuse Lewy pathology', highlightColor: '#800080' }],
          warningSymptoms: ['Memory problems', 'Visual hallucinations', 'Executive dysfunction'],
          preventable: false,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'levodopa',
          name: 'Levodopa/Carbidopa',
          modality: 'pharmacological',
          description: 'Gold standard dopamine replacement therapy',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'advanced'],
          goals: ['Improve motor symptoms', 'Maintain function'],
          explanations: {
            level1: 'Medicine that replaces the dopamine your brain is missing.',
            level2: 'Levodopa converts to dopamine in the brain, improving movement. Carbidopa prevents breakdown before it reaches the brain.',
            level3: 'Start low, titrate slowly. Monitor for motor fluctuations and dyskinesias. Consider extended-release formulations.',
            level4: 'Levodopa crosses BBB and is converted to dopamine by AADC. Carbidopa inhibits peripheral AADC. Consider enteral formulations for advanced disease.',
            level5: 'Pulsatile dopamine stimulation from oral levodopa contributes to motor complications. Continuous dopaminergic stimulation strategies aim to reduce this.',
          },
        },
        {
          treatmentId: 'dbs',
          name: 'Deep Brain Stimulation',
          modality: 'surgical',
          description: 'Electrodes in subthalamic nucleus or globus pallidus',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['advanced'],
          goals: ['Reduce motor fluctuations', 'Reduce dyskinesias', 'Reduce medication burden'],
          explanations: {
            level1: 'A surgery that puts tiny wires in your brain to help control movement.',
            level2: 'Electrodes send signals to deep parts of the brain that control movement.',
            level3: 'Consider for patients with good levodopa response but disabling motor fluctuations/dyskinesias.',
            level4: 'STN-DBS allows medication reduction. GPi-DBS better for severe dyskinesias.',
            level5: 'High-frequency stimulation modulates pathological oscillatory activity in basal ganglia circuits.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'substantia-nigra', structureName: 'Substantia Nigra', role: 'primary-site', involvement: 'Dopamine neuron degeneration', highlightColor: '#800080', showByDefault: true }],
        secondaryStructures: [{ structureId: 'basal-ganglia', structureName: 'Basal Ganglia', role: 'target-organ', involvement: 'Dopamine deficient', highlightColor: '#9370DB', showByDefault: false }],
        systemsInvolved: ['Nervous'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
        focusRegion: 'head',
      },
      explanations: {
        level1: 'A brain condition that causes shaking, stiffness, and slow movement because the brain stops making enough dopamine.',
        level2: "Parkinson's happens when cells that make dopamine die off. Dopamine helps control movement, so without enough, movements become slow, stiff, and shaky.",
        level3: "Diagnose clinically with bradykinesia plus tremor or rigidity. Look for asymmetry. Excellent levodopa response supports diagnosis.",
        level4: "Cardinal features: bradykinesia, rest tremor, rigidity, postural instability. Motor fluctuations develop in most within 5 years of levodopa.",
        level5: "Pathology spreads in caudal-rostral pattern (Braak staging). Alpha-synuclein aggregates as Lewy bodies. LRRK2, GBA, SNCA mutations inform molecular pathogenesis.",
      },
      relatedConditions: ['essential-tremor', 'lewy-body-dementia'],
      epidemiology: { prevalence: '1% of population over 60', incidence: '10-20 per 100,000 annually', demographics: 'Men > women, increases with age' },
      clinicalPearls: ['Resting tremor improves with action - essential tremor is the opposite', 'Non-motor symptoms often cause more disability than motor symptoms', 'DaTscan confirms dopaminergic deficit when diagnosis uncertain'],
      patientEducation: ['Regular exercise improves symptoms', 'Take levodopa on schedule', 'Report hallucinations', 'Physical therapy helps maintain mobility'],
      emergencyWarnings: ['Sudden inability to move', 'High fever with rigidity', 'Severe confusion or hallucinations'],
    },
  ],

  // Alzheimer's Disease
  [
    'alzheimers-disease',
    {
      conditionId: 'alzheimers-disease',
      name: "Alzheimer's Disease",
      aliases: ['AD', 'Senile Dementia of Alzheimer Type', 'SDAT'],
      icdCode: 'G30.9',
      category: 'neurologic',
      subcategory: 'Dementia',
      description: "The most common cause of dementia, characterized by progressive memory loss and cognitive decline due to accumulation of amyloid plaques and tau tangles in the brain.",
      pathophysiology: {
        summary: "Alzheimer's disease results from accumulation of amyloid-beta plaques and tau neurofibrillary tangles, leading to synaptic loss, neuroinflammation, and progressive neurodegeneration.",
        mechanisms: [
          { name: 'Amyloid Plaque Accumulation', description: 'Extracellular deposits of amyloid-beta protein disrupt neuronal function', systemsInvolved: ['Nervous'], keyMediators: ['Amyloid-beta 42', 'APP', 'Secretases'], contribution: 'Initiates pathological cascade' },
          { name: 'Tau Tangle Formation', description: 'Hyperphosphorylated tau forms intracellular neurofibrillary tangles', systemsInvolved: ['Nervous'], keyMediators: ['Tau protein', 'Kinases'], contribution: 'Correlates with cognitive decline' },
        ],
        riskFactors: [
          { name: 'Age', type: 'non-modifiable', impact: 'major', description: 'Risk doubles every 5 years after 65' },
          { name: 'APOE ε4 allele', type: 'non-modifiable', impact: 'major', description: 'Major genetic risk factor' },
          { name: 'Cardiovascular risk factors', type: 'modifiable', impact: 'moderate', description: 'Hypertension, diabetes increase risk' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Memory Loss', prevalence: 'very-common', description: 'Short-term memory affected early, especially episodic memory' },
          { name: 'Disorientation', prevalence: 'very-common', description: 'Confusion about time, place, and eventually person' },
          { name: 'Language Difficulties', prevalence: 'common', description: 'Word-finding problems, reduced verbal fluency' },
        ],
        associatedSymptoms: [
          { name: 'Behavioral changes', prevalence: 'common', description: 'Apathy, agitation, depression' },
          { name: 'Sleep disturbances', prevalence: 'common', description: 'Sundowning, insomnia' },
        ],
        physicalFindings: [
          { name: 'Impaired recall', examType: 'Cognitive', description: 'Cannot remember 3 words after 5 minutes', diagnosticValue: 'Characteristic' },
          { name: 'Clock drawing test abnormal', examType: 'Cognitive', description: 'Difficulty drawing clock face', diagnosticValue: 'Screening tool' },
        ],
        labFindings: [{ testName: 'CSF biomarkers', abnormality: 'Low Aβ42, elevated p-tau', normalRange: 'Varies by assay', significance: 'Supports diagnosis of AD pathology' }],
      },
      progression: {
        naturalHistory: "Progressive decline over 8-12 years from diagnosis. Preclinical phase with amyloid accumulation precedes symptoms by 10-20 years.",
        timelineSteps: [
          {
            phaseId: 'preclinical',
            phase: 'preclinical',
            displayName: 'Preclinical AD',
            timeframe: '10-20 years before symptoms',
            description: 'Amyloid accumulation without symptoms',
            symptoms: [],
            anatomicalChanges: [{ structureId: 'cortex', structureName: 'Cerebral Cortex', changeType: 'infiltration', description: 'Amyloid plaque deposition', severity: 'mild', visualIndicator: { color: '#DAA520', pulse: false, opacity: 0.3 }, isNewAtPhase: true }],
            reversibility: 'irreversible',
            typicalTreatments: ['Risk factor modification'],
          },
          {
            phaseId: 'mci',
            phase: 'early',
            displayName: 'Mild Cognitive Impairment',
            timeframe: 'Years',
            description: 'Memory complaints with objective impairment but preserved function',
            symptoms: ['Forgetfulness', 'Word-finding difficulty'],
            anatomicalChanges: [{ structureId: 'hippocampus', structureName: 'Hippocampus', changeType: 'atrophy', description: 'Hippocampal volume loss', severity: 'moderate', visualIndicator: { color: '#DAA520', pulse: false, opacity: 0.5 }, isNewAtPhase: true }],
            reversibility: 'irreversible',
            typicalTreatments: ['Cognitive stimulation', 'Exercise', 'Consider anti-amyloid therapy'],
          },
          {
            phaseId: 'dementia',
            phase: 'established',
            displayName: 'Dementia',
            timeframe: '8-12 years',
            description: 'Functional impairment requiring assistance',
            symptoms: ['Memory loss', 'Disorientation', 'Behavioral changes'],
            anatomicalChanges: [{ structureId: 'cortex', structureName: 'Cerebral Cortex', changeType: 'atrophy', description: 'Global cortical atrophy', severity: 'severe', visualIndicator: { color: '#DAA520', pulse: false, opacity: 0.8 }, isNewAtPhase: false }],
            reversibility: 'irreversible',
            typicalTreatments: ['Cholinesterase inhibitors', 'Memantine', 'Supportive care'],
          },
        ],
        prognosis: 'Progressive decline over 8-12 years. Terminal stage requires total care.',
      },
      complications: [
        {
          complicationId: 'ad-aspiration',
          name: 'Aspiration Pneumonia',
          category: 'acute',
          severity: 'major',
          riskLevel: 'high',
          description: 'Pneumonia from swallowing dysfunction in advanced disease',
          mechanism: 'Loss of swallowing coordination leads to aspiration',
          affectedStructures: [{ structureId: 'lungs', structureName: 'Lungs', effect: 'Infection', highlightColor: '#DAA520' }],
          warningSymptoms: ['Coughing with eating', 'Recurrent pneumonias', 'Weight loss'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'cholinesterase-inhibitor',
          name: 'Cholinesterase Inhibitors',
          modality: 'pharmacological',
          description: 'Donepezil, rivastigmine, or galantamine',
          efficacy: 'moderately-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Slow cognitive decline', 'Maintain function'],
          explanations: {
            level1: 'Medicine that helps brain cells communicate better.',
            level2: 'These drugs boost acetylcholine, a brain chemical that helps memory.',
            level3: 'Modest symptomatic benefit. Start low, titrate slowly. GI side effects common.',
            level4: 'Inhibit acetylcholinesterase. Benefits symptomatic, not disease-modifying.',
            level5: 'Cholinergic deficit from basal forebrain degeneration. NNT ~7 for stabilization.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'hippocampus', structureName: 'Hippocampus', role: 'primary-site', involvement: 'Early atrophy and tau pathology', highlightColor: '#DAA520', showByDefault: true }],
        secondaryStructures: [{ structureId: 'cortex', structureName: 'Cerebral Cortex', role: 'target-organ', involvement: 'Progressive atrophy', highlightColor: '#F0E68C', showByDefault: false }],
        systemsInvolved: ['Nervous'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
        focusRegion: 'head',
      },
      explanations: {
        level1: 'A brain disease that causes people to slowly lose their memory and ability to think clearly.',
        level2: "Alzheimer's happens when proteins build up in the brain and kill brain cells.",
        level3: "Suspect in progressive memory loss. Rule out reversible causes. MRI shows hippocampal atrophy.",
        level4: "Amnestic presentation most common. CSF biomarkers and amyloid PET support diagnosis.",
        level5: "Amyloid cascade hypothesis. Anti-amyloid antibodies show modest slowing in early AD.",
      },
      relatedConditions: ['vascular-dementia', 'lewy-body-dementia'],
      epidemiology: { prevalence: '10% over 65, 30% over 85', incidence: 'Doubles every 5 years after 65', demographics: 'Women > men, APOE ε4 increases risk' },
      clinicalPearls: ['Always rule out reversible causes of dementia', 'Short-term memory affected early', 'Caregiver support is essential'],
      patientEducation: ['Keep a routine', 'Use memory aids', 'Stay active', 'Plan for future care early'],
      emergencyWarnings: ['Wandering and getting lost', 'Inability to eat or drink', 'Sudden worsening (rule out infection)'],
    },
  ],

  // Multiple Sclerosis
  [
    'multiple-sclerosis',
    {
      conditionId: 'multiple-sclerosis',
      name: 'Multiple Sclerosis',
      aliases: ['MS', 'Disseminated Sclerosis'],
      icdCode: 'G35',
      category: 'neurologic',
      subcategory: 'Demyelinating Disease',
      description: "An autoimmune disease where the immune system attacks the protective myelin coating of nerves, causing communication problems between the brain and body.",
      pathophysiology: {
        summary: "MS results from autoimmune demyelination of CNS white matter, causing conduction block and axonal damage with repeated inflammatory attacks.",
        mechanisms: [
          { name: 'Autoimmune Demyelination', description: 'T and B cells attack myelin in CNS white matter', systemsInvolved: ['Nervous', 'Immune'], keyMediators: ['Autoreactive T cells', 'B cells', 'Cytokines'], contribution: 'Primary cause of relapses' },
          { name: 'Axonal Damage', description: 'Secondary neurodegeneration from chronic inflammation', systemsInvolved: ['Nervous'], keyMediators: ['Glutamate', 'Nitric oxide'], contribution: 'Drives progressive disability' },
        ],
        riskFactors: [
          { name: 'EBV infection', type: 'non-modifiable', impact: 'major', description: 'Prior EBV infection strongly associated' },
          { name: 'Vitamin D deficiency', type: 'modifiable', impact: 'moderate', description: 'Low vitamin D increases risk' },
          { name: 'Smoking', type: 'modifiable', impact: 'moderate', description: 'Increases risk and accelerates progression' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Visual disturbance', prevalence: 'very-common', description: 'Optic neuritis with painful vision loss' },
          { name: 'Numbness/tingling', prevalence: 'very-common', description: 'Sensory symptoms from spinal cord lesions' },
          { name: 'Weakness', prevalence: 'very-common', description: 'Motor symptoms from corticospinal tract involvement' },
        ],
        associatedSymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Often most disabling symptom' },
          { name: "Lhermitte's sign", prevalence: 'common', description: 'Electric sensation with neck flexion' },
        ],
        physicalFindings: [
          { name: 'Optic neuritis', examType: 'Ophthalmologic', description: 'Afferent pupillary defect', diagnosticValue: 'Common presenting sign' },
          { name: 'Internuclear ophthalmoplegia', examType: 'Neurological', description: 'Impaired adduction with nystagmus', diagnosticValue: 'Highly suggestive' },
        ],
        labFindings: [{ testName: 'CSF analysis', abnormality: 'Oligoclonal bands, elevated IgG index', normalRange: 'No OCBs', significance: 'Supports diagnosis' }],
      },
      progression: {
        naturalHistory: "Highly variable course. 85% start with relapsing-remitting disease; many transition to secondary progressive over 10-20 years. DMTs have improved long-term outcomes.",
        timelineSteps: [
          {
            phaseId: 'cis',
            phase: 'early',
            displayName: 'Clinically Isolated Syndrome',
            timeframe: 'First attack',
            description: 'Single demyelinating event without dissemination in time',
            symptoms: ['Optic neuritis', 'Transverse myelitis', 'Brainstem syndrome'],
            anatomicalChanges: [{ structureId: 'white-matter', structureName: 'White Matter', changeType: 'inflammation', description: 'Focal demyelination', severity: 'moderate', visualIndicator: { color: '#4169E1', pulse: true, opacity: 0.6 }, isNewAtPhase: true }],
            reversibility: 'partially-reversible',
            typicalTreatments: ['High-dose steroids', 'Consider DMT'],
          },
          {
            phaseId: 'rrms',
            phase: 'established',
            displayName: 'Relapsing-Remitting MS',
            timeframe: 'Years to decades',
            description: 'Discrete attacks with partial or complete recovery',
            symptoms: ['Variable neurological symptoms'],
            anatomicalChanges: [{ structureId: 'white-matter', structureName: 'White Matter', changeType: 'degeneration', description: 'Multiple demyelinating plaques', severity: 'moderate', visualIndicator: { color: '#4169E1', pulse: false, opacity: 0.7 }, isNewAtPhase: false }],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Disease-modifying therapies', 'Steroids for relapses'],
          },
          {
            phaseId: 'spms',
            phase: 'advanced',
            displayName: 'Secondary Progressive MS',
            timeframe: '10-20 years after RRMS',
            description: 'Progressive disability without distinct relapses',
            symptoms: ['Progressive weakness', 'Spasticity', 'Cognitive decline'],
            anatomicalChanges: [{ structureId: 'brain', structureName: 'Brain', changeType: 'atrophy', description: 'Brain volume loss', severity: 'severe', visualIndicator: { color: '#4169E1', pulse: false, opacity: 0.8 }, isNewAtPhase: true }],
            reversibility: 'irreversible',
            typicalTreatments: ['Siponimod', 'Symptom management', 'Rehabilitation'],
          },
        ],
        prognosis: 'Variable. Most maintain ambulation at 15 years. DMTs significantly improve outcomes.',
      },
      complications: [
        {
          complicationId: 'ms-mobility',
          name: 'Mobility Impairment',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Progressive difficulty walking',
          mechanism: 'Accumulated spinal cord damage',
          affectedStructures: [{ structureId: 'spinal-cord', structureName: 'Spinal Cord', effect: 'Demyelination', highlightColor: '#4169E1' }],
          warningSymptoms: ['Increasing weakness', 'Falls', 'Need for aids'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'dmt',
          name: 'Disease-Modifying Therapies',
          modality: 'pharmacological',
          description: 'Immunomodulatory treatments to reduce relapses',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Reduce relapse rate', 'Slow disability'],
          explanations: {
            level1: 'Medicines that calm the immune system so it stops attacking nerves.',
            level2: 'These drugs reduce attack frequency and prevent new damage.',
            level3: 'High-efficacy DMTs early may prevent secondary progression.',
            level4: 'Risk stratification based on JCV status. Monitor for PML with natalizumab.',
            level5: 'DMTs target B-cell depletion, T-cell trafficking, or S1P modulation.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [{ structureId: 'white-matter', structureName: 'CNS White Matter', role: 'primary-site', involvement: 'Demyelinating plaques', highlightColor: '#4169E1', showByDefault: true }],
        secondaryStructures: [{ structureId: 'optic-nerve', structureName: 'Optic Nerve', role: 'secondary-site', involvement: 'Common inflammation site', highlightColor: '#6495ED', showByDefault: false }],
        systemsInvolved: ['Nervous'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
        focusRegion: 'head',
      },
      explanations: {
        level1: "A disease where your body attacks the coating around nerves.",
        level2: "MS damages myelin around nerves, slowing or blocking signals.",
        level3: "Diagnose with McDonald criteria. MRI shows periventricular lesions.",
        level4: "Early high-efficacy DMT increasingly favored.",
        level5: "Autoreactive T/B cells cross BBB. Axonal damage drives progression.",
      },
      relatedConditions: ['optic-neuritis', 'neuromyelitis-optica'],
      epidemiology: { prevalence: '100-300 per 100,000', incidence: '3-5 per 100,000 annually', demographics: 'Women 3x > men, onset 20-40 years' },
      clinicalPearls: ['Optic neuritis with APD is classic', 'MRI key for diagnosis', 'Heat worsens symptoms (Uhthoff)'],
      patientEducation: ['Stay on DMT even when well', 'Report new symptoms promptly', 'Manage fatigue'],
      emergencyWarnings: ['Sudden severe weakness', 'Vision loss', 'Difficulty breathing'],
    },
  ],

  // Ischemic Stroke
  [
    'ischemic-stroke',
    {
      conditionId: 'ischemic-stroke',
      name: 'Ischemic Stroke',
      aliases: ['Cerebral Infarction', 'Brain Attack', 'CVA'],
      icdCode: 'I63.9',
      category: 'neurologic',
      subcategory: 'Cerebrovascular Disease',
      description:
        'Sudden loss of brain function due to blocked blood supply, requiring emergency treatment to restore blood flow and limit brain damage.',
      pathophysiology: {
        summary:
          'Arterial occlusion causes cerebral ischemia, leading to ATP depletion, ion pump failure, excitotoxicity, and neuronal death in the affected territory.',
        mechanisms: [
          {
            name: 'Arterial Occlusion',
            description:
              'Thromboembolism blocks cerebral artery, stopping blood flow to downstream tissue',
            systemsInvolved: ['Cardiovascular', 'Nervous'],
            keyMediators: ['Thrombus', 'Embolus', 'Atherosclerotic plaque'],
            contribution: 'primary',
          },
          {
            name: 'Ischemic Cascade',
            description:
              'ATP depletion leads to ion pump failure, depolarization, glutamate release, and calcium influx causing cell death',
            systemsInvolved: ['Nervous'],
            keyMediators: ['Glutamate', 'Calcium', 'Free radicals'],
            contribution: 'primary',
          },
          {
            name: 'Penumbral Tissue',
            description:
              'Tissue surrounding infarct core is hypoperfused but potentially salvageable with timely reperfusion',
            systemsInvolved: ['Nervous', 'Cardiovascular'],
            keyMediators: ['Collateral blood flow'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Hypertension', type: 'modifiable', impact: 'major', description: 'Most important modifiable risk factor', intervention: 'Blood pressure control' },
          { name: 'Atrial Fibrillation', type: 'modifiable', impact: 'major', description: 'Major source of cardioembolism', intervention: 'Anticoagulation' },
          { name: 'Diabetes', type: 'modifiable', impact: 'moderate', description: 'Accelerates atherosclerosis', intervention: 'Glycemic control' },
          { name: 'Smoking', type: 'modifiable', impact: 'moderate', description: 'Promotes atherosclerosis and thrombosis', intervention: 'Smoking cessation' },
          { name: 'Age', type: 'non-modifiable', impact: 'major', description: 'Risk doubles each decade after 55' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Unilateral Weakness', prevalence: 'very-common', description: 'Sudden weakness affecting face, arm, or leg on one side (hemiparesis)' },
          { name: 'Facial Droop', prevalence: 'very-common', description: 'Asymmetric smile, drooping on one side' },
          { name: 'Speech Difficulty', prevalence: 'very-common', description: 'Slurred speech (dysarthria) or language impairment (aphasia)' },
        ],
        associatedSymptoms: [
          { name: 'Vision Loss', prevalence: 'common', description: 'Sudden visual field cut or monocular vision loss' },
          { name: 'Ataxia', prevalence: 'common', description: 'Difficulty with coordination and balance' },
          { name: 'Confusion', prevalence: 'common', description: 'Sudden alteration in mental status' },
          { name: 'Severe Headache', prevalence: 'uncommon', description: 'Sudden severe headache (more common in hemorrhagic)' },
        ],
        physicalFindings: [
          { name: 'Hemiparesis', examType: 'neurological', description: 'Weakness on one side of body', diagnosticValue: 'Key finding for stroke diagnosis' },
          { name: 'Arm Drift', examType: 'neurological', description: 'Affected arm drifts down when held out with eyes closed' },
          { name: 'Facial Asymmetry', examType: 'neurological', description: 'Drooping on one side of face when smiling' },
          { name: 'Dysarthria/Aphasia', examType: 'neurological', description: 'Slurred speech or inability to speak/understand' },
        ],
        labFindings: [
          { testName: 'CT Head', abnormality: 'Hypodense area or normal early', normalRange: 'N/A', significance: 'Rule out hemorrhage; may be normal in first hours' },
          { testName: 'MRI DWI', abnormality: 'Restricted diffusion', normalRange: 'N/A', significance: 'Most sensitive for acute ischemia' },
          { testName: 'CT Angiography', abnormality: 'Vessel occlusion', normalRange: 'N/A', significance: 'Identifies large vessel occlusion for thrombectomy' },
          { testName: 'Blood Glucose', abnormality: 'May be elevated or low', normalRange: '70-100 mg/dL', significance: 'Hypoglycemia can mimic stroke; hyperglycemia worsens outcomes' },
        ],
      },
      progression: {
        naturalHistory:
          'Without treatment, ischemic core expands into penumbra. Time is brain - every minute of occlusion causes further neuronal death. With successful reperfusion, outcomes significantly improved.',
        timelineSteps: [
          {
            phaseId: 'hyperacute',
            phase: 'early',
            displayName: 'Hyperacute Phase',
            timeframe: '0-6 hours',
            description: 'Critical window for reperfusion therapy to save penumbral tissue',
            symptoms: ['Sudden focal neurological deficit', 'Maximum deficit often at onset'],
            anatomicalChanges: [
              { structureId: 'brain', structureName: 'Brain', changeType: 'ischemia', description: 'Cytotoxic edema forming in ischemic territory', severity: 'severe', visualIndicator: { color: '#FF4500', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['IV Alteplase (tPA)', 'Mechanical thrombectomy for LVO'],
          },
          {
            phaseId: 'acute',
            phase: 'established',
            displayName: 'Acute Phase',
            timeframe: '1-7 days',
            description: 'Infarct evolution and medical stabilization',
            symptoms: ['Stable or gradually improving deficits', 'Risk of complications'],
            anatomicalChanges: [
              { structureId: 'brain', structureName: 'Brain', changeType: 'necrosis', description: 'Infarct maturation and vasogenic edema', severity: 'severe', visualIndicator: { color: '#FF4500', pulse: false, opacity: 0.9 }, isNewAtPhase: false },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Secondary prevention workup', 'Early rehabilitation', 'DVT prophylaxis'],
          },
          {
            phaseId: 'subacute',
            phase: 'chronic',
            displayName: 'Subacute/Recovery Phase',
            timeframe: 'Weeks to months',
            description: 'Neuroplasticity allows functional recovery through rehabilitation',
            symptoms: ['Gradual improvement', 'Residual deficits may persist'],
            anatomicalChanges: [
              { structureId: 'brain', structureName: 'Brain', changeType: 'structural-damage', description: 'Encephalomalacia and gliosis', severity: 'moderate', visualIndicator: { color: '#FF4500', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Intensive rehabilitation', 'Long-term secondary prevention'],
          },
        ],
        prognosis:
          'Outcomes depend on stroke severity, time to treatment, and rehabilitation. Approximately 30% achieve functional independence; early reperfusion dramatically improves outcomes.',
      },
      complications: [
        {
          complicationId: 'hemorrhagic-transformation',
          name: 'Hemorrhagic Transformation',
          category: 'acute',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Bleeding into infarcted brain tissue, may worsen neurological status',
          mechanism: 'Reperfusion into damaged vessels or spontaneous bleeding in infarct',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Hemorrhage within infarct', highlightColor: '#FF0000' }],
          warningSymptoms: ['Sudden neurological worsening', 'Decreased consciousness', 'New severe headache'],
          preventable: true,
        },
        {
          complicationId: 'cerebral-edema',
          name: 'Malignant Cerebral Edema',
          category: 'acute',
          severity: 'major',
          riskLevel: 'low',
          description: 'Massive brain swelling causing herniation, especially in large MCA strokes',
          mechanism: 'Cytotoxic and vasogenic edema causing mass effect',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Diffuse swelling with midline shift', highlightColor: '#FF0000' }],
          warningSymptoms: ['Decreasing consciousness', 'Pupillary changes', 'Cushing reflex'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'iv-tpa',
          name: 'IV Alteplase (tPA)',
          modality: 'pharmacological',
          description: 'Thrombolytic therapy to dissolve clot and restore blood flow',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute'],
          goals: ['Dissolve thrombus', 'Restore cerebral blood flow', 'Salvage penumbra'],
          explanations: {
            level1: 'A clot-busting medicine given through an IV to open the blocked blood vessel in your brain.',
            level2: 'tPA dissolves blood clots. It must be given within 4.5 hours of symptom onset. The earlier it is given, the better it works.',
            level3: 'Target door-to-needle <60 minutes. Review exclusion criteria carefully. BP must be <185/110 before and <180/105 for 24 hours after.',
            level4: 'NNT ~7 for reduced disability. Symptomatic ICH risk ~6%. Tenecteplase non-inferior and may be superior for LVO.',
            level5: 'Alteplase activates plasminogen to plasmin, which degrades fibrin. Selection by perfusion imaging can extend window. WAKE-UP and EXTEND trials support imaging-based selection.',
          },
        },
        {
          treatmentId: 'thrombectomy',
          name: 'Mechanical Thrombectomy',
          modality: 'interventional',
          description: 'Catheter-based retrieval of clot from large cerebral vessels',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute'],
          goals: ['Remove large vessel occlusion', 'Achieve TICI 2b-3 reperfusion', 'Limit infarct growth'],
          explanations: {
            level1: 'A procedure where doctors thread a small tube through blood vessels to the brain to pull out the clot.',
            level2: 'For large clots in major brain arteries, a catheter can mechanically remove the clot. This can be done up to 24 hours in selected patients.',
            level3: 'Indicated for LVO (ICA, M1, proximal M2, basilar). Use perfusion imaging for extended window. Combine with IV tPA if eligible.',
            level4: 'DAWN/DEFUSE-3 extended window to 24 hours with favorable perfusion mismatch. First-pass effect and TICI 2b-3 correlate with outcomes.',
            level5: 'Stent retrievers and aspiration devices used. Collateral status critical for extended window selection. Anesthesia type remains debated.',
          },
        },
        {
          treatmentId: 'antiplatelet',
          name: 'Antiplatelet Therapy',
          modality: 'pharmacological',
          description: 'Aspirin and/or clopidogrel for secondary prevention',
          efficacy: 'moderately-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['established', 'chronic'],
          goals: ['Prevent recurrent stroke', 'Reduce cardiovascular events'],
          explanations: {
            level1: 'Blood-thinning medicines like aspirin to prevent another stroke.',
            level2: 'Aspirin makes platelets less sticky so clots are less likely to form. This prevents future strokes.',
            level3: 'Aspirin 81-325mg daily for non-cardioembolic stroke. Dual antiplatelet (aspirin + clopidogrel) for 21-90 days for minor stroke/TIA.',
            level4: 'POINT/CHANCE trials support short-term DAPT for minor stroke/TIA. Beyond 90 days, monotherapy preferred due to bleeding risk.',
            level5: 'CYP2C19 polymorphisms affect clopidogrel efficacy. Ticagrelor may be alternative. P2Y12 testing available but not widely used.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'brain', structureName: 'Brain', role: 'primary-site', involvement: 'Ischemic territory depends on occluded vessel', highlightColor: '#FF4500', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'carotid-artery', structureName: 'Carotid Artery', role: 'secondary-site', involvement: 'Common site of atherosclerosis and occlusion', highlightColor: '#FF6347', showByDefault: false },
          { structureId: 'middle-cerebral-artery', structureName: 'Middle Cerebral Artery', role: 'secondary-site', involvement: 'Most common site of LVO', highlightColor: '#FF6347', showByDefault: false },
        ],
        systemsInvolved: ['Nervous', 'Cardiovascular'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous', 'cardiovascular'],
        focusRegion: 'head',
      },
      explanations: {
        level1: 'A brain attack where a blood clot blocks blood flow to part of your brain, causing sudden problems like weakness on one side or trouble speaking.',
        level2: 'When an artery to the brain gets blocked, that area of brain stops getting oxygen and starts to die. Fast treatment within hours can save brain tissue and prevent disability.',
        level3: 'Time is brain - every minute counts. Use FAST (Face drooping, Arm weakness, Speech difficulty, Time to call 911). CT first to rule out hemorrhage, then IV tPA if eligible. Thrombectomy for large vessel occlusion.',
        level4: 'Stroke etiologies by TOAST: large artery atherosclerosis, cardioembolism (esp. AFib), small vessel/lacunar, other determined, cryptogenic. Workup includes vessel imaging, cardiac monitoring, echo. Tailor secondary prevention to etiology.',
        level5: 'Ischemic cascade: ATP depletion → Na/K pump failure → depolarization → glutamate release → NMDA/AMPA activation → Ca2+ influx → mitochondrial dysfunction → ROS → apoptosis/necrosis. Penumbra defined by CBF 10-20 mL/100g/min. Perfusion mismatch guides extended-window therapy.',
      },
      relatedConditions: ['transient-ischemic-attack', 'atrial-fibrillation', 'carotid-stenosis', 'hypertension'],
      epidemiology: {
        prevalence: '3% of US adults have had a stroke',
        incidence: '800,000 strokes per year in US (87% ischemic)',
        demographics: 'Risk doubles each decade after 55; higher in Black and Hispanic populations',
      },
      clinicalPearls: [
        'FAST: Face drooping, Arm weakness, Speech difficulty, Time to call 911',
        'Last known well time (not symptom discovery time) determines tPA eligibility',
        'Wake-up strokes may be treated based on perfusion imaging (WAKE-UP, EXTEND trials)',
        'LVO can be treated up to 24 hours with favorable perfusion mismatch',
        'Dual antiplatelet for 21-90 days after minor stroke/TIA',
      ],
      patientEducation: [
        'Call 911 immediately for any stroke symptoms - time is critical',
        'Note the exact time symptoms started or when last seen normal',
        'Take secondary prevention medications daily as prescribed',
        'Control blood pressure, diabetes, and cholesterol',
        'Stop smoking - it significantly increases stroke risk',
      ],
      emergencyWarnings: [
        'Any sudden weakness, numbness, confusion, or trouble speaking',
        'Sudden vision loss or severe headache',
        'FAST symptoms require immediate 911 call - every minute counts',
      ],
    },
  ],

  // Peripheral Artery Disease
  [
    'peripheral-artery-disease',
    {
      conditionId: 'peripheral-artery-disease',
      name: 'Peripheral Artery Disease',
      aliases: ['PAD', 'Peripheral Vascular Disease', 'Claudication'],
      icdCode: 'I70.209',
      category: 'cardiovascular',
      subcategory: 'Vascular Disease',
      description:
        'Narrowing of arteries to the legs due to atherosclerosis, causing reduced blood flow that leads to leg pain with walking and, in severe cases, risk of limb loss.',
      pathophysiology: {
        summary:
          'Atherosclerotic plaque progressively narrows peripheral arteries, reducing blood flow to leg muscles. During exercise, oxygen demand exceeds supply, causing ischemic pain (claudication).',
        mechanisms: [
          {
            name: 'Atherosclerosis',
            description:
              'Lipid accumulation, inflammation, and fibrosis cause progressive arterial narrowing',
            systemsInvolved: ['Cardiovascular'],
            keyMediators: ['LDL cholesterol', 'Macrophages', 'Smooth muscle cells'],
            contribution: 'primary',
          },
          {
            name: 'Endothelial Dysfunction',
            description:
              'Impaired vasodilation and increased thrombogenicity contribute to reduced flow',
            systemsInvolved: ['Cardiovascular'],
            keyMediators: ['Nitric oxide', 'Endothelin'],
            contribution: 'secondary',
          },
          {
            name: 'Thrombosis',
            description:
              'Acute thrombus on ruptured plaque can cause sudden critical ischemia',
            systemsInvolved: ['Cardiovascular', 'Hematologic'],
            keyMediators: ['Platelets', 'Thrombin', 'Fibrin'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Smoking', type: 'modifiable', impact: 'major', description: 'Strongest modifiable risk factor - 4x increased risk', intervention: 'Smoking cessation' },
          { name: 'Diabetes', type: 'modifiable', impact: 'major', description: 'Increases risk 2-4x, accelerates disease', intervention: 'Glycemic control' },
          { name: 'Hypertension', type: 'modifiable', impact: 'moderate', description: 'Contributes to atherosclerosis and endothelial injury', intervention: 'Blood pressure control' },
          { name: 'Hyperlipidemia', type: 'modifiable', impact: 'moderate', description: 'LDL promotes plaque formation', intervention: 'Statin therapy' },
          { name: 'Age >65', type: 'non-modifiable', impact: 'major', description: 'Prevalence increases with age' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Intermittent Claudication', prevalence: 'very-common', description: 'Reproducible leg muscle pain (typically calf) with walking, relieved by rest within minutes' },
          { name: 'Reduced Walking Distance', prevalence: 'very-common', description: 'Limited ability to walk due to leg pain; distance is typically reproducible' },
        ],
        associatedSymptoms: [
          { name: 'Cold Feet', prevalence: 'common', description: 'Reduced blood flow causes cooler extremities' },
          { name: 'Hair Loss on Legs', prevalence: 'common', description: 'Trophic change due to chronic ischemia' },
          { name: 'Rest Pain', prevalence: 'uncommon', description: 'Pain at rest indicates severe disease (critical limb ischemia)' },
          { name: 'Non-healing Wounds', prevalence: 'uncommon', description: 'Ischemic ulcers indicate critical limb ischemia' },
        ],
        physicalFindings: [
          { name: 'Diminished Pulses', examType: 'vascular', description: 'Reduced or absent dorsalis pedis and posterior tibial pulses', diagnosticValue: 'Key finding suggesting arterial disease' },
          { name: 'Ankle-Brachial Index <0.9', examType: 'vascular', description: 'Ratio of ankle to brachial systolic BP; diagnostic standard', diagnosticValue: 'Diagnostic for PAD' },
          { name: 'Trophic Changes', examType: 'inspection', description: 'Shiny skin, hair loss, thickened nails, muscle atrophy' },
          { name: 'Pallor with Elevation', examType: 'vascular', description: 'Blanching of foot with elevation, rubor on dependency' },
        ],
        labFindings: [
          { testName: 'Ankle-Brachial Index', abnormality: '≤0.9', normalRange: '1.0-1.3', significance: 'Diagnostic for PAD; <0.4 indicates severe disease' },
          { testName: 'Toe-Brachial Index', abnormality: '<0.7', normalRange: '≥0.7', significance: 'Useful when ABI >1.3 due to arterial calcification (diabetics)' },
          { testName: 'Duplex Ultrasound', abnormality: 'Stenosis or occlusion', normalRange: 'N/A', significance: 'Localizes disease for intervention planning' },
          { testName: 'CT/MR Angiography', abnormality: 'Stenosis, occlusion, collaterals', normalRange: 'N/A', significance: 'Detailed anatomic mapping before revascularization' },
        ],
      },
      progression: {
        naturalHistory:
          'PAD is a chronic progressive disease, but limb outcomes are generally favorable with risk factor modification. Only 1-2% of claudicants progress to critical limb ischemia annually. Cardiovascular mortality is the main risk.',
        timelineSteps: [
          {
            phaseId: 'asymptomatic',
            phase: 'preclinical',
            displayName: 'Asymptomatic PAD',
            timeframe: 'Years to decades',
            description: 'Low ABI without symptoms; represents systemic atherosclerosis',
            symptoms: ['None - detected by screening ABI'],
            anatomicalChanges: [
              { structureId: 'leg-arteries', structureName: 'Leg Arteries', changeType: 'stenosis', description: 'Early plaque formation with mild narrowing', severity: 'mild', visualIndicator: { color: '#8B4513', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Risk factor modification', 'Antiplatelet therapy', 'Statin'],
          },
          {
            phaseId: 'claudication',
            phase: 'established',
            displayName: 'Intermittent Claudication',
            timeframe: 'Years',
            description: 'Reproducible leg pain with walking due to exercise-induced ischemia',
            symptoms: ['Calf or thigh pain with walking', 'Pain relieved by rest within 10 minutes'],
            anatomicalChanges: [
              { structureId: 'leg-arteries', structureName: 'Leg Arteries', changeType: 'stenosis', description: 'Significant luminal narrowing (>50%)', severity: 'moderate', visualIndicator: { color: '#8B4513', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Supervised exercise therapy', 'Cilostazol', 'Aggressive risk factor modification'],
          },
          {
            phaseId: 'cli',
            phase: 'advanced',
            displayName: 'Critical Limb Ischemia',
            timeframe: 'Weeks to months',
            description: 'Limb-threatening ischemia with rest pain, ulcers, or gangrene',
            symptoms: ['Rest pain (worse at night, better with dependency)', 'Non-healing wounds', 'Gangrene'],
            anatomicalChanges: [
              { structureId: 'leg-arteries', structureName: 'Leg Arteries', changeType: 'stenosis', description: 'Severe multisegment disease or occlusion', severity: 'severe', visualIndicator: { color: '#8B4513', pulse: false, opacity: 0.9 }, isNewAtPhase: false },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Urgent revascularization', 'Wound care', 'Amputation if not revascularizable'],
          },
        ],
        prognosis:
          'Limb prognosis is generally good with treatment - only 1-2% progress to CLI annually. However, PAD indicates systemic atherosclerosis with 3-6x increased cardiovascular mortality.',
      },
      complications: [
        {
          complicationId: 'cli-amputation',
          name: 'Limb Amputation',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'low',
          description: 'Loss of limb when blood flow cannot be restored',
          mechanism: 'Insufficient arterial inflow for tissue viability',
          affectedStructures: [{ structureId: 'leg', structureName: 'Lower Extremity', effect: 'Ischemic necrosis requiring amputation', highlightColor: '#000000' }],
          warningSymptoms: ['Non-healing wounds', 'Rest pain', 'Gangrene', 'Worsening tissue loss'],
          preventable: true,
        },
        {
          complicationId: 'acute-limb-ischemia',
          name: 'Acute Limb Ischemia',
          category: 'acute',
          severity: 'major',
          riskLevel: 'low',
          description: 'Sudden severe reduction in limb perfusion threatening viability',
          mechanism: 'Acute thrombosis on chronic plaque or embolism',
          affectedStructures: [{ structureId: 'leg-arteries', structureName: 'Leg Arteries', effect: 'Complete occlusion', highlightColor: '#FF0000' }],
          warningSymptoms: ['Sudden severe leg pain', 'Pale, cold, pulseless limb', 'Paresthesias', 'Weakness'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'supervised-exercise',
          name: 'Supervised Exercise Therapy',
          modality: 'rehabilitative',
          description: 'Structured walking program that is first-line treatment for claudication',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['preclinical', 'established'],
          goals: ['Increase walking distance', 'Improve quality of life', 'Reduce cardiovascular risk'],
          explanations: {
            level1: 'A walking program where you walk until leg pain occurs, rest, then repeat - this helps your legs build new blood vessels.',
            level2: 'Regular supervised walking exercise improves blood flow and muscle function. Studies show it can double your pain-free walking distance.',
            level3: 'SET improves claudication distance by 100-150%. At least 30-45 minutes, 3x/week for 12 weeks minimum. Walk to moderate claudication, rest, repeat.',
            level4: 'SET is as effective as revascularization for improving walking distance in claudication. Coverage for SET is now mandated by CMS.',
            level5: 'Exercise promotes arteriogenesis (collateral development), improves endothelial function, enhances muscle oxygen extraction, and modulates pain perception through central mechanisms.',
          },
        },
        {
          treatmentId: 'risk-factor-modification',
          name: 'Risk Factor Modification',
          modality: 'lifestyle',
          description: 'Smoking cessation, statin, antiplatelet, BP and glucose control',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['preclinical', 'established', 'advanced'],
          goals: ['Reduce cardiovascular events', 'Slow disease progression', 'Reduce amputation risk'],
          explanations: {
            level1: 'Stop smoking, take your medications, and control blood pressure and diabetes - this protects your heart and legs.',
            level2: 'The same factors that cause PAD also cause heart attacks and strokes. Controlling them reduces your risk of dying from heart disease.',
            level3: 'Smoking cessation is the single most important intervention. High-intensity statin for all PAD patients. Antiplatelet therapy (aspirin or clopidogrel).',
            level4: 'GDMT reduces cardiovascular mortality more than limb outcomes. LDL target <70. Consider PCSK9 inhibitor if not at goal. Rivaroxaban 2.5mg BID + aspirin reduces MACE and MALE.',
            level5: 'COMPASS trial showed rivaroxaban 2.5mg BID + aspirin reduced MACE by 24% and major adverse limb events by 46% vs aspirin alone in stable atherosclerosis.',
          },
        },
        {
          treatmentId: 'revascularization',
          name: 'Revascularization',
          modality: 'interventional',
          description: 'Endovascular (angioplasty/stent) or surgical bypass to restore blood flow',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established', 'advanced'],
          goals: ['Restore blood flow', 'Relieve disabling claudication', 'Achieve limb salvage in CLI'],
          explanations: {
            level1: 'Procedures to open blocked arteries or create a detour around the blockage using a catheter or surgery.',
            level2: 'For severe symptoms or limb-threatening ischemia, doctors can open arteries with balloon and stent, or create a bypass around the blockage.',
            level3: 'Endovascular first for most lesions. Consider surgical bypass for extensive disease, long occlusions, or failed endovascular. CLI requires urgent revascularization.',
            level4: 'TASC II classification guides approach. Drug-coated balloons improve patency for femoropopliteal disease. Limb salvage is the goal for CLI.',
            level5: 'Patency depends on lesion characteristics, runoff, and patient factors. Infrapopliteal intervention primarily for CLI/wound healing. Surveillance for restenosis is important.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'femoral-artery', structureName: 'Femoral Artery', role: 'primary-site', involvement: 'Most common site of PAD stenosis', highlightColor: '#8B4513', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'popliteal-artery', structureName: 'Popliteal Artery', role: 'secondary-site', involvement: 'Common site of disease', highlightColor: '#A0522D', showByDefault: false },
          { structureId: 'tibial-arteries', structureName: 'Tibial Arteries', role: 'secondary-site', involvement: 'Distal disease, especially in diabetics', highlightColor: '#A0522D', showByDefault: false },
        ],
        systemsInvolved: ['Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular'],
        focusRegion: 'lower-extremity',
      },
      explanations: {
        level1: 'Blocked arteries in your legs that cause pain when walking because your muscles are not getting enough blood.',
        level2: 'The same fatty buildup (atherosclerosis) that causes heart disease also narrows arteries to your legs. During walking, muscles need more blood than the narrowed arteries can supply, causing cramping pain.',
        level3: 'PAD is a marker of systemic atherosclerosis with high cardiovascular mortality. Screen with ABI in at-risk patients. Smoking cessation is the most important intervention. Supervised exercise is first-line for claudication.',
        level4: 'ABI 0.9-0.7 is mild, 0.7-0.4 moderate, <0.4 severe. GDMT reduces CV events: high-intensity statin, antiplatelet, BP control. Revascularization does not improve survival - focus is on symptoms and limb salvage.',
        level5: 'PAD patients have 3-6x increased cardiovascular mortality compared to age-matched controls. Lower extremity revascularization improves limb outcomes but not survival. COMPASS trial supports low-dose rivaroxaban + aspirin for vascular protection.',
      },
      relatedConditions: ['coronary-artery-disease', 'carotid-stenosis', 'diabetes', 'hypertension'],
      epidemiology: {
        prevalence: '8-10% of adults over 65; up to 20% of those over 70',
        incidence: 'Increases with age; ~500,000 new cases annually in US',
        demographics: 'Smokers (4x risk), diabetics (2-4x risk), Black patients have higher prevalence',
      },
      clinicalPearls: [
        'PAD is a marker of systemic atherosclerosis - patients have 3-6x higher cardiovascular mortality',
        'Claudication distance is reproducible - ask patients if their walking distance has changed',
        'Screen with ABI in diabetics, smokers, and adults over 65',
        'Smoking cessation is the single most important intervention',
        'Supervised exercise therapy is first-line for claudication and is as effective as revascularization',
      ],
      patientEducation: [
        'Stop smoking - this is the most important thing you can do for your legs and your heart',
        'Walk regularly - exercise helps your body build new blood vessels around the blockages',
        'Inspect your feet daily for sores or color changes',
        'Take your statin and antiplatelet medication as prescribed',
        'Control blood pressure and blood sugar',
      ],
      emergencyWarnings: [
        'Sudden severe leg pain with a pale, cold, or numb leg - this is a medical emergency',
        'New rest pain or sores that will not heal',
        'Signs of infection in any foot wound (redness, warmth, pus, fever)',
      ],
    },
  ],

  // Sepsis
  [
    'sepsis',
    {
      conditionId: 'sepsis',
      name: 'Sepsis',
      aliases: ['Septicemia', 'Blood Poisoning', 'Systemic Inflammatory Response'],
      icdCode: 'A41.9',
      category: 'infectious',
      subcategory: 'Systemic Infection',
      description:
        'A life-threatening condition where the body\'s response to infection causes widespread inflammation and organ dysfunction. Early recognition and treatment are critical for survival.',
      pathophysiology: {
        summary:
          'Infection triggers an overwhelming immune response with widespread inflammation, endothelial dysfunction, and microvascular thrombosis leading to impaired tissue perfusion and multiple organ failure.',
        mechanisms: [
          {
            name: 'Dysregulated Immune Response',
            description:
              'Pathogen-associated molecular patterns trigger massive cytokine release (cytokine storm) causing systemic inflammation',
            systemsInvolved: ['Immune', 'Cardiovascular', 'All organs'],
            keyMediators: ['TNF-alpha', 'IL-1', 'IL-6', 'PAMPs', 'DAMPs'],
            contribution: 'primary',
          },
          {
            name: 'Endothelial Dysfunction',
            description:
              'Inflammation damages blood vessel lining causing increased permeability, fluid shifts, and impaired blood flow regulation',
            systemsInvolved: ['Cardiovascular'],
            keyMediators: ['Nitric oxide', 'Endothelin', 'Complement'],
            contribution: 'primary',
          },
          {
            name: 'Coagulopathy',
            description:
              'Widespread activation of clotting with microvascular thrombosis impairs tissue oxygenation',
            systemsInvolved: ['Hematologic', 'Cardiovascular'],
            keyMediators: ['Tissue factor', 'Thrombin', 'Plasminogen activator inhibitor'],
            contribution: 'secondary',
          },
          {
            name: 'Mitochondrial Dysfunction',
            description:
              'Impaired cellular oxygen utilization even when oxygen delivery is adequate',
            systemsInvolved: ['All organs'],
            keyMediators: ['Reactive oxygen species', 'Nitric oxide'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Age >65 or <1 year', type: 'non-modifiable', impact: 'major', description: 'Extremes of age have impaired immune function' },
          { name: 'Immunosuppression', type: 'partially-modifiable', impact: 'major', description: 'Chemotherapy, transplant medications, HIV/AIDS increase infection risk', intervention: 'Prophylactic antibiotics when appropriate' },
          { name: 'Chronic Disease', type: 'partially-modifiable', impact: 'moderate', description: 'Diabetes, kidney disease, liver disease impair immune response', intervention: 'Optimize chronic disease management' },
          { name: 'Recent Surgery/Hospitalization', type: 'partially-modifiable', impact: 'moderate', description: 'Invasive procedures and hospital exposure increase infection risk', intervention: 'Infection prevention protocols' },
          { name: 'Indwelling Devices', type: 'modifiable', impact: 'moderate', description: 'Catheters, central lines, ventilators provide entry for pathogens', intervention: 'Remove unnecessary devices promptly' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Fever or Hypothermia', prevalence: 'very-common', description: 'Temperature >38.3°C (101°F) or <36°C (96.8°F); hypothermia indicates severe sepsis' },
          { name: 'Altered Mental Status', prevalence: 'very-common', description: 'Confusion, agitation, lethargy, or decreased responsiveness indicating brain dysfunction' },
          { name: 'Rapid Breathing', prevalence: 'very-common', description: 'Respiratory rate >22 breaths/minute as body tries to compensate for metabolic acidosis' },
          { name: 'Rapid Heart Rate', prevalence: 'very-common', description: 'Heart rate >90 bpm as heart works harder to maintain blood pressure' },
        ],
        associatedSymptoms: [
          { name: 'Chills and Shaking', prevalence: 'common', description: 'Rigors indicate bacteremia (bacteria in bloodstream)' },
          { name: 'Low Blood Pressure', prevalence: 'common', description: 'Systolic BP <100 indicates septic shock' },
          { name: 'Decreased Urine Output', prevalence: 'common', description: 'Sign of kidney dysfunction from poor perfusion' },
          { name: 'Mottled Skin', prevalence: 'uncommon', description: 'Patchy discoloration indicates poor microcirculation' },
        ],
        physicalFindings: [
          { name: 'Hypotension', examType: 'vital signs', description: 'MAP <65 mmHg or systolic <100 mmHg', diagnosticValue: 'Indicates septic shock when present with infection' },
          { name: 'Tachycardia', examType: 'vital signs', description: 'Heart rate >90 bpm', diagnosticValue: 'Part of systemic inflammatory response' },
          { name: 'Warm Extremities (early)', examType: 'circulation', description: 'Vasodilation causes warm, flushed skin initially', diagnosticValue: 'Indicates hyperdynamic early sepsis' },
          { name: 'Cool, Mottled Extremities (late)', examType: 'circulation', description: 'Poor perfusion causes cold, discolored skin', diagnosticValue: 'Indicates decompensated shock' },
        ],
        labFindings: [
          { testName: 'Lactate', abnormality: '>2 mmol/L', normalRange: '<2 mmol/L', significance: 'Indicates tissue hypoperfusion; >4 indicates severe sepsis' },
          { testName: 'White Blood Cell Count', abnormality: '>12,000 or <4,000', normalRange: '4,500-11,000/μL', significance: 'Elevated or severely depressed indicates infection/immune response' },
          { testName: 'Procalcitonin', abnormality: '>0.5 ng/mL', normalRange: '<0.1 ng/mL', significance: 'Bacterial infection marker; helps distinguish from viral' },
          { testName: 'Creatinine', abnormality: 'Rising', normalRange: '0.7-1.3 mg/dL', significance: 'Indicates acute kidney injury from poor perfusion' },
          { testName: 'Platelets', abnormality: '<150,000 or falling', normalRange: '150,000-400,000/μL', significance: 'Consumption in microvascular thrombosis' },
        ],
      },
      progression: {
        naturalHistory:
          'Sepsis progresses rapidly from infection to systemic inflammation to organ dysfunction. Without treatment, mortality approaches 40-60%. Each hour of delayed antibiotics increases mortality by 7-8%.',
        timelineSteps: [
          {
            phaseId: 'infection',
            phase: 'early',
            displayName: 'Localized Infection',
            timeframe: 'Hours to days',
            description: 'Infection at a primary site (lungs, urinary tract, abdomen, skin) before systemic spread',
            symptoms: ['Symptoms specific to infection site', 'Possible low-grade fever', 'Malaise'],
            anatomicalChanges: [
              { structureId: 'infection-site', structureName: 'Primary Infection Site', changeType: 'inflammation', description: 'Localized infection and inflammation', severity: 'mild', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Antibiotics', 'Source control'],
          },
          {
            phaseId: 'sepsis',
            phase: 'established',
            displayName: 'Sepsis',
            timeframe: 'Hours',
            description: 'Life-threatening organ dysfunction caused by dysregulated response to infection',
            symptoms: ['Fever or hypothermia', 'Tachycardia', 'Tachypnea', 'Altered mental status'],
            anatomicalChanges: [
              { structureId: 'cardiovascular-system', structureName: 'Cardiovascular System', changeType: 'dysfunction', description: 'Vasodilation and cardiac dysfunction', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
              { structureId: 'kidneys', structureName: 'Kidneys', changeType: 'dysfunction', description: 'Decreased perfusion causing AKI', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['IV antibiotics', 'IV fluids', 'Source control', 'ICU monitoring'],
          },
          {
            phaseId: 'septic-shock',
            phase: 'severe',
            displayName: 'Septic Shock',
            timeframe: 'Hours',
            description: 'Subset of sepsis with circulatory failure requiring vasopressors and lactate >2 despite fluid resuscitation',
            symptoms: ['Hypotension despite fluids', 'Oliguria', 'Mental status changes', 'Mottled skin'],
            anatomicalChanges: [
              { structureId: 'cardiovascular-system', structureName: 'Cardiovascular System', changeType: 'dysfunction', description: 'Vasoplegic shock with cardiac depression', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: false },
              { structureId: 'kidneys', structureName: 'Kidneys', changeType: 'ischemia', description: 'Severe hypoperfusion and AKI', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.8 }, isNewAtPhase: false },
              { structureId: 'liver', structureName: 'Liver', changeType: 'dysfunction', description: 'Hepatic dysfunction from shock', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Vasopressors (norepinephrine)', 'Continued antibiotics', 'Source control', 'Organ support'],
          },
          {
            phaseId: 'mods',
            phase: 'end-stage',
            displayName: 'Multiple Organ Dysfunction',
            timeframe: 'Days',
            description: 'Progressive failure of multiple organs despite treatment',
            symptoms: ['Respiratory failure requiring ventilation', 'Renal failure requiring dialysis', 'Coagulopathy', 'Hepatic failure'],
            anatomicalChanges: [
              { structureId: 'lungs', structureName: 'Lungs', changeType: 'dysfunction', description: 'ARDS requiring mechanical ventilation', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.9 }, isNewAtPhase: true },
              { structureId: 'kidneys', structureName: 'Kidneys', changeType: 'necrosis', description: 'Acute tubular necrosis requiring RRT', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.9 }, isNewAtPhase: false },
              { structureId: 'brain', structureName: 'Brain', changeType: 'dysfunction', description: 'Septic encephalopathy', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.9 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Mechanical ventilation', 'Renal replacement therapy', 'Continued vasopressors', 'Supportive care'],
          },
        ],
        prognosis:
          'Overall mortality 15-30% for sepsis, 40-60% for septic shock. Each additional organ failure increases mortality by 15-20%. Early recognition and treatment dramatically improve survival.',
      },
      complications: [
        {
          complicationId: 'ards',
          name: 'Acute Respiratory Distress Syndrome (ARDS)',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'high',
          description: 'Severe lung inflammation causing respiratory failure requiring mechanical ventilation',
          mechanism: 'Inflammatory mediators damage alveolar-capillary membrane causing pulmonary edema',
          affectedStructures: [{ structureId: 'lungs', structureName: 'Lungs', effect: 'Bilateral pulmonary infiltrates and severe hypoxemia', highlightColor: '#dc2626' }],
          warningSymptoms: ['Severe shortness of breath', 'Rapid shallow breathing', 'Low oxygen levels', 'Blue lips or fingertips'],
          preventable: false,
        },
        {
          complicationId: 'aki-sepsis',
          name: 'Acute Kidney Injury',
          category: 'acute',
          severity: 'major',
          riskLevel: 'high',
          description: 'Kidney failure from hypoperfusion and direct inflammatory injury',
          mechanism: 'Renal hypoperfusion, microvascular dysfunction, and direct tubular toxicity',
          affectedStructures: [{ structureId: 'kidneys', structureName: 'Kidneys', effect: 'Acute tubular injury with decreased filtration', highlightColor: '#f97316' }],
          warningSymptoms: ['Decreased urine output', 'Swelling', 'Confusion', 'Nausea'],
          preventable: true,
        },
        {
          complicationId: 'dic',
          name: 'Disseminated Intravascular Coagulation (DIC)',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Widespread activation of clotting causing both thrombosis and bleeding',
          mechanism: 'Tissue factor release triggers coagulation cascade; consumption of clotting factors causes bleeding',
          affectedStructures: [{ structureId: 'blood-vessels', structureName: 'Microvasculature', effect: 'Microvascular thrombosis with concurrent bleeding', highlightColor: '#7c3aed' }],
          warningSymptoms: ['Unexplained bleeding', 'Petechiae', 'Bruising', 'Blood in urine or stool'],
          preventable: false,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'antibiotics-empiric',
          name: 'Empiric Broad-Spectrum Antibiotics',
          modality: 'pharmacological',
          description: 'Immediate administration of antibiotics covering likely pathogens before culture results',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'severe'],
          goals: ['Kill bacteria', 'Prevent progression', 'Reduce mortality'],
          timeToEffect: 'Hours to days',
          explanations: {
            level1: 'Strong medications that kill the germs causing your infection. Given through an IV as soon as sepsis is suspected.',
            level2: 'Antibiotics are started immediately to fight the infection before we know exactly which germ is causing it. Every hour of delay can increase the risk of death.',
            level3: 'Administer within 1 hour of recognition. Cover gram-positive, gram-negative, and anaerobes based on suspected source. De-escalate when cultures return.',
            level4: 'Surviving Sepsis Campaign recommends antibiotics within 1 hour. Each hour delay increases mortality 7-8%. Typical regimens: vancomycin + piperacillin-tazobactam or cefepime.',
            level5: 'Pharmacokinetic considerations in sepsis: increased Vd, altered protein binding, augmented or decreased renal clearance. Consider loading doses and therapeutic drug monitoring.',
          },
        },
        {
          treatmentId: 'fluid-resuscitation',
          name: 'IV Fluid Resuscitation',
          modality: 'supportive',
          description: 'Rapid administration of intravenous crystalloid fluids to restore tissue perfusion',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'severe'],
          goals: ['Restore intravascular volume', 'Improve tissue perfusion', 'Increase blood pressure'],
          timeToEffect: 'Minutes',
          explanations: {
            level1: 'Fluids given through an IV to help your blood pressure and get blood flowing to your organs.',
            level2: 'Sepsis causes blood vessels to leak fluid. IV fluids replace lost volume and help your heart pump blood to vital organs.',
            level3: 'Initial bolus 30 mL/kg crystalloid within first 3 hours. Reassess with dynamic measures (pulse pressure variation, passive leg raise). Avoid fluid overload.',
            level4: 'Balanced crystalloids (LR, Plasmalyte) preferred over normal saline. Target MAP ≥65 mmHg, urine output ≥0.5 mL/kg/hr, lactate clearance.',
            level5: 'CLOVERS trial showed restrictive vs liberal fluids had similar outcomes. Focus on perfusion markers rather than fixed volumes. Fluid responsiveness testing guides ongoing resuscitation.',
          },
        },
        {
          treatmentId: 'vasopressors',
          name: 'Vasopressor Therapy',
          modality: 'pharmacological',
          description: 'Medications to constrict blood vessels and raise blood pressure when fluids alone are insufficient',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['severe', 'end-stage'],
          goals: ['Maintain blood pressure', 'Ensure organ perfusion', 'Support cardiac function'],
          timeToEffect: 'Minutes',
          explanations: {
            level1: 'Powerful medications that help squeeze your blood vessels to keep your blood pressure up when fluids are not enough.',
            level2: 'When IV fluids cannot maintain your blood pressure, we add medications that tighten blood vessels. This ensures blood reaches your vital organs.',
            level3: 'Norepinephrine is first-line. Add vasopressin as second agent. Consider dobutamine if cardiac dysfunction present. Target MAP ≥65 mmHg.',
            level4: 'VASST showed vasopressin-sparing effect on norepinephrine dose. Add hydrocortisone 200mg/day if refractory to vasopressors. Phenylephrine avoided due to pure vasoconstriction.',
            level5: 'Catecholamine dose thresholds associated with mortality; consider adjunctive therapies (angiotensin II, methylene blue) in refractory shock. Monitor for peripheral ischemia.',
          },
        },
        {
          treatmentId: 'source-control',
          name: 'Source Control',
          modality: 'surgical',
          description: 'Removal or drainage of the source of infection (abscess drainage, infected device removal)',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'severe'],
          goals: ['Remove infection source', 'Allow antibiotics to work', 'Prevent reinfection'],
          explanations: {
            level1: 'If there is an abscess or infected device, doctors need to remove or drain it so antibiotics can work.',
            level2: 'Antibiotics work better when we remove the source of infection - like draining an abscess, removing an infected catheter, or operating on infected tissue.',
            level3: 'Identify and control source within 6-12 hours when feasible. Percutaneous drainage preferred over surgery when possible. Remove all infected devices.',
            level4: 'Delay in source control associated with increased mortality. Balance surgical risk vs benefit in unstable patients. IR drainage often possible in critically ill.',
            level5: 'Damage control surgery principles apply in hemodynamically unstable patients. Staged approach with temporary closure may be necessary. Coordinate with surgery and IR early.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'cardiovascular-system', structureName: 'Cardiovascular System', role: 'primary-site', involvement: 'Vasodilation and cardiac dysfunction drive shock', highlightColor: '#dc2626', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'lungs', structureName: 'Lungs', role: 'target-organ', involvement: 'ARDS and respiratory failure', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'kidneys', structureName: 'Kidneys', role: 'target-organ', involvement: 'Acute kidney injury', highlightColor: '#f97316', showByDefault: true },
          { structureId: 'liver', structureName: 'Liver', role: 'target-organ', involvement: 'Hepatic dysfunction', highlightColor: '#f59e0b', showByDefault: false },
          { structureId: 'brain', structureName: 'Brain', role: 'target-organ', involvement: 'Septic encephalopathy', highlightColor: '#8b5cf6', showByDefault: false },
        ],
        systemsInvolved: ['Cardiovascular', 'Immune', 'Respiratory', 'Renal', 'Hepatic', 'Neurologic'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular', 'respiratory', 'urinary'],
      },
      explanations: {
        level1: 'A serious infection that spreads through your whole body and can make your organs stop working. It is a medical emergency that needs immediate treatment.',
        level2: 'When an infection gets into your bloodstream, your immune system overreacts and causes inflammation everywhere. This damages blood vessels and organs. Quick treatment with antibiotics and fluids is critical.',
        level3: 'Sepsis is life-threatening organ dysfunction caused by dysregulated host response to infection. Identified by qSOFA (≥2 of: RR≥22, altered mentation, SBP≤100) or SOFA score ≥2. Hour-1 bundle: lactate, cultures, antibiotics, fluids.',
        level4: 'Sepsis-3 definition: suspected infection + SOFA ≥2. qSOFA screens outside ICU. Septic shock: sepsis + vasopressors needed for MAP≥65 + lactate >2 despite fluids. Mortality 15-30% sepsis, 40-60% septic shock.',
        level5: 'Pathophysiology involves PAMPs/DAMPs activating innate immunity via TLRs, complement, and inflammasomes. Endothelial glycocalyx degradation causes capillary leak. Immunoparalysis follows initial hyperinflammation. Metabolic reprogramming affects mitochondrial function.',
      },
      relatedConditions: ['pneumonia', 'urinary-tract-infection', 'cellulitis', 'acute-kidney-injury'],
      epidemiology: {
        prevalence: '1.7 million cases annually in the US; leading cause of death in hospitals',
        incidence: '~50 per 100,000 people per year; increasing due to aging population',
        demographics: 'Higher risk in elderly, immunocompromised, those with chronic illness',
      },
      clinicalPearls: [
        'Time is critical - every hour of delayed antibiotics increases mortality by 7-8%',
        'Sepsis can occur without fever - hypothermia actually indicates worse prognosis',
        'Lactate >4 indicates severe tissue hypoperfusion even with normal blood pressure',
        'Source control is as important as antibiotics - look for drainable collections',
        'Mental status changes may be the first sign of sepsis, especially in elderly',
      ],
      patientEducation: [
        'Sepsis is a medical emergency - if you have signs of infection with confusion, rapid breathing, or feeling very unwell, call 911',
        'Know the signs: fever, chills, rapid heart rate, rapid breathing, confusion, extreme pain',
        'Take all prescribed antibiotics exactly as directed to prevent resistance',
        'If you have a weakened immune system, be extra vigilant about infection signs',
        'Complete recovery is possible, but some people have long-lasting effects (post-sepsis syndrome)',
      ],
      emergencyWarnings: [
        'Confusion or altered mental status with signs of infection - call 911 immediately',
        'Rapid breathing or difficulty breathing with infection',
        'Cold, clammy, or mottled skin',
        'Not urinating for several hours',
        'Feeling like you might die - trust your instincts and get emergency care',
      ],
    },
  ],

  // Pneumonia
  [
    'pneumonia',
    {
      conditionId: 'pneumonia',
      name: 'Pneumonia',
      aliases: ['Lung Infection', 'Community-Acquired Pneumonia', 'CAP'],
      icdCode: 'J18.9',
      category: 'respiratory',
      subcategory: 'Lung Infection',
      description:
        'An infection that inflames the air sacs in one or both lungs, which may fill with fluid or pus, causing cough with phlegm, fever, chills, and difficulty breathing.',
      pathophysiology: {
        summary:
          'Pathogens reach the lower respiratory tract and overwhelm local defenses, causing alveolar inflammation, fluid accumulation, and impaired gas exchange.',
        mechanisms: [
          {
            name: 'Pathogen Invasion',
            description:
              'Bacteria, viruses, or fungi bypass upper airway defenses and colonize alveoli',
            systemsInvolved: ['Respiratory'],
            keyMediators: ['Pathogen virulence factors', 'Adhesins'],
            contribution: 'primary',
          },
          {
            name: 'Inflammatory Response',
            description:
              'Alveolar macrophages and neutrophils respond, releasing cytokines and causing inflammation',
            systemsInvolved: ['Respiratory', 'Immune'],
            keyMediators: ['IL-1', 'IL-6', 'TNF-alpha', 'Neutrophils'],
            contribution: 'primary',
          },
          {
            name: 'Alveolar Flooding',
            description:
              'Increased capillary permeability causes protein-rich fluid and inflammatory cells to fill alveoli',
            systemsInvolved: ['Respiratory'],
            keyMediators: ['Inflammatory exudate', 'Fibrin'],
            contribution: 'secondary',
          },
          {
            name: 'Impaired Gas Exchange',
            description:
              'Fluid-filled alveoli cannot participate in oxygen exchange, causing hypoxemia',
            systemsInvolved: ['Respiratory'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Age >65 or <2 years', type: 'non-modifiable', impact: 'major', description: 'Weakened immune defenses and reduced cough reflex' },
          { name: 'Smoking', type: 'modifiable', impact: 'major', description: 'Damages cilia and impairs mucociliary clearance', intervention: 'Smoking cessation' },
          { name: 'Chronic Lung Disease', type: 'partially-modifiable', impact: 'major', description: 'COPD, asthma impair local defenses', intervention: 'Optimize underlying condition' },
          { name: 'Immunosuppression', type: 'partially-modifiable', impact: 'major', description: 'Increased susceptibility to opportunistic pathogens', intervention: 'Prophylactic measures' },
          { name: 'Aspiration Risk', type: 'partially-modifiable', impact: 'moderate', description: 'Dysphagia, GERD, sedation increase aspiration', intervention: 'Aspiration precautions' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Productive Cough', prevalence: 'very-common', description: 'Cough producing sputum that may be yellow, green, rust-colored, or blood-tinged' },
          { name: 'Fever and Chills', prevalence: 'very-common', description: 'Temperature elevation with shaking chills (rigors) suggesting bacteremia' },
          { name: 'Shortness of Breath', prevalence: 'very-common', description: 'Dyspnea at rest or with minimal exertion from impaired gas exchange' },
          { name: 'Pleuritic Chest Pain', prevalence: 'common', description: 'Sharp pain with breathing from inflammation of pleura overlying infected lung' },
        ],
        associatedSymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Systemic illness causes profound tiredness' },
          { name: 'Confusion', prevalence: 'common', description: 'Especially in elderly; may be only symptom in older adults' },
          { name: 'Decreased Appetite', prevalence: 'common', description: 'Systemic inflammation suppresses appetite' },
          { name: 'Muscle Aches', prevalence: 'common', description: 'Myalgia from systemic inflammatory response' },
        ],
        physicalFindings: [
          { name: 'Crackles/Rales', examType: 'auscultation', description: 'Inspiratory crackles over affected lung from fluid in alveoli', diagnosticValue: 'Highly suggestive of pneumonia' },
          { name: 'Decreased Breath Sounds', examType: 'auscultation', description: 'Diminished air entry over consolidated lung', diagnosticValue: 'Indicates consolidation or effusion' },
          { name: 'Dullness to Percussion', examType: 'percussion', description: 'Loss of normal resonance over consolidated lung', diagnosticValue: 'Suggests consolidation or effusion' },
          { name: 'Increased Tactile Fremitus', examType: 'palpation', description: 'Enhanced vibration transmission through consolidated lung', diagnosticValue: 'Suggests consolidation' },
          { name: 'Egophony', examType: 'auscultation', description: 'E-to-A change - "E" sounds like "A" over consolidated lung', diagnosticValue: 'Classic sign of consolidation' },
        ],
        labFindings: [
          { testName: 'Chest X-ray', abnormality: 'Infiltrate or consolidation', normalRange: 'Clear lung fields', significance: 'Gold standard for diagnosis; shows location and extent' },
          { testName: 'White Blood Cell Count', abnormality: '>11,000 or <4,000', normalRange: '4,500-11,000/μL', significance: 'Elevated suggests bacterial; low may indicate severe infection' },
          { testName: 'Procalcitonin', abnormality: '>0.25 ng/mL', normalRange: '<0.1 ng/mL', significance: 'Elevated supports bacterial etiology' },
          { testName: 'Oxygen Saturation', abnormality: '<94%', normalRange: '94-100%', significance: 'Indicates severity and need for supplemental oxygen' },
          { testName: 'Sputum Culture', abnormality: 'Pathogen identified', normalRange: 'Normal flora', significance: 'Identifies causative organism for targeted therapy' },
        ],
      },
      progression: {
        naturalHistory:
          'Pneumonia typically develops over hours to days. With appropriate treatment, most healthy adults improve within 3-5 days, though complete recovery takes weeks. Severe cases can rapidly progress to respiratory failure.',
        timelineSteps: [
          {
            phaseId: 'congestion',
            phase: 'early',
            displayName: 'Congestion Phase',
            timeframe: '0-24 hours',
            description: 'Initial vascular engorgement and fluid extravasation into alveoli',
            symptoms: ['Onset of cough', 'Low-grade fever', 'Malaise'],
            anatomicalChanges: [
              { structureId: 'lungs', structureName: 'Affected Lung Lobe', changeType: 'edema', description: 'Vascular congestion and early alveolar edema', severity: 'mild', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Antibiotics', 'Supportive care'],
          },
          {
            phaseId: 'red-hepatization',
            phase: 'established',
            displayName: 'Red Hepatization',
            timeframe: '24-72 hours',
            description: 'Alveoli fill with red blood cells, neutrophils, and fibrin; lung becomes solid like liver',
            symptoms: ['High fever', 'Productive cough', 'Dyspnea', 'Pleuritic chest pain'],
            anatomicalChanges: [
              { structureId: 'lungs', structureName: 'Affected Lung Lobe', changeType: 'inflammation', description: 'Consolidation with RBCs, neutrophils, fibrin filling alveoli', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.7 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Antibiotics', 'Oxygen', 'IV fluids'],
          },
          {
            phaseId: 'gray-hepatization',
            phase: 'established',
            displayName: 'Gray Hepatization',
            timeframe: '3-5 days',
            description: 'RBCs break down, neutrophils predominate; continued consolidation',
            symptoms: ['Persistent fever', 'Thick purulent sputum', 'Continued dyspnea'],
            anatomicalChanges: [
              { structureId: 'lungs', structureName: 'Affected Lung Lobe', changeType: 'inflammation', description: 'Grayish consolidation with neutrophils and fibrin', severity: 'moderate', visualIndicator: { color: '#78716c', pulse: false, opacity: 0.7 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Continue antibiotics', 'Respiratory therapy'],
          },
          {
            phaseId: 'resolution',
            phase: 'chronic',
            displayName: 'Resolution',
            timeframe: '1-3 weeks',
            description: 'Macrophages clear debris; alveolar architecture gradually restored',
            symptoms: ['Improving cough', 'Resolving fever', 'Gradual return of energy'],
            anatomicalChanges: [
              { structureId: 'lungs', structureName: 'Affected Lung Lobe', changeType: 'inflammation', description: 'Gradual clearing of exudate and restoration of normal architecture', severity: 'mild', visualIndicator: { color: '#22c55e', pulse: false, opacity: 0.4 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Complete antibiotic course', 'Rest', 'Pulmonary rehabilitation if needed'],
          },
        ],
        prognosis:
          'Most healthy adults recover completely. Mortality varies: <1% for young healthy adults, 5-15% for hospitalized patients, up to 30% for ICU patients. Elderly and immunocompromised have higher mortality.',
      },
      complications: [
        {
          complicationId: 'parapneumonic-effusion',
          name: 'Parapneumonic Effusion/Empyema',
          category: 'acute',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Infected fluid collection in pleural space adjacent to pneumonia',
          mechanism: 'Inflammation spreads to pleura causing fluid accumulation; can become infected (empyema)',
          affectedStructures: [{ structureId: 'pleura', structureName: 'Pleural Space', effect: 'Fluid and pus accumulation compressing lung', highlightColor: '#f97316' }],
          warningSymptoms: ['Worsening shortness of breath', 'Persistent fever despite antibiotics', 'Pleuritic chest pain'],
          preventable: true,
        },
        {
          complicationId: 'lung-abscess',
          name: 'Lung Abscess',
          category: 'acute',
          severity: 'major',
          riskLevel: 'low',
          description: 'Localized collection of pus within lung tissue',
          mechanism: 'Necrosis of lung tissue with cavity formation, often from aspiration or virulent organisms',
          affectedStructures: [{ structureId: 'lungs', structureName: 'Lung Parenchyma', effect: 'Cavity containing pus and necrotic tissue', highlightColor: '#dc2626' }],
          warningSymptoms: ['Putrid sputum', 'Night sweats', 'Weight loss', 'Persistent fever'],
          preventable: true,
        },
        {
          complicationId: 'respiratory-failure-pna',
          name: 'Acute Respiratory Failure',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Inability to maintain adequate oxygenation requiring mechanical ventilation',
          mechanism: 'Extensive alveolar involvement prevents adequate gas exchange',
          affectedStructures: [{ structureId: 'lungs', structureName: 'Lungs', effect: 'Bilateral involvement with severe hypoxemia', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['Severe shortness of breath', 'Confusion', 'Rapid deterioration', 'Blue lips'],
          preventable: false,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'antibiotics-cap',
          name: 'Antibiotic Therapy',
          modality: 'pharmacological',
          description: 'Antibiotics targeting likely pathogens based on severity and risk factors',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Eradicate infection', 'Prevent complications', 'Reduce mortality'],
          timeToEffect: '48-72 hours for improvement',
          explanations: {
            level1: 'Medications that kill the germs causing your lung infection. Most people feel better within a few days.',
            level2: 'Antibiotics are chosen based on where you got pneumonia and how sick you are. Most cases can be treated with pills at home; severe cases need IV antibiotics in the hospital.',
            level3: 'Outpatient: amoxicillin or doxycycline, add macrolide if comorbidities. Inpatient: beta-lactam + macrolide or respiratory fluoroquinolone. Duration typically 5-7 days.',
            level4: 'ATS/IDSA guidelines stratify by severity (CURB-65, PSI). Cover S. pneumoniae, H. influenzae, atypicals. Add MRSA/Pseudomonas coverage for risk factors or severe CAP.',
            level5: 'Procalcitonin-guided therapy may safely reduce antibiotic duration. Extended infusion beta-lactams improve outcomes in severe cases. De-escalate based on cultures.',
          },
        },
        {
          treatmentId: 'oxygen-therapy-pna',
          name: 'Supplemental Oxygen',
          modality: 'supportive',
          description: 'Providing additional oxygen to maintain adequate blood oxygen levels',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'severe'],
          goals: ['Maintain SpO2 ≥92%', 'Reduce work of breathing', 'Prevent tissue hypoxia'],
          explanations: {
            level1: 'Extra oxygen through a mask or nasal tubes to help you breathe easier and keep your organs healthy.',
            level2: 'When pneumonia affects your lungs\' ability to get oxygen into your blood, supplemental oxygen helps make sure your body gets enough.',
            level3: 'Target SpO2 92-96% (88-92% in COPD). Nasal cannula for mild hypoxemia; high-flow nasal cannula or NIV for moderate; intubation for severe respiratory failure.',
            level4: 'High-flow nasal cannula improves oxygenation and may prevent intubation. Avoid hyperoxia (SpO2 >96%) which may be harmful. HFNC delivers up to 60 L/min with FiO2 up to 100%.',
            level5: 'ROX index (SpO2/FiO2 divided by RR) predicts HFNC failure; <4.88 at 12 hours suggests need for intubation. Awake prone positioning may improve oxygenation.',
          },
        },
        {
          treatmentId: 'vaccination-prevention',
          name: 'Vaccination (Prevention)',
          modality: 'preventive',
          description: 'Pneumococcal and influenza vaccines to prevent pneumonia',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['preclinical'],
          goals: ['Prevent pneumonia', 'Reduce severity if infection occurs', 'Decrease mortality'],
          explanations: {
            level1: 'Shots that help your body fight off the germs that cause pneumonia before you get sick.',
            level2: 'Pneumonia and flu vaccines significantly reduce your risk of getting pneumonia. They\'re especially important if you\'re older or have chronic illness.',
            level3: 'Pneumococcal vaccines (PCV20 or PCV15+PPSV23) for all adults ≥65 and high-risk younger adults. Annual influenza vaccine for everyone ≥6 months.',
            level4: 'PCV20 preferred as single lifetime dose for most adults. Immunocompromised may need additional doses. COVID-19 vaccination also reduces pneumonia risk.',
            level5: 'Conjugate vaccines induce T-cell dependent response with memory; PPSV23 covers more serotypes but with T-cell independent response. Herd immunity effects reduce community transmission.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'lungs', structureName: 'Lungs', role: 'primary-site', involvement: 'Alveolar infection and consolidation', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'bronchi', structureName: 'Bronchi', role: 'secondary-site', involvement: 'Airway inflammation and mucus production', highlightColor: '#f97316', showByDefault: false },
          { structureId: 'pleura', structureName: 'Pleura', role: 'secondary-site', involvement: 'Inflammation causing pleuritic pain', highlightColor: '#f59e0b', showByDefault: false },
        ],
        systemsInvolved: ['Respiratory', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['respiratory'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1: 'An infection in your lungs that fills the tiny air sacs with fluid and pus, making it hard to breathe and causing fever and cough.',
        level2: 'Germs (usually bacteria or viruses) infect your lungs, causing inflammation. Your body fights back, but the battle fills your air sacs with fluid, making breathing difficult. Antibiotics cure most bacterial pneumonia.',
        level3: 'Pneumonia is alveolar infection causing consolidation and impaired gas exchange. Presents with productive cough, fever, dyspnea, and pleuritic pain. CXR confirms diagnosis. Treat with appropriate antibiotics based on severity.',
        level4: 'Stratify severity using CURB-65 or PSI to guide disposition. Most common pathogens: S. pneumoniae, H. influenzae, M. pneumoniae. Consider resistant organisms and atypicals based on risk factors. Follow-up CXR at 6 weeks.',
        level5: 'Host defense failure allows alveolar colonization. Inflammatory cascade involves alveolar macrophages, neutrophils, complement, and cytokines. Consolidation progresses through stages: congestion, red hepatization, gray hepatization, resolution. Biomarkers (PCT, CRP) guide antibiotic decisions.',
      },
      relatedConditions: ['copd', 'asthma', 'influenza', 'covid-19', 'sepsis'],
      epidemiology: {
        prevalence: '4-5 million cases annually in the US; leading infectious cause of death',
        incidence: '24.8 cases per 10,000 adults annually; increases with age',
        demographics: 'Higher risk in elderly, smokers, immunocompromised, chronic disease',
      },
      clinicalPearls: [
        'Elderly may present atypically with confusion alone - always consider pneumonia',
        'Failure to improve by day 3 suggests resistant organism, complication, or wrong diagnosis',
        'Parapneumonic effusion occurs in 20-40% - tap if significant to rule out empyema',
        'Sputum cultures are only useful if obtained before antibiotics and with good quality sample',
        'Clinical stability (not CXR) determines readiness for discharge and oral switch',
      ],
      patientEducation: [
        'Take all antibiotics exactly as prescribed, even if you feel better before finishing',
        'Rest and drink plenty of fluids to help your body fight the infection',
        'Use a humidifier and take over-the-counter medications for symptom relief',
        'Get vaccinated - pneumonia and flu shots greatly reduce your risk',
        'Do not smoke - it damages your lungs\' ability to fight infection',
      ],
      emergencyWarnings: [
        'Severe difficulty breathing or feeling like you cannot catch your breath',
        'Confusion or altered mental status',
        'Chest pain that is severe or worsening',
        'Coughing up blood',
        'Blue lips, fingertips, or skin',
        'High fever not responding to medication',
      ],
    },
  ],

  // Acute Kidney Injury
  [
    'acute-kidney-injury',
    {
      conditionId: 'acute-kidney-injury',
      name: 'Acute Kidney Injury',
      aliases: ['AKI', 'Acute Renal Failure', 'ARF'],
      icdCode: 'N17.9',
      category: 'urologic',
      subcategory: 'Renal Failure',
      description:
        'A sudden decline in kidney function occurring over hours to days, characterized by decreased urine output and buildup of waste products in the blood. Often reversible with prompt treatment.',
      pathophysiology: {
        summary:
          'AKI results from decreased renal perfusion (prerenal), direct kidney injury (intrinsic), or urinary obstruction (postrenal), leading to inability to filter blood and maintain fluid/electrolyte balance.',
        mechanisms: [
          {
            name: 'Prerenal Azotemia',
            description:
              'Decreased blood flow to kidneys from hypovolemia, hypotension, or heart failure',
            systemsInvolved: ['Cardiovascular', 'Renal'],
            keyMediators: ['Renin-angiotensin system', 'ADH', 'Catecholamines'],
            contribution: 'primary',
          },
          {
            name: 'Acute Tubular Necrosis',
            description:
              'Direct damage to renal tubular cells from ischemia or nephrotoxins',
            systemsInvolved: ['Renal'],
            keyMediators: ['Reactive oxygen species', 'Inflammatory cytokines'],
            contribution: 'primary',
          },
          {
            name: 'Tubular Obstruction',
            description:
              'Sloughed tubular cells and debris obstruct tubular flow',
            systemsInvolved: ['Renal'],
            contribution: 'secondary',
          },
          {
            name: 'Postrenal Obstruction',
            description:
              'Blockage of urinary outflow causing back-pressure and kidney damage',
            systemsInvolved: ['Renal', 'Urologic'],
            contribution: 'primary',
          },
        ],
        riskFactors: [
          { name: 'Pre-existing CKD', type: 'non-modifiable', impact: 'major', description: 'Reduced kidney reserve makes AKI more likely and severe' },
          { name: 'Dehydration/Hypovolemia', type: 'modifiable', impact: 'major', description: 'Decreased renal perfusion is the most common cause', intervention: 'Adequate hydration' },
          { name: 'Nephrotoxic Medications', type: 'modifiable', impact: 'major', description: 'NSAIDs, aminoglycosides, contrast dye, ACE inhibitors in certain settings', intervention: 'Avoid or minimize exposure' },
          { name: 'Sepsis', type: 'partially-modifiable', impact: 'major', description: 'Inflammation and hypoperfusion damage kidneys', intervention: 'Early sepsis treatment' },
          { name: 'Advanced Age', type: 'non-modifiable', impact: 'moderate', description: 'Decreased renal reserve and comorbidities' },
          { name: 'Diabetes', type: 'partially-modifiable', impact: 'moderate', description: 'Diabetic nephropathy increases susceptibility', intervention: 'Glycemic control' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Decreased Urine Output', prevalence: 'very-common', description: 'Oliguria (<400 mL/day) or anuria; some AKI is non-oliguric' },
          { name: 'Fluid Retention', prevalence: 'common', description: 'Swelling in legs, ankles, or around eyes from inability to excrete fluid' },
          { name: 'Fatigue', prevalence: 'common', description: 'Weakness and tiredness from uremia and anemia' },
        ],
        associatedSymptoms: [
          { name: 'Nausea and Vomiting', prevalence: 'common', description: 'Uremia causes GI symptoms' },
          { name: 'Confusion', prevalence: 'uncommon', description: 'Uremic encephalopathy in severe cases' },
          { name: 'Shortness of Breath', prevalence: 'common', description: 'Fluid overload causes pulmonary edema' },
          { name: 'Decreased Appetite', prevalence: 'common', description: 'Uremia suppresses appetite' },
        ],
        physicalFindings: [
          { name: 'Peripheral Edema', examType: 'inspection', description: 'Bilateral leg swelling from fluid retention', diagnosticValue: 'Indicates volume overload' },
          { name: 'Jugular Venous Distension', examType: 'inspection', description: 'Elevated JVP from fluid overload', diagnosticValue: 'Indicates volume overload' },
          { name: 'Pulmonary Crackles', examType: 'auscultation', description: 'Fluid in lungs from pulmonary edema', diagnosticValue: 'Indicates severe fluid overload' },
          { name: 'Asterixis', examType: 'neurologic', description: 'Flapping tremor of hands with arms extended', diagnosticValue: 'Indicates uremic encephalopathy' },
        ],
        labFindings: [
          { testName: 'Serum Creatinine', abnormality: 'Rising (≥0.3 mg/dL or ≥50%)', normalRange: '0.7-1.3 mg/dL', significance: 'Defines AKI by KDIGO criteria' },
          { testName: 'Blood Urea Nitrogen (BUN)', abnormality: 'Elevated', normalRange: '7-20 mg/dL', significance: 'Rises with decreased kidney function' },
          { testName: 'Potassium', abnormality: '>5.0 mEq/L', normalRange: '3.5-5.0 mEq/L', significance: 'Hyperkalemia is life-threatening complication' },
          { testName: 'Urinalysis', abnormality: 'Muddy brown casts (ATN), protein, blood', normalRange: 'Clear', significance: 'Helps identify etiology' },
          { testName: 'Fractional Excretion of Sodium', abnormality: '<1% (prerenal) or >2% (intrinsic)', normalRange: '1-2%', significance: 'Distinguishes prerenal from intrinsic AKI' },
        ],
      },
      progression: {
        naturalHistory:
          'AKI can range from mild, reversible injury to severe kidney failure requiring dialysis. Most prerenal AKI reverses with fluid resuscitation. ATN typically takes 1-3 weeks to recover. Some patients develop chronic kidney disease.',
        timelineSteps: [
          {
            phaseId: 'initiation',
            phase: 'acute',
            displayName: 'Initiation Phase',
            timeframe: 'Hours to days',
            description: 'Initial insult (ischemia, toxin, obstruction) damages kidney',
            symptoms: ['May be asymptomatic initially', 'Symptoms of underlying cause'],
            anatomicalChanges: [
              { structureId: 'kidneys', structureName: 'Kidneys', changeType: 'ischemia', description: 'Initial tubular injury from insult', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Remove cause', 'Fluid resuscitation if prerenal', 'Relieve obstruction if postrenal'],
          },
          {
            phaseId: 'extension',
            phase: 'acute',
            displayName: 'Extension/Maintenance Phase',
            timeframe: '1-2 weeks',
            description: 'Continued injury, inflammation, and tubular cell death even after initial insult removed',
            symptoms: ['Oliguria or anuria', 'Rising creatinine', 'Fluid overload', 'Electrolyte abnormalities'],
            anatomicalChanges: [
              { structureId: 'kidneys', structureName: 'Kidneys', changeType: 'necrosis', description: 'Established tubular necrosis with inflammation', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.7 }, isNewAtPhase: false },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Supportive care', 'Fluid and electrolyte management', 'Dialysis if severe'],
          },
          {
            phaseId: 'recovery',
            phase: 'chronic',
            displayName: 'Recovery Phase',
            timeframe: 'Weeks to months',
            description: 'Tubular cells regenerate and kidney function gradually returns',
            symptoms: ['Polyuria (increased urine output)', 'Gradual improvement in creatinine', 'Risk of electrolyte wasting'],
            anatomicalChanges: [
              { structureId: 'kidneys', structureName: 'Kidneys', changeType: 'inflammation', description: 'Tubular regeneration and healing', severity: 'mild', visualIndicator: { color: '#22c55e', pulse: false, opacity: 0.5 }, isNewAtPhase: false },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Monitor electrolytes during polyuric phase', 'Avoid nephrotoxins', 'Follow-up for CKD'],
          },
        ],
        prognosis:
          'Prognosis depends on severity and underlying cause. Mild AKI often fully recovers. Severe AKI requiring dialysis has 50-80% mortality in ICU. Survivors have increased risk of CKD and cardiovascular events.',
      },
      complications: [
        {
          complicationId: 'hyperkalemia',
          name: 'Hyperkalemia',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'high',
          description: 'Dangerously high potassium levels causing cardiac arrhythmias',
          mechanism: 'Kidneys cannot excrete potassium; also released from damaged cells',
          affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'Conduction abnormalities and risk of cardiac arrest', highlightColor: '#dc2626' }],
          warningSymptoms: ['Muscle weakness', 'Palpitations', 'Nausea', 'Tingling'],
          preventable: true,
        },
        {
          complicationId: 'pulmonary-edema-aki',
          name: 'Pulmonary Edema',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Fluid accumulation in lungs from inability to excrete fluid',
          mechanism: 'Volume overload with impaired kidney excretion',
          affectedStructures: [{ structureId: 'lungs', structureName: 'Lungs', effect: 'Alveolar flooding causing hypoxemia', highlightColor: '#06b6d4' }],
          warningSymptoms: ['Severe shortness of breath', 'Orthopnea', 'Pink frothy sputum', 'Anxiety'],
          preventable: true,
        },
        {
          complicationId: 'uremic-encephalopathy',
          name: 'Uremic Encephalopathy',
          category: 'acute',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Brain dysfunction from accumulation of uremic toxins',
          mechanism: 'Uremic toxins cross blood-brain barrier affecting neuronal function',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Diffuse dysfunction causing confusion and altered consciousness', highlightColor: '#8b5cf6' }],
          warningSymptoms: ['Confusion', 'Lethargy', 'Seizures', 'Asterixis'],
          preventable: true,
        },
        {
          complicationId: 'ckd-progression',
          name: 'Progression to Chronic Kidney Disease',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Incomplete recovery leading to permanent kidney damage',
          mechanism: 'Tubular loss and fibrosis from severe or repeated injury',
          affectedStructures: [{ structureId: 'kidneys', structureName: 'Kidneys', effect: 'Permanent nephron loss and fibrosis', highlightColor: '#78716c' }],
          warningSymptoms: ['Persistently elevated creatinine after 3 months', 'Persistent proteinuria'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'fluid-management-aki',
          name: 'Fluid Management',
          modality: 'supportive',
          description: 'IV fluids for prerenal AKI; fluid restriction for volume overload',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['acute'],
          goals: ['Restore renal perfusion (prerenal)', 'Prevent fluid overload', 'Maintain electrolyte balance'],
          explanations: {
            level1: 'If your kidneys are not getting enough blood, IV fluids help. If there is too much fluid, we may restrict fluids and give medications to help you urinate.',
            level2: 'Dehydration is a common cause of kidney problems. IV fluids restore blood flow to your kidneys. If your kidneys cannot get rid of fluid, we may need to limit fluids to prevent them from backing up into your lungs.',
            level3: 'Assess volume status carefully - prerenal needs fluids, established AKI with overload needs restriction. Target euvolemia. Balanced crystalloids preferred over saline.',
            level4: 'FENa <1% suggests prerenal (preserved tubular function). Fluid challenge with monitoring for response. Avoid fluid overload which worsens outcomes in established AKI.',
            level5: 'FACTT trial showed conservative fluid strategy improved outcomes in ALI. Bioimpedance and POCUS can guide volume assessment. Chloride-rich fluids may worsen AKI - use balanced crystalloids.',
          },
        },
        {
          treatmentId: 'stop-nephrotoxins',
          name: 'Discontinue Nephrotoxins',
          modality: 'supportive',
          description: 'Stop medications and exposures that damage kidneys',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['acute'],
          goals: ['Remove ongoing injury', 'Allow kidney recovery', 'Prevent worsening'],
          explanations: {
            level1: 'We stop any medications or substances that might be hurting your kidneys to let them heal.',
            level2: 'Certain medications (like some pain relievers and antibiotics) can damage kidneys. Stopping these helps your kidneys recover.',
            level3: 'Hold NSAIDs, ACE inhibitors/ARBs (temporarily), aminoglycosides, and other nephrotoxins. Adjust doses of renally-cleared medications. Avoid IV contrast if possible.',
            level4: 'Triple whammy (NSAID + ACE/ARB + diuretic) is a common precipitant. If contrast needed, use iso-osmolar, minimize volume, ensure hydration.',
            level5: 'Contrast-induced AKI is largely volume-related - adequate hydration is key prevention. Metformin hold is precautionary - restart when creatinine stable. Vancomycin trough monitoring prevents toxicity.',
          },
        },
        {
          treatmentId: 'dialysis-aki',
          name: 'Renal Replacement Therapy (Dialysis)',
          modality: 'interventional',
          description: 'Mechanical filtration of blood when kidneys cannot function adequately',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['acute'],
          goals: ['Remove toxins and excess fluid', 'Correct electrolytes', 'Bridge to kidney recovery'],
          explanations: {
            level1: 'A machine filters your blood and removes waste and extra fluid when your kidneys cannot do it. This is usually temporary until your kidneys recover.',
            level2: 'Dialysis does the job of your kidneys - filtering waste from your blood and removing excess fluid. You might need it for a short time until your kidneys heal.',
            level3: 'Indications: refractory hyperkalemia, severe metabolic acidosis, volume overload unresponsive to diuretics, uremic complications. CRRT vs intermittent HD based on hemodynamic stability.',
            level4: 'AKIKI and IDEAL-ICU trials suggest delayed RRT initiation safe if no urgent indication. CRRT preferred for hemodynamically unstable patients. Citrate anticoagulation if no contraindication.',
            level5: 'RRT dose of 20-25 mL/kg/hr is standard. Higher doses not beneficial per ATN and RENAL trials. Early initiation does not improve outcomes but increases RRT exposure.',
          },
        },
        {
          treatmentId: 'relieve-obstruction',
          name: 'Relieve Urinary Obstruction',
          modality: 'interventional',
          description: 'Catheterization or nephrostomy to relieve postrenal AKI',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['acute'],
          goals: ['Relieve obstruction', 'Allow kidney recovery', 'Prevent permanent damage'],
          explanations: {
            level1: 'If something is blocking urine from leaving your body, we need to open that blockage with a catheter or tube.',
            level2: 'A blockage anywhere from your kidneys to bladder can cause kidney damage. Placing a catheter or tube drains the urine and lets your kidneys recover.',
            level3: 'Bladder catheter for outlet obstruction. Nephrostomy tube or ureteral stent for upper tract obstruction. Urgent decompression prevents permanent damage. Expect post-obstructive diuresis.',
            level4: 'Renal ultrasound is first-line imaging for obstruction. Even partial obstruction can cause AKI. Monitor closely for post-obstructive diuresis - replace losses appropriately.',
            level5: 'Time to decompression correlates with recovery. Prolonged obstruction causes tubular atrophy and interstitial fibrosis. Post-obstructive diuresis reflects osmotic (urea) and pressure-related factors.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'kidneys', structureName: 'Kidneys', role: 'primary-site', involvement: 'Acute decline in filtration and tubular function', highlightColor: '#dc2626', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'ureters', structureName: 'Ureters', role: 'secondary-site', involvement: 'Potential site of obstruction', highlightColor: '#f97316', showByDefault: false },
          { structureId: 'bladder', structureName: 'Bladder', role: 'secondary-site', involvement: 'Potential site of obstruction', highlightColor: '#f97316', showByDefault: false },
          { structureId: 'heart', structureName: 'Heart', role: 'secondary-site', involvement: 'Affected by hyperkalemia and volume overload', highlightColor: '#ef4444', showByDefault: false },
        ],
        systemsInvolved: ['Urinary', 'Cardiovascular'],
        recommendedView: 'posterior',
        recommendedLayers: ['urinary'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: 'Your kidneys suddenly stopped working well. They are not filtering waste from your blood or making enough urine. With treatment, they usually recover.',
        level2: 'Something caused your kidneys to suddenly stop working - either not enough blood flow, a toxin, or a blockage. Your blood is building up waste products. We need to find and fix the cause.',
        level3: 'AKI is defined by KDIGO as creatinine rise ≥0.3 mg/dL in 48 hours or ≥50% in 7 days, or urine output <0.5 mL/kg/hr for 6 hours. Classify as prerenal, intrinsic, or postrenal to guide treatment.',
        level4: 'Stage 1: Cr 1.5-1.9x or ≥0.3 rise. Stage 2: 2-2.9x. Stage 3: ≥3x or ≥4.0 or RRT. FENa <1% prerenal, >2% intrinsic (ATN). Muddy brown casts diagnostic of ATN. NGAL and KIM-1 are novel biomarkers.',
        level5: 'AKI pathophysiology involves tubular injury, inflammation, vascular dysfunction, and maladaptive repair. Extension phase continues injury despite removal of insult through ongoing inflammation and hypoxia. AKI-to-CKD transition involves incomplete repair, fibrosis, and capillary rarefaction.',
      },
      relatedConditions: ['chronic-kidney-disease', 'sepsis', 'heart-failure', 'hypertension'],
      epidemiology: {
        prevalence: 'Occurs in 10-15% of hospitalized patients; 50-60% of ICU patients',
        incidence: 'Increasing due to aging population and more nephrotoxic exposures',
        demographics: 'Higher risk in elderly, diabetics, those with CKD, hospitalized patients',
      },
      clinicalPearls: [
        'Always check a post-void residual or bladder scan - postrenal AKI is easily reversible',
        'Prerenal AKI has FENa <1% and responds rapidly to fluids',
        'Contrast-induced AKI is largely preventable with adequate hydration',
        'Monitor potassium closely - hyperkalemia can be fatal',
        'Even mild AKI increases risk of death and CKD - follow up after discharge',
      ],
      patientEducation: [
        'Stay well hydrated, especially when sick, exercising, or in hot weather',
        'Avoid NSAIDs (ibuprofen, naproxen) which can harm kidneys, especially if dehydrated',
        'Tell all your doctors about your kidney problem so they can adjust medications',
        'If you have less urine output or swelling, contact your doctor promptly',
        'Follow up with your doctor to make sure your kidneys have fully recovered',
      ],
      emergencyWarnings: [
        'No urine output for 12 or more hours',
        'Severe swelling, especially sudden swelling',
        'Difficulty breathing or feeling like you cannot catch your breath',
        'Chest pain or irregular heartbeat',
        'Confusion or difficulty staying awake',
        'Muscle weakness or numbness',
      ],
    },
  ],

  // Acute Pancreatitis
  [
    'acute-pancreatitis',
    {
      conditionId: 'acute-pancreatitis',
      name: 'Acute Pancreatitis',
      aliases: ['Pancreatitis', 'Inflamed Pancreas'],
      icdCode: 'K85.9',
      category: 'gastrointestinal',
      subcategory: 'Pancreatic Disease',
      description:
        'Sudden inflammation of the pancreas that can range from mild, self-limited disease to severe, life-threatening illness with organ failure and local complications.',
      pathophysiology: {
        summary:
          'Premature activation of pancreatic digestive enzymes within the pancreas leads to autodigestion, local inflammation, and potentially systemic inflammatory response.',
        mechanisms: [
          {
            name: 'Premature Enzyme Activation',
            description:
              'Trypsinogen activates to trypsin within pancreatic acinar cells, triggering cascade of enzyme activation',
            systemsInvolved: ['Gastrointestinal'],
            keyMediators: ['Trypsin', 'Phospholipase A2', 'Elastase'],
            contribution: 'primary',
          },
          {
            name: 'Acinar Cell Injury',
            description:
              'Activated enzymes cause autodigestion and necrosis of pancreatic tissue',
            systemsInvolved: ['Gastrointestinal'],
            keyMediators: ['Cathepsin B', 'Calcium signaling'],
            contribution: 'primary',
          },
          {
            name: 'Inflammatory Response',
            description:
              'Damaged cells release cytokines triggering local and systemic inflammation',
            systemsInvolved: ['Immune', 'All organs'],
            keyMediators: ['IL-1', 'IL-6', 'TNF-alpha', 'PAF'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Gallstones', type: 'modifiable', impact: 'major', description: 'Most common cause (~40%) - stones block pancreatic duct', intervention: 'Cholecystectomy after recovery' },
          { name: 'Alcohol Use', type: 'modifiable', impact: 'major', description: 'Second most common cause (~30%) - toxic to acinar cells', intervention: 'Alcohol cessation' },
          { name: 'Hypertriglyceridemia', type: 'partially-modifiable', impact: 'moderate', description: 'TG >1000 mg/dL can trigger pancreatitis', intervention: 'Lipid control, fibrates' },
          { name: 'Medications', type: 'modifiable', impact: 'moderate', description: 'Certain drugs (azathioprine, valproic acid, etc.)', intervention: 'Discontinue offending agent' },
          { name: 'ERCP', type: 'partially-modifiable', impact: 'moderate', description: 'Post-procedural pancreatitis occurs in 3-5%', intervention: 'Rectal indomethacin prophylaxis' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Epigastric Pain', prevalence: 'very-common', description: 'Severe, steady pain in upper abdomen radiating to back, worse after eating' },
          { name: 'Nausea and Vomiting', prevalence: 'very-common', description: 'Persistent nausea with vomiting that does not relieve pain' },
          { name: 'Abdominal Tenderness', prevalence: 'very-common', description: 'Tenderness to palpation in epigastrium' },
        ],
        associatedSymptoms: [
          { name: 'Fever', prevalence: 'common', description: 'Low-grade fever from inflammation; high fever suggests infection' },
          { name: 'Tachycardia', prevalence: 'common', description: 'Due to pain, dehydration, and inflammation' },
          { name: 'Abdominal Distension', prevalence: 'common', description: 'Ileus and fluid accumulation' },
          { name: 'Jaundice', prevalence: 'uncommon', description: 'Suggests gallstone etiology with bile duct obstruction' },
        ],
        physicalFindings: [
          { name: 'Epigastric Tenderness', examType: 'palpation', description: 'Tenderness in upper abdomen without rebound', diagnosticValue: 'Present in most cases' },
          { name: 'Guarding', examType: 'palpation', description: 'Voluntary guarding over epigastrium', diagnosticValue: 'Suggests peritoneal irritation' },
          { name: 'Decreased Bowel Sounds', examType: 'auscultation', description: 'Ileus from inflammation', diagnosticValue: 'Common finding' },
          { name: 'Cullen Sign', examType: 'inspection', description: 'Periumbilical bruising', diagnosticValue: 'Rare; indicates severe hemorrhagic pancreatitis' },
          { name: 'Grey Turner Sign', examType: 'inspection', description: 'Flank bruising', diagnosticValue: 'Rare; indicates severe hemorrhagic pancreatitis' },
        ],
        labFindings: [
          { testName: 'Serum Lipase', abnormality: '>3x upper limit of normal', normalRange: '0-160 U/L', significance: 'Most sensitive and specific marker; remains elevated longer than amylase' },
          { testName: 'Serum Amylase', abnormality: '>3x upper limit of normal', normalRange: '30-110 U/L', significance: 'Rises early but normalizes within 3-5 days' },
          { testName: 'Liver Function Tests', abnormality: 'Elevated ALT >150 U/L', normalRange: '7-56 U/L', significance: 'Strongly suggests gallstone etiology' },
          { testName: 'Triglycerides', abnormality: '>1000 mg/dL', normalRange: '<150 mg/dL', significance: 'If elevated, is the etiology' },
          { testName: 'CT Abdomen', abnormality: 'Pancreatic edema, necrosis, collections', normalRange: 'Normal pancreas', significance: 'Confirms diagnosis; assesses severity' },
        ],
      },
      progression: {
        naturalHistory:
          'Most cases (80-85%) are mild and self-limiting, resolving within a week. Severe cases with organ failure or necrosis carry 20-30% mortality.',
        timelineSteps: [
          {
            phaseId: 'early',
            phase: 'acute',
            displayName: 'Early Phase (First Week)',
            timeframe: '0-7 days',
            description: 'Inflammatory response and potential organ failure; severity determined by systemic response',
            symptoms: ['Severe epigastric pain', 'Nausea and vomiting', 'Fever', 'Tachycardia'],
            anatomicalChanges: [
              { structureId: 'pancreas', structureName: 'Pancreas', changeType: 'inflammation', description: 'Edematous swelling and inflammation', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['NPO', 'IV fluids', 'Pain control', 'Monitoring for organ failure'],
          },
          {
            phaseId: 'late',
            phase: 'established',
            displayName: 'Late Phase (After Week 1)',
            timeframe: '1-4 weeks',
            description: 'Local complications develop - necrosis, fluid collections, pseudocysts',
            symptoms: ['Persistent pain', 'Fever if infected', 'Abdominal mass', 'Poor oral intake'],
            anatomicalChanges: [
              { structureId: 'pancreas', structureName: 'Pancreas', changeType: 'necrosis', description: 'Necrosis of pancreatic/peripancreatic tissue', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Continue supportive care', 'Enteral nutrition', 'Drainage of collections if infected'],
          },
          {
            phaseId: 'recovery',
            phase: 'chronic',
            displayName: 'Recovery Phase',
            timeframe: 'Weeks to months',
            description: 'Resolution of inflammation, resorption of collections, return of function',
            symptoms: ['Improving pain', 'Tolerance of oral diet', 'Resolution of collections'],
            anatomicalChanges: [
              { structureId: 'pancreas', structureName: 'Pancreas', changeType: 'inflammation', description: 'Gradual healing and resolution', severity: 'mild', visualIndicator: { color: '#22c55e', pulse: false, opacity: 0.4 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Oral diet', 'Address underlying cause', 'Cholecystectomy if gallstones'],
          },
        ],
        prognosis:
          'Mild interstitial pancreatitis: <5% mortality. Severe necrotizing pancreatitis with organ failure: 20-30% mortality. Infected necrosis: 30-40% mortality.',
      },
      complications: [
        {
          complicationId: 'pancreatic-necrosis',
          name: 'Pancreatic Necrosis',
          category: 'acute',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Death of pancreatic tissue due to autodigestion and ischemia',
          mechanism: 'Severe enzyme release and vascular compromise cause tissue death',
          affectedStructures: [{ structureId: 'pancreas', structureName: 'Pancreas', effect: 'Necrotic tissue that may become infected', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['Persistent fever', 'Worsening pain', 'Failure to improve', 'New organ failure'],
          preventable: false,
        },
        {
          complicationId: 'infected-necrosis',
          name: 'Infected Pancreatic Necrosis',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Bacterial infection of necrotic pancreatic tissue',
          mechanism: 'Bacterial translocation from gut colonizes necrotic tissue',
          affectedStructures: [{ structureId: 'pancreas', structureName: 'Pancreas', effect: 'Infected necrotic tissue requiring drainage', highlightColor: '#dc2626' }],
          warningSymptoms: ['High fever', 'Rising white count', 'Worsening clinical status', 'Gas on CT'],
          preventable: true,
        },
        {
          complicationId: 'pseudocyst',
          name: 'Pancreatic Pseudocyst',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Walled-off collection of pancreatic fluid without epithelial lining',
          mechanism: 'Pancreatic duct disruption leads to fluid collection that walls off over 4+ weeks',
          affectedStructures: [{ structureId: 'pancreas', structureName: 'Peripancreatic Area', effect: 'Fluid collection that may cause symptoms or become infected', highlightColor: '#f97316' }],
          warningSymptoms: ['Persistent pain', 'Early satiety', 'Palpable mass', 'Biliary obstruction'],
          preventable: false,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'fluid-resuscitation-panc',
          name: 'Aggressive IV Fluid Resuscitation',
          modality: 'supportive',
          description: 'Large-volume crystalloid administration to maintain organ perfusion',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['acute'],
          goals: ['Maintain tissue perfusion', 'Prevent organ failure', 'Support pancreatic microcirculation'],
          explanations: {
            level1: 'You will receive a lot of IV fluids to support your body while your pancreas heals.',
            level2: 'Pancreatitis causes fluid to leak out of blood vessels. IV fluids replace this loss and ensure blood flow to vital organs.',
            level3: 'Goal-directed fluid resuscitation targeting heart rate, MAP, urine output, and hematocrit. Lactated Ringer\'s preferred. 250-500 mL/hr initially, titrate to goals.',
            level4: 'WATERFALL trial showed that aggressive vs moderate fluid resuscitation had similar outcomes, and aggressive fluids may cause more fluid overload. Target euvolemia.',
            level5: 'Pancreatic microcirculation is sensitive to hypovolemia. Third-spacing significant. Balance fluid resuscitation against risk of abdominal compartment syndrome and pulmonary edema.',
          },
        },
        {
          treatmentId: 'pain-control-panc',
          name: 'Pain Management',
          modality: 'pharmacological',
          description: 'Opioid analgesics for severe pain control',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['acute', 'established'],
          goals: ['Relieve suffering', 'Allow patient comfort', 'Enable nutrition'],
          explanations: {
            level1: 'We will give you strong pain medications to keep you comfortable while your pancreas heals.',
            level2: 'Pancreatitis pain is severe. We use powerful pain medications like morphine or hydromorphone to control it.',
            level3: 'Hydromorphone or fentanyl preferred. PCA pump for severe cases. No evidence morphine worsens pancreatitis via Sphincter of Oddi spasm. Multimodal analgesia helpful.',
            level4: 'Epidural analgesia may improve outcomes in severe pancreatitis by improving splanchnic perfusion. NSAIDs avoided due to renal concerns in acute setting.',
            level5: 'Pain control is humane and does not mask clinical deterioration. Regional techniques (epidural, TAP blocks) reduce opioid requirements and may improve ileus.',
          },
        },
        {
          treatmentId: 'enteral-nutrition-panc',
          name: 'Early Enteral Nutrition',
          modality: 'supportive',
          description: 'Tube feeding started early to maintain gut function and reduce complications',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute', 'established'],
          goals: ['Maintain gut barrier', 'Prevent bacterial translocation', 'Provide nutrition'],
          explanations: {
            level1: 'We start feeding through a tube early, even while your stomach rests, because it helps your gut stay healthy.',
            level2: 'Feeding through a tube keeps your intestines working and prevents bacteria from crossing into your blood. This reduces infections.',
            level3: 'Nasogastric or nasojejunal feeding within 24-48 hours if oral intake not possible. NG is as effective as NJ. Standard polymeric formula adequate.',
            level4: 'PYTHON trial showed NG equal to NJ. Meta-analyses confirm early enteral feeding reduces mortality, infection, organ failure vs TPN. Start even in severe pancreatitis.',
            level5: 'Enteral feeding maintains gut mucosal integrity, reduces bacterial translocation (a major driver of infected necrosis), and provides immunonutrition. TPN only if EN fails.',
          },
        },
        {
          treatmentId: 'ercp-gallstone',
          name: 'ERCP for Gallstone Pancreatitis',
          modality: 'interventional',
          description: 'Endoscopic removal of bile duct stones causing pancreatitis',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['acute'],
          goals: ['Relieve biliary obstruction', 'Prevent cholangitis', 'Treat cause'],
          explanations: {
            level1: 'If a gallstone is blocking your bile duct, we can remove it with a scope procedure.',
            level2: 'A small camera is passed through your mouth to your bile duct. We can remove the stone and place a stent to keep the duct open.',
            level3: 'Urgent ERCP (<24h) indicated for cholangitis or persistent biliary obstruction. Not needed for mild gallstone pancreatitis without obstruction. Cholecystectomy during same admission for mild cases.',
            level4: 'APEC trial: routine early ERCP not beneficial without cholangitis. Tokyo Guidelines define cholangitis criteria. Same-admission cholecystectomy reduces recurrence.',
            level5: 'EUS may identify choledocholithiasis before committing to ERCP. Sphincterotomy facilitates stone clearance. Pancreatic duct stent and rectal indomethacin prevent post-ERCP pancreatitis.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'pancreas', structureName: 'Pancreas', role: 'primary-site', involvement: 'Inflamed and potentially necrotic', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'gallbladder', structureName: 'Gallbladder', role: 'secondary-site', involvement: 'Source of gallstones causing pancreatitis', highlightColor: '#f97316', showByDefault: true },
          { structureId: 'common-bile-duct', structureName: 'Common Bile Duct', role: 'secondary-site', involvement: 'May be obstructed by stones', highlightColor: '#f59e0b', showByDefault: false },
        ],
        systemsInvolved: ['Gastrointestinal', 'Hepatobiliary'],
        recommendedView: 'anterior',
        recommendedLayers: ['digestive'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: 'Your pancreas, an organ that helps digest food, has become inflamed and swollen. This causes severe belly pain but usually gets better with supportive care.',
        level2: 'The pancreas makes enzymes to digest food. In pancreatitis, these enzymes activate too early and start digesting the pancreas itself, causing pain and inflammation.',
        level3: 'Acute pancreatitis is diagnosed by 2 of 3: characteristic pain, lipase >3x normal, imaging findings. Most common causes are gallstones and alcohol. Atlanta classification defines severity. Most cases are mild and self-limited.',
        level4: 'Revised Atlanta Classification: mild (no organ failure or local complications), moderately severe (transient organ failure <48h or local complications), severe (persistent organ failure >48h). BISAP, APACHE II predict severity.',
        level5: 'Pathophysiology involves aberrant calcium signaling in acinar cells, premature trypsinogen activation, and autophagy failure. SIRS in first week predicts mortality. Infected necrosis occurs week 2-4 via bacterial translocation. Walled-off necrosis can be drained endoscopically or surgically.',
      },
      relatedConditions: ['gallstones', 'alcohol-use-disorder', 'chronic-pancreatitis'],
      epidemiology: {
        prevalence: '5-80 per 100,000 annually depending on population',
        incidence: '34 per 100,000 per year in the US; increasing due to obesity/gallstones',
        demographics: 'Gallstone pancreatitis more common in women; alcohol pancreatitis more common in men',
      },
      clinicalPearls: [
        'Lipase is more sensitive and specific than amylase - lipase is the preferred test',
        'ALT >150 strongly suggests gallstone etiology',
        'CT is not needed for diagnosis - use it to assess severity or detect complications',
        'Early enteral nutrition reduces mortality - "feed the gut"',
        'Same-admission cholecystectomy for mild gallstone pancreatitis prevents recurrence',
      ],
      patientEducation: [
        'Avoid alcohol completely - even small amounts can trigger another attack',
        'If gallstones caused your pancreatitis, you will likely need your gallbladder removed',
        'Start with clear liquids and advance diet slowly as tolerated',
        'Eat small, low-fat meals as you recover',
        'Seek immediate care for severe abdominal pain, fever, or vomiting',
      ],
      emergencyWarnings: [
        'Severe abdominal pain that does not improve or gets worse',
        'Fever with chills',
        'Persistent vomiting',
        'Rapid heartbeat or feeling faint',
        'Difficulty breathing',
        'Confusion or altered mental status',
      ],
    },
  ],

  // Meningitis
  [
    'meningitis',
    {
      conditionId: 'meningitis',
      name: 'Meningitis',
      aliases: ['Bacterial Meningitis', 'Viral Meningitis', 'Brain Infection'],
      icdCode: 'G03.9',
      category: 'infectious',
      subcategory: 'CNS Infection',
      description:
        'Inflammation of the protective membranes (meninges) covering the brain and spinal cord, most commonly caused by viral or bacterial infection. Bacterial meningitis is a medical emergency.',
      pathophysiology: {
        summary:
          'Pathogens enter the CNS via bloodstream or direct spread, triggering inflammation of the meninges with cerebral edema, increased intracranial pressure, and potential brain injury.',
        mechanisms: [
          {
            name: 'Pathogen Entry',
            description:
              'Bacteria or viruses cross the blood-brain barrier after bloodstream infection or direct spread from adjacent sites',
            systemsInvolved: ['Neurologic', 'Immune'],
            keyMediators: ['Adhesion molecules', 'Capsular polysaccharides'],
            contribution: 'primary',
          },
          {
            name: 'Meningeal Inflammation',
            description:
              'Immune response in CSF causes meningeal inflammation with neutrophil infiltration',
            systemsInvolved: ['Neurologic', 'Immune'],
            keyMediators: ['IL-1', 'TNF-alpha', 'Complement', 'Neutrophils'],
            contribution: 'primary',
          },
          {
            name: 'Blood-Brain Barrier Disruption',
            description:
              'Inflammation increases BBB permeability, allowing more inflammation and edema',
            systemsInvolved: ['Neurologic'],
            keyMediators: ['Matrix metalloproteinases', 'Cytokines'],
            contribution: 'secondary',
          },
          {
            name: 'Cerebral Edema',
            description:
              'Vasogenic and cytotoxic edema cause increased intracranial pressure',
            systemsInvolved: ['Neurologic'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Unvaccinated Status', type: 'modifiable', impact: 'major', description: 'Lack of vaccines against pneumococcus, meningococcus, Hib', intervention: 'Vaccination' },
          { name: 'Immunocompromised', type: 'partially-modifiable', impact: 'major', description: 'HIV, asplenia, complement deficiency increase risk', intervention: 'Prophylactic vaccination' },
          { name: 'Close Contact Exposure', type: 'partially-modifiable', impact: 'major', description: 'College dormitories, military barracks, household contacts', intervention: 'Chemoprophylaxis' },
          { name: 'Age <5 or >65', type: 'non-modifiable', impact: 'moderate', description: 'Extremes of age have increased susceptibility' },
          { name: 'CSF Leak', type: 'partially-modifiable', impact: 'moderate', description: 'Skull fracture or surgery creates direct entry route', intervention: 'Surgical repair' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Severe Headache', prevalence: 'very-common', description: 'Often described as the worst headache of life' },
          { name: 'Fever', prevalence: 'very-common', description: 'High fever, often with chills' },
          { name: 'Neck Stiffness', prevalence: 'very-common', description: 'Meningismus - resistance to passive neck flexion' },
          { name: 'Altered Mental Status', prevalence: 'common', description: 'Confusion, lethargy, or decreased consciousness' },
        ],
        associatedSymptoms: [
          { name: 'Photophobia', prevalence: 'common', description: 'Sensitivity to light' },
          { name: 'Nausea and Vomiting', prevalence: 'common', description: 'From increased intracranial pressure' },
          { name: 'Seizures', prevalence: 'uncommon', description: 'Indicates cerebral involvement' },
          { name: 'Petechial Rash', prevalence: 'uncommon', description: 'Characteristic of meningococcal meningitis' },
        ],
        physicalFindings: [
          { name: 'Nuchal Rigidity', examType: 'neurologic', description: 'Resistance to passive neck flexion', diagnosticValue: 'Classic meningeal sign; absent in elderly' },
          { name: 'Kernig Sign', examType: 'neurologic', description: 'Pain on knee extension with hip flexed', diagnosticValue: 'Meningeal irritation sign' },
          { name: 'Brudzinski Sign', examType: 'neurologic', description: 'Hip flexion when neck is flexed', diagnosticValue: 'Meningeal irritation sign' },
          { name: 'Petechiae/Purpura', examType: 'inspection', description: 'Non-blanching rash', diagnosticValue: 'Strongly suggests meningococcemia' },
          { name: 'Papilledema', examType: 'fundoscopy', description: 'Swelling of optic disc', diagnosticValue: 'Indicates increased ICP - defer LP' },
        ],
        labFindings: [
          { testName: 'CSF Analysis', abnormality: 'Elevated WBC, protein; low glucose', normalRange: 'WBC <5, protein <45, glucose >40', significance: 'Diagnostic; pattern distinguishes bacterial vs viral' },
          { testName: 'CSF Gram Stain', abnormality: 'Bacteria visible', normalRange: 'No organisms', significance: 'Identifies causative organism in 60-90%' },
          { testName: 'Blood Cultures', abnormality: 'Positive', normalRange: 'Negative', significance: 'Identify organism in 50-75% of bacterial meningitis' },
          { testName: 'CSF PCR', abnormality: 'Positive for pathogen', normalRange: 'Negative', significance: 'Rapid, sensitive identification of bacteria and viruses' },
          { testName: 'CT Head', abnormality: 'Mass effect, hydrocephalus', normalRange: 'Normal', significance: 'Obtain before LP if focal signs or decreased consciousness' },
        ],
      },
      progression: {
        naturalHistory:
          'Bacterial meningitis progresses rapidly over hours. Without treatment, mortality approaches 100%. Viral meningitis is typically self-limited. Early treatment dramatically improves outcomes.',
        timelineSteps: [
          {
            phaseId: 'early',
            phase: 'early',
            displayName: 'Early Infection',
            timeframe: 'Hours',
            description: 'Pathogen enters CNS; early meningeal inflammation',
            symptoms: ['Fever', 'Headache', 'Malaise', 'Early neck stiffness'],
            anatomicalChanges: [
              { structureId: 'meninges', structureName: 'Meninges', changeType: 'inflammation', description: 'Early meningeal inflammation', severity: 'mild', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Empiric antibiotics immediately', 'Dexamethasone', 'Supportive care'],
          },
          {
            phaseId: 'established',
            phase: 'established',
            displayName: 'Established Meningitis',
            timeframe: 'Hours to days',
            description: 'Full meningeal inflammation with cerebral edema',
            symptoms: ['Severe headache', 'High fever', 'Marked neck stiffness', 'Photophobia', 'Confusion'],
            anatomicalChanges: [
              { structureId: 'meninges', structureName: 'Meninges', changeType: 'inflammation', description: 'Purulent inflammation of meninges', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: false },
              { structureId: 'brain', structureName: 'Brain', changeType: 'edema', description: 'Cerebral edema with increased ICP', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['IV antibiotics', 'Dexamethasone', 'ICU monitoring', 'ICP management'],
          },
          {
            phaseId: 'complicated',
            phase: 'severe',
            displayName: 'Complicated Meningitis',
            timeframe: 'Days',
            description: 'Neurologic complications develop despite treatment',
            symptoms: ['Seizures', 'Focal deficits', 'Coma', 'Hearing loss'],
            anatomicalChanges: [
              { structureId: 'brain', structureName: 'Brain', changeType: 'ischemia', description: 'Vasculitis-related infarcts', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Continued antibiotics', 'Seizure management', 'Neurosurgical consultation if needed'],
          },
        ],
        prognosis:
          'Bacterial meningitis mortality: 10-30% with treatment, nearly 100% without. Survivors: 20-30% have permanent neurologic sequelae (hearing loss, cognitive deficits). Viral meningitis: typically full recovery.',
      },
      complications: [
        {
          complicationId: 'hearing-loss',
          name: 'Sensorineural Hearing Loss',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Permanent hearing loss from cochlear damage',
          mechanism: 'Labyrinthitis and cochlear inflammation from meningeal spread',
          affectedStructures: [{ structureId: 'cochlea', structureName: 'Inner Ear', effect: 'Hair cell damage causing hearing loss', highlightColor: '#f97316' }],
          warningSymptoms: ['Difficulty hearing', 'Ringing in ears', 'Balance problems'],
          preventable: true,
        },
        {
          complicationId: 'cerebral-edema-meningitis',
          name: 'Cerebral Edema and Herniation',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Brain swelling causing herniation and death',
          mechanism: 'Vasogenic and cytotoxic edema from inflammation',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Swelling with potential herniation', highlightColor: '#dc2626' }],
          warningSymptoms: ['Decreased consciousness', 'Unequal pupils', 'Abnormal posturing', 'Respiratory changes'],
          preventable: true,
        },
        {
          complicationId: 'hydrocephalus',
          name: 'Hydrocephalus',
          category: 'acute',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Impaired CSF drainage causing buildup',
          mechanism: 'Inflammation blocks CSF drainage at arachnoid granulations',
          affectedStructures: [{ structureId: 'ventricles', structureName: 'Cerebral Ventricles', effect: 'Enlarged ventricles with increased ICP', highlightColor: '#8b5cf6' }],
          warningSymptoms: ['Worsening headache', 'Decreased consciousness', 'Visual changes', 'Gait problems'],
          preventable: false,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'empiric-antibiotics-meningitis',
          name: 'Empiric Antibiotics',
          modality: 'pharmacological',
          description: 'Broad-spectrum antibiotics covering likely pathogens, started immediately',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'severe'],
          goals: ['Kill bacteria', 'Reduce mortality', 'Prevent complications'],
          timeToEffect: 'Hours for bacterial killing; days for clinical improvement',
          explanations: {
            level1: 'Strong antibiotics are given through an IV right away to kill the infection in your brain. Every minute counts.',
            level2: 'We start antibiotics immediately without waiting for test results because bacterial meningitis progresses rapidly. The antibiotics cover all likely bacteria.',
            level3: 'Empiric therapy: vancomycin + ceftriaxone for adults. Add ampicillin for age >50 or immunocompromised (Listeria coverage). Adjust when cultures return.',
            level4: 'Do not delay antibiotics for LP or imaging. Penetration of CSF is critical - use high doses. Daptomycin does not penetrate CNS. Duration: 7-21 days depending on organism.',
            level5: 'CSF sterilization occurs within hours of appropriate therapy. Time to first antibiotic dose is the strongest modifiable predictor of outcome. Repeat LP not routinely needed if improving.',
          },
        },
        {
          treatmentId: 'dexamethasone-meningitis',
          name: 'Adjunctive Dexamethasone',
          modality: 'pharmacological',
          description: 'Steroid given before or with first antibiotic dose to reduce inflammation',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Reduce inflammation', 'Decrease mortality', 'Prevent hearing loss'],
          explanations: {
            level1: 'A steroid medication is given to reduce swelling in your brain and protect your hearing.',
            level2: 'Steroids help calm the inflammation caused by the infection and the immune response. This can prevent brain damage and hearing loss.',
            level3: 'Dexamethasone 0.15 mg/kg q6h x 4 days, given before or with first antibiotic dose. Most beneficial for pneumococcal meningitis. Continue if pneumococcus confirmed.',
            level4: 'European studies show mortality benefit for pneumococcal meningitis. Benefits less clear for other organisms. Do not give if antibiotics already started >1 hour ago.',
            level5: 'Dexamethasone reduces TNF release from antibiotic-induced bacterial lysis. May reduce CSF penetration of some antibiotics (vancomycin) - use higher doses. No benefit if already pretreated.',
          },
        },
        {
          treatmentId: 'vaccination-prevention-meningitis',
          name: 'Vaccination (Prevention)',
          modality: 'preventive',
          description: 'Vaccines against common causes: pneumococcus, meningococcus, Hib',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['preclinical'],
          goals: ['Prevent meningitis', 'Protect community through herd immunity'],
          explanations: {
            level1: 'Vaccines can prevent most types of bacterial meningitis. Make sure you and your family are up to date.',
            level2: 'There are vaccines against the three main bacteria that cause meningitis. These are recommended for children and young adults especially.',
            level3: 'Hib vaccine nearly eliminated Hib meningitis. PCV13/PCV20 covers pneumococcus. MenACWY and MenB cover meningococcus. Ensure adolescents and college students are vaccinated.',
            level4: 'ACIP recommends MenACWY at 11-12 with booster at 16. MenB shared decision for 16-23 year olds. Asplenic and complement-deficient patients need both vaccines.',
            level5: 'Conjugate vaccines produce T-cell dependent response with memory and mucosal immunity reducing carriage. Herd immunity from reduced nasopharyngeal carriage protects unvaccinated.',
          },
        },
        {
          treatmentId: 'chemoprophylaxis',
          name: 'Chemoprophylaxis for Contacts',
          modality: 'preventive',
          description: 'Antibiotics for close contacts to prevent secondary cases',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['preclinical'],
          goals: ['Prevent secondary cases', 'Eliminate carriage', 'Protect contacts'],
          explanations: {
            level1: 'People who had close contact with you may need to take antibiotics to prevent them from getting sick too.',
            level2: 'For certain types of meningitis (meningococcal), people who were in close contact should take preventive antibiotics because the bacteria can spread.',
            level3: 'Chemoprophylaxis for meningococcal meningitis: rifampin, ciprofloxacin, or ceftriaxone for household and intimate contacts. Also for H. influenzae if unvaccinated children in household.',
            level4: 'Public health must be notified for meningococcal disease. Prophylaxis within 24 hours most effective. Single-dose ciprofloxacin or ceftriaxone preferred for compliance.',
            level5: 'Goal is nasopharyngeal eradication, not treatment. Rifampin requires multiple doses and has interactions. Healthcare workers only need prophylaxis for unprotected airway procedures.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'meninges', structureName: 'Meninges', role: 'primary-site', involvement: 'Primary site of infection and inflammation', highlightColor: '#dc2626', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'brain', structureName: 'Brain', role: 'secondary-site', involvement: 'Cerebral edema and potential infarction', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'spinal-cord', structureName: 'Spinal Cord', role: 'secondary-site', involvement: 'Spinal meningeal involvement', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Neurologic', 'Immune'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
        focusRegion: 'head',
      },
      explanations: {
        level1: 'An infection of the protective covering around your brain and spinal cord. This is very serious and needs emergency treatment.',
        level2: 'Germs (usually bacteria or viruses) infect the membranes surrounding your brain, causing inflammation and swelling. Bacterial meningitis can be life-threatening and needs immediate antibiotics.',
        level3: 'Meningitis presents with fever, headache, neck stiffness, and altered mental status. Bacterial meningitis is a medical emergency - give empiric antibiotics immediately, then LP. CSF analysis distinguishes bacterial from viral.',
        level4: 'Classic triad (fever, neck stiffness, altered mental status) present in only 44%. LP shows: bacterial - high WBC (PMN), low glucose, high protein; viral - lymphocytes, normal glucose. Give dexamethasone with first antibiotic dose.',
        level5: 'Blood-brain barrier penetration is critical for antibiotic selection. Inflammation paradoxically improves penetration. S. pneumoniae most common in adults; N. meningitidis in adolescents. Dexamethasone modulates antibiotic-induced bacteriolysis and cytokine release.',
      },
      relatedConditions: ['encephalitis', 'brain-abscess', 'sepsis'],
      epidemiology: {
        prevalence: '0.5-5 per 100,000 annually; decreased with vaccines',
        incidence: 'S. pneumoniae and N. meningitidis most common in developed countries',
        demographics: 'Bimodal age distribution (infants and elderly); young adults for meningococcal',
      },
      clinicalPearls: [
        'Do not delay antibiotics for LP or imaging - give empiric therapy immediately',
        'Classic triad present in <50% - have high suspicion',
        'Give dexamethasone before or with first antibiotic dose for suspected bacterial meningitis',
        'CT before LP only if: immunocompromised, history of CNS disease, new seizure, papilledema, altered consciousness, focal deficit',
        'Notify public health immediately for meningococcal disease - contacts need prophylaxis',
      ],
      patientEducation: [
        'Bacterial meningitis is a medical emergency - every minute of treatment delay matters',
        'Make sure you and your family have meningitis vaccines - they prevent most cases',
        'College students living in dorms should be vaccinated against meningococcal disease',
        'Seek immediate care for severe headache with fever and neck stiffness',
        'Close contacts of bacterial meningitis cases need preventive antibiotics',
      ],
      emergencyWarnings: [
        'Severe headache with fever and stiff neck - call 911 immediately',
        'Confusion, drowsiness, or difficulty staying awake',
        'Seizures',
        'A rash that does not fade when pressed (use glass test)',
        'Sensitivity to bright lights',
        'Difficulty waking up or being less responsive',
      ],
    },
  ],

  // Aortic Stenosis
  [
    'aortic-stenosis',
    {
      conditionId: 'aortic-stenosis',
      name: 'Aortic Stenosis',
      aliases: ['AS', 'Aortic Valve Stenosis', 'Calcific Aortic Stenosis'],
      icdCode: 'I35.0',
      category: 'cardiovascular',
      subcategory: 'Valvular Heart Disease',
      description:
        'Narrowing of the aortic valve that obstructs blood flow from the left ventricle to the aorta. Most commonly caused by age-related calcification. Progressive disease that becomes symptomatic when severe.',
      pathophysiology: {
        summary:
          'Progressive calcification and fibrosis of aortic valve leaflets causes narrowing, increasing afterload on the left ventricle which compensates with hypertrophy until decompensation occurs.',
        mechanisms: [
          {
            name: 'Valve Calcification',
            description:
              'Lipid deposition, inflammation, and calcification of valve leaflets similar to atherosclerosis',
            systemsInvolved: ['Cardiovascular'],
            keyMediators: ['LDL', 'Macrophages', 'Calcium', 'Bone morphogenic proteins'],
            contribution: 'primary',
          },
          {
            name: 'Pressure Overload',
            description:
              'Narrowed valve increases resistance, requiring higher pressures to eject blood',
            systemsInvolved: ['Cardiovascular'],
            keyMediators: ['Afterload increase'],
            contribution: 'primary',
          },
          {
            name: 'Left Ventricular Hypertrophy',
            description:
              'Heart muscle thickens to maintain cardiac output against increased afterload',
            systemsInvolved: ['Cardiovascular'],
            keyMediators: ['Angiotensin II', 'Mechanical stretch'],
            contribution: 'compensatory',
          },
          {
            name: 'Diastolic Dysfunction',
            description:
              'Stiff, hypertrophied ventricle impairs filling, causing symptoms',
            systemsInvolved: ['Cardiovascular'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Age >65', type: 'non-modifiable', impact: 'major', description: 'Degenerative calcification increases with age' },
          { name: 'Bicuspid Aortic Valve', type: 'non-modifiable', impact: 'major', description: 'Congenital malformation accelerates degeneration by 10-20 years' },
          { name: 'Cardiovascular Risk Factors', type: 'modifiable', impact: 'moderate', description: 'Hypertension, hyperlipidemia, diabetes accelerate calcification', intervention: 'Risk factor modification' },
          { name: 'Chronic Kidney Disease', type: 'partially-modifiable', impact: 'moderate', description: 'Abnormal calcium-phosphate metabolism accelerates calcification' },
          { name: 'Rheumatic Heart Disease', type: 'partially-modifiable', impact: 'moderate', description: 'Commissural fusion causes stenosis; less common now' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Exertional Dyspnea', prevalence: 'very-common', description: 'Shortness of breath with activity from elevated filling pressures' },
          { name: 'Angina', prevalence: 'common', description: 'Chest pain with exertion from supply-demand mismatch in hypertrophied ventricle' },
          { name: 'Syncope', prevalence: 'common', description: 'Fainting with exertion from inability to increase cardiac output; ominous symptom' },
        ],
        associatedSymptoms: [
          { name: 'Fatigue', prevalence: 'common', description: 'Low cardiac output limits exercise tolerance' },
          { name: 'Heart Failure Symptoms', prevalence: 'common', description: 'Orthopnea, edema in advanced disease' },
          { name: 'Dizziness', prevalence: 'common', description: 'Decreased cerebral perfusion with exertion' },
        ],
        physicalFindings: [
          { name: 'Systolic Ejection Murmur', examType: 'auscultation', description: 'Harsh, crescendo-decrescendo murmur at right upper sternal border radiating to carotids', diagnosticValue: 'Classic finding; louder murmur suggests more severe stenosis' },
          { name: 'Diminished S2', examType: 'auscultation', description: 'Soft or absent aortic component of S2', diagnosticValue: 'Indicates severe calcification with immobile leaflets' },
          { name: 'Parvus et Tardus Pulse', examType: 'palpation', description: 'Weak and delayed carotid upstroke', diagnosticValue: 'Classic sign of severe AS' },
          { name: 'Narrow Pulse Pressure', examType: 'vital signs', description: 'Reduced difference between systolic and diastolic BP', diagnosticValue: 'Reflects reduced stroke volume' },
          { name: 'S4 Gallop', examType: 'auscultation', description: 'Fourth heart sound from atrial contraction into stiff ventricle', diagnosticValue: 'Indicates LV hypertrophy' },
        ],
        labFindings: [
          { testName: 'Echocardiogram', abnormality: 'Aortic valve area <1.0 cm², mean gradient >40 mmHg', normalRange: 'AVA 3-4 cm², no gradient', significance: 'Gold standard for diagnosis and severity assessment' },
          { testName: 'ECG', abnormality: 'LV hypertrophy pattern', normalRange: 'Normal', significance: 'Strain pattern suggests severe disease' },
          { testName: 'BNP/NT-proBNP', abnormality: 'Elevated', normalRange: 'BNP <100 pg/mL', significance: 'Elevated in symptomatic AS; prognostic value' },
          { testName: 'Cardiac CT', abnormality: 'Heavy valve calcification', normalRange: 'Minimal calcification', significance: 'Calcium score helps assess severity when echo equivocal' },
        ],
      },
      progression: {
        naturalHistory:
          'AS progresses slowly over years but accelerates with time. Once symptomatic, prognosis is poor without intervention: 50% mortality at 2 years for heart failure, 3 years for syncope, 5 years for angina.',
        timelineSteps: [
          {
            phaseId: 'mild',
            phase: 'early',
            displayName: 'Mild AS',
            timeframe: 'Years',
            description: 'Aortic valve area 1.5-2.0 cm²; asymptomatic with mild obstruction',
            symptoms: ['Usually asymptomatic', 'Murmur detected on exam'],
            anatomicalChanges: [
              { structureId: 'aortic-valve', structureName: 'Aortic Valve', changeType: 'calcification', description: 'Early calcification and thickening of leaflets', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Serial echocardiography', 'Risk factor modification', 'No restriction on activity'],
          },
          {
            phaseId: 'moderate',
            phase: 'established',
            displayName: 'Moderate AS',
            timeframe: 'Years',
            description: 'Aortic valve area 1.0-1.5 cm²; usually still asymptomatic',
            symptoms: ['May remain asymptomatic', 'Mild exertional symptoms possible'],
            anatomicalChanges: [
              { structureId: 'aortic-valve', structureName: 'Aortic Valve', changeType: 'calcification', description: 'Progressive calcification with restricted leaflet motion', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
              { structureId: 'left-ventricle', structureName: 'Left Ventricle', changeType: 'hypertrophy', description: 'Compensatory concentric hypertrophy', severity: 'mild', visualIndicator: { color: '#3b82f6', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['More frequent monitoring', 'Symptom surveillance'],
          },
          {
            phaseId: 'severe-asymptomatic',
            phase: 'advanced',
            displayName: 'Severe AS (Asymptomatic)',
            timeframe: 'Months to years',
            description: 'Aortic valve area <1.0 cm²; compensated, may become symptomatic anytime',
            symptoms: ['May be asymptomatic', 'Subtle exertional limitation'],
            anatomicalChanges: [
              { structureId: 'aortic-valve', structureName: 'Aortic Valve', changeType: 'calcification', description: 'Severely calcified, immobile leaflets', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.8 }, isNewAtPhase: false },
              { structureId: 'left-ventricle', structureName: 'Left Ventricle', changeType: 'hypertrophy', description: 'Significant concentric LVH', severity: 'moderate', visualIndicator: { color: '#3b82f6', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Close monitoring', 'Exercise testing', 'Consider early intervention'],
          },
          {
            phaseId: 'severe-symptomatic',
            phase: 'severe',
            displayName: 'Severe Symptomatic AS',
            timeframe: 'Urgent',
            description: 'Symptoms indicate decompensation; high mortality without valve replacement',
            symptoms: ['Dyspnea on exertion', 'Angina', 'Syncope', 'Heart failure'],
            anatomicalChanges: [
              { structureId: 'left-ventricle', structureName: 'Left Ventricle', changeType: 'dysfunction', description: 'LV may begin to dilate and fail', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Aortic valve replacement (TAVR or SAVR)', 'Medical optimization while awaiting'],
          },
        ],
        prognosis:
          'Without intervention, average survival after symptom onset: heart failure 2 years, syncope 3 years, angina 5 years. After valve replacement, survival approaches age-matched population.',
      },
      complications: [
        {
          complicationId: 'sudden-death-as',
          name: 'Sudden Cardiac Death',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Fatal arrhythmia from severe LVH and ischemia',
          mechanism: 'Ventricular arrhythmia from hypertrophied, ischemic myocardium',
          affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'Fatal ventricular arrhythmia', highlightColor: '#dc2626' }],
          warningSymptoms: ['Syncope with exertion', 'Palpitations', 'Near-syncope'],
          preventable: true,
        },
        {
          complicationId: 'heart-failure-as',
          name: 'Heart Failure',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'high',
          description: 'LV decompensation from chronic pressure overload',
          mechanism: 'Exhaustion of compensatory mechanisms leads to ventricular dilation and failure',
          affectedStructures: [{ structureId: 'left-ventricle', structureName: 'Left Ventricle', effect: 'Dilation and reduced function', highlightColor: '#ef4444' }],
          warningSymptoms: ['Worsening dyspnea', 'Orthopnea', 'Edema', 'Fatigue'],
          preventable: true,
        },
        {
          complicationId: 'endocarditis-as',
          name: 'Infective Endocarditis',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'low',
          description: 'Infection of abnormal valve',
          mechanism: 'Damaged valve endothelium promotes bacterial adherence',
          affectedStructures: [{ structureId: 'aortic-valve', structureName: 'Aortic Valve', effect: 'Vegetations and further valve destruction', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['Fever', 'New murmur', 'Embolic phenomena', 'Fatigue'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'tavr',
          name: 'Transcatheter Aortic Valve Replacement (TAVR)',
          modality: 'interventional',
          description: 'Minimally invasive valve replacement via catheter',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['advanced', 'severe'],
          goals: ['Relieve obstruction', 'Improve symptoms', 'Improve survival'],
          explanations: {
            level1: 'A new valve is placed through a tube in your leg, without open heart surgery. This is now the most common way to replace heart valves.',
            level2: 'A catheter carries a new valve through your blood vessels to your heart, where it is expanded inside the old valve. Recovery is much faster than surgery.',
            level3: 'TAVR now preferred for most patients with severe symptomatic AS. Transfemoral access preferred. PARTNER and EVOLUT trials showed non-inferiority to SAVR across risk spectrums.',
            level4: 'TAVR indicated for symptomatic severe AS, low-flow severe AS with symptoms. Consider for asymptomatic very severe AS or with dropping EF. Heart team decision for approach.',
            level5: 'TAVR has higher rates of permanent pacemaker and paravalvular leak; SAVR has higher stroke and bleeding. Lifetime valve management strategy important in younger patients.',
          },
        },
        {
          treatmentId: 'savr',
          name: 'Surgical Aortic Valve Replacement (SAVR)',
          modality: 'surgical',
          description: 'Open heart surgery to replace aortic valve',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['advanced', 'severe'],
          goals: ['Relieve obstruction', 'Improve symptoms', 'Improve survival'],
          explanations: {
            level1: 'Open heart surgery to remove your diseased valve and sew in a new one. It works very well but requires several weeks of recovery.',
            level2: 'Traditional valve replacement requires stopping the heart and opening the chest. The old valve is removed and a new one sewn in. May be preferred for younger patients.',
            level3: 'SAVR preferred when: CABG also needed, unsuitable anatomy for TAVR, endocarditis, younger patients (durability concerns). Mechanical vs bioprosthetic valve decision is important.',
            level4: 'Mechanical valves require lifelong anticoagulation. Bioprosthetic valves degenerate (10-20 years). Younger patients may need reintervention; lifetime management strategy crucial.',
            level5: 'Valve-in-valve TAVR possible for failed bioprosthetic valves. Patient-prosthesis mismatch associated with worse outcomes. Avoid mismatch by sizing appropriately.',
          },
        },
        {
          treatmentId: 'medical-management-as',
          name: 'Medical Management',
          modality: 'pharmacological',
          description: 'Medications for symptom control in those not candidates for valve replacement',
          efficacy: 'limited-effectiveness',
          evidenceLevel: 'level-2b',
          isFirstLine: false,
          appropriatePhases: ['early', 'established', 'advanced'],
          goals: ['Symptom palliation', 'Bridge to intervention', 'Risk factor modification'],
          explanations: {
            level1: 'Medications cannot cure the valve problem but can help with symptoms and other heart conditions.',
            level2: 'No medication can fix or slow the valve narrowing. But we can treat high blood pressure, heart failure symptoms, and rhythm problems.',
            level3: 'No medical therapy alters disease progression. Diuretics for congestion; cautious use of antihypertensives. Statins do not slow progression. Monitor closely for symptoms.',
            level4: 'Avoid excessive preload or afterload reduction. Beta-blockers useful for heart rate control. GDMT for HFrEF if EF reduced. Atrial fibrillation requires anticoagulation and rate control.',
            level5: 'Vasodilators traditionally feared but can be used cautiously in decompensated AS with elevated SVR. Nitroprusside may improve hemodynamics in cardiogenic shock while awaiting intervention.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'aortic-valve', structureName: 'Aortic Valve', role: 'primary-site', involvement: 'Calcified and stenotic valve', highlightColor: '#dc2626', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'left-ventricle', structureName: 'Left Ventricle', role: 'secondary-site', involvement: 'Concentric hypertrophy from pressure overload', highlightColor: '#3b82f6', showByDefault: true },
          { structureId: 'ascending-aorta', structureName: 'Ascending Aorta', role: 'collateral', involvement: 'Post-stenotic dilation possible', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1: 'The main valve letting blood out of your heart has become stiff and narrow. This makes your heart work harder and can cause problems over time.',
        level2: 'The aortic valve, which opens to let blood flow from your heart to your body, has calcified and no longer opens fully. This is like trying to push water through a narrowed pipe - your heart has to work much harder.',
        level3: 'Aortic stenosis causes pressure overload on the left ventricle. Severity by echo: mild AVA >1.5, moderate 1.0-1.5, severe <1.0 cm². Once symptomatic, valve replacement indicated. TAVR now first-line for most.',
        level4: 'Severe AS: AVA <1.0 cm², mean gradient >40 mmHg, Vmax >4 m/s. Low-flow, low-gradient AS requires dobutamine stress echo. Asymptomatic severe AS with EF <50%, very severe (Vmax >5), or symptoms on exercise testing may warrant intervention.',
        level5: 'Calcific AS shares pathophysiology with atherosclerosis. LVH is initially compensatory (concentric) maintaining wall stress. Transition to decompensation involves myocyte death, fibrosis, and diastolic then systolic dysfunction. Myocardial fibrosis predicts outcomes.',
      },
      relatedConditions: ['bicuspid-aortic-valve', 'heart-failure', 'coronary-artery-disease'],
      epidemiology: {
        prevalence: '2-4% in adults >65; 4-5% in those >75; most common valvular disease requiring intervention',
        incidence: 'Increasing with aging population',
        demographics: 'Male predominance; bicuspid valve presents 10-20 years earlier',
      },
      clinicalPearls: [
        'The murmur does NOT correlate with severity - murmur gets quieter as LV fails',
        'Symptoms are the key - onset of any symptom (dyspnea, angina, syncope) triggers intervention',
        'Do not give vasodilators without close monitoring - preload dependent',
        'TAVR is now appropriate for most patients, including those at low surgical risk',
        'Exercise testing can unmask symptoms in "asymptomatic" patients',
      ],
      patientEducation: [
        'The only effective treatment is valve replacement - no medications can fix the valve',
        'Report any new shortness of breath, chest pain, or fainting immediately',
        'Avoid strenuous exercise if you have severe stenosis',
        'Good dental hygiene is important to prevent valve infection',
        'TAVR is a much less invasive option than open surgery for most patients',
      ],
      emergencyWarnings: [
        'Fainting or passing out, especially with exertion',
        'Severe shortness of breath',
        'Chest pain that does not go away',
        'Unable to lie flat due to breathing difficulty',
        'Rapid, irregular heartbeat with dizziness',
      ],
    },
  ],

  // Cellulitis
  [
    'cellulitis',
    {
      conditionId: 'cellulitis',
      name: 'Cellulitis',
      aliases: ['Skin Infection', 'Soft Tissue Infection'],
      icdCode: 'L03.90',
      category: 'infectious',
      subcategory: 'Skin and Soft Tissue Infection',
      description:
        'A common bacterial infection of the deeper layers of skin (dermis and subcutaneous tissue) causing redness, swelling, warmth, and pain. Usually caused by streptococci or staphylococci.',
      pathophysiology: {
        summary:
          'Bacteria enter through breaks in the skin barrier and spread through the dermis and subcutaneous tissue, triggering inflammation and immune response.',
        mechanisms: [
          {
            name: 'Skin Barrier Breach',
            description:
              'Bacteria enter through cuts, cracks, insect bites, or areas of compromised skin',
            systemsInvolved: ['Integumentary'],
            keyMediators: ['Bacterial adhesins', 'Proteases'],
            contribution: 'primary',
          },
          {
            name: 'Bacterial Spread',
            description:
              'Bacteria multiply and spread through tissue planes using enzymes',
            systemsInvolved: ['Integumentary'],
            keyMediators: ['Hyaluronidase', 'Streptokinase', 'DNases'],
            contribution: 'primary',
          },
          {
            name: 'Inflammatory Response',
            description:
              'Immune response causes vasodilation, increased permeability, and neutrophil infiltration',
            systemsInvolved: ['Immune', 'Integumentary'],
            keyMediators: ['IL-1', 'IL-6', 'TNF-alpha', 'Neutrophils'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Skin Breakdown', type: 'modifiable', impact: 'major', description: 'Cuts, abrasions, ulcers, dermatitis, athlete\'s foot', intervention: 'Skin care, treat underlying conditions' },
          { name: 'Lymphedema', type: 'partially-modifiable', impact: 'major', description: 'Impaired lymphatic drainage allows bacterial growth', intervention: 'Compression, skin care' },
          { name: 'Peripheral Vascular Disease', type: 'partially-modifiable', impact: 'major', description: 'Poor circulation impairs healing and immunity', intervention: 'Vascular care' },
          { name: 'Diabetes', type: 'partially-modifiable', impact: 'major', description: 'Impaired immunity and neuropathy increase risk', intervention: 'Glycemic control' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'Skin folds, lymphedema, poor circulation', intervention: 'Weight management' },
          { name: 'Prior Cellulitis', type: 'non-modifiable', impact: 'major', description: 'Previous episodes damage lymphatics, increasing recurrence' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Skin Redness', prevalence: 'very-common', description: 'Spreading area of erythema without sharp borders' },
          { name: 'Swelling', prevalence: 'very-common', description: 'Edema of affected area' },
          { name: 'Warmth', prevalence: 'very-common', description: 'Increased temperature of affected skin' },
          { name: 'Pain/Tenderness', prevalence: 'very-common', description: 'Affected area is tender to touch' },
        ],
        associatedSymptoms: [
          { name: 'Fever', prevalence: 'common', description: 'Systemic response to infection' },
          { name: 'Chills', prevalence: 'common', description: 'May indicate bacteremia' },
          { name: 'Malaise', prevalence: 'common', description: 'General feeling of unwellness' },
          { name: 'Lymphadenopathy', prevalence: 'common', description: 'Swollen lymph nodes draining affected area' },
        ],
        physicalFindings: [
          { name: 'Spreading Erythema', examType: 'inspection', description: 'Red area that expands over hours to days; mark the border to track progression', diagnosticValue: 'Key diagnostic feature' },
          { name: 'Peau d\'Orange', examType: 'inspection', description: 'Orange-peel appearance from lymphatic involvement', diagnosticValue: 'Indicates deeper infection' },
          { name: 'Lymphangitis', examType: 'inspection', description: 'Red streaking toward regional lymph nodes', diagnosticValue: 'Indicates lymphatic spread' },
          { name: 'Crepitus', examType: 'palpation', description: 'Crackling sensation from gas in tissues', diagnosticValue: 'Suggests necrotizing infection - surgical emergency' },
        ],
        labFindings: [
          { testName: 'White Blood Cell Count', abnormality: 'Elevated', normalRange: '4,500-11,000/μL', significance: 'Indicates infection; very high suggests severe infection' },
          { testName: 'Blood Cultures', abnormality: 'Positive (uncommon)', normalRange: 'Negative', significance: 'Positive in <5% of uncomplicated cellulitis' },
          { testName: 'CRP/ESR', abnormality: 'Elevated', normalRange: 'CRP <10 mg/L', significance: 'Markers of inflammation; useful for monitoring' },
        ],
      },
      progression: {
        naturalHistory:
          'Untreated, cellulitis can spread rapidly and lead to bacteremia, abscess, or necrotizing fasciitis. With treatment, improvement expected within 48-72 hours.',
        timelineSteps: [
          {
            phaseId: 'early',
            phase: 'early',
            displayName: 'Early Cellulitis',
            timeframe: '0-24 hours',
            description: 'Initial infection with localized erythema and swelling',
            symptoms: ['Localized redness', 'Mild swelling', 'Tenderness'],
            anatomicalChanges: [
              { structureId: 'skin', structureName: 'Dermis', changeType: 'inflammation', description: 'Early dermal inflammation', severity: 'mild', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Oral antibiotics', 'Elevation', 'Monitor for spread'],
          },
          {
            phaseId: 'established',
            phase: 'established',
            displayName: 'Established Cellulitis',
            timeframe: '1-3 days',
            description: 'Spreading infection with systemic symptoms',
            symptoms: ['Expanding erythema', 'Significant swelling', 'Fever', 'Malaise'],
            anatomicalChanges: [
              { structureId: 'skin', structureName: 'Dermis and Subcutaneous', changeType: 'inflammation', description: 'Deep tissue inflammation spreading through tissue planes', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['IV antibiotics if severe', 'Hospitalization if needed', 'Monitor closely'],
          },
          {
            phaseId: 'resolution',
            phase: 'chronic',
            displayName: 'Resolution',
            timeframe: '5-14 days',
            description: 'Healing with gradual resolution of inflammation',
            symptoms: ['Decreasing redness', 'Reducing swelling', 'Possible residual hyperpigmentation'],
            anatomicalChanges: [
              { structureId: 'skin', structureName: 'Skin', changeType: 'inflammation', description: 'Healing inflammation with possible post-inflammatory changes', severity: 'mild', visualIndicator: { color: '#22c55e', pulse: false, opacity: 0.4 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Complete antibiotic course', 'Address underlying risk factors', 'Prevent recurrence'],
          },
        ],
        prognosis:
          'Excellent with appropriate treatment. Most cases resolve completely within 7-10 days. Risk of recurrence high (8-20% within 3 years) especially with underlying risk factors.',
      },
      complications: [
        {
          complicationId: 'abscess',
          name: 'Abscess Formation',
          category: 'acute',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Localized collection of pus requiring drainage',
          mechanism: 'Bacteria walled off by immune response forming purulent collection',
          affectedStructures: [{ structureId: 'subcutaneous', structureName: 'Subcutaneous Tissue', effect: 'Pus collection requiring drainage', highlightColor: '#f97316' }],
          warningSymptoms: ['Fluctuant swelling', 'Point tenderness', 'Failure to improve on antibiotics'],
          preventable: true,
        },
        {
          complicationId: 'necrotizing-fasciitis',
          name: 'Necrotizing Fasciitis',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'low',
          description: 'Rapidly progressive deep soft tissue infection with tissue death',
          mechanism: 'Aggressive bacteria destroy fascia and spread along tissue planes',
          affectedStructures: [{ structureId: 'fascia', structureName: 'Deep Fascia', effect: 'Necrosis spreading along fascial planes', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['Pain out of proportion', 'Rapid spread', 'Dusky skin', 'Crepitus', 'Toxic appearance'],
          preventable: false,
        },
        {
          complicationId: 'bacteremia-cellulitis',
          name: 'Bacteremia/Sepsis',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'low',
          description: 'Bacteria enter bloodstream causing systemic infection',
          mechanism: 'Local infection spreads to bloodstream',
          affectedStructures: [{ structureId: 'blood', structureName: 'Bloodstream', effect: 'Systemic bacterial infection', highlightColor: '#dc2626' }],
          warningSymptoms: ['High fever', 'Chills', 'Rapid heart rate', 'Confusion', 'Low blood pressure'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'oral-antibiotics-cellulitis',
          name: 'Oral Antibiotics',
          modality: 'pharmacological',
          description: 'First-line treatment for uncomplicated cellulitis',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Eradicate infection', 'Prevent spread', 'Prevent complications'],
          explanations: {
            level1: 'Antibiotic pills that kill the bacteria causing your skin infection. Most people get better within a few days.',
            level2: 'Antibiotics by mouth are usually enough for uncomplicated cellulitis. The typical course is 5-7 days. Make sure to finish all the pills.',
            level3: 'First-line: cephalexin (if no MRSA risk) or TMP-SMX or doxycycline (if MRSA suspected). If purulent, cover MRSA. Duration 5-7 days typically adequate.',
            level4: 'IDSA guidelines: non-purulent cellulitis - cover strep; purulent - cover MRSA. I+D is primary treatment for abscess. Durations as short as 5 days effective.',
            level5: 'Beta-hemolytic streptococci are primary cause of non-purulent cellulitis. MRSA more common with purulence. PVL-positive S. aureus associated with recurrent furunculosis.',
          },
        },
        {
          treatmentId: 'iv-antibiotics-cellulitis',
          name: 'IV Antibiotics',
          modality: 'pharmacological',
          description: 'For severe cellulitis, failed oral therapy, or immunocompromised',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: false,
          appropriatePhases: ['established', 'severe'],
          goals: ['Rapidly eradicate infection', 'Treat severe disease', 'Prevent complications'],
          explanations: {
            level1: 'Stronger antibiotics given through an IV when the infection is severe or spreading quickly.',
            level2: 'If the infection is severe, spreading rapidly, or you are very sick, you may need antibiotics directly into your vein. This gets higher levels to the infection faster.',
            level3: 'IV indications: failed oral therapy, severe systemic symptoms, rapidly progressing, immunocompromised, facial cellulitis. Transition to oral when improving.',
            level4: 'Vancomycin if MRSA suspected. Piperacillin-tazobactam if diabetic foot or mixed infection. Consider outpatient parenteral therapy (OPAT) for stable patients.',
            level5: 'Antibiotic levels may not matter as much as source control. If no improvement by 48-72 hours, reassess diagnosis (DVT, stasis dermatitis, necrotizing infection).',
          },
        },
        {
          treatmentId: 'elevation-compression',
          name: 'Elevation and Supportive Care',
          modality: 'supportive',
          description: 'Elevating affected limb to reduce swelling and improve drainage',
          efficacy: 'effective',
          evidenceLevel: 'level-2b',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'chronic'],
          goals: ['Reduce edema', 'Improve lymphatic drainage', 'Speed healing'],
          explanations: {
            level1: 'Keeping your leg or arm raised helps the swelling go down and helps your body fight the infection.',
            level2: 'Elevation uses gravity to reduce swelling and improve blood flow. This helps the antibiotics reach the infected area and speeds healing.',
            level3: 'Elevate affected extremity above heart level. Mark borders to monitor progression. Treat underlying edema (compression when acute infection resolved). Cool compresses may help comfort.',
            level4: 'Lymphedema management is key to preventing recurrence. Compression therapy, pneumatic devices, and skin care protocols reduce recurrence rates significantly.',
            level5: 'Edema impairs local immunity by diluting complement and immunoglobulins, and stretching skin creates micro-fissures for bacterial entry. Breaking the edema-infection cycle is critical.',
          },
        },
        {
          treatmentId: 'incision-drainage',
          name: 'Incision and Drainage',
          modality: 'surgical',
          description: 'Drainage of abscess if present; I+D is primary treatment for skin abscess',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['established'],
          goals: ['Remove pus', 'Allow antibiotics to work', 'Speed healing'],
          explanations: {
            level1: 'If there is a pocket of pus, the doctor needs to open it and drain it out. This is the most important treatment for an abscess.',
            level2: 'Antibiotics cannot penetrate a pus pocket well. Draining the abscess removes the infection and lets the antibiotics work.',
            level3: 'I+D is primary treatment for abscess - antibiotics alone insufficient. Pack wound loosely, remove packing in 24-48 hours. Antibiotics indicated for surrounding cellulitis or systemic symptoms.',
            level4: 'TMP-SMX or doxycycline after I+D reduces failure rates per IDSA. Loop drainage technique may reduce need for packing. Culture not routinely needed.',
            level5: 'Most abscesses heal well with I+D alone if no surrounding cellulitis. Antibiotics reduce recurrence at same site but not overall recurrence. Decolonization for recurrent furunculosis.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'skin', structureName: 'Dermis', role: 'primary-site', involvement: 'Primary site of infection', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'subcutaneous', structureName: 'Subcutaneous Tissue', role: 'secondary-site', involvement: 'Spread of infection to deeper tissue', highlightColor: '#f97316', showByDefault: true },
          { structureId: 'lymph-nodes', structureName: 'Regional Lymph Nodes', role: 'secondary-site', involvement: 'Reactive lymphadenopathy', highlightColor: '#f59e0b', showByDefault: false },
        ],
        systemsInvolved: ['Integumentary', 'Immune', 'Lymphatic'],
        recommendedView: 'anterior',
        recommendedLayers: ['integumentary'],
      },
      explanations: {
        level1: 'A bacterial infection of the skin that causes redness, swelling, warmth, and pain. Usually treated easily with antibiotics.',
        level2: 'Bacteria get under the skin through a cut or crack and spread in the deeper layers. This causes your immune system to react, leading to the redness, swelling, and warmth you see.',
        level3: 'Cellulitis is a clinical diagnosis based on spreading erythema, warmth, swelling, and tenderness without sharp borders. Most common organisms: group A strep (non-purulent) and S. aureus (purulent). Treat with appropriate antibiotics and elevation.',
        level4: 'Distinguish from abscess (fluctuant), erysipelas (sharp borders, superficial), necrotizing infection (pain out of proportion, crepitus, rapid spread). Blood cultures positive in <5% and not routinely indicated. Consider imaging if deep infection suspected.',
        level5: 'Group A strep produces spreading factors (hyaluronidase, streptokinase) causing diffuse cellulitis. S. aureus more commonly causes focal abscess. PVL-positive S. aureus associated with necrosis and abscess formation.',
      },
      relatedConditions: ['abscess', 'necrotizing-fasciitis', 'lymphedema', 'diabetes'],
      epidemiology: {
        prevalence: '14.5 million cases annually in the US',
        incidence: '200 per 100,000 person-years',
        demographics: 'More common with increasing age, obesity, diabetes, lymphedema',
      },
      clinicalPearls: [
        'Draw a line around the border to track whether infection is spreading or improving',
        'Expect erythema to worsen in first 24-48 hours even with appropriate antibiotics',
        'Pain out of proportion to exam findings should raise concern for necrotizing fasciitis',
        'Bilateral lower extremity cellulitis is rare - consider stasis dermatitis',
        'Address underlying risk factors (tinea pedis, edema) to prevent recurrence',
      ],
      patientEducation: [
        'Take all antibiotics as prescribed, even if you start feeling better',
        'Elevate the affected area as much as possible to reduce swelling',
        'Draw a line around the red area to track if it is spreading',
        'Keep the skin clean and treat any athlete\'s foot or dry, cracked skin',
        'Return if redness spreads beyond the line, fever worsens, or pain gets much worse',
      ],
      emergencyWarnings: [
        'Rapidly spreading redness (faster than one inch per hour)',
        'Skin turning purple, black, or developing blisters',
        'Severe pain that seems worse than the redness suggests',
        'High fever, confusion, or feeling very ill',
        'Crackling sensation when pressing on the skin',
        'Numbness in the affected area',
      ],
    },
  ],

  // Pulmonary Embolism
  [
    'pulmonary-embolism',
    {
      conditionId: 'pulmonary-embolism',
      name: 'Pulmonary Embolism',
      aliases: ['PE', 'Blood Clot in Lung', 'Lung Clot'],
      icdCode: 'I26.99',
      category: 'cardiovascular',
      subcategory: 'Thromboembolic Disease',
      description:
        'A blockage in one or more arteries in the lungs, usually caused by blood clots that travel from the legs (deep vein thrombosis). Can be life-threatening but is treatable if caught early.',
      pathophysiology: {
        summary:
          'Thrombi, usually originating from deep veins of the legs, embolize to the pulmonary arteries, causing obstruction, V/Q mismatch, and increased pulmonary vascular resistance.',
        mechanisms: [
          {
            name: 'Venous Thromboembolism',
            description: 'Clots form in deep veins (usually legs) and break off, traveling through the venous system to the pulmonary arteries',
            systemsInvolved: ['Cardiovascular', 'Respiratory'],
            keyMediators: ['Coagulation factors', 'Platelets', 'Fibrin'],
            contribution: 'primary',
          },
          {
            name: 'Pulmonary Vascular Obstruction',
            description: 'Emboli physically obstruct pulmonary arteries, increasing resistance and right heart strain',
            systemsInvolved: ['Cardiovascular', 'Respiratory'],
            contribution: 'primary',
          },
          {
            name: 'V/Q Mismatch',
            description: 'Ventilated but unperfused lung creates dead space and hypoxemia',
            systemsInvolved: ['Respiratory'],
            keyMediators: ['Serotonin', 'Thromboxane'],
            contribution: 'secondary',
          },
          {
            name: 'Right Ventricular Failure',
            description: 'Massive PE causes acute RV pressure overload and failure',
            systemsInvolved: ['Cardiovascular'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Recent Surgery/Immobilization', type: 'partially-modifiable', impact: 'major', description: 'Stasis promotes clot formation', intervention: 'Early mobilization, prophylaxis' },
          { name: 'Active Cancer', type: 'partially-modifiable', impact: 'major', description: 'Hypercoagulable state from cancer', intervention: 'Anticoagulation' },
          { name: 'Prior VTE', type: 'non-modifiable', impact: 'major', description: 'History of clots greatly increases risk' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'Increases venous stasis and hypercoagulability', intervention: 'Weight loss' },
          { name: 'Hormonal Therapy', type: 'modifiable', impact: 'moderate', description: 'Estrogen increases clotting risk', intervention: 'Consider alternatives' },
          { name: 'Thrombophilia', type: 'non-modifiable', impact: 'moderate', description: 'Factor V Leiden, prothrombin mutation' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Sudden Shortness of Breath', prevalence: 'very-common', description: 'Acute onset dyspnea, often without other explanation' },
          { name: 'Pleuritic Chest Pain', prevalence: 'common', description: 'Sharp, stabbing pain that worsens with breathing' },
          { name: 'Tachycardia', prevalence: 'very-common', description: 'Heart racing as body compensates for reduced oxygen delivery' },
        ],
        associatedSymptoms: [
          { name: 'Cough', prevalence: 'common', description: 'May be dry or produce blood-tinged sputum' },
          { name: 'Hemoptysis', prevalence: 'uncommon', description: 'Coughing up blood suggests pulmonary infarction' },
          { name: 'Leg Swelling/Pain', prevalence: 'common', description: 'Signs of DVT that may be the clot source' },
          { name: 'Syncope', prevalence: 'uncommon', description: 'Fainting suggests massive PE with hemodynamic compromise' },
        ],
        physicalFindings: [
          { name: 'Tachycardia', examType: 'vital signs', description: 'Heart rate >100 bpm', diagnosticValue: 'Very common but nonspecific' },
          { name: 'Tachypnea', examType: 'vital signs', description: 'Respiratory rate >20', diagnosticValue: 'Common finding' },
          { name: 'Hypoxemia', examType: 'vital signs', description: 'Low oxygen saturation', diagnosticValue: 'Common but can be normal in small PE' },
          { name: 'Unilateral Leg Swelling', examType: 'inspection', description: 'Asymmetric leg edema suggesting DVT', diagnosticValue: 'Important clue to diagnosis' },
          { name: 'JVD', examType: 'inspection', description: 'Jugular venous distension from right heart strain', diagnosticValue: 'Suggests significant PE' },
        ],
        labFindings: [
          { testName: 'D-dimer', abnormality: 'Elevated', normalRange: '<500 ng/mL', significance: 'Sensitive but not specific; useful for ruling out PE' },
          { testName: 'CT Pulmonary Angiogram', abnormality: 'Filling defect in pulmonary arteries', normalRange: 'No filling defects', significance: 'Gold standard for diagnosis' },
          { testName: 'Troponin', abnormality: 'Elevated', normalRange: '<0.04 ng/mL', significance: 'Indicates RV strain; prognostic' },
          { testName: 'BNP/NT-proBNP', abnormality: 'Elevated', normalRange: 'BNP <100 pg/mL', significance: 'Indicates RV strain; prognostic' },
          { testName: 'ECG', abnormality: 'Sinus tachycardia, S1Q3T3, RV strain', normalRange: 'Normal sinus rhythm', significance: 'Nonspecific but may show RV strain' },
        ],
      },
      progression: {
        naturalHistory:
          'Untreated PE has high mortality (30%). With anticoagulation, mortality drops to 2-8%. Massive PE can cause death within hours from right heart failure.',
        timelineSteps: [
          {
            phaseId: 'acute',
            phase: 'acute',
            displayName: 'Acute PE',
            timeframe: 'Hours to days',
            description: 'Clot lodges in pulmonary artery causing acute symptoms',
            symptoms: ['Sudden dyspnea', 'Chest pain', 'Tachycardia', 'Anxiety'],
            anatomicalChanges: [
              { structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', changeType: 'stenosis', description: 'Thrombus blocking blood flow', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Anticoagulation', 'Supportive care', 'Consider thrombolysis if massive'],
          },
          {
            phaseId: 'subacute',
            phase: 'established',
            displayName: 'Clot Resolution',
            timeframe: 'Weeks to months',
            description: 'Gradual clot lysis and resolution with anticoagulation',
            symptoms: ['Improving dyspnea', 'Persistent mild symptoms possible'],
            anatomicalChanges: [
              { structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', changeType: 'stenosis', description: 'Thrombus gradually resolving', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Continued anticoagulation (3+ months)', 'Activity as tolerated'],
          },
          {
            phaseId: 'cteph',
            phase: 'chronic',
            displayName: 'Chronic Thromboembolic Disease',
            timeframe: 'Months to years',
            description: 'Incomplete clot resolution leads to chronic pulmonary hypertension (rare)',
            symptoms: ['Progressive exertional dyspnea', 'Exercise intolerance', 'RV failure signs'],
            anatomicalChanges: [
              { structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', changeType: 'fibrosis', description: 'Organized thrombus with vascular remodeling', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Lifelong anticoagulation', 'Pulmonary endarterectomy', 'Pulmonary vasodilators'],
          },
        ],
        prognosis:
          'With treatment, 90-day mortality is 2-8%. Massive PE mortality 30-50% despite treatment. CTEPH develops in 2-4% of PE survivors.',
      },
      complications: [
        {
          complicationId: 'cardiogenic-shock-pe',
          name: 'Cardiogenic Shock',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Right ventricular failure causing hemodynamic collapse',
          mechanism: 'Massive clot burden causes acute RV pressure overload and failure',
          affectedStructures: [{ structureId: 'right-ventricle', structureName: 'Right Ventricle', effect: 'Acute dilation and failure', highlightColor: '#dc2626' }],
          warningSymptoms: ['Low blood pressure', 'Syncope', 'Cool extremities', 'Altered consciousness'],
          preventable: true,
        },
        {
          complicationId: 'pulmonary-infarction',
          name: 'Pulmonary Infarction',
          category: 'acute',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Death of lung tissue from blocked blood supply',
          mechanism: 'Complete arterial obstruction with inadequate collateral flow',
          affectedStructures: [{ structureId: 'lungs', structureName: 'Lung Parenchyma', effect: 'Hemorrhagic infarction', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['Hemoptysis', 'Pleuritic pain', 'Fever', 'Pleural effusion'],
          preventable: true,
        },
        {
          complicationId: 'cteph-complication',
          name: 'Chronic Thromboembolic Pulmonary Hypertension',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'low',
          description: 'Persistent pulmonary hypertension from unresolved clot',
          mechanism: 'Incomplete thrombus resolution leads to vascular remodeling and obstruction',
          affectedStructures: [{ structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', effect: 'Chronic obstruction and remodeling', highlightColor: '#8b5cf6' }],
          warningSymptoms: ['Persistent dyspnea after PE treatment', 'Exercise intolerance', 'Leg swelling'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'anticoagulation-pe',
          name: 'Anticoagulation Therapy',
          modality: 'pharmacological',
          description: 'Blood thinners to prevent clot growth and allow natural lysis',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute', 'established', 'chronic'],
          goals: ['Prevent clot extension', 'Prevent new clots', 'Allow natural clot resolution'],
          timeToEffect: 'Immediate prevention; weeks for clot resolution',
          explanations: {
            level1: 'Blood thinner medications prevent the clot from growing bigger and stop new clots from forming while your body dissolves the clot.',
            level2: 'Anticoagulants do not dissolve the clot directly but prevent it from growing. Your body\'s natural systems then break down the clot over weeks to months.',
            level3: 'DOACs (rivaroxaban, apixaban) are first-line for most patients. Heparin bridge then warfarin, or LMWH for cancer. Duration: 3 months minimum; longer for unprovoked or recurrent.',
            level4: 'EINSTEIN, AMPLIFY trials established DOACs for VTE. Cancer patients: LMWH or edoxaban/rivaroxaban. Massive PE may need thrombolysis before anticoagulation alone.',
            level5: 'DOACs have advantage of fixed dosing and fewer interactions. Thrombin inhibitors (dabigatran) vs factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) - similar efficacy.',
          },
        },
        {
          treatmentId: 'thrombolysis-pe',
          name: 'Thrombolytic Therapy',
          modality: 'pharmacological',
          description: 'Clot-dissolving medication for massive or high-risk PE',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['acute'],
          goals: ['Rapidly dissolve clot', 'Restore pulmonary blood flow', 'Prevent death'],
          timeToEffect: 'Hours',
          explanations: {
            level1: 'Powerful medication that dissolves the blood clot quickly. Used when the clot is so large it threatens your life.',
            level2: 'Thrombolytics actively break down the clot rather than just preventing growth. They carry bleeding risk so are used only for severe cases.',
            level3: 'Indicated for massive PE with hemodynamic instability. Alteplase 100mg over 2 hours is standard. Consider for submassive PE with RV dysfunction and clinical deterioration.',
            level4: 'PEITHO trial: thrombolysis reduced hemodynamic decompensation but increased major bleeding in submassive PE. Catheter-directed thrombolysis may offer benefits with less bleeding.',
            level5: 'Half-dose thrombolysis (50mg alteplase) may be effective with less bleeding. Tenecteplase is an alternative. Catheter-directed techniques allow lower doses and mechanical disruption.',
          },
        },
        {
          treatmentId: 'ivc-filter',
          name: 'Inferior Vena Cava Filter',
          modality: 'interventional',
          description: 'Mechanical filter to catch clots before they reach the lungs',
          efficacy: 'effective',
          evidenceLevel: 'level-2a',
          isFirstLine: false,
          appropriatePhases: ['acute'],
          goals: ['Prevent recurrent PE', 'Mechanical protection when anticoagulation contraindicated'],
          explanations: {
            level1: 'A small filter placed in a large vein to catch blood clots before they reach your lungs. Used when blood thinners cannot be taken.',
            level2: 'The filter is a metal device placed in the main vein from your legs to catch clots. It is used when you cannot take blood thinners due to bleeding risk.',
            level3: 'Indicated when anticoagulation is absolutely contraindicated. Retrievable filters should be removed when anticoagulation becomes safe. Long-term filters increase DVT risk.',
            level4: 'PREPIC2 showed no benefit adding filter to anticoagulation. Retrieve filters as soon as possible. Consider for massive PE before thrombolysis or thrombectomy.',
            level5: 'Filter complications include IVC thrombosis, filter migration, and fracture. Anticoagulation should be started as soon as possible even with filter in place.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', role: 'primary-site', involvement: 'Site of clot obstruction', highlightColor: '#dc2626', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'right-ventricle', structureName: 'Right Ventricle', role: 'secondary-site', involvement: 'Pressure overload and potential failure', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'deep-veins', structureName: 'Deep Leg Veins', role: 'secondary-site', involvement: 'Origin of most emboli', highlightColor: '#3b82f6', showByDefault: false },
        ],
        systemsInvolved: ['Cardiovascular', 'Respiratory'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular', 'respiratory'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1: 'A blood clot has traveled to your lungs and is blocking blood flow. This is serious but treatable with blood thinners.',
        level2: 'A clot, usually from your leg veins, broke loose and traveled through your bloodstream to your lungs. It blocks the arteries in your lungs, making it hard for your heart to pump blood through.',
        level3: 'PE is diagnosed using clinical probability (Wells score), D-dimer, and CT pulmonary angiogram. Risk-stratify using hemodynamics, RV function, and biomarkers. Treat with anticoagulation; consider thrombolysis for massive PE.',
        level4: 'sPESI or PESI score stratifies risk. Submassive PE (RV dysfunction + elevated troponin/BNP but stable) is intermediate risk. Massive PE = hemodynamic instability requiring pressors or thrombolysis.',
        level5: 'Hemodynamic significance depends on clot burden and cardiopulmonary reserve. RV failure is the primary cause of death. Pulmonary vascular resistance increases exponentially when >30-50% of bed is obstructed.',
      },
      relatedConditions: ['deep-vein-thrombosis', 'atrial-fibrillation', 'heart-failure'],
      epidemiology: {
        prevalence: '600,000-900,000 VTE events annually in the US',
        incidence: '60-70 per 100,000 per year; increases with age',
        demographics: 'Risk increases with age, surgery, cancer, immobility, hormones',
      },
      clinicalPearls: [
        'PE can occur with normal oxygen saturation - do not be falsely reassured',
        'D-dimer is sensitive but not specific - use clinical probability scores first',
        'Look for DVT in patients with PE - most emboli come from leg veins',
        'Syncope with PE suggests massive clot burden',
        'DOACs are now first-line for most patients, including those with cancer',
      ],
      patientEducation: [
        'Take your blood thinner exactly as prescribed - missing doses can be dangerous',
        'Report any unusual bleeding (blood in urine, black stool, bruising) immediately',
        'Stay active and avoid prolonged sitting or bed rest',
        'On long trips, get up and walk, stay hydrated, and consider compression stockings',
        'Tell all your doctors you are on blood thinners before any procedure',
      ],
      emergencyWarnings: [
        'Sudden severe shortness of breath',
        'Fainting or feeling like you might faint',
        'Chest pain, especially sharp pain with breathing',
        'Coughing up blood',
        'Rapid or irregular heartbeat with lightheadedness',
        'Sudden leg swelling with redness or pain',
      ],
    },
  ],

  // Deep Vein Thrombosis
  [
    'deep-vein-thrombosis',
    {
      conditionId: 'deep-vein-thrombosis',
      name: 'Deep Vein Thrombosis',
      aliases: ['DVT', 'Blood Clot in Leg', 'Venous Thrombosis'],
      icdCode: 'I82.40',
      category: 'cardiovascular',
      subcategory: 'Thromboembolic Disease',
      description:
        'A blood clot that forms in a deep vein, usually in the leg. The main danger is that the clot can break loose and travel to the lungs (pulmonary embolism).',
      pathophysiology: {
        summary:
          'Thrombus forms in deep veins due to Virchow\'s triad: stasis, endothelial injury, and hypercoagulability. Clots can propagate proximally and embolize to the lungs.',
        mechanisms: [
          {
            name: 'Venous Stasis',
            description: 'Slow blood flow allows accumulation of clotting factors and reduces washout of activated factors',
            systemsInvolved: ['Cardiovascular'],
            keyMediators: ['Reduced shear stress', 'Hypoxia'],
            contribution: 'primary',
          },
          {
            name: 'Endothelial Injury',
            description: 'Damage to vein wall exposes tissue factor and activates coagulation',
            systemsInvolved: ['Cardiovascular'],
            keyMediators: ['Tissue factor', 'Von Willebrand factor'],
            contribution: 'primary',
          },
          {
            name: 'Hypercoagulability',
            description: 'Increased tendency of blood to clot from inherited or acquired factors',
            systemsInvolved: ['Hematologic'],
            keyMediators: ['Factor V Leiden', 'Prothrombin mutation', 'Cancer procoagulants'],
            contribution: 'primary',
          },
        ],
        riskFactors: [
          { name: 'Recent Surgery', type: 'partially-modifiable', impact: 'major', description: 'Especially orthopedic, cancer, or abdominal surgery', intervention: 'Prophylaxis' },
          { name: 'Immobility', type: 'modifiable', impact: 'major', description: 'Prolonged bed rest, long travel, paralysis', intervention: 'Early mobilization' },
          { name: 'Cancer', type: 'partially-modifiable', impact: 'major', description: 'Active malignancy increases clotting risk', intervention: 'Anticoagulation' },
          { name: 'Prior VTE', type: 'non-modifiable', impact: 'major', description: 'Previous clot greatly increases recurrence risk' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'BMI >30 increases risk', intervention: 'Weight loss' },
          { name: 'Estrogen Use', type: 'modifiable', impact: 'moderate', description: 'Oral contraceptives, HRT', intervention: 'Consider alternatives' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Leg Swelling', prevalence: 'very-common', description: 'Unilateral leg edema, often with >3 cm calf circumference difference' },
          { name: 'Leg Pain', prevalence: 'very-common', description: 'Calf pain or tenderness, may worsen with walking' },
          { name: 'Warmth', prevalence: 'common', description: 'Increased temperature over affected area' },
        ],
        associatedSymptoms: [
          { name: 'Redness', prevalence: 'common', description: 'Erythema over thrombosed vein' },
          { name: 'Prominent Superficial Veins', prevalence: 'uncommon', description: 'Collateral vessels become visible' },
          { name: 'Low-grade Fever', prevalence: 'uncommon', description: 'May occur with extensive clot' },
        ],
        physicalFindings: [
          { name: 'Unilateral Edema', examType: 'inspection', description: 'Asymmetric leg swelling', diagnosticValue: 'Key clinical finding' },
          { name: 'Calf Tenderness', examType: 'palpation', description: 'Tenderness over deep veins', diagnosticValue: 'Common but nonspecific' },
          { name: 'Homan Sign', examType: 'palpation', description: 'Calf pain with dorsiflexion (unreliable)', diagnosticValue: 'Poor sensitivity and specificity - not recommended' },
          { name: 'Pitting Edema', examType: 'palpation', description: 'Edema that leaves indentation', diagnosticValue: 'Indicates significant swelling' },
        ],
        labFindings: [
          { testName: 'D-dimer', abnormality: 'Elevated', normalRange: '<500 ng/mL', significance: 'Sensitive for ruling out DVT if low clinical probability' },
          { testName: 'Compression Ultrasound', abnormality: 'Non-compressible vein', normalRange: 'Full compressibility', significance: 'Gold standard for diagnosis' },
          { testName: 'Venous Doppler', abnormality: 'Absent or reduced flow', normalRange: 'Normal flow', significance: 'Adjunct to compression ultrasound' },
        ],
      },
      progression: {
        naturalHistory:
          'Untreated DVT has 50% risk of PE. With anticoagulation, clots typically resolve over weeks to months. Risk of post-thrombotic syndrome in 20-50%.',
        timelineSteps: [
          {
            phaseId: 'acute',
            phase: 'acute',
            displayName: 'Acute DVT',
            timeframe: '0-14 days',
            description: 'Fresh clot in deep vein with acute inflammation',
            symptoms: ['Leg swelling', 'Pain', 'Warmth', 'Redness'],
            anatomicalChanges: [
              { structureId: 'deep-veins', structureName: 'Deep Leg Veins', changeType: 'stenosis', description: 'Fresh thrombus occluding vein', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Anticoagulation', 'Compression', 'Elevation', 'Early ambulation'],
          },
          {
            phaseId: 'subacute',
            phase: 'established',
            displayName: 'Clot Organization',
            timeframe: '2 weeks - 3 months',
            description: 'Clot organizing and partially recanalizing',
            symptoms: ['Improving swelling', 'Residual discomfort'],
            anatomicalChanges: [
              { structureId: 'deep-veins', structureName: 'Deep Leg Veins', changeType: 'inflammation', description: 'Clot organizing with early recanalization', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 }, isNewAtPhase: false },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Continued anticoagulation', 'Compression stockings'],
          },
          {
            phaseId: 'chronic',
            phase: 'chronic',
            displayName: 'Post-Thrombotic Changes',
            timeframe: 'Months to years',
            description: 'Chronic venous changes from valve damage',
            symptoms: ['Chronic leg swelling', 'Heaviness', 'Skin changes', 'Possible ulceration'],
            anatomicalChanges: [
              { structureId: 'deep-veins', structureName: 'Deep Leg Veins', changeType: 'fibrosis', description: 'Valve damage and chronic obstruction', severity: 'moderate', visualIndicator: { color: '#78716c', pulse: false, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Compression therapy', 'Elevation', 'Skin care', 'Consider extended anticoagulation'],
          },
        ],
        prognosis:
          'With treatment, <5% progress to PE. Post-thrombotic syndrome develops in 20-50%. Recurrence risk 5-10% per year after stopping anticoagulation.',
      },
      complications: [
        {
          complicationId: 'pe-from-dvt',
          name: 'Pulmonary Embolism',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'high',
          description: 'Clot breaks loose and travels to the lungs',
          mechanism: 'Thrombus fragments embolize through right heart to pulmonary arteries',
          affectedStructures: [{ structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', effect: 'Arterial obstruction', highlightColor: '#dc2626' }],
          warningSymptoms: ['Sudden shortness of breath', 'Chest pain', 'Rapid heartbeat', 'Coughing blood'],
          preventable: true,
        },
        {
          complicationId: 'post-thrombotic-syndrome',
          name: 'Post-Thrombotic Syndrome',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'high',
          description: 'Chronic venous insufficiency from valve damage',
          mechanism: 'Thrombus damages venous valves causing reflux and chronic venous hypertension',
          affectedStructures: [{ structureId: 'leg-veins', structureName: 'Leg Veins', effect: 'Chronic venous insufficiency', highlightColor: '#8b5cf6' }],
          warningSymptoms: ['Persistent leg swelling', 'Heaviness', 'Skin discoloration', 'Leg ulcers'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'anticoagulation-dvt',
          name: 'Anticoagulation Therapy',
          modality: 'pharmacological',
          description: 'Blood thinners to prevent clot growth and PE',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute', 'established', 'chronic'],
          goals: ['Prevent PE', 'Prevent clot extension', 'Allow clot resolution'],
          explanations: {
            level1: 'Blood thinner pills or shots prevent the clot from getting bigger and stop new clots while your body dissolves the existing clot.',
            level2: 'Anticoagulants stop the clot from growing larger and prevent pieces from breaking off to your lungs. Your body slowly dissolves the clot over weeks.',
            level3: 'DOACs (rivaroxaban, apixaban) are first-line. Alternative: LMWH bridge to warfarin. Duration 3 months for provoked, longer for unprovoked. Cancer patients: LMWH or DOACs.',
            level4: 'Single-drug approach with rivaroxaban or apixaban avoids need for parenteral bridge. Extended therapy beyond 3 months reduces recurrence but increases bleeding.',
            level5: 'Risk of recurrence after stopping: 5% per year provoked, 10% per year unprovoked. Weigh bleeding risk (HAS-BLED) vs recurrence risk (HERDOO2, Vienna prediction model).',
          },
        },
        {
          treatmentId: 'compression-therapy',
          name: 'Compression Stockings',
          modality: 'supportive',
          description: 'Graduated compression to reduce swelling and prevent PTS',
          efficacy: 'effective',
          evidenceLevel: 'level-2a',
          isFirstLine: true,
          appropriatePhases: ['acute', 'established', 'chronic'],
          goals: ['Reduce acute swelling', 'Prevent post-thrombotic syndrome', 'Improve symptoms'],
          explanations: {
            level1: 'Special tight stockings that squeeze your leg to reduce swelling and help blood flow back to your heart.',
            level2: 'Compression stockings apply pressure that helps push blood out of the leg veins and reduces swelling. They may help prevent long-term leg problems.',
            level3: 'Start compression early during acute DVT. 30-40 mmHg stockings recommended. SOX trial questioned PTS prevention benefit but stockings help symptoms.',
            level4: 'SOX trial found no reduction in PTS with compression, but had adherence issues. Compression still recommended for symptomatic relief in acute DVT.',
            level5: 'Compression works by reducing venous diameter and improving valve function, reducing ambulatory venous pressure. May be most beneficial in iliofemoral DVT.',
          },
        },
        {
          treatmentId: 'catheter-directed-thrombolysis',
          name: 'Catheter-Directed Thrombolysis',
          modality: 'interventional',
          description: 'Direct clot dissolution for extensive proximal DVT',
          efficacy: 'effective',
          evidenceLevel: 'level-1b',
          isFirstLine: false,
          appropriatePhases: ['acute'],
          goals: ['Rapidly dissolve clot', 'Reduce PTS risk', 'Restore venous patency'],
          explanations: {
            level1: 'A tube is threaded to the clot to deliver clot-dissolving medicine directly. Used for very large clots.',
            level2: 'A catheter delivers clot-busting drugs directly into the clot, dissolving it faster than blood thinners alone. This may reduce long-term leg problems.',
            level3: 'Consider for extensive iliofemoral DVT with severe symptoms in patients with low bleeding risk. ATTRACT trial showed reduced PTS severity but not incidence.',
            level4: 'ATTRACT showed CDT reduced moderate-severe PTS but not overall PTS rates. Consider for young patients with iliofemoral DVT and severe symptoms.',
            level5: 'Pharmacomechanical thrombectomy combines CDT with mechanical devices to reduce lytic dose and treatment time. CAVA trial ongoing for acute management.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'deep-veins', structureName: 'Deep Leg Veins', role: 'primary-site', involvement: 'Site of thrombus formation', highlightColor: '#dc2626', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'calf-muscles', structureName: 'Calf Muscles', role: 'secondary-site', involvement: 'Muscle pump dysfunction', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular'],
        focusRegion: 'lower-extremity',
      },
      explanations: {
        level1: 'A blood clot has formed in a large vein in your leg. The clot could travel to your lungs, so you need blood thinners to prevent this.',
        level2: 'Blood has clotted in the deep veins of your leg, causing pain and swelling. The danger is that pieces could break off and block blood vessels in your lungs.',
        level3: 'DVT is diagnosed using Wells score to determine pre-test probability, D-dimer for low probability, and compression ultrasound. Proximal DVT requires anticoagulation; isolated calf DVT may be observed.',
        level4: 'Wells criteria stratify probability. D-dimer is useful only if low/moderate probability. Age-adjusted D-dimer (age x 10 if >50) improves specificity. Proximal DVT has higher PE risk than distal.',
        level5: 'Clot formation follows Virchow\'s triad. Location matters: iliofemoral DVT has higher PE and PTS risk than calf DVT. Consider thrombophilia testing for unprovoked VTE, especially if young or family history.',
      },
      relatedConditions: ['pulmonary-embolism', 'chronic-venous-insufficiency'],
      epidemiology: {
        prevalence: '600,000-900,000 VTE events annually in the US',
        incidence: '100-200 per 100,000 per year; increases with age',
        demographics: 'Risk increases with age, surgery, immobility, cancer, hormones',
      },
      clinicalPearls: [
        'Always consider PE in patients with DVT - 50% have silent PE on imaging',
        'Wells score helps determine if D-dimer or ultrasound is the next step',
        'Calf DVT has lower PE risk but can propagate - consider repeat ultrasound',
        'Early ambulation is safe and encouraged despite traditional teaching',
        'Extended anticoagulation decision depends on provoked vs unprovoked and bleeding risk',
      ],
      patientEducation: [
        'Take blood thinners exactly as prescribed - this prevents the clot from reaching your lungs',
        'Move around as much as you can - bed rest is not needed and may be harmful',
        'Wear compression stockings as directed to reduce swelling',
        'On long trips, walk every 1-2 hours, stay hydrated, and flex your calves',
        'Seek emergency care if you develop sudden shortness of breath or chest pain',
      ],
      emergencyWarnings: [
        'Sudden difficulty breathing',
        'Chest pain, especially with breathing',
        'Coughing up blood',
        'Rapid heartbeat with lightheadedness',
        'Severe increase in leg swelling or pain',
        'Signs of bleeding from blood thinners (blood in urine, black stool, severe bruising)',
      ],
    },
  ],

  // Urinary Tract Infection
  [
    'urinary-tract-infection',
    {
      conditionId: 'urinary-tract-infection',
      name: 'Urinary Tract Infection',
      aliases: ['UTI', 'Bladder Infection', 'Cystitis'],
      icdCode: 'N39.0',
      category: 'infectious',
      subcategory: 'Genitourinary Infection',
      description:
        'An infection in any part of the urinary system, most commonly affecting the bladder (cystitis). More common in women. Usually easily treated with antibiotics.',
      pathophysiology: {
        summary:
          'Bacteria, usually from the GI tract, ascend through the urethra to colonize the bladder, causing inflammation and the characteristic symptoms of dysuria, frequency, and urgency.',
        mechanisms: [
          {
            name: 'Bacterial Ascension',
            description: 'Bacteria from periurethral area ascend the urethra to reach the bladder',
            systemsInvolved: ['Urinary'],
            keyMediators: ['Fimbriae', 'Adhesins'],
            contribution: 'primary',
          },
          {
            name: 'Bladder Colonization',
            description: 'Bacteria adhere to bladder epithelium and multiply, evading immune defenses',
            systemsInvolved: ['Urinary'],
            keyMediators: ['Type 1 fimbriae', 'Biofilm formation'],
            contribution: 'primary',
          },
          {
            name: 'Inflammatory Response',
            description: 'Immune response causes mucosal inflammation and symptoms',
            systemsInvolved: ['Urinary', 'Immune'],
            keyMediators: ['IL-6', 'IL-8', 'Neutrophils'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Female Sex', type: 'non-modifiable', impact: 'major', description: 'Short urethra allows easier bacterial ascent' },
          { name: 'Sexual Activity', type: 'partially-modifiable', impact: 'major', description: 'Introduces bacteria to periurethral area', intervention: 'Post-coital voiding' },
          { name: 'Menopause', type: 'non-modifiable', impact: 'moderate', description: 'Estrogen loss changes vaginal flora' },
          { name: 'Urinary Retention', type: 'partially-modifiable', impact: 'moderate', description: 'Incomplete emptying allows bacterial growth', intervention: 'Address underlying cause' },
          { name: 'Catheter Use', type: 'partially-modifiable', impact: 'major', description: 'Direct route for bacteria to enter bladder', intervention: 'Remove when no longer needed' },
          { name: 'Diabetes', type: 'partially-modifiable', impact: 'moderate', description: 'Glycosuria promotes bacterial growth', intervention: 'Glycemic control' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Dysuria', prevalence: 'very-common', description: 'Pain or burning sensation when urinating' },
          { name: 'Urinary Frequency', prevalence: 'very-common', description: 'Needing to urinate more often than usual' },
          { name: 'Urinary Urgency', prevalence: 'very-common', description: 'Sudden strong urge to urinate' },
        ],
        associatedSymptoms: [
          { name: 'Suprapubic Pain', prevalence: 'common', description: 'Discomfort in lower abdomen above pubic bone' },
          { name: 'Hematuria', prevalence: 'common', description: 'Blood in urine' },
          { name: 'Cloudy or Foul-Smelling Urine', prevalence: 'common', description: 'Changes in urine appearance or odor' },
          { name: 'Fever', prevalence: 'uncommon', description: 'Suggests upper tract involvement (pyelonephritis)' },
        ],
        physicalFindings: [
          { name: 'Suprapubic Tenderness', examType: 'palpation', description: 'Tenderness over bladder area', diagnosticValue: 'Suggests cystitis' },
          { name: 'CVA Tenderness', examType: 'palpation', description: 'Flank pain with percussion', diagnosticValue: 'Suggests pyelonephritis - not simple UTI' },
          { name: 'Normal Pelvic Exam', examType: 'pelvic', description: 'Rules out vaginitis', diagnosticValue: 'Important to distinguish from vaginal infection' },
        ],
        labFindings: [
          { testName: 'Urinalysis', abnormality: 'Positive leukocyte esterase, nitrites, pyuria', normalRange: 'Negative', significance: 'Supports UTI diagnosis' },
          { testName: 'Urine Culture', abnormality: '>100,000 CFU/mL', normalRange: 'No growth or <10,000', significance: 'Confirms infection and identifies organism' },
          { testName: 'Dipstick', abnormality: 'Positive nitrites', normalRange: 'Negative', significance: 'High specificity for Gram-negative bacteria' },
        ],
      },
      progression: {
        naturalHistory:
          'Simple UTI may resolve spontaneously in 25-42% of cases. With antibiotics, symptoms typically improve within 24-48 hours. Untreated, can progress to pyelonephritis.',
        timelineSteps: [
          {
            phaseId: 'early',
            phase: 'early',
            displayName: 'Early UTI',
            timeframe: '0-24 hours',
            description: 'Initial bacterial colonization with early symptoms',
            symptoms: ['Mild dysuria', 'Increased frequency', 'Discomfort'],
            anatomicalChanges: [
              { structureId: 'bladder', structureName: 'Bladder', changeType: 'inflammation', description: 'Early mucosal inflammation', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Antibiotics', 'Increased fluids', 'Pain relief'],
          },
          {
            phaseId: 'established',
            phase: 'established',
            displayName: 'Established Cystitis',
            timeframe: '1-3 days',
            description: 'Full bladder infection with classic symptoms',
            symptoms: ['Significant dysuria', 'Frequency', 'Urgency', 'Suprapubic pain'],
            anatomicalChanges: [
              { structureId: 'bladder', structureName: 'Bladder', changeType: 'inflammation', description: 'Mucosal inflammation with edema', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Antibiotics', 'Symptomatic treatment'],
          },
          {
            phaseId: 'resolution',
            phase: 'chronic',
            displayName: 'Resolution',
            timeframe: '3-7 days with treatment',
            description: 'Infection clearing with antibiotic treatment',
            symptoms: ['Improving symptoms', 'Resolution of dysuria'],
            anatomicalChanges: [
              { structureId: 'bladder', structureName: 'Bladder', changeType: 'inflammation', description: 'Resolving inflammation', severity: 'mild', visualIndicator: { color: '#22c55e', pulse: false, opacity: 0.4 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Complete antibiotic course'],
          },
        ],
        prognosis:
          'Excellent with treatment. Symptoms improve within 1-2 days. Recurrence common (25% within 6 months). Prevention strategies help frequent sufferers.',
      },
      complications: [
        {
          complicationId: 'pyelonephritis',
          name: 'Pyelonephritis (Kidney Infection)',
          category: 'acute',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Infection ascending to involve the kidneys',
          mechanism: 'Bacteria ascend from bladder to kidneys via ureters',
          affectedStructures: [{ structureId: 'kidneys', structureName: 'Kidneys', effect: 'Parenchymal infection', highlightColor: '#dc2626' }],
          warningSymptoms: ['High fever', 'Back/flank pain', 'Nausea/vomiting', 'Feeling very ill'],
          preventable: true,
        },
        {
          complicationId: 'urosepsis',
          name: 'Urosepsis',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'low',
          description: 'Systemic infection originating from urinary tract',
          mechanism: 'Bacteria enter bloodstream from infected urinary tract',
          affectedStructures: [{ structureId: 'blood', structureName: 'Bloodstream', effect: 'Systemic bacterial infection', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['High fever', 'Confusion', 'Rapid heartbeat', 'Low blood pressure'],
          preventable: true,
        },
        {
          complicationId: 'recurrent-uti',
          name: 'Recurrent UTIs',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Repeated infections requiring prevention strategies',
          mechanism: 'Recurrent colonization from periurethral flora or persistence',
          affectedStructures: [{ structureId: 'bladder', structureName: 'Bladder', effect: 'Repeated infections', highlightColor: '#f97316' }],
          warningSymptoms: ['Multiple UTIs per year', 'Symptoms despite treatment'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'antibiotics-uti',
          name: 'Antibiotic Therapy',
          modality: 'pharmacological',
          description: 'Short-course antibiotics to eradicate infection',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Eradicate bacteria', 'Relieve symptoms', 'Prevent progression'],
          timeToEffect: '24-48 hours for symptom improvement',
          explanations: {
            level1: 'Antibiotic pills that kill the bacteria causing your bladder infection. You should feel better within a day or two.',
            level2: 'A short course of antibiotics (usually 3-5 days) effectively treats most bladder infections. Symptoms improve quickly but finish all the pills.',
            level3: 'First-line: nitrofurantoin 5 days, TMP-SMX 3 days, or fosfomycin single dose. Avoid fluoroquinolones for uncomplicated UTI. Culture-guided therapy for complicated UTI.',
            level4: 'Resistance to TMP-SMX is >20% in many areas. Nitrofurantoin has maintained efficacy. Fosfomycin is slightly less effective but useful for multidrug-resistant organisms.',
            level5: 'Phenazopyridine provides symptomatic relief but masks symptoms - use only for 1-2 days. Consider prophylaxis for recurrent UTI: post-coital or daily low-dose antibiotics.',
          },
        },
        {
          treatmentId: 'symptomatic-treatment',
          name: 'Symptomatic Treatment',
          modality: 'supportive',
          description: 'Pain relief and increased fluids',
          efficacy: 'effective',
          evidenceLevel: 'level-2b',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Relieve pain', 'Flush bacteria', 'Comfort'],
          explanations: {
            level1: 'Drinking lots of water and taking pain medicine helps you feel better while the antibiotics work.',
            level2: 'Drinking plenty of fluids helps flush bacteria out. Pain relievers reduce discomfort. Some medications turn urine orange but provide quick pain relief.',
            level3: 'Phenazopyridine (AZO) provides urinary analgesic effect but does not treat infection. NSAIDs for pain. Adequate hydration aids bacterial clearance.',
            level4: 'Some evidence that increased fluids reduce UTI recurrence. Avoid bladder irritants (caffeine, alcohol) during acute infection.',
            level5: 'Non-antibiotic approaches (NSAIDs alone) may resolve some UTIs but with higher pyelonephritis risk. Reserved for patients who cannot take antibiotics.',
          },
        },
        {
          treatmentId: 'prevention-uti',
          name: 'Prevention Strategies',
          modality: 'preventive',
          description: 'Behavioral and prophylactic measures for recurrent UTI',
          efficacy: 'effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['preclinical'],
          goals: ['Prevent recurrence', 'Reduce antibiotic use'],
          explanations: {
            level1: 'Simple habits like urinating after sex and drinking cranberry juice may help prevent bladder infections from coming back.',
            level2: 'For frequent UTIs, prevention includes urinating after sex, staying hydrated, vaginal estrogen for postmenopausal women, and possibly cranberry products.',
            level3: 'Post-coital voiding, increased fluid intake. Vaginal estrogen reduces recurrence in postmenopausal women. Cranberry products have modest evidence. Consider prophylactic antibiotics for recurrent UTI.',
            level4: 'D-mannose may prevent recurrence. Methenamine hippurate is alternative to antibiotic prophylaxis. Probiotic vaginal suppositories under study.',
            level5: 'Lactobacillus probiotics restore vaginal flora. Bacterial interference with E. coli 83972 shows promise. Vaccines targeting uropathogenic E. coli in development.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'bladder', structureName: 'Bladder', role: 'primary-site', involvement: 'Primary site of infection', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'urethra', structureName: 'Urethra', role: 'secondary-site', involvement: 'Route of bacterial entry', highlightColor: '#f97316', showByDefault: false },
          { structureId: 'kidneys', structureName: 'Kidneys', role: 'secondary-site', involvement: 'Potential for ascending infection', highlightColor: '#f59e0b', showByDefault: false },
        ],
        systemsInvolved: ['Urinary'],
        recommendedView: 'anterior',
        recommendedLayers: ['urinary'],
        focusRegion: 'pelvis',
      },
      explanations: {
        level1: 'Bacteria have infected your bladder, causing pain when you urinate and making you need to go frequently. Antibiotics will clear it up quickly.',
        level2: 'Bacteria, usually from the intestines, have traveled up into your bladder and are causing infection. This is very common, especially in women, and easily treated.',
        level3: 'UTI is diagnosed clinically with dysuria, frequency, and urgency. Urinalysis with pyuria and bacteriuria supports diagnosis. Culture for complicated UTI or treatment failure. Treat with short-course antibiotics.',
        level4: 'Uncomplicated cystitis: healthy premenopausal, non-pregnant woman with no structural abnormalities. All others are complicated. In men, consider prostatitis. Asymptomatic bacteriuria does not require treatment except in pregnancy.',
        level5: 'Uropathogenic E. coli (UPEC) causes 80% of UTIs. Type 1 fimbriae bind mannose receptors. Biofilm formation on uroepithelium creates intracellular reservoirs that may explain recurrence.',
      },
      relatedConditions: ['pyelonephritis', 'urinary-incontinence', 'benign-prostatic-hyperplasia'],
      epidemiology: {
        prevalence: '50-60% of women will have a UTI in their lifetime',
        incidence: '11% of women per year; increases with age',
        demographics: 'Much more common in women; rare in young men',
      },
      clinicalPearls: [
        'In elderly, UTI may present with confusion alone - UTI is often over-diagnosed as cause of delirium',
        'Do not treat asymptomatic bacteriuria except in pregnancy',
        'Dysuria with vaginal symptoms suggests vaginitis, not UTI',
        'Fluoroquinolones should be reserved for complicated infections',
        'Men with UTI need evaluation for underlying urologic abnormality',
      ],
      patientEducation: [
        'Finish all antibiotics even if you feel better to prevent the infection from returning',
        'Drink plenty of water to help flush bacteria out',
        'Urinate when you feel the urge - do not hold it',
        'Urinate after sexual activity to help flush bacteria',
        'If you get frequent UTIs, talk to your doctor about prevention strategies',
      ],
      emergencyWarnings: [
        'High fever (over 101°F/38.3°C)',
        'Severe back or side pain',
        'Nausea and vomiting',
        'Blood in urine that increases',
        'Symptoms that get worse or do not improve within 2-3 days of starting antibiotics',
        'Confusion (especially in elderly)',
      ],
    },
  ],

  // Cirrhosis
  [
    'cirrhosis',
    {
      conditionId: 'cirrhosis',
      name: 'Cirrhosis',
      aliases: ['Liver Cirrhosis', 'Chronic Liver Disease', 'End-Stage Liver Disease'],
      icdCode: 'K74.60',
      category: 'gastrointestinal',
      subcategory: 'Hepatic Disease',
      description:
        'Late-stage scarring (fibrosis) of the liver caused by many forms of liver disease and conditions. The damage is permanent but progression can often be slowed or stopped.',
      pathophysiology: {
        summary:
          'Chronic liver injury leads to hepatocyte death, inflammation, and progressive fibrosis that distorts liver architecture, impairs function, and increases portal pressure.',
        mechanisms: [
          {
            name: 'Chronic Hepatocyte Injury',
            description: 'Repeated injury from alcohol, viruses, or metabolic disease causes hepatocyte death',
            systemsInvolved: ['Hepatobiliary'],
            keyMediators: ['Oxidative stress', 'Cytokines', 'Apoptosis'],
            contribution: 'primary',
          },
          {
            name: 'Stellate Cell Activation',
            description: 'Hepatic stellate cells transform into myofibroblasts and produce collagen',
            systemsInvolved: ['Hepatobiliary'],
            keyMediators: ['TGF-beta', 'PDGF', 'Collagen'],
            contribution: 'primary',
          },
          {
            name: 'Fibrosis and Nodule Formation',
            description: 'Progressive collagen deposition creates fibrotic bands and regenerative nodules',
            systemsInvolved: ['Hepatobiliary'],
            contribution: 'primary',
          },
          {
            name: 'Portal Hypertension',
            description: 'Architectural distortion increases resistance to portal blood flow',
            systemsInvolved: ['Hepatobiliary', 'Cardiovascular'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Chronic Alcohol Use', type: 'modifiable', impact: 'major', description: 'Most common cause in Western countries', intervention: 'Alcohol cessation' },
          { name: 'Hepatitis B/C', type: 'partially-modifiable', impact: 'major', description: 'Chronic viral hepatitis leads to fibrosis', intervention: 'Antiviral treatment' },
          { name: 'NAFLD/NASH', type: 'partially-modifiable', impact: 'major', description: 'Fatty liver disease from obesity/diabetes', intervention: 'Weight loss, metabolic control' },
          { name: 'Autoimmune Hepatitis', type: 'partially-modifiable', impact: 'moderate', description: 'Immune attack on liver cells', intervention: 'Immunosuppression' },
          { name: 'Hemochromatosis', type: 'partially-modifiable', impact: 'moderate', description: 'Iron overload damages liver', intervention: 'Phlebotomy' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Often the first and most persistent symptom' },
          { name: 'Abdominal Swelling', prevalence: 'common', description: 'Ascites from fluid accumulation' },
          { name: 'Jaundice', prevalence: 'common', description: 'Yellow skin and eyes from bilirubin buildup' },
        ],
        associatedSymptoms: [
          { name: 'Easy Bruising', prevalence: 'common', description: 'Decreased clotting factors' },
          { name: 'Confusion', prevalence: 'common', description: 'Hepatic encephalopathy from ammonia buildup' },
          { name: 'Leg Swelling', prevalence: 'common', description: 'Edema from low albumin' },
          { name: 'Loss of Appetite', prevalence: 'common', description: 'Anorexia and early satiety' },
          { name: 'Itching', prevalence: 'common', description: 'Pruritus from bile salt accumulation' },
        ],
        physicalFindings: [
          { name: 'Ascites', examType: 'inspection', description: 'Fluid wave, shifting dullness', diagnosticValue: 'Indicates decompensation' },
          { name: 'Spider Angiomata', examType: 'inspection', description: 'Small red vascular lesions on upper body', diagnosticValue: 'Characteristic of cirrhosis' },
          { name: 'Palmar Erythema', examType: 'inspection', description: 'Redness of palm thenar/hypothenar eminences', diagnosticValue: 'Suggests chronic liver disease' },
          { name: 'Caput Medusae', examType: 'inspection', description: 'Dilated periumbilical veins', diagnosticValue: 'Indicates portal hypertension' },
          { name: 'Asterixis', examType: 'neurologic', description: 'Flapping tremor', diagnosticValue: 'Indicates hepatic encephalopathy' },
          { name: 'Hepatomegaly/Splenomegaly', examType: 'palpation', description: 'Enlarged liver (early) or shrunken; enlarged spleen', diagnosticValue: 'Splenomegaly suggests portal hypertension' },
        ],
        labFindings: [
          { testName: 'Albumin', abnormality: '<3.5 g/dL', normalRange: '3.5-5.0 g/dL', significance: 'Decreased synthetic function' },
          { testName: 'Bilirubin', abnormality: 'Elevated', normalRange: '<1.2 mg/dL', significance: 'Impaired excretion; prognostic' },
          { testName: 'INR', abnormality: 'Elevated (>1.5)', normalRange: '<1.1', significance: 'Decreased clotting factor synthesis' },
          { testName: 'Platelet Count', abnormality: '<150,000', normalRange: '150,000-400,000', significance: 'Splenic sequestration from portal hypertension' },
          { testName: 'Ammonia', abnormality: 'Elevated', normalRange: '<50 μmol/L', significance: 'Contributes to encephalopathy' },
        ],
      },
      progression: {
        naturalHistory:
          'Cirrhosis is irreversible but progression can be slowed by treating underlying cause. Compensated cirrhosis can remain stable for years. Decompensation dramatically worsens prognosis.',
        timelineSteps: [
          {
            phaseId: 'compensated',
            phase: 'early',
            displayName: 'Compensated Cirrhosis',
            timeframe: 'Years',
            description: 'Liver maintains adequate function despite scarring; often asymptomatic',
            symptoms: ['May be asymptomatic', 'Fatigue', 'Mild symptoms'],
            anatomicalChanges: [
              { structureId: 'liver', structureName: 'Liver', changeType: 'fibrosis', description: 'Fibrosis and nodular regeneration with preserved function', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Treat underlying cause', 'Avoid hepatotoxins', 'Screen for varices and HCC'],
          },
          {
            phaseId: 'decompensated',
            phase: 'severe',
            displayName: 'Decompensated Cirrhosis',
            timeframe: 'Progressive',
            description: 'Liver can no longer maintain adequate function; complications develop',
            symptoms: ['Ascites', 'Jaundice', 'Encephalopathy', 'Variceal bleeding'],
            anatomicalChanges: [
              { structureId: 'liver', structureName: 'Liver', changeType: 'fibrosis', description: 'Advanced fibrosis with synthetic failure', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.8 }, isNewAtPhase: false },
              { structureId: 'spleen', structureName: 'Spleen', changeType: 'hypertrophy', description: 'Splenomegaly from portal hypertension', severity: 'moderate', visualIndicator: { color: '#8b5cf6', pulse: false, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Manage complications', 'Liver transplant evaluation', 'Palliative care if not transplant candidate'],
          },
        ],
        prognosis:
          'Compensated: 80% 5-year survival. Decompensated: 50% 5-year survival. MELD score predicts mortality and transplant priority.',
      },
      complications: [
        {
          complicationId: 'variceal-bleeding',
          name: 'Esophageal Variceal Bleeding',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'high',
          description: 'Hemorrhage from dilated esophageal veins',
          mechanism: 'Portal hypertension causes collateral vessels to dilate and rupture',
          affectedStructures: [{ structureId: 'esophagus', structureName: 'Esophageal Varices', effect: 'Massive hemorrhage', highlightColor: '#dc2626' }],
          warningSymptoms: ['Vomiting blood', 'Black tarry stools', 'Lightheadedness', 'Rapid heartbeat'],
          preventable: true,
        },
        {
          complicationId: 'hepatic-encephalopathy',
          name: 'Hepatic Encephalopathy',
          category: 'acute',
          severity: 'major',
          riskLevel: 'high',
          description: 'Brain dysfunction from liver failure',
          mechanism: 'Ammonia and other toxins accumulate due to impaired liver metabolism',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Metabolic encephalopathy', highlightColor: '#8b5cf6' }],
          warningSymptoms: ['Confusion', 'Forgetfulness', 'Personality changes', 'Sleep disturbances'],
          preventable: true,
        },
        {
          complicationId: 'hepatocellular-carcinoma',
          name: 'Hepatocellular Carcinoma (HCC)',
          category: 'chronic',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Liver cancer developing in cirrhotic liver',
          mechanism: 'Chronic inflammation and regeneration promote malignant transformation',
          affectedStructures: [{ structureId: 'liver', structureName: 'Liver', effect: 'Malignant tumor', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['Weight loss', 'Worsening liver function', 'New mass on imaging'],
          preventable: false,
        },
        {
          complicationId: 'sbp',
          name: 'Spontaneous Bacterial Peritonitis',
          category: 'acute',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Infection of ascitic fluid',
          mechanism: 'Bacterial translocation across gut wall to ascitic fluid',
          affectedStructures: [{ structureId: 'peritoneum', structureName: 'Peritoneal Cavity', effect: 'Infected ascites', highlightColor: '#ef4444' }],
          warningSymptoms: ['Fever', 'Abdominal pain', 'Worsening encephalopathy', 'Worsening kidney function'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'treat-underlying-cause',
          name: 'Treat Underlying Cause',
          modality: 'pharmacological',
          description: 'Address the condition causing liver damage',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'severe'],
          goals: ['Stop progression', 'Allow some regression of fibrosis', 'Prevent decompensation'],
          explanations: {
            level1: 'The most important treatment is stopping whatever is damaging your liver - whether that is alcohol, a virus, or excess weight.',
            level2: 'Treating the cause can stop further damage and may even allow some improvement. This could mean stopping alcohol, curing hepatitis, or losing weight.',
            level3: 'Alcohol cessation, HCV cure with DAAs, HBV suppression, weight loss for NAFLD. Eliminating cause can reverse early fibrosis and prevent decompensation even in cirrhosis.',
            level4: 'SVR in HCV cirrhosis reduces decompensation, HCC risk, and mortality. HBV suppression reduces but does not eliminate HCC risk. 10% weight loss can improve NASH.',
            level5: 'Fibrosis regression is possible with successful treatment. LSM by elastography can track improvement. Compensated patients who achieve cause elimination may have near-normal survival.',
          },
        },
        {
          treatmentId: 'ascites-management',
          name: 'Ascites Management',
          modality: 'pharmacological',
          description: 'Diuretics and sodium restriction to control fluid accumulation',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['severe'],
          goals: ['Reduce ascites', 'Improve comfort', 'Prevent SBP'],
          explanations: {
            level1: 'Water pills and limiting salt help reduce the fluid buildup in your belly.',
            level2: 'Diuretics remove excess fluid through your urine, and eating less salt prevents more fluid from accumulating. Sometimes fluid needs to be drained with a needle.',
            level3: 'Sodium restriction (<2g/day) plus spironolactone and furosemide (100:40 ratio). Large-volume paracentesis with albumin for tense ascites. Transjugular intrahepatic portosystemic shunt (TIPS) for refractory ascites.',
            level4: 'Monitor electrolytes and creatinine with diuretics. Albumin 6-8g per liter removed for LVP >5L. SBP prophylaxis with norfloxacin for high-risk patients.',
            level5: 'Ascites indicates decompensation with median survival 2-3 years. Refer for transplant evaluation. Midodrine and octreotide may help in hepatorenal syndrome.',
          },
        },
        {
          treatmentId: 'liver-transplant',
          name: 'Liver Transplantation',
          modality: 'surgical',
          description: 'Replacing diseased liver with a healthy donor liver',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['severe', 'end-stage'],
          goals: ['Cure liver disease', 'Restore normal function', 'Extend survival'],
          explanations: {
            level1: 'A liver transplant replaces your damaged liver with a healthy one from a donor. This is the only cure for severe liver disease.',
            level2: 'When cirrhosis becomes severe and other treatments do not work, a transplant can give you a new, healthy liver. You need to be healthy enough for major surgery and commit to lifelong medications.',
            level3: 'Refer when MELD ≥15 or decompensation occurs. Absolute contraindications: active alcohol/substance use, uncontrolled infection, advanced malignancy. Living donor transplantation is an option.',
            level4: '1-year survival >90%, 5-year >75%. Post-transplant requires lifelong immunosuppression. Recurrence of primary disease (HCV now curable, NAFLD may recur) is consideration.',
            level5: 'MELD score prioritizes organ allocation. Exceptions granted for HCC within Milan criteria, hepatopulmonary syndrome. Extended criteria donors expand donor pool.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'liver', structureName: 'Liver', role: 'primary-site', involvement: 'Fibrosis and nodular regeneration', highlightColor: '#f97316', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'spleen', structureName: 'Spleen', role: 'secondary-site', involvement: 'Splenomegaly from portal hypertension', highlightColor: '#8b5cf6', showByDefault: true },
          { structureId: 'portal-vein', structureName: 'Portal Vein', role: 'secondary-site', involvement: 'Portal hypertension', highlightColor: '#ef4444', showByDefault: false },
        ],
        systemsInvolved: ['Hepatobiliary', 'Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['digestive'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: 'Your liver has become scarred and does not work as well as it should. Stopping whatever caused the damage is the most important step.',
        level2: 'Years of liver damage have caused scar tissue to replace normal liver. This scarring is permanent, but treating the cause can prevent it from getting worse and sometimes allow some improvement.',
        level3: 'Cirrhosis is end-stage liver fibrosis with nodular regeneration. Classified as compensated or decompensated (ascites, encephalopathy, variceal bleeding, jaundice). MELD score guides prognosis and transplant timing.',
        level4: 'Child-Pugh and MELD scores classify severity. Portal hypertension drives most complications. Screen for varices with EGD. Screen for HCC with ultrasound and AFP every 6 months.',
        level5: 'Hepatic stellate cells are key fibrogenic cells. Fibrosis regression possible with successful treatment of underlying cause. Sinusoidal capillarization and intrahepatic shunting contribute to portal hypertension.',
      },
      relatedConditions: ['hepatitis-c', 'alcoholic-liver-disease', 'nafld', 'hepatocellular-carcinoma'],
      epidemiology: {
        prevalence: '0.27% of US population; 4.5 million Americans',
        incidence: 'Increasing due to NAFLD/NASH epidemic',
        demographics: 'Alcohol-related more common in men; NAFLD rising in all groups',
      },
      clinicalPearls: [
        'Compensated cirrhosis can remain stable for years - treating the cause is critical',
        'Once decompensation occurs, refer for transplant evaluation',
        'All cirrhotics need HCC surveillance with ultrasound every 6 months',
        'Screen for varices with EGD at diagnosis; beta-blockers reduce bleeding risk',
        'Low threshold for paracentesis if new ascites or clinical change - rule out SBP',
      ],
      patientEducation: [
        'Stopping alcohol completely is the most important thing you can do if alcohol is the cause',
        'Avoid all medications that can harm the liver, including many over-the-counter drugs - always ask first',
        'Eat a healthy diet with adequate protein but limit salt to reduce fluid buildup',
        'Get vaccinated for hepatitis A and B if not already immune',
        'Keep all appointments for monitoring and cancer screening',
      ],
      emergencyWarnings: [
        'Vomiting blood or having black, tarry stools',
        'Increasing confusion, sleepiness, or difficulty thinking',
        'Fever with abdominal pain (may indicate infection in belly fluid)',
        'Rapidly increasing belly swelling',
        'New yellowing of skin or eyes',
        'Severe weakness or fainting',
      ],
    },
  ],

  // Gastroesophageal Reflux Disease (GERD)
  [
    'gerd',
    {
      conditionId: 'gerd',
      name: 'Gastroesophageal Reflux Disease',
      aliases: ['GERD', 'Acid Reflux', 'Heartburn'],
      icdCode: 'K21.0',
      category: 'gastrointestinal',
      subcategory: 'Esophageal Disorders',
      description:
        'A chronic digestive disease where stomach acid or bile flows back into the esophagus, irritating the lining and causing heartburn and other symptoms.',
      pathophysiology: {
        summary:
          'Dysfunction of the lower esophageal sphincter allows gastric contents to reflux into the esophagus, causing mucosal injury and symptoms.',
        mechanisms: [
          {
            name: 'Lower Esophageal Sphincter Dysfunction',
            description: 'Transient relaxations or reduced resting pressure allows reflux',
            systemsInvolved: ['Gastrointestinal'],
            keyMediators: ['Vagal reflexes', 'Nitric oxide'],
            contribution: 'primary',
          },
          {
            name: 'Hiatal Hernia',
            description: 'Displacement of gastroesophageal junction impairs sphincter function',
            systemsInvolved: ['Gastrointestinal'],
            contribution: 'secondary',
          },
          {
            name: 'Delayed Gastric Emptying',
            description: 'Increased gastric volume increases reflux pressure',
            systemsInvolved: ['Gastrointestinal'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Obesity', type: 'modifiable', impact: 'major', description: 'Increases intra-abdominal pressure', intervention: 'Weight loss' },
          { name: 'Hiatal Hernia', type: 'partially-modifiable', impact: 'major', description: 'Disrupts LES function', intervention: 'Surgical repair in severe cases' },
          { name: 'Smoking', type: 'modifiable', impact: 'moderate', description: 'Reduces LES pressure', intervention: 'Smoking cessation' },
          { name: 'Certain Foods', type: 'modifiable', impact: 'moderate', description: 'Trigger foods vary by individual', intervention: 'Dietary modification' },
          { name: 'Pregnancy', type: 'non-modifiable', impact: 'moderate', description: 'Increased abdominal pressure and hormonal effects' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Heartburn', prevalence: 'very-common', description: 'Burning sensation behind sternum, often after meals' },
          { name: 'Regurgitation', prevalence: 'very-common', description: 'Sour or bitter taste from stomach contents in throat' },
          { name: 'Dysphagia', prevalence: 'common', description: 'Difficulty swallowing, especially solids' },
        ],
        associatedSymptoms: [
          { name: 'Chronic Cough', prevalence: 'common', description: 'Especially at night, from microaspiration' },
          { name: 'Hoarseness', prevalence: 'common', description: 'Laryngeal irritation from acid reflux' },
          { name: 'Chest Pain', prevalence: 'common', description: 'Can mimic cardiac pain' },
          { name: 'Dental Erosion', prevalence: 'uncommon', description: 'Acid damage to tooth enamel' },
        ],
        physicalFindings: [
          { name: 'Usually Normal', examType: 'general', description: 'Physical exam is typically unremarkable', diagnosticValue: 'Normal exam does not exclude GERD' },
          { name: 'Dental Erosions', examType: 'inspection', description: 'Erosion of posterior teeth enamel', diagnosticValue: 'Suggests chronic acid exposure' },
        ],
        labFindings: [
          { testName: 'Upper Endoscopy', abnormality: 'Esophagitis, erosions, Barrett\'s esophagus', normalRange: 'Normal mucosa', significance: 'Gold standard for mucosal evaluation' },
          { testName: 'pH Monitoring', abnormality: 'Acid exposure >4% of time', normalRange: '<4% time pH<4', significance: 'Quantifies reflux; used when diagnosis uncertain' },
          { testName: 'Esophageal Manometry', abnormality: 'LES hypotension, ineffective motility', normalRange: 'Normal LES and motility', significance: 'Evaluates function before surgery' },
        ],
      },
      progression: {
        naturalHistory:
          'GERD is typically chronic and relapsing. Most patients manage symptoms with lifestyle changes and medications. Untreated, can lead to esophagitis, strictures, and Barrett\'s esophagus.',
        timelineSteps: [
          {
            phaseId: 'symptomatic',
            phase: 'early',
            displayName: 'Symptomatic GERD',
            timeframe: 'Ongoing',
            description: 'Typical symptoms without visible mucosal damage (NERD)',
            symptoms: ['Heartburn', 'Regurgitation', 'Responds to acid suppression'],
            anatomicalChanges: [
              { structureId: 'esophagus', structureName: 'Esophagus', changeType: 'inflammation', description: 'Microscopic inflammation without visible erosions', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Lifestyle modifications', 'PPIs or H2 blockers'],
          },
          {
            phaseId: 'erosive',
            phase: 'established',
            displayName: 'Erosive Esophagitis',
            timeframe: 'Months to years',
            description: 'Visible mucosal breaks from acid injury',
            symptoms: ['More severe symptoms', 'Possibly dysphagia', 'Chest pain'],
            anatomicalChanges: [
              { structureId: 'esophagus', structureName: 'Esophageal Mucosa', changeType: 'inflammation', description: 'Erosions and ulcerations of esophageal lining', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['PPIs (often high-dose)', 'Lifestyle modifications'],
          },
          {
            phaseId: 'barretts',
            phase: 'chronic',
            displayName: 'Barrett\'s Esophagus',
            timeframe: 'Years',
            description: 'Metaplasia of esophageal lining - precancerous',
            symptoms: ['May have decreased heartburn', 'Requires surveillance'],
            anatomicalChanges: [
              { structureId: 'esophagus', structureName: 'Esophageal Mucosa', changeType: 'degeneration', description: 'Intestinal metaplasia replacing squamous epithelium', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['PPIs', 'Endoscopic surveillance', 'Ablation if dysplasia'],
          },
        ],
        prognosis:
          'Most patients achieve good symptom control with treatment. Barrett\'s esophagus develops in 5-15% of chronic GERD. Annual risk of esophageal cancer in Barrett\'s is 0.5%.',
      },
      complications: [
        {
          complicationId: 'esophageal-stricture',
          name: 'Esophageal Stricture',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'low',
          description: 'Narrowing of esophagus from scarring',
          mechanism: 'Chronic inflammation leads to fibrosis and luminal narrowing',
          affectedStructures: [{ structureId: 'esophagus', structureName: 'Esophagus', effect: 'Narrowing causing dysphagia', highlightColor: '#f97316' }],
          warningSymptoms: ['Progressive difficulty swallowing', 'Food getting stuck', 'Weight loss'],
          preventable: true,
        },
        {
          complicationId: 'barretts-esophagus',
          name: 'Barrett\'s Esophagus',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Precancerous change in esophageal lining',
          mechanism: 'Chronic acid injury causes metaplasia to intestinal-type epithelium',
          affectedStructures: [{ structureId: 'esophagus', structureName: 'Esophageal Mucosa', effect: 'Metaplasia with cancer risk', highlightColor: '#dc2626' }],
          warningSymptoms: ['Long-standing GERD', 'May have improved symptoms paradoxically'],
          preventable: true,
        },
        {
          complicationId: 'esophageal-adenocarcinoma',
          name: 'Esophageal Adenocarcinoma',
          category: 'chronic',
          severity: 'life-threatening',
          riskLevel: 'low',
          description: 'Cancer arising from Barrett\'s esophagus',
          mechanism: 'Dysplasia in Barrett\'s epithelium progresses to carcinoma',
          affectedStructures: [{ structureId: 'esophagus', structureName: 'Esophagus', effect: 'Malignant tumor', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['Progressive dysphagia', 'Weight loss', 'GI bleeding', 'Anemia'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'lifestyle-modifications',
          name: 'Lifestyle Modifications',
          modality: 'lifestyle',
          description: 'Dietary and behavioral changes to reduce reflux',
          efficacy: 'effective',
          evidenceLevel: 'level-2a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Reduce reflux episodes', 'Improve symptoms', 'Reduce medication need'],
          explanations: {
            level1: 'Simple changes like losing weight, not eating late, and avoiding trigger foods can help reduce heartburn.',
            level2: 'Lifestyle changes include weight loss, elevating the head of bed, avoiding late meals, and identifying personal trigger foods (acidic, spicy, fatty foods, alcohol, caffeine).',
            level3: 'Weight loss is most effective intervention. Avoid meals 3 hours before bed. Elevate head of bed 6-8 inches. Avoid known triggers. Smoking cessation.',
            level4: 'Evidence strongest for weight loss and head-of-bed elevation. Dietary restrictions should be individualized. Lifestyle changes recommended as adjunct to pharmacotherapy.',
            level5: 'Physiologic basis: weight loss reduces intra-abdominal pressure; head elevation uses gravity; postprandial period has highest reflux; tobacco reduces LES pressure.',
          },
        },
        {
          treatmentId: 'ppi-therapy',
          name: 'Proton Pump Inhibitor Therapy',
          modality: 'pharmacological',
          description: 'Acid-suppressing medication that blocks gastric acid production',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'chronic'],
          goals: ['Heal esophagitis', 'Relieve symptoms', 'Prevent complications'],
          explanations: {
            level1: 'Pills that stop your stomach from making acid, which prevents the burning feeling in your chest.',
            level2: 'PPIs are the most effective medications for acid reflux. They work by blocking the acid pumps in your stomach lining.',
            level3: 'PPIs (omeprazole, pantoprazole, etc.) taken 30-60 min before meals. 8-week course for erosive esophagitis. Step-down to lowest effective dose or on-demand for maintenance.',
            level4: 'PPIs heal erosive esophagitis in 80-90% at 8 weeks. Twice-daily dosing for refractory cases. Long-term use concerns (C. diff, osteoporosis, B12) are minimal at appropriate doses.',
            level5: 'PPIs irreversibly inhibit H+/K+-ATPase; need synthesis of new pumps for recovery. Nocturnal acid breakthrough may occur - can add bedtime H2 blocker. CYP2C19 polymorphisms affect metabolism.',
          },
        },
        {
          treatmentId: 'fundoplication',
          name: 'Surgical Fundoplication',
          modality: 'surgical',
          description: 'Surgery to strengthen the lower esophageal sphincter',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established', 'chronic'],
          goals: ['Restore LES function', 'Eliminate need for medications', 'Prevent reflux'],
          explanations: {
            level1: 'Surgery that wraps part of your stomach around the lower esophagus to prevent acid from coming back up.',
            level2: 'For patients who cannot or do not want to take lifelong medication, surgery can recreate a valve to stop reflux.',
            level3: 'Laparoscopic Nissen (360°) or partial fundoplication. Best for those with documented reflux responding to PPIs but preferring surgery. Requires manometry pre-op.',
            level4: 'Long-term PPI equivalence. Potential complications: dysphagia, gas-bloat, inability to vomit. Patient selection crucial. LINX device is alternative.',
            level5: 'Surgical outcomes depend on patient selection: objective reflux documentation, PPI response, and normal esophageal motility predict success. Reoperation rates 5-15%.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'esophagus', structureName: 'Esophagus', role: 'primary-site', involvement: 'Site of acid injury', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'lower-esophageal-sphincter', structureName: 'Lower Esophageal Sphincter', role: 'secondary-site', involvement: 'Dysfunctional barrier', highlightColor: '#f97316', showByDefault: true },
          { structureId: 'stomach', structureName: 'Stomach', role: 'secondary-site', involvement: 'Source of refluxate', highlightColor: '#f59e0b', showByDefault: false },
        ],
        systemsInvolved: ['Gastrointestinal'],
        recommendedView: 'anterior',
        recommendedLayers: ['digestive'],
        focusRegion: 'thorax',
      },
      explanations: {
        level1: 'Stomach acid keeps coming back up into your food pipe (esophagus), causing burning pain and discomfort. Lifestyle changes and medications can control it.',
        level2: 'The valve between your stomach and esophagus does not close properly, allowing acid to wash back up. This irritates the esophageal lining and causes heartburn.',
        level3: 'GERD is diagnosed clinically by typical symptoms responding to acid suppression. Endoscopy is indicated for alarm symptoms, refractory cases, or screening high-risk patients for Barrett\'s.',
        level4: 'Empiric PPI trial is diagnostic and therapeutic. LA classification grades erosive esophagitis. Barrett\'s requires histologic confirmation. pH testing useful when diagnosis unclear.',
        level5: 'Pathophysiology involves transient LES relaxations (TLESRs), hiatal hernia, impaired esophageal clearance, and mucosal sensitivity. Impedance-pH distinguishes acid from non-acid reflux.',
      },
      relatedConditions: ['esophageal-cancer', 'hiatal-hernia', 'dyspepsia'],
      epidemiology: {
        prevalence: '18-28% of North American adults have weekly GERD symptoms',
        incidence: 'Increasing, likely due to obesity epidemic',
        demographics: 'More common with obesity, increasing age, Caucasians',
      },
      clinicalPearls: [
        'Alarm symptoms (dysphagia, weight loss, anemia, GI bleeding) require endoscopy',
        'PPIs should be taken 30-60 minutes before meals for maximum efficacy',
        'Nocturnal symptoms may require bedtime H2 blocker addition',
        'Long-standing GERD (>5-10 years) in high-risk patients warrants Barrett\'s screening',
        'Some patients have non-erosive reflux disease (NERD) with normal endoscopy',
      ],
      patientEducation: [
        'Lose weight if overweight - this is the most effective lifestyle change',
        'Do not eat within 3 hours of bedtime',
        'Elevate the head of your bed 6-8 inches (pillows alone are not effective)',
        'Identify and avoid your personal trigger foods',
        'Take PPIs 30-60 minutes before your first meal of the day',
      ],
      emergencyWarnings: [
        'Difficulty swallowing that is getting worse',
        'Food getting stuck in your chest',
        'Vomiting blood or material that looks like coffee grounds',
        'Black, tarry stools',
        'Unintentional weight loss',
        'Chest pain (should be evaluated to rule out heart problems)',
      ],
    },
  ],

  // Hypothyroidism
  [
    'hypothyroidism',
    {
      conditionId: 'hypothyroidism',
      name: 'Hypothyroidism',
      aliases: ['Underactive Thyroid', 'Low Thyroid', 'Hashimoto\'s Thyroiditis'],
      icdCode: 'E03.9',
      category: 'endocrine',
      subcategory: 'Thyroid Disorders',
      description:
        'A condition in which the thyroid gland does not produce enough thyroid hormone, causing the body\'s metabolism to slow down.',
      pathophysiology: {
        summary:
          'Insufficient thyroid hormone production leads to decreased metabolic rate and affects virtually every organ system.',
        mechanisms: [
          {
            name: 'Autoimmune Destruction',
            description: 'In Hashimoto\'s thyroiditis, antibodies attack thyroid tissue',
            systemsInvolved: ['Endocrine', 'Immune'],
            keyMediators: ['Anti-TPO antibodies', 'Anti-thyroglobulin antibodies', 'T lymphocytes'],
            contribution: 'primary',
          },
          {
            name: 'Decreased T4/T3 Production',
            description: 'Damaged thyroid cannot produce adequate hormones',
            systemsInvolved: ['Endocrine'],
            keyMediators: ['T4', 'T3'],
            contribution: 'primary',
          },
          {
            name: 'Elevated TSH',
            description: 'Pituitary increases TSH in attempt to stimulate thyroid',
            systemsInvolved: ['Endocrine'],
            keyMediators: ['TSH'],
            contribution: 'compensatory',
          },
        ],
        riskFactors: [
          { name: 'Female Sex', type: 'non-modifiable', impact: 'major', description: 'Women are 5-8x more likely to develop hypothyroidism' },
          { name: 'Age >60', type: 'non-modifiable', impact: 'moderate', description: 'Prevalence increases with age' },
          { name: 'Autoimmune Disease', type: 'partially-modifiable', impact: 'major', description: 'Other autoimmune conditions increase risk' },
          { name: 'Family History', type: 'non-modifiable', impact: 'moderate', description: 'Thyroid disease runs in families' },
          { name: 'Previous Thyroid Treatment', type: 'non-modifiable', impact: 'major', description: 'Radiation or surgery to thyroid' },
          { name: 'Iodine Deficiency', type: 'modifiable', impact: 'major', description: 'Rare in developed countries', intervention: 'Adequate iodine intake' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Tiredness and low energy despite adequate sleep' },
          { name: 'Cold Intolerance', prevalence: 'very-common', description: 'Feeling cold when others are comfortable' },
          { name: 'Weight Gain', prevalence: 'common', description: 'Modest weight gain from decreased metabolism' },
          { name: 'Constipation', prevalence: 'common', description: 'Slowed GI motility' },
        ],
        associatedSymptoms: [
          { name: 'Dry Skin', prevalence: 'common', description: 'Decreased sweating and sebum production' },
          { name: 'Hair Loss', prevalence: 'common', description: 'Thinning and brittle hair' },
          { name: 'Depression', prevalence: 'common', description: 'Low mood and cognitive slowing' },
          { name: 'Muscle Weakness', prevalence: 'common', description: 'Proximal muscle weakness' },
          { name: 'Menstrual Irregularities', prevalence: 'common', description: 'Heavy or irregular periods in women' },
        ],
        physicalFindings: [
          { name: 'Bradycardia', examType: 'vital signs', description: 'Slow heart rate', diagnosticValue: 'Common finding' },
          { name: 'Delayed Ankle Reflexes', examType: 'neurologic', description: 'Slow relaxation phase of deep tendon reflexes', diagnosticValue: 'Classic finding' },
          { name: 'Periorbital Edema', examType: 'inspection', description: 'Puffy appearance around eyes', diagnosticValue: 'Suggests hypothyroidism' },
          { name: 'Dry, Cool Skin', examType: 'inspection', description: 'Decreased sweating', diagnosticValue: 'Common finding' },
          { name: 'Goiter', examType: 'palpation', description: 'Enlarged thyroid (may or may not be present)', diagnosticValue: 'Suggests Hashimoto\'s if present' },
        ],
        labFindings: [
          { testName: 'TSH', abnormality: 'Elevated (>4.5 mU/L)', normalRange: '0.4-4.0 mU/L', significance: 'Most sensitive test for primary hypothyroidism' },
          { testName: 'Free T4', abnormality: 'Low', normalRange: '0.8-1.8 ng/dL', significance: 'Confirms hypothyroidism when TSH elevated' },
          { testName: 'Anti-TPO Antibodies', abnormality: 'Positive', normalRange: 'Negative', significance: 'Confirms autoimmune (Hashimoto\'s) etiology' },
          { testName: 'Lipid Panel', abnormality: 'Elevated cholesterol', normalRange: 'LDL <100 mg/dL', significance: 'Hypothyroidism raises LDL cholesterol' },
        ],
      },
      progression: {
        naturalHistory:
          'Hypothyroidism is usually permanent and requires lifelong treatment. With proper thyroid hormone replacement, patients can expect normal quality of life.',
        timelineSteps: [
          {
            phaseId: 'subclinical',
            phase: 'early',
            displayName: 'Subclinical Hypothyroidism',
            timeframe: 'Months to years',
            description: 'Elevated TSH with normal T4 - may be asymptomatic',
            symptoms: ['May be asymptomatic', 'Subtle fatigue'],
            anatomicalChanges: [
              { structureId: 'thyroid', structureName: 'Thyroid Gland', changeType: 'inflammation', description: 'Early autoimmune infiltration', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Monitor TSH', 'Consider treatment if TSH >10 or symptomatic'],
          },
          {
            phaseId: 'overt',
            phase: 'established',
            displayName: 'Overt Hypothyroidism',
            timeframe: 'Ongoing',
            description: 'Elevated TSH with low T4 and symptoms',
            symptoms: ['Fatigue', 'Cold intolerance', 'Weight gain', 'Constipation'],
            anatomicalChanges: [
              { structureId: 'thyroid', structureName: 'Thyroid Gland', changeType: 'atrophy', description: 'Progressive destruction of thyroid tissue', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Levothyroxine replacement'],
          },
          {
            phaseId: 'myxedema',
            phase: 'severe',
            displayName: 'Myxedema Coma',
            timeframe: 'Emergency',
            description: 'Severe, life-threatening hypothyroidism (rare)',
            symptoms: ['Altered mental status', 'Hypothermia', 'Hypotension', 'Hypoventilation'],
            anatomicalChanges: [
              { structureId: 'thyroid', structureName: 'Thyroid Gland', changeType: 'atrophy', description: 'Severe thyroid failure', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.8 }, isNewAtPhase: false },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['IV levothyroxine', 'Supportive care', 'ICU management'],
          },
        ],
        prognosis:
          'Excellent with treatment. Patients on adequate levothyroxine replacement have normal life expectancy and quality of life. Untreated severe hypothyroidism can be fatal.',
      },
      complications: [
        {
          complicationId: 'cardiovascular-hypothyroid',
          name: 'Cardiovascular Disease',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Increased risk of heart disease from elevated cholesterol',
          mechanism: 'Hypothyroidism impairs LDL clearance and causes diastolic hypertension',
          affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'Accelerated atherosclerosis', highlightColor: '#ef4444' }],
          warningSymptoms: ['Chest pain', 'Shortness of breath', 'Exercise intolerance'],
          preventable: true,
        },
        {
          complicationId: 'myxedema-coma',
          name: 'Myxedema Coma',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'low',
          description: 'Severe decompensated hypothyroidism',
          mechanism: 'Extreme thyroid hormone deficiency causes multiorgan failure',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Encephalopathy and coma', highlightColor: '#dc2626' }],
          warningSymptoms: ['Confusion', 'Hypothermia', 'Extreme fatigue', 'Respiratory depression'],
          preventable: true,
        },
        {
          complicationId: 'infertility-hypothyroid',
          name: 'Infertility and Pregnancy Complications',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Difficulty conceiving and pregnancy complications',
          mechanism: 'Thyroid hormone is essential for ovulation and fetal development',
          affectedStructures: [{ structureId: 'reproductive-system', structureName: 'Reproductive System', effect: 'Anovulation and pregnancy complications', highlightColor: '#f97316' }],
          warningSymptoms: ['Difficulty getting pregnant', 'Irregular periods', 'Miscarriage'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'levothyroxine',
          name: 'Levothyroxine Replacement',
          modality: 'pharmacological',
          description: 'Synthetic thyroid hormone to replace what the thyroid cannot produce',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'severe'],
          goals: ['Normalize TSH', 'Relieve symptoms', 'Prevent complications'],
          timeToEffect: 'Weeks for symptoms; 6-8 weeks for TSH normalization',
          explanations: {
            level1: 'A pill that replaces the thyroid hormone your body is not making. Taking it every morning gives your body what it needs.',
            level2: 'Levothyroxine is the same hormone your thyroid would normally make. You take it once daily on an empty stomach, and it replaces what you are missing.',
            level3: 'Start low in elderly/cardiac patients. Full replacement ~1.6 mcg/kg. Take on empty stomach 30-60 min before food. Check TSH in 6-8 weeks; goal TSH 0.5-2.5 in most patients.',
            level4: 'Steady state takes 6 weeks (half-life 7 days). Medications and supplements can interfere with absorption. Once stable, annual TSH sufficient. Dose may need increase in pregnancy.',
            level5: 'T4 monotherapy is standard despite theoretical appeal of T4/T3 combination. Thyroxine is converted to T3 peripherally. Some patients with DIO2 polymorphisms may benefit from combination therapy.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'thyroid', structureName: 'Thyroid Gland', role: 'primary-site', involvement: 'Unable to produce adequate hormone', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'pituitary', structureName: 'Pituitary Gland', role: 'secondary-site', involvement: 'Produces elevated TSH', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Endocrine'],
        recommendedView: 'anterior',
        recommendedLayers: ['endocrine'],
        focusRegion: 'head-neck',
      },
      explanations: {
        level1: 'Your thyroid gland is not making enough hormone, so your body runs too slowly. A daily pill replaces this hormone and makes you feel normal.',
        level2: 'The thyroid controls your metabolism. When it underproduces hormones, everything slows down - you feel tired, cold, and gain weight. Taking thyroid hormone medication fixes this.',
        level3: 'Hypothyroidism is diagnosed when TSH is elevated with low free T4 (or normal T4 in subclinical). Most common cause is Hashimoto\'s thyroiditis. Treat with levothyroxine; goal TSH 0.5-2.5.',
        level4: 'Hashimoto\'s is characterized by anti-TPO antibodies. Subclinical hypothyroidism (TSH elevated, T4 normal) treat if TSH >10, symptomatic, or pregnant. Central hypothyroidism has low/normal TSH with low T4.',
        level5: 'Hashimoto\'s involves T-cell mediated destruction of thyrocytes. Anti-TPO antibodies are a marker but not directly pathogenic. Genetic susceptibility (HLA-DR, CTLA-4) and environmental triggers (iodine excess, selenium deficiency).',
      },
      relatedConditions: ['hashimotos-thyroiditis', 'hyperthyroidism', 'thyroid-nodules'],
      epidemiology: {
        prevalence: '5% overt, 5-10% subclinical; up to 20% in elderly women',
        incidence: 'Increases with age',
        demographics: 'Women 5-8x more common than men; increases with age',
      },
      clinicalPearls: [
        'TSH is the most sensitive test - check it first',
        'Start low, go slow in elderly and those with cardiac disease',
        'Take levothyroxine on empty stomach, 30-60 min before other medications',
        'Wait 6-8 weeks after dose change before rechecking TSH',
        'Many things interfere with absorption: calcium, iron, coffee, fiber, PPIs',
      ],
      patientEducation: [
        'Take levothyroxine at the same time every day, ideally first thing in the morning on an empty stomach',
        'Wait at least 30-60 minutes before eating or taking other medications',
        'Do not stop taking your medication even if you feel better - you will need it lifelong',
        'Get your blood tested regularly to make sure your dose is correct',
        'Tell your doctor about all other medications and supplements you take',
      ],
      emergencyWarnings: [
        'Extreme fatigue with confusion or altered mental status',
        'Hypothermia (low body temperature)',
        'Slow heart rate with lightheadedness',
        'Severe constipation or abdominal swelling',
        'In pregnant women: any worsening symptoms need urgent evaluation',
      ],
    },
  ],

  // Hyperthyroidism
  [
    'hyperthyroidism',
    {
      conditionId: 'hyperthyroidism',
      name: 'Hyperthyroidism',
      aliases: ['Overactive Thyroid', 'Graves\' Disease', 'Thyrotoxicosis'],
      icdCode: 'E05.90',
      category: 'endocrine',
      subcategory: 'Thyroid Disorders',
      description:
        'A condition in which the thyroid gland produces too much thyroid hormone, causing the body\'s metabolism to speed up.',
      pathophysiology: {
        summary:
          'Excess thyroid hormone production increases metabolic rate and affects virtually every organ system, particularly the heart and nervous system.',
        mechanisms: [
          {
            name: 'Graves\' Disease',
            description: 'Autoantibodies stimulate TSH receptors causing unregulated hormone production',
            systemsInvolved: ['Endocrine', 'Immune'],
            keyMediators: ['TSH receptor stimulating antibodies (TRAb)', 'TSI'],
            contribution: 'primary',
          },
          {
            name: 'Toxic Nodular Goiter',
            description: 'Autonomously functioning thyroid nodules overproduce hormone',
            systemsInvolved: ['Endocrine'],
            contribution: 'primary',
          },
          {
            name: 'Increased T4/T3',
            description: 'Excess hormone increases metabolic rate systemically',
            systemsInvolved: ['Endocrine', 'All systems'],
            keyMediators: ['T4', 'T3'],
            contribution: 'primary',
          },
        ],
        riskFactors: [
          { name: 'Female Sex', type: 'non-modifiable', impact: 'major', description: 'Women are 5-10x more likely' },
          { name: 'Family History', type: 'non-modifiable', impact: 'moderate', description: 'Autoimmune thyroid disease clusters in families' },
          { name: 'Other Autoimmune Disease', type: 'partially-modifiable', impact: 'moderate', description: 'Type 1 diabetes, RA increase risk' },
          { name: 'Excess Iodine', type: 'modifiable', impact: 'moderate', description: 'Can trigger hyperthyroidism in susceptible individuals', intervention: 'Avoid excess iodine' },
          { name: 'Smoking', type: 'modifiable', impact: 'moderate', description: 'Increases risk of Graves\' ophthalmopathy', intervention: 'Smoking cessation' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Palpitations', prevalence: 'very-common', description: 'Rapid or irregular heartbeat' },
          { name: 'Heat Intolerance', prevalence: 'very-common', description: 'Feeling hot when others are comfortable' },
          { name: 'Weight Loss', prevalence: 'very-common', description: 'Unintentional weight loss despite increased appetite' },
          { name: 'Tremor', prevalence: 'very-common', description: 'Fine tremor of outstretched hands' },
        ],
        associatedSymptoms: [
          { name: 'Anxiety/Nervousness', prevalence: 'very-common', description: 'Feeling jittery or anxious' },
          { name: 'Insomnia', prevalence: 'common', description: 'Difficulty sleeping' },
          { name: 'Diarrhea', prevalence: 'common', description: 'Increased bowel frequency' },
          { name: 'Irregular Periods', prevalence: 'common', description: 'Light or missed periods' },
          { name: 'Eye Changes', prevalence: 'common', description: 'In Graves\': bulging eyes (exophthalmos)' },
        ],
        physicalFindings: [
          { name: 'Tachycardia', examType: 'vital signs', description: 'Heart rate often >100 bpm', diagnosticValue: 'Very common finding' },
          { name: 'Fine Tremor', examType: 'neurologic', description: 'Tremor when arms extended', diagnosticValue: 'Classic sign' },
          { name: 'Warm, Moist Skin', examType: 'inspection', description: 'Increased sweating', diagnosticValue: 'Common finding' },
          { name: 'Lid Lag', examType: 'inspection', description: 'Upper lid lags behind when looking down', diagnosticValue: 'Sign of thyrotoxicosis' },
          { name: 'Diffuse Goiter', examType: 'palpation', description: 'Symmetrically enlarged thyroid (Graves\')', diagnosticValue: 'Suggests Graves\' disease' },
          { name: 'Exophthalmos', examType: 'inspection', description: 'Bulging eyes', diagnosticValue: 'Pathognomonic for Graves\'' },
        ],
        labFindings: [
          { testName: 'TSH', abnormality: 'Suppressed (<0.1 mU/L)', normalRange: '0.4-4.0 mU/L', significance: 'Most sensitive test' },
          { testName: 'Free T4', abnormality: 'Elevated', normalRange: '0.8-1.8 ng/dL', significance: 'Confirms hyperthyroidism' },
          { testName: 'Free T3', abnormality: 'Elevated', normalRange: '2.3-4.2 pg/mL', significance: 'May be elevated when T4 normal (T3 toxicosis)' },
          { testName: 'TSH Receptor Antibodies', abnormality: 'Positive', normalRange: 'Negative', significance: 'Confirms Graves\' disease' },
          { testName: 'Radioiodine Uptake', abnormality: 'Increased (Graves\') or Decreased (thyroiditis)', normalRange: '10-30% at 24 hours', significance: 'Differentiates causes' },
        ],
      },
      progression: {
        naturalHistory:
          'Untreated hyperthyroidism can lead to serious complications including heart arrhythmias and thyroid storm. Most cases respond well to treatment.',
        timelineSteps: [
          {
            phaseId: 'subclinical',
            phase: 'early',
            displayName: 'Subclinical Hyperthyroidism',
            timeframe: 'Variable',
            description: 'Low TSH with normal T4/T3 - may be asymptomatic',
            symptoms: ['May be asymptomatic', 'Mild symptoms possible'],
            anatomicalChanges: [
              { structureId: 'thyroid', structureName: 'Thyroid Gland', changeType: 'hypertrophy', description: 'Early thyroid hyperactivity', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Monitor', 'Treat if TSH <0.1 or symptomatic'],
          },
          {
            phaseId: 'overt',
            phase: 'established',
            displayName: 'Overt Hyperthyroidism',
            timeframe: 'Ongoing until treated',
            description: 'Suppressed TSH with elevated T4/T3 and symptoms',
            symptoms: ['Palpitations', 'Weight loss', 'Tremor', 'Heat intolerance'],
            anatomicalChanges: [
              { structureId: 'thyroid', structureName: 'Thyroid Gland', changeType: 'hypertrophy', description: 'Hyperactive thyroid with increased blood flow', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Antithyroid drugs', 'Beta-blockers', 'Radioiodine', 'Surgery'],
          },
          {
            phaseId: 'thyroid-storm',
            phase: 'severe',
            displayName: 'Thyroid Storm',
            timeframe: 'Emergency',
            description: 'Life-threatening decompensated hyperthyroidism',
            symptoms: ['High fever', 'Extreme tachycardia', 'Delirium', 'Cardiovascular collapse'],
            anatomicalChanges: [
              { structureId: 'heart', structureName: 'Heart', changeType: 'dysfunction', description: 'Cardiac decompensation', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['ICU admission', 'PTU + iodine', 'Beta-blockers', 'Glucocorticoids', 'Supportive care'],
          },
        ],
        prognosis:
          'Good with treatment. Graves\' disease may remit with antithyroid drugs (30-50%); definitive treatment (radioiodine or surgery) results in hypothyroidism requiring lifelong replacement.',
      },
      complications: [
        {
          complicationId: 'atrial-fibrillation',
          name: 'Atrial Fibrillation',
          category: 'acute',
          severity: 'major',
          riskLevel: 'high',
          description: 'Irregular heart rhythm from thyroid excess',
          mechanism: 'Thyroid hormone increases cardiac automaticity and irritability',
          affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'Arrhythmia with stroke risk', highlightColor: '#dc2626' }],
          warningSymptoms: ['Irregular heartbeat', 'Palpitations', 'Shortness of breath', 'Dizziness'],
          preventable: true,
        },
        {
          complicationId: 'thyroid-storm',
          name: 'Thyroid Storm',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'low',
          description: 'Life-threatening decompensation of hyperthyroidism',
          mechanism: 'Acute surge in thyroid hormone effects, often triggered by stress/infection',
          affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'Cardiovascular collapse', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['High fever', 'Severe agitation', 'Extreme fast heartbeat', 'Confusion'],
          preventable: true,
        },
        {
          complicationId: 'graves-ophthalmopathy',
          name: 'Graves\' Ophthalmopathy',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Eye disease specific to Graves\' disease',
          mechanism: 'Autoimmune inflammation of orbital tissues',
          affectedStructures: [{ structureId: 'eyes', structureName: 'Orbits', effect: 'Proptosis, vision changes', highlightColor: '#f97316' }],
          warningSymptoms: ['Bulging eyes', 'Double vision', 'Eye pain', 'Vision loss'],
          preventable: false,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'antithyroid-drugs',
          name: 'Antithyroid Medications',
          modality: 'pharmacological',
          description: 'Drugs that block thyroid hormone production',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Block hormone production', 'Achieve remission (Graves\')', 'Prepare for definitive therapy'],
          timeToEffect: 'Weeks to months',
          explanations: {
            level1: 'Pills that stop your thyroid from making too much hormone. They help control your symptoms while deciding on long-term treatment.',
            level2: 'Methimazole or propylthiouracil blocks the thyroid\'s ability to make hormones. For Graves\' disease, taking them for 12-18 months may allow remission.',
            level3: 'Methimazole is preferred (once daily, less hepatotoxic). PTU preferred in first trimester pregnancy and thyroid storm. Monitor for agranulocytosis (0.2-0.5%).',
            level4: 'Start beta-blockers for symptom control while waiting for antithyroid effect. Check CBC and LFTs baseline. Warn about sore throat/fever - stop drug and check WBC immediately.',
            level5: 'Antithyroid drugs inhibit thyroid peroxidase. PTU also blocks peripheral T4 to T3 conversion (useful in storm). Remission more likely with small goiter, low TRAb, and mild disease.',
          },
        },
        {
          treatmentId: 'radioiodine-therapy',
          name: 'Radioactive Iodine Therapy',
          modality: 'interventional',
          description: 'Radioactive iodine destroys thyroid tissue',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established'],
          goals: ['Permanently reduce thyroid function', 'Definitive cure'],
          explanations: {
            level1: 'A one-time drink of radioactive iodine that is absorbed by your thyroid and destroys the overactive tissue. You will then take thyroid pills for life.',
            level2: 'The thyroid absorbs iodine to make hormones. Radioactive iodine is taken up and destroys thyroid cells. Most people become hypothyroid and need levothyroxine replacement.',
            level3: 'Single oral dose. Avoid pregnancy for 6-12 months. Most patients become hypothyroid within 6 months. May worsen Graves\' ophthalmopathy - consider steroid cover.',
            level4: 'Contraindicated in pregnancy. May exacerbate eye disease - glucocorticoid prophylaxis in moderate-severe ophthalmopathy. Achieve euthyroidism with methimazole first in severe disease.',
            level5: 'I-131 beta emission destroys follicular cells. Radiation thyroiditis may cause transient hyperthyroid flare. Higher doses needed for toxic multinodular goiter than Graves\'.',
          },
        },
        {
          treatmentId: 'thyroidectomy',
          name: 'Thyroidectomy',
          modality: 'surgical',
          description: 'Surgical removal of the thyroid gland',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established'],
          goals: ['Definitive cure', 'Immediate resolution'],
          explanations: {
            level1: 'Surgery to remove your thyroid gland. After surgery, you will take thyroid pills for life.',
            level2: 'Removing the thyroid provides definitive treatment, especially for large goiters or when radioiodine is not suitable.',
            level3: 'Total or near-total thyroidectomy. Preferred for: large goiter, suspicious nodules, moderate-severe Graves\' ophthalmopathy, pregnancy (2nd trimester). Requires experienced surgeon.',
            level4: 'Complications: hypoparathyroidism (transient 20%, permanent 1-2%), recurrent laryngeal nerve injury (<1% with experienced surgeon). Achieve euthyroidism pre-op.',
            level5: 'Total thyroidectomy preferred over subtotal to reduce recurrence risk. Monitor calcium post-op. Pre-operative Lugol\'s iodine may reduce vascularity.',
          },
        },
        {
          treatmentId: 'beta-blockers-thyroid',
          name: 'Beta-Blocker Therapy',
          modality: 'pharmacological',
          description: 'Symptomatic relief while awaiting treatment effect',
          efficacy: 'effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'severe'],
          goals: ['Control heart rate', 'Reduce tremor', 'Improve symptoms'],
          explanations: {
            level1: 'Medicines that slow your heart rate and reduce symptoms like tremor and palpitations while waiting for other treatments to work.',
            level2: 'Beta-blockers control symptoms quickly but do not fix the underlying thyroid problem. They are used alongside other treatments.',
            level3: 'Propranolol preferred (also blocks T4 to T3 conversion). Atenolol or metoprolol alternatives. Use in all symptomatic patients until euthyroid.',
            level4: 'Can use even with asthma in select cases (beta-1 selective). Non-selective beta-blockers reduce peripheral conversion. Continue until euthyroid achieved.',
            level5: 'Beta-blockers antagonize adrenergic effects of thyroid hormone excess. Propranolol also inhibits type 1 deiodinase. Essential adjunct but not definitive therapy.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'thyroid', structureName: 'Thyroid Gland', role: 'primary-site', involvement: 'Overproduces thyroid hormones', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'heart', structureName: 'Heart', role: 'target-organ', involvement: 'Target of excess hormone causing tachycardia', highlightColor: '#dc2626', showByDefault: true },
          { structureId: 'eyes', structureName: 'Eyes', role: 'secondary-site', involvement: 'Affected in Graves\' ophthalmopathy', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Endocrine', 'Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['endocrine'],
        focusRegion: 'head-neck',
      },
      explanations: {
        level1: 'Your thyroid gland is making too much hormone, causing your body to run too fast. Medication, radioactive iodine, or surgery can fix this.',
        level2: 'The thyroid controls your metabolism. When it produces too much hormone, everything speeds up - your heart races, you lose weight, and feel anxious. Treatment restores balance.',
        level3: 'Hyperthyroidism is diagnosed when TSH is suppressed with elevated T4/T3. Most common cause is Graves\' disease. Treatment options: antithyroid drugs, radioiodine, or surgery.',
        level4: 'TSI/TRAb confirms Graves\'. Radioiodine uptake differentiates Graves\' (high uptake) from thyroiditis (low uptake). Treatment choice depends on patient factors, local expertise, and preference.',
        level5: 'Graves\' disease involves TSH receptor-stimulating antibodies activating TSHR independent of TSH. Toxic nodular goiter involves somatic mutations (TSHR, Gsα) causing autonomous function. Destructive thyroiditis releases preformed hormone.',
      },
      relatedConditions: ['graves-disease', 'hypothyroidism', 'thyroid-nodules', 'atrial-fibrillation'],
      epidemiology: {
        prevalence: '1.3% prevalence; Graves\' most common cause',
        incidence: 'Graves\' peaks in 30-50 year olds',
        demographics: 'Women 5-10x more common than men',
      },
      clinicalPearls: [
        'Always check TSH first - it is the most sensitive test',
        'Radioiodine uptake scan differentiates causes: high = Graves\'/toxic nodule; low = thyroiditis',
        'Start beta-blockers for symptom control while awaiting definitive treatment',
        'Warn all patients on antithyroid drugs about sore throat/fever - stop drug and check WBC immediately',
        'Graves\' ophthalmopathy may worsen with radioiodine - consider steroids or surgery instead',
      ],
      patientEducation: [
        'If taking antithyroid drugs, report sore throat or fever immediately - it could indicate a rare but serious reaction',
        'Beta-blockers help with symptoms but do not treat the underlying problem',
        'Most patients eventually become hypothyroid and need thyroid hormone replacement',
        'If you have Graves\' disease, do not smoke - it makes eye disease worse',
        'Return for regular monitoring even after treatment - thyroid levels can change',
      ],
      emergencyWarnings: [
        'Extreme fever with rapid heart rate (thyroid storm - call 911)',
        'Very rapid or irregular heartbeat',
        'Severe weakness or confusion',
        'Sore throat or fever while taking antithyroid drugs (stop medication and seek care)',
        'Eye pain, double vision, or vision changes',
      ],
    },
  ],

  // Osteoarthritis
  [
    'osteoarthritis',
    {
      conditionId: 'osteoarthritis',
      name: 'Osteoarthritis',
      aliases: ['OA', 'Degenerative Joint Disease', 'Wear and Tear Arthritis'],
      icdCode: 'M19.90',
      category: 'musculoskeletal',
      subcategory: 'Joint Disease',
      description:
        'The most common form of arthritis, caused by breakdown of cartilage in joints. Results in pain, stiffness, and loss of function, most commonly affecting knees, hips, hands, and spine.',
      pathophysiology: {
        summary:
          'Progressive loss of articular cartilage with underlying bone changes, osteophyte formation, and synovial inflammation leads to pain and functional limitation.',
        mechanisms: [
          {
            name: 'Cartilage Degradation',
            description: 'Imbalance between cartilage synthesis and breakdown',
            systemsInvolved: ['Musculoskeletal'],
            keyMediators: ['MMPs', 'ADAMTS', 'IL-1', 'TNF-alpha'],
            contribution: 'primary',
          },
          {
            name: 'Subchondral Bone Changes',
            description: 'Bone sclerosis and cyst formation beneath damaged cartilage',
            systemsInvolved: ['Musculoskeletal'],
            contribution: 'secondary',
          },
          {
            name: 'Osteophyte Formation',
            description: 'Bone spurs form at joint margins as attempted repair',
            systemsInvolved: ['Musculoskeletal'],
            contribution: 'secondary',
          },
          {
            name: 'Synovial Inflammation',
            description: 'Low-grade inflammation contributes to pain and progression',
            systemsInvolved: ['Musculoskeletal', 'Immune'],
            keyMediators: ['Cytokines', 'Prostaglandins'],
            contribution: 'secondary',
          },
        ],
        riskFactors: [
          { name: 'Age', type: 'non-modifiable', impact: 'major', description: 'Risk increases substantially after age 50' },
          { name: 'Obesity', type: 'modifiable', impact: 'major', description: 'Excess weight increases joint stress', intervention: 'Weight loss' },
          { name: 'Joint Injury', type: 'partially-modifiable', impact: 'major', description: 'Prior injury increases OA risk', intervention: 'Injury prevention' },
          { name: 'Female Sex', type: 'non-modifiable', impact: 'moderate', description: 'Higher prevalence in women, especially after menopause' },
          { name: 'Genetics', type: 'non-modifiable', impact: 'moderate', description: 'Family history increases risk' },
          { name: 'Occupation', type: 'partially-modifiable', impact: 'moderate', description: 'Repetitive joint stress', intervention: 'Ergonomic modifications' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Joint Pain', prevalence: 'very-common', description: 'Pain that worsens with activity and improves with rest' },
          { name: 'Stiffness', prevalence: 'very-common', description: 'Morning stiffness lasting <30 minutes; stiffness after inactivity' },
          { name: 'Decreased Range of Motion', prevalence: 'common', description: 'Difficulty with full joint movement' },
        ],
        associatedSymptoms: [
          { name: 'Joint Swelling', prevalence: 'common', description: 'Bony enlargement or effusion' },
          { name: 'Crepitus', prevalence: 'common', description: 'Grinding or crackling sensation with movement' },
          { name: 'Joint Instability', prevalence: 'uncommon', description: 'Giving way, especially in knees' },
          { name: 'Weakness', prevalence: 'common', description: 'Muscle weakness from disuse' },
        ],
        physicalFindings: [
          { name: 'Bony Enlargement', examType: 'palpation', description: 'Heberden\'s (DIP) and Bouchard\'s (PIP) nodes in hands', diagnosticValue: 'Classic OA findings' },
          { name: 'Crepitus', examType: 'palpation', description: 'Grating sensation with joint movement', diagnosticValue: 'Suggests cartilage loss' },
          { name: 'Limited Range of Motion', examType: 'movement', description: 'Decreased flexion/extension', diagnosticValue: 'Common finding' },
          { name: 'Joint Line Tenderness', examType: 'palpation', description: 'Tenderness along joint margins', diagnosticValue: 'Common finding' },
          { name: 'Malalignment', examType: 'inspection', description: 'Varus (bow-legged) or valgus (knock-kneed) deformity', diagnosticValue: 'Indicates advanced disease' },
        ],
        labFindings: [
          { testName: 'X-ray', abnormality: 'Joint space narrowing, osteophytes, sclerosis, cysts', normalRange: 'Normal joint space, no osteophytes', significance: 'Confirms diagnosis and severity' },
          { testName: 'Laboratory Tests', abnormality: 'Usually normal', normalRange: 'Normal ESR, CRP, RF', significance: 'Normal labs help exclude inflammatory arthritis' },
          { testName: 'MRI', abnormality: 'Cartilage loss, bone marrow lesions, meniscal tears', normalRange: 'Intact cartilage', significance: 'More sensitive but rarely needed for diagnosis' },
        ],
      },
      progression: {
        naturalHistory:
          'OA is typically slowly progressive over years to decades. Rate varies significantly between individuals. Not all joints progress, and symptoms may stabilize.',
        timelineSteps: [
          {
            phaseId: 'early',
            phase: 'early',
            displayName: 'Early OA',
            timeframe: 'Years',
            description: 'Mild cartilage changes with intermittent symptoms',
            symptoms: ['Occasional pain with activity', 'Minimal stiffness'],
            anatomicalChanges: [
              { structureId: 'cartilage', structureName: 'Articular Cartilage', changeType: 'degeneration', description: 'Surface irregularities and early cartilage thinning', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Exercise', 'Weight loss if needed', 'Activity modification'],
          },
          {
            phaseId: 'moderate',
            phase: 'established',
            displayName: 'Moderate OA',
            timeframe: 'Years to decades',
            description: 'Significant cartilage loss with more consistent symptoms',
            symptoms: ['Regular pain with activity', 'Morning stiffness', 'Crepitus'],
            anatomicalChanges: [
              { structureId: 'cartilage', structureName: 'Articular Cartilage', changeType: 'degeneration', description: 'Significant cartilage loss with subchondral changes', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
              { structureId: 'bone', structureName: 'Subchondral Bone', changeType: 'degeneration', description: 'Osteophyte formation and sclerosis', severity: 'moderate', visualIndicator: { color: '#78716c', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Physical therapy', 'NSAIDs', 'Intra-articular injections'],
          },
          {
            phaseId: 'severe',
            phase: 'severe',
            displayName: 'Severe/End-Stage OA',
            timeframe: 'Progressive',
            description: 'Bone-on-bone contact with significant disability',
            symptoms: ['Constant pain', 'Severe functional limitation', 'Night pain', 'Deformity'],
            anatomicalChanges: [
              { structureId: 'cartilage', structureName: 'Articular Cartilage', changeType: 'necrosis', description: 'Complete cartilage loss (bone-on-bone)', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.8 }, isNewAtPhase: false },
              { structureId: 'joint', structureName: 'Joint Structure', changeType: 'structural-damage', description: 'Deformity and malalignment', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Joint replacement surgery', 'Pain management'],
          },
        ],
        prognosis:
          'Variable. Many patients maintain function with conservative treatment. Knee and hip OA may eventually require joint replacement. Hand OA often stabilizes.',
      },
      complications: [
        {
          complicationId: 'functional-disability',
          name: 'Functional Disability',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'high',
          description: 'Progressive difficulty with daily activities',
          mechanism: 'Pain and joint damage limit mobility',
          affectedStructures: [{ structureId: 'joints', structureName: 'Affected Joints', effect: 'Impaired function', highlightColor: '#f97316' }],
          warningSymptoms: ['Difficulty walking', 'Unable to climb stairs', 'Difficulty with ADLs'],
          preventable: true,
        },
        {
          complicationId: 'joint-deformity',
          name: 'Joint Deformity',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Malalignment from cartilage loss',
          mechanism: 'Asymmetric cartilage loss causes angular deformity',
          affectedStructures: [{ structureId: 'knee', structureName: 'Knee', effect: 'Varus or valgus deformity', highlightColor: '#dc2626' }],
          warningSymptoms: ['Visible bowing or angulation', 'Worsening pain with standing'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'exercise-oa',
          name: 'Exercise and Physical Therapy',
          modality: 'lifestyle',
          description: 'Strengthening and aerobic exercise to improve joint function',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'severe'],
          goals: ['Strengthen muscles', 'Improve range of motion', 'Reduce pain'],
          explanations: {
            level1: 'Exercise is one of the best treatments for arthritis. It strengthens muscles around the joint and helps with pain.',
            level2: 'Strong muscles support arthritic joints and reduce stress on them. Low-impact exercise like walking, swimming, and cycling is best.',
            level3: 'Quadriceps strengthening for knee OA; core and hip strengthening for hip OA. Aquatic therapy reduces joint loading. Aerobic exercise improves overall function.',
            level4: 'Exercise effect size comparable to NSAIDs for pain. Combining strengthening with aerobic exercise is most beneficial. Supervised therapy may be more effective than home programs initially.',
            level5: 'Exercise reduces IL-6 and TNF-alpha, increases proteoglycan synthesis in cartilage. Mechanical loading within physiologic range is chondroprotective. Muscle weakness precedes and predicts OA progression.',
          },
        },
        {
          treatmentId: 'weight-loss-oa',
          name: 'Weight Loss',
          modality: 'lifestyle',
          description: 'Reducing body weight to decrease joint stress',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Reduce joint loading', 'Improve function', 'Slow progression'],
          explanations: {
            level1: 'Losing weight takes pressure off your joints. Even a small amount of weight loss can make a big difference.',
            level2: 'Every pound you lose removes about 4 pounds of pressure on your knees. Weight loss also reduces inflammation throughout your body.',
            level3: 'Target 5-10% weight loss. IDEA trial showed diet + exercise superior to either alone. Weight loss may reduce need for surgery.',
            level4: 'Force multiplier effect: 1 lb weight loss = 4 lb reduction in knee load per step. Adipokines from fat tissue also promote cartilage degradation independent of mechanical load.',
            level5: 'Weight loss reduces leptin and inflammatory cytokines, improves adipokine profile. Combined with exercise, achieves greater symptom reduction than either alone. May slow structural progression.',
          },
        },
        {
          treatmentId: 'nsaids-oa',
          name: 'Anti-inflammatory Medications (NSAIDs)',
          modality: 'pharmacological',
          description: 'Medications to reduce pain and inflammation',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'severe'],
          goals: ['Reduce pain', 'Decrease inflammation', 'Improve function'],
          explanations: {
            level1: 'Anti-inflammatory pills like ibuprofen help reduce pain and swelling in arthritic joints.',
            level2: 'NSAIDs block the production of chemicals that cause pain and inflammation. They work well but should not be used long-term due to side effects.',
            level3: 'Use lowest effective dose for shortest duration. Topical NSAIDs preferred for localized OA (knee, hands). Consider GI and CV risk profile when selecting agent.',
            level4: 'Topical NSAIDs have similar efficacy to oral with fewer systemic effects. COX-2 selective agents (celecoxib) have lower GI risk but similar CV risk. Consider PPI co-therapy with oral NSAIDs.',
            level5: 'NSAIDs inhibit prostaglandin synthesis. Prostaglandins mediate pain sensitization and inflammation but also have gastroprotective and renal effects. Individual COX-2/COX-1 selectivity affects risk profile.',
          },
        },
        {
          treatmentId: 'intraarticular-injections',
          name: 'Intra-articular Injections',
          modality: 'interventional',
          description: 'Corticosteroid or hyaluronic acid injections into the joint',
          efficacy: 'effective',
          evidenceLevel: 'level-1b',
          isFirstLine: false,
          appropriatePhases: ['established', 'severe'],
          goals: ['Provide pain relief', 'Reduce inflammation', 'Delay surgery'],
          explanations: {
            level1: 'Injections of medication directly into the joint can provide relief when pills are not enough.',
            level2: 'Steroid injections reduce inflammation quickly but the effect is temporary. Hyaluronic acid injections may help lubricate the joint.',
            level3: 'Corticosteroids: rapid relief, effects last weeks-months, limit to 3-4/year per joint. Hyaluronic acid: more controversial, may benefit some patients.',
            level4: 'AAOS conditionally recommends against hyaluronic acid. Corticosteroids recommended. Repeated steroid injections may accelerate cartilage loss per recent studies - use judiciously.',
            level5: 'Corticosteroids suppress synovial inflammation and cytokine production. Recent concerns about accelerated cartilage loss with repeated injections. Hyaluronic acid may provide shock absorption but evidence mixed.',
          },
        },
        {
          treatmentId: 'joint-replacement',
          name: 'Total Joint Replacement',
          modality: 'surgical',
          description: 'Surgical replacement of damaged joint with prosthesis',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['severe'],
          goals: ['Eliminate pain', 'Restore function', 'Improve quality of life'],
          explanations: {
            level1: 'When other treatments no longer work, surgery to replace the worn-out joint can dramatically reduce pain and improve function.',
            level2: 'Total joint replacement removes damaged bone and cartilage and replaces them with metal and plastic components. Most people have excellent results.',
            level3: 'Consider when pain significantly impacts quality of life despite conservative treatment. Knee and hip replacement highly successful. Post-op PT essential.',
            level4: '90-95% of knee and hip replacements functioning well at 15-20 years. Avoid in too-young patients if possible due to revision risk. Optimize comorbidities pre-op.',
            level5: 'Modern implants have excellent survivorship. Minimally invasive and robotic-assisted techniques may improve precision. Patient-specific factors (BMI, diabetes) affect outcomes.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'knee', structureName: 'Knee Joint', role: 'primary-site', involvement: 'Most commonly affected joint', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'hip', structureName: 'Hip Joint', role: 'primary-site', involvement: 'Second most commonly affected large joint', highlightColor: '#f97316', showByDefault: true },
          { structureId: 'hands', structureName: 'Hand Joints', role: 'primary-site', involvement: 'DIP, PIP, and CMC commonly affected', highlightColor: '#f59e0b', showByDefault: false },
        ],
        systemsInvolved: ['Musculoskeletal'],
        recommendedView: 'anterior',
        recommendedLayers: ['skeletal'],
      },
      explanations: {
        level1: 'The cartilage that cushions your joints has worn down over time, causing pain and stiffness. Exercise, weight loss, and medications can help manage symptoms.',
        level2: 'Osteoarthritis is \"wear and tear\" arthritis. The smooth cartilage that allows joints to glide breaks down, causing bone to rub on bone. Unlike rheumatoid arthritis, it is not from the immune system attacking joints.',
        level3: 'OA is diagnosed clinically with characteristic symptoms (mechanical pain, brief morning stiffness) and X-ray findings (joint space narrowing, osteophytes, sclerosis). No lab markers. First-line: exercise, weight loss, and analgesics.',
        level4: 'ACR criteria: knee pain + 3 of (age >50, stiffness <30 min, crepitus, bony tenderness, bony enlargement, no warmth). X-ray severity does not correlate well with symptoms. MRI rarely needed.',
        level5: 'Pathophysiology involves chondrocyte dysfunction, altered matrix turnover, and subchondral bone changes. Low-grade synovitis contributes to pain. Mechanotransduction and inflammatory pathways both important therapeutic targets.',
      },
      relatedConditions: ['rheumatoid-arthritis', 'gout', 'bursitis'],
      epidemiology: {
        prevalence: '10-15% of adults over 60; increases with age',
        incidence: 'Most common cause of disability in older adults',
        demographics: 'More common in women, especially knee and hand OA',
      },
      clinicalPearls: [
        'Morning stiffness <30 minutes helps distinguish OA from inflammatory arthritis',
        'X-ray findings do not correlate well with symptoms - treat the patient, not the X-ray',
        'Exercise is as effective as NSAIDs for pain relief and has additional benefits',
        'Weight loss of just 5-10% can significantly reduce knee pain',
        'Topical NSAIDs are effective and safer than oral for localized OA',
      ],
      patientEducation: [
        'Exercise is one of the most effective treatments - find activities you enjoy that do not hurt your joints',
        'If overweight, losing even a small amount can significantly reduce pain',
        'Apply heat for stiffness, cold for swelling and pain',
        'Use assistive devices (canes, braces) as needed - they help, not harm',
        'Pace your activities - do not overdo it on good days',
      ],
      emergencyWarnings: [
        'Sudden severe joint swelling with redness and fever (may indicate infection)',
        'Joint that locks or gives way causing falls',
        'Rapidly worsening symptoms over days',
        'New numbness or weakness in limb',
      ],
    },
  ],

  // Rheumatoid Arthritis
  [
    'rheumatoid-arthritis',
    {
      conditionId: 'rheumatoid-arthritis',
      name: 'Rheumatoid Arthritis',
      aliases: ['RA', 'Inflammatory Arthritis'],
      icdCode: 'M06.9',
      category: 'musculoskeletal',
      subcategory: 'Autoimmune/Inflammatory',
      description:
        'A chronic autoimmune disease that causes inflammation in the joints, leading to pain, swelling, and potential joint damage. Unlike osteoarthritis, RA is caused by the immune system attacking joint tissue.',
      pathophysiology: {
        summary:
          'Autoimmune attack on synovial tissue causes chronic inflammation, synovial proliferation (pannus), and eventual destruction of cartilage and bone in affected joints.',
        mechanisms: [
          {
            name: 'Autoimmune Synovitis',
            description: 'T cells and B cells infiltrate the synovium, triggering chronic inflammation',
            systemsInvolved: ['Immune', 'Musculoskeletal'],
            keyMediators: ['TNF-alpha', 'IL-6', 'IL-1', 'Autoantibodies'],
            contribution: 'Primary driver of joint inflammation and destruction',
          },
          {
            name: 'Pannus Formation',
            description: 'Inflamed synovium proliferates into invasive granulation tissue',
            systemsInvolved: ['Musculoskeletal'],
            keyMediators: ['Fibroblast-like synoviocytes', 'MMPs'],
            contribution: 'Directly erodes cartilage and bone',
          },
          {
            name: 'Systemic Inflammation',
            description: 'Inflammatory cytokines affect organs beyond joints',
            systemsInvolved: ['Cardiovascular', 'Respiratory', 'Hematologic'],
            contribution: 'Causes fatigue, anemia, and increased cardiovascular risk',
          },
        ],
        riskFactors: [
          { name: 'Female Sex', type: 'non-modifiable', impact: 'major', description: '2-3x more common in women' },
          { name: 'Genetics', type: 'non-modifiable', impact: 'major', description: 'HLA-DR4 and other genetic factors' },
          { name: 'Smoking', type: 'modifiable', impact: 'major', description: 'Strongest modifiable risk factor; affects disease severity', intervention: 'Smoking cessation' },
          { name: 'Family History', type: 'non-modifiable', impact: 'moderate', description: 'First-degree relatives have 3-5x increased risk' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'Associated with disease activity and reduced treatment response', intervention: 'Weight management' },
        ],
        geneticFactors: ['HLA-DR4', 'PTPN22', 'STAT4'],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Symmetric Joint Pain', prevalence: 'very-common', description: 'Pain and tenderness in multiple joints, typically affecting both sides equally', location: 'Small joints of hands and feet initially' },
          { name: 'Morning Stiffness', prevalence: 'very-common', description: 'Joint stiffness lasting >1 hour after waking (longer than OA)', timing: 'Mornings, improves with activity' },
          { name: 'Joint Swelling', prevalence: 'very-common', description: 'Soft, boggy swelling of affected joints', quality: 'Warm, tender, puffy' },
        ],
        associatedSymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Profound tiredness from systemic inflammation' },
          { name: 'Low-Grade Fever', prevalence: 'common', description: 'Mild elevations during flares' },
          { name: 'Weight Loss', prevalence: 'common', description: 'Unintentional weight loss from chronic inflammation' },
        ],
        physicalFindings: [
          { name: 'Synovitis', examType: 'palpation', description: 'Boggy swelling over joints, especially MCPs and PIPs', diagnosticValue: 'Key finding' },
          { name: 'Warmth', examType: 'palpation', description: 'Joints feel warm compared to surrounding tissue', diagnosticValue: 'Indicates active inflammation' },
          { name: 'Ulnar Deviation', examType: 'inspection', description: 'Fingers drift toward ulnar side', diagnosticValue: 'Late finding of structural damage' },
          { name: 'Swan Neck/Boutonniere', examType: 'inspection', description: 'Characteristic finger deformities', diagnosticValue: 'Late findings' },
          { name: 'Rheumatoid Nodules', examType: 'palpation', description: 'Firm subcutaneous nodules over pressure points', diagnosticValue: 'Present in 20-30% of seropositive patients' },
        ],
        labFindings: [
          { testName: 'RF (Rheumatoid Factor)', abnormality: 'Positive', normalRange: '<14 IU/mL', significance: 'Present in 70-80% of RA patients; not specific' },
          { testName: 'Anti-CCP', abnormality: 'Positive', normalRange: 'Negative', significance: 'More specific than RF; predicts erosive disease' },
          { testName: 'ESR/CRP', abnormality: 'Elevated', normalRange: 'ESR <20 mm/hr, CRP <3 mg/L', significance: 'Markers of inflammation; track disease activity' },
          { testName: 'CBC', abnormality: 'Anemia of chronic disease, thrombocytosis', normalRange: 'Normal', significance: 'Reflects chronic inflammation' },
        ],
        imagingFindings: [
          { modality: 'X-ray', finding: 'Joint space narrowing, erosions, periarticular osteopenia', significance: 'Classic findings but may be absent early', structures: ['Hands', 'Feet'] },
          { modality: 'Ultrasound', finding: 'Synovial thickening, increased vascularity (power Doppler)', significance: 'Sensitive for early synovitis', structures: ['Joints'] },
          { modality: 'MRI', finding: 'Bone marrow edema, early erosions, synovitis', significance: 'Most sensitive for early changes', structures: ['Hands', 'Feet', 'Wrists'] },
        ],
      },
      progression: {
        naturalHistory:
          'Without treatment, RA typically progresses over months to years with joint destruction and disability. Modern DMARDs can achieve remission in many patients.',
        typicalOnsetToDiagnosis: '3-6 months',
        timelineSteps: [
          {
            phaseId: 'early',
            phase: 'early',
            displayName: 'Early RA',
            timeframe: '0-6 months',
            description: 'Initial joint symptoms without structural damage',
            symptoms: ['Joint pain and swelling', 'Morning stiffness >1 hour', 'Fatigue'],
            anatomicalChanges: [
              { structureId: 'hands-joints', structureName: 'Hand Joints (MCP, PIP)', changeType: 'inflammation', description: 'Synovial inflammation with swelling', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Methotrexate', 'NSAIDs', 'Low-dose prednisone'],
            goalsOfCare: ['Achieve remission or low disease activity', 'Prevent joint damage'],
          },
          {
            phaseId: 'established',
            phase: 'established',
            displayName: 'Established RA',
            timeframe: '6 months - 2 years',
            description: 'Ongoing inflammation with early erosive changes',
            symptoms: ['Persistent synovitis', 'Moderate disability', 'Systemic symptoms'],
            anatomicalChanges: [
              { structureId: 'hands-joints', structureName: 'Hand Joints', changeType: 'structural-damage', description: 'Early erosions and cartilage loss', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Methotrexate + biologic DMARD', 'Triple therapy'],
          },
          {
            phaseId: 'advanced',
            phase: 'advanced',
            displayName: 'Advanced RA',
            timeframe: '>2 years',
            description: 'Significant joint damage and deformity',
            symptoms: ['Joint deformities', 'Significant disability', 'Extra-articular manifestations'],
            anatomicalChanges: [
              { structureId: 'hands-joints', structureName: 'Hand Joints', changeType: 'degeneration', description: 'Severe erosions, joint destruction, deformity', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.8 }, isNewAtPhase: false },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Biologic DMARDs', 'JAK inhibitors', 'Surgical intervention'],
          },
        ],
        prognosis:
          'With modern treatment, many patients achieve remission or low disease activity. Early, aggressive treatment prevents joint damage.',
      },
      complications: [
        {
          complicationId: 'joint-destruction',
          name: 'Joint Destruction and Deformity',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Progressive destruction of cartilage and bone leading to deformity',
          mechanism: 'Chronic synovitis and pannus invasion erode cartilage and bone',
          affectedStructures: [{ structureId: 'hands-joints', structureName: 'Joints', effect: 'Erosions, subluxation, deformity', highlightColor: '#dc2626' }],
          warningSymptoms: ['Progressive joint deformity', 'Loss of function', 'Visible changes'],
          prevention: ['Early DMARD therapy', 'Treat to target'],
          preventable: true,
        },
        {
          complicationId: 'cardiovascular-ra',
          name: 'Cardiovascular Disease',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Increased risk of heart attack and stroke from chronic inflammation',
          mechanism: 'Systemic inflammation accelerates atherosclerosis',
          affectedStructures: [{ structureId: 'heart', structureName: 'Cardiovascular System', effect: 'Accelerated atherosclerosis', highlightColor: '#ef4444' }],
          warningSymptoms: ['Chest pain', 'Shortness of breath', 'Stroke symptoms'],
          prevention: ['Control disease activity', 'Manage traditional CV risk factors'],
          preventable: true,
        },
        {
          complicationId: 'interstitial-lung-disease-ra',
          name: 'Interstitial Lung Disease',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'low',
          description: 'Scarring of lung tissue from RA or medications',
          mechanism: 'Autoimmune inflammation affects lung interstitium',
          affectedStructures: [{ structureId: 'lungs', structureName: 'Lungs', effect: 'Interstitial fibrosis', highlightColor: '#78716c' }],
          warningSymptoms: ['Progressive shortness of breath', 'Dry cough', 'Exercise intolerance'],
          preventable: false,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'methotrexate-ra',
          name: 'Methotrexate',
          modality: 'pharmacological',
          description: 'Anchor drug for RA; disease-modifying antirheumatic drug (DMARD)',
          mechanism: 'Multiple anti-inflammatory mechanisms including folate antagonism',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'advanced'],
          goals: ['Reduce inflammation', 'Prevent joint damage', 'Achieve remission'],
          timeToEffect: '6-12 weeks for full effect',
          sideEffects: ['Nausea', 'Mouth sores', 'Liver toxicity', 'Bone marrow suppression'],
          monitoring: ['CBC', 'LFTs', 'Creatinine every 8-12 weeks'],
          explanations: {
            level1: 'Methotrexate is the main medication used to treat rheumatoid arthritis. It slows down the immune system attack on your joints.',
            level2: 'This medication is taken once weekly (not daily!) and can prevent long-term joint damage. You will need blood tests to monitor for side effects. Take folic acid to reduce side effects.',
            level3: 'Methotrexate is first-line csDMARD for RA. Start 10-15 mg/week, titrate to 20-25 mg. Use with folic acid 1 mg daily. Monitor for hepatotoxicity and cytopenias.',
            level4: 'Anchor drug per ACR/EULAR guidelines. Oral bioavailability decreases >15 mg - consider subcutaneous. Combination with biologics more effective than monotherapy for most.',
            level5: 'Mechanism not fully understood - adenosine release, polyglutamates, anti-proliferative effects all contribute. ATIC polymorphisms may predict response. Risk of lymphoproliferative disorders small but real.',
          },
        },
        {
          treatmentId: 'biologic-dmards',
          name: 'Biologic DMARDs',
          modality: 'pharmacological',
          description: 'Targeted therapies (TNF inhibitors, IL-6 inhibitors, etc.)',
          mechanism: 'Block specific inflammatory cytokines or cells',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established', 'advanced'],
          goals: ['Achieve remission', 'Prevent progression', 'Improve function'],
          timeToEffect: '2-12 weeks',
          explanations: {
            level1: 'If methotrexate alone is not enough, biologic medications target specific parts of the immune system causing inflammation.',
            level2: 'These are injections or infusions that block inflammatory chemicals like TNF-alpha or IL-6. They can make a dramatic difference for many people.',
            level3: 'TNF inhibitors (adalimumab, etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation blocker (abatacept), B-cell depleting (rituximab). Usually combined with MTX.',
            level4: 'Choose based on comorbidities, patient preference, and cost. Screen for TB and hepatitis B before starting. IL-6 inhibitors may mask infection signs.',
            level5: 'Biosimilars now available and cost-effective. JAK inhibitors (tofacitinib, upadacitinib) oral alternatives with similar efficacy but some safety concerns (VTE, malignancy).',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'hands-joints', structureName: 'Hand Joints (MCP, PIP)', role: 'primary-site', involvement: 'Classic early involvement', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'wrist', structureName: 'Wrist', role: 'primary-site', involvement: 'Commonly affected with synovitis', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'feet-joints', structureName: 'Foot Joints (MTP)', role: 'primary-site', involvement: 'Often affected early', highlightColor: '#f97316', showByDefault: false },
          { structureId: 'knee', structureName: 'Knee', role: 'secondary-site', involvement: 'Large joint may be affected', highlightColor: '#f59e0b', showByDefault: false },
        ],
        systemsInvolved: ['Musculoskeletal', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['skeletal', 'muscular'],
      },
      explanations: {
        level1: 'Your immune system is mistakenly attacking your joints, causing pain and swelling. Medications can calm this attack and prevent damage.',
        level2: 'Rheumatoid arthritis is an autoimmune disease where the body attacks its own joint tissue. Unlike "wear and tear" arthritis, it causes inflammation throughout the body and needs treatment with disease-modifying drugs, not just pain relievers.',
        level3: 'RA is characterized by symmetric polyarthritis, morning stiffness >1 hour, and positive RF/anti-CCP. Treat early and aggressively with MTX ± biologics. Goal is remission or low disease activity.',
        level4: 'ACR/EULAR 2010 criteria: score ≥6 points (joint involvement, serology, acute phase reactants, duration). Treat-to-target approach with CDAI/DAS28 monitoring. Early erosions predict poor outcomes.',
        level5: 'Complex pathophysiology involving citrullination, NETs, Th17 responses, and fibroblast-like synoviocyte activation. Seropositive and seronegative RA may have different mechanisms. Bone erosions from RANKL-mediated osteoclast activation.',
      },
      relatedConditions: ['osteoarthritis', 'psoriatic-arthritis', 'lupus'],
      epidemiology: {
        prevalence: '0.5-1% of adults worldwide',
        incidence: '~40 per 100,000 person-years',
        demographics: '2-3x more common in women; peak onset 40-60 years',
      },
      clinicalPearls: [
        'Morning stiffness >1 hour distinguishes RA from OA',
        'Anti-CCP is more specific than RF and predicts erosive disease',
        'Treat early and aggressively - window of opportunity in first 3-6 months',
        'Always combine methotrexate with folic acid to reduce side effects',
        'RA patients have 2x cardiovascular risk - manage aggressively',
      ],
      patientEducation: [
        'Take methotrexate once weekly on the same day - not daily!',
        'Report any fever, cough, or signs of infection promptly',
        'Exercise and physical therapy help maintain function',
        'Smoking makes RA worse and reduces treatment effectiveness - quitting helps',
        'Fatigue is a real symptom of RA - pace yourself and rest when needed',
      ],
      emergencyWarnings: [
        'High fever - may indicate serious infection (DMARDs suppress immunity)',
        'Sudden onset shortness of breath (lung disease or medication toxicity)',
        'New neck pain with numbness/weakness (cervical spine involvement)',
        'Severe abdominal pain (medication side effects)',
      ],
    },
  ],

  // Gout
  [
    'gout',
    {
      conditionId: 'gout',
      name: 'Gout',
      aliases: ['Gouty Arthritis', 'Crystal Arthritis', 'Podagra'],
      icdCode: 'M10.9',
      category: 'musculoskeletal',
      subcategory: 'Crystal Arthropathy',
      description:
        'A form of inflammatory arthritis caused by deposition of monosodium urate crystals in joints, typically causing sudden, severe attacks of pain, redness, and swelling.',
      pathophysiology: {
        summary:
          'Chronic hyperuricemia leads to urate crystal deposition in joints and soft tissues. Crystals trigger intense inflammatory response through NLRP3 inflammasome activation.',
        mechanisms: [
          {
            name: 'Hyperuricemia',
            description: 'Elevated uric acid levels exceed saturation point, allowing crystal formation',
            systemsInvolved: ['Metabolic', 'Renal'],
            keyMediators: ['Uric acid', 'Purine metabolism'],
            contribution: 'Prerequisite for crystal formation',
          },
          {
            name: 'Crystal Deposition',
            description: 'Monosodium urate crystals precipitate in joints and soft tissues',
            systemsInvolved: ['Musculoskeletal'],
            contribution: 'Creates substrate for inflammatory attacks',
          },
          {
            name: 'Inflammasome Activation',
            description: 'Crystals activate NLRP3 inflammasome in macrophages',
            systemsInvolved: ['Immune'],
            keyMediators: ['IL-1β', 'Neutrophils', 'NLRP3'],
            contribution: 'Drives intense acute inflammation',
          },
        ],
        riskFactors: [
          { name: 'High Purine Diet', type: 'modifiable', impact: 'moderate', description: 'Red meat, organ meats, shellfish, beer', intervention: 'Dietary modification' },
          { name: 'Alcohol', type: 'modifiable', impact: 'major', description: 'Beer and liquor increase uric acid', intervention: 'Limit or avoid alcohol' },
          { name: 'Obesity', type: 'modifiable', impact: 'major', description: 'Increases uric acid production and decreases excretion', intervention: 'Weight loss' },
          { name: 'Chronic Kidney Disease', type: 'partially-modifiable', impact: 'major', description: 'Reduced uric acid excretion' },
          { name: 'Diuretics', type: 'partially-modifiable', impact: 'moderate', description: 'Thiazides and loop diuretics raise uric acid', intervention: 'Consider alternatives' },
          { name: 'Male Sex', type: 'non-modifiable', impact: 'major', description: '3-4x more common in men' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Sudden Severe Joint Pain', prevalence: 'very-common', description: 'Explosive onset of excruciating pain, often waking patient at night', timing: 'Maximal within 12-24 hours' },
          { name: 'Joint Redness and Swelling', prevalence: 'very-common', description: 'Affected joint appears red, hot, and swollen', quality: 'Shiny, tense skin' },
          { name: 'Exquisite Tenderness', prevalence: 'very-common', description: 'Even light touch (bed sheet) is unbearable' },
        ],
        associatedSymptoms: [
          { name: 'Fever', prevalence: 'common', description: 'Low-grade fever during attacks' },
          { name: 'Malaise', prevalence: 'common', description: 'General feeling of illness' },
        ],
        physicalFindings: [
          { name: 'Monoarthritis', examType: 'inspection', description: 'Single joint involvement (classically first MTP - podagra)', diagnosticValue: 'Classic presentation' },
          { name: 'Erythema', examType: 'inspection', description: 'Bright red skin over joint', diagnosticValue: 'Characteristic finding' },
          { name: 'Tophi', examType: 'inspection/palpation', description: 'Chalky white deposits in chronic gout', diagnosticValue: 'Pathognomonic for chronic gout' },
        ],
        labFindings: [
          { testName: 'Serum Uric Acid', abnormality: 'Usually elevated (>6.8 mg/dL)', normalRange: '3.5-7.2 mg/dL', significance: 'May be normal during acute attack' },
          { testName: 'Joint Aspiration', abnormality: 'Negatively birefringent needle-shaped crystals', normalRange: 'No crystals', significance: 'Gold standard for diagnosis' },
          { testName: 'Inflammatory Markers', abnormality: 'Elevated ESR, CRP, WBC', normalRange: 'Normal', significance: 'Confirms acute inflammation' },
        ],
        imagingFindings: [
          { modality: 'X-ray', finding: 'Punched-out erosions with overhanging edges (chronic)', significance: 'Normal early; erosions in chronic gout', structures: ['Affected joints'] },
          { modality: 'Dual-energy CT', finding: 'Urate deposits in joints and soft tissue', significance: 'Can detect subclinical tophi', structures: ['Joints', 'Soft tissue'] },
          { modality: 'Ultrasound', finding: 'Double contour sign on cartilage', significance: 'Highly specific for gout', structures: ['Articular cartilage'] },
        ],
      },
      progression: {
        naturalHistory:
          'Attacks initially resolve completely but become more frequent and prolonged without treatment. Chronic tophaceous gout develops with persistent hyperuricemia.',
        timelineSteps: [
          {
            phaseId: 'acute-flare',
            phase: 'acute',
            displayName: 'Acute Gout Flare',
            timeframe: 'Hours to days',
            description: 'Sudden onset of severe inflammatory arthritis',
            symptoms: ['Severe pain', 'Redness', 'Swelling', 'Unable to bear weight'],
            anatomicalChanges: [
              { structureId: 'first-mtp', structureName: 'First MTP Joint (Big Toe)', changeType: 'inflammation', description: 'Intense inflammatory response to crystals', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['NSAIDs', 'Colchicine', 'Corticosteroids'],
          },
          {
            phaseId: 'intercritical',
            phase: 'remission',
            displayName: 'Intercritical Period',
            timeframe: 'Weeks to years',
            description: 'Symptom-free period between attacks',
            symptoms: ['None (asymptomatic)', 'Hyperuricemia persists'],
            anatomicalChanges: [
              { structureId: 'first-mtp', structureName: 'First MTP Joint', changeType: 'dysfunction', description: 'Subclinical crystal deposits remain', severity: 'mild', visualIndicator: { color: '#f59e0b', pulse: false, opacity: 0.3 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Urate-lowering therapy', 'Lifestyle modification'],
            goalsOfCare: ['Lower serum uric acid <6 mg/dL', 'Prevent future attacks'],
          },
          {
            phaseId: 'chronic-tophaceous',
            phase: 'chronic',
            displayName: 'Chronic Tophaceous Gout',
            timeframe: 'Years',
            description: 'Persistent symptoms with visible urate deposits',
            symptoms: ['Chronic joint pain', 'Visible tophi', 'Joint damage', 'Functional limitation'],
            anatomicalChanges: [
              { structureId: 'multiple-joints', structureName: 'Multiple Joints', changeType: 'structural-damage', description: 'Tophi with bone erosion', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Intensive urate-lowering therapy', 'Pegloticase', 'Surgery for tophi'],
          },
        ],
        prognosis:
          'Excellent with proper treatment. Urate-lowering therapy can dissolve tophi and prevent attacks. Untreated, leads to chronic pain and joint destruction.',
      },
      complications: [
        {
          complicationId: 'chronic-arthropathy',
          name: 'Chronic Gouty Arthropathy',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Persistent joint damage and deformity from years of attacks',
          mechanism: 'Cumulative damage from inflammation and tophi',
          affectedStructures: [{ structureId: 'joints', structureName: 'Affected Joints', effect: 'Erosions, destruction, deformity', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['Chronic pain', 'Visible deformity', 'Decreased function'],
          prevention: ['Maintain uric acid <6 mg/dL', 'Adherence to therapy'],
          preventable: true,
        },
        {
          complicationId: 'uric-acid-nephropathy',
          name: 'Uric Acid Nephropathy',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Kidney damage from uric acid crystal deposition',
          mechanism: 'Urate crystals deposit in renal tubules and interstitium',
          affectedStructures: [{ structureId: 'kidneys', structureName: 'Kidneys', effect: 'Chronic interstitial nephritis', highlightColor: '#f97316' }],
          warningSymptoms: ['Decreased urine output', 'Elevated creatinine', 'Kidney stones'],
          prevention: ['Adequate hydration', 'Urate-lowering therapy'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'nsaids-gout',
          name: 'NSAIDs for Acute Attack',
          modality: 'pharmacological',
          description: 'First-line treatment for acute gout flare',
          mechanism: 'Reduce inflammation by inhibiting prostaglandin synthesis',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute'],
          goals: ['Rapid pain relief', 'Reduce inflammation'],
          timeToEffect: '24-48 hours',
          contraindications: ['CKD', 'Active peptic ulcer', 'Heart failure'],
          explanations: {
            level1: 'Anti-inflammatory pain medications taken at the first sign of an attack can quickly reduce pain and swelling.',
            level2: 'NSAIDs like indomethacin or naproxen work best when started early in the attack. Take for 5-7 days until the attack resolves.',
            level3: 'Indomethacin 50 mg TID or naproxen 500 mg BID are traditional choices. COX-2 selective (celecoxib) option if GI concerns. Continue until attack resolves.',
            level4: 'NSAIDs equally effective. Start at full dose immediately - do not titrate up. Avoid in CKD, heart failure, or GI bleeding history.',
            level5: 'Mechanism: primarily inhibition of cyclooxygenase and prostaglandin synthesis. Crystal-induced inflammation also involves leukotriene pathways not affected by NSAIDs.',
          },
        },
        {
          treatmentId: 'colchicine-gout',
          name: 'Colchicine',
          modality: 'pharmacological',
          description: 'Anti-inflammatory specific for gout',
          mechanism: 'Inhibits neutrophil migration and inflammasome activation',
          efficacy: 'effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['acute', 'established'],
          goals: ['Abort acute attack', 'Prophylaxis during ULT initiation'],
          timeToEffect: '12-24 hours',
          explanations: {
            level1: 'Colchicine is a medication specifically for gout that works best when taken at the very first sign of an attack.',
            level2: 'Low-dose colchicine (1.2 mg then 0.6 mg one hour later) is effective and causes fewer stomach problems than the old high-dose regimens.',
            level3: 'AGREE trial established low-dose regimen: 1.2 mg followed by 0.6 mg in 1 hour. Also used for prophylaxis at 0.6 mg daily/BID when starting ULT.',
            level4: 'Efficacy drops significantly if started >24-36 hours into flare. Reduce dose in CKD. Avoid with strong CYP3A4 inhibitors (clarithromycin). Check for myopathy/neuropathy.',
            level5: 'Disrupts microtubule polymerization, inhibiting neutrophil chemotaxis and NLRP3 inflammasome assembly. Polyploidy-related GI effects limiting.',
          },
        },
        {
          treatmentId: 'allopurinol',
          name: 'Allopurinol',
          modality: 'pharmacological',
          description: 'First-line urate-lowering therapy',
          mechanism: 'Xanthine oxidase inhibitor - reduces uric acid production',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['remission', 'chronic'],
          goals: ['Lower serum uric acid <6 mg/dL', 'Prevent attacks', 'Dissolve tophi'],
          timeToEffect: 'Weeks to months; attack prevention after 3-6 months at target',
          explanations: {
            level1: 'This daily medication lowers the uric acid in your blood, which prevents future attacks and helps dissolve the crystite deposits.',
            level2: 'Allopurinol does not help during an attack - it is for long-term prevention. Start at a low dose and increase gradually. You may have more attacks at first, so take prophylaxis.',
            level3: 'Start low (100 mg daily, 50 mg if CKD), titrate every 2-4 weeks to target uric acid <6 mg/dL. Use colchicine or NSAID prophylaxis for 3-6 months.',
            level4: 'Start low to reduce flare risk (ALL study). HLA-B*5801 testing in high-risk populations (Asian, Black) before starting. Target <5 mg/dL for tophaceous gout.',
            level5: 'Inhibits xanthine oxidase, blocking conversion of hypoxanthine to xanthine to uric acid. Oxypurinol active metabolite renally excreted. DRESS syndrome rare but serious.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'first-mtp', structureName: 'First Metatarsophalangeal Joint (Big Toe)', role: 'primary-site', involvement: 'Classic "podagra" - most common site', highlightColor: '#dc2626', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'ankle', structureName: 'Ankle', role: 'secondary-site', involvement: 'Common alternative site', highlightColor: '#f97316', showByDefault: false },
          { structureId: 'knee', structureName: 'Knee', role: 'secondary-site', involvement: 'May be affected, especially in elderly', highlightColor: '#f59e0b', showByDefault: false },
        ],
        systemsInvolved: ['Musculoskeletal', 'Metabolic', 'Renal'],
        recommendedView: 'inferior',
        recommendedLayers: ['skeletal'],
        focusRegion: 'foot',
      },
      explanations: {
        level1: 'Gout is caused by too much uric acid in the blood, which forms tiny crystals in your joints. This causes sudden, severe pain attacks that can be treated and prevented.',
        level2: 'When uric acid levels get too high, crystals form in joints (especially the big toe). The immune system attacks these crystals, causing intense inflammation. Medications can treat attacks and prevent them by lowering uric acid.',
        level3: 'Diagnose by joint aspiration showing negatively birefringent needle-shaped crystals. Treat acute attacks with NSAIDs, colchicine, or steroids. Long-term: urate-lowering therapy (allopurinol, febuxostat) to target uric acid <6 mg/dL.',
        level4: 'ACR guidelines: initiate ULT for recurrent flares, tophi, or CKD with uric acid >9. Start low, go slow. Prophylaxis with colchicine for 3-6 months when initiating ULT to prevent mobilization flares.',
        level5: 'NLRP3 inflammasome activation by crystals leads to IL-1β release driving neutrophilic inflammation. MSU crystals also activate complement and TLR2/4. Trained immunity may explain flare triggers.',
      },
      relatedConditions: ['pseudogout', 'rheumatoid-arthritis', 'chronic-kidney-disease'],
      comorbidities: ['hypertension', 'diabetes', 'metabolic-syndrome', 'chronic-kidney-disease'],
      epidemiology: {
        prevalence: '3-4% of US adults; increasing',
        incidence: '2.7 per 1,000 person-years',
        demographics: '3-4x more common in men; postmenopausal women at increased risk',
      },
      clinicalPearls: [
        'Serum uric acid may be normal during acute attack - do not rule out gout based on this',
        'Joint aspiration is gold standard - "crystal proven" gout is the goal',
        'Start ULT low and titrate - flares at initiation are common and expected',
        'Do not stop ULT during an acute attack - treat the attack and continue',
        'Thiazides and loop diuretics are common culprits - review medication list',
      ],
      patientEducation: [
        'Limit red meat, organ meats, and shellfish (high in purines)',
        'Avoid or limit beer and liquor - wine in moderation may be okay',
        'Stay well hydrated - drink plenty of water',
        'Urate-lowering medication is for life - stopping leads to more attacks',
        'You may have more attacks when starting allopurinol - this is normal and temporary',
      ],
      emergencyWarnings: [
        'Fever with joint symptoms (may indicate septic arthritis)',
        'Multiple joints suddenly inflamed (may be infection or other condition)',
        'Rash after starting allopurinol (stop immediately - may be serious reaction)',
        'Attack not improving after 48 hours of treatment',
      ],
    },
  ],

  // Iron Deficiency Anemia
  [
    'iron-deficiency-anemia',
    {
      conditionId: 'iron-deficiency-anemia',
      name: 'Iron Deficiency Anemia',
      aliases: ['IDA', 'Anemia from Iron Deficiency'],
      icdCode: 'D50.9',
      category: 'hematologic',
      subcategory: 'Nutritional Anemia',
      description:
        'The most common cause of anemia worldwide, occurring when the body lacks sufficient iron to produce adequate hemoglobin for red blood cells.',
      pathophysiology: {
        summary:
          'Iron deficiency leads to inadequate hemoglobin synthesis, resulting in small (microcytic), pale (hypochromic) red blood cells with reduced oxygen-carrying capacity.',
        mechanisms: [
          {
            name: 'Depleted Iron Stores',
            description: 'Body\'s iron stores (ferritin) are exhausted before anemia develops',
            systemsInvolved: ['Hematologic', 'Hepatic'],
            contribution: 'Initial stage of iron deficiency',
          },
          {
            name: 'Impaired Hemoglobin Synthesis',
            description: 'Insufficient iron for heme synthesis leads to microcytic, hypochromic RBCs',
            systemsInvolved: ['Hematologic'],
            keyMediators: ['Iron', 'Transferrin', 'Ferritin', 'Hepcidin'],
            contribution: 'Direct cause of anemia',
          },
          {
            name: 'Tissue Iron Deficiency',
            description: 'Non-heme iron-dependent enzymes are impaired',
            systemsInvolved: ['Neurologic', 'Muscular'],
            contribution: 'Causes fatigue and other non-anemia symptoms',
          },
        ],
        riskFactors: [
          { name: 'Menstrual Blood Loss', type: 'partially-modifiable', impact: 'major', description: 'Most common cause in premenopausal women', intervention: 'Treat heavy periods' },
          { name: 'GI Blood Loss', type: 'partially-modifiable', impact: 'major', description: 'Occult bleeding from ulcers, cancer, etc.', intervention: 'Investigate and treat source' },
          { name: 'Poor Dietary Intake', type: 'modifiable', impact: 'moderate', description: 'Vegetarian/vegan diets, poor nutrition', intervention: 'Dietary counseling, supplementation' },
          { name: 'Malabsorption', type: 'partially-modifiable', impact: 'moderate', description: 'Celiac disease, gastric surgery, H. pylori', intervention: 'Treat underlying condition' },
          { name: 'Pregnancy', type: 'non-modifiable', impact: 'moderate', description: 'Increased iron demands' },
          { name: 'Frequent Blood Donation', type: 'modifiable', impact: 'moderate', description: 'Regular donors at risk', intervention: 'Iron supplementation' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Persistent tiredness and low energy due to reduced oxygen delivery' },
          { name: 'Weakness', prevalence: 'very-common', description: 'Generalized weakness affecting daily activities' },
          { name: 'Dyspnea on Exertion', prevalence: 'common', description: 'Shortness of breath with activity due to reduced oxygen-carrying capacity' },
        ],
        associatedSymptoms: [
          { name: 'Pica', prevalence: 'uncommon', description: 'Craving for non-food items (ice, dirt, starch)', quality: 'Pagophagia (ice craving) most common' },
          { name: 'Restless Legs', prevalence: 'common', description: 'Uncomfortable urge to move legs, especially at rest' },
          { name: 'Brittle Nails', prevalence: 'common', description: 'Nails become thin and break easily' },
          { name: 'Hair Loss', prevalence: 'common', description: 'Increased hair shedding' },
        ],
        physicalFindings: [
          { name: 'Pallor', examType: 'inspection', description: 'Pale conjunctivae, nail beds, palmar creases', diagnosticValue: 'Classic finding' },
          { name: 'Koilonychia', examType: 'inspection', description: 'Spoon-shaped nails', diagnosticValue: 'Specific but late finding' },
          { name: 'Angular Cheilitis', examType: 'inspection', description: 'Cracking at corners of mouth', diagnosticValue: 'Suggests iron deficiency' },
          { name: 'Glossitis', examType: 'inspection', description: 'Smooth, red tongue', diagnosticValue: 'Indicates nutritional deficiency' },
          { name: 'Tachycardia', examType: 'vital signs', description: 'Compensatory increased heart rate', diagnosticValue: 'Proportional to severity' },
        ],
        labFindings: [
          { testName: 'Hemoglobin', abnormality: 'Low', normalRange: 'M: 13.5-17.5, F: 12-16 g/dL', significance: 'Defines anemia' },
          { testName: 'MCV', abnormality: 'Low (<80 fL)', normalRange: '80-100 fL', significance: 'Microcytic anemia' },
          { testName: 'Ferritin', abnormality: 'Low (<30 ng/mL)', normalRange: '30-300 ng/mL', significance: 'Best single test for iron stores' },
          { testName: 'Serum Iron', abnormality: 'Low', normalRange: '60-170 mcg/dL', significance: 'Decreased in iron deficiency' },
          { testName: 'TIBC', abnormality: 'High', normalRange: '250-370 mcg/dL', significance: 'Increased when iron-deficient' },
          { testName: 'Transferrin Saturation', abnormality: 'Low (<20%)', normalRange: '20-50%', significance: 'Iron/TIBC; low in deficiency' },
          { testName: 'Peripheral Smear', abnormality: 'Microcytic, hypochromic RBCs', normalRange: 'Normocytic, normochromic', significance: 'Visual confirmation' },
        ],
      },
      progression: {
        naturalHistory:
          'Iron deficiency progresses through stages: depleted stores, iron-deficient erythropoiesis, then iron deficiency anemia. Reversible with treatment.',
        timelineSteps: [
          {
            phaseId: 'depleted-stores',
            phase: 'preclinical',
            displayName: 'Iron Depletion',
            timeframe: 'Early',
            description: 'Iron stores depleted but no anemia yet',
            symptoms: ['Usually asymptomatic', 'May have fatigue'],
            anatomicalChanges: [
              { structureId: 'bone-marrow', structureName: 'Bone Marrow', changeType: 'dysfunction', description: 'Absent iron stores on stain', severity: 'mild', visualIndicator: { color: '#f59e0b', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            labMarkers: ['Low ferritin', 'Normal Hgb'],
            reversibility: 'reversible',
          },
          {
            phaseId: 'iron-deficient-erythropoiesis',
            phase: 'early',
            displayName: 'Iron-Deficient Erythropoiesis',
            timeframe: 'Progressive',
            description: 'Insufficient iron for RBC production',
            symptoms: ['Mild fatigue', 'May be asymptomatic'],
            anatomicalChanges: [
              { structureId: 'bone-marrow', structureName: 'Bone Marrow', changeType: 'dysfunction', description: 'Impaired hemoglobin synthesis', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
            ],
            labMarkers: ['Low ferritin', 'Low serum iron', 'High TIBC', 'Hgb may be low-normal'],
            reversibility: 'reversible',
          },
          {
            phaseId: 'frank-anemia',
            phase: 'established',
            displayName: 'Iron Deficiency Anemia',
            timeframe: 'Progressive without treatment',
            description: 'Frank anemia with microcytosis',
            symptoms: ['Fatigue', 'Dyspnea', 'Pica', 'Poor concentration'],
            anatomicalChanges: [
              { structureId: 'red-blood-cells', structureName: 'Red Blood Cells', changeType: 'atrophy', description: 'Microcytic, hypochromic cells', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            labMarkers: ['Low Hgb', 'Low MCV', 'Low ferritin', 'Low iron, high TIBC'],
            reversibility: 'reversible',
            typicalTreatments: ['Oral iron supplementation', 'Treat underlying cause'],
          },
          {
            phaseId: 'severe-anemia',
            phase: 'severe',
            displayName: 'Severe Anemia',
            timeframe: 'Advanced disease',
            description: 'Significantly reduced hemoglobin with major symptoms',
            symptoms: ['Severe fatigue', 'Dyspnea at rest', 'Tachycardia', 'Angina possible'],
            anatomicalChanges: [
              { structureId: 'heart', structureName: 'Heart', changeType: 'hypertrophy', description: 'Compensatory cardiac output increase', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['IV iron', 'Consider transfusion if symptomatic'],
          },
        ],
        prognosis:
          'Excellent with treatment. Iron supplementation replenishes stores within months. Finding and treating the underlying cause is essential.',
      },
      complications: [
        {
          complicationId: 'high-output-heart-failure',
          name: 'High-Output Heart Failure',
          category: 'acute',
          severity: 'major',
          riskLevel: 'low',
          description: 'Heart failure from chronic compensation for severe anemia',
          mechanism: 'Prolonged increased cardiac output leads to ventricular dysfunction',
          affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'Ventricular dilation and dysfunction', highlightColor: '#dc2626' }],
          warningSymptoms: ['Severe dyspnea', 'Peripheral edema', 'Orthopnea'],
          prevention: ['Early recognition and treatment', 'Transfusion if severe'],
          preventable: true,
        },
        {
          complicationId: 'cognitive-impairment',
          name: 'Cognitive and Developmental Effects',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Impaired cognition and development, especially in children',
          mechanism: 'Iron essential for neurotransmitter synthesis and myelination',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Impaired cognitive function', highlightColor: '#8b5cf6' }],
          warningSymptoms: ['Poor concentration', 'Developmental delays', 'Poor school performance'],
          prevention: ['Screen and treat promptly'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'oral-iron',
          name: 'Oral Iron Supplementation',
          modality: 'pharmacological',
          description: 'First-line treatment with ferrous sulfate or other oral preparations',
          mechanism: 'Replaces depleted iron stores; absorbed in duodenum',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Replenish iron stores', 'Normalize hemoglobin', 'Resolve symptoms'],
          timeToEffect: 'Hemoglobin rises 1 g/dL per 2-3 weeks; stores replenish over 3-6 months',
          sideEffects: ['GI upset', 'Constipation', 'Dark stools', 'Nausea'],
          explanations: {
            level1: 'Iron pills are the main treatment. They will bring your iron levels and red blood cells back to normal over a few months.',
            level2: 'Take iron on an empty stomach with vitamin C (orange juice) for best absorption. Side effects like constipation are common but manageable. Your stool will turn dark - this is normal.',
            level3: 'Ferrous sulfate 325 mg (65 mg elemental iron) daily to TID. Alternate day dosing may improve absorption and tolerability. Continue 3-6 months after hemoglobin normalizes to replenish stores.',
            level4: 'Recent data supports alternate-day dosing due to hepcidin kinetics. Ferric maltol and polysaccharide-iron complex better tolerated but may be less effective. Check reticulocyte count at 1-2 weeks.',
            level5: 'Hepcidin rises with iron dosing, blocking absorption for 24-48 hours, supporting alternate-day regimens. DMT-1 and ferroportin are rate-limiting. Inhibitors: tea, coffee, calcium, PPIs.',
          },
        },
        {
          treatmentId: 'iv-iron',
          name: 'Intravenous Iron',
          modality: 'pharmacological',
          description: 'Parenteral iron for malabsorption, intolerance, or rapid repletion',
          mechanism: 'Bypasses GI absorption; directly available for erythropoiesis',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established', 'severe'],
          goals: ['Rapid iron repletion', 'Bypass malabsorption'],
          timeToEffect: 'Faster than oral; Hgb response in 1-2 weeks',
          explanations: {
            level1: 'If iron pills do not work or cause too many side effects, iron can be given through a vein (IV) instead.',
            level2: 'IV iron works faster than pills and is useful when you cannot absorb iron or have very low levels. It is given as an infusion, often just one or two visits.',
            level3: 'Modern formulations (ferric carboxymaltose, iron isomaltoside) allow single-dose repletion of 1000+ mg. Low molecular weight iron dextran, ferumoxytol also options. Premedication not routinely needed.',
            level4: 'Preferred in CKD, IBD, post-bariatric surgery, heart failure, active bleeding. Calculate dose based on weight and target Hgb. Monitor for hypophosphatemia with ferric carboxymaltose.',
            level5: 'IV iron taken up by macrophages, then released to transferrin. Newer formulations have dextran-free matrices reducing anaphylaxis risk. Fishbane reaction (flushing, chest tightness) self-limited, not allergic.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'bone-marrow', structureName: 'Bone Marrow', role: 'primary-site', involvement: 'Site of impaired RBC production', highlightColor: '#dc2626', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'red-blood-cells', structureName: 'Red Blood Cells', role: 'target-organ', involvement: 'Microcytic, hypochromic cells', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'gi-tract', structureName: 'GI Tract', role: 'secondary-site', involvement: 'Often source of blood loss', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Hematologic', 'Cardiovascular', 'Gastrointestinal'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular'],
      },
      explanations: {
        level1: 'Your body does not have enough iron to make healthy red blood cells. This makes you feel tired because your blood cannot carry enough oxygen. Iron pills can fix this.',
        level2: 'Iron is needed to make hemoglobin, the protein in red blood cells that carries oxygen. Without enough iron, your body makes smaller, paler red cells that are less effective. Finding why you are low on iron is important.',
        level3: 'IDA presents with microcytic, hypochromic anemia. Diagnose with low ferritin (<30), low iron, high TIBC. Always identify the cause - in men and postmenopausal women, GI workup is essential to rule out occult malignancy.',
        level4: 'Ferritin is acute phase reactant - may be falsely normal with inflammation. In this setting, use transferrin saturation <20%, or check soluble transferrin receptor. Reticulocyte Hgb content detects early deficiency.',
        level5: 'Iron homeostasis regulated by hepcidin - suppressed in iron deficiency allowing absorption. Erythroferrone (ERFE) from erythroblasts suppresses hepcidin during increased erythropoiesis. HIF pathway activates with hypoxia.',
      },
      relatedConditions: ['anemia-chronic-disease', 'thalassemia', 'gi-bleeding'],
      epidemiology: {
        prevalence: '~2% in US adults; up to 50% in developing countries',
        incidence: 'Most common nutritional deficiency worldwide',
        demographics: 'Most common in premenopausal women, children, elderly',
      },
      clinicalPearls: [
        'Ferritin is the best single test - low ferritin is virtually diagnostic',
        'In men and postmenopausal women, assume GI blood loss until proven otherwise',
        'Do not start iron until you have a plan to find the cause',
        'Check reticulocyte count at 1-2 weeks to assess response to therapy',
        'Pica (especially ice craving) is highly suggestive of iron deficiency',
      ],
      patientEducation: [
        'Take iron on an empty stomach if tolerated, with orange juice or vitamin C',
        'Avoid taking iron with tea, coffee, calcium, or antacids - they block absorption',
        'Continue iron for 3-6 months after your blood tests normalize to refill stores',
        'Dark stools are normal and expected - do not stop taking the iron',
        'Return if you notice blood in stool, black tarry stools, or heavy menstrual bleeding',
      ],
      emergencyWarnings: [
        'Signs of severe anemia: chest pain, severe shortness of breath, lightheadedness',
        'Black, tarry stools (melena) - may indicate GI bleeding',
        'Vomiting blood',
        'Heavy menstrual bleeding soaking a pad every hour',
      ],
    },
  ],

  // Multiple Sclerosis
  [
    'multiple-sclerosis',
    {
      conditionId: 'multiple-sclerosis',
      name: 'Multiple Sclerosis',
      aliases: ['MS', 'Disseminated Sclerosis'],
      icdCode: 'G35',
      category: 'neurologic',
      subcategory: 'Demyelinating Disease',
      description:
        'A chronic autoimmune disease affecting the central nervous system, where the immune system attacks myelin (the protective covering of nerve fibers), causing communication problems between the brain and body.',
      pathophysiology: {
        summary:
          'Autoimmune inflammation targets CNS myelin, causing demyelination, axonal damage, and gliosis (scarring). Results in impaired nerve signal transmission.',
        mechanisms: [
          {
            name: 'Autoimmune Demyelination',
            description: 'T cells and B cells attack myelin sheaths in the CNS',
            systemsInvolved: ['Immune', 'Neurologic'],
            keyMediators: ['Autoreactive T cells', 'B cells', 'Cytokines', 'Antibodies'],
            contribution: 'Primary mechanism of disease',
          },
          {
            name: 'Inflammation',
            description: 'Inflammatory lesions (plaques) form in white matter',
            systemsInvolved: ['Neurologic'],
            keyMediators: ['IL-17', 'IFN-gamma', 'TNF-alpha'],
            contribution: 'Causes acute symptoms during relapses',
          },
          {
            name: 'Axonal Degeneration',
            description: 'Progressive damage to nerve fibers themselves',
            systemsInvolved: ['Neurologic'],
            contribution: 'Drives disability accumulation',
          },
        ],
        riskFactors: [
          { name: 'Genetics', type: 'non-modifiable', impact: 'moderate', description: 'HLA-DRB1*15:01 and other genes; family history increases risk 10-20x' },
          { name: 'Vitamin D Deficiency', type: 'modifiable', impact: 'moderate', description: 'Low vitamin D associated with higher risk', intervention: 'Supplementation' },
          { name: 'EBV Infection', type: 'non-modifiable', impact: 'major', description: 'Prior EBV infection strongly associated; may be necessary cause' },
          { name: 'Smoking', type: 'modifiable', impact: 'moderate', description: 'Increases risk and disease progression', intervention: 'Smoking cessation' },
          { name: 'Northern Latitude', type: 'non-modifiable', impact: 'moderate', description: 'Higher prevalence farther from equator' },
          { name: 'Female Sex', type: 'non-modifiable', impact: 'moderate', description: '2-3x more common in women' },
        ],
        environmentalFactors: ['Low sunlight/vitamin D', 'EBV infection', 'Smoking', 'Obesity in adolescence'],
        geneticFactors: ['HLA-DRB1*15:01', 'IL7R', 'IL2RA'],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Visual Disturbances', prevalence: 'very-common', description: 'Blurred vision, double vision, or loss of vision (optic neuritis)', timing: 'Often first symptom' },
          { name: 'Numbness/Tingling', prevalence: 'very-common', description: 'Sensory symptoms in limbs, face, or trunk', quality: 'Pins and needles, band-like sensation' },
          { name: 'Weakness', prevalence: 'very-common', description: 'Motor weakness affecting limbs', location: 'Variable depending on lesion location' },
          { name: 'Fatigue', prevalence: 'very-common', description: 'Profound fatigue disproportionate to activity', timing: 'Often worse in heat' },
        ],
        associatedSymptoms: [
          { name: 'Gait Difficulties', prevalence: 'common', description: 'Unsteady walking, balance problems' },
          { name: 'Bladder Dysfunction', prevalence: 'common', description: 'Urgency, frequency, incontinence' },
          { name: 'Cognitive Changes', prevalence: 'common', description: 'Memory, attention, processing speed affected' },
          { name: 'Lhermitte Sign', prevalence: 'uncommon', description: 'Electric shock sensation down spine with neck flexion' },
          { name: 'Uhthoff Phenomenon', prevalence: 'common', description: 'Worsening of symptoms with heat' },
        ],
        physicalFindings: [
          { name: 'Optic Disc Pallor', examType: 'fundoscopy', description: 'Pale optic disc from prior optic neuritis', diagnosticValue: 'Suggests prior demyelinating event' },
          { name: 'Internuclear Ophthalmoplegia', examType: 'eye movements', description: 'Impaired adduction with nystagmus of abducting eye', diagnosticValue: 'Highly suggestive of MS' },
          { name: 'Hyperreflexia', examType: 'reflexes', description: 'Brisk reflexes in affected limbs', diagnosticValue: 'Upper motor neuron sign' },
          { name: 'Babinski Sign', examType: 'reflexes', description: 'Upgoing plantar response', diagnosticValue: 'Upper motor neuron sign' },
          { name: 'Cerebellar Signs', examType: 'coordination', description: 'Intention tremor, ataxia, dysarthria', diagnosticValue: 'Indicates cerebellar involvement' },
        ],
        labFindings: [
          { testName: 'MRI Brain/Spine', abnormality: 'White matter lesions, gadolinium enhancement', normalRange: 'No lesions', significance: 'Key diagnostic tool' },
          { testName: 'CSF Analysis', abnormality: 'Oligoclonal bands, elevated IgG index', normalRange: 'No OCBs', significance: 'Supports CNS inflammation' },
          { testName: 'Evoked Potentials', abnormality: 'Delayed responses', normalRange: 'Normal latencies', significance: 'Detects subclinical demyelination' },
        ],
        imagingFindings: [
          { modality: 'MRI Brain', finding: 'Periventricular, juxtacortical, infratentorial white matter lesions', significance: 'McDonald criteria requires dissemination in space', structures: ['White matter'] },
          { modality: 'MRI Spine', finding: 'Spinal cord lesions (typically short segment)', significance: 'Common site of involvement', structures: ['Spinal cord'] },
          { modality: 'MRI with contrast', finding: 'Gadolinium-enhancing lesions indicate active inflammation', significance: 'Dissemination in time', structures: ['CNS'] },
        ],
      },
      progression: {
        naturalHistory:
          '85% start with relapsing-remitting MS (RRMS). Without treatment, most convert to secondary progressive MS (SPMS) over 15-20 years.',
        timelineSteps: [
          {
            phaseId: 'cis',
            phase: 'preclinical',
            displayName: 'Clinically Isolated Syndrome',
            timeframe: 'First episode',
            description: 'First demyelinating event; may or may not progress to MS',
            symptoms: ['Single neurological episode', 'Optic neuritis, transverse myelitis, or brainstem syndrome'],
            anatomicalChanges: [
              { structureId: 'optic-nerve', structureName: 'Optic Nerve (example)', changeType: 'inflammation', description: 'Demyelinating lesion', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['High-dose steroids', 'Consider DMT if high-risk MRI'],
          },
          {
            phaseId: 'rrms',
            phase: 'established',
            displayName: 'Relapsing-Remitting MS',
            timeframe: 'Years to decades',
            description: 'Episodes of new/worsening symptoms followed by recovery',
            symptoms: ['Relapses (flares)', 'Variable recovery', 'Periods of stability'],
            anatomicalChanges: [
              { structureId: 'brain-white-matter', structureName: 'Brain White Matter', changeType: 'inflammation', description: 'Multiple demyelinating plaques', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Disease-modifying therapies', 'Steroids for relapses'],
            goalsOfCare: ['Reduce relapse frequency', 'Prevent disability accumulation'],
          },
          {
            phaseId: 'spms',
            phase: 'advanced',
            displayName: 'Secondary Progressive MS',
            timeframe: '15-20 years after RRMS onset',
            description: 'Gradual worsening without distinct relapses',
            symptoms: ['Progressive disability', 'Fewer distinct relapses', 'Walking difficulty common'],
            anatomicalChanges: [
              { structureId: 'brain-white-matter', structureName: 'Brain and Spinal Cord', changeType: 'atrophy', description: 'Brain atrophy, axonal loss', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Siponimod, ocrelizumab if still active', 'Symptomatic management'],
          },
        ],
        prognosis:
          'Highly variable. Modern DMTs dramatically reduce relapses and disability. Some patients remain minimally affected for decades; others progress more rapidly.',
      },
      complications: [
        {
          complicationId: 'mobility-disability',
          name: 'Mobility Impairment',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Progressive difficulty walking and mobility',
          mechanism: 'Accumulated damage to motor pathways in brain and spinal cord',
          affectedStructures: [{ structureId: 'spinal-cord', structureName: 'Spinal Cord', effect: 'Corticospinal tract damage', highlightColor: '#dc2626' }],
          warningSymptoms: ['Progressive leg weakness', 'Need for assistive devices', 'Falls'],
          prevention: ['Effective DMT', 'Physical therapy', 'Exercise'],
          preventable: true,
        },
        {
          complicationId: 'bladder-dysfunction-ms',
          name: 'Neurogenic Bladder',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Bladder control problems from spinal cord involvement',
          mechanism: 'Demyelination affects bladder control pathways',
          affectedStructures: [{ structureId: 'bladder', structureName: 'Bladder', effect: 'Detrusor dysfunction', highlightColor: '#f97316' }],
          warningSymptoms: ['Urgency', 'Frequency', 'Incontinence', 'Retention'],
          treatment: 'Antimuscarinics, botox, intermittent catheterization',
          preventable: false,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'dmt-ms',
          name: 'Disease-Modifying Therapies',
          modality: 'pharmacological',
          description: 'Medications that reduce relapse frequency and slow disability',
          mechanism: 'Modulate or suppress immune system to reduce CNS inflammation',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['established'],
          goals: ['Reduce relapses', 'Prevent new lesions', 'Slow disability'],
          explanations: {
            level1: 'Medications taken regularly help calm your immune system so it attacks your nerves less often. This prevents future damage.',
            level2: 'Disease-modifying therapies (DMTs) reduce how often you have MS attacks and slow down the disease. There are many options - pills, injections, or infusions.',
            level3: 'High-efficacy DMTs (natalizumab, ocrelizumab, alemtuzumab) most effective. Platform therapies (interferons, glatiramer) less effective but safer. Treat early and effectively.',
            level4: 'Escalation vs. induction approaches debated. NEDA (no evidence of disease activity) as treatment goal. Consider patient factors, JC virus status for natalizumab.',
            level5: 'Mechanisms vary: interferons immunomodulatory, fingolimod S1P receptor modulation, natalizumab anti-VLA4 blocks lymphocyte migration, ocrelizumab B-cell depletion.',
          },
        },
        {
          treatmentId: 'steroids-ms-relapse',
          name: 'High-Dose Corticosteroids',
          modality: 'pharmacological',
          description: 'Treatment for acute MS relapses',
          mechanism: 'Reduces acute inflammation; speeds relapse recovery',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute', 'established'],
          goals: ['Speed recovery from relapse', 'Reduce relapse severity'],
          timeToEffect: 'Days',
          explanations: {
            level1: 'When you have an MS attack, a short course of strong anti-inflammatory medication can help you recover faster.',
            level2: 'High-dose steroids (usually IV methylprednisolone) are given for 3-5 days during a relapse. They speed recovery but do not change long-term outcome.',
            level3: 'Methylprednisolone 1g IV daily x 3-5 days. Oral prednisone taper sometimes added. High-dose oral steroids may be alternative in some patients.',
            level4: 'Speeds recovery but does not improve final outcome. Reserve for functionally significant relapses. ACTH gel rarely used alternative.',
            level5: 'Steroids reduce BBB permeability, decrease inflammatory cell migration, and induce T-cell apoptosis. MRI enhancement resolves faster but does not correlate with functional recovery.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'brain-white-matter', structureName: 'Brain White Matter', role: 'primary-site', involvement: 'Site of demyelinating plaques', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'spinal-cord', structureName: 'Spinal Cord', role: 'primary-site', involvement: 'Common site of lesions', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'optic-nerve', structureName: 'Optic Nerve', role: 'secondary-site', involvement: 'Optic neuritis common', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Neurologic', 'Immune'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
      },
      explanations: {
        level1: 'Your immune system is mistakenly attacking the coating on your nerves. This causes problems with how your brain talks to your body. Medications can help calm your immune system.',
        level2: 'MS causes your immune system to attack myelin, the protective covering on nerve fibers. This creates "scars" that block nerve signals, causing symptoms like vision problems, numbness, and weakness. Modern treatments can dramatically reduce attacks.',
        level3: 'MS is diagnosed using McDonald criteria: dissemination in space (multiple CNS locations) and time (multiple events). MRI is key. DMTs reduce relapses and disability - "time is brain."',
        level4: 'McDonald 2017 criteria allow earlier diagnosis. OCBs can substitute for DIT. High-efficacy DMT early may be superior to escalation. NEDA an important treatment goal. Monitor for PML with natalizumab.',
        level5: 'Pathogenesis involves CD4 and CD8 T cells, B cells (ocrelizumab efficacy proves role), and innate immunity. EBV necessary but not sufficient. Cortical lesions and meningeal inflammation drive progression.',
      },
      relatedConditions: ['neuromyelitis-optica', 'optic-neuritis', 'transverse-myelitis'],
      epidemiology: {
        prevalence: '~1 million in US; 2.8 million worldwide',
        incidence: '3-5 per 100,000 person-years',
        demographics: '2-3x more common in women; peak onset 20-40 years',
      },
      clinicalPearls: [
        'Internuclear ophthalmoplegia is highly suggestive of MS in young patients',
        'Uhthoff phenomenon (heat worsening) is classic',
        'MRI is more sensitive than clinical exam for disease activity',
        'Start DMT early - window of opportunity matters',
        'Fatigue is the most common disabling symptom - treat it',
      ],
      patientEducation: [
        'MS is manageable - many people live full, active lives',
        'Take your disease-modifying therapy consistently - it prevents future damage',
        'Avoid overheating - it can temporarily worsen symptoms',
        'Report new or worsening symptoms promptly - early treatment of relapses helps',
        'Stay active - exercise improves many MS symptoms and overall health',
      ],
      emergencyWarnings: [
        'Sudden severe vision loss',
        'Rapid onset weakness or inability to walk',
        'Loss of bladder/bowel control',
        'Symptoms suggesting relapse not improving with steroids',
      ],
    },
  ],

  // Appendicitis
  [
    'appendicitis',
    {
      conditionId: 'appendicitis',
      name: 'Appendicitis',
      aliases: ['Acute Appendicitis', 'Inflamed Appendix'],
      icdCode: 'K35.80',
      category: 'gastrointestinal',
      subcategory: 'Acute Abdomen',
      description:
        'Inflammation of the appendix, typically causing acute abdominal pain that classically starts around the navel and moves to the lower right abdomen. A surgical emergency if not treated.',
      pathophysiology: {
        summary:
          'Obstruction of the appendiceal lumen (usually by fecalith or lymphoid hyperplasia) leads to bacterial overgrowth, inflammation, and risk of perforation.',
        mechanisms: [
          {
            name: 'Luminal Obstruction',
            description: 'Blockage of appendix lumen by fecalith, lymphoid tissue, or other cause',
            systemsInvolved: ['Gastrointestinal'],
            contribution: 'Initiating event in most cases',
          },
          {
            name: 'Bacterial Proliferation',
            description: 'Trapped bacteria multiply in obstructed appendix',
            systemsInvolved: ['Gastrointestinal', 'Immune'],
            keyMediators: ['E. coli', 'Bacteroides', 'Enterococci'],
            contribution: 'Drives inflammatory response',
          },
          {
            name: 'Vascular Compromise',
            description: 'Increased intraluminal pressure compromises blood flow',
            systemsInvolved: ['Gastrointestinal'],
            contribution: 'Leads to ischemia and risk of perforation',
          },
        ],
        riskFactors: [
          { name: 'Age 10-30', type: 'non-modifiable', impact: 'major', description: 'Peak incidence in this age group' },
          { name: 'Male Sex', type: 'non-modifiable', impact: 'minor', description: 'Slightly higher risk in males' },
          { name: 'Low Fiber Diet', type: 'modifiable', impact: 'minor', description: 'May contribute to fecalith formation', intervention: 'High-fiber diet' },
          { name: 'Family History', type: 'non-modifiable', impact: 'minor', description: 'Some familial clustering observed' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Periumbilical Pain Moving to RLQ', prevalence: 'very-common', description: 'Classic migration of pain from around navel to right lower quadrant over 12-24 hours', timing: 'Typically over 12-24 hours' },
          { name: 'Anorexia', prevalence: 'very-common', description: 'Loss of appetite is nearly universal' },
          { name: 'Nausea/Vomiting', prevalence: 'common', description: 'Typically begins after pain (if vomiting before pain, consider other diagnoses)' },
        ],
        associatedSymptoms: [
          { name: 'Low-Grade Fever', prevalence: 'common', description: 'Temperature 99-101°F; higher suggests perforation' },
          { name: 'Constipation', prevalence: 'common', description: 'Unable to pass gas or stool' },
          { name: 'Diarrhea', prevalence: 'uncommon', description: 'May occur with pelvic appendix' },
        ],
        physicalFindings: [
          { name: 'McBurney Point Tenderness', examType: 'palpation', description: 'Maximal tenderness 1/3 distance from ASIS to umbilicus', diagnosticValue: 'Classic finding' },
          { name: 'Rebound Tenderness', examType: 'palpation', description: 'Pain worsens when pressure released', diagnosticValue: 'Suggests peritoneal irritation' },
          { name: 'Rovsing Sign', examType: 'palpation', description: 'RLQ pain with LLQ palpation', diagnosticValue: 'Peritoneal irritation' },
          { name: 'Psoas Sign', examType: 'special test', description: 'RLQ pain with right hip extension', diagnosticValue: 'Retrocecal appendix' },
          { name: 'Obturator Sign', examType: 'special test', description: 'RLQ pain with internal rotation of flexed right hip', diagnosticValue: 'Pelvic appendix' },
          { name: 'Guarding', examType: 'palpation', description: 'Voluntary or involuntary muscle rigidity', diagnosticValue: 'Peritoneal inflammation' },
        ],
        labFindings: [
          { testName: 'WBC', abnormality: 'Elevated (10,000-18,000) with left shift', normalRange: '4,500-11,000/mcL', significance: 'Supports inflammation; very high WBC suggests perforation' },
          { testName: 'CRP', abnormality: 'Elevated', normalRange: '<3 mg/L', significance: 'Inflammatory marker' },
          { testName: 'Urinalysis', abnormality: 'May show mild pyuria/hematuria', normalRange: 'Normal', significance: 'Helps exclude UTI; mild abnormalities can occur with appendicitis' },
        ],
        imagingFindings: [
          { modality: 'CT Abdomen/Pelvis', finding: 'Dilated appendix >6mm, periappendiceal fat stranding, appendicolith', significance: 'Gold standard; sensitivity >95%', structures: ['Appendix'] },
          { modality: 'Ultrasound', finding: 'Non-compressible appendix >6mm, target sign', significance: 'First-line in children and pregnant women', structures: ['Appendix'] },
          { modality: 'MRI', finding: 'Enlarged appendix with inflammation', significance: 'Alternative in pregnancy', structures: ['Appendix'] },
        ],
      },
      progression: {
        naturalHistory:
          'Untreated appendicitis typically perforates within 24-72 hours, leading to localized abscess or diffuse peritonitis. Perforation increases morbidity and mortality.',
        timelineSteps: [
          {
            phaseId: 'early',
            phase: 'early',
            displayName: 'Early Appendicitis',
            timeframe: '0-12 hours',
            description: 'Luminal obstruction with early inflammation',
            symptoms: ['Vague periumbilical pain', 'Anorexia', 'Nausea'],
            anatomicalChanges: [
              { structureId: 'appendix', structureName: 'Appendix', changeType: 'inflammation', description: 'Mucosal inflammation and edema', severity: 'mild', visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
          },
          {
            phaseId: 'acute',
            phase: 'acute',
            displayName: 'Acute Appendicitis',
            timeframe: '12-24 hours',
            description: 'Full-thickness inflammation with peritoneal irritation',
            symptoms: ['RLQ pain (classic location)', 'Fever', 'Point tenderness'],
            anatomicalChanges: [
              { structureId: 'appendix', structureName: 'Appendix', changeType: 'inflammation', description: 'Transmural inflammation, serosal involvement', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Appendectomy', 'IV antibiotics'],
          },
          {
            phaseId: 'gangrenous',
            phase: 'severe',
            displayName: 'Gangrenous Appendicitis',
            timeframe: '24-48 hours',
            description: 'Ischemia and necrosis of appendiceal wall',
            symptoms: ['Severe pain', 'High fever', 'Tachycardia'],
            anatomicalChanges: [
              { structureId: 'appendix', structureName: 'Appendix', changeType: 'necrosis', description: 'Gangrenous, friable wall at risk of rupture', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Urgent appendectomy', 'Broad-spectrum antibiotics'],
          },
          {
            phaseId: 'perforated',
            phase: 'severe',
            displayName: 'Perforated Appendicitis',
            timeframe: '>48-72 hours',
            description: 'Appendix ruptures causing peritonitis or abscess',
            symptoms: ['Diffuse abdominal pain', 'High fever', 'Shock possible', 'Paradoxical pain relief then worsening'],
            anatomicalChanges: [
              { structureId: 'appendix', structureName: 'Appendix', changeType: 'necrosis', description: 'Perforated with spillage of contents', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.9 }, isNewAtPhase: false },
              { structureId: 'peritoneum', structureName: 'Peritoneum', changeType: 'inflammation', description: 'Peritonitis or abscess formation', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Surgery', 'Antibiotics', 'Drainage if abscess'],
          },
        ],
        prognosis:
          'Excellent with early diagnosis and surgery. Non-perforated appendectomy has <1% mortality. Perforation increases morbidity significantly.',
      },
      complications: [
        {
          complicationId: 'perforation',
          name: 'Appendiceal Perforation',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Rupture of the appendix causing peritonitis or abscess',
          mechanism: 'Progressive inflammation and necrosis lead to wall breakdown',
          affectedStructures: [{ structureId: 'appendix', structureName: 'Appendix', effect: 'Rupture with spillage', highlightColor: '#7f1d1d' }, { structureId: 'peritoneum', structureName: 'Peritoneum', effect: 'Contamination and inflammation', highlightColor: '#dc2626' }],
          warningSymptoms: ['Sudden worsening of pain', 'High fever >101.5°F', 'Rigid abdomen', 'Signs of sepsis'],
          timing: 'Typically 24-72 hours after symptom onset',
          prevention: ['Early diagnosis and surgery'],
          preventable: true,
        },
        {
          complicationId: 'abscess',
          name: 'Periappendiceal Abscess',
          category: 'acute',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Walled-off collection of pus from contained perforation',
          mechanism: 'Omentum and bowel wall off perforation, containing infection',
          affectedStructures: [{ structureId: 'rlq-abdomen', structureName: 'Right Lower Quadrant', effect: 'Localized abscess', highlightColor: '#f97316' }],
          warningSymptoms: ['Persistent fever despite antibiotics', 'RLQ mass', 'Continued pain'],
          treatment: 'Drainage ± interval appendectomy',
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'appendectomy',
          name: 'Appendectomy',
          modality: 'surgical',
          description: 'Surgical removal of the appendix',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'acute', 'severe'],
          goals: ['Remove source of infection', 'Prevent perforation', 'Cure disease'],
          timeToEffect: 'Immediate',
          explanations: {
            level1: 'Surgery to remove your appendix is the main treatment. The appendix is not needed, and removing it prevents it from bursting.',
            level2: 'Appendectomy is usually done laparoscopically (small incisions with a camera). Most people go home the same day or next day and recover in 1-2 weeks.',
            level3: 'Laparoscopic appendectomy preferred. For uncomplicated appendicitis, evidence supports both surgery and antibiotics-only, but surgery has lower recurrence.',
            level4: 'Antibiotics-first approach reasonable for uncomplicated cases per CODA trial, but ~30% need surgery within 90 days. Interval appendectomy for abscess after drainage + antibiotics.',
            level5: 'Laparoscopic vs open: faster recovery, less wound infection, more intra-abdominal abscesses. Stump appendicitis rare with adequate stump management. Single-incision techniques evolving.',
          },
        },
        {
          treatmentId: 'antibiotics-appendicitis',
          name: 'Antibiotics',
          modality: 'pharmacological',
          description: 'Antimicrobial therapy for infection',
          mechanism: 'Kill bacteria causing inflammation',
          efficacy: 'effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['acute', 'severe'],
          goals: ['Treat infection', 'Prevent sepsis', 'Alternative to surgery in select cases'],
          explanations: {
            level1: 'Antibiotics are given to fight the infection. They are always used before and after surgery, and sometimes instead of surgery.',
            level2: 'IV antibiotics are started as soon as appendicitis is diagnosed. For uncomplicated cases, some patients may be treated with antibiotics alone without surgery.',
            level3: 'Typical regimens: ceftriaxone + metronidazole, or piperacillin-tazobactam. Duration: 24 hours for uncomplicated, 3-5 days for perforated (some institutions longer).',
            level4: 'CODA trial showed non-inferiority of antibiotics-first for uncomplicated appendicitis at 30 days, but 29% needed appendectomy within 90 days. CT-confirmed no appendicolith needed.',
            level5: 'Polymicrobial infection: Gram-negatives (E. coli, Klebsiella), anaerobes (Bacteroides), Enterococcus. Coverage for these organisms essential. Antibiotic resistance growing concern.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'appendix', structureName: 'Appendix', role: 'primary-site', involvement: 'Site of inflammation', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'cecum', structureName: 'Cecum', role: 'secondary-site', involvement: 'Base of appendix attachment', highlightColor: '#f97316', showByDefault: true },
          { structureId: 'peritoneum', structureName: 'Peritoneum', role: 'secondary-site', involvement: 'May become involved if perforated', highlightColor: '#f59e0b', showByDefault: false },
        ],
        systemsInvolved: ['Gastrointestinal'],
        recommendedView: 'anterior',
        recommendedLayers: ['digestive'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: 'Your appendix is inflamed and needs to be removed. The appendix is a small pouch attached to your intestine that can get blocked and infected.',
        level2: 'Appendicitis happens when the appendix gets blocked and infected. The classic symptom is pain that starts around the belly button and moves to the lower right side. Surgery to remove it is the standard treatment.',
        level3: 'Diagnose with clinical exam (migration of pain, RLQ tenderness, peritoneal signs) plus CT scan (sensitivity >95%). Alvarado score can help risk-stratify. Early appendectomy is standard of care.',
        level4: 'Imaging before surgery is now standard. CT vs ultrasound depends on population - US first in children and pregnant women. Antibiotics-only is an option for uncomplicated cases, but discuss recurrence risk.',
        level5: 'Pathophysiology: obstruction → secretion continues → distension → ischemia → bacterial invasion → perforation. Appendicolith on CT predicts complicated course. Neuroendocrine tumors incidental finding in 1%.',
      },
      relatedConditions: ['peritonitis', 'bowel-obstruction', 'mesenteric-adenitis'],
      epidemiology: {
        prevalence: '~7% lifetime risk',
        incidence: '~100 per 100,000 person-years',
        demographics: 'Peak age 10-30 years; slightly more common in males',
      },
      clinicalPearls: [
        'Classic history: periumbilical pain migrating to RLQ, then anorexia, then nausea/vomiting',
        'Vomiting before pain suggests something other than appendicitis',
        'Atypical presentations common: retrocecal (back pain), pelvic (urinary symptoms), pregnancy',
        'High WBC with left shift + high CRP increases likelihood of perforation',
        'CT scan is the test of choice; ultrasound first in children and pregnant women',
      ],
      patientEducation: [
        'Do not eat or drink anything once appendicitis is suspected (in case you need surgery)',
        'Surgery is usually minimally invasive with a quick recovery',
        'You do not need your appendix - removing it does not affect your health',
        'After surgery, gradually return to normal activity over 1-2 weeks',
        'Call if you develop fever, worsening pain, or redness at incision sites',
      ],
      emergencyWarnings: [
        'Sudden severe abdominal pain',
        'Rigid, board-like abdomen',
        'High fever >102°F',
        'Signs of shock: lightheadedness, rapid heartbeat, cold clammy skin',
        'Sudden relief of pain followed by diffuse abdominal pain (may indicate rupture)',
      ],
    },
  ],

  // Parkinson's Disease
  [
    'parkinsons-disease',
    {
      conditionId: 'parkinsons-disease',
      name: "Parkinson's Disease",
      aliases: ['PD', 'Parkinsonism', 'Shaking Palsy'],
      icdCode: 'G20',
      category: 'neurologic',
      subcategory: 'Movement Disorder',
      description:
        'A progressive neurodegenerative disorder affecting movement, caused by loss of dopamine-producing neurons in the brain. Characterized by tremor, rigidity, slow movement, and postural instability.',
      pathophysiology: {
        summary:
          'Progressive loss of dopaminergic neurons in the substantia nigra leads to dopamine deficiency in the basal ganglia, disrupting motor control circuits.',
        mechanisms: [
          {
            name: 'Dopaminergic Neurodegeneration',
            description: 'Loss of dopamine-producing neurons in substantia nigra pars compacta',
            systemsInvolved: ['Neurologic'],
            keyMediators: ['Alpha-synuclein', 'Lewy bodies', 'Dopamine'],
            contribution: 'Primary cause of motor symptoms',
          },
          {
            name: 'Basal Ganglia Dysfunction',
            description: 'Dopamine deficiency causes imbalance in movement control circuits',
            systemsInvolved: ['Neurologic'],
            contribution: 'Explains bradykinesia, rigidity',
          },
          {
            name: 'Alpha-Synuclein Aggregation',
            description: 'Abnormal protein accumulation forms Lewy bodies',
            systemsInvolved: ['Neurologic'],
            keyMediators: ['Alpha-synuclein', 'Ubiquitin'],
            contribution: 'Hallmark pathology; spreads through nervous system',
          },
        ],
        riskFactors: [
          { name: 'Age', type: 'non-modifiable', impact: 'major', description: 'Risk increases significantly after age 60' },
          { name: 'Male Sex', type: 'non-modifiable', impact: 'moderate', description: '1.5x more common in men' },
          { name: 'Genetics', type: 'non-modifiable', impact: 'moderate', description: 'LRRK2, SNCA, GBA mutations; family history' },
          { name: 'Pesticide Exposure', type: 'partially-modifiable', impact: 'moderate', description: 'Rural living, well water, herbicides', intervention: 'Minimize exposure' },
          { name: 'Head Trauma', type: 'partially-modifiable', impact: 'minor', description: 'Repeated head injuries may increase risk' },
        ],
        geneticFactors: ['LRRK2', 'SNCA', 'PARK2 (Parkin)', 'PINK1', 'GBA'],
        environmentalFactors: ['Pesticide exposure', 'Rural living', 'Well water'],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Resting Tremor', prevalence: 'very-common', description: 'Tremor at rest that decreases with movement; typically starts unilaterally', quality: '4-6 Hz, "pill-rolling"', location: 'Hand, spreading to other limbs' },
          { name: 'Bradykinesia', prevalence: 'very-common', description: 'Slowness of movement; required for diagnosis', quality: 'Difficulty initiating movement, reduced amplitude' },
          { name: 'Rigidity', prevalence: 'very-common', description: 'Increased muscle tone throughout range of motion', quality: '"Cogwheel" or "lead-pipe" rigidity' },
          { name: 'Postural Instability', prevalence: 'common', description: 'Impaired balance and posture; typically later in disease', timing: 'Develops later in disease course' },
        ],
        associatedSymptoms: [
          { name: 'Masked Facies', prevalence: 'very-common', description: 'Reduced facial expression' },
          { name: 'Micrographia', prevalence: 'common', description: 'Small, cramped handwriting' },
          { name: 'Hypophonia', prevalence: 'common', description: 'Soft, monotone voice' },
          { name: 'Constipation', prevalence: 'very-common', description: 'May precede motor symptoms by years' },
          { name: 'REM Sleep Behavior Disorder', prevalence: 'common', description: 'Acting out dreams; often precedes diagnosis' },
          { name: 'Anosmia', prevalence: 'common', description: 'Loss of smell; early non-motor symptom' },
          { name: 'Depression/Anxiety', prevalence: 'common', description: 'Common neuropsychiatric symptoms' },
        ],
        physicalFindings: [
          { name: 'Resting Tremor', examType: 'observation', description: '4-6 Hz tremor at rest, decreases with action', diagnosticValue: 'Cardinal feature' },
          { name: 'Cogwheel Rigidity', examType: 'passive range of motion', description: 'Ratchety resistance to passive movement', diagnosticValue: 'Characteristic finding' },
          { name: 'Bradykinesia', examType: 'motor exam', description: 'Decreased speed/amplitude with finger taps, hand movements', diagnosticValue: 'Required for diagnosis' },
          { name: 'Shuffling Gait', examType: 'gait assessment', description: 'Short shuffling steps, reduced arm swing, festination', diagnosticValue: 'Classic finding' },
          { name: 'Pull Test', examType: 'balance test', description: 'Retropulsion with sternal push', diagnosticValue: 'Assesses postural instability' },
        ],
        labFindings: [
          { testName: 'Clinical Diagnosis', abnormality: 'No specific test; diagnosis is clinical', normalRange: 'N/A', significance: 'Based on UK Brain Bank criteria' },
          { testName: 'DaTscan', abnormality: 'Reduced dopamine transporter uptake', normalRange: 'Normal symmetric uptake', significance: 'Supports diagnosis if uncertain; not required' },
        ],
        imagingFindings: [
          { modality: 'MRI Brain', finding: 'Usually normal; helps rule out other causes', significance: 'Excludes structural lesions, normal pressure hydrocephalus', structures: ['Brain'] },
          { modality: 'DaTscan (SPECT)', finding: 'Reduced dopamine transporter binding in striatum', significance: 'Differentiates PD from essential tremor', structures: ['Basal ganglia'] },
        ],
      },
      progression: {
        naturalHistory:
          'Progressive disease over 10-20+ years. Motor symptoms worsen gradually. Non-motor symptoms and medication complications develop over time.',
        typicalOnsetToDiagnosis: '1-2 years (early symptoms often missed)',
        timelineSteps: [
          {
            phaseId: 'prodromal',
            phase: 'preclinical',
            displayName: 'Prodromal Phase',
            timeframe: 'Years before motor symptoms',
            description: 'Non-motor symptoms precede diagnosis',
            symptoms: ['Constipation', 'Anosmia', 'REM sleep behavior disorder', 'Depression'],
            anatomicalChanges: [
              { structureId: 'brainstem', structureName: 'Brainstem', changeType: 'degeneration', description: 'Early Lewy body deposition', severity: 'mild', visualIndicator: { color: '#f59e0b', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
          },
          {
            phaseId: 'early',
            phase: 'early',
            displayName: 'Early PD',
            timeframe: 'Diagnosis to ~5 years',
            description: 'Unilateral symptoms, good response to medications',
            symptoms: ['Unilateral tremor', 'Mild bradykinesia', 'Minimal disability'],
            anatomicalChanges: [
              { structureId: 'substantia-nigra', structureName: 'Substantia Nigra', changeType: 'degeneration', description: '60-80% dopamine neuron loss at diagnosis', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['MAO-B inhibitors', 'Dopamine agonists', 'Levodopa'],
            goalsOfCare: ['Symptom control', 'Maintain function', 'Delay complications'],
          },
          {
            phaseId: 'moderate',
            phase: 'established',
            displayName: 'Moderate PD',
            timeframe: '5-10 years',
            description: 'Bilateral symptoms, medication fluctuations develop',
            symptoms: ['Bilateral symptoms', 'Motor fluctuations', 'Some disability'],
            anatomicalChanges: [
              { structureId: 'substantia-nigra', structureName: 'Substantia Nigra', changeType: 'atrophy', description: 'Progressive neuronal loss', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.8 }, isNewAtPhase: false },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Levodopa + adjuncts', 'Consider DBS'],
          },
          {
            phaseId: 'advanced',
            phase: 'advanced',
            displayName: 'Advanced PD',
            timeframe: '>10 years',
            description: 'Significant disability, complications of long-term treatment',
            symptoms: ['Postural instability', 'Falls', 'Dyskinesias', 'Cognitive impairment', 'Autonomic dysfunction'],
            anatomicalChanges: [
              { structureId: 'brain', structureName: 'Brain', changeType: 'atrophy', description: 'Widespread Lewy body pathology', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: false, opacity: 0.9 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Complex medication regimens', 'DBS', 'Palliative care'],
          },
        ],
        prognosis:
          'Variable but progressive. Average life expectancy reduced by 1-2 years. Many live 20+ years with good quality of life with treatment.',
      },
      complications: [
        {
          complicationId: 'falls-pd',
          name: 'Falls and Injuries',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'high',
          description: 'Increased fall risk from postural instability, freezing of gait',
          mechanism: 'Impaired postural reflexes, freezing episodes, orthostatic hypotension',
          affectedStructures: [{ structureId: 'musculoskeletal', structureName: 'Bones/Joints', effect: 'Fractures from falls', highlightColor: '#dc2626' }],
          warningSymptoms: ['Freezing of gait', 'Near-falls', 'Lightheadedness'],
          prevention: ['Physical therapy', 'Home safety', 'Treat orthostatic hypotension'],
          preventable: true,
        },
        {
          complicationId: 'dementia-pd',
          name: "Parkinson's Disease Dementia",
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Cognitive decline occurring >1 year after motor symptoms',
          mechanism: 'Cortical Lewy bodies and cholinergic deficits',
          affectedStructures: [{ structureId: 'cerebral-cortex', structureName: 'Cerebral Cortex', effect: 'Widespread Lewy body pathology', highlightColor: '#8b5cf6' }],
          warningSymptoms: ['Visual hallucinations', 'Memory problems', 'Executive dysfunction'],
          treatment: 'Rivastigmine, supportive care',
          preventable: false,
        },
        {
          complicationId: 'dyskinesia',
          name: 'Levodopa-Induced Dyskinesia',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'high',
          description: 'Involuntary movements from long-term levodopa use',
          mechanism: 'Pulsatile dopamine stimulation causes receptor changes',
          affectedStructures: [{ structureId: 'basal-ganglia', structureName: 'Basal Ganglia', effect: 'Receptor dysregulation', highlightColor: '#f97316' }],
          warningSymptoms: ['Involuntary writhing movements', 'Peak-dose choreiform movements'],
          prevention: ['Delay levodopa if possible', 'Use lowest effective dose', 'Continuous delivery strategies'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'levodopa-pd',
          name: 'Levodopa/Carbidopa',
          modality: 'pharmacological',
          description: 'Most effective symptomatic treatment; dopamine precursor',
          mechanism: 'Crosses blood-brain barrier and converts to dopamine',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'advanced'],
          goals: ['Improve motor symptoms', 'Maintain function'],
          timeToEffect: 'Days to weeks',
          sideEffects: ['Nausea', 'Dyskinesia (long-term)', 'Motor fluctuations', 'Hallucinations'],
          explanations: {
            level1: 'Levodopa is the most effective medication for PD. It replaces the dopamine your brain is missing.',
            level2: 'Levodopa is converted to dopamine in your brain. It is combined with carbidopa to prevent nausea. It dramatically improves movement symptoms.',
            level3: 'Start low, go slow. Immediate-release vs controlled-release forms. Motor complications develop over years - not a reason to delay treatment if needed.',
            level4: 'PD MED and other trials showed no benefit to delaying levodopa. Start when symptoms require treatment. Frequency of dosing increases over time.',
            level5: 'Pulsatile stimulation of denervated striatal receptors may contribute to dyskinesia. Continuous delivery (pumps, extended-release) may reduce complications.',
          },
        },
        {
          treatmentId: 'dopamine-agonists',
          name: 'Dopamine Agonists',
          modality: 'pharmacological',
          description: 'Directly stimulate dopamine receptors',
          mechanism: 'Bind to D2/D3 dopamine receptors without requiring conversion',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Symptom control', 'Delay levodopa complications'],
          explanations: {
            level1: 'These medications mimic dopamine in your brain and can be used alone or with levodopa.',
            level2: 'Dopamine agonists (pramipexole, ropinirole, rotigotine patch) directly activate dopamine receptors. May cause sleepiness and impulse control disorders.',
            level3: 'Often used as initial monotherapy in younger patients. Watch for impulse control disorders (gambling, hypersexuality), daytime sleepiness, ankle edema.',
            level4: 'Lower dyskinesia risk than levodopa but less effective for motor symptoms. Non-ergot agonists preferred. Screen for and warn about ICDs.',
            level5: 'Longer half-life than levodopa provides more continuous receptor stimulation. D3 selectivity may explain neuropsychiatric effects. Apomorphine for rescue.',
          },
        },
        {
          treatmentId: 'dbs-pd',
          name: 'Deep Brain Stimulation',
          modality: 'surgical',
          description: 'Surgical implantation of electrodes to modulate brain circuits',
          mechanism: 'High-frequency stimulation of STN or GPi modulates motor circuits',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established', 'advanced'],
          goals: ['Reduce motor fluctuations', 'Reduce dyskinesia', 'Reduce medication needs'],
          explanations: {
            level1: 'A surgical option where a device like a pacemaker for the brain helps control symptoms when medications are not working well enough.',
            level2: 'Deep brain stimulation involves implanting electrodes in specific brain areas. A device sends electrical pulses to help control tremor and other symptoms.',
            level3: 'Best candidates: good levodopa response, motor fluctuations/dyskinesia, no significant cognitive impairment. STN vs GPi targets. Does not slow progression.',
            level4: 'EARLYSTIM showed benefit even in early fluctuators. Screen for cognitive impairment (DBS does not help and may worsen). MRI-compatible and directional leads improving.',
            level5: 'Mechanism: likely disruption of pathological oscillatory activity in basal ganglia circuits. Adaptive DBS and new targets (PPN for gait) under investigation.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'substantia-nigra', structureName: 'Substantia Nigra', role: 'primary-site', involvement: 'Dopamine neuron loss', highlightColor: '#dc2626', showByDefault: true },
          { structureId: 'basal-ganglia', structureName: 'Basal Ganglia', role: 'target-organ', involvement: 'Motor circuit dysfunction', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'brainstem', structureName: 'Brainstem', role: 'secondary-site', involvement: 'Early Lewy body pathology', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Neurologic'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
      },
      explanations: {
        level1: "Parkinson's disease happens when brain cells that make dopamine (a chemical messenger) die. This causes tremor, stiffness, and slow movement. Medications can help replace the missing dopamine.",
        level2: "PD is caused by loss of dopamine-producing cells in a part of the brain called the substantia nigra. This disrupts movement control. Symptoms include tremor, stiffness, slow movement, and balance problems. Treatment replaces dopamine.",
        level3: "Diagnose clinically: bradykinesia plus tremor or rigidity. Good response to levodopa supports diagnosis. DaTscan if uncertain. Treat with levodopa, dopamine agonists, MAO-B inhibitors. DBS for motor fluctuations.",
        level4: "UK Brain Bank criteria: bradykinesia + one of tremor/rigidity, plus supportive features and exclusion criteria. MDS criteria include non-motor features. Prodromal markers (RBD, anosmia) precede motor symptoms.",
        level5: "Braak staging describes caudal-to-rostral spread of alpha-synuclein pathology. Gut-brain axis implicated (enteric neurons affected early). GBA mutations most common genetic risk factor. Disease-modifying trials ongoing.",
      },
      relatedConditions: ['essential-tremor', 'lewy-body-dementia', 'multiple-system-atrophy'],
      epidemiology: {
        prevalence: '~1% of people over 60; ~1 million in US',
        incidence: '13-20 per 100,000 person-years',
        demographics: '1.5x more common in men; average onset age 60',
      },
      clinicalPearls: [
        'Tremor alone is not PD - bradykinesia is required for diagnosis',
        'Good response to levodopa strongly supports the diagnosis',
        'Non-motor symptoms (constipation, anosmia, RBD) often precede motor symptoms by years',
        'There is no benefit to delaying levodopa when symptoms warrant treatment',
        'Always screen for impulse control disorders when using dopamine agonists',
      ],
      patientEducation: [
        'Exercise is one of the most important things you can do - it helps symptoms and may slow progression',
        'Medications work best when taken on a consistent schedule',
        'Report any hallucinations, confusion, or new behaviors to your doctor',
        'Physical and occupational therapy help maintain function',
        'Many people live well with PD for decades with proper treatment',
      ],
      emergencyWarnings: [
        'Sudden inability to move (akinetic crisis) - may need urgent medication adjustment',
        'High fever with severe rigidity (neuroleptic malignant syndrome if on antipsychotics)',
        'Falls with head injury',
        'New confusion or hallucinations',
        'Difficulty swallowing leading to choking',
      ],
    },
  ],

  // Migraine
  [
    'migraine',
    {
      conditionId: 'migraine',
      name: 'Migraine',
      aliases: ['Migraine Headache', 'Sick Headache'],
      icdCode: 'G43.909',
      category: 'neurologic',
      subcategory: 'Headache Disorder',
      description:
        'A common neurological disorder characterized by recurrent episodes of moderate-to-severe headache, often with nausea, light sensitivity, and sound sensitivity. Can be debilitating but is treatable.',
      pathophysiology: {
        summary:
          'Migraine involves activation of the trigeminovascular system with release of vasoactive neuropeptides, cortical spreading depression, and central sensitization.',
        mechanisms: [
          {
            name: 'Trigeminovascular Activation',
            description: 'Trigeminal nerve releases CGRP and other neuropeptides causing neurogenic inflammation',
            systemsInvolved: ['Neurologic', 'Vascular'],
            keyMediators: ['CGRP', 'Substance P', 'Serotonin'],
            contribution: 'Central to migraine pain generation',
          },
          {
            name: 'Cortical Spreading Depression',
            description: 'Wave of neuronal depolarization across cortex',
            systemsInvolved: ['Neurologic'],
            contribution: 'Underlies migraine aura',
          },
          {
            name: 'Central Sensitization',
            description: 'Increased sensitivity of pain pathways in brainstem and thalamus',
            systemsInvolved: ['Neurologic'],
            contribution: 'Explains allodynia and why early treatment is more effective',
          },
        ],
        riskFactors: [
          { name: 'Female Sex', type: 'non-modifiable', impact: 'major', description: '3x more common in women (hormonal influence)' },
          { name: 'Family History', type: 'non-modifiable', impact: 'major', description: '50-70% heritability' },
          { name: 'Stress', type: 'modifiable', impact: 'major', description: 'Common trigger', intervention: 'Stress management' },
          { name: 'Poor Sleep', type: 'modifiable', impact: 'moderate', description: 'Both too much and too little sleep trigger attacks', intervention: 'Sleep hygiene' },
          { name: 'Hormonal Changes', type: 'partially-modifiable', impact: 'moderate', description: 'Menstruation, oral contraceptives' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Headache', prevalence: 'very-common', description: 'Moderate-to-severe, often unilateral, pulsating/throbbing', timing: '4-72 hours untreated', location: 'Often unilateral, frontotemporal' },
          { name: 'Nausea/Vomiting', prevalence: 'very-common', description: 'Accompanying nausea, sometimes vomiting' },
          { name: 'Photophobia', prevalence: 'very-common', description: 'Light sensitivity; seek dark rooms' },
          { name: 'Phonophobia', prevalence: 'very-common', description: 'Sound sensitivity' },
        ],
        associatedSymptoms: [
          { name: 'Aura', prevalence: 'common', description: 'Visual, sensory, or speech symptoms preceding headache (25-30%)', timing: '5-60 minutes, before or with headache' },
          { name: 'Osmophobia', prevalence: 'common', description: 'Sensitivity to smells' },
          { name: 'Worsening with Activity', prevalence: 'very-common', description: 'Headache worsens with routine physical activity' },
        ],
        physicalFindings: [
          { name: 'Normal Neurological Exam', examType: 'neurological', description: 'Exam typically normal between attacks', diagnosticValue: 'Abnormal exam suggests secondary cause' },
          { name: 'Cutaneous Allodynia', examType: 'sensory', description: 'Scalp tenderness during attacks', diagnosticValue: 'Indicates central sensitization' },
        ],
        labFindings: [
          { testName: 'Clinical Diagnosis', abnormality: 'No specific test - diagnosis is clinical', normalRange: 'N/A', significance: 'Based on ICHD-3 criteria' },
        ],
        imagingFindings: [
          { modality: 'MRI Brain', finding: 'Usually normal; white matter lesions may be seen (usually incidental)', significance: 'Obtained to rule out secondary causes if indicated', structures: ['Brain'] },
        ],
      },
      progression: {
        naturalHistory:
          'Episodic migraine can be well-controlled. Some patients develop chronic migraine (≥15 headache days/month). May improve with age, especially after menopause in women.',
        timelineSteps: [
          {
            phaseId: 'prodrome',
            phase: 'preclinical',
            displayName: 'Prodrome',
            timeframe: 'Hours to days before headache',
            description: 'Warning symptoms before the headache',
            symptoms: ['Fatigue', 'Mood changes', 'Food cravings', 'Neck stiffness', 'Yawning'],
            anatomicalChanges: [
              { structureId: 'hypothalamus', structureName: 'Hypothalamus', changeType: 'dysfunction', description: 'Hypothalamic activation', severity: 'mild', visualIndicator: { color: '#f59e0b', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
          },
          {
            phaseId: 'aura',
            phase: 'early',
            displayName: 'Aura (if present)',
            timeframe: '5-60 minutes',
            description: 'Reversible neurological symptoms',
            symptoms: ['Visual disturbances (zigzag lines, scotoma)', 'Sensory symptoms (tingling)', 'Speech difficulty'],
            anatomicalChanges: [
              { structureId: 'occipital-cortex', structureName: 'Occipital Cortex', changeType: 'dysfunction', description: 'Cortical spreading depression', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
          },
          {
            phaseId: 'headache',
            phase: 'acute',
            displayName: 'Headache Phase',
            timeframe: '4-72 hours',
            description: 'Main attack with headache and associated symptoms',
            symptoms: ['Moderate-severe headache', 'Nausea', 'Photo/phonophobia', 'Worsening with activity'],
            anatomicalChanges: [
              { structureId: 'trigeminal-system', structureName: 'Trigeminovascular System', changeType: 'inflammation', description: 'Neurogenic inflammation, CGRP release', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Triptans', 'NSAIDs', 'Antiemetics', 'CGRP antagonists'],
          },
          {
            phaseId: 'postdrome',
            phase: 'established',
            displayName: 'Postdrome',
            timeframe: 'Hours to days after headache',
            description: '"Migraine hangover"',
            symptoms: ['Fatigue', 'Difficulty concentrating', 'Mood changes'],
            anatomicalChanges: [],
            reversibility: 'reversible',
          },
        ],
        prognosis:
          'Chronic condition but manageable. Many patients have reduced frequency with age. Preventive treatments can significantly reduce attack frequency.',
      },
      complications: [
        {
          complicationId: 'chronic-migraine',
          name: 'Chronic Migraine',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Headache ≥15 days/month for >3 months, with migraine features ≥8 days',
          mechanism: 'Progressive sensitization of pain pathways; medication overuse',
          affectedStructures: [{ structureId: 'brain', structureName: 'Pain Processing Centers', effect: 'Central sensitization', highlightColor: '#dc2626' }],
          warningSymptoms: ['Increasing headache frequency', 'More medication use', 'Less response to acute treatment'],
          prevention: ['Avoid medication overuse', 'Early preventive treatment', 'Lifestyle modifications'],
          preventable: true,
        },
        {
          complicationId: 'medication-overuse-headache',
          name: 'Medication Overuse Headache',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Worsening of headache from frequent use of acute medications',
          mechanism: 'Downregulation of pain inhibition with frequent analgesic use',
          affectedStructures: [{ structureId: 'brainstem', structureName: 'Brainstem Pain Modulatory System', effect: 'Impaired pain inhibition', highlightColor: '#f97316' }],
          warningSymptoms: ['Using acute medication >10-15 days/month', 'Waking with headache', 'Medication less effective'],
          prevention: ['Limit acute medication use', 'Track headache days', 'Start preventives early'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'triptans',
          name: 'Triptans',
          modality: 'pharmacological',
          description: 'First-line acute treatment for moderate-severe migraine',
          mechanism: '5-HT1B/1D receptor agonists; cause vasoconstriction and inhibit CGRP release',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute'],
          goals: ['Abort migraine attack', 'Reduce pain and associated symptoms'],
          timeToEffect: '30-60 minutes (varies by formulation)',
          contraindications: ['Cardiovascular disease', 'Uncontrolled hypertension', 'Hemiplegic migraine'],
          explanations: {
            level1: 'Triptans are medications designed specifically for migraines. They work best when taken early in an attack.',
            level2: 'Triptans (like sumatriptan) target serotonin receptors in the brain to stop the migraine process. Take at the first sign of headache for best results.',
            level3: 'Multiple triptans available with different onset times and routes. If one fails, try another. Contraindicated in CAD. Limit use to avoid medication overuse headache.',
            level4: 'Sumatriptan: SC fastest, intranasal intermediate, oral most convenient. Rizatriptan, eletriptan have faster onset. Frovatriptan longest half-life for menstrual migraine.',
            level5: '5-HT1B receptors on blood vessels cause vasoconstriction; 5-HT1D on trigeminal nerve terminals inhibit neuropeptide release. Central effects also contribute.',
          },
        },
        {
          treatmentId: 'cgrp-antagonists',
          name: 'CGRP Antagonists (Gepants)',
          modality: 'pharmacological',
          description: 'Newer acute treatment targeting CGRP pathway',
          mechanism: 'Block CGRP receptor to inhibit migraine pathophysiology',
          efficacy: 'effective',
          evidenceLevel: 'level-1b',
          isFirstLine: false,
          appropriatePhases: ['acute'],
          goals: ['Abort migraine', 'Option for triptan non-responders or contraindications'],
          explanations: {
            level1: 'Newer medications that work differently from triptans and can be used if triptans do not work or you cannot take them.',
            level2: 'CGRP antagonists (ubrogepant, rimegepant) block a chemical (CGRP) involved in migraine pain. Safe for people with heart disease.',
            level3: 'Gepants do not cause vasoconstriction - safe in cardiovascular disease. Rimegepant also approved for prevention (every other day). No medication overuse headache concern.',
            level4: 'Ubrogepant and rimegepant FDA approved for acute treatment. Rimegepant also for prevention. Lower NNT than triptans but no cardiovascular concerns.',
            level5: 'CGRP is key mediator of trigeminovascular activation. Gepants are small molecule CGRP receptor antagonists. Different from monoclonal antibodies which target CGRP ligand or receptor.',
          },
        },
        {
          treatmentId: 'migraine-prevention',
          name: 'Preventive Medications',
          modality: 'pharmacological',
          description: 'Daily medications to reduce migraine frequency',
          mechanism: 'Various - reduce neuronal excitability, modulate serotonin, block CGRP',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['chronic'],
          goals: ['Reduce migraine frequency by ≥50%', 'Reduce severity', 'Improve quality of life'],
          explanations: {
            level1: 'If you have frequent migraines, taking a daily medication can help prevent them from occurring.',
            level2: 'Preventive medications include blood pressure pills (propranolol), antidepressants (amitriptyline), seizure medications (topiramate), and newer CGRP antibodies (monthly injections).',
            level3: 'Consider prevention if ≥4 headache days/month or significant disability. First-line: propranolol, amitriptyline, topiramate. CGRP antibodies very effective with few side effects.',
            level4: 'CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) have transformed prevention - high efficacy, good tolerability, monthly dosing. OnabotulinumtoxinA for chronic migraine.',
            level5: 'Traditional preventives reduce neuronal excitability (anticonvulsants), modulate descending pain pathways (antidepressants), or have unclear mechanisms (beta blockers). CGRP antibodies specifically target migraine pathophysiology.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'trigeminal-system', structureName: 'Trigeminovascular System', role: 'primary-site', involvement: 'Pain generation and transmission', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'brainstem', structureName: 'Brainstem', role: 'secondary-site', involvement: 'Pain modulation', highlightColor: '#f97316', showByDefault: false },
          { structureId: 'thalamus', structureName: 'Thalamus', role: 'secondary-site', involvement: 'Sensory processing', highlightColor: '#f59e0b', showByDefault: false },
        ],
        systemsInvolved: ['Neurologic'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
      },
      explanations: {
        level1: 'Migraine is a type of severe headache that often comes with nausea and sensitivity to light and sound. It can be very disabling but treatments can help.',
        level2: 'Migraine is a brain disorder, not just a headache. Your brain becomes extra sensitive during an attack. Triggers can set off attacks, but you can learn to manage them with medications and lifestyle changes.',
        level3: 'Diagnose clinically using ICHD-3 criteria: ≥5 attacks of 4-72 hour headache with nausea/vomiting or photo/phonophobia, plus 2 of: unilateral, pulsating, moderate-severe, worse with activity. Treat acute attacks early; prevent if frequent.',
        level4: 'Red flags requiring workup: thunderclap onset, new after 50, progressive, abnormal exam, systemic symptoms. Medication overuse headache common - limit acute meds to <10-15 days/month. CGRP pathway revolutionizing treatment.',
        level5: 'Trigeminovascular theory: activation of trigeminal afferents releases CGRP causing neurogenic inflammation. Cortical spreading depression underlies aura. Thalamic and brainstem nuclei involved in central sensitization and photophobia.',
      },
      relatedConditions: ['tension-headache', 'cluster-headache', 'medication-overuse-headache'],
      epidemiology: {
        prevalence: '~12% of population; 18% of women, 6% of men',
        incidence: 'Peak incidence in 30s-40s',
        demographics: '3x more common in women; often starts in adolescence',
      },
      clinicalPearls: [
        'Treat early - medications work better before central sensitization develops',
        'More than 10-15 days/month of acute medication use risks medication overuse headache',
        'Aura without headache can occur - still migraine',
        'Menstrual migraines may respond to timed prevention around periods',
        'CGRP antibodies are a game-changer for prevention - consider early if traditional preventives fail',
      ],
      patientEducation: [
        'Keep a headache diary to identify triggers and track frequency',
        'Take acute medications at the first sign of headache - do not wait',
        'Limit acute medication use to avoid making headaches worse long-term',
        'Regular sleep, meals, hydration, and exercise help prevent attacks',
        'Migraine is a real neurological condition - not "just a headache"',
      ],
      emergencyWarnings: [
        'Worst headache of your life (thunderclap headache)',
        'Headache with fever and stiff neck',
        'New headache with vision changes or weakness',
        'Headache after head injury',
        'Headache pattern completely different from usual migraines',
      ],
    },
  ],

  // Diverticulitis
  [
    'diverticulitis',
    {
      conditionId: 'diverticulitis',
      name: 'Diverticulitis',
      aliases: ['Acute Diverticulitis', 'Diverticular Disease'],
      icdCode: 'K57.32',
      category: 'gastrointestinal',
      subcategory: 'Colonic Disease',
      description:
        'Inflammation or infection of diverticula (small pouches) that can form in the walls of the large intestine. Causes abdominal pain, often in the left lower abdomen, and may lead to serious complications.',
      pathophysiology: {
        summary:
          'Diverticula form at weak points in the colonic wall. Obstruction of a diverticulum by fecal material leads to microperforation, inflammation, and sometimes abscess or perforation.',
        mechanisms: [
          {
            name: 'Diverticulum Formation',
            description: 'Increased intraluminal pressure causes herniation at weak points where vessels penetrate muscularis',
            systemsInvolved: ['Gastrointestinal'],
            contribution: 'Underlying structural abnormality',
          },
          {
            name: 'Microperforation',
            description: 'Fecal impaction leads to erosion and microscopic perforation of diverticulum',
            systemsInvolved: ['Gastrointestinal'],
            contribution: 'Initiates inflammatory process',
          },
          {
            name: 'Inflammation and Infection',
            description: 'Bacterial translocation causes localized or spreading infection',
            systemsInvolved: ['Gastrointestinal', 'Immune'],
            keyMediators: ['Colonic bacteria', 'Inflammatory cytokines'],
            contribution: 'Drives clinical syndrome',
          },
        ],
        riskFactors: [
          { name: 'Low Fiber Diet', type: 'modifiable', impact: 'major', description: 'May contribute to diverticulosis formation', intervention: 'High-fiber diet' },
          { name: 'Age >40', type: 'non-modifiable', impact: 'major', description: 'Diverticulosis increases with age' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'Increases risk of diverticulitis and complications', intervention: 'Weight loss' },
          { name: 'Sedentary Lifestyle', type: 'modifiable', impact: 'moderate', description: 'Associated with increased risk', intervention: 'Regular exercise' },
          { name: 'NSAIDs/Steroids', type: 'modifiable', impact: 'moderate', description: 'May increase risk of complications', intervention: 'Use cautiously' },
          { name: 'Smoking', type: 'modifiable', impact: 'moderate', description: 'Increases risk of complications', intervention: 'Smoking cessation' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Left Lower Quadrant Pain', prevalence: 'very-common', description: 'Constant aching or cramping pain, often described as "left-sided appendicitis"', location: 'Left lower quadrant (Western populations)' },
          { name: 'Fever', prevalence: 'common', description: 'Low-grade fever; high fever suggests complicated disease' },
          { name: 'Change in Bowel Habits', prevalence: 'common', description: 'Constipation or diarrhea' },
        ],
        associatedSymptoms: [
          { name: 'Nausea/Vomiting', prevalence: 'common', description: 'May occur, especially with complicated disease' },
          { name: 'Bloating', prevalence: 'common', description: 'Abdominal distension' },
          { name: 'Urinary Symptoms', prevalence: 'uncommon', description: 'Due to bladder irritation from adjacent inflammation' },
        ],
        physicalFindings: [
          { name: 'LLQ Tenderness', examType: 'palpation', description: 'Localized tenderness in left lower quadrant', diagnosticValue: 'Classic finding' },
          { name: 'Rebound/Guarding', examType: 'palpation', description: 'Suggests peritoneal irritation', diagnosticValue: 'May indicate complicated disease' },
          { name: 'Palpable Mass', examType: 'palpation', description: 'May indicate phlegmon or abscess', diagnosticValue: 'Suggests complicated disease' },
          { name: 'Fever', examType: 'vital signs', description: 'Temperature elevation', diagnosticValue: 'Proportional to severity' },
        ],
        labFindings: [
          { testName: 'WBC', abnormality: 'Elevated with left shift', normalRange: '4,500-11,000/mcL', significance: 'Confirms inflammation/infection' },
          { testName: 'CRP', abnormality: 'Elevated', normalRange: '<3 mg/L', significance: 'Useful for monitoring; very high suggests complicated disease' },
          { testName: 'Urinalysis', abnormality: 'Sterile pyuria possible', normalRange: 'Normal', significance: 'Bladder irritation from adjacent inflammation' },
        ],
        imagingFindings: [
          { modality: 'CT Abdomen/Pelvis', finding: 'Colonic wall thickening >4mm, pericolic fat stranding, diverticula', significance: 'Gold standard; also detects complications', structures: ['Colon'] },
          { modality: 'CT with contrast', finding: 'Abscess, free air, fistula', significance: 'Identifies complicated diverticulitis', structures: ['Colon', 'Peritoneum'] },
        ],
      },
      progression: {
        naturalHistory:
          'Most episodes resolve with antibiotics or spontaneously. About 15-30% develop complications. Recurrence occurs in 20-35%.',
        timelineSteps: [
          {
            phaseId: 'uncomplicated',
            phase: 'acute',
            displayName: 'Uncomplicated Diverticulitis',
            timeframe: 'Days',
            description: 'Localized inflammation without abscess or perforation',
            symptoms: ['LLQ pain', 'Low-grade fever', 'Change in bowel habits'],
            anatomicalChanges: [
              { structureId: 'sigmoid-colon', structureName: 'Sigmoid Colon', changeType: 'inflammation', description: 'Localized inflammation around diverticulum', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Antibiotics (or observation)', 'Clear liquid diet', 'Outpatient management'],
          },
          {
            phaseId: 'complicated',
            phase: 'severe',
            displayName: 'Complicated Diverticulitis',
            timeframe: 'Days to weeks',
            description: 'Abscess, perforation, fistula, or obstruction',
            symptoms: ['Severe pain', 'High fever', 'Peritoneal signs', 'Unable to tolerate oral intake'],
            anatomicalChanges: [
              { structureId: 'sigmoid-colon', structureName: 'Sigmoid Colon', changeType: 'necrosis', description: 'Perforation or abscess formation', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['IV antibiotics', 'Drainage', 'Surgery if needed'],
          },
        ],
        prognosis:
          'Uncomplicated diverticulitis has excellent prognosis. Complicated disease increases morbidity. Elective surgery reduces recurrence risk.',
      },
      complications: [
        {
          complicationId: 'abscess-diverticulitis',
          name: 'Pericolic Abscess',
          category: 'acute',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Walled-off collection of pus adjacent to inflamed colon',
          mechanism: 'Contained perforation with localized infection',
          affectedStructures: [{ structureId: 'pericolic-area', structureName: 'Pericolic Space', effect: 'Abscess formation', highlightColor: '#dc2626' }],
          warningSymptoms: ['Persistent fever despite antibiotics', 'Palpable mass', 'Increasing pain'],
          treatment: 'Percutaneous drainage + antibiotics; surgery if fails',
          preventable: true,
        },
        {
          complicationId: 'free-perforation',
          name: 'Free Perforation with Peritonitis',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'low',
          description: 'Perforation into peritoneal cavity causing generalized peritonitis',
          mechanism: 'Full-thickness perforation without containment',
          affectedStructures: [{ structureId: 'peritoneum', structureName: 'Peritoneal Cavity', effect: 'Fecal/purulent contamination', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['Sudden severe pain', 'Rigid abdomen', 'High fever', 'Shock'],
          treatment: 'Emergency surgery',
          preventable: true,
        },
        {
          complicationId: 'fistula-diverticulitis',
          name: 'Fistula Formation',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'low',
          description: 'Abnormal connection to bladder, vagina, or other structures',
          mechanism: 'Chronic inflammation erodes into adjacent organs',
          affectedStructures: [{ structureId: 'bladder', structureName: 'Bladder (colovesical most common)', effect: 'Fistula tract', highlightColor: '#f97316' }],
          warningSymptoms: ['Pneumaturia (air in urine)', 'Fecaluria', 'Recurrent UTIs'],
          treatment: 'Surgical resection with fistula repair',
          preventable: false,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'antibiotics-diverticulitis',
          name: 'Antibiotic Therapy',
          modality: 'pharmacological',
          description: 'Antimicrobial treatment for infection',
          mechanism: 'Kill bacteria causing infection',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute'],
          goals: ['Treat infection', 'Prevent complications'],
          timeToEffect: '48-72 hours for improvement',
          explanations: {
            level1: 'Antibiotics fight the infection in your colon. Most people improve within a few days.',
            level2: 'For uncomplicated diverticulitis, oral antibiotics taken at home for 7-10 days usually work. Recent studies suggest some mild cases may not even need antibiotics.',
            level3: 'Oral regimens: ciprofloxacin + metronidazole, or amoxicillin-clavulanate. AVOD trial suggests observation without antibiotics reasonable for uncomplicated cases. IV for complicated disease.',
            level4: 'DIABOLO, AVOD trials showed non-inferiority of observation vs antibiotics for uncomplicated diverticulitis. Reserve antibiotics for immunocompromised or complicated cases per some guidelines.',
            level5: 'Polymicrobial infection with Gram-negatives and anaerobes. Duration 7-10 days traditional but shorter courses may be adequate. Antibiotic stewardship increasingly emphasized.',
          },
        },
        {
          treatmentId: 'surgery-diverticulitis',
          name: 'Surgical Resection',
          modality: 'surgical',
          description: 'Removal of affected segment of colon',
          mechanism: 'Removes diseased tissue; eliminates source of infection/recurrence',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['severe'],
          goals: ['Treat complications', 'Prevent recurrence'],
          explanations: {
            level1: 'Surgery removes the part of the colon with the diverticula. This cures the problem and prevents it from coming back.',
            level2: 'Surgery is needed for complications (abscess that cannot be drained, perforation, fistula) or can be done electively to prevent recurrence in selected patients.',
            level3: 'Emergency: often Hartmann procedure (end colostomy) for perforation. Elective: primary anastomosis preferred. Laparoscopic when feasible. Sigmoid resection with proximal margin in non-diseased colon.',
            level4: 'DIRECT trial: laparoscopic lavage inferior to resection for perforated diverticulitis. Elective resection reduces recurrence but decision individualized based on patient factors.',
            level5: 'Resection should include the rectosigmoid junction proximally to prevent anastomotic tension and reduce recurrence. Extended resection unnecessary. Robotic approaches increasing.',
          },
        },
        {
          treatmentId: 'high-fiber-diet',
          name: 'High-Fiber Diet',
          modality: 'lifestyle',
          description: 'Dietary modification to prevent recurrence',
          mechanism: 'Increases stool bulk, reduces intraluminal pressure',
          efficacy: 'moderately-effective',
          evidenceLevel: 'level-2b',
          isFirstLine: true,
          appropriatePhases: ['chronic'],
          goals: ['Prevent recurrence', 'Promote colonic health'],
          explanations: {
            level1: 'Eating more fiber (fruits, vegetables, whole grains) helps keep your colon healthy and may prevent more episodes.',
            level2: 'After recovery, gradually increase fiber intake to 25-35 grams daily. Fiber helps form bulky, soft stools that are easier to pass.',
            level3: 'Evidence for fiber preventing diverticulitis is moderate but reasonable recommendation. Avoid seeds/nuts restriction is no longer supported. Increase fiber gradually to avoid bloating.',
            level4: 'The old advice to avoid nuts, seeds, and popcorn has been debunked by large cohort studies. Focus on overall fiber intake and healthy diet.',
            level5: 'Mechanism: fiber increases stool bulk, decreases transit time, and reduces intraluminal pressure. Colonic microbiome effects may also be important.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'sigmoid-colon', structureName: 'Sigmoid Colon', role: 'primary-site', involvement: 'Most common site of diverticulitis (Western)', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'descending-colon', structureName: 'Descending Colon', role: 'secondary-site', involvement: 'May also be involved', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Gastrointestinal'],
        recommendedView: 'anterior',
        recommendedLayers: ['digestive'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: 'Diverticulitis is when small pouches in your intestine become inflamed or infected. It causes pain (usually on the left side of your belly) and can be treated with antibiotics.',
        level2: 'Diverticula are small pockets that form in the colon wall with age. When one becomes blocked and inflamed, it causes diverticulitis. Most cases respond to antibiotics, but some need drainage or surgery.',
        level3: 'Diagnose with CT showing wall thickening, fat stranding, and diverticula. Classify as uncomplicated or complicated (abscess, perforation, fistula). Uncomplicated: outpatient antibiotics or observation. Complicated: drainage/surgery.',
        level4: 'Hinchey classification guides management: I-II (abscess) may be drained percutaneously; III-IV (perforation) usually need surgery. Elective sigmoid resection controversial - individualize based on recurrence, complications, patient factors.',
        level5: 'Pathophysiology: structural weakness at vasa recta penetration + increased intraluminal pressure. Microperforation leads to pericolic phlegmon/abscess. Complicated disease involves contained or free perforation.',
      },
      relatedConditions: ['diverticulosis', 'colon-cancer', 'irritable-bowel-syndrome'],
      epidemiology: {
        prevalence: '50% of people >60 have diverticulosis; ~10-25% develop diverticulitis',
        incidence: 'Increasing, especially in younger patients',
        demographics: 'Rare <40; increases with age; left-sided in West, right-sided in Asia',
      },
      clinicalPearls: [
        'CT is gold standard - do not diagnose empirically on first episode',
        'You no longer need to avoid nuts, seeds, and popcorn',
        'Colonoscopy after recovery (6-8 weeks) to rule out malignancy',
        'Not all diverticulitis needs antibiotics - observation reasonable for uncomplicated',
        'Right-sided diverticulitis mimics appendicitis - CT distinguishes them',
      ],
      patientEducation: [
        'Gradually increase fiber in your diet after recovery',
        'You can eat nuts, seeds, and popcorn - they do not cause diverticulitis',
        'Stay well hydrated and exercise regularly',
        'See your doctor for a colonoscopy after recovery to make sure there are no other problems',
        'Return if pain worsens, fever increases, or you cannot keep fluids down',
      ],
      emergencyWarnings: [
        'Sudden severe abdominal pain',
        'High fever >102°F',
        'Unable to eat or drink',
        'Rigid abdomen or severe tenderness',
        'Blood in stool (may indicate different diagnosis)',
      ],
    },
  ],

  // Psoriasis
  [
    'psoriasis',
    {
      conditionId: 'psoriasis',
      name: 'Psoriasis',
      aliases: ['Plaque Psoriasis', 'Psoriatic Skin Disease'],
      icdCode: 'L40.0',
      category: 'dermatologic',
      subcategory: 'Inflammatory Skin Disease',
      description:
        'A chronic autoimmune skin condition that causes skin cells to multiply rapidly, resulting in raised, red, scaly patches on the skin. It is not contagious and can range from mild to severe.',
      pathophysiology: {
        summary:
          'Dysregulated immune response with T-cell activation leads to keratinocyte hyperproliferation, causing rapid skin cell turnover (3-4 days vs normal 28 days) and characteristic plaques.',
        mechanisms: [
          {
            name: 'T-Cell Mediated Inflammation',
            description: 'Th1 and Th17 cells activate and release inflammatory cytokines',
            systemsInvolved: ['Immune', 'Integumentary'],
            keyMediators: ['IL-17', 'IL-23', 'TNF-alpha', 'IL-22'],
            contribution: 'Drives inflammatory cascade',
          },
          {
            name: 'Keratinocyte Hyperproliferation',
            description: 'Skin cells multiply 10x faster than normal',
            systemsInvolved: ['Integumentary'],
            contribution: 'Creates scale and thickened plaques',
          },
          {
            name: 'Angiogenesis',
            description: 'New blood vessel formation in dermis',
            systemsInvolved: ['Cardiovascular', 'Integumentary'],
            contribution: 'Explains erythema (redness)',
          },
        ],
        riskFactors: [
          { name: 'Genetics', type: 'non-modifiable', impact: 'major', description: 'HLA-Cw6 and many other genes; family history strongly increases risk' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'Associated with more severe disease', intervention: 'Weight loss' },
          { name: 'Smoking', type: 'modifiable', impact: 'moderate', description: 'Increases risk and severity', intervention: 'Smoking cessation' },
          { name: 'Stress', type: 'modifiable', impact: 'moderate', description: 'Common trigger for flares', intervention: 'Stress management' },
          { name: 'Streptococcal Infection', type: 'partially-modifiable', impact: 'moderate', description: 'Can trigger guttate psoriasis', intervention: 'Treat infections promptly' },
          { name: 'Medications', type: 'partially-modifiable', impact: 'minor', description: 'Beta-blockers, lithium, antimalarials can trigger/worsen' },
        ],
        geneticFactors: ['HLA-Cw6', 'IL12B', 'IL23R', 'TNFAIP3'],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Raised Red Plaques', prevalence: 'very-common', description: 'Well-demarcated, erythematous patches with sharp borders', location: 'Elbows, knees, scalp, lower back' },
          { name: 'Silver-White Scale', prevalence: 'very-common', description: 'Thick, silvery scale that can be scraped off', quality: '"Micaceous" scale' },
          { name: 'Itching', prevalence: 'common', description: 'Pruritus varies from mild to severe' },
        ],
        associatedSymptoms: [
          { name: 'Nail Changes', prevalence: 'common', description: 'Pitting, onycholysis, thickening, oil spots' },
          { name: 'Joint Pain', prevalence: 'common', description: '~30% develop psoriatic arthritis' },
          { name: 'Psychosocial Impact', prevalence: 'very-common', description: 'Depression, anxiety, social isolation' },
        ],
        physicalFindings: [
          { name: 'Erythematous Plaques', examType: 'inspection', description: 'Red, raised, well-demarcated plaques', diagnosticValue: 'Hallmark finding' },
          { name: 'Silvery Scale', examType: 'inspection', description: 'Characteristic silver-white scale', diagnosticValue: 'Distinguishing feature' },
          { name: 'Auspitz Sign', examType: 'inspection', description: 'Pinpoint bleeding when scale removed', diagnosticValue: 'Classic sign' },
          { name: 'Koebner Phenomenon', examType: 'history/inspection', description: 'New lesions at sites of skin trauma', diagnosticValue: 'Common in psoriasis' },
          { name: 'Nail Pitting', examType: 'inspection', description: 'Small depressions in nail plate', diagnosticValue: 'Supports diagnosis' },
        ],
        labFindings: [
          { testName: 'Clinical Diagnosis', abnormality: 'Diagnosis is clinical; no specific test', normalRange: 'N/A', significance: 'Based on appearance' },
          { testName: 'Skin Biopsy', abnormality: 'Parakeratosis, acanthosis, Munro microabscesses', normalRange: 'Normal skin histology', significance: 'If diagnosis uncertain' },
        ],
      },
      progression: {
        naturalHistory:
          'Chronic, lifelong condition with periods of flares and remission. Severity varies widely. Not curable but very manageable with modern treatments.',
        timelineSteps: [
          {
            phaseId: 'mild',
            phase: 'early',
            displayName: 'Mild Psoriasis',
            timeframe: 'Variable',
            description: '<3% body surface area affected',
            symptoms: ['Few plaques', 'Minimal symptoms', 'Limited impact on quality of life'],
            anatomicalChanges: [
              { structureId: 'skin', structureName: 'Skin', changeType: 'inflammation', description: 'Localized plaques', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Topical steroids', 'Vitamin D analogs', 'Moisturizers'],
          },
          {
            phaseId: 'moderate',
            phase: 'established',
            displayName: 'Moderate Psoriasis',
            timeframe: 'Variable',
            description: '3-10% body surface area or high-impact areas',
            symptoms: ['More extensive plaques', 'Significant itching', 'Social impact'],
            anatomicalChanges: [
              { structureId: 'skin', structureName: 'Skin', changeType: 'inflammation', description: 'Multiple plaques', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Phototherapy', 'Systemic medications', 'Combination topicals'],
          },
          {
            phaseId: 'severe',
            phase: 'advanced',
            displayName: 'Severe Psoriasis',
            timeframe: 'Variable',
            description: '>10% BSA or severe impact on quality of life',
            symptoms: ['Extensive involvement', 'Severe symptoms', 'Major quality of life impairment'],
            anatomicalChanges: [
              { structureId: 'skin', structureName: 'Skin', changeType: 'inflammation', description: 'Widespread plaques', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.7 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Biologic agents', 'Systemic immunosuppressants'],
          },
        ],
        prognosis:
          'Not curable but highly treatable. Modern biologics can achieve near-complete clearance. Associated with increased cardiovascular risk.',
      },
      complications: [
        {
          complicationId: 'psoriatic-arthritis',
          name: 'Psoriatic Arthritis',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Inflammatory arthritis occurring in ~30% of psoriasis patients',
          mechanism: 'Shared inflammatory pathways affect joints',
          affectedStructures: [{ structureId: 'joints', structureName: 'Joints', effect: 'Inflammatory arthritis', highlightColor: '#ef4444' }],
          warningSymptoms: ['Joint pain', 'Morning stiffness', 'Swelling (especially fingers/toes)', 'Nail changes'],
          treatment: 'DMARDs, biologics',
          preventable: false,
        },
        {
          complicationId: 'cardiovascular-psoriasis',
          name: 'Cardiovascular Disease',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Increased risk of heart attack and stroke',
          mechanism: 'Chronic systemic inflammation accelerates atherosclerosis',
          affectedStructures: [{ structureId: 'cardiovascular', structureName: 'Cardiovascular System', effect: 'Accelerated atherosclerosis', highlightColor: '#dc2626' }],
          warningSymptoms: ['Chest pain', 'Shortness of breath'],
          prevention: ['Control psoriasis', 'Manage cardiovascular risk factors'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'topical-steroids-psoriasis',
          name: 'Topical Corticosteroids',
          modality: 'pharmacological',
          description: 'First-line treatment for limited psoriasis',
          mechanism: 'Reduce inflammation and slow skin cell turnover',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Clear plaques', 'Reduce symptoms'],
          explanations: {
            level1: 'Steroid creams applied to the skin reduce redness, scaling, and itching.',
            level2: 'Topical steroids come in different strengths. Use stronger ones for thick plaques on body, milder ones for face/skin folds. Do not use continuously to avoid skin thinning.',
            level3: 'Match potency to body site and plaque thickness. Weekend/pulse therapy can maintain clearance. Combination with vitamin D analogs (calcipotriene) improves efficacy.',
            level4: 'Tachyphylaxis can occur with continuous use. Rotate with non-steroidal topicals. Foam and solution vehicles for scalp. Fixed-combination products (calcipotriene/betamethasone) convenient.',
            level5: 'Mechanism: suppress T-cell function, reduce cytokine production, decrease keratinocyte proliferation. Skin atrophy from collagen/GAG loss with prolonged use.',
          },
        },
        {
          treatmentId: 'biologics-psoriasis',
          name: 'Biologic Therapies',
          modality: 'pharmacological',
          description: 'Targeted immune therapies for moderate-severe psoriasis',
          mechanism: 'Block specific cytokines (IL-17, IL-23, TNF) driving inflammation',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established', 'advanced'],
          goals: ['PASI 90/100 (near-complete clearance)', 'Improve quality of life'],
          explanations: {
            level1: 'Advanced medications given by injection that target the specific immune cells causing psoriasis. Very effective for clearing skin.',
            level2: 'Biologics block specific immune chemicals causing psoriasis. Given as injections (self-administered or at office). Can achieve 90-100% clearance.',
            level3: 'IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (guselkumab, risankizumab), TNF inhibitors. IL-17/23 blockers most effective. Screen for TB before starting.',
            level4: 'IL-17 and IL-23 inhibitors achieving PASI 90-100 in majority. Choice based on efficacy, safety, dosing convenience. Consider psoriatic arthritis when selecting.',
            level5: 'IL-23 inhibitors target upstream of IL-17; may have more durable responses. Risankizumab and guselkumab showing excellent long-term data. Biosimilars reducing costs for TNF inhibitors.',
          },
        },
        {
          treatmentId: 'phototherapy-psoriasis',
          name: 'Phototherapy',
          modality: 'interventional',
          description: 'Controlled UV light exposure',
          mechanism: 'UV light suppresses skin immune cells and slows cell turnover',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Clear plaques', 'Maintain remission'],
          explanations: {
            level1: 'Special UV light treatments given in a doctor\'s office can clear psoriasis.',
            level2: 'Phototherapy uses controlled UV light to slow skin cell growth. Requires multiple sessions per week. Very effective for widespread psoriasis.',
            level3: 'Narrowband UVB preferred over broadband. 2-3x weekly, 20-30 treatments for clearance. PUVA (psoralen + UVA) for refractory cases. Home units available.',
            level4: 'NB-UVB has replaced PUVA as first-line phototherapy due to better safety. Excimer laser for localized disease. Combine with topicals for better results.',
            level5: 'UVB induces T-cell apoptosis, shifts cytokine profile, and induces regulatory T cells. Cumulative UV dose linked to skin cancer risk - track lifetime exposure.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'skin', structureName: 'Skin (Epidermis)', role: 'primary-site', involvement: 'Keratinocyte hyperproliferation', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'joints', structureName: 'Joints', role: 'secondary-site', involvement: 'Psoriatic arthritis in 30%', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Integumentary', 'Immune', 'Musculoskeletal'],
        recommendedView: 'anterior',
        recommendedLayers: ['integumentary'],
      },
      explanations: {
        level1: 'Psoriasis is a skin condition where your immune system causes skin cells to grow too fast, making thick, scaly patches. It is not contagious and can be treated.',
        level2: 'In psoriasis, your immune system mistakenly attacks healthy skin, causing cells to build up rapidly on the surface. This creates red, scaly plaques. Modern treatments can clear the skin almost completely.',
        level3: 'Diagnose clinically by appearance. Assess severity using BSA and PASI. Mild disease: topicals. Moderate-severe: phototherapy or systemics. Biologics (IL-17, IL-23 inhibitors) achieve PASI 90 in most patients.',
        level4: 'Screen for psoriatic arthritis (CASPAR criteria), metabolic syndrome, and cardiovascular risk. Treat-to-target with PASI goals. IL-23 inhibitors emerging as most effective class.',
        level5: 'Pathogenesis: dendritic cells present antigens to T cells → Th17 differentiation → IL-17/IL-22 production → keratinocyte proliferation. IL-23 maintains Th17 cells. Genetic variants affect IL-23/IL-17 pathway.',
      },
      relatedConditions: ['psoriatic-arthritis', 'eczema', 'seborrheic-dermatitis'],
      comorbidities: ['metabolic-syndrome', 'cardiovascular-disease', 'depression', 'inflammatory-bowel-disease'],
      epidemiology: {
        prevalence: '2-3% of population',
        incidence: 'Bimodal onset: 20-30 years and 50-60 years',
        demographics: 'Equal in men and women; less common in darker skin',
      },
      clinicalPearls: [
        'Nail involvement and scalp involvement are very common - examine these areas',
        'Always screen for psoriatic arthritis - early treatment prevents joint damage',
        'Patients have increased cardiovascular risk - assess and manage',
        'Biologics can achieve >90% clearance in most patients',
        'Psoriasis is associated with significant psychological burden - address this',
      ],
      patientEducation: [
        'Psoriasis is not contagious - you cannot give it to others',
        'Moisturizing regularly helps reduce scale and itching',
        'Avoid triggers you have identified (stress, skin injury, infections)',
        'Modern treatments can make your skin almost completely clear',
        'Tell your doctor if you develop joint pain - it may need different treatment',
      ],
      emergencyWarnings: [
        'Widespread redness covering most of body with fever (erythrodermic psoriasis)',
        'Pustules covering large areas with fever',
        'Signs of serious infection',
        'Severe allergic reaction to medication',
      ],
    },
  ],

  // Atopic Dermatitis (Eczema)
  [
    'atopic-dermatitis',
    {
      conditionId: 'atopic-dermatitis',
      name: 'Atopic Dermatitis',
      aliases: ['Eczema', 'Atopic Eczema'],
      icdCode: 'L20.9',
      category: 'dermatologic',
      subcategory: 'Inflammatory Skin Disease',
      description:
        'A chronic, relapsing inflammatory skin condition characterized by dry, itchy skin and recurrent rashes. Often associated with other allergic conditions like asthma and hay fever (the "atopic triad").',
      pathophysiology: {
        summary:
          'Atopic dermatitis results from skin barrier dysfunction (especially filaggrin deficiency), immune dysregulation with Th2 predominance, and environmental triggers.',
        mechanisms: [
          {
            name: 'Skin Barrier Dysfunction',
            description: 'Defects in filaggrin and other barrier proteins allow allergen penetration and water loss',
            systemsInvolved: ['Integumentary'],
            keyMediators: ['Filaggrin', 'Ceramides', 'Tight junction proteins'],
            contribution: 'Fundamental defect predisposing to inflammation',
          },
          {
            name: 'Th2 Immune Response',
            description: 'Type 2 inflammatory response with elevated IgE and eosinophils',
            systemsInvolved: ['Immune', 'Integumentary'],
            keyMediators: ['IL-4', 'IL-13', 'IL-31', 'IgE'],
            contribution: 'Drives acute inflammation and itch',
          },
          {
            name: 'Itch-Scratch Cycle',
            description: 'Scratching damages skin, worsens barrier, increases inflammation',
            systemsInvolved: ['Integumentary', 'Neurologic'],
            contribution: 'Perpetuates and worsens disease',
          },
        ],
        riskFactors: [
          { name: 'Family History', type: 'non-modifiable', impact: 'major', description: 'Strong genetic component; parental atopy increases risk' },
          { name: 'Filaggrin Mutations', type: 'non-modifiable', impact: 'major', description: 'Loss-of-function mutations strongly associated' },
          { name: 'Urban Environment', type: 'partially-modifiable', impact: 'moderate', description: 'Higher prevalence in cities' },
          { name: 'Early Allergen Exposure', type: 'partially-modifiable', impact: 'moderate', description: 'Early sensitization to allergens' },
          { name: 'Dry Climate', type: 'partially-modifiable', impact: 'minor', description: 'Low humidity worsens skin dryness' },
        ],
        geneticFactors: ['FLG (filaggrin)', 'IL-4', 'IL-13', 'TSLP'],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Pruritus (Itch)', prevalence: 'very-common', description: 'Intense itching, often worse at night; the hallmark symptom', quality: 'Can be severe and disrupt sleep' },
          { name: 'Dry Skin', prevalence: 'very-common', description: 'Generalized xerosis (dry skin)', quality: 'Rough, scaly texture' },
          { name: 'Rash', prevalence: 'very-common', description: 'Erythematous, oozing, or lichenified patches', location: 'Age-dependent distribution' },
        ],
        associatedSymptoms: [
          { name: 'Sleep Disturbance', prevalence: 'common', description: 'Itching disrupts sleep' },
          { name: 'Asthma/Allergies', prevalence: 'common', description: 'Part of atopic march' },
          { name: 'Skin Infections', prevalence: 'common', description: 'Increased susceptibility to S. aureus, herpes' },
        ],
        physicalFindings: [
          { name: 'Acute Lesions', examType: 'inspection', description: 'Erythema, vesicles, weeping, crusting', diagnosticValue: 'Active inflammation' },
          { name: 'Chronic Lesions', examType: 'inspection', description: 'Lichenification (thickened skin with prominent lines)', diagnosticValue: 'Chronic scratching' },
          { name: 'Distribution Pattern', examType: 'inspection', description: 'Infants: face, extensor surfaces. Children/adults: flexural areas', diagnosticValue: 'Helps diagnosis' },
          { name: 'Dennie-Morgan Lines', examType: 'inspection', description: 'Extra fold under lower eyelids', diagnosticValue: 'Associated feature' },
          { name: 'Excoriations', examType: 'inspection', description: 'Scratch marks on skin', diagnosticValue: 'Evidence of pruritus' },
        ],
        labFindings: [
          { testName: 'Clinical Diagnosis', abnormality: 'No specific test - diagnosis is clinical', normalRange: 'N/A', significance: 'Based on criteria (Hanifin and Rajka)' },
          { testName: 'IgE', abnormality: 'Often elevated', normalRange: '<100 IU/mL', significance: 'Supports atopic diathesis but not required' },
        ],
      },
      progression: {
        naturalHistory:
          'Often begins in infancy; many children outgrow it. Distribution changes with age. Can persist or recur in adulthood. Associated with allergic march.',
        timelineSteps: [
          {
            phaseId: 'infantile',
            phase: 'early',
            displayName: 'Infantile Phase',
            timeframe: '0-2 years',
            description: 'First presentation, often on face and extensors',
            symptoms: ['Cheek rash', 'Scalp involvement', 'Extensor surfaces', 'Oozing, crusting'],
            anatomicalChanges: [
              { structureId: 'skin-face', structureName: 'Facial Skin', changeType: 'inflammation', description: 'Acute eczematous dermatitis', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
          },
          {
            phaseId: 'childhood',
            phase: 'established',
            displayName: 'Childhood Phase',
            timeframe: '2-12 years',
            description: 'Shifts to flexural distribution',
            symptoms: ['Antecubital and popliteal fossae involvement', 'Wrists, ankles', 'Lichenification develops'],
            anatomicalChanges: [
              { structureId: 'skin-flexural', structureName: 'Flexural Skin', changeType: 'inflammation', description: 'Chronic eczematous changes', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
          },
          {
            phaseId: 'adult',
            phase: 'chronic',
            displayName: 'Adult Phase',
            timeframe: '>12 years',
            description: 'Chronic, lichenified plaques',
            symptoms: ['Flexural involvement', 'Hand eczema common', 'Lichenification', 'May have limited or generalized disease'],
            anatomicalChanges: [
              { structureId: 'skin', structureName: 'Skin', changeType: 'fibrosis', description: 'Lichenification from chronic inflammation', severity: 'moderate', visualIndicator: { color: '#78716c', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
            ],
            reversibility: 'partially-reversible',
          },
        ],
        prognosis:
          '60-70% of children see significant improvement by adolescence. Adult-onset or persistent cases can be chronic. Modern treatments including biologics offer excellent control.',
      },
      complications: [
        {
          complicationId: 'skin-infection-ad',
          name: 'Secondary Skin Infection',
          category: 'acute',
          severity: 'moderate',
          riskLevel: 'high',
          description: 'Bacterial (S. aureus) or viral (eczema herpeticum) superinfection',
          mechanism: 'Disrupted skin barrier allows pathogen entry; scratching spreads infection',
          affectedStructures: [{ structureId: 'skin', structureName: 'Skin', effect: 'Infection and increased inflammation', highlightColor: '#dc2626' }],
          warningSymptoms: ['Honey-colored crusting (impetigo)', 'Increased redness and warmth', 'Fever', 'Grouped vesicles (herpes)'],
          prevention: ['Good skin care', 'Avoid triggers', 'Treat flares promptly'],
          treatment: 'Antibiotics or antivirals',
          preventable: true,
        },
        {
          complicationId: 'eczema-herpeticum',
          name: 'Eczema Herpeticum',
          category: 'acute',
          severity: 'major',
          riskLevel: 'low',
          description: 'Widespread herpes simplex infection in eczematous skin',
          mechanism: 'HSV spreads rapidly in compromised skin barrier',
          affectedStructures: [{ structureId: 'skin', structureName: 'Skin', effect: 'Widespread vesicles and erosions', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['Painful punched-out erosions', 'Grouped vesicles', 'Fever', 'Rapid worsening'],
          treatment: 'Urgent antiviral therapy (acyclovir)',
          preventable: false,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'emollients-ad',
          name: 'Emollients and Moisturizers',
          modality: 'supportive',
          description: 'Foundation of eczema management; repairs skin barrier',
          mechanism: 'Restore hydration and barrier function; reduce water loss',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'chronic'],
          goals: ['Maintain skin hydration', 'Reduce flares', 'Steroid-sparing'],
          explanations: {
            level1: 'Keeping your skin moisturized is the most important treatment for eczema. Apply cream or ointment multiple times daily.',
            level2: 'Moisturizers repair the skin barrier and lock in water. Apply within 3 minutes of bathing. Ointments are more effective than lotions. Use liberally.',
            level3: 'Emollients are cornerstone of therapy - use 250-500g/week for widespread eczema. Ointments > creams > lotions for efficacy. Apply even when clear.',
            level4: 'Ceramide-containing moisturizers may be beneficial. "Soak and seal" technique after bathing. Prescription barrier repair creams available.',
            level5: 'Emollients reduce TEWL, may reduce S. aureus colonization, and have anti-inflammatory properties. Essential for maintaining remission between flares.',
          },
        },
        {
          treatmentId: 'topical-steroids-ad',
          name: 'Topical Corticosteroids',
          modality: 'pharmacological',
          description: 'First-line anti-inflammatory treatment for active eczema',
          mechanism: 'Reduce inflammation and immune response in skin',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Control flares', 'Reduce itch', 'Clear active lesions'],
          explanations: {
            level1: 'Steroid creams reduce redness, swelling, and itching. Use them during flares as directed.',
            level2: 'Use the right strength for the right area - mild for face, stronger for body. Apply in a thin layer once or twice daily during flares.',
            level3: 'Match potency to severity and location. Finger-tip unit guides dosing. Proactive therapy (2x weekly to prone areas) prevents flares.',
            level4: 'Side effects (atrophy, striae) from appropriate use are overestimated - "steroid phobia" leads to undertreatment. Wet wraps amplify efficacy.',
            level5: 'TCS reduce inflammatory cell infiltration, cytokine production, and TEWL. Proactive approach reduces total steroid use vs. reactive treatment alone.',
          },
        },
        {
          treatmentId: 'dupilumab',
          name: 'Dupilumab',
          modality: 'pharmacological',
          description: 'Biologic for moderate-severe atopic dermatitis',
          mechanism: 'IL-4/IL-13 receptor antagonist; blocks Th2 inflammation',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established', 'chronic'],
          goals: ['Significant clearance', 'Reduce itch', 'Improve quality of life'],
          explanations: {
            level1: 'A biologic injection that blocks the immune chemicals causing your eczema. Given every 2 weeks.',
            level2: 'Dupilumab is for moderate-to-severe eczema that has not responded to other treatments. It dramatically reduces itch and clears skin in most patients.',
            level3: 'FDA approved for ages 6 months+. Blocks IL-4Rα, inhibiting both IL-4 and IL-13. IGA 0/1 achieved in ~40%. Generally well-tolerated; conjunctivitis main side effect.',
            level4: 'Can be combined with TCS. Also approved for asthma and chronic sinusitis - may help all atopic manifestations. JAK inhibitors (upadacitinib, abrocitinib) are oral alternatives.',
            level5: 'IL-4/IL-13 drive Th2 skewing, IgE class switching, barrier dysfunction, and itch. Dupilumab addresses multiple pathways. Tralokinumab (IL-13 specific) also approved.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'skin-epidermis', structureName: 'Skin (Epidermis)', role: 'primary-site', involvement: 'Barrier dysfunction and inflammation', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'skin-dermis', structureName: 'Dermis', role: 'secondary-site', involvement: 'Inflammatory infiltrate', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Integumentary', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['integumentary'],
      },
      explanations: {
        level1: 'Eczema is itchy, dry skin caused by a sensitive immune system and a weak skin barrier. Keeping skin moisturized and using medication during flares controls it well.',
        level2: 'Atopic dermatitis is an inflammatory skin condition where the skin barrier does not work properly, allowing irritants in and water out. This triggers the immune system, causing itching and rash. Moisturizers and anti-inflammatory creams are the main treatments.',
        level3: 'Diagnose clinically using Hanifin and Rajka criteria. Mainstays: emollients (fundamental), topical steroids (first-line anti-inflammatory), topical calcineurin inhibitors (steroid-sparing). Biologics (dupilumab) for moderate-severe.',
        level4: 'Proactive therapy with TCS or TCI 2x weekly prevents flares better than reactive treatment alone. Address steroid phobia. Screen for food allergies in refractory cases. New JAK inhibitors expand options.',
        level5: 'Pathophysiology: FLG mutations → barrier dysfunction → allergen penetration → Th2 immune response (IL-4, IL-13) → inflammation and itch. IL-31 major pruritogen. S. aureus colonization perpetuates inflammation.',
      },
      relatedConditions: ['asthma', 'seasonal-allergies', 'food-allergy', 'psoriasis'],
      comorbidities: ['asthma', 'seasonal-allergies', 'food-allergy'],
      epidemiology: {
        prevalence: '15-20% of children; 7-10% of adults',
        incidence: 'Most common in first year of life',
        demographics: 'More common in developed countries; all ethnicities affected',
      },
      clinicalPearls: [
        'Itch is the hallmark - "the itch that rashes" (scratching causes visible lesions)',
        'Distribution changes with age: infants (face, extensors) → children/adults (flexures)',
        'Moisturizers are fundamental - not just nice to have',
        'Steroid phobia leads to undertreated disease - address it',
        'Consider eczema herpeticum if painful, rapidly spreading lesions with systemic symptoms',
      ],
      patientEducation: [
        'Moisturize liberally and often - this is the foundation of treatment',
        'Use lukewarm water for baths (not hot), and moisturize within 3 minutes of bathing',
        'Identify and avoid your triggers (certain fabrics, soaps, allergens)',
        'Use steroids as prescribed - they are safe when used correctly',
        'Trim nails short to minimize damage from scratching',
      ],
      emergencyWarnings: [
        'Rapidly spreading painful rash with fever (eczema herpeticum)',
        'Signs of skin infection: increasing redness, warmth, pus, fever',
        'Severe flare not responding to usual treatment',
        'Widespread severe eczema with poor oral intake or dehydration',
      ],
    },
  ],

  // Systemic Lupus Erythematosus
  [
    'systemic-lupus-erythematosus',
    {
      conditionId: 'systemic-lupus-erythematosus',
      name: 'Systemic Lupus Erythematosus',
      aliases: ['SLE', 'Lupus'],
      icdCode: 'M32.9',
      category: 'immunologic',
      subcategory: 'Autoimmune Disease',
      description:
        'A chronic autoimmune disease where the immune system attacks the body\'s own tissues, potentially affecting the skin, joints, kidneys, brain, and other organs. Characterized by periods of flares and remission.',
      pathophysiology: {
        summary:
          'Loss of self-tolerance leads to production of autoantibodies (especially anti-dsDNA and anti-nuclear antibodies) that form immune complexes, causing inflammation in multiple organs.',
        mechanisms: [
          {
            name: 'Loss of Self-Tolerance',
            description: 'Failure of immune system to recognize self-antigens leads to autoantibody production',
            systemsInvolved: ['Immune'],
            keyMediators: ['B cells', 'T cells', 'Dendritic cells'],
            contribution: 'Fundamental defect',
          },
          {
            name: 'Autoantibody Production',
            description: 'Production of antibodies against nuclear components (ANA, anti-dsDNA, etc.)',
            systemsInvolved: ['Immune'],
            keyMediators: ['ANA', 'Anti-dsDNA', 'Anti-Smith', 'Anti-phospholipid antibodies'],
            contribution: 'Pathogenic antibodies damage tissues',
          },
          {
            name: 'Immune Complex Deposition',
            description: 'Antibody-antigen complexes deposit in tissues causing inflammation',
            systemsInvolved: ['Immune', 'Vascular'],
            keyMediators: ['Complement', 'Fc receptors'],
            contribution: 'Causes tissue damage in kidneys, skin, vessels',
          },
          {
            name: 'Interferon Pathway Activation',
            description: 'Type I interferon signaling drives inflammation',
            systemsInvolved: ['Immune'],
            keyMediators: ['IFN-α', 'IFN-β'],
            contribution: 'Key inflammatory pathway - target for new therapies',
          },
        ],
        riskFactors: [
          { name: 'Female Sex', type: 'non-modifiable', impact: 'major', description: '9:1 female predominance; estrogen effects on immune system' },
          { name: 'Genetics', type: 'non-modifiable', impact: 'major', description: 'Multiple genes including HLA-DR2/DR3, complement deficiencies' },
          { name: 'African/Asian/Hispanic Ancestry', type: 'non-modifiable', impact: 'moderate', description: 'Higher incidence and severity' },
          { name: 'UV Light Exposure', type: 'modifiable', impact: 'moderate', description: 'Can trigger flares', intervention: 'Sun protection' },
          { name: 'Certain Medications', type: 'modifiable', impact: 'minor', description: 'Drug-induced lupus (hydralazine, procainamide, etc.)' },
        ],
        geneticFactors: ['HLA-DR2', 'HLA-DR3', 'C1q deficiency', 'C4 deficiency', 'TREX1'],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Profound, often disabling fatigue' },
          { name: 'Joint Pain/Arthritis', prevalence: 'very-common', description: 'Polyarthralgia or non-erosive arthritis, often symmetric', location: 'Multiple joints, especially small joints' },
          { name: 'Skin Rash', prevalence: 'very-common', description: 'Malar (butterfly) rash, photosensitivity, discoid lesions' },
          { name: 'Fever', prevalence: 'common', description: 'Low-grade fever during flares' },
        ],
        associatedSymptoms: [
          { name: 'Photosensitivity', prevalence: 'common', description: 'Skin reaction to sun exposure' },
          { name: 'Oral Ulcers', prevalence: 'common', description: 'Painless mouth sores' },
          { name: 'Raynaud Phenomenon', prevalence: 'common', description: 'Fingers/toes turn white then blue with cold' },
          { name: 'Hair Loss', prevalence: 'common', description: 'Alopecia, often diffuse or at hairline' },
          { name: 'Serositis', prevalence: 'common', description: 'Pleuritis or pericarditis' },
        ],
        physicalFindings: [
          { name: 'Malar Rash', examType: 'inspection', description: 'Butterfly-shaped rash over cheeks and nose, spares nasolabial folds', diagnosticValue: 'Classic SLE finding' },
          { name: 'Discoid Lesions', examType: 'inspection', description: 'Coin-shaped scarring plaques', diagnosticValue: 'Chronic cutaneous lupus' },
          { name: 'Arthritis', examType: 'joint exam', description: 'Non-erosive, non-deforming (usually), symmetric', diagnosticValue: 'Common manifestation' },
          { name: 'Oral/Nasal Ulcers', examType: 'inspection', description: 'Usually painless mucosal ulcers', diagnosticValue: 'Classification criterion' },
          { name: 'Edema', examType: 'inspection', description: 'May indicate nephrotic syndrome from lupus nephritis', diagnosticValue: 'Suggests renal involvement' },
        ],
        labFindings: [
          { testName: 'ANA', abnormality: 'Positive (>97% sensitivity)', normalRange: 'Negative', significance: 'Screening test; very sensitive but not specific' },
          { testName: 'Anti-dsDNA', abnormality: 'Positive', normalRange: 'Negative', significance: 'Specific for SLE; correlates with disease activity and nephritis' },
          { testName: 'Anti-Smith', abnormality: 'Positive', normalRange: 'Negative', significance: 'Highly specific for SLE (low sensitivity)' },
          { testName: 'Complement (C3, C4)', abnormality: 'Low', normalRange: 'Normal', significance: 'Consumed in active disease; tracks activity' },
          { testName: 'CBC', abnormality: 'Cytopenias (anemia, leukopenia, thrombocytopenia)', normalRange: 'Normal', significance: 'Autoimmune destruction' },
          { testName: 'Urinalysis', abnormality: 'Proteinuria, hematuria, casts', normalRange: 'Normal', significance: 'Indicates lupus nephritis' },
        ],
        imagingFindings: [
          { modality: 'Chest X-ray', finding: 'Pleural effusion, pericardial effusion', significance: 'Serositis', structures: ['Chest'] },
          { modality: 'Echocardiogram', finding: 'Pericardial effusion, valve abnormalities', significance: 'Cardiac involvement', structures: ['Heart'] },
        ],
      },
      progression: {
        naturalHistory:
          'Chronic disease with unpredictable flares and remissions. Renal involvement (lupus nephritis) is a major determinant of prognosis. Modern treatments have dramatically improved survival.',
        timelineSteps: [
          {
            phaseId: 'mild',
            phase: 'early',
            displayName: 'Mild SLE',
            timeframe: 'Variable',
            description: 'Constitutional symptoms, skin/joint involvement',
            symptoms: ['Fatigue', 'Arthralgia/arthritis', 'Rash', 'Photosensitivity'],
            anatomicalChanges: [
              { structureId: 'skin', structureName: 'Skin', changeType: 'inflammation', description: 'Malar rash, photosensitive eruptions', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
              { structureId: 'joints', structureName: 'Joints', changeType: 'inflammation', description: 'Non-erosive synovitis', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Hydroxychloroquine', 'NSAIDs', 'Low-dose steroids'],
          },
          {
            phaseId: 'moderate',
            phase: 'established',
            displayName: 'Moderate SLE',
            timeframe: 'Variable',
            description: 'More significant organ involvement',
            symptoms: ['Serositis', 'Cytopenias', 'More severe rash', 'Nephritis (early)'],
            anatomicalChanges: [
              { structureId: 'pleura', structureName: 'Pleura/Pericardium', changeType: 'inflammation', description: 'Serositis', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Hydroxychloroquine', 'Moderate-dose steroids', 'Immunosuppressants'],
          },
          {
            phaseId: 'severe',
            phase: 'severe',
            displayName: 'Severe SLE',
            timeframe: 'Variable',
            description: 'Major organ involvement',
            symptoms: ['Proliferative nephritis', 'CNS lupus', 'Severe cytopenias', 'Catastrophic APS'],
            anatomicalChanges: [
              { structureId: 'kidneys', structureName: 'Kidneys', changeType: 'inflammation', description: 'Lupus nephritis with glomerular damage', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['High-dose steroids', 'Cyclophosphamide/MMF', 'Rituximab', 'Belimumab'],
          },
        ],
        prognosis:
          '10-year survival now >90% with modern treatment. Renal and CNS involvement worsen prognosis. Leading causes of death: infections, cardiovascular disease, active lupus.',
      },
      complications: [
        {
          complicationId: 'lupus-nephritis',
          name: 'Lupus Nephritis',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Kidney inflammation from immune complex deposition',
          mechanism: 'Anti-dsDNA antibodies and immune complexes deposit in glomeruli',
          affectedStructures: [{ structureId: 'kidneys', structureName: 'Kidneys', effect: 'Glomerulonephritis', highlightColor: '#dc2626' }],
          warningSymptoms: ['Foamy urine', 'Swelling (edema)', 'Hypertension', 'Decreased urine output'],
          prevention: ['Screen with urinalysis regularly', 'Control disease activity', 'Hydroxychloroquine reduces risk'],
          treatment: 'Immunosuppression (MMF, cyclophosphamide), steroids',
          preventable: true,
        },
        {
          complicationId: 'cns-lupus',
          name: 'CNS Lupus (Neuropsychiatric SLE)',
          category: 'both',
          severity: 'major',
          riskLevel: 'low',
          description: 'Brain and nervous system involvement',
          mechanism: 'Vasculitis, antibodies crossing blood-brain barrier, microinfarcts',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Inflammation, vasculitis', highlightColor: '#8b5cf6' }],
          warningSymptoms: ['Severe headache', 'Seizures', 'Psychosis', 'Cognitive dysfunction', 'Stroke symptoms'],
          treatment: 'High-dose steroids, immunosuppression',
          preventable: false,
        },
        {
          complicationId: 'cardiovascular-sle',
          name: 'Cardiovascular Disease',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Accelerated atherosclerosis and increased cardiovascular events',
          mechanism: 'Chronic inflammation, steroids, traditional risk factors, antiphospholipid antibodies',
          affectedStructures: [{ structureId: 'heart', structureName: 'Cardiovascular System', effect: 'Accelerated atherosclerosis', highlightColor: '#ef4444' }],
          warningSymptoms: ['Chest pain', 'Shortness of breath'],
          prevention: ['Control disease activity', 'Minimize steroid use', 'Manage traditional risk factors'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'hydroxychloroquine-sle',
          name: 'Hydroxychloroquine',
          modality: 'pharmacological',
          description: 'Cornerstone of SLE treatment; should be on it if no contraindication',
          mechanism: 'Immunomodulatory effects; reduces flares, damage accrual, mortality',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'severe'],
          goals: ['Reduce flares', 'Reduce damage accrual', 'Improve survival'],
          timeToEffect: 'Weeks to months',
          explanations: {
            level1: 'Hydroxychloroquine is taken daily to help control lupus and prevent flares. Almost everyone with lupus should be on it.',
            level2: 'This medication reduces lupus flares, protects organs from damage, and even improves survival. It is very safe for most people. Requires periodic eye exams.',
            level3: 'All SLE patients should be on HCQ unless contraindicated. Reduces flares, thrombosis risk, damage accrual, and mortality. Annual eye exam after 5 years for retinal toxicity.',
            level4: 'Benefits: steroid-sparing, anti-thrombotic, lipid-lowering, may reduce nephritis risk. Target serum level >750 ng/mL. Safe in pregnancy.',
            level5: 'Mechanisms: inhibits TLR7/9 signaling, reduces IFN-α production, stabilizes lysosomes, blocks antigen processing. Landmark data from Hopkins cohort on mortality benefit.',
          },
        },
        {
          treatmentId: 'steroids-sle',
          name: 'Corticosteroids',
          modality: 'pharmacological',
          description: 'Rapid-acting immunosuppression for flares',
          mechanism: 'Broad suppression of inflammatory pathways',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute', 'severe'],
          goals: ['Control acute flares', 'Bridge to steroid-sparing agents'],
          explanations: {
            level1: 'Steroids (like prednisone) quickly reduce inflammation during lupus flares but have side effects with long-term use.',
            level2: 'Steroids are effective but cause problems with prolonged use (weight gain, osteoporosis, infections). The goal is always to use the lowest dose for the shortest time.',
            level3: 'High-dose for severe flares, then taper. Goal: prednisone ≤7.5 mg daily (ideally off). Long-term steroids major contributor to damage accrual. Add steroid-sparing agents.',
            level4: 'Pulse methylprednisolone 250-1000 mg x 3 days for severe flares. APLC study showed more damage with higher steroid exposure. Minimize cumulative dose.',
            level5: 'Steroids suppress NF-κB, reduce cytokine production, induce lymphocyte apoptosis. But also cause metabolic, cardiovascular, bone, and infectious complications.',
          },
        },
        {
          treatmentId: 'belimumab',
          name: 'Belimumab',
          modality: 'pharmacological',
          description: 'Biologic targeting B-cell survival factor',
          mechanism: 'Blocks BLyS (BAFF), reducing B-cell survival and autoantibody production',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established', 'severe'],
          goals: ['Reduce flares', 'Steroid-sparing', 'Reduce disease activity'],
          explanations: {
            level1: 'A biologic injection that helps control lupus by targeting specific immune cells.',
            level2: 'Belimumab blocks a protein that helps immune cells survive. Given monthly (or weekly SC). Helps reduce flares and steroid needs.',
            level3: 'First FDA-approved biologic for SLE. Add-on therapy for active disease despite standard treatment. BLISS trials showed reduced flares and steroid use. Also approved for lupus nephritis.',
            level4: 'BLISS-LN showed benefit in lupus nephritis on top of standard of care. SC weekly dosing available. Anifrolumab (anti-IFN) also approved for moderate-severe SLE.',
            level5: 'BLyS/BAFF supports autoreactive B cell survival. Belimumab preferentially affects newly formed and transitional B cells while preserving memory. Combination with rituximab under study.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'skin', structureName: 'Skin', role: 'primary-site', involvement: 'Malar rash, photosensitivity', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'joints', structureName: 'Joints', role: 'primary-site', involvement: 'Non-erosive arthritis', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'kidneys', structureName: 'Kidneys', role: 'target-organ', involvement: 'Lupus nephritis', highlightColor: '#dc2626', showByDefault: true },
          { structureId: 'heart', structureName: 'Heart', role: 'secondary-site', involvement: 'Pericarditis, endocarditis', highlightColor: '#f97316', showByDefault: false },
          { structureId: 'brain', structureName: 'Brain', role: 'secondary-site', involvement: 'Neuropsychiatric manifestations', highlightColor: '#8b5cf6', showByDefault: false },
        ],
        systemsInvolved: ['Immune', 'Integumentary', 'Musculoskeletal', 'Renal', 'Cardiovascular', 'Neurologic'],
        recommendedView: 'anterior',
        recommendedLayers: ['skeletal', 'integumentary'],
      },
      explanations: {
        level1: 'Lupus is a disease where your immune system attacks your own body. It can affect many parts of the body including skin, joints, and kidneys. Medications can control it.',
        level2: 'In lupus, your immune system makes antibodies that attack your own tissues. This causes inflammation in the skin, joints, kidneys, and other organs. Treatment focuses on calming the immune system and protecting organs.',
        level3: 'SLE is autoimmune with multi-organ involvement. Key labs: ANA (sensitive), anti-dsDNA (specific, tracks activity), complement (tracks activity). All patients should be on HCQ. Monitor for nephritis.',
        level4: 'ACR/EULAR 2019 criteria for classification. Treat-to-target approach (DORIS remission criteria). Lupus nephritis requires biopsy for classification. Belimumab and anifrolumab expand treatment options.',
        level5: 'Pathogenesis: defective clearance of apoptotic debris → exposure of nuclear antigens → loss of tolerance → autoantibody production → immune complex deposition and complement activation. Type I IFN signature central.',
      },
      relatedConditions: ['rheumatoid-arthritis', 'antiphospholipid-syndrome', 'sjogrens-syndrome'],
      comorbidities: ['antiphospholipid-syndrome', 'cardiovascular-disease', 'osteoporosis'],
      epidemiology: {
        prevalence: '20-150 per 100,000',
        incidence: '1-10 per 100,000 person-years',
        demographics: '9:1 female predominance; higher incidence in Black, Asian, Hispanic populations; peak onset 15-45 years',
      },
      clinicalPearls: [
        'ANA is sensitive but not specific - positive in many healthy people',
        'Anti-dsDNA correlates with disease activity and nephritis',
        'All patients should be on hydroxychloroquine unless contraindicated',
        'Screen for lupus nephritis regularly with urinalysis',
        'Minimize steroid exposure - major driver of damage accrual',
      ],
      patientEducation: [
        'Protect yourself from the sun - UV light can trigger flares',
        'Take hydroxychloroquine every day as prescribed',
        'Report new symptoms promptly - lupus can affect many organs',
        'Get regular check-ups including kidney function tests',
        'Pregnancy requires careful planning - discuss with your doctor',
      ],
      emergencyWarnings: [
        'Chest pain or shortness of breath (pericarditis, PE, heart attack)',
        'Severe headache, seizures, or confusion (CNS lupus)',
        'Decreased urine output or severe swelling (kidney failure)',
        'High fever (may indicate infection or severe flare)',
        'Sudden weakness or numbness (stroke from antiphospholipid syndrome)',
      ],
    },
  ],

  // Epilepsy
  [
    'epilepsy',
    {
      conditionId: 'epilepsy',
      name: 'Epilepsy',
      aliases: ['Seizure Disorder', 'Convulsive Disorder'],
      icdCode: 'G40.909',
      category: 'neurologic',
      subcategory: 'Seizure Disorder',
      description:
        'A chronic neurological disorder characterized by recurrent unprovoked seizures due to abnormal electrical activity in the brain. Highly treatable with medications for most patients.',
      pathophysiology: {
        summary:
          'Seizures result from abnormal, excessive, synchronous neuronal activity in the brain. The underlying cause determines seizure type and treatment approach.',
        mechanisms: [
          {
            name: 'Excitation/Inhibition Imbalance',
            description: 'Imbalance between excitatory (glutamate) and inhibitory (GABA) neurotransmission',
            systemsInvolved: ['Neurologic'],
            keyMediators: ['Glutamate', 'GABA', 'Voltage-gated channels'],
            contribution: 'Fundamental mechanism of seizure generation',
          },
          {
            name: 'Abnormal Neuronal Networks',
            description: 'Structural or functional abnormalities create epileptogenic focus',
            systemsInvolved: ['Neurologic'],
            contribution: 'Determines seizure type and surgical candidacy',
          },
          {
            name: 'Kindling and Epileptogenesis',
            description: 'Repeated seizures can make brain more susceptible to future seizures',
            systemsInvolved: ['Neurologic'],
            contribution: 'May explain disease progression',
          },
        ],
        riskFactors: [
          { name: 'Head Trauma', type: 'partially-modifiable', impact: 'moderate', description: 'Significant head injury increases risk', intervention: 'Prevention of head injuries' },
          { name: 'Stroke', type: 'partially-modifiable', impact: 'moderate', description: 'Most common cause in elderly' },
          { name: 'CNS Infection', type: 'partially-modifiable', impact: 'moderate', description: 'Meningitis, encephalitis' },
          { name: 'Brain Tumor', type: 'partially-modifiable', impact: 'moderate', description: 'May present with seizures' },
          { name: 'Genetics', type: 'non-modifiable', impact: 'moderate', description: 'Some epilepsies have genetic basis' },
          { name: 'Perinatal Injury', type: 'non-modifiable', impact: 'moderate', description: 'Hypoxic-ischemic injury at birth' },
        ],
        geneticFactors: ['SCN1A', 'KCNQ2', 'Many others depending on syndrome'],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Seizures', prevalence: 'very-common', description: 'Recurrent unprovoked seizures - defining feature', quality: 'Varies by seizure type' },
          { name: 'Post-ictal Confusion', prevalence: 'common', description: 'Confusion, fatigue, headache after seizure' },
          { name: 'Aura', prevalence: 'common', description: 'Warning sensation before some seizures (actually a focal seizure)', quality: 'Déjà vu, rising sensation, smell, visual' },
        ],
        associatedSymptoms: [
          { name: 'Memory Problems', prevalence: 'common', description: 'Especially with temporal lobe epilepsy' },
          { name: 'Mood Disorders', prevalence: 'common', description: 'Depression and anxiety more common' },
        ],
        physicalFindings: [
          { name: 'Usually Normal', examType: 'neurological', description: 'Exam typically normal between seizures', diagnosticValue: 'Abnormalities suggest structural cause' },
          { name: 'Post-ictal Signs', examType: 'neurological', description: 'Todd paralysis, confusion if examined after seizure', diagnosticValue: 'Helps localize' },
        ],
        labFindings: [
          { testName: 'EEG', abnormality: 'Epileptiform discharges (spikes, sharp waves)', normalRange: 'Normal background', significance: 'Key diagnostic tool; may be normal between seizures' },
          { testName: 'Serum Glucose, Electrolytes', abnormality: 'Rule out metabolic causes', normalRange: 'Normal', significance: 'Exclude reversible causes' },
        ],
        imagingFindings: [
          { modality: 'MRI Brain', finding: 'May show structural abnormality (tumor, MTS, malformation)', significance: 'Identifies underlying cause; guides management', structures: ['Brain'] },
        ],
      },
      progression: {
        naturalHistory:
          'Variable. ~70% achieve seizure freedom with medications. Some require multiple drugs or surgery. Certain syndromes may remit (childhood absence epilepsy) or progress (some genetic epilepsies).',
        timelineSteps: [
          {
            phaseId: 'new-onset',
            phase: 'early',
            displayName: 'New-Onset Epilepsy',
            timeframe: 'Initial presentation',
            description: 'After 2+ unprovoked seizures or 1 seizure with high recurrence risk',
            symptoms: ['Seizures', 'Anxiety about recurrence', 'Lifestyle adjustments'],
            anatomicalChanges: [
              { structureId: 'brain', structureName: 'Brain (varies by focus)', changeType: 'dysfunction', description: 'Epileptogenic focus', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['First-line ASM based on seizure type'],
            goalsOfCare: ['Seizure freedom', 'Minimize side effects', 'Maintain quality of life'],
          },
          {
            phaseId: 'controlled',
            phase: 'established',
            displayName: 'Controlled Epilepsy',
            timeframe: 'Ongoing',
            description: 'Seizure-free on medication',
            symptoms: ['No seizures', 'May have medication side effects'],
            anatomicalChanges: [],
            reversibility: 'reversible',
            typicalTreatments: ['Continuation of effective ASM'],
          },
          {
            phaseId: 'drug-resistant',
            phase: 'chronic',
            displayName: 'Drug-Resistant Epilepsy',
            timeframe: 'After failing 2+ appropriate ASMs',
            description: 'Seizures persist despite adequate trials of medications',
            symptoms: ['Ongoing seizures', 'Seizure-related injuries', 'Quality of life impact'],
            anatomicalChanges: [],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Additional ASMs', 'Epilepsy surgery evaluation', 'Neurostimulation', 'Dietary therapy'],
          },
        ],
        prognosis:
          'Good for most - ~70% achieve seizure freedom with medications. Drug-resistant epilepsy (~30%) has worse prognosis but may benefit from surgery or devices.',
      },
      complications: [
        {
          complicationId: 'sudep',
          name: 'SUDEP (Sudden Unexpected Death in Epilepsy)',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'low',
          description: 'Sudden death in epilepsy patient with no other cause found',
          mechanism: 'Likely seizure-induced cardiac or respiratory arrest',
          affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'Fatal arrhythmia', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['None - occurs without warning'],
          prevention: ['Optimal seizure control', 'Nocturnal supervision', 'Seizure detection devices'],
          preventable: true,
        },
        {
          complicationId: 'status-epilepticus',
          name: 'Status Epilepticus',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'low',
          description: 'Prolonged seizure (>5 min) or repeated seizures without recovery',
          mechanism: 'Failure of seizure termination mechanisms',
          affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Excitotoxic injury', highlightColor: '#dc2626' }],
          warningSymptoms: ['Seizure lasting >5 minutes', 'Multiple seizures without waking'],
          treatment: 'Emergency - benzodiazepines, IV anti-seizure medications',
          preventable: true,
        },
        {
          complicationId: 'seizure-injuries',
          name: 'Seizure-Related Injuries',
          category: 'acute',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Injuries from falls, burns, drowning during seizures',
          mechanism: 'Loss of consciousness and motor control',
          affectedStructures: [{ structureId: 'body', structureName: 'Various', effect: 'Trauma', highlightColor: '#f97316' }],
          warningSymptoms: ['Uncontrolled seizures', 'Lack of warning/aura'],
          prevention: ['Seizure control', 'Safety precautions'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'asms',
          name: 'Anti-Seizure Medications (ASMs)',
          modality: 'pharmacological',
          description: 'First-line treatment for most epilepsies',
          mechanism: 'Various - modulate ion channels, enhance GABA, reduce glutamate',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Seizure freedom', 'Minimal side effects'],
          explanations: {
            level1: 'Medications taken daily to prevent seizures. Most people with epilepsy can control their seizures with medication.',
            level2: 'Anti-seizure medications work by calming the electrical activity in the brain. Finding the right one may take time. Taking them consistently every day is essential.',
            level3: 'Choose based on seizure/epilepsy type, comorbidities, drug interactions, teratogenicity. First-line for focal: levetiracetam, lamotrigine, oxcarbazepine. For generalized: valproate (not in women of childbearing age), lamotrigine, levetiracetam.',
            level4: 'SANAD trials inform choice. Monotherapy preferred. If first fails, try second monotherapy before polytherapy. Generic substitution issues with some. Therapeutic drug monitoring for some agents.',
            level5: 'Mechanisms: sodium channel blockade (carbamazepine, lamotrigine), GABA enhancement (benzodiazepines, barbiturates), SV2A modulation (levetiracetam), multiple (valproate). Newer agents: brivaracetam, cenobamate.',
          },
        },
        {
          treatmentId: 'epilepsy-surgery',
          name: 'Epilepsy Surgery',
          modality: 'surgical',
          description: 'Resection or disconnection of epileptogenic focus',
          mechanism: 'Remove or isolate brain tissue generating seizures',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['chronic'],
          goals: ['Seizure freedom without medications (or fewer)', 'Improve quality of life'],
          explanations: {
            level1: 'If medications do not work, surgery to remove the part of the brain causing seizures can cure epilepsy in some people.',
            level2: 'Epilepsy surgery is very effective for certain types of epilepsy, especially temporal lobe epilepsy. It requires extensive testing to make sure it is safe and will help.',
            level3: 'Refer early for surgical evaluation if drug-resistant (failed 2 appropriate ASMs). Best outcomes for MTS/temporal lobe epilepsy (~70% seizure-free). Extensive pre-surgical evaluation required.',
            level4: 'Surgery underutilized - median time to surgery >20 years in some studies. ERSET/ETLE trials showed superiority over continued medical therapy for appropriate candidates.',
            level5: 'Pre-surgical evaluation: video-EEG, high-resolution MRI, neuropsychological testing, often invasive monitoring. Resective surgery (lobectomy), laser ablation, and disconnection procedures available.',
          },
        },
        {
          treatmentId: 'vns',
          name: 'Vagus Nerve Stimulation (VNS)',
          modality: 'interventional',
          description: 'Implanted device that stimulates vagus nerve',
          mechanism: 'Modulates brain networks through vagal afferents',
          efficacy: 'moderately-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: false,
          appropriatePhases: ['chronic'],
          goals: ['Reduce seizure frequency', 'Option when surgery not possible'],
          explanations: {
            level1: 'A device implanted under the skin sends electrical pulses to a nerve to help reduce seizures.',
            level2: 'VNS is like a pacemaker for the brain. It does not cure epilepsy but can reduce seizures by 50% in many people.',
            level3: 'Option for drug-resistant epilepsy when resective surgery not feasible. ~50% responder rate. Newer models have seizure detection capability.',
            level4: 'Palliative not curative. Efficacy may improve over years. Side effects: hoarseness, cough. RNS (responsive neurostimulation) and DBS alternatives for selected patients.',
            level5: 'Mechanism not fully understood - likely modulates noradrenergic and serotonergic systems via nucleus tractus solitarius projections. Anti-inflammatory effects may also contribute.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'brain', structureName: 'Brain (varies by focus)', role: 'primary-site', involvement: 'Epileptogenic focus', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'temporal-lobe', structureName: 'Temporal Lobe', role: 'primary-site', involvement: 'Most common focal epilepsy site', highlightColor: '#dc2626', showByDefault: false },
        ],
        systemsInvolved: ['Neurologic'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
      },
      explanations: {
        level1: 'Epilepsy causes repeated seizures because of abnormal electrical activity in the brain. Medications control seizures in most people.',
        level2: 'Seizures happen when brain cells fire abnormally all at once. This can cause convulsions, staring spells, or other symptoms depending on where in the brain it starts. Daily medications prevent most seizures.',
        level3: 'Diagnose after 2+ unprovoked seizures or 1 with >60% recurrence risk. Characterize seizure type and epilepsy syndrome. EEG and MRI essential. Choose ASM based on seizure type. Refer drug-resistant cases for surgery evaluation.',
        level4: 'ILAE 2017 classification: focal vs. generalized onset. Drug-resistant = failure of 2 appropriate ASMs. Surgery underutilized. SUDEP risk counseling important.',
        level5: 'Epileptogenesis: structural/genetic abnormalities → altered ion channel function and synaptic transmission → neuronal network hyperexcitability → synchronous firing → clinical seizure. Mechanisms of drug resistance: target hypothesis, transporter hypothesis.',
      },
      relatedConditions: ['febrile-seizures', 'brain-tumor', 'stroke'],
      epidemiology: {
        prevalence: '~1% of population; 65 million people worldwide',
        incidence: '50-100 per 100,000 person-years',
        demographics: 'Bimodal: highest in children and elderly; all populations affected',
      },
      clinicalPearls: [
        'One seizure is not epilepsy - need 2+ unprovoked or 1 with >60% recurrence risk',
        'Always get an EEG and MRI (can be normal and still have epilepsy)',
        'Drug-resistant = failure of 2 appropriately chosen and dosed ASMs',
        'Refer drug-resistant patients for surgical evaluation - surgery is underutilized',
        'Counsel about SUDEP - seizure control is the best prevention',
      ],
      patientEducation: [
        'Take your medication every day at the same time - missed doses can trigger seizures',
        'Get enough sleep - sleep deprivation is a common seizure trigger',
        'Avoid alcohol excess - it can trigger seizures and interact with medications',
        'Know your triggers and try to avoid them',
        'Know the driving laws in your state regarding epilepsy',
      ],
      emergencyWarnings: [
        'Seizure lasting more than 5 minutes (call 911)',
        'Repeated seizures without waking up between them',
        'Difficulty breathing or turning blue during seizure',
        'Seizure in water',
        'Injury during seizure',
        'First-ever seizure',
      ],
    },
  ],

  // Crohn's Disease
  [
    'crohns-disease',
    {
      conditionId: 'crohns-disease',
      name: "Crohn's Disease",
      aliases: ['CD', 'Regional Enteritis', 'Crohn Disease'],
      icdCode: 'K50.90',
      category: 'gastrointestinal',
      subcategory: 'Inflammatory Bowel Disease',
      description:
        'A chronic inflammatory bowel disease that can affect any part of the GI tract from mouth to anus, most commonly the terminal ileum and colon. Characterized by transmural inflammation with skip lesions.',
      pathophysiology: {
        summary:
          'Crohn\'s results from dysregulated immune response to gut microbiota in genetically susceptible individuals, causing transmural inflammation that can lead to strictures, fistulas, and abscesses.',
        mechanisms: [
          {
            name: 'Genetic Susceptibility',
            description: 'NOD2 and other gene variants affect immune response to bacteria',
            systemsInvolved: ['Immune', 'Gastrointestinal'],
            keyMediators: ['NOD2', 'ATG16L1', 'IL23R'],
            contribution: 'Predisposition to disease',
          },
          {
            name: 'Dysregulated Immune Response',
            description: 'Th1/Th17 predominant inflammation in response to gut flora',
            systemsInvolved: ['Immune', 'Gastrointestinal'],
            keyMediators: ['TNF-alpha', 'IL-12', 'IL-23', 'IFN-gamma'],
            contribution: 'Drives chronic inflammation',
          },
          {
            name: 'Transmural Inflammation',
            description: 'Inflammation extends through full thickness of bowel wall',
            systemsInvolved: ['Gastrointestinal'],
            contribution: 'Leads to strictures, fistulas, abscesses',
          },
        ],
        riskFactors: [
          { name: 'Family History', type: 'non-modifiable', impact: 'major', description: '20% have affected relative; genetic component strong' },
          { name: 'Smoking', type: 'modifiable', impact: 'major', description: 'Increases risk 2-4x and worsens disease', intervention: 'Smoking cessation' },
          { name: 'Genetics', type: 'non-modifiable', impact: 'major', description: 'NOD2 mutations and other variants' },
          { name: 'Western Diet', type: 'modifiable', impact: 'moderate', description: 'High fat, low fiber associated with increased risk' },
          { name: 'Antibiotics in Childhood', type: 'non-modifiable', impact: 'minor', description: 'May affect microbiome development' },
        ],
        geneticFactors: ['NOD2', 'ATG16L1', 'IL23R', 'IRGM'],
        environmentalFactors: ['Smoking', 'Diet', 'Antibiotics', 'Urban environment'],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Abdominal Pain', prevalence: 'very-common', description: 'Crampy, often right lower quadrant (ileitis)', location: 'Depends on disease location' },
          { name: 'Diarrhea', prevalence: 'very-common', description: 'Chronic, may be bloody (colonic disease)', quality: 'Often watery; may have mucus' },
          { name: 'Weight Loss', prevalence: 'common', description: 'From malabsorption, decreased intake, inflammation' },
          { name: 'Fatigue', prevalence: 'very-common', description: 'From anemia, inflammation, malnutrition' },
        ],
        associatedSymptoms: [
          { name: 'Fever', prevalence: 'common', description: 'Low-grade with flares' },
          { name: 'Perianal Symptoms', prevalence: 'common', description: 'Fistulas, abscesses, fissures' },
          { name: 'Extraintestinal Manifestations', prevalence: 'common', description: 'Arthritis, uveitis, skin lesions, liver disease' },
        ],
        physicalFindings: [
          { name: 'Abdominal Tenderness', examType: 'palpation', description: 'Often RLQ if ileal disease', diagnosticValue: 'Helps localize disease' },
          { name: 'Abdominal Mass', examType: 'palpation', description: 'May indicate phlegmon or abscess', diagnosticValue: 'Suggests complication' },
          { name: 'Perianal Findings', examType: 'inspection', description: 'Fistula openings, tags, fissures', diagnosticValue: 'Characteristic of Crohn\'s' },
          { name: 'Aphthous Ulcers', examType: 'inspection', description: 'Oral ulcers', diagnosticValue: 'Extraintestinal manifestation' },
        ],
        labFindings: [
          { testName: 'CRP/ESR', abnormality: 'Elevated', normalRange: 'CRP <3 mg/L', significance: 'Markers of inflammation' },
          { testName: 'Fecal Calprotectin', abnormality: 'Elevated', normalRange: '<50 mcg/g', significance: 'Correlates with intestinal inflammation; useful for monitoring' },
          { testName: 'CBC', abnormality: 'Anemia, thrombocytosis', normalRange: 'Normal', significance: 'Iron deficiency or anemia of chronic disease' },
          { testName: 'Albumin', abnormality: 'Low', normalRange: '3.5-5.0 g/dL', significance: 'Reflects malnutrition and inflammation' },
        ],
        imagingFindings: [
          { modality: 'CT/MR Enterography', finding: 'Bowel wall thickening, strictures, fistulas', significance: 'Assesses extent and complications', structures: ['Small bowel', 'Colon'] },
          { modality: 'MRI Pelvis', finding: 'Perianal fistulas and abscesses', significance: 'Best for perianal disease', structures: ['Perianal area'] },
          { modality: 'Colonoscopy', finding: 'Aphthous ulcers, cobblestoning, skip lesions', significance: 'Gold standard for diagnosis and monitoring; allows biopsy', structures: ['Colon', 'Terminal ileum'] },
        ],
      },
      progression: {
        naturalHistory:
          'Progressive disease with risk of complications over time. ~50% develop strictures or fistulas within 20 years. Early, effective treatment may change natural history.',
        timelineSteps: [
          {
            phaseId: 'inflammatory',
            phase: 'early',
            displayName: 'Inflammatory Phenotype',
            timeframe: 'Early disease',
            description: 'Inflammation without strictures or fistulas',
            symptoms: ['Diarrhea', 'Abdominal pain', 'Weight loss', 'Fatigue'],
            anatomicalChanges: [
              { structureId: 'terminal-ileum', structureName: 'Terminal Ileum', changeType: 'inflammation', description: 'Transmural inflammation, ulceration', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Steroids for induction', 'Immunomodulators', 'Biologics'],
            goalsOfCare: ['Achieve remission', 'Mucosal healing', 'Prevent progression'],
          },
          {
            phaseId: 'stricturing',
            phase: 'established',
            displayName: 'Stricturing Phenotype',
            timeframe: 'Progressive disease',
            description: 'Fibrotic narrowing of bowel causing obstruction',
            symptoms: ['Obstructive symptoms', 'Crampy pain after eating', 'Nausea/vomiting', 'Bloating'],
            anatomicalChanges: [
              { structureId: 'small-bowel', structureName: 'Small Bowel', changeType: 'fibrosis', description: 'Fibrotic stricture with narrowed lumen', severity: 'severe', visualIndicator: { color: '#78716c', pulse: false, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Endoscopic dilation', 'Strictureplasty', 'Resection'],
          },
          {
            phaseId: 'penetrating',
            phase: 'advanced',
            displayName: 'Penetrating Phenotype',
            timeframe: 'Progressive disease',
            description: 'Fistulas and/or abscesses',
            symptoms: ['Fistula drainage', 'Perianal pain', 'Fever (abscess)', 'Pneumaturia (colovesical)'],
            anatomicalChanges: [
              { structureId: 'bowel', structureName: 'Bowel', changeType: 'structural-damage', description: 'Fistula tracts and abscess formation', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Antibiotics', 'Biologics (anti-TNF)', 'Drainage', 'Surgery'],
          },
        ],
        prognosis:
          'Chronic disease requiring lifelong management. Most patients have good quality of life with treatment. ~50-80% require surgery at some point.',
      },
      complications: [
        {
          complicationId: 'stricture-obstruction',
          name: 'Intestinal Stricture and Obstruction',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Fibrotic narrowing causing bowel obstruction',
          mechanism: 'Chronic inflammation leads to fibrosis and fixed narrowing',
          affectedStructures: [{ structureId: 'small-bowel', structureName: 'Small Bowel', effect: 'Fibrotic stricture', highlightColor: '#78716c' }],
          warningSymptoms: ['Crampy pain after eating', 'Nausea/vomiting', 'Bloating', 'Inability to pass gas/stool'],
          treatment: 'Endoscopic dilation, strictureplasty, or resection',
          preventable: true,
        },
        {
          complicationId: 'fistulas-cd',
          name: 'Fistulas',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Abnormal connections between bowel and other structures',
          mechanism: 'Transmural inflammation erodes through bowel wall',
          affectedStructures: [{ structureId: 'perianal', structureName: 'Perianal Area (most common)', effect: 'Fistula tract', highlightColor: '#dc2626' }],
          warningSymptoms: ['Drainage from perianal area', 'Passage of stool through vagina/bladder', 'Skin irritation'],
          treatment: 'Antibiotics, anti-TNF therapy, seton placement, surgery',
          preventable: true,
        },
        {
          complicationId: 'abscess-cd',
          name: 'Intra-abdominal Abscess',
          category: 'acute',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Walled-off infection from perforation',
          mechanism: 'Transmural inflammation and microperforation',
          affectedStructures: [{ structureId: 'abdomen', structureName: 'Abdominal Cavity', effect: 'Abscess', highlightColor: '#7f1d1d' }],
          warningSymptoms: ['Fever', 'Localized tenderness', 'Palpable mass'],
          treatment: 'Drainage (percutaneous or surgical) + antibiotics',
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'anti-tnf-cd',
          name: 'Anti-TNF Biologics',
          modality: 'pharmacological',
          description: 'Biologic therapy targeting TNF-alpha',
          mechanism: 'Block TNF-alpha, a key inflammatory cytokine',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['early', 'established', 'advanced'],
          goals: ['Induce and maintain remission', 'Mucosal healing', 'Steroid-sparing', 'Prevent surgery'],
          explanations: {
            level1: 'Biologic medications given by injection or IV that block inflammation. Very effective for controlling Crohn\'s.',
            level2: 'Anti-TNF drugs (infliximab, adalimumab) target a specific inflammatory protein. They can heal the bowel lining and are especially good for fistulas.',
            level3: 'First-line biologics for moderate-severe CD. Infliximab IV or adalimumab SC. Combination with immunomodulator (azathioprine) improves efficacy. Monitor for infections, TB screening before starting.',
            level4: 'SONIC showed combination infliximab + AZA superior to either alone. Therapeutic drug monitoring improves outcomes. Consider early use in high-risk patients.',
            level5: 'TNF-alpha drives granuloma formation, epithelial apoptosis, and angiogenesis. Anti-TNF induces T-cell apoptosis, blocks inflammatory cascade. Antibody development and loss of response challenges.',
          },
        },
        {
          treatmentId: 'vedolizumab',
          name: 'Vedolizumab',
          modality: 'pharmacological',
          description: 'Gut-selective integrin inhibitor',
          mechanism: 'Blocks α4β7 integrin, preventing lymphocyte trafficking to gut',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established'],
          goals: ['Induce and maintain remission', 'Alternative to anti-TNF'],
          explanations: {
            level1: 'A biologic that works specifically in the gut with fewer body-wide effects.',
            level2: 'Vedolizumab blocks immune cells from getting into the intestine. It is safer in some ways because it works mainly in the gut, not the whole body.',
            level3: 'Gut-selective - lower systemic immunosuppression than anti-TNF. IV infusion. May be slower onset than anti-TNF. GEMINI trials showed efficacy. Good option for anti-TNF failure.',
            level4: 'Consider for patients with prior malignancy, older patients, or anti-TNF intolerance. Can be used with immunomodulators. Subcutaneous formulation available.',
            level5: 'α4β7 integrin on lymphocytes binds MAdCAM-1 on gut endothelium. Vedolizumab blocks this, reducing lymphocyte infiltration. Gut selectivity from MAdCAM-1 being gut-specific.',
          },
        },
        {
          treatmentId: 'surgery-cd',
          name: 'Surgical Resection',
          modality: 'surgical',
          description: 'Removal of diseased bowel segment',
          mechanism: 'Remove site of disease and complications',
          efficacy: 'effective',
          evidenceLevel: 'level-2a',
          isFirstLine: false,
          appropriatePhases: ['established', 'advanced'],
          goals: ['Treat complications', 'Remove medically refractory disease', 'Improve quality of life'],
          explanations: {
            level1: 'Surgery to remove the diseased part of the intestine. It does not cure Crohn\'s but can help when medications do not work.',
            level2: 'Surgery is needed for strictures, fistulas, or abscesses that do not respond to medication. Crohn\'s can come back at the surgical site, so medications after surgery are important.',
            level3: 'Not curative - disease recurs at anastomosis in most untreated patients. Bowel-sparing techniques preferred (strictureplasty). Post-op biologics reduce recurrence.',
            level4: 'Indicated for: refractory disease, strictures, fistulas, abscesses, dysplasia. Prophylactic medications (anti-TNF, thiopurines) after ileocecal resection reduce recurrence.',
            level5: 'Endoscopic recurrence at anastomosis in >70% at 1 year without prophylaxis. Rutgeerts score grades recurrence. Early colonoscopy (6-12 months) post-op guides treatment escalation.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'terminal-ileum', structureName: 'Terminal Ileum', role: 'primary-site', involvement: 'Most common location', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'colon', structureName: 'Colon', role: 'primary-site', involvement: 'Common involvement', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'perianal', structureName: 'Perianal Area', role: 'secondary-site', involvement: 'Perianal fistulas', highlightColor: '#dc2626', showByDefault: false },
        ],
        systemsInvolved: ['Gastrointestinal', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['digestive'],
        focusRegion: 'abdomen',
      },
      explanations: {
        level1: "Crohn's disease is when your immune system attacks your intestines, causing pain, diarrhea, and other problems. Medications can control it, but it is a lifelong condition.",
        level2: "Crohn's is an inflammatory bowel disease where the immune system inflames the intestinal wall. It can affect any part of the GI tract but often affects the end of the small intestine. Medications and sometimes surgery are needed.",
        level3: 'Diagnose with colonoscopy/ileoscopy (aphthous ulcers, skip lesions, granulomas on biopsy) and imaging (CT/MR enterography). Treat based on severity/phenotype. Biologics first-line for moderate-severe. Treat to target: clinical remission + mucosal healing.',
        level4: 'Montreal classification: location (L1-L4), behavior (B1-B3), perianal modifier. Early effective therapy may prevent complications. Therapeutic drug monitoring optimizes biologics. New targets: IL-23 inhibitors (risankizumab, ustekinumab).',
        level5: 'Pathogenesis: genetic susceptibility (NOD2 → defective bacterial sensing) + environmental triggers + microbiome dysbiosis → barrier dysfunction → inappropriate immune response. Th1/Th17 cytokines drive transmural granulomatous inflammation.',
      },
      relatedConditions: ['ulcerative-colitis', 'irritable-bowel-syndrome', 'celiac-disease'],
      comorbidities: ['anemia', 'osteoporosis', 'arthritis'],
      epidemiology: {
        prevalence: '100-300 per 100,000 in Western countries',
        incidence: '3-20 per 100,000 person-years',
        demographics: 'Peak onset 15-30 years; second smaller peak 50-70; more common in Caucasians and Ashkenazi Jews',
      },
      clinicalPearls: [
        'Can affect any part of GI tract from mouth to anus - think of it with unusual presentations',
        'Smoking makes Crohn\'s worse - opposite of ulcerative colitis',
        'Perianal disease (fistulas, abscesses) is highly suggestive of Crohn\'s',
        'Disease often progresses from inflammatory to stricturing or penetrating over time',
        'Treat to target: clinical remission PLUS mucosal healing',
      ],
      patientEducation: [
        'If you smoke, quitting is one of the most important things you can do - smoking makes Crohn\'s worse',
        'Take your medications consistently even when feeling well - this prevents flares',
        'Report new symptoms like fever, severe pain, or perianal drainage promptly',
        'Nutritional support is important - work with a dietitian if needed',
        'Crohn\'s is manageable - most people with Crohn\'s lead full, active lives',
      ],
      emergencyWarnings: [
        'Severe abdominal pain with fever (may indicate abscess or perforation)',
        'Unable to keep food/water down (obstruction)',
        'Significant rectal bleeding',
        'Signs of dehydration from severe diarrhea',
        'New severe perianal pain with fever (abscess)',
      ],
    },
  ],
  // Celiac Disease
  [
    'celiac-disease',
    {
      conditionId: 'celiac-disease',
      name: 'Celiac Disease',
      aliases: ['Celiac Sprue', 'Gluten-Sensitive Enteropathy', 'Nontropical Sprue'],
      icdCode: 'K90.0',
      category: 'gastrointestinal',
      subcategory: 'Autoimmune/Malabsorption',
      description: 'An autoimmune disorder where gluten ingestion damages the small intestine, causing nutrient malabsorption.',
      pathophysiology: {
        summary: 'Gluten triggers an immune response that damages small intestinal villi, leading to malabsorption.',
        mechanisms: [
          { name: 'Gluten-Triggered Autoimmunity', description: 'Gluten peptides cross intestinal barrier and trigger T-cell mediated inflammation', systemsInvolved: ['Immune', 'GI'], keyMediators: ['Tissue transglutaminase', 'Anti-endomysial antibodies', 'IFN-gamma'], contribution: 'Direct villous damage' },
          { name: 'Villous Atrophy', description: 'Chronic inflammation destroys absorptive villi', systemsInvolved: ['GI'], contribution: 'Malabsorption of nutrients' },
        ],
        riskFactors: [
          { name: 'Family History', type: 'non-modifiable', impact: 'major', description: '10-15% risk in first-degree relatives' },
          { name: 'HLA-DQ2/DQ8 Genes', type: 'non-modifiable', impact: 'major', description: 'Required genetic susceptibility' },
          { name: 'Type 1 Diabetes', type: 'non-modifiable', impact: 'moderate', description: 'Autoimmune association' },
          { name: 'Autoimmune Thyroid Disease', type: 'non-modifiable', impact: 'moderate', description: 'Autoimmune association' },
        ],
        geneticFactors: ['HLA-DQ2 (95%)', 'HLA-DQ8 (5%)'],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Chronic Diarrhea', prevalence: 'common', description: 'Loose, foul-smelling, fatty stools', quality: 'Steatorrhea' },
          { name: 'Abdominal Bloating', prevalence: 'very-common', description: 'Distension and discomfort after eating' },
          { name: 'Fatigue', prevalence: 'very-common', description: 'From anemia and malnutrition' },
        ],
        associatedSymptoms: [
          { name: 'Weight Loss', prevalence: 'common', description: 'From malabsorption' },
          { name: 'Iron Deficiency Anemia', prevalence: 'common', description: 'May be only presenting sign' },
          { name: 'Dermatitis Herpetiformis', prevalence: 'uncommon', description: 'Itchy blistering skin rash' },
          { name: 'Bone Pain', prevalence: 'uncommon', description: 'From vitamin D and calcium malabsorption' },
        ],
        labFindings: [
          { testName: 'Anti-tTG IgA', abnormality: 'Elevated', significance: 'Screening test of choice' },
          { testName: 'Anti-Endomysial Ab', abnormality: 'Positive', significance: 'Highly specific confirmation' },
          { testName: 'Total IgA', abnormality: 'Check for deficiency', significance: 'IgA deficiency causes false negatives' },
        ],
      },
      progression: {
        naturalHistory: 'Progressive villous atrophy with ongoing gluten exposure; reversible with strict gluten-free diet.',
        timelineSteps: [
          {
            phaseId: 'silent',
            phase: 'preclinical',
            displayName: 'Silent/Latent Phase',
            timeframe: 'Years before diagnosis',
            description: 'Positive serology but minimal or no symptoms',
            symptoms: ['Often none', 'May have mild GI symptoms attributed to other causes'],
            anatomicalChanges: [
              { structureId: 'small-intestine', structureName: 'Small Intestine', changeType: 'inflammation', description: 'Early intraepithelial lymphocytosis', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
          },
          {
            phaseId: 'active',
            phase: 'established',
            displayName: 'Active Celiac Disease',
            timeframe: 'At diagnosis',
            description: 'Symptomatic with villous atrophy',
            symptoms: ['Diarrhea', 'Bloating', 'Fatigue', 'Weight loss', 'Nutritional deficiencies'],
            anatomicalChanges: [
              { structureId: 'small-intestine', structureName: 'Small Intestinal Villi', changeType: 'atrophy', description: 'Villous atrophy with crypt hyperplasia', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Strict gluten-free diet', 'Nutritional supplementation'],
          },
          {
            phaseId: 'refractory',
            phase: 'severe',
            displayName: 'Refractory Celiac Disease',
            timeframe: 'If unresponsive to GFD',
            description: 'Persistent symptoms and villous atrophy despite strict GFD for >12 months',
            symptoms: ['Persistent diarrhea', 'Severe malnutrition', 'Weight loss'],
            anatomicalChanges: [
              { structureId: 'small-intestine', structureName: 'Small Intestinal Mucosa', changeType: 'atrophy', description: 'Persistent villous atrophy', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: false },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Immunosuppressants', 'Nutritional support', 'Monitor for lymphoma'],
          },
        ],
        prognosis: 'Excellent with strict gluten-free diet adherence; increased lymphoma risk if untreated.',
      },
      complications: [
        { complicationId: 'osteoporosis', name: 'Osteoporosis', category: 'chronic', severity: 'moderate', riskLevel: 'moderate', description: 'From calcium/vitamin D malabsorption', mechanism: 'Chronic malabsorption leads to bone loss', affectedStructures: [{ structureId: 'bones', structureName: 'Bones', effect: 'Decreased density', highlightColor: '#71717a' }], warningSymptoms: ['Back pain', 'Fractures with minimal trauma'], preventable: true },
        { complicationId: 'enteropathy-lymphoma', name: 'Enteropathy-Associated T-cell Lymphoma', category: 'chronic', severity: 'life-threatening', riskLevel: 'low', description: 'Rare intestinal lymphoma in untreated/refractory celiac', mechanism: 'Chronic inflammation and immune dysregulation', affectedStructures: [{ structureId: 'small-intestine', structureName: 'Small Intestine', effect: 'Malignant transformation', highlightColor: '#7f1d1d' }], warningSymptoms: ['Recurrent symptoms despite GFD', 'Abdominal pain', 'Weight loss'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'gfd', name: 'Gluten-Free Diet', modality: 'lifestyle', description: 'Complete elimination of wheat, barley, rye', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['preclinical', 'established', 'severe'], goals: ['Mucosal healing', 'Symptom resolution', 'Prevent complications'], explanations: { level1: 'Avoid all foods with wheat, barley, and rye', level2: 'A strict diet that eliminates gluten allows your intestine to heal', level3: 'GFD removes the antigenic trigger, allowing villous regeneration and symptom resolution', level4: 'Eliminating gluten prevents the adaptive immune response against tissue transglutaminase-modified gliadin', level5: 'GFD removes deamidated gliadin peptides that bind HLA-DQ2/8 and activate CD4+ T cells, halting the inflammatory cascade' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'small-intestine', structureName: 'Small Intestine', role: 'primary-site', involvement: 'Villous atrophy and malabsorption', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'duodenum', structureName: 'Duodenum', role: 'primary-site', involvement: 'Most severely affected segment', highlightColor: '#f97316', showByDefault: true },
        ],
        systemsInvolved: ['Gastrointestinal', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['digestive'],
      },
      explanations: {
        level1: 'Celiac disease means your body reacts badly to gluten (found in bread, pasta). Eating gluten-free helps you feel better.',
        level2: 'When you eat gluten, your immune system attacks your small intestine. This makes it hard to absorb nutrients. A gluten-free diet lets your intestine heal.',
        level3: 'Celiac is an autoimmune condition where gluten triggers inflammation in the small intestine, causing villous atrophy and malabsorption. Diagnosed by serology and biopsy.',
        level4: 'Gluten peptides trigger a T-cell mediated response against tissue transglutaminase in genetically susceptible individuals (HLA-DQ2/8), causing villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis.',
        level5: 'Celiac pathogenesis involves gliadin crossing the epithelial barrier, deamidation by tTG creating immunogenic epitopes that bind HLA-DQ2/8, activating gluten-specific CD4+ T cells that release IFN-γ and other cytokines causing epithelial damage and villous remodeling.',
      },
      relatedConditions: ['dermatitis-herpetiformis', 'type-1-diabetes', 'autoimmune-thyroiditis'],
      clinicalPearls: [
        'Always check IgA level - IgA deficiency causes false-negative serology',
        'Iron deficiency anemia may be the only presenting sign',
        'Biopsy while still eating gluten for accurate diagnosis',
        'Screen first-degree relatives',
      ],
      patientEducation: [
        'Read all food labels carefully - gluten hides in many products',
        'Cross-contamination matters - separate cooking utensils may be needed',
        'Most people feel better within weeks of starting GFD',
        'Annual follow-up to monitor adherence and complications',
      ],
      emergencyWarnings: [
        'Severe abdominal pain (possible perforation or obstruction)',
        'Significant unintentional weight loss despite GFD',
        'Worsening symptoms despite strict GFD (evaluate for refractory disease)',
      ],
    },
  ],
  // Hypothyroidism
  [
    'hypothyroidism',
    {
      conditionId: 'hypothyroidism',
      name: 'Hypothyroidism',
      aliases: ['Underactive Thyroid', 'Low Thyroid', 'Myxedema (severe)'],
      icdCode: 'E03.9',
      category: 'endocrine',
      subcategory: 'Thyroid Disorders',
      description: 'A condition where the thyroid gland does not produce enough thyroid hormone, slowing metabolism.',
      pathophysiology: {
        summary: 'Insufficient thyroid hormone production leads to decreased metabolic rate affecting multiple organ systems.',
        mechanisms: [
          { name: 'Thyroid Hormone Deficiency', description: 'Low T3/T4 reduces cellular metabolic activity', systemsInvolved: ['Endocrine', 'All systems'], keyMediators: ['T3', 'T4', 'TSH'], contribution: 'Slowed metabolism throughout body' },
          { name: 'Autoimmune Destruction (Hashimoto)', description: 'Most common cause - immune cells destroy thyroid tissue', systemsInvolved: ['Immune', 'Endocrine'], keyMediators: ['Anti-TPO antibodies', 'Antithyroglobulin antibodies'], contribution: 'Progressive loss of thyroid function' },
        ],
        riskFactors: [
          { name: 'Female Sex', type: 'non-modifiable', impact: 'major', description: '5-8x more common in women' },
          { name: 'Age >60', type: 'non-modifiable', impact: 'moderate', description: 'Prevalence increases with age' },
          { name: 'Family History', type: 'non-modifiable', impact: 'moderate', description: 'Genetic predisposition' },
          { name: 'Other Autoimmune Diseases', type: 'non-modifiable', impact: 'moderate', description: 'Type 1 DM, celiac, etc.' },
          { name: 'Previous Thyroid Treatment', type: 'partially-modifiable', impact: 'major', description: 'Post-radioiodine or surgery' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Persistent tiredness despite adequate rest' },
          { name: 'Weight Gain', prevalence: 'very-common', description: 'Modest weight increase from slowed metabolism' },
          { name: 'Cold Intolerance', prevalence: 'common', description: 'Feeling cold when others are comfortable' },
          { name: 'Constipation', prevalence: 'common', description: 'Slowed GI motility' },
        ],
        associatedSymptoms: [
          { name: 'Dry Skin', prevalence: 'common', description: 'Rough, coarse skin' },
          { name: 'Hair Loss', prevalence: 'common', description: 'Thinning hair, especially outer eyebrows' },
          { name: 'Depression', prevalence: 'common', description: 'Low mood, cognitive slowing' },
          { name: 'Menstrual Irregularities', prevalence: 'common', description: 'Heavy or irregular periods' },
          { name: 'Bradycardia', prevalence: 'uncommon', description: 'Slow heart rate' },
        ],
        physicalFindings: [
          { name: 'Goiter', examType: 'Neck examination', description: 'Enlarged thyroid (in some causes)', diagnosticValue: 'Present in Hashimoto\'s, iodine deficiency' },
          { name: 'Delayed DTRs', examType: 'Neurologic', description: 'Delayed relaxation phase of reflexes', diagnosticValue: 'Classic finding' },
          { name: 'Periorbital Edema', examType: 'General', description: 'Puffy appearance around eyes', diagnosticValue: 'Suggestive' },
        ],
        labFindings: [
          { testName: 'TSH', abnormality: 'Elevated', normalRange: '0.4-4.0 mIU/L', significance: 'Most sensitive screening test' },
          { testName: 'Free T4', abnormality: 'Low or low-normal', normalRange: '0.8-1.8 ng/dL', significance: 'Confirms diagnosis' },
          { testName: 'Anti-TPO Antibodies', abnormality: 'Positive (in Hashimoto\'s)', significance: 'Identifies autoimmune cause' },
        ],
      },
      progression: {
        naturalHistory: 'Often slowly progressive; easily managed with thyroid hormone replacement.',
        timelineSteps: [
          {
            phaseId: 'subclinical',
            phase: 'preclinical',
            displayName: 'Subclinical Hypothyroidism',
            timeframe: 'May persist or progress',
            description: 'Elevated TSH but normal T4; often asymptomatic',
            symptoms: ['Usually none', 'Subtle fatigue possible'],
            anatomicalChanges: [
              { structureId: 'thyroid', structureName: 'Thyroid Gland', changeType: 'inflammation', description: 'Early autoimmune infiltration (if Hashimoto\'s)', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Observation', 'Consider treatment if TSH >10 or symptomatic'],
          },
          {
            phaseId: 'overt',
            phase: 'established',
            displayName: 'Overt Hypothyroidism',
            timeframe: 'At diagnosis',
            description: 'Low T4 with symptoms',
            symptoms: ['Fatigue', 'Weight gain', 'Cold intolerance', 'Constipation', 'Dry skin'],
            anatomicalChanges: [
              { structureId: 'thyroid', structureName: 'Thyroid Gland', changeType: 'atrophy', description: 'Thyroid tissue destruction/atrophy', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Levothyroxine replacement'],
            goalsOfCare: ['Normalize TSH', 'Resolve symptoms'],
          },
          {
            phaseId: 'myxedema',
            phase: 'severe',
            displayName: 'Myxedema Coma',
            timeframe: 'Rare, life-threatening',
            description: 'Severe hypothyroidism with altered mental status - medical emergency',
            symptoms: ['Hypothermia', 'Altered consciousness', 'Respiratory depression', 'Bradycardia'],
            anatomicalChanges: [
              { structureId: 'brain', structureName: 'Brain', changeType: 'dysfunction', description: 'Metabolic encephalopathy', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['IV levothyroxine', 'ICU care', 'Treat precipitant'],
          },
        ],
        prognosis: 'Excellent with treatment; requires lifelong thyroid hormone replacement.',
      },
      complications: [
        { complicationId: 'cardiovascular', name: 'Cardiovascular Effects', category: 'chronic', severity: 'moderate', riskLevel: 'moderate', description: 'Hyperlipidemia, diastolic hypertension, CAD risk', mechanism: 'Altered lipid metabolism and cardiac function', affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'Decreased contractility', highlightColor: '#f97316' }], warningSymptoms: ['Chest pain', 'Shortness of breath'], preventable: true },
        { complicationId: 'myxedema-coma', name: 'Myxedema Coma', category: 'acute', severity: 'life-threatening', riskLevel: 'low', description: 'Severe hypothyroidism with multi-organ failure', mechanism: 'Extreme thyroid hormone deficiency', affectedStructures: [{ structureId: 'brain', structureName: 'Brain', effect: 'Encephalopathy', highlightColor: '#dc2626' }], warningSymptoms: ['Confusion', 'Hypothermia', 'Decreased consciousness'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'levothyroxine', name: 'Levothyroxine (T4)', modality: 'pharmacological', description: 'Synthetic thyroid hormone replacement', mechanism: 'Replaces deficient T4, converted to T3 in tissues', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['preclinical', 'established', 'severe'], goals: ['Normalize TSH', 'Resolve symptoms'], medicationIds: ['levothyroxine'], monitoring: ['TSH every 6-8 weeks until stable, then annually'], explanations: { level1: 'A daily pill that replaces the hormone your thyroid isn\'t making', level2: 'Levothyroxine is the same hormone your thyroid should produce. Taking it daily restores normal levels.', level3: 'Levothyroxine is synthetic T4 that normalizes TSH through negative feedback. Dose adjusted based on TSH levels.', level4: 'Levothyroxine provides physiologic T4 replacement, with peripheral conversion to active T3. Goal TSH typically 0.5-2.5 mIU/L.', level5: 'T4 monotherapy relies on tissue-specific deiodinase activity for T3 conversion. Steady-state takes 6 weeks due to 7-day T4 half-life. Absorption affected by food, calcium, iron.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'thyroid', structureName: 'Thyroid Gland', role: 'primary-site', involvement: 'Decreased hormone production', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'pituitary', structureName: 'Pituitary Gland', role: 'secondary-site', involvement: 'Elevated TSH secretion', highlightColor: '#3b82f6', showByDefault: false },
        ],
        systemsInvolved: ['Endocrine', 'Cardiovascular', 'Neurologic'],
        recommendedView: 'anterior',
        recommendedLayers: ['endocrine'],
      },
      explanations: {
        level1: 'Your thyroid gland isn\'t making enough hormone, so your body runs too slow. A daily pill fixes this.',
        level2: 'The thyroid controls your metabolism. When it\'s underactive, you feel tired, gain weight, and feel cold. Medication replaces the missing hormone.',
        level3: 'Hypothyroidism occurs when thyroid hormone production is insufficient. Most commonly autoimmune (Hashimoto\'s). Diagnosed by elevated TSH, treated with levothyroxine.',
        level4: 'Primary hypothyroidism shows elevated TSH with low free T4. Hashimoto\'s thyroiditis is the most common cause in iodine-sufficient areas. Treatment targets TSH normalization.',
        level5: 'Thyroid hormone deficiency decreases basal metabolic rate through reduced Na/K-ATPase activity and thermogenesis. Hashimoto\'s involves CD4+ T cell and antibody-mediated thyroid destruction. Subclinical hypothyroidism (elevated TSH, normal T4) may progress at 2-5% per year.',
      },
      relatedConditions: ['hyperthyroidism', 'hashimoto-thyroiditis', 'thyroid-nodules'],
      clinicalPearls: [
        'TSH is the most sensitive test - check it first',
        'Take levothyroxine on empty stomach, 30-60 min before food',
        'Many medications interfere with absorption (calcium, iron, PPIs)',
        'Adjust dose slowly in elderly and those with heart disease',
      ],
      patientEducation: [
        'Take your medication at the same time every day, ideally morning on empty stomach',
        'Don\'t skip doses - it takes weeks to notice, but levels will drop',
        'Report new symptoms like palpitations or anxiety (may indicate overreplacement)',
        'You\'ll need regular blood tests to keep your dose right',
      ],
      emergencyWarnings: [
        'Confusion, extreme fatigue, or altered consciousness (myxedema coma)',
        'Severe chest pain',
        'Very slow heart rate with dizziness',
      ],
    },
  ],
  // Hyperthyroidism / Graves Disease
  [
    'hyperthyroidism',
    {
      conditionId: 'hyperthyroidism',
      name: 'Hyperthyroidism',
      aliases: ['Overactive Thyroid', 'Thyrotoxicosis', 'Graves Disease (most common cause)'],
      icdCode: 'E05.90',
      category: 'endocrine',
      subcategory: 'Thyroid Disorders',
      description: 'Excess thyroid hormone production causing increased metabolism and multiple systemic effects.',
      pathophysiology: {
        summary: 'Excess thyroid hormones increase metabolic rate, affecting cardiovascular, neurologic, and other systems.',
        mechanisms: [
          { name: 'TSH Receptor Stimulation (Graves)', description: 'Autoantibodies stimulate TSH receptors, causing unregulated hormone production', systemsInvolved: ['Immune', 'Endocrine'], keyMediators: ['TSH receptor antibodies (TRAb)', 'T3', 'T4'], contribution: 'Autonomous thyroid hormone overproduction' },
          { name: 'Autonomous Nodules', description: 'Thyroid nodules produce hormones independent of TSH', systemsInvolved: ['Endocrine'], contribution: 'Unregulated hormone production from nodule(s)' },
        ],
        riskFactors: [
          { name: 'Female Sex', type: 'non-modifiable', impact: 'major', description: '5-10x more common in women' },
          { name: 'Family History', type: 'non-modifiable', impact: 'moderate', description: 'Genetic predisposition' },
          { name: 'Other Autoimmune Diseases', type: 'non-modifiable', impact: 'moderate', description: 'Associated conditions' },
          { name: 'Smoking', type: 'modifiable', impact: 'moderate', description: 'Increases Graves\' ophthalmopathy risk', intervention: 'Smoking cessation' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Palpitations', prevalence: 'very-common', description: 'Racing or irregular heartbeat' },
          { name: 'Heat Intolerance', prevalence: 'very-common', description: 'Feeling hot when others are comfortable' },
          { name: 'Weight Loss', prevalence: 'very-common', description: 'Despite normal or increased appetite' },
          { name: 'Anxiety/Nervousness', prevalence: 'very-common', description: 'Feeling jittery or anxious' },
          { name: 'Tremor', prevalence: 'common', description: 'Fine tremor of hands' },
        ],
        associatedSymptoms: [
          { name: 'Diarrhea', prevalence: 'common', description: 'Increased GI motility' },
          { name: 'Muscle Weakness', prevalence: 'common', description: 'Proximal myopathy' },
          { name: 'Menstrual Changes', prevalence: 'common', description: 'Light or absent periods' },
          { name: 'Eye Changes', prevalence: 'common', description: 'Graves\' ophthalmopathy - bulging eyes, double vision' },
        ],
        physicalFindings: [
          { name: 'Tachycardia', examType: 'Vital signs', description: 'Resting heart rate >100', diagnosticValue: 'Common finding' },
          { name: 'Goiter', examType: 'Neck exam', description: 'Diffuse thyroid enlargement', diagnosticValue: 'Often present in Graves\'' },
          { name: 'Exophthalmos', examType: 'Eye exam', description: 'Bulging eyes', diagnosticValue: 'Specific for Graves\'' },
          { name: 'Lid Lag', examType: 'Eye exam', description: 'Upper lid lags behind globe on downward gaze', diagnosticValue: 'Classic finding' },
          { name: 'Fine Tremor', examType: 'Neurologic', description: 'Fine tremor with outstretched hands', diagnosticValue: 'Common' },
        ],
        labFindings: [
          { testName: 'TSH', abnormality: 'Suppressed (<0.1)', normalRange: '0.4-4.0 mIU/L', significance: 'Most sensitive test' },
          { testName: 'Free T4', abnormality: 'Elevated', normalRange: '0.8-1.8 ng/dL', significance: 'Confirms hyperthyroidism' },
          { testName: 'Free T3', abnormality: 'Elevated', significance: 'May be elevated when T4 is normal (T3 toxicosis)' },
          { testName: 'TSH Receptor Antibodies', abnormality: 'Positive', significance: 'Diagnostic for Graves\'' },
        ],
      },
      progression: {
        naturalHistory: 'Can be episodic (thyroiditis) or progressive (Graves\'); definitive treatment often leads to hypothyroidism.',
        timelineSteps: [
          {
            phaseId: 'subclinical',
            phase: 'preclinical',
            displayName: 'Subclinical Hyperthyroidism',
            timeframe: 'Variable',
            description: 'Suppressed TSH with normal T3/T4',
            symptoms: ['Often asymptomatic', 'May have mild symptoms'],
            anatomicalChanges: [
              { structureId: 'thyroid', structureName: 'Thyroid Gland', changeType: 'hypertrophy', description: 'Early thyroid enlargement', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
          },
          {
            phaseId: 'overt',
            phase: 'established',
            displayName: 'Overt Hyperthyroidism',
            timeframe: 'At diagnosis',
            description: 'Elevated thyroid hormones with symptoms',
            symptoms: ['Palpitations', 'Weight loss', 'Heat intolerance', 'Anxiety', 'Tremor'],
            anatomicalChanges: [
              { structureId: 'thyroid', structureName: 'Thyroid Gland', changeType: 'hypertrophy', description: 'Diffuse enlargement (Graves) or nodular', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
              { structureId: 'heart', structureName: 'Heart', changeType: 'dysfunction', description: 'Increased cardiac output, possible AFib', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Antithyroid drugs', 'Beta-blockers', 'Radioiodine', 'Surgery'],
          },
          {
            phaseId: 'thyroid-storm',
            phase: 'severe',
            displayName: 'Thyroid Storm',
            timeframe: 'Medical emergency',
            description: 'Life-threatening thyrotoxicosis',
            symptoms: ['High fever', 'Severe tachycardia/AFib', 'Altered mental status', 'GI symptoms'],
            anatomicalChanges: [
              { structureId: 'heart', structureName: 'Heart', changeType: 'dysfunction', description: 'High-output failure, arrhythmias', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['ICU care', 'PTU', 'Beta-blockers', 'Iodine', 'Glucocorticoids'],
          },
        ],
        prognosis: 'Good with treatment; definitive therapy (RAI, surgery) often leads to hypothyroidism requiring lifelong levothyroxine.',
      },
      complications: [
        { complicationId: 'afib', name: 'Atrial Fibrillation', category: 'both', severity: 'major', riskLevel: 'moderate', description: 'Irregular heart rhythm from excess thyroid hormone', mechanism: 'Thyroid hormone increases cardiac excitability', affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'Arrhythmia', highlightColor: '#ef4444' }], warningSymptoms: ['Irregular palpitations', 'Shortness of breath', 'Fatigue'], preventable: true },
        { complicationId: 'osteoporosis', name: 'Osteoporosis', category: 'chronic', severity: 'moderate', riskLevel: 'moderate', description: 'Bone loss from chronic thyroid hormone excess', mechanism: 'Increased bone turnover', affectedStructures: [{ structureId: 'bones', structureName: 'Bones', effect: 'Decreased density', highlightColor: '#71717a' }], warningSymptoms: ['Fractures', 'Back pain'], preventable: true },
        { complicationId: 'graves-ophthalmopathy', name: 'Graves\' Ophthalmopathy', category: 'chronic', severity: 'moderate', riskLevel: 'moderate', description: 'Autoimmune inflammation of orbital tissues', mechanism: 'Cross-reactive antibodies affect orbital fibroblasts', affectedStructures: [{ structureId: 'eyes', structureName: 'Eyes/Orbits', effect: 'Proptosis, diplopia', highlightColor: '#f97316' }], warningSymptoms: ['Bulging eyes', 'Double vision', 'Eye pain'], preventable: false },
      ],
      treatmentOptions: [
        { treatmentId: 'methimazole', name: 'Methimazole', modality: 'pharmacological', description: 'Antithyroid medication', mechanism: 'Blocks thyroid hormone synthesis', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['established'], goals: ['Normalize thyroid levels', 'Control symptoms'], medicationIds: ['methimazole'], sideEffects: ['Rash', 'Agranulocytosis (rare)', 'Hepatotoxicity'], monitoring: ['CBC', 'LFTs'], explanations: { level1: 'A pill that stops your thyroid from making too much hormone', level2: 'Methimazole blocks the thyroid from producing excess hormone, bringing levels back to normal', level3: 'Methimazole inhibits thyroid peroxidase, reducing T3/T4 synthesis. Takes 4-8 weeks for full effect.', level4: 'Thionamide that inhibits TPO-mediated iodination and coupling reactions. Preferred over PTU except in first trimester pregnancy.', level5: 'Methimazole inhibits TPO-catalyzed oxidation of iodide and iodotyrosine coupling. Has immunomodulatory effects reducing TRAb. Rare but serious risk of agranulocytosis requires monitoring for fever/sore throat.' } },
        { treatmentId: 'radioiodine', name: 'Radioactive Iodine (I-131)', modality: 'interventional', description: 'Definitive treatment destroying thyroid tissue', mechanism: 'Radioactive iodine concentrates in thyroid and destroys tissue', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: false, appropriatePhases: ['established'], goals: ['Permanent resolution of hyperthyroidism'], contraindications: ['Pregnancy', 'Breastfeeding', 'Severe ophthalmopathy'], explanations: { level1: 'A one-time radioactive pill that permanently treats your overactive thyroid', level2: 'Radioactive iodine is absorbed by your thyroid and destroys the overactive cells. You\'ll likely need thyroid hormone pills afterward.', level3: 'RAI therapy delivers targeted radiation to thyroid tissue, causing destruction over weeks-months. Most patients become hypothyroid and require levothyroxine.', level4: 'I-131 is selectively taken up by thyroid follicular cells via NIS, emitting beta particles that cause DNA damage and cellular death. Typical dose 10-15 mCi for Graves\'.', level5: 'RAI exploits thyroid-specific NIS expression for targeted radiotherapy. Beta emission (range ~2mm) destroys follicular cells while sparing surrounding tissue. Post-RAI hypothyroidism is expected outcome requiring lifelong T4 replacement.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'thyroid', structureName: 'Thyroid Gland', role: 'primary-site', involvement: 'Excess hormone production', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'heart', structureName: 'Heart', role: 'target-organ', involvement: 'Tachycardia, AFib risk', highlightColor: '#f97316', showByDefault: true },
          { structureId: 'eyes', structureName: 'Eyes', role: 'target-organ', involvement: 'Graves\' ophthalmopathy', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Endocrine', 'Cardiovascular', 'Neurologic', 'Musculoskeletal'],
        recommendedView: 'anterior',
        recommendedLayers: ['endocrine'],
      },
      explanations: {
        level1: 'Your thyroid is making too much hormone, making your body run too fast. Treatment can slow it down.',
        level2: 'An overactive thyroid speeds up your metabolism, causing weight loss, rapid heartbeat, and anxiety. Medications or other treatments can fix this.',
        level3: 'Hyperthyroidism is excess thyroid hormone, most commonly from Graves\' disease (autoimmune). Presents with hypermetabolic symptoms. Treated with antithyroid drugs, RAI, or surgery.',
        level4: 'Graves\' disease causes 70-80% of hyperthyroidism - TSH receptor antibodies cause autonomous hormone production. Diagnosis: suppressed TSH, elevated T4/T3, positive TRAb.',
        level5: 'Graves\' pathogenesis involves TRAb (thyroid-stimulating immunoglobulins) binding TSH receptors, activating cAMP cascade independent of TSH. This causes follicular hyperplasia and increased T3/T4 synthesis. Eye disease involves separate orbital fibroblast autoimmunity.',
      },
      relatedConditions: ['hypothyroidism', 'thyroid-nodules', 'thyroiditis'],
      clinicalPearls: [
        'Always check TSH first - suppressed TSH is the hallmark',
        'Beta-blockers provide rapid symptom relief while awaiting antithyroid effect',
        'RAI is contraindicated in pregnancy and may worsen ophthalmopathy',
        'Monitor for agranulocytosis on antithyroid drugs - educate about fever/sore throat',
      ],
      patientEducation: [
        'Most treatments are very effective - this is a manageable condition',
        'Report fever, sore throat, or mouth sores immediately (rare but serious drug reaction)',
        'After radioiodine, you\'ll likely need thyroid hormone pills for life',
        'Eye symptoms may worsen initially with treatment - report new vision changes',
      ],
      emergencyWarnings: [
        'High fever with rapid heart rate and confusion (thyroid storm)',
        'Chest pain or severe palpitations',
        'Sudden vision changes or severe eye pain',
        'Fever and sore throat while on antithyroid medication (agranulocytosis)',
      ],
    },
  ],
  // Chronic Kidney Disease
  [
    'chronic-kidney-disease',
    {
      conditionId: 'chronic-kidney-disease',
      name: 'Chronic Kidney Disease',
      aliases: ['CKD', 'Chronic Renal Failure', 'Chronic Renal Insufficiency'],
      icdCode: 'N18.9',
      category: 'urologic',
      subcategory: 'Renal Disease',
      description: 'Progressive loss of kidney function over months to years, affecting waste filtration and fluid/electrolyte balance.',
      pathophysiology: {
        summary: 'Progressive nephron loss leads to decreased GFR, accumulation of waste products, and inability to maintain homeostasis.',
        mechanisms: [
          { name: 'Nephron Loss', description: 'Gradual destruction of functional nephrons from various causes', systemsInvolved: ['Renal'], keyMediators: ['GFR decline', 'Creatinine accumulation'], contribution: 'Reduced filtration capacity' },
          { name: 'Glomerular Hyperfiltration', description: 'Remaining nephrons compensate by hyperfiltrating, causing further damage', systemsInvolved: ['Renal'], keyMediators: ['Angiotensin II', 'Intraglomerular pressure'], contribution: 'Accelerates progression' },
          { name: 'Tubulointerstitial Fibrosis', description: 'Chronic injury leads to scarring and loss of tubular function', systemsInvolved: ['Renal'], contribution: 'Impaired concentration, secretion' },
        ],
        riskFactors: [
          { name: 'Diabetes', type: 'modifiable', impact: 'major', description: 'Leading cause of CKD', intervention: 'Glycemic control' },
          { name: 'Hypertension', type: 'modifiable', impact: 'major', description: 'Second leading cause', intervention: 'Blood pressure control' },
          { name: 'Age >60', type: 'non-modifiable', impact: 'moderate', description: 'GFR naturally declines with age' },
          { name: 'Family History', type: 'non-modifiable', impact: 'moderate', description: 'Genetic predisposition' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'Independent risk factor', intervention: 'Weight management' },
          { name: 'NSAIDs Use', type: 'modifiable', impact: 'moderate', description: 'Nephrotoxic', intervention: 'Avoid chronic use' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Often Asymptomatic Early', prevalence: 'very-common', description: 'Many patients have no symptoms until advanced stages' },
          { name: 'Fatigue', prevalence: 'common', description: 'From anemia and uremia', timing: 'Stage 3-5' },
          { name: 'Edema', prevalence: 'common', description: 'Swelling in legs, ankles', timing: 'Stage 3-5' },
          { name: 'Decreased Urine Output', prevalence: 'uncommon', description: 'May occur in advanced disease' },
        ],
        associatedSymptoms: [
          { name: 'Nausea/Vomiting', prevalence: 'common', description: 'From uremia', timing: 'Advanced stages' },
          { name: 'Pruritus', prevalence: 'common', description: 'Itching from phosphate accumulation' },
          { name: 'Sleep Disturbances', prevalence: 'common', description: 'Restless legs, insomnia' },
          { name: 'Cognitive Changes', prevalence: 'uncommon', description: 'Uremic encephalopathy' },
        ],
        labFindings: [
          { testName: 'Creatinine', abnormality: 'Elevated', significance: 'Marker of reduced GFR' },
          { testName: 'eGFR', abnormality: '<60 mL/min/1.73m² for >3 months', significance: 'Defines CKD' },
          { testName: 'Urine Albumin/Creatinine Ratio', abnormality: '>30 mg/g', significance: 'Indicates kidney damage' },
          { testName: 'Hemoglobin', abnormality: 'Low', significance: 'Anemia of CKD (reduced EPO)' },
          { testName: 'Potassium', abnormality: 'May be elevated', significance: 'Risk of hyperkalemia' },
          { testName: 'Phosphorus', abnormality: 'Elevated', significance: 'CKD-mineral bone disorder' },
        ],
      },
      progression: {
        naturalHistory: 'Progressive decline in GFR; rate varies by cause and management. May progress to ESRD requiring dialysis or transplant.',
        timelineSteps: [
          {
            phaseId: 'stage-1-2',
            phase: 'early',
            displayName: 'CKD Stage 1-2 (GFR ≥60)',
            timeframe: 'Years',
            description: 'Kidney damage with normal or mildly reduced GFR',
            symptoms: ['Usually asymptomatic', 'May have proteinuria'],
            anatomicalChanges: [
              { structureId: 'kidneys', structureName: 'Kidneys', changeType: 'inflammation', description: 'Early nephron damage, possibly normal size', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Treat underlying cause', 'BP control', 'ACE/ARB', 'Lifestyle modification'],
            goalsOfCare: ['Slow progression', 'Manage risk factors'],
          },
          {
            phaseId: 'stage-3',
            phase: 'established',
            displayName: 'CKD Stage 3 (GFR 30-59)',
            timeframe: 'Years',
            description: 'Moderate reduction in kidney function',
            symptoms: ['May have fatigue', 'Mild edema', 'Nocturia'],
            anatomicalChanges: [
              { structureId: 'kidneys', structureName: 'Kidneys', changeType: 'atrophy', description: 'Beginning nephron loss, possible size reduction', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Intensify BP control', 'SGLT2 inhibitors', 'Manage complications'],
          },
          {
            phaseId: 'stage-4',
            phase: 'advanced',
            displayName: 'CKD Stage 4 (GFR 15-29)',
            timeframe: 'Months to years',
            description: 'Severe reduction - preparing for RRT',
            symptoms: ['Fatigue', 'Nausea', 'Anorexia', 'Edema', 'Pruritus'],
            anatomicalChanges: [
              { structureId: 'kidneys', structureName: 'Kidneys', changeType: 'atrophy', description: 'Significant nephron loss, small kidneys', severity: 'severe', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: false },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Nephrology co-management', 'RRT planning', 'Dietary restrictions'],
            goalsOfCare: ['Prepare for dialysis/transplant', 'Symptom management'],
          },
          {
            phaseId: 'stage-5',
            phase: 'end-stage',
            displayName: 'CKD Stage 5 / ESRD (GFR <15)',
            timeframe: 'Ongoing',
            description: 'End-stage renal disease requiring renal replacement therapy',
            symptoms: ['Severe uremic symptoms', 'Volume overload', 'Electrolyte disturbances'],
            anatomicalChanges: [
              { structureId: 'kidneys', structureName: 'Kidneys', changeType: 'atrophy', description: 'Severely atrophic, scarred kidneys', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: false },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Dialysis (HD or PD)', 'Kidney transplant', 'Conservative management'],
          },
        ],
        prognosis: 'Variable - depends on cause, rate of progression, and management. Transplant offers best outcomes for ESRD.',
      },
      complications: [
        { complicationId: 'anemia', name: 'Anemia of CKD', category: 'chronic', severity: 'moderate', riskLevel: 'high', description: 'From reduced erythropoietin production', mechanism: 'Kidneys produce less EPO', affectedStructures: [{ structureId: 'bone-marrow', structureName: 'Bone Marrow', effect: 'Reduced RBC production', highlightColor: '#f97316' }], warningSymptoms: ['Fatigue', 'Shortness of breath', 'Pallor'], preventable: false, treatment: 'ESAs, iron supplementation' },
        { complicationId: 'ckd-mbd', name: 'CKD-Mineral Bone Disorder', category: 'chronic', severity: 'moderate', riskLevel: 'high', description: 'Abnormal calcium/phosphorus/PTH causing bone disease', mechanism: 'Reduced vitamin D activation, phosphorus retention', affectedStructures: [{ structureId: 'bones', structureName: 'Bones', effect: 'Bone disease', highlightColor: '#71717a' }], warningSymptoms: ['Bone pain', 'Fractures', 'Calcifications'], preventable: true },
        { complicationId: 'cardiovascular', name: 'Cardiovascular Disease', category: 'chronic', severity: 'major', riskLevel: 'high', description: 'CKD is major CV risk factor', mechanism: 'Hypertension, LVH, accelerated atherosclerosis', affectedStructures: [{ structureId: 'heart', structureName: 'Heart', effect: 'LVH, CAD, heart failure', highlightColor: '#ef4444' }], warningSymptoms: ['Chest pain', 'Shortness of breath', 'Edema'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'ace-arb', name: 'ACE Inhibitors / ARBs', modality: 'pharmacological', description: 'Medications that protect kidneys and lower blood pressure', mechanism: 'Reduce intraglomerular pressure and proteinuria', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established', 'advanced'], goals: ['Slow progression', 'Reduce proteinuria', 'Control BP'], medicationIds: ['lisinopril', 'losartan'], monitoring: ['Creatinine', 'Potassium'], explanations: { level1: 'Blood pressure pills that also protect your kidneys', level2: 'These medications lower blood pressure and reduce stress on your kidneys, slowing down kidney disease.', level3: 'ACE-I/ARBs reduce intraglomerular pressure and proteinuria, key factors in CKD progression. Monitor for hyperkalemia and AKI.', level4: 'RAAS blockade reduces efferent arteriolar pressure, decreasing hyperfiltration. Proteinuria reduction correlates with renal protection. Accept up to 30% creatinine rise.', level5: 'ACE-I/ARBs block angiotensin II-mediated efferent arteriolar constriction, reducing glomerular hypertension. Also decrease TGF-β mediated fibrosis. CREDENCE and DAPA-CKD trials established SGLT2i as additional renoprotective agents.' } },
        { treatmentId: 'sglt2i', name: 'SGLT2 Inhibitors', modality: 'pharmacological', description: 'Newer kidney-protective medications (empagliflozin, dapagliflozin)', mechanism: 'Reduce hyperfiltration and have anti-inflammatory effects', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established', 'advanced'], goals: ['Slow progression', 'Reduce cardiovascular risk'], explanations: { level1: 'A newer medication that protects your kidneys and heart', level2: 'SGLT2 inhibitors are a newer class of medications shown to slow kidney disease and reduce heart failure risk.', level3: 'SGLT2 inhibitors reduce hyperfiltration and have direct renoprotective effects independent of diabetes. Now indicated for CKD.', level4: 'SGLT2 inhibitors cause afferent arteriolar constriction via tubuloglomerular feedback, reducing hyperfiltration. Also decrease inflammation, fibrosis, and improve cardiac outcomes.', level5: 'SGLT2 inhibition increases distal sodium delivery, activating macula densa-mediated afferent arteriolar constriction. Additional benefits include improved mitochondrial function, reduced oxidative stress, and decreased tubulointerstitial inflammation.' } },
        { treatmentId: 'dialysis', name: 'Dialysis', modality: 'supportive', description: 'Artificial kidney function when kidneys fail', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['end-stage'], goals: ['Replace kidney function', 'Remove toxins and fluid'], explanations: { level1: 'A treatment that cleans your blood when your kidneys can no longer do it', level2: 'Dialysis uses a machine to filter waste and extra fluid from your blood, doing the job your kidneys can no longer do.', level3: 'Dialysis is renal replacement therapy for ESRD. Hemodialysis uses a machine; peritoneal dialysis uses the peritoneum as a membrane.', level4: 'Hemodialysis provides intermittent clearance via diffusion and ultrafiltration. PD offers continuous clearance and preserves residual function longer. Both have distinct advantages and complications.', level5: 'HD clearance follows single-pool kinetics; adequacy measured by Kt/V >1.2. PD uses peritoneal membrane transport characteristics. Vascular access (fistula preferred) or PD catheter required. Transplant offers superior survival.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'kidneys', structureName: 'Kidneys', role: 'primary-site', involvement: 'Progressive nephron loss and fibrosis', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'heart', structureName: 'Heart', role: 'target-organ', involvement: 'LVH, cardiovascular disease', highlightColor: '#f97316', showByDefault: false },
          { structureId: 'bones', structureName: 'Bones', role: 'target-organ', involvement: 'CKD-mineral bone disorder', highlightColor: '#71717a', showByDefault: false },
        ],
        systemsInvolved: ['Renal', 'Cardiovascular', 'Skeletal', 'Hematologic'],
        recommendedView: 'posterior',
        recommendedLayers: ['urinary'],
      },
      explanations: {
        level1: 'Your kidneys are slowly losing their ability to filter waste from your blood. Treatment can slow this down.',
        level2: 'Chronic kidney disease means your kidneys gradually lose function over time. Controlling blood pressure and blood sugar helps protect them.',
        level3: 'CKD is progressive nephron loss, staged by GFR. Most common causes are diabetes and hypertension. Treatment focuses on slowing progression and managing complications.',
        level4: 'CKD involves maladaptive responses to nephron loss including hyperfiltration, RAAS activation, and fibrosis. Management includes RAAS blockade, SGLT2 inhibitors, and treating CKD-MBD and anemia.',
        level5: 'CKD pathophysiology involves a common pathway of glomerulosclerosis and tubulointerstitial fibrosis regardless of etiology. Hyperfiltration injury, TGF-β mediated fibrosis, and tubular-interstitial inflammation drive progression. Novel therapies target these pathways.',
      },
      relatedConditions: ['diabetes', 'hypertension', 'glomerulonephritis', 'polycystic-kidney-disease'],
      clinicalPearls: [
        'eGFR decline >4 mL/min/year is rapid progression - investigate cause',
        'ACE-I/ARB: accept up to 30% creatinine rise if stable and K+ okay',
        'SGLT2 inhibitors now indicated for CKD with or without diabetes',
        'Refer to nephrology by stage 4 for RRT planning',
      ],
      patientEducation: [
        'Your kidneys can function for a long time with proper care',
        'Blood pressure and diabetes control are the most important things you can do',
        'Avoid NSAIDs (ibuprofen, naproxen) - they can harm kidneys',
        'Stay hydrated but follow fluid restrictions if advised',
        'Discuss all supplements and medications with your doctor',
      ],
      emergencyWarnings: [
        'Severe shortness of breath (fluid overload)',
        'Chest pain',
        'Confusion or decreased alertness (uremia)',
        'Unable to urinate',
        'Severe nausea/vomiting unable to keep anything down',
      ],
    },
  ],
  // Benign Prostatic Hyperplasia
  [
    'benign-prostatic-hyperplasia',
    {
      conditionId: 'benign-prostatic-hyperplasia',
      name: 'Benign Prostatic Hyperplasia',
      aliases: ['BPH', 'Enlarged Prostate', 'Benign Prostatic Hypertrophy'],
      icdCode: 'N40.0',
      category: 'urologic',
      subcategory: 'Prostate Disorders',
      description: 'Non-cancerous enlargement of the prostate gland causing urinary symptoms in aging men.',
      pathophysiology: {
        summary: 'Prostate enlargement compresses the urethra, causing lower urinary tract symptoms (LUTS).',
        mechanisms: [
          { name: 'Prostatic Hyperplasia', description: 'Proliferation of stromal and glandular cells in the transition zone', systemsInvolved: ['Urologic'], keyMediators: ['DHT', 'Growth factors', 'Estrogen/androgen imbalance'], contribution: 'Physical enlargement causing obstruction' },
          { name: 'Smooth Muscle Contraction', description: 'Alpha-adrenergic mediated prostatic smooth muscle tone', systemsInvolved: ['Urologic'], keyMediators: ['Alpha-1 adrenergic receptors'], contribution: 'Dynamic component of obstruction' },
        ],
        riskFactors: [
          { name: 'Age', type: 'non-modifiable', impact: 'major', description: 'Prevalence increases with age: 50% at age 50, 80% by age 80' },
          { name: 'Family History', type: 'non-modifiable', impact: 'moderate', description: 'Genetic predisposition' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'Associated with BPH', intervention: 'Weight management' },
          { name: 'Diabetes', type: 'partially-modifiable', impact: 'moderate', description: 'Associated with BPH' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Weak Urinary Stream', prevalence: 'very-common', description: 'Decreased force of urine flow' },
          { name: 'Urinary Frequency', prevalence: 'very-common', description: 'Needing to urinate often' },
          { name: 'Nocturia', prevalence: 'very-common', description: 'Waking at night to urinate' },
          { name: 'Hesitancy', prevalence: 'common', description: 'Difficulty starting urination' },
          { name: 'Incomplete Emptying', prevalence: 'common', description: 'Feeling bladder is not empty' },
        ],
        associatedSymptoms: [
          { name: 'Urgency', prevalence: 'common', description: 'Sudden strong need to urinate' },
          { name: 'Intermittency', prevalence: 'common', description: 'Stream starts and stops' },
          { name: 'Straining', prevalence: 'common', description: 'Need to push to urinate' },
          { name: 'Post-void Dribbling', prevalence: 'common', description: 'Dripping after urination' },
        ],
        physicalFindings: [
          { name: 'Enlarged Prostate on DRE', examType: 'Digital rectal exam', description: 'Enlarged, smooth, firm prostate', diagnosticValue: 'Confirms enlargement, assesses for nodules' },
        ],
        labFindings: [
          { testName: 'PSA', abnormality: 'May be elevated', significance: 'Rule out prostate cancer' },
          { testName: 'Urinalysis', abnormality: 'Usually normal', significance: 'Rule out UTI, hematuria' },
          { testName: 'Creatinine', abnormality: 'Usually normal', significance: 'Assess for obstruction-related kidney injury' },
        ],
      },
      progression: {
        naturalHistory: 'Slowly progressive; symptoms may fluctuate. Many men live with mild symptoms without treatment.',
        timelineSteps: [
          {
            phaseId: 'mild',
            phase: 'early',
            displayName: 'Mild BPH (IPSS 1-7)',
            timeframe: 'Years',
            description: 'Mild symptoms, minimal impact on quality of life',
            symptoms: ['Occasional nocturia', 'Mild hesitancy', 'Slight decrease in stream'],
            anatomicalChanges: [
              { structureId: 'prostate', structureName: 'Prostate Gland', changeType: 'hypertrophy', description: 'Mild enlargement', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Watchful waiting', 'Lifestyle modifications'],
          },
          {
            phaseId: 'moderate',
            phase: 'established',
            displayName: 'Moderate BPH (IPSS 8-19)',
            timeframe: 'Years',
            description: 'Bothersome symptoms affecting quality of life',
            symptoms: ['Frequent nocturia', 'Weak stream', 'Incomplete emptying', 'Urgency'],
            anatomicalChanges: [
              { structureId: 'prostate', structureName: 'Prostate Gland', changeType: 'hypertrophy', description: 'Moderate enlargement compressing urethra', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Alpha-blockers', '5-alpha reductase inhibitors', 'Combination therapy'],
          },
          {
            phaseId: 'severe',
            phase: 'severe',
            displayName: 'Severe BPH (IPSS 20-35)',
            timeframe: 'Variable',
            description: 'Severe symptoms, may develop complications',
            symptoms: ['Significant nocturia', 'Very weak stream', 'Straining', 'High post-void residual'],
            anatomicalChanges: [
              { structureId: 'prostate', structureName: 'Prostate Gland', changeType: 'hypertrophy', description: 'Significant enlargement causing obstruction', severity: 'severe', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: false },
              { structureId: 'bladder', structureName: 'Bladder', changeType: 'hypertrophy', description: 'Bladder wall thickening from obstruction', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Surgical intervention (TURP, laser)', 'Minimally invasive procedures'],
          },
        ],
        prognosis: 'Good with treatment. Symptoms can be effectively managed with medications or procedures.',
      },
      complications: [
        { complicationId: 'urinary-retention', name: 'Acute Urinary Retention', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Complete inability to urinate', mechanism: 'Complete obstruction of urethra', affectedStructures: [{ structureId: 'bladder', structureName: 'Bladder', effect: 'Overdistension', highlightColor: '#ef4444' }], warningSymptoms: ['Unable to urinate', 'Severe lower abdominal pain', 'Distended bladder'], preventable: true, treatment: 'Catheterization' },
        { complicationId: 'utis', name: 'Recurrent UTIs', category: 'chronic', severity: 'moderate', riskLevel: 'moderate', description: 'Infections from incomplete bladder emptying', mechanism: 'Residual urine promotes bacterial growth', affectedStructures: [{ structureId: 'bladder', structureName: 'Bladder', effect: 'Infection', highlightColor: '#f97316' }], warningSymptoms: ['Burning urination', 'Fever', 'Cloudy urine'], preventable: true },
        { complicationId: 'bladder-stones', name: 'Bladder Stones', category: 'chronic', severity: 'moderate', riskLevel: 'low', description: 'Stones forming from urinary stasis', mechanism: 'Concentrated stagnant urine precipitates stones', affectedStructures: [{ structureId: 'bladder', structureName: 'Bladder', effect: 'Stone formation', highlightColor: '#71717a' }], warningSymptoms: ['Blood in urine', 'Interrupted stream', 'Lower abdominal pain'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'alpha-blockers', name: 'Alpha-Blockers (tamsulosin, alfuzosin)', modality: 'pharmacological', description: 'Relax smooth muscle in prostate and bladder neck', mechanism: 'Block alpha-1 adrenergic receptors', efficacy: 'effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['early', 'established'], goals: ['Improve urine flow', 'Reduce symptoms'], medicationIds: ['tamsulosin'], sideEffects: ['Dizziness', 'Orthostatic hypotension', 'Retrograde ejaculation'], explanations: { level1: 'Pills that relax the prostate muscle to help urine flow better', level2: 'Alpha-blockers relax the muscles in your prostate and bladder opening, making it easier to urinate.', level3: 'Alpha-1 blockers reduce dynamic obstruction by relaxing prostatic smooth muscle. Work within days. Don\'t reduce prostate size.', level4: 'Selective alpha-1A blockers (tamsulosin) target prostatic smooth muscle with less hypotension than non-selective agents. Rapid onset but no effect on prostate volume.', level5: 'Alpha-1A receptors mediate prostate smooth muscle contraction; blockade reduces urethral resistance. Uroselective agents minimize vascular alpha-1B effects. IPSS improvement of 4-6 points typical.' } },
        { treatmentId: '5ari', name: '5-Alpha Reductase Inhibitors (finasteride, dutasteride)', modality: 'pharmacological', description: 'Shrink the prostate over time', mechanism: 'Block conversion of testosterone to DHT', efficacy: 'effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['established', 'severe'], goals: ['Reduce prostate size', 'Slow progression'], medicationIds: ['finasteride'], sideEffects: ['Decreased libido', 'Erectile dysfunction', 'Decreased PSA'], explanations: { level1: 'Pills that gradually shrink the prostate', level2: '5-ARIs reduce the hormone that makes the prostate grow. They shrink the prostate over several months.', level3: '5-ARIs inhibit DHT production, reducing prostate volume 20-30% over 6-12 months. Best for larger prostates. Reduce PSA by ~50%.', level4: 'Finasteride inhibits type 2 5-alpha reductase; dutasteride inhibits both type 1 and 2. Reduce prostate volume and risk of AUR/surgery. Takes 6+ months for benefit.', level5: 'DHT is the primary androgen driving prostatic growth. 5-ARIs reduce intraprostatic DHT 70-90%. Combination therapy (MTOPS, CombAT trials) shows synergistic benefit over monotherapy for large prostates.' } },
        { treatmentId: 'turp', name: 'TURP (Transurethral Resection of Prostate)', modality: 'surgical', description: 'Gold standard surgical treatment', mechanism: 'Removes obstructing prostate tissue via urethra', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: false, appropriatePhases: ['severe'], goals: ['Relieve obstruction', 'Improve symptoms'], sideEffects: ['Retrograde ejaculation', 'Bleeding', 'Urethral stricture'], explanations: { level1: 'Surgery to remove the part of the prostate blocking urine flow', level2: 'TURP removes extra prostate tissue through a scope, creating a wider channel for urine.', level3: 'TURP is the gold standard surgical treatment, removing the obstructing adenoma transurethrally. Excellent long-term outcomes.', level4: 'TURP removes the transition zone adenoma using electrocautery or laser. 80-90% symptom improvement. Retrograde ejaculation occurs in most patients.', level5: 'TURP achieves 15+ point IPSS improvement and 200%+ Qmax improvement. Alternative techniques (HoLEP, PVP) offer similar efficacy with different side effect profiles. Choice depends on prostate size and surgeon expertise.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'prostate', structureName: 'Prostate Gland', role: 'primary-site', involvement: 'Hyperplasia causing obstruction', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'urethra', structureName: 'Prostatic Urethra', role: 'secondary-site', involvement: 'Compressed by enlarged prostate', highlightColor: '#f97316', showByDefault: true },
          { structureId: 'bladder', structureName: 'Bladder', role: 'target-organ', involvement: 'Compensatory hypertrophy, may develop dysfunction', highlightColor: '#fbbf24', showByDefault: false },
        ],
        systemsInvolved: ['Urologic', 'Reproductive'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['urinary', 'reproductive'],
      },
      explanations: {
        level1: 'Your prostate has grown larger with age and is squeezing the tube that carries urine. This makes it harder to urinate.',
        level2: 'BPH is a normal part of aging where the prostate enlarges and presses on the urethra, causing urinary problems. Medications can help relax or shrink the prostate.',
        level3: 'BPH involves stromal and glandular hyperplasia in the transition zone, causing static and dynamic obstruction. Treated with alpha-blockers, 5-ARIs, or surgery.',
        level4: 'BPH pathophysiology involves DHT-mediated glandular proliferation and alpha-adrenergic smooth muscle tone. IPSS guides severity. Alpha-blockers address dynamic component; 5-ARIs reduce volume.',
        level5: 'BPH involves stromal-epithelial interactions mediated by DHT and growth factors. Two components of obstruction: static (tissue volume) and dynamic (smooth muscle tone). Combination therapy addresses both. BOO can lead to detrusor dysfunction requiring urodynamic evaluation.',
      },
      relatedConditions: ['prostate-cancer', 'overactive-bladder', 'urethral-stricture'],
      clinicalPearls: [
        'IPSS questionnaire is essential for quantifying symptom severity',
        'Always check PSA to screen for prostate cancer',
        'Alpha-blockers work quickly; 5-ARIs take months but provide more durable effect',
        'Post-void residual >100-200 mL suggests significant obstruction',
      ],
      patientEducation: [
        'BPH is not cancer and doesn\'t increase your cancer risk',
        'Avoid fluids before bed to reduce nighttime urination',
        'Limit caffeine and alcohol - they can worsen symptoms',
        'Medications work well for most men; surgery is an option if needed',
        'Report any blood in urine or inability to urinate immediately',
      ],
      emergencyWarnings: [
        'Complete inability to urinate (urinary retention)',
        'Severe pain in lower abdomen or back',
        'Blood in urine',
        'Fever with urinary symptoms (possible infection)',
      ],
    },
  ],
  // Peripheral Artery Disease
  [
    'peripheral-artery-disease',
    {
      conditionId: 'peripheral-artery-disease',
      name: 'Peripheral Artery Disease',
      aliases: ['PAD', 'Peripheral Vascular Disease', 'PVD', 'Claudication'],
      icdCode: 'I73.9',
      category: 'cardiovascular',
      subcategory: 'Vascular Disease',
      description: 'Atherosclerotic narrowing of arteries to the legs, causing reduced blood flow and symptoms like leg pain with walking.',
      pathophysiology: {
        summary: 'Atherosclerosis narrows peripheral arteries, limiting blood flow and causing ischemia especially during exertion.',
        mechanisms: [
          { name: 'Atherosclerosis', description: 'Plaque buildup narrows arterial lumen', systemsInvolved: ['Cardiovascular'], keyMediators: ['LDL cholesterol', 'Inflammation', 'Endothelial dysfunction'], contribution: 'Progressive stenosis of limb arteries' },
          { name: 'Endothelial Dysfunction', description: 'Impaired vasodilation limits compensatory responses', systemsInvolved: ['Cardiovascular'], keyMediators: ['Nitric oxide', 'Prostacyclin'], contribution: 'Reduced blood flow adaptation' },
        ],
        riskFactors: [
          { name: 'Smoking', type: 'modifiable', impact: 'major', description: 'Strongest risk factor - 4x risk', intervention: 'Smoking cessation' },
          { name: 'Diabetes', type: 'partially-modifiable', impact: 'major', description: '2-4x increased risk', intervention: 'Glycemic control' },
          { name: 'Hypertension', type: 'modifiable', impact: 'major', description: 'Major risk factor', intervention: 'Blood pressure control' },
          { name: 'Hyperlipidemia', type: 'modifiable', impact: 'major', description: 'Drives atherosclerosis', intervention: 'Statins, lifestyle' },
          { name: 'Age >50', type: 'non-modifiable', impact: 'moderate', description: 'Prevalence increases with age' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Intermittent Claudication', prevalence: 'common', description: 'Leg pain/cramping with walking that resolves with rest', quality: 'Reproducible at consistent distance', location: 'Calf most common' },
          { name: 'Rest Pain', prevalence: 'uncommon', description: 'Severe pain at rest, especially at night', timing: 'Advanced disease (CLI)' },
        ],
        associatedSymptoms: [
          { name: 'Cold Feet', prevalence: 'common', description: 'Reduced blood flow causes cooler extremities' },
          { name: 'Hair Loss on Legs', prevalence: 'common', description: 'Chronic ischemia affects hair follicles' },
          { name: 'Non-healing Wounds', prevalence: 'uncommon', description: 'In advanced disease', timing: 'CLI' },
          { name: 'Erectile Dysfunction', prevalence: 'common', description: 'Often presents before claudication' },
        ],
        physicalFindings: [
          { name: 'Diminished Pulses', examType: 'Peripheral vascular', description: 'Decreased or absent pedal pulses', diagnosticValue: 'Key finding' },
          { name: 'ABI <0.9', examType: 'Ankle-brachial index', description: 'Ratio of ankle to arm blood pressure', diagnosticValue: 'Diagnostic' },
          { name: 'Pallor on Elevation', examType: 'Peripheral vascular', description: 'Leg becomes pale when elevated', diagnosticValue: 'Suggests significant disease' },
          { name: 'Dependent Rubor', examType: 'Peripheral vascular', description: 'Redness when legs dependent', diagnosticValue: 'Suggests severe ischemia' },
        ],
        labFindings: [
          { testName: 'Lipid Panel', abnormality: 'Often elevated LDL', significance: 'Guide statin therapy' },
          { testName: 'HbA1c', abnormality: 'May be elevated', significance: 'Assess diabetes control' },
          { testName: 'ABI', abnormality: '<0.9 diagnostic, <0.4 severe', significance: 'Quantifies disease severity' },
        ],
      },
      progression: {
        naturalHistory: 'Usually stable or slowly progressive; risk of CV events is greater than risk of limb loss.',
        timelineSteps: [
          {
            phaseId: 'asymptomatic',
            phase: 'preclinical',
            displayName: 'Asymptomatic PAD',
            timeframe: 'Years',
            description: 'Abnormal ABI but no symptoms',
            symptoms: ['None'],
            anatomicalChanges: [
              { structureId: 'leg-arteries', structureName: 'Leg Arteries', changeType: 'stenosis', description: 'Early plaque formation', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Risk factor modification', 'Antiplatelet therapy', 'Statins'],
          },
          {
            phaseId: 'claudication',
            phase: 'established',
            displayName: 'Intermittent Claudication',
            timeframe: 'Years',
            description: 'Leg pain with walking, relieved by rest',
            symptoms: ['Calf pain with walking', 'Predictable walking distance', 'Relief with rest'],
            anatomicalChanges: [
              { structureId: 'leg-arteries', structureName: 'Femoral/Popliteal Arteries', changeType: 'stenosis', description: 'Significant stenosis limiting flow', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Supervised exercise therapy', 'Cilostazol', 'Revascularization if severe'],
            goalsOfCare: ['Improve walking distance', 'Prevent CV events', 'Risk factor control'],
          },
          {
            phaseId: 'cli',
            phase: 'severe',
            displayName: 'Critical Limb Ischemia',
            timeframe: 'Urgent',
            description: 'Rest pain, tissue loss - limb threatened',
            symptoms: ['Rest pain', 'Non-healing wounds', 'Gangrene'],
            anatomicalChanges: [
              { structureId: 'leg-arteries', structureName: 'Leg Arteries', changeType: 'stenosis', description: 'Severe multi-level disease', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: false },
              { structureId: 'foot', structureName: 'Foot/Toes', changeType: 'ischemia', description: 'Tissue ischemia/necrosis', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Urgent revascularization', 'Wound care', 'Amputation if unsalvageable'],
          },
        ],
        prognosis: 'Most patients remain stable; CLI develops in ~10%. High CV mortality - PAD is a coronary artery disease equivalent.',
      },
      complications: [
        { complicationId: 'amputation', name: 'Amputation', category: 'chronic', severity: 'major', riskLevel: 'low', description: 'Loss of limb from irreversible ischemia', mechanism: 'Tissue death from inadequate blood supply', affectedStructures: [{ structureId: 'lower-extremity', structureName: 'Lower Extremity', effect: 'Tissue loss', highlightColor: '#7f1d1d' }], warningSymptoms: ['Non-healing wounds', 'Gangrene', 'Rest pain'], preventable: true },
        { complicationId: 'mi-stroke', name: 'MI/Stroke', category: 'acute', severity: 'life-threatening', riskLevel: 'high', description: 'PAD indicates systemic atherosclerosis', mechanism: 'Coronary/carotid atherosclerosis', affectedStructures: [{ structureId: 'heart', structureName: 'Heart/Brain', effect: 'Ischemic event', highlightColor: '#dc2626' }], warningSymptoms: ['Chest pain', 'Neurologic symptoms'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'exercise', name: 'Supervised Exercise Therapy', modality: 'rehabilitative', description: 'Structured walking program', mechanism: 'Improves collateral circulation and muscle efficiency', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['established'], goals: ['Increase walking distance', 'Improve quality of life'], explanations: { level1: 'A walking program supervised by therapists to help you walk farther without pain', level2: 'Regular, supervised walking builds new blood vessel pathways and makes your muscles more efficient, letting you walk farther.', level3: 'Supervised exercise therapy is first-line for claudication. Walk-rest-walk cycles improve maximal walking distance by 100-150%.', level4: 'SET promotes angiogenesis, improves endothelial function, and enhances oxidative metabolism. 30-45 min sessions 3x/week for 12+ weeks.', level5: 'SET mechanisms include NO-mediated vasodilation, mitochondrial biogenesis, and collateral vessel development. Evidence shows SET equals or exceeds revascularization for claudication outcomes.' } },
        { treatmentId: 'revascularization', name: 'Revascularization', modality: 'interventional', description: 'Restore blood flow via angioplasty/stenting or bypass surgery', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: false, appropriatePhases: ['established', 'severe'], goals: ['Restore perfusion', 'Limb salvage in CLI'], explanations: { level1: 'Procedures to open blocked arteries or create bypasses around them', level2: 'Doctors can open blocked arteries with balloons/stents or surgically bypass them to restore blood flow.', level3: 'Endovascular (angioplasty/stent) or surgical bypass restores flow. Reserved for lifestyle-limiting claudication failing medical therapy, or CLI.', level4: 'Endovascular-first approach preferred for most lesions; surgical bypass for extensive disease or failed endovascular. TransAtlantic Inter-Society Consensus (TASC) guides approach.', level5: 'Treatment decisions based on lesion anatomy (TASC classification), patient comorbidities, and clinical severity. Patency rates vary by lesion location and intervention type. Limb salvage rates >80% for CLI with appropriate revascularization.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'leg-arteries', structureName: 'Femoral/Popliteal Arteries', role: 'primary-site', involvement: 'Atherosclerotic stenosis', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'aorta', structureName: 'Aorta', role: 'secondary-site', involvement: 'Aortoiliac disease possible', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular'],
      },
      explanations: {
        level1: 'Arteries to your legs are narrowed by buildup, so less blood gets through. This causes leg pain when walking.',
        level2: 'PAD is like coronary artery disease but in your legs. Fatty plaque narrows the arteries, causing pain with activity. Walking programs and medications help.',
        level3: 'PAD is atherosclerosis of lower extremity arteries. Presents as claudication (pain with walking). ABI <0.9 is diagnostic. Treatment includes risk factor modification, exercise, and revascularization for severe cases.',
        level4: 'PAD affects 8-10% of adults >65. Claudication occurs when oxygen demand exceeds supply during exertion. ABI sensitivity ~90%. PAD is a CAD equivalent requiring aggressive risk factor management.',
        level5: 'PAD pathophysiology involves endothelial dysfunction, inflammation, and thrombosis superimposed on atherosclerosis. Claudication results from mismatch between metabolic demand and arterial supply. CLI indicates chronic ischemia threatening limb viability (Rutherford 4-6). Revascularization guided by anatomic distribution (aortoiliac vs femoropopliteal vs tibial).',
      },
      relatedConditions: ['coronary-artery-disease', 'carotid-artery-disease', 'diabetes', 'hypertension'],
      clinicalPearls: [
        'PAD patients have 6x higher CV mortality - treat as CAD equivalent',
        'ABI <0.9 is diagnostic; <0.4 indicates severe disease',
        'Supervised exercise therapy is as effective as revascularization for claudication',
        'Always examine feet and check pulses in at-risk patients',
      ],
      patientEducation: [
        'Quitting smoking is the single most important thing you can do',
        'Walking daily helps build new blood vessel pathways',
        'Check your feet regularly for sores or color changes',
        'PAD increases heart attack and stroke risk - take your medications',
        'Don\'t ignore rest pain or sores that won\'t heal',
      ],
      emergencyWarnings: [
        'Sudden severe leg pain, coldness, or numbness (acute limb ischemia)',
        'New non-healing sores or black areas on feet/toes',
        'Rest pain keeping you awake at night',
        'Chest pain or sudden neurologic symptoms',
      ],
    },
  ],
  // Deep Vein Thrombosis
  [
    'deep-vein-thrombosis',
    {
      conditionId: 'deep-vein-thrombosis',
      name: 'Deep Vein Thrombosis',
      aliases: ['DVT', 'Blood Clot in Leg', 'Venous Thromboembolism'],
      icdCode: 'I82.40',
      category: 'cardiovascular',
      subcategory: 'Venous Disease',
      description: 'Blood clot formation in a deep vein, most commonly in the legs, which can break loose and travel to the lungs.',
      pathophysiology: {
        summary: 'Blood clot forms in deep veins due to stasis, vessel injury, or hypercoagulability (Virchow\'s triad).',
        mechanisms: [
          { name: 'Virchow\'s Triad - Stasis', description: 'Slow or turbulent blood flow allows clot formation', systemsInvolved: ['Cardiovascular'], contribution: 'Immobility, compression, venous insufficiency' },
          { name: 'Virchow\'s Triad - Endothelial Injury', description: 'Vessel wall damage exposes procoagulant factors', systemsInvolved: ['Cardiovascular'], contribution: 'Surgery, trauma, inflammation' },
          { name: 'Virchow\'s Triad - Hypercoagulability', description: 'Increased clotting tendency', systemsInvolved: ['Hematologic'], keyMediators: ['Factor V Leiden', 'Prothrombin mutation', 'Antiphospholipid antibodies'], contribution: 'Genetic or acquired clotting disorders' },
        ],
        riskFactors: [
          { name: 'Immobility', type: 'modifiable', impact: 'major', description: 'Surgery, bed rest, long travel', intervention: 'Early mobilization, prophylaxis' },
          { name: 'Surgery/Trauma', type: 'partially-modifiable', impact: 'major', description: 'Especially orthopedic', intervention: 'Pharmacologic prophylaxis' },
          { name: 'Malignancy', type: 'partially-modifiable', impact: 'major', description: '4-7x increased risk' },
          { name: 'Oral Contraceptives/HRT', type: 'modifiable', impact: 'moderate', description: 'Estrogen increases clotting', intervention: 'Alternative contraception' },
          { name: 'Thrombophilia', type: 'non-modifiable', impact: 'moderate', description: 'Factor V Leiden, etc.' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'Increases risk', intervention: 'Weight loss' },
          { name: 'Prior VTE', type: 'non-modifiable', impact: 'major', description: '30% recurrence risk' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Leg Swelling', prevalence: 'very-common', description: 'Unilateral swelling of affected leg', quality: 'Usually below level of clot' },
          { name: 'Leg Pain', prevalence: 'common', description: 'Aching or tenderness', location: 'Calf most common' },
          { name: 'Warmth', prevalence: 'common', description: 'Affected area feels warm' },
        ],
        associatedSymptoms: [
          { name: 'Redness', prevalence: 'common', description: 'Erythema over affected area' },
          { name: 'May Be Asymptomatic', prevalence: 'common', description: 'Many DVTs discovered incidentally' },
        ],
        physicalFindings: [
          { name: 'Unilateral Edema', examType: 'Inspection', description: 'Measurable difference in calf circumference', diagnosticValue: '>3 cm difference increases probability' },
          { name: 'Calf Tenderness', examType: 'Palpation', description: 'Tenderness along deep veins', diagnosticValue: 'Suggestive but not specific' },
          { name: 'Homan\'s Sign', examType: 'Provocation', description: 'Calf pain with dorsiflexion', diagnosticValue: 'Poor sensitivity/specificity - not recommended' },
        ],
        labFindings: [
          { testName: 'D-dimer', abnormality: 'Elevated', significance: 'Sensitive but not specific - useful to rule out' },
        ],
        imagingFindings: [
          { modality: 'Compression Ultrasound', finding: 'Non-compressible vein', significance: 'Diagnostic gold standard', structures: ['Deep veins'] },
        ],
      },
      progression: {
        naturalHistory: 'Acute event; without treatment high risk of extension, PE, or post-thrombotic syndrome.',
        timelineSteps: [
          {
            phaseId: 'acute',
            phase: 'acute',
            displayName: 'Acute DVT',
            timeframe: 'Days to weeks',
            description: 'New clot formation with acute symptoms',
            symptoms: ['Leg swelling', 'Pain', 'Warmth', 'Redness'],
            anatomicalChanges: [
              { structureId: 'leg-veins', structureName: 'Deep Leg Veins', changeType: 'stenosis', description: 'Thrombus occluding vein', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Anticoagulation', 'Compression stockings', 'Leg elevation'],
          },
          {
            phaseId: 'treatment',
            phase: 'established',
            displayName: 'Treatment Phase',
            timeframe: '3-6 months',
            description: 'Anticoagulation to prevent extension and PE',
            symptoms: ['Symptoms gradually improve'],
            anatomicalChanges: [
              { structureId: 'leg-veins', structureName: 'Deep Leg Veins', changeType: 'stenosis', description: 'Thrombus organizing/resolving', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 }, isNewAtPhase: false },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Continue anticoagulation', 'Graduated compression'],
            goalsOfCare: ['Prevent PE', 'Prevent extension', 'Prevent recurrence'],
          },
          {
            phaseId: 'post-thrombotic',
            phase: 'chronic',
            displayName: 'Post-Thrombotic Syndrome',
            timeframe: 'Months to years after DVT',
            description: 'Chronic venous insufficiency from valve damage',
            symptoms: ['Chronic leg swelling', 'Pain', 'Skin changes', 'Ulcers'],
            anatomicalChanges: [
              { structureId: 'leg-veins', structureName: 'Deep Vein Valves', changeType: 'dysfunction', description: 'Damaged valves cause venous reflux', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Compression therapy', 'Wound care for ulcers', 'Exercise'],
          },
        ],
        prognosis: 'Good with treatment; 30% develop post-thrombotic syndrome. Recurrence risk ~30% over 10 years.',
      },
      complications: [
        { complicationId: 'pe', name: 'Pulmonary Embolism', category: 'acute', severity: 'life-threatening', riskLevel: 'high', description: 'Clot breaks loose and travels to lungs', mechanism: 'Embolization from DVT to pulmonary arteries', affectedStructures: [{ structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', effect: 'Obstruction', highlightColor: '#dc2626' }], warningSymptoms: ['Sudden shortness of breath', 'Chest pain', 'Coughing blood', 'Rapid heart rate'], preventable: true },
        { complicationId: 'pts', name: 'Post-Thrombotic Syndrome', category: 'chronic', severity: 'moderate', riskLevel: 'moderate', description: 'Chronic venous insufficiency from DVT', mechanism: 'Valve damage and residual obstruction', affectedStructures: [{ structureId: 'leg-veins', structureName: 'Leg Veins', effect: 'Venous insufficiency', highlightColor: '#f97316' }], warningSymptoms: ['Chronic leg swelling', 'Skin changes', 'Leg ulcers'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'anticoagulation', name: 'Anticoagulation', modality: 'pharmacological', description: 'Blood thinners to prevent clot extension and PE', mechanism: 'Inhibits clotting cascade', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute', 'established'], goals: ['Prevent PE', 'Prevent clot extension', 'Allow natural clot resolution'], medicationIds: ['rivaroxaban', 'apixaban', 'warfarin', 'enoxaparin'], monitoring: ['Bleeding signs', 'INR for warfarin'], explanations: { level1: 'Blood-thinning medicine to stop the clot from growing and prevent it from going to your lungs', level2: 'Anticoagulants prevent the clot from getting bigger and reduce the risk of it breaking off. Your body will slowly dissolve the clot.', level3: 'Anticoagulation is standard treatment. DOACs (rivaroxaban, apixaban) are first-line. Duration depends on provoked vs unprovoked and bleeding risk.', level4: 'DOACs inhibit factor Xa (rivaroxaban, apixaban, edoxaban) or thrombin (dabigatran). Non-inferior to warfarin with less bleeding. Duration: 3 months provoked, extended if unprovoked.', level5: 'Anticoagulation prevents thrombus propagation while fibrinolysis occurs. Factor Xa inhibitors block the final common pathway. Extended anticoagulation decision based on recurrence risk (unprovoked, male, elevated D-dimer) vs bleeding risk (HAS-BLED).' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'leg-veins', structureName: 'Deep Leg Veins', role: 'primary-site', involvement: 'Site of thrombus formation', highlightColor: '#dc2626', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', role: 'target-organ', involvement: 'Potential site of embolism', highlightColor: '#ef4444', showByDefault: false },
        ],
        systemsInvolved: ['Cardiovascular', 'Hematologic'],
        recommendedView: 'anterior',
        recommendedLayers: ['cardiovascular'],
      },
      explanations: {
        level1: 'A blood clot has formed in a deep vein in your leg. It needs treatment to prevent it from traveling to your lungs.',
        level2: 'DVT is a blood clot in a leg vein. The main danger is the clot breaking loose and blocking arteries in your lungs. Blood thinners prevent this.',
        level3: 'DVT results from Virchow\'s triad: stasis, endothelial injury, hypercoagulability. Diagnosed by compression ultrasound. Treatment is anticoagulation to prevent PE and recurrence.',
        level4: 'DVT probability assessed by Wells score; D-dimer can rule out in low-probability patients. Proximal DVT has higher PE risk than distal. Treatment duration based on provoked vs unprovoked etiology.',
        level5: 'Venous thrombosis occurs at sites of valve pockets where stasis promotes clotting. Factor Xa and thrombin generation leads to fibrin clot formation. DOACs provide reliable anticoagulation without monitoring. Extended anticoagulation warranted for unprovoked VTE with acceptable bleeding risk.',
      },
      relatedConditions: ['pulmonary-embolism', 'thrombophilia', 'post-thrombotic-syndrome'],
      clinicalPearls: [
        'Use Wells score + D-dimer to rule out DVT in low-risk patients',
        'DOACs are first-line unless contraindicated (renal failure, cancer)',
        'Unprovoked DVT warrants evaluation for occult malignancy',
        'Compression stockings for at least 2 years to prevent PTS',
      ],
      patientEducation: [
        'Take your blood thinner exactly as prescribed - missing doses increases clot risk',
        'Watch for signs of bleeding (bruising, blood in stool/urine)',
        'Wear compression stockings as directed',
        'Stay active - walking helps prevent recurrence',
        'Seek immediate care for sudden shortness of breath or chest pain',
      ],
      emergencyWarnings: [
        'Sudden shortness of breath (pulmonary embolism)',
        'Chest pain, especially with breathing',
        'Coughing up blood',
        'Rapid heart rate with lightheadedness',
        'Signs of severe bleeding',
      ],
    },
  ],
  // Pulmonary Embolism
  [
    'pulmonary-embolism',
    {
      conditionId: 'pulmonary-embolism',
      name: 'Pulmonary Embolism',
      aliases: ['PE', 'Blood Clot in Lung', 'Lung Clot'],
      icdCode: 'I26.99',
      category: 'respiratory',
      subcategory: 'Pulmonary Vascular',
      description: 'Blockage of pulmonary arteries by blood clots, usually from DVT, causing impaired gas exchange and potential cardiovascular collapse.',
      pathophysiology: {
        summary: 'Clot from deep veins travels to pulmonary arteries, blocking blood flow and causing V/Q mismatch and right heart strain.',
        mechanisms: [
          { name: 'Vascular Obstruction', description: 'Clot blocks pulmonary arterial blood flow', systemsInvolved: ['Respiratory', 'Cardiovascular'], contribution: 'Increased pulmonary vascular resistance, V/Q mismatch' },
          { name: 'Right Ventricular Strain', description: 'Acute pressure overload on right ventricle', systemsInvolved: ['Cardiovascular'], keyMediators: ['Increased PVR', 'RV dilation'], contribution: 'Potential hemodynamic collapse' },
          { name: 'Hypoxemia', description: 'V/Q mismatch causes low oxygen levels', systemsInvolved: ['Respiratory'], contribution: 'Respiratory distress' },
        ],
        riskFactors: [
          { name: 'DVT', type: 'non-modifiable', impact: 'major', description: 'Most PE originates from leg DVT' },
          { name: 'Immobility', type: 'modifiable', impact: 'major', description: 'Surgery, hospitalization, travel', intervention: 'Prophylaxis, early mobilization' },
          { name: 'Malignancy', type: 'partially-modifiable', impact: 'major', description: 'Hypercoagulable state' },
          { name: 'Surgery', type: 'partially-modifiable', impact: 'major', description: 'Especially orthopedic', intervention: 'Prophylaxis' },
          { name: 'Estrogen', type: 'modifiable', impact: 'moderate', description: 'OCP, HRT, pregnancy' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Dyspnea', prevalence: 'very-common', description: 'Sudden shortness of breath', quality: 'Often sudden onset' },
          { name: 'Pleuritic Chest Pain', prevalence: 'common', description: 'Sharp pain worse with breathing' },
          { name: 'Tachypnea', prevalence: 'very-common', description: 'Rapid breathing' },
        ],
        associatedSymptoms: [
          { name: 'Tachycardia', prevalence: 'very-common', description: 'Rapid heart rate' },
          { name: 'Cough', prevalence: 'common', description: 'May be dry or with blood' },
          { name: 'Hemoptysis', prevalence: 'uncommon', description: 'Coughing up blood' },
          { name: 'Syncope', prevalence: 'uncommon', description: 'Fainting - suggests massive PE' },
          { name: 'Leg Swelling', prevalence: 'common', description: 'From underlying DVT' },
        ],
        physicalFindings: [
          { name: 'Tachycardia', examType: 'Vital signs', description: 'Heart rate >100', diagnosticValue: 'Common' },
          { name: 'Tachypnea', examType: 'Vital signs', description: 'Respiratory rate >20', diagnosticValue: 'Common' },
          { name: 'Hypoxia', examType: 'Vital signs', description: 'Low oxygen saturation', diagnosticValue: 'Common but may be absent' },
          { name: 'JVD', examType: 'Cardiovascular', description: 'Elevated JVP from RV failure', diagnosticValue: 'Suggests massive PE' },
        ],
        labFindings: [
          { testName: 'D-dimer', abnormality: 'Elevated', significance: 'Sensitive; negative D-dimer rules out in low-risk' },
          { testName: 'Troponin', abnormality: 'May be elevated', significance: 'Indicates RV strain - prognostic' },
          { testName: 'BNP', abnormality: 'May be elevated', significance: 'Indicates RV strain - prognostic' },
          { testName: 'ABG', abnormality: 'Hypoxemia, respiratory alkalosis', significance: 'Supports diagnosis' },
        ],
        imagingFindings: [
          { modality: 'CT Pulmonary Angiography', finding: 'Filling defect in pulmonary arteries', significance: 'Diagnostic gold standard', structures: ['Pulmonary arteries'] },
          { modality: 'Echocardiography', finding: 'RV dilation, McConnell\'s sign', significance: 'Assesses RV function for risk stratification', structures: ['Right ventricle'] },
        ],
      },
      progression: {
        naturalHistory: 'Acute life-threatening event; severity depends on clot burden and cardiovascular reserve.',
        timelineSteps: [
          {
            phaseId: 'acute-low-risk',
            phase: 'acute',
            displayName: 'Low-Risk PE',
            timeframe: 'Acute presentation',
            description: 'Hemodynamically stable, no RV dysfunction',
            symptoms: ['Dyspnea', 'Chest pain', 'Stable vital signs'],
            anatomicalChanges: [
              { structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', changeType: 'stenosis', description: 'Segmental/subsegmental clot', severity: 'mild', visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Anticoagulation', 'May treat as outpatient if low-risk'],
          },
          {
            phaseId: 'intermediate-risk',
            phase: 'acute',
            displayName: 'Intermediate-Risk PE',
            timeframe: 'Acute presentation',
            description: 'Stable but RV dysfunction or elevated biomarkers',
            symptoms: ['Dyspnea', 'Tachycardia', 'Normal BP but at risk for deterioration'],
            anatomicalChanges: [
              { structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', changeType: 'stenosis', description: 'Larger clot burden', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
              { structureId: 'right-ventricle', structureName: 'Right Ventricle', changeType: 'dilation', description: 'RV strain/dilation', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Hospital admission', 'Anticoagulation', 'Close monitoring'],
          },
          {
            phaseId: 'massive',
            phase: 'severe',
            displayName: 'Massive/High-Risk PE',
            timeframe: 'Medical emergency',
            description: 'Hemodynamic instability - shock or hypotension',
            symptoms: ['Severe dyspnea', 'Hypotension', 'Syncope', 'Altered consciousness'],
            anatomicalChanges: [
              { structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', changeType: 'stenosis', description: 'Large central clot burden', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: false },
              { structureId: 'right-ventricle', structureName: 'Right Ventricle', changeType: 'dysfunction', description: 'Acute RV failure', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: false },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Systemic thrombolysis', 'Catheter-directed therapy', 'Surgical embolectomy', 'Hemodynamic support'],
          },
        ],
        prognosis: 'Low-risk PE mortality <1%; massive PE mortality 25-50% without treatment.',
      },
      complications: [
        { complicationId: 'death', name: 'Cardiovascular Collapse/Death', category: 'acute', severity: 'life-threatening', riskLevel: 'moderate', description: 'RV failure leading to death', mechanism: 'Acute RV pressure overload', affectedStructures: [{ structureId: 'right-ventricle', structureName: 'Right Ventricle', effect: 'Failure', highlightColor: '#7f1d1d' }], warningSymptoms: ['Hypotension', 'Syncope', 'Cardiac arrest'], preventable: true },
        { complicationId: 'cteph', name: 'Chronic Thromboembolic Pulmonary Hypertension', category: 'chronic', severity: 'major', riskLevel: 'low', description: 'Persistent pulmonary hypertension from unresolved PE', mechanism: 'Organized clot causes chronic obstruction', affectedStructures: [{ structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', effect: 'Chronic obstruction', highlightColor: '#f97316' }], warningSymptoms: ['Progressive dyspnea', 'Exercise intolerance'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'anticoagulation', name: 'Anticoagulation', modality: 'pharmacological', description: 'Blood thinners to prevent clot extension', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute'], goals: ['Prevent clot extension', 'Allow endogenous fibrinolysis'], medicationIds: ['rivaroxaban', 'apixaban', 'enoxaparin'], explanations: { level1: 'Blood-thinning medicine to stop the clot from growing while your body dissolves it', level2: 'Anticoagulants prevent the clot from getting bigger. Your body\'s natural system will slowly break down the clot.', level3: 'Anticoagulation is standard for hemodynamically stable PE. DOACs are preferred. Duration 3+ months depending on risk factors.', level4: 'Low-molecular-weight heparin bridging no longer needed with DOAC use. Risk stratification with PESI/sPESI guides outpatient vs inpatient treatment.', level5: 'Anticoagulation halts thrombus propagation while plasmin-mediated fibrinolysis dissolves clot. DOACs show non-inferior efficacy with less major bleeding vs VKA. Extended anticoagulation for unprovoked PE based on recurrence vs bleeding risk.' } },
        { treatmentId: 'thrombolysis', name: 'Systemic Thrombolysis', modality: 'pharmacological', description: 'Clot-dissolving medication for massive PE', mechanism: 'Activates plasminogen to rapidly dissolve clot', efficacy: 'highly-effective', evidenceLevel: 'level-1b', isFirstLine: false, appropriatePhases: ['severe'], goals: ['Rapid clot dissolution', 'Restore hemodynamics'], contraindications: ['Recent surgery', 'Active bleeding', 'Stroke'], sideEffects: ['Major bleeding', 'Intracranial hemorrhage'], explanations: { level1: 'A powerful medicine that dissolves the clot quickly when PE is life-threatening', level2: 'Thrombolysis rapidly dissolves the blood clot when PE is causing dangerous low blood pressure. It has bleeding risks but can be lifesaving.', level3: 'Systemic tPA indicated for massive PE with hemodynamic instability. Reduces mortality but increases bleeding risk. Consider catheter-directed therapy as alternative.', level4: 'tPA (alteplase) 100mg over 2 hours or accelerated regimen. Contraindications include recent surgery, stroke, bleeding. Number needed to treat ~10 for mortality benefit in massive PE.', level5: 'tPA converts plasminogen to plasmin, degrading fibrin. Indicated for high-risk PE (shock, sustained hypotension). PEITHO trial showed reduced decompensation but increased bleeding in intermediate-risk PE. Catheter-directed therapy offers localized delivery with potentially lower bleeding risk.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'pulmonary-arteries', structureName: 'Pulmonary Arteries', role: 'primary-site', involvement: 'Site of embolism', highlightColor: '#dc2626', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'right-ventricle', structureName: 'Right Ventricle', role: 'target-organ', involvement: 'Pressure overload, strain', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'leg-veins', structureName: 'Deep Leg Veins', role: 'secondary-site', involvement: 'Source of embolus', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Respiratory', 'Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['respiratory', 'cardiovascular'],
      },
      explanations: {
        level1: 'A blood clot has traveled to your lungs and is blocking blood flow. This is serious and needs immediate treatment.',
        level2: 'PE occurs when a blood clot from your legs travels to your lungs. It can cause shortness of breath and low oxygen. Blood thinners and sometimes clot-dissolving drugs are used.',
        level3: 'PE results from embolization of DVT to pulmonary arteries. Severity ranges from incidental to massive with shock. Diagnosed by CTPA. Risk stratification guides treatment intensity.',
        level4: 'PE causes V/Q mismatch and increased PVR. Risk stratified by hemodynamics (massive), RV dysfunction/biomarkers (submassive), or neither (low-risk). DOACs are first-line; thrombolysis for massive PE.',
        level5: 'PE pathophysiology involves mechanical obstruction plus vasoconstriction from serotonin/thromboxane release. RV failure occurs when wall stress exceeds compensatory capacity. PESI score predicts 30-day mortality. Thrombolysis accelerates clot resolution but at cost of increased bleeding - benefit clearest in high-risk PE.',
      },
      relatedConditions: ['deep-vein-thrombosis', 'right-heart-failure', 'cteph'],
      clinicalPearls: [
        'Massive PE = hypotension; requires immediate reperfusion therapy',
        'Normal D-dimer rules out PE in low-probability patients',
        'RV dysfunction on echo/CT is key for intermediate-risk classification',
        'Most PE originates from DVT - check legs',
      ],
      patientEducation: [
        'PE is serious but treatable - you\'re receiving the right care',
        'Blood thinners are essential - take exactly as prescribed',
        'Report any bleeding, especially severe or unusual',
        'Seek immediate care if symptoms worsen',
        'You may need blood thinners for several months to prevent recurrence',
      ],
      emergencyWarnings: [
        'Worsening shortness of breath',
        'Feeling faint or passing out',
        'Chest pain getting worse',
        'Coughing up blood',
        'Signs of severe bleeding',
      ],
    },
  ],
  // Peptic Ulcer Disease
  [
    'peptic-ulcer-disease',
    {
      conditionId: 'peptic-ulcer-disease',
      name: 'Peptic Ulcer Disease',
      aliases: ['PUD', 'Stomach Ulcer', 'Duodenal Ulcer', 'Gastric Ulcer'],
      icdCode: 'K27.9',
      category: 'gastrointestinal',
      subcategory: 'Upper GI',
      description: 'Erosions in the stomach or duodenal lining, commonly caused by H. pylori infection or NSAID use.',
      pathophysiology: {
        summary: 'Disruption of protective mucosal barrier allows acid damage to stomach/duodenal lining.',
        mechanisms: [
          { name: 'H. pylori Infection', description: 'Bacteria damages mucosa and increases acid secretion', systemsInvolved: ['GI'], keyMediators: ['Urease', 'Cytotoxins', 'Inflammation'], contribution: 'Disrupts mucosal defense, increases gastrin' },
          { name: 'NSAID Injury', description: 'NSAIDs inhibit prostaglandin synthesis, reducing mucosal protection', systemsInvolved: ['GI'], keyMediators: ['Prostaglandin E2', 'COX-1 inhibition'], contribution: 'Decreased mucus/bicarbonate, impaired blood flow' },
          { name: 'Acid-Pepsin Damage', description: 'Gastric acid and pepsin digest unprotected mucosa', systemsInvolved: ['GI'], contribution: 'Direct tissue injury' },
        ],
        riskFactors: [
          { name: 'H. pylori Infection', type: 'modifiable', impact: 'major', description: 'Present in 70-90% of duodenal ulcers', intervention: 'Eradication therapy' },
          { name: 'NSAID Use', type: 'modifiable', impact: 'major', description: 'Major cause of gastric ulcers', intervention: 'Discontinue or use with PPI' },
          { name: 'Smoking', type: 'modifiable', impact: 'moderate', description: 'Delays healing, increases recurrence', intervention: 'Cessation' },
          { name: 'Stress (Critical Illness)', type: 'partially-modifiable', impact: 'moderate', description: 'Stress ulcers in ICU patients', intervention: 'Prophylaxis' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Epigastric Pain', prevalence: 'very-common', description: 'Burning or gnawing upper abdominal pain', quality: 'Burning, gnawing', location: 'Epigastrium' },
          { name: 'Pain Relation to Meals', prevalence: 'common', description: 'Gastric: worse with eating; Duodenal: better with eating, worse 2-3 hrs later' },
        ],
        associatedSymptoms: [
          { name: 'Nausea', prevalence: 'common', description: 'May occur with pain' },
          { name: 'Bloating', prevalence: 'common', description: 'Early satiety, fullness' },
          { name: 'Heartburn', prevalence: 'common', description: 'Often coexists' },
          { name: 'Night Pain', prevalence: 'common', description: 'Duodenal ulcers often wake patient at night' },
        ],
        labFindings: [
          { testName: 'H. pylori Testing', abnormality: 'Positive', significance: 'Guides treatment - test all patients' },
          { testName: 'CBC', abnormality: 'Anemia if bleeding', significance: 'Assess for blood loss' },
          { testName: 'Stool Guaiac', abnormality: 'May be positive', significance: 'Occult bleeding' },
        ],
        imagingFindings: [
          { modality: 'Upper Endoscopy (EGD)', finding: 'Mucosal break/crater', significance: 'Diagnostic gold standard; allows biopsy', structures: ['Stomach', 'Duodenum'] },
        ],
      },
      progression: {
        naturalHistory: 'Chronic relapsing without treatment of underlying cause; complications can occur.',
        timelineSteps: [
          {
            phaseId: 'active',
            phase: 'acute',
            displayName: 'Active Ulcer',
            timeframe: 'Weeks',
            description: 'Symptomatic ulcer causing pain',
            symptoms: ['Epigastric pain', 'Nausea', 'Bloating'],
            anatomicalChanges: [
              { structureId: 'stomach', structureName: 'Stomach/Duodenum', changeType: 'inflammation', description: 'Mucosal erosion/ulceration', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['PPI therapy', 'H. pylori eradication if positive', 'Stop NSAIDs'],
            goalsOfCare: ['Symptom relief', 'Ulcer healing', 'Prevent complications'],
          },
          {
            phaseId: 'healing',
            phase: 'established',
            displayName: 'Healing Phase',
            timeframe: '4-8 weeks on treatment',
            description: 'Ulcer healing with appropriate therapy',
            symptoms: ['Improving pain', 'May be asymptomatic'],
            anatomicalChanges: [
              { structureId: 'stomach', structureName: 'Stomach/Duodenum', changeType: 'inflammation', description: 'Granulation and re-epithelialization', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.5 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Continue PPI', 'Confirm H. pylori eradication'],
          },
          {
            phaseId: 'complicated',
            phase: 'severe',
            displayName: 'Complicated Ulcer',
            timeframe: 'Variable',
            description: 'Bleeding, perforation, or obstruction',
            symptoms: ['Hematemesis/melena (bleeding)', 'Severe sudden pain (perforation)', 'Vomiting (obstruction)'],
            anatomicalChanges: [
              { structureId: 'stomach', structureName: 'Stomach/Duodenum', changeType: 'structural-damage', description: 'Deep ulcer with vessel erosion or perforation', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Endoscopic hemostasis', 'Surgical repair if perforated', 'IV PPI'],
          },
        ],
        prognosis: 'Excellent with H. pylori eradication and NSAID avoidance; recurrence common without addressing cause.',
      },
      complications: [
        { complicationId: 'gi-bleeding', name: 'GI Bleeding', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Ulcer erodes into blood vessel', mechanism: 'Vessel erosion in ulcer base', affectedStructures: [{ structureId: 'stomach', structureName: 'Stomach/Duodenum', effect: 'Hemorrhage', highlightColor: '#dc2626' }], warningSymptoms: ['Vomiting blood', 'Black tarry stools', 'Lightheadedness'], preventable: true },
        { complicationId: 'perforation', name: 'Perforation', category: 'acute', severity: 'life-threatening', riskLevel: 'low', description: 'Ulcer erodes through wall', mechanism: 'Full-thickness erosion', affectedStructures: [{ structureId: 'stomach', structureName: 'Stomach/Duodenum', effect: 'Full-thickness hole', highlightColor: '#7f1d1d' }], warningSymptoms: ['Sudden severe abdominal pain', 'Rigid abdomen', 'Fever'], preventable: true },
        { complicationId: 'gastric-outlet-obstruction', name: 'Gastric Outlet Obstruction', category: 'chronic', severity: 'moderate', riskLevel: 'low', description: 'Scarring causes obstruction', mechanism: 'Cicatricial stenosis from chronic ulcer', affectedStructures: [{ structureId: 'pylorus', structureName: 'Pylorus', effect: 'Stenosis', highlightColor: '#f97316' }], warningSymptoms: ['Early satiety', 'Vomiting undigested food', 'Weight loss'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'ppi', name: 'Proton Pump Inhibitors', modality: 'pharmacological', description: 'Acid suppression to allow healing', mechanism: 'Blocks gastric H+/K+-ATPase', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute', 'established'], goals: ['Reduce acid', 'Promote healing'], medicationIds: ['omeprazole', 'pantoprazole'], explanations: { level1: 'Pills that reduce stomach acid so the ulcer can heal', level2: 'PPIs block acid production in your stomach, creating an environment where the ulcer can heal.', level3: 'PPIs inhibit the proton pump, reducing gastric acid by >90%. Standard 4-8 week course heals most ulcers.', level4: 'PPIs irreversibly inhibit H+/K+-ATPase. Healing rates >90% at 8 weeks for duodenal ulcers. Twice daily dosing for complicated ulcers.', level5: 'PPIs covalently bind parietal cell proton pumps, eliminating acid secretion until new pumps synthesize. Acid suppression allows mucosal prostaglandin-mediated healing. IV PPI for acute bleeding maintains pH >6 to stabilize clot.' } },
        { treatmentId: 'h-pylori', name: 'H. pylori Eradication', modality: 'pharmacological', description: 'Triple or quadruple therapy to eradicate H. pylori', mechanism: 'Antibiotics + PPI eliminate infection', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute', 'established'], goals: ['Cure infection', 'Prevent recurrence'], explanations: { level1: 'A combination of antibiotics and acid medicine to kill the bacteria causing your ulcer', level2: 'H. pylori bacteria cause most ulcers. A 2-week course of antibiotics plus acid medicine cures the infection and prevents ulcer return.', level3: 'Clarithromycin triple therapy or bismuth quadruple therapy for 14 days. Confirm eradication 4+ weeks after treatment.', level4: 'Rising clarithromycin resistance makes quadruple therapy preferred in many regions. Bismuth quadruple: PPI + bismuth + metronidazole + tetracycline. Eradication dramatically reduces ulcer recurrence.', level5: 'H. pylori eradication reduces ulcer recurrence from 60-80% to <5%. Treatment choice guided by local resistance patterns and prior antibiotic exposure. Sequential and concomitant regimens offer alternatives to standard triple therapy.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'stomach', structureName: 'Stomach', role: 'primary-site', involvement: 'Site of gastric ulcers', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'duodenum', structureName: 'Duodenum', role: 'primary-site', involvement: 'Site of duodenal ulcers', highlightColor: '#ef4444', showByDefault: true },
        ],
        systemsInvolved: ['Gastrointestinal'],
        recommendedView: 'anterior',
        recommendedLayers: ['digestive'],
      },
      explanations: {
        level1: 'An ulcer is a sore in your stomach or the first part of your intestine. Medicine can heal it and prevent it from coming back.',
        level2: 'Ulcers form when the protective lining of the stomach is damaged, usually by bacteria or pain medications. Treatment kills the bacteria and reduces acid.',
        level3: 'PUD results from imbalance between aggressive (acid, pepsin, H. pylori, NSAIDs) and protective factors. Test and treat H. pylori; avoid NSAIDs. PPIs heal most ulcers.',
        level4: 'H. pylori and NSAIDs account for >90% of PUD. Duodenal ulcers are almost always benign; gastric ulcers require biopsy to exclude malignancy. Eradication reduces recurrence from 80% to <5%.',
        level5: 'H. pylori produces urease, creating alkaline microenvironment while inducing inflammation via CagA and VacA. NSAIDs inhibit COX-1-mediated prostaglandin synthesis, reducing mucus, bicarbonate, and mucosal blood flow. Acid hypersecretion in duodenal ulcer disease relates to H. pylori-induced gastrin elevation.',
      },
      relatedConditions: ['gerd', 'gastritis', 'gi-bleeding'],
      clinicalPearls: [
        'Test all ulcer patients for H. pylori - it changes management',
        'Gastric ulcers need biopsy to rule out malignancy',
        'NSAIDs and H. pylori have synergistic ulcer risk',
        'Confirm H. pylori eradication 4+ weeks after completing therapy',
      ],
      patientEducation: [
        'Complete the full antibiotic course even if you feel better',
        'Avoid NSAIDs (ibuprofen, naproxen) - use acetaminophen for pain instead',
        'Smoking delays healing and increases recurrence - try to quit',
        'Alcohol can irritate ulcers - limit intake while healing',
        'Seek immediate care for vomiting blood, black stools, or sudden severe pain',
      ],
      emergencyWarnings: [
        'Vomiting blood or coffee-ground material',
        'Black, tarry stools',
        'Sudden severe abdominal pain',
        'Feeling faint or lightheaded',
        'Fever with abdominal pain',
      ],
    },
  ],
  // Gallstones / Cholelithiasis
  [
    'gallstones',
    {
      conditionId: 'gallstones',
      name: 'Gallstones',
      aliases: ['Cholelithiasis', 'Gallbladder Stones', 'Biliary Colic'],
      icdCode: 'K80.20',
      category: 'gastrointestinal',
      subcategory: 'Hepatobiliary',
      description: 'Hard deposits (stones) that form in the gallbladder, which can cause pain when they block bile ducts.',
      pathophysiology: {
        summary: 'Supersaturation of bile with cholesterol or bilirubin leads to stone formation in the gallbladder.',
        mechanisms: [
          { name: 'Cholesterol Supersaturation', description: 'Excess cholesterol in bile precipitates as crystals', systemsInvolved: ['Hepatobiliary'], keyMediators: ['Cholesterol', 'Bile salts', 'Lecithin'], contribution: 'Cholesterol stones (80% of stones)' },
          { name: 'Gallbladder Hypomotility', description: 'Incomplete emptying allows crystal aggregation', systemsInvolved: ['Hepatobiliary'], contribution: 'Stone growth and retention' },
          { name: 'Bilirubin Precipitation', description: 'Excess unconjugated bilirubin forms pigment stones', systemsInvolved: ['Hepatobiliary'], contribution: 'Pigment stones (hemolysis, cirrhosis)' },
        ],
        riskFactors: [
          { name: 'Female Sex', type: 'non-modifiable', impact: 'major', description: '2-3x more common in women' },
          { name: 'Obesity', type: 'modifiable', impact: 'major', description: 'Increases cholesterol secretion', intervention: 'Weight management' },
          { name: 'Age >40', type: 'non-modifiable', impact: 'moderate', description: 'Prevalence increases with age' },
          { name: 'Rapid Weight Loss', type: 'modifiable', impact: 'moderate', description: 'Increases stone formation', intervention: 'Gradual weight loss' },
          { name: 'Pregnancy/Estrogen', type: 'partially-modifiable', impact: 'moderate', description: 'Increases cholesterol saturation' },
          { name: 'Family History', type: 'non-modifiable', impact: 'moderate', description: 'Genetic component' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Biliary Colic', prevalence: 'common', description: 'Episodic RUQ pain after fatty meals', quality: 'Steady, intense, cramping', location: 'Right upper quadrant, may radiate to back/scapula', timing: '30 min to several hours' },
        ],
        associatedSymptoms: [
          { name: 'Nausea/Vomiting', prevalence: 'common', description: 'Often accompanies pain' },
          { name: 'Asymptomatic', prevalence: 'very-common', description: 'Most gallstones never cause symptoms' },
          { name: 'Bloating', prevalence: 'common', description: 'Dyspepsia, intolerance to fatty foods' },
        ],
        physicalFindings: [
          { name: 'RUQ Tenderness', examType: 'Abdominal', description: 'Tenderness in right upper quadrant', diagnosticValue: 'Present during acute episode' },
          { name: 'Murphy\'s Sign', examType: 'Abdominal', description: 'Inspiratory arrest with RUQ palpation', diagnosticValue: 'Suggests cholecystitis if positive' },
        ],
        labFindings: [
          { testName: 'LFTs', abnormality: 'Usually normal with stones; elevated with obstruction', significance: 'Elevated suggests CBD stone' },
          { testName: 'Lipase', abnormality: 'Elevated if pancreatitis', significance: 'Gallstone pancreatitis' },
        ],
        imagingFindings: [
          { modality: 'Abdominal Ultrasound', finding: 'Echogenic foci with acoustic shadowing', significance: 'Diagnostic - 95%+ sensitivity for gallbladder stones', structures: ['Gallbladder'] },
        ],
      },
      progression: {
        naturalHistory: 'Most gallstones remain asymptomatic. Once symptomatic, recurrent attacks and complications are common.',
        timelineSteps: [
          {
            phaseId: 'asymptomatic',
            phase: 'preclinical',
            displayName: 'Asymptomatic Gallstones',
            timeframe: 'Years to lifetime',
            description: 'Stones present but causing no symptoms',
            symptoms: ['None'],
            anatomicalChanges: [
              { structureId: 'gallbladder', structureName: 'Gallbladder', changeType: 'calcification', description: 'Stone(s) in gallbladder lumen', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Expectant management', 'No treatment needed'],
          },
          {
            phaseId: 'symptomatic',
            phase: 'established',
            displayName: 'Symptomatic Gallstones (Biliary Colic)',
            timeframe: 'Episodic',
            description: 'Recurrent RUQ pain episodes',
            symptoms: ['RUQ pain after meals', 'Nausea', 'May have fatty food intolerance'],
            anatomicalChanges: [
              { structureId: 'gallbladder', structureName: 'Gallbladder', changeType: 'stenosis', description: 'Stone intermittently obstructing cystic duct', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Elective cholecystectomy', 'Dietary modification if declining surgery'],
            goalsOfCare: ['Prevent recurrent attacks', 'Prevent complications'],
          },
          {
            phaseId: 'complicated',
            phase: 'severe',
            displayName: 'Complicated Gallstone Disease',
            timeframe: 'Acute emergency',
            description: 'Cholecystitis, choledocholithiasis, or pancreatitis',
            symptoms: ['Persistent severe pain', 'Fever', 'Jaundice (if CBD stone)'],
            anatomicalChanges: [
              { structureId: 'gallbladder', structureName: 'Gallbladder', changeType: 'inflammation', description: 'Acute cholecystitis if wall inflamed', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Urgent cholecystectomy', 'ERCP if CBD stone', 'Antibiotics'],
          },
        ],
        prognosis: 'Excellent after cholecystectomy. Asymptomatic stones: ~20% become symptomatic over 20 years.',
      },
      complications: [
        { complicationId: 'cholecystitis', name: 'Acute Cholecystitis', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Gallbladder inflammation from prolonged obstruction', mechanism: 'Persistent cystic duct obstruction causes wall ischemia and infection', affectedStructures: [{ structureId: 'gallbladder', structureName: 'Gallbladder', effect: 'Inflammation', highlightColor: '#dc2626' }], warningSymptoms: ['Persistent RUQ pain >6 hours', 'Fever', 'Murphy\'s sign'], preventable: true },
        { complicationId: 'choledocholithiasis', name: 'Common Bile Duct Stones', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Stone in common bile duct causing obstruction', mechanism: 'Stone migrates or forms in CBD', affectedStructures: [{ structureId: 'bile-duct', structureName: 'Common Bile Duct', effect: 'Obstruction', highlightColor: '#ef4444' }], warningSymptoms: ['Jaundice', 'Dark urine', 'Light stools', 'Elevated LFTs'], preventable: true },
        { complicationId: 'gallstone-pancreatitis', name: 'Gallstone Pancreatitis', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Pancreatic inflammation from stone obstructing ampulla', mechanism: 'Stone blocks pancreatic duct outflow', affectedStructures: [{ structureId: 'pancreas', structureName: 'Pancreas', effect: 'Acute inflammation', highlightColor: '#dc2626' }], warningSymptoms: ['Severe epigastric pain radiating to back', 'Nausea/vomiting'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'cholecystectomy', name: 'Laparoscopic Cholecystectomy', modality: 'surgical', description: 'Surgical removal of gallbladder', mechanism: 'Eliminates source of stones', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['established', 'severe'], goals: ['Eliminate symptoms', 'Prevent complications'], explanations: { level1: 'Keyhole surgery to remove your gallbladder - you don\'t need it to live normally', level2: 'Laparoscopic cholecystectomy removes the gallbladder through small incisions. It\'s the definitive treatment that prevents future stone problems.', level3: 'Lap chole is gold standard for symptomatic gallstones. Same-day or overnight surgery with quick recovery. Open conversion rare.', level4: 'Laparoscopic cholecystectomy has <1% major complication rate. Intraoperative cholangiography or preop MRCP if CBD stones suspected. Early cholecystectomy for cholecystitis improves outcomes.', level5: 'Lap chole via critical view of safety technique minimizes bile duct injury risk. Index cholecystectomy during same admission for gallstone pancreatitis reduces recurrence. Subtotal cholecystectomy option for severe inflammation.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'gallbladder', structureName: 'Gallbladder', role: 'primary-site', involvement: 'Site of stone formation', highlightColor: '#ef4444', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'bile-duct', structureName: 'Common Bile Duct', role: 'secondary-site', involvement: 'May be obstructed by stones', highlightColor: '#f97316', showByDefault: false },
          { structureId: 'pancreas', structureName: 'Pancreas', role: 'target-organ', involvement: 'Risk of gallstone pancreatitis', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Gastrointestinal', 'Hepatobiliary'],
        recommendedView: 'anterior',
        recommendedLayers: ['digestive'],
      },
      explanations: {
        level1: 'Hard stones have formed in your gallbladder. If they cause pain, surgery to remove the gallbladder fixes the problem.',
        level2: 'Gallstones form when bile hardens into stones. Most cause no problems, but if they do, removing the gallbladder is a safe, effective treatment.',
        level3: 'Cholelithiasis results from cholesterol supersaturation or bilirubin precipitation. Symptomatic stones warrant cholecystectomy. Asymptomatic stones generally observed.',
        level4: 'Cholesterol stones form from cholesterol-supersaturated bile with nucleating factors. 4 F\'s: Female, Forty, Fat, Fertile. Biliary colic is transient cystic duct obstruction; cholecystitis is prolonged obstruction with inflammation.',
        level5: 'Cholesterol stone formation requires cholesterol supersaturation (lithogenic index >1), nucleation (mucin, calcium), and stasis. Hepatic cholesterol hypersecretion and bile salt hyposecretion create supersaturation. Laparoscopic cholecystectomy is definitive; ursodiol has limited role for small cholesterol stones in poor surgical candidates.',
      },
      relatedConditions: ['cholecystitis', 'choledocholithiasis', 'pancreatitis'],
      clinicalPearls: [
        'Most gallstones are asymptomatic and need no treatment',
        'Once symptomatic, recurrence rate is high - offer cholecystectomy',
        'Elevated LFTs suggest CBD stone - get MRCP or EUS before surgery',
        'Gallstone pancreatitis warrants same-admission cholecystectomy when recovered',
      ],
      patientEducation: [
        'Not all gallstones cause problems - many people have them without knowing',
        'If you\'ve had an attack, more are likely - surgery prevents this',
        'You can live completely normally without a gallbladder',
        'A low-fat diet may help reduce symptoms before surgery',
        'Seek care immediately for persistent pain, fever, or yellowing skin/eyes',
      ],
      emergencyWarnings: [
        'Pain lasting more than 6 hours (may indicate cholecystitis)',
        'Fever with abdominal pain',
        'Yellowing of skin or eyes (jaundice)',
        'Severe pain radiating to back with nausea/vomiting (pancreatitis)',
      ],
    },
  ],
  // Acute Pancreatitis
  [
    'acute-pancreatitis',
    {
      conditionId: 'acute-pancreatitis',
      name: 'Acute Pancreatitis',
      aliases: ['Pancreatitis', 'Inflamed Pancreas'],
      icdCode: 'K85.9',
      category: 'gastrointestinal',
      subcategory: 'Pancreatic Disease',
      description: 'Acute inflammation of the pancreas, most commonly caused by gallstones or alcohol, causing severe abdominal pain.',
      pathophysiology: {
        summary: 'Premature activation of pancreatic enzymes causes autodigestion and inflammation of the pancreas.',
        mechanisms: [
          { name: 'Enzyme Autoactivation', description: 'Trypsinogen prematurely converted to trypsin within pancreas', systemsInvolved: ['GI'], keyMediators: ['Trypsin', 'Phospholipase A2', 'Elastase'], contribution: 'Autodigestion of pancreatic tissue' },
          { name: 'Inflammatory Cascade', description: 'Local inflammation triggers systemic inflammatory response', systemsInvolved: ['GI', 'Immune'], keyMediators: ['IL-1', 'IL-6', 'TNF-alpha'], contribution: 'SIRS, multi-organ dysfunction in severe cases' },
        ],
        riskFactors: [
          { name: 'Gallstones', type: 'modifiable', impact: 'major', description: 'Most common cause (~40%)', intervention: 'Cholecystectomy' },
          { name: 'Alcohol Use', type: 'modifiable', impact: 'major', description: 'Second most common cause (~30%)', intervention: 'Cessation' },
          { name: 'Hypertriglyceridemia', type: 'modifiable', impact: 'moderate', description: 'TG >1000 mg/dL', intervention: 'Lipid management' },
          { name: 'ERCP', type: 'partially-modifiable', impact: 'moderate', description: 'Post-procedure complication' },
          { name: 'Medications', type: 'modifiable', impact: 'minor', description: 'Various drugs implicated' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Epigastric Pain', prevalence: 'very-common', description: 'Severe pain radiating to back', quality: 'Boring, constant', location: 'Epigastric, radiates to back' },
          { name: 'Nausea/Vomiting', prevalence: 'very-common', description: 'Often severe' },
        ],
        associatedSymptoms: [
          { name: 'Anorexia', prevalence: 'very-common', description: 'Unable to eat' },
          { name: 'Abdominal Distension', prevalence: 'common', description: 'From ileus' },
        ],
        physicalFindings: [
          { name: 'Epigastric Tenderness', examType: 'Abdominal', description: 'Guarding in upper abdomen', diagnosticValue: 'Key finding' },
          { name: 'Cullen\'s Sign', examType: 'Abdominal', description: 'Periumbilical ecchymosis', diagnosticValue: 'Suggests severe/necrotizing' },
          { name: 'Grey Turner\'s Sign', examType: 'Abdominal', description: 'Flank ecchymosis', diagnosticValue: 'Suggests severe/necrotizing' },
        ],
        labFindings: [
          { testName: 'Lipase', abnormality: 'Elevated >3x ULN', significance: 'Diagnostic - most sensitive/specific' },
          { testName: 'Amylase', abnormality: 'Elevated >3x ULN', significance: 'Less specific than lipase' },
          { testName: 'LFTs', abnormality: 'Elevated ALT suggests gallstone etiology', significance: 'Guides workup' },
        ],
        imagingFindings: [
          { modality: 'CT Abdomen (contrast)', finding: 'Pancreatic enlargement, peripancreatic fluid, necrosis', significance: 'Gold standard for severity assessment', structures: ['Pancreas'] },
        ],
      },
      progression: {
        naturalHistory: 'Most cases mild with recovery in days; 20% develop severe disease with complications.',
        timelineSteps: [
          {
            phaseId: 'mild',
            phase: 'acute',
            displayName: 'Mild Acute Pancreatitis',
            timeframe: 'Days',
            description: 'No organ failure or local complications',
            symptoms: ['Severe pain', 'Nausea/vomiting', 'Unable to eat'],
            anatomicalChanges: [
              { structureId: 'pancreas', structureName: 'Pancreas', changeType: 'inflammation', description: 'Interstitial edematous pancreatitis', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['NPO', 'IV fluids', 'Pain control', 'Advance diet as tolerated'],
          },
          {
            phaseId: 'moderate-severe',
            phase: 'acute',
            displayName: 'Moderately Severe Pancreatitis',
            timeframe: 'Days to weeks',
            description: 'Transient organ failure (<48h) or local complications',
            symptoms: ['Severe pain', 'Signs of SIRS', 'Local complications'],
            anatomicalChanges: [
              { structureId: 'pancreas', structureName: 'Pancreas', changeType: 'necrosis', description: 'Developing necrosis or fluid collections', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['ICU monitoring', 'Aggressive fluid resuscitation', 'Consider enteral nutrition'],
          },
          {
            phaseId: 'severe',
            phase: 'severe',
            displayName: 'Severe Acute Pancreatitis',
            timeframe: 'Days to weeks',
            description: 'Persistent organ failure >48 hours',
            symptoms: ['Multiorgan dysfunction', 'Shock', 'Respiratory failure'],
            anatomicalChanges: [
              { structureId: 'pancreas', structureName: 'Pancreas', changeType: 'necrosis', description: 'Extensive necrotizing pancreatitis', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: true, opacity: 0.9 }, isNewAtPhase: false },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['ICU care', 'Organ support', 'Enteral feeding', 'Delayed necrosectomy if infected'],
          },
        ],
        prognosis: 'Mild: excellent recovery. Severe: 15-30% mortality. Gallstone pancreatitis recurs without cholecystectomy.',
      },
      complications: [
        { complicationId: 'necrosis', name: 'Pancreatic Necrosis', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Death of pancreatic tissue', mechanism: 'Ischemia and enzyme-mediated damage', affectedStructures: [{ structureId: 'pancreas', structureName: 'Pancreas', effect: 'Tissue death', highlightColor: '#7f1d1d' }], warningSymptoms: ['Persistent fever', 'Worsening symptoms after initial improvement'], preventable: false },
        { complicationId: 'pseudocyst', name: 'Pancreatic Pseudocyst', category: 'chronic', severity: 'moderate', riskLevel: 'moderate', description: 'Walled-off fluid collection', mechanism: 'Organized peripancreatic fluid', affectedStructures: [{ structureId: 'pancreas', structureName: 'Peripancreatic area', effect: 'Fluid collection', highlightColor: '#f97316' }], warningSymptoms: ['Persistent pain', 'Early satiety', 'Palpable mass'], preventable: false },
      ],
      treatmentOptions: [
        { treatmentId: 'supportive', name: 'Supportive Care', modality: 'supportive', description: 'Fluids, pain control, nutrition', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute'], goals: ['Maintain perfusion', 'Rest pancreas', 'Pain relief'], explanations: { level1: 'IV fluids and pain medicine while your pancreas heals', level2: 'Treatment focuses on fluids to keep you hydrated, pain control, and letting your pancreas rest and heal on its own.', level3: 'Early aggressive fluid resuscitation (250-500mL/hr initially). Goal-directed therapy. Early enteral feeding when tolerated. Avoid prophylactic antibiotics.', level4: 'Lactated Ringer\'s preferred. BUN and hematocrit guide fluid adequacy. Enteral feeding maintains gut barrier and reduces infectious complications. Reserve antibiotics for documented infection.', level5: 'Fluid resuscitation counters third-spacing and maintains pancreatic microcirculation. Early enteral nutrition preserves intestinal barrier function and reduces translocation. Infected necrosis requires antibiotics and consideration of intervention (endoscopic or surgical drainage).' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'pancreas', structureName: 'Pancreas', role: 'primary-site', involvement: 'Inflammation and autodigestion', highlightColor: '#dc2626', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'gallbladder', structureName: 'Gallbladder', role: 'secondary-site', involvement: 'Source of gallstones causing obstruction', highlightColor: '#f97316', showByDefault: false },
        ],
        systemsInvolved: ['Gastrointestinal', 'Endocrine'],
        recommendedView: 'anterior',
        recommendedLayers: ['digestive'],
      },
      explanations: {
        level1: 'Your pancreas is inflamed and irritated, causing severe belly pain. Most people recover with rest and fluids.',
        level2: 'Pancreatitis happens when digestive enzymes start damaging the pancreas itself. Most common causes are gallstones and alcohol. Treatment is supportive.',
        level3: 'Acute pancreatitis is diagnosed by 2 of 3: typical pain, lipase >3x ULN, characteristic imaging. Severity classified by organ failure and local complications. Supportive care is mainstay.',
        level4: 'Trypsinogen activation within acinar cells triggers enzyme cascade and autodigestion. Revised Atlanta classification: mild (no complications), moderate (transient organ failure or local complications), severe (persistent organ failure).',
        level5: 'Intracellular trypsin activation occurs via cathepsin B-mediated conversion or impaired autophagy. This triggers phospholipase A2, elastase activation and NF-κB mediated cytokine release. SIRS and MODS result from inflammatory mediator spillover. Early fluid resuscitation maintains microcirculation; goal-directed by BUN, hematocrit, lactate.',
      },
      relatedConditions: ['gallstones', 'chronic-pancreatitis', 'pancreatic-pseudocyst'],
      clinicalPearls: [
        'Lipase >3x ULN is more specific than amylase',
        'Elevated ALT suggests gallstone etiology',
        'CT not needed for diagnosis; reserve for complications/severity',
        'Same-admission cholecystectomy for gallstone pancreatitis reduces recurrence',
      ],
      patientEducation: [
        'Most cases of pancreatitis heal on their own with supportive care',
        'If caused by gallstones, you\'ll need gallbladder removal to prevent recurrence',
        'Avoid alcohol - it can cause pancreatitis and delay healing',
        'Start with clear liquids, then advance diet slowly as tolerated',
        'Return immediately if symptoms worsen or fever develops',
      ],
      emergencyWarnings: [
        'Fever with worsening pain (infected necrosis)',
        'Persistent vomiting unable to keep anything down',
        'Confusion or altered mental status',
        'Difficulty breathing',
        'Blood in vomit or stool',
      ],
    },
  ],
  // Cirrhosis
  [
    'cirrhosis',
    {
      conditionId: 'cirrhosis',
      name: 'Cirrhosis',
      aliases: ['Liver Cirrhosis', 'Chronic Liver Disease', 'End-Stage Liver Disease'],
      icdCode: 'K74.60',
      category: 'gastrointestinal',
      subcategory: 'Hepatic Disease',
      description: 'Chronic liver damage leading to scarring (fibrosis) that impairs liver function and blood flow.',
      pathophysiology: {
        summary: 'Chronic liver injury leads to progressive fibrosis, nodular regeneration, and loss of hepatic function.',
        mechanisms: [
          { name: 'Hepatic Fibrosis', description: 'Chronic injury activates stellate cells, producing collagen', systemsInvolved: ['Hepatic'], keyMediators: ['TGF-β', 'Hepatic stellate cells', 'Collagen'], contribution: 'Progressive scarring and architectural distortion' },
          { name: 'Portal Hypertension', description: 'Increased resistance to portal flow', systemsInvolved: ['Hepatic', 'Cardiovascular'], keyMediators: ['Increased intrahepatic resistance', 'Splanchnic vasodilation'], contribution: 'Varices, ascites, splenomegaly' },
          { name: 'Hepatocellular Dysfunction', description: 'Loss of functional hepatocytes', systemsInvolved: ['Hepatic'], contribution: 'Impaired synthesis, metabolism, detoxification' },
        ],
        riskFactors: [
          { name: 'Chronic Alcohol Use', type: 'modifiable', impact: 'major', description: 'Major cause in Western countries', intervention: 'Abstinence' },
          { name: 'Hepatitis B/C', type: 'partially-modifiable', impact: 'major', description: 'Major cause worldwide', intervention: 'Antiviral treatment' },
          { name: 'NAFLD/NASH', type: 'modifiable', impact: 'major', description: 'Increasingly common', intervention: 'Weight loss, metabolic control' },
          { name: 'Autoimmune Hepatitis', type: 'partially-modifiable', impact: 'moderate', description: 'Treatable but may progress' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Often earliest symptom' },
          { name: 'May Be Asymptomatic', prevalence: 'common', description: 'Compensated cirrhosis often silent' },
        ],
        associatedSymptoms: [
          { name: 'Abdominal Distension', prevalence: 'common', description: 'From ascites', timing: 'Decompensated' },
          { name: 'Jaundice', prevalence: 'common', description: 'Yellowing of skin/eyes', timing: 'Decompensated' },
          { name: 'Easy Bruising', prevalence: 'common', description: 'Impaired clotting factor synthesis' },
          { name: 'Confusion', prevalence: 'uncommon', description: 'Hepatic encephalopathy' },
        ],
        physicalFindings: [
          { name: 'Ascites', examType: 'Abdominal', description: 'Shifting dullness, fluid wave', diagnosticValue: 'Suggests decompensation' },
          { name: 'Spider Angiomata', examType: 'Skin', description: 'Vascular spiders on upper body', diagnosticValue: 'Classic finding' },
          { name: 'Palmar Erythema', examType: 'Hands', description: 'Red palms', diagnosticValue: 'Suggestive' },
          { name: 'Asterixis', examType: 'Neurologic', description: 'Flapping tremor', diagnosticValue: 'Suggests encephalopathy' },
          { name: 'Caput Medusae', examType: 'Abdominal', description: 'Dilated periumbilical veins', diagnosticValue: 'Suggests portal hypertension' },
        ],
        labFindings: [
          { testName: 'Albumin', abnormality: 'Low', significance: 'Reduced synthetic function' },
          { testName: 'INR/PT', abnormality: 'Elevated', significance: 'Reduced clotting factor synthesis' },
          { testName: 'Bilirubin', abnormality: 'Elevated', significance: 'Impaired excretion' },
          { testName: 'Platelets', abnormality: 'Low', significance: 'Splenic sequestration' },
          { testName: 'AST/ALT', abnormality: 'May be elevated or normal', significance: 'Inflammation; often normal in cirrhosis' },
        ],
        imagingFindings: [
          { modality: 'Ultrasound', finding: 'Nodular liver surface, splenomegaly, ascites', significance: 'First-line imaging', structures: ['Liver', 'Spleen'] },
          { modality: 'FibroScan', finding: 'Elevated liver stiffness', significance: 'Non-invasive fibrosis assessment' },
        ],
      },
      progression: {
        naturalHistory: 'Progressive without treatment of underlying cause; compensated cirrhosis may remain stable for years.',
        timelineSteps: [
          {
            phaseId: 'compensated',
            phase: 'established',
            displayName: 'Compensated Cirrhosis',
            timeframe: 'Years',
            description: 'Cirrhosis present but liver maintaining function',
            symptoms: ['Often asymptomatic', 'Fatigue', 'May have mild portal hypertension'],
            anatomicalChanges: [
              { structureId: 'liver', structureName: 'Liver', changeType: 'fibrosis', description: 'Nodular fibrosis but maintained function', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Treat underlying cause', 'Surveillance for HCC', 'Variceal screening'],
            goalsOfCare: ['Prevent decompensation', 'Screen for complications'],
          },
          {
            phaseId: 'decompensated',
            phase: 'advanced',
            displayName: 'Decompensated Cirrhosis',
            timeframe: 'Variable',
            description: 'Development of ascites, variceal bleeding, encephalopathy, or jaundice',
            symptoms: ['Ascites', 'Confusion', 'Jaundice', 'Variceal bleeding'],
            anatomicalChanges: [
              { structureId: 'liver', structureName: 'Liver', changeType: 'fibrosis', description: 'Advanced fibrosis with functional failure', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: false },
              { structureId: 'spleen', structureName: 'Spleen', changeType: 'hypertrophy', description: 'Splenomegaly from portal hypertension', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Diuretics for ascites', 'Lactulose for encephalopathy', 'Beta-blockers for varices', 'Transplant evaluation'],
          },
          {
            phaseId: 'esld',
            phase: 'end-stage',
            displayName: 'End-Stage Liver Disease',
            timeframe: 'Months',
            description: 'Severe decompensation, MELD score high, transplant needed',
            symptoms: ['Refractory ascites', 'Recurrent encephalopathy', 'Hepatorenal syndrome'],
            anatomicalChanges: [
              { structureId: 'liver', structureName: 'Liver', changeType: 'atrophy', description: 'Shrunken, nodular liver with minimal function', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Liver transplantation', 'Palliative care if not candidate'],
          },
        ],
        prognosis: 'Compensated: 50% 10-year survival. Decompensated: 50% 2-year survival without transplant.',
      },
      complications: [
        { complicationId: 'ascites', name: 'Ascites', category: 'chronic', severity: 'moderate', riskLevel: 'high', description: 'Fluid accumulation in abdomen', mechanism: 'Portal hypertension and hypoalbuminemia', affectedStructures: [{ structureId: 'abdomen', structureName: 'Peritoneal Cavity', effect: 'Fluid accumulation', highlightColor: '#3b82f6' }], warningSymptoms: ['Abdominal distension', 'Weight gain', 'Dyspnea'], preventable: true },
        { complicationId: 'varices', name: 'Esophageal Varices', category: 'both', severity: 'life-threatening', riskLevel: 'high', description: 'Dilated veins that can bleed', mechanism: 'Portal hypertension causes collateral flow', affectedStructures: [{ structureId: 'esophagus', structureName: 'Esophagus', effect: 'Dilated veins', highlightColor: '#dc2626' }], warningSymptoms: ['Vomiting blood', 'Black stools'], preventable: true },
        { complicationId: 'hcc', name: 'Hepatocellular Carcinoma', category: 'chronic', severity: 'life-threatening', riskLevel: 'moderate', description: 'Primary liver cancer', mechanism: 'Chronic inflammation and regeneration', affectedStructures: [{ structureId: 'liver', structureName: 'Liver', effect: 'Malignancy', highlightColor: '#7f1d1d' }], warningSymptoms: ['New liver mass', 'Worsening liver function', 'Elevated AFP'], preventable: false },
      ],
      treatmentOptions: [
        { treatmentId: 'treat-cause', name: 'Treat Underlying Cause', modality: 'pharmacological', description: 'Address alcohol, hepatitis, metabolic disease', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['established', 'advanced'], goals: ['Halt progression', 'Allow some fibrosis regression'], explanations: { level1: 'Stopping the damage to your liver by treating the cause', level2: 'The most important treatment is addressing what\'s causing the liver damage - quitting alcohol, treating hepatitis, or managing metabolic conditions.', level3: 'Treating etiology can halt progression and allow fibrosis regression. HCV cure, alcohol abstinence, and NASH management are key.', level4: 'DAAs cure HCV with fibrosis regression possible. Alcohol abstinence improves survival even in decompensated disease. NASH treatment focuses on metabolic syndrome.', level5: 'Etiologic treatment allows hepatic stellate cell quiescence and MMP-mediated matrix degradation. SVR in HCV associated with fibrosis regression in 60%. Alcohol abstinence key prognostic factor regardless of severity.' } },
        { treatmentId: 'transplant', name: 'Liver Transplantation', modality: 'surgical', description: 'Definitive treatment for ESLD', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: false, appropriatePhases: ['advanced', 'end-stage'], goals: ['Cure liver failure', 'Restore function'], explanations: { level1: 'Replacing your damaged liver with a healthy one from a donor', level2: 'For severe liver disease, a liver transplant can cure the condition. It requires lifelong medications to prevent rejection.', level3: 'Transplant is definitive for ESLD. MELD score prioritizes allocation. Requires lifelong immunosuppression. 5-year survival >70%.', level4: 'Indications: decompensated cirrhosis, HCC within Milan criteria, acute liver failure. Contraindications include active substance abuse, uncontrolled infection, advanced extrahepatic malignancy.', level5: 'MELD-Na prioritizes organ allocation based on mortality risk. Living donor and split liver expand donor pool. Immunosuppression balances rejection and infection risk. Long-term outcomes limited by recurrent disease and metabolic complications.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'liver', structureName: 'Liver', role: 'primary-site', involvement: 'Fibrosis and nodular regeneration', highlightColor: '#dc2626', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'spleen', structureName: 'Spleen', role: 'target-organ', involvement: 'Splenomegaly from portal hypertension', highlightColor: '#f97316', showByDefault: true },
          { structureId: 'esophagus', structureName: 'Esophageal Veins', role: 'collateral', involvement: 'Varices from portal hypertension', highlightColor: '#ef4444', showByDefault: false },
        ],
        systemsInvolved: ['Gastrointestinal', 'Hepatic', 'Cardiovascular'],
        recommendedView: 'anterior',
        recommendedLayers: ['digestive'],
      },
      explanations: {
        level1: 'Your liver has developed scarring from long-term damage. Treatment focuses on preventing more damage and managing complications.',
        level2: 'Cirrhosis is scarring of the liver from chronic injury. The liver can still function with mild cirrhosis, but severe cases cause serious complications.',
        level3: 'Cirrhosis is end-stage fibrosis from any chronic liver disease. Classified as compensated or decompensated. Treatment targets etiology and complications.',
        level4: 'Hepatic stellate cell activation drives fibrogenesis. Portal hypertension results from increased intrahepatic resistance. MELD score predicts 3-month mortality. Child-Pugh classifies severity.',
        level5: 'Fibrosis represents imbalance between ECM synthesis (stellate cells) and degradation (MMPs/TIMPs). Portal hypertension increases splanchnic vasodilation via NO, creating hyperdynamic circulation. Ascites forms via underfill theory (RAAS activation) and sinusoidal hypertension.',
      },
      relatedConditions: ['hepatitis-b', 'hepatitis-c', 'alcoholic-liver-disease', 'nafld'],
      clinicalPearls: [
        'Child-Pugh classifies severity; MELD predicts mortality and transplant priority',
        'Compensated can become decompensated but rarely the reverse',
        'Screen for varices with EGD at diagnosis',
        'HCC surveillance with US ± AFP every 6 months',
      ],
      patientEducation: [
        'Avoid alcohol completely - even small amounts can worsen damage',
        'Some medications are dangerous with liver disease - always check before taking anything new',
        'Low-sodium diet helps control fluid retention',
        'Keep all appointments - regular monitoring catches problems early',
        'Vaccines for hepatitis A/B and pneumonia are important',
      ],
      emergencyWarnings: [
        'Vomiting blood or black tarry stools (variceal bleeding)',
        'Confusion, disorientation, or drowsiness (encephalopathy)',
        'Fever with abdominal pain (possible infection)',
        'Rapid increase in abdominal size',
        'Yellowing skin/eyes getting worse',
      ],
    },
  ],
  // Kidney Stones
  [
    'kidney-stones',
    {
      conditionId: 'kidney-stones',
      name: 'Kidney Stones',
      aliases: ['Nephrolithiasis', 'Renal Calculi', 'Urolithiasis', 'Renal Colic'],
      icdCode: 'N20.0',
      category: 'urologic',
      subcategory: 'Renal Disease',
      description: 'Hard mineral deposits that form in the kidneys and can cause severe pain when passing through the urinary tract.',
      pathophysiology: {
        summary: 'Supersaturation of urine with stone-forming substances leads to crystal formation and aggregation.',
        mechanisms: [
          { name: 'Supersaturation', description: 'Excess solutes in urine exceed solubility', systemsInvolved: ['Renal'], keyMediators: ['Calcium', 'Oxalate', 'Uric acid', 'Phosphate'], contribution: 'Crystal nucleation' },
          { name: 'Inhibitor Deficiency', description: 'Lack of stone inhibitors allows crystal growth', systemsInvolved: ['Renal'], keyMediators: ['Citrate', 'Magnesium', 'Glycosaminoglycans'], contribution: 'Uninhibited crystal aggregation' },
        ],
        riskFactors: [
          { name: 'Dehydration', type: 'modifiable', impact: 'major', description: 'Low urine volume concentrates solutes', intervention: 'Increase fluid intake to >2.5L urine/day' },
          { name: 'High Sodium Diet', type: 'modifiable', impact: 'moderate', description: 'Increases urinary calcium', intervention: 'Low sodium diet' },
          { name: 'Obesity', type: 'modifiable', impact: 'moderate', description: 'Increases uric acid excretion', intervention: 'Weight loss' },
          { name: 'Family History', type: 'non-modifiable', impact: 'moderate', description: 'Genetic predisposition' },
          { name: 'Prior Kidney Stones', type: 'non-modifiable', impact: 'major', description: '50% recurrence at 5 years' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Renal Colic', prevalence: 'very-common', description: 'Severe, colicky flank pain radiating to groin', quality: 'Severe, waves of pain', location: 'Flank radiating to groin/labia/testicle' },
        ],
        associatedSymptoms: [
          { name: 'Hematuria', prevalence: 'very-common', description: 'Blood in urine, often microscopic' },
          { name: 'Nausea/Vomiting', prevalence: 'common', description: 'From severe pain' },
          { name: 'Urinary Urgency/Frequency', prevalence: 'common', description: 'When stone in distal ureter' },
        ],
        physicalFindings: [
          { name: 'CVA Tenderness', examType: 'Back', description: 'Costovertebral angle tenderness', diagnosticValue: 'Suggestive' },
          { name: 'Restlessness', examType: 'General', description: 'Patient unable to find comfortable position', diagnosticValue: 'Distinguishes from peritonitis' },
        ],
        labFindings: [
          { testName: 'Urinalysis', abnormality: 'Hematuria, crystals', significance: 'Supports diagnosis' },
          { testName: 'BMP', abnormality: 'Check calcium, creatinine', significance: 'Metabolic workup' },
        ],
        imagingFindings: [
          { modality: 'Non-contrast CT Abdomen', finding: 'Stone visualized in collecting system/ureter', significance: 'Gold standard - 95%+ sensitivity', structures: ['Kidneys', 'Ureters'] },
        ],
      },
      progression: {
        naturalHistory: 'Acute event; most small stones pass spontaneously. 50% recurrence within 5 years without prevention.',
        timelineSteps: [
          {
            phaseId: 'acute',
            phase: 'acute',
            displayName: 'Acute Renal Colic',
            timeframe: 'Hours to days',
            description: 'Stone causing obstruction and severe pain',
            symptoms: ['Severe flank pain', 'Hematuria', 'Nausea'],
            anatomicalChanges: [
              { structureId: 'ureter', structureName: 'Ureter', changeType: 'stenosis', description: 'Stone obstructing ureter', severity: 'moderate', visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
              { structureId: 'kidney', structureName: 'Kidney', changeType: 'dilation', description: 'Hydronephrosis from obstruction', severity: 'mild', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Pain control (NSAIDs, opioids)', 'IV fluids', 'Alpha-blocker (MET)', 'Watch for passage'],
          },
          {
            phaseId: 'complicated',
            phase: 'severe',
            displayName: 'Complicated Stone',
            timeframe: 'Urgent',
            description: 'Obstruction with infection or renal failure',
            symptoms: ['Fever', 'Unable to pass stone', 'Rising creatinine'],
            anatomicalChanges: [
              { structureId: 'kidney', structureName: 'Kidney', changeType: 'dilation', description: 'Moderate-severe hydronephrosis', severity: 'severe', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Urgent decompression (ureteral stent or nephrostomy)', 'Antibiotics if infected', 'Definitive stone treatment later'],
          },
        ],
        prognosis: 'Excellent for individual episode. High recurrence without prevention measures.',
      },
      complications: [
        { complicationId: 'obstruction', name: 'Ureteral Obstruction', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Complete blockage of ureter', mechanism: 'Stone lodges in ureter', affectedStructures: [{ structureId: 'ureter', structureName: 'Ureter', effect: 'Obstruction', highlightColor: '#ef4444' }], warningSymptoms: ['Worsening pain', 'Decreased urine output', 'Fever'], preventable: false },
        { complicationId: 'obstructive-pyelo', name: 'Obstructive Pyelonephritis', category: 'acute', severity: 'life-threatening', riskLevel: 'moderate', description: 'Infected, obstructed kidney - surgical emergency', mechanism: 'Bacteria in obstructed collecting system', affectedStructures: [{ structureId: 'kidney', structureName: 'Kidney', effect: 'Infected hydronephrosis', highlightColor: '#dc2626' }], warningSymptoms: ['High fever', 'Rigors', 'Severe flank pain'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'met', name: 'Medical Expulsive Therapy', modality: 'pharmacological', description: 'Alpha-blocker to facilitate stone passage', mechanism: 'Relaxes ureteral smooth muscle', efficacy: 'moderately-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute'], goals: ['Facilitate passage', 'Reduce pain episodes'], medicationIds: ['tamsulosin'], explanations: { level1: 'A pill that relaxes the tube from kidney to bladder, helping the stone pass', level2: 'Alpha-blockers relax the ureter, making it easier for stones to pass. Works best for stones 5-10mm.', level3: 'Tamsulosin or similar alpha-blocker increases stone passage rate. Most effective for distal ureteral stones 5-10mm.', level4: 'MET increases spontaneous passage rates by ~30%. NNT ~4. Best evidence for distal stones 5-10mm. Some controversy on smaller stones.', level5: 'Alpha-1 adrenergic blockade reduces ureteral tone and peristaltic frequency. SUSPEND trial questioned benefit for small stones. Most effective in distal ureter. Consider with NSAIDs for synergistic effect.' } },
        { treatmentId: 'ureteroscopy', name: 'Ureteroscopy', modality: 'surgical', description: 'Endoscopic stone removal', mechanism: 'Direct visualization and laser fragmentation', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: false, appropriatePhases: ['acute'], goals: ['Stone removal', 'Relieve obstruction'], explanations: { level1: 'A thin scope goes up through your bladder to remove or break up the stone', level2: 'A tiny camera is passed through your urethra to the stone, which is broken up with a laser and removed.', level3: 'Ureteroscopy with laser lithotripsy is first-line intervention for most ureteral stones. High success rate. May require stent.', level4: 'Holmium:YAG laser fragments stones. Flexible ureteroscopy reaches most locations. Stone-free rates >90% for ureteral stones. Post-op stent controversial for uncomplicated cases.', level5: 'URS allows direct visualization, dusting or basketing stones. Holmium laser enables fragmentation of all stone types. Ureteral access sheath reduces intrarenal pressures but may increase stricture risk. Alpha-blockers post-stent improve symptoms.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'kidneys', structureName: 'Kidneys', role: 'primary-site', involvement: 'Site of stone formation', highlightColor: '#ef4444', showByDefault: true },
          { structureId: 'ureters', structureName: 'Ureters', role: 'primary-site', involvement: 'Site of obstruction/colic', highlightColor: '#ef4444', showByDefault: true },
        ],
        systemsInvolved: ['Urologic'],
        recommendedView: 'posterior',
        recommendedLayers: ['urinary'],
      },
      explanations: {
        level1: 'Hard stones have formed in your kidney and are trying to pass through. This causes severe pain. Most pass on their own with time.',
        level2: 'Kidney stones form when minerals in urine concentrate and crystallize. Passing a stone causes severe pain. Small stones usually pass; larger ones may need procedures.',
        level3: 'Nephrolithiasis results from supersaturated urine. Calcium oxalate most common (80%). CT is diagnostic gold standard. MET for small stones; procedures for larger or complicated.',
        level4: 'Stone composition: calcium oxalate (80%), uric acid (10%), struvite (10%). Size and location predict passage. <5mm: 90% pass. >10mm: <10% pass. URS/PCNL for failed passage.',
        level5: 'Randall plaques (subepithelial calcium phosphate deposits) serve as nucleation sites. Low urine volume most important modifiable risk. Citrate inhibits stone formation. 24-hour urine guides targeted prevention.',
      },
      relatedConditions: ['uti', 'hydronephrosis', 'chronic-kidney-disease'],
      clinicalPearls: [
        'Stone size predicts passage: <5mm usually pass; >10mm rarely pass',
        'Fever + obstructing stone is a urologic emergency',
        'Non-contrast CT is gold standard for diagnosis',
        '24-hour urine collection guides prevention in recurrent stone formers',
      ],
      patientEducation: [
        'Drink enough to make >2.5 liters of urine daily - urine should be light yellow',
        'Strain your urine to catch the stone for analysis',
        'Pain can be severe but usually peaks and improves as stone moves',
        'Reduce sodium intake to lower stone risk',
        'Seek care immediately if you develop fever or can\'t control pain',
      ],
      emergencyWarnings: [
        'Fever with kidney stone symptoms (infected obstruction - emergency)',
        'Unable to urinate',
        'Pain uncontrolled by medications',
        'Vomiting unable to keep anything down',
        'Severe pain on both sides (suggests bilateral obstruction)',
      ],
    },
  ],
  // Urinary Tract Infection
  [
    'urinary-tract-infection',
    {
      conditionId: 'urinary-tract-infection',
      name: 'Urinary Tract Infection',
      aliases: ['UTI', 'Bladder Infection', 'Cystitis', 'Pyelonephritis (upper)'],
      icdCode: 'N39.0',
      category: 'urologic',
      subcategory: 'Infectious Disease',
      description: 'Bacterial infection of the urinary tract, ranging from simple bladder infection to serious kidney infection.',
      pathophysiology: {
        summary: 'Bacteria, usually from the gut, ascend the urethra and colonize the urinary tract.',
        mechanisms: [
          { name: 'Ascending Infection', description: 'Bacteria ascend urethra to bladder', systemsInvolved: ['Urologic'], keyMediators: ['E. coli fimbriae', 'Bacterial adhesins'], contribution: 'Colonization of bladder mucosa' },
          { name: 'Host Factors', description: 'Short female urethra, sexual activity, catheterization', systemsInvolved: ['Urologic'], contribution: 'Facilitate bacterial entry' },
        ],
        riskFactors: [
          { name: 'Female Sex', type: 'non-modifiable', impact: 'major', description: 'Short urethra proximity to rectum' },
          { name: 'Sexual Activity', type: 'modifiable', impact: 'major', description: 'Increases risk ("honeymoon cystitis")', intervention: 'Post-coital voiding' },
          { name: 'Menopause', type: 'non-modifiable', impact: 'moderate', description: 'Loss of estrogen changes vaginal flora' },
          { name: 'Catheterization', type: 'partially-modifiable', impact: 'major', description: 'Direct bacterial introduction', intervention: 'Minimize catheter use' },
          { name: 'Urinary Retention/Obstruction', type: 'partially-modifiable', impact: 'moderate', description: 'Stasis promotes bacterial growth' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Dysuria', prevalence: 'very-common', description: 'Burning or pain with urination' },
          { name: 'Urinary Frequency', prevalence: 'very-common', description: 'Frequent urge to urinate' },
          { name: 'Urinary Urgency', prevalence: 'very-common', description: 'Sudden strong need to urinate' },
        ],
        associatedSymptoms: [
          { name: 'Suprapubic Pain', prevalence: 'common', description: 'Lower abdominal discomfort' },
          { name: 'Hematuria', prevalence: 'common', description: 'Blood in urine' },
          { name: 'Fever/Flank Pain', prevalence: 'uncommon', description: 'Suggests pyelonephritis', timing: 'Upper UTI' },
          { name: 'Cloudy/Foul-Smelling Urine', prevalence: 'common', description: 'From bacteria and WBCs' },
        ],
        labFindings: [
          { testName: 'Urinalysis', abnormality: 'Pyuria, bacteriuria, nitrites, leukocyte esterase', significance: 'Supports diagnosis' },
          { testName: 'Urine Culture', abnormality: '>10^5 CFU/mL', significance: 'Gold standard; guides therapy for complicated UTI' },
        ],
      },
      progression: {
        naturalHistory: 'Can progress from cystitis to pyelonephritis to urosepsis if untreated.',
        timelineSteps: [
          {
            phaseId: 'uncomplicated',
            phase: 'acute',
            displayName: 'Uncomplicated Cystitis',
            timeframe: 'Days',
            description: 'Simple bladder infection in healthy, non-pregnant woman',
            symptoms: ['Dysuria', 'Frequency', 'Urgency', 'Suprapubic pain'],
            anatomicalChanges: [
              { structureId: 'bladder', structureName: 'Bladder', changeType: 'inflammation', description: 'Mucosal inflammation', severity: 'mild', visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Nitrofurantoin 5 days', 'TMP-SMX 3 days', 'Fosfomycin single dose'],
          },
          {
            phaseId: 'pyelonephritis',
            phase: 'severe',
            displayName: 'Pyelonephritis',
            timeframe: 'Days',
            description: 'Kidney infection with systemic symptoms',
            symptoms: ['Fever', 'Flank pain', 'Nausea/vomiting', 'UTI symptoms'],
            anatomicalChanges: [
              { structureId: 'kidney', structureName: 'Kidney', changeType: 'inflammation', description: 'Renal parenchymal infection', severity: 'moderate', visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Fluoroquinolone 7 days', 'TMP-SMX 14 days', 'IV antibiotics if severe'],
          },
          {
            phaseId: 'urosepsis',
            phase: 'severe',
            displayName: 'Urosepsis',
            timeframe: 'Emergency',
            description: 'Systemic infection from urinary source',
            symptoms: ['High fever', 'Hypotension', 'Altered mental status', 'Tachycardia'],
            anatomicalChanges: [
              { structureId: 'kidney', structureName: 'Kidneys', changeType: 'dysfunction', description: 'Sepsis-related organ dysfunction', severity: 'severe', visualIndicator: { color: '#7f1d1d', pulse: true, opacity: 0.8 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['IV antibiotics', 'Fluid resuscitation', 'Source control if obstruction'],
          },
        ],
        prognosis: 'Excellent for uncomplicated UTI. Pyelonephritis can cause renal scarring. Urosepsis has significant mortality.',
      },
      complications: [
        { complicationId: 'pyelonephritis', name: 'Pyelonephritis', category: 'acute', severity: 'major', riskLevel: 'moderate', description: 'Ascending infection to kidneys', mechanism: 'Bacteria ascend from bladder to kidney', affectedStructures: [{ structureId: 'kidney', structureName: 'Kidney', effect: 'Parenchymal infection', highlightColor: '#dc2626' }], warningSymptoms: ['Fever', 'Flank pain', 'Nausea/vomiting'], preventable: true },
        { complicationId: 'urosepsis', name: 'Urosepsis', category: 'acute', severity: 'life-threatening', riskLevel: 'low', description: 'Systemic sepsis from urinary source', mechanism: 'Bacteremia from urinary tract', affectedStructures: [{ structureId: 'bloodstream', structureName: 'Systemic', effect: 'Sepsis', highlightColor: '#7f1d1d' }], warningSymptoms: ['High fever', 'Hypotension', 'Confusion'], preventable: true },
      ],
      treatmentOptions: [
        { treatmentId: 'antibiotics', name: 'Antibiotics', modality: 'pharmacological', description: 'Targeted antimicrobial therapy', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['acute', 'severe'], goals: ['Eradicate infection', 'Prevent complications'], medicationIds: ['nitrofurantoin', 'trimethoprim-sulfamethoxazole', 'ciprofloxacin'], explanations: { level1: 'Antibiotic pills to kill the bacteria causing your infection', level2: 'A short course of antibiotics clears the infection. Different antibiotics are used depending on whether the infection is in your bladder or kidneys.', level3: 'Empiric therapy based on local resistance. Uncomplicated: nitrofurantoin, TMP-SMX, or fosfomycin. Pyelonephritis: fluoroquinolone or TMP-SMX.', level4: 'IDSA guidelines recommend nitrofurantoin 100mg BID x 5d or TMP-SMX x 3d for uncomplicated cystitis. Avoid fluoroquinolones due to resistance concerns. Culture guides complicated UTI.', level5: 'Nitrofurantoin concentrates in urine with activity against most uropathogens. TMP-SMX achieves high renal/urinary concentrations. Growing fluoroquinolone resistance limits empiric use. Pyelonephritis requires tissue-penetrating agents.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'bladder', structureName: 'Bladder', role: 'primary-site', involvement: 'Site of cystitis', highlightColor: '#f97316', showByDefault: true },
          { structureId: 'kidneys', structureName: 'Kidneys', role: 'primary-site', involvement: 'Site of pyelonephritis', highlightColor: '#dc2626', showByDefault: false },
        ],
        systemsInvolved: ['Urologic'],
        recommendedView: 'anterior',
        recommendedLayers: ['urinary'],
      },
      explanations: {
        level1: 'Bacteria have infected your bladder (or kidneys), causing pain when you urinate. Antibiotics will cure it.',
        level2: 'UTIs happen when bacteria get into the urinary tract. Most are simple bladder infections treated with a few days of antibiotics.',
        level3: 'UTIs are classified as uncomplicated (healthy woman, bladder only) or complicated (male, pregnant, catheter, pyelonephritis). Antibiotic choice guided by classification and local resistance.',
        level4: 'E. coli causes 80% of community UTIs. Uncomplicated cystitis can be treated empirically; complicated UTI warrants culture. Pyuria without bacteriuria suggests STI or interstitial cystitis.',
        level5: 'Uropathogenic E. coli express P fimbriae for mucosal adhesion. Host defense includes urinary flow, low pH, Tamm-Horsfall protein, and innate immunity. Complicated UTIs require longer therapy due to tissue invasion and potential resistant organisms. Catheter-associated UTIs require catheter change for eradication.',
      },
      relatedConditions: ['kidney-stones', 'benign-prostatic-hyperplasia', 'interstitial-cystitis'],
      clinicalPearls: [
        'Uncomplicated cystitis in women can be treated empirically without culture',
        'Males with UTI are complicated by definition - get culture, consider evaluation',
        'Fever/flank pain = pyelonephritis, not simple cystitis',
        'Asymptomatic bacteriuria treated only in pregnancy and before urologic procedures',
      ],
      patientEducation: [
        'Complete the full antibiotic course even if you feel better',
        'Drink plenty of water to flush bacteria',
        'Wipe front to back to prevent bacterial spread',
        'Urinate after sexual activity',
        'Don\'t hold your urine - empty your bladder regularly',
      ],
      emergencyWarnings: [
        'Fever with UTI symptoms (may indicate kidney infection)',
        'Severe flank pain',
        'Blood in urine that persists',
        'Symptoms not improving after 2-3 days of antibiotics',
        'Confusion, rapid breathing, or very fast heart rate (sepsis)',
      ],
    },
  ],
  // Anemia of Chronic Disease
  [
    'anemia-chronic-disease',
    {
      conditionId: 'anemia-chronic-disease',
      name: 'Anemia of Chronic Disease',
      aliases: ['ACD', 'Anemia of Inflammation', 'Anemia of Chronic Inflammation'],
      icdCode: 'D63.8',
      category: 'hematologic',
      subcategory: 'Anemia',
      description: 'Anemia associated with chronic inflammatory, infectious, or malignant conditions, caused by impaired iron utilization.',
      pathophysiology: {
        summary: 'Inflammatory cytokines increase hepcidin, which blocks iron absorption and release, causing functional iron deficiency.',
        mechanisms: [
          { name: 'Hepcidin Upregulation', description: 'IL-6 increases hepatic hepcidin production', systemsInvolved: ['Hematologic', 'Immune'], keyMediators: ['Hepcidin', 'IL-6', 'IL-1'], contribution: 'Iron sequestration in macrophages' },
          { name: 'Impaired EPO Response', description: 'Inflammatory cytokines blunt erythropoietin production and response', systemsInvolved: ['Hematologic'], keyMediators: ['TNF-alpha', 'IFN-gamma'], contribution: 'Reduced red cell production' },
          { name: 'Reduced RBC Survival', description: 'Inflammation shortens red cell lifespan', systemsInvolved: ['Hematologic'], contribution: 'Increased RBC turnover' },
        ],
        riskFactors: [
          { name: 'Chronic Infection', type: 'partially-modifiable', impact: 'major', description: 'TB, HIV, osteomyelitis, etc.' },
          { name: 'Autoimmune Disease', type: 'partially-modifiable', impact: 'major', description: 'RA, SLE, IBD' },
          { name: 'Malignancy', type: 'partially-modifiable', impact: 'major', description: 'Cancer-related inflammation' },
          { name: 'CKD', type: 'partially-modifiable', impact: 'major', description: 'Reduced EPO plus inflammation' },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          { name: 'Fatigue', prevalence: 'very-common', description: 'Often attributed to underlying disease' },
          { name: 'May Be Asymptomatic', prevalence: 'common', description: 'Anemia often mild' },
        ],
        associatedSymptoms: [
          { name: 'Symptoms of Underlying Disease', prevalence: 'very-common', description: 'Dominates clinical picture' },
        ],
        labFindings: [
          { testName: 'Hemoglobin', abnormality: 'Low (usually 8-11 g/dL)', significance: 'Usually mild-moderate' },
          { testName: 'MCV', abnormality: 'Normal or low', significance: 'Normocytic or microcytic' },
          { testName: 'Serum Iron', abnormality: 'Low', significance: 'Iron sequestered' },
          { testName: 'TIBC', abnormality: 'Low or normal', significance: 'Distinguishes from IDA (high in IDA)' },
          { testName: 'Ferritin', abnormality: 'Normal or high', significance: 'Key distinguisher from IDA (low in IDA)' },
          { testName: 'Reticulocyte Count', abnormality: 'Low/inappropriate', significance: 'Inadequate marrow response' },
        ],
      },
      progression: {
        naturalHistory: 'Parallels underlying disease; improves when underlying condition controlled.',
        timelineSteps: [
          {
            phaseId: 'mild',
            phase: 'established',
            displayName: 'Mild ACD',
            timeframe: 'Ongoing with underlying disease',
            description: 'Hemoglobin 10-12 g/dL',
            symptoms: ['Mild fatigue', 'Often asymptomatic'],
            anatomicalChanges: [
              { structureId: 'bone-marrow', structureName: 'Bone Marrow', changeType: 'dysfunction', description: 'Impaired iron utilization', severity: 'mild', visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 }, isNewAtPhase: true },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Treat underlying disease'],
          },
          {
            phaseId: 'moderate-severe',
            phase: 'established',
            displayName: 'Moderate-Severe ACD',
            timeframe: 'With severe/prolonged inflammation',
            description: 'Hemoglobin <10 g/dL, symptomatic',
            symptoms: ['Fatigue', 'Dyspnea on exertion', 'Decreased exercise tolerance'],
            anatomicalChanges: [
              { structureId: 'bone-marrow', structureName: 'Bone Marrow', changeType: 'dysfunction', description: 'Significant iron sequestration', severity: 'moderate', visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 }, isNewAtPhase: false },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Treat underlying disease', 'Consider IV iron', 'ESAs in select cases'],
          },
        ],
        prognosis: 'Improves with control of underlying condition. Transfusion rarely needed.',
      },
      complications: [],
      treatmentOptions: [
        { treatmentId: 'treat-underlying', name: 'Treat Underlying Disease', modality: 'pharmacological', description: 'Address the inflammatory/infectious cause', efficacy: 'highly-effective', evidenceLevel: 'level-1a', isFirstLine: true, appropriatePhases: ['established'], goals: ['Reduce inflammation', 'Improve iron utilization'], explanations: { level1: 'Treating the condition causing inflammation helps your body use iron normally again', level2: 'The best treatment for anemia of chronic disease is treating the underlying condition. As inflammation decreases, anemia improves.', level3: 'Treating the underlying inflammatory condition reduces hepcidin and allows iron mobilization. This is the primary therapy.', level4: 'Controlling inflammation reduces IL-6-driven hepcidin expression, releasing sequestered iron. DMARDs in RA, treating infection, controlling malignancy all improve ACD.', level5: 'Inflammatory cytokine reduction decreases hepatic hepcidin transcription. Iron then available for erythropoiesis. Novel hepcidin antagonists in development. IV iron may overcome hepcidin block. ESAs have modest benefit in cancer and CKD.' } },
      ],
      anatomyMapping: {
        primaryStructures: [
          { structureId: 'bone-marrow', structureName: 'Bone Marrow', role: 'primary-site', involvement: 'Impaired red cell production', highlightColor: '#f97316', showByDefault: true },
        ],
        secondaryStructures: [
          { structureId: 'liver', structureName: 'Liver', role: 'secondary-site', involvement: 'Hepcidin production', highlightColor: '#fbbf24', showByDefault: false },
        ],
        systemsInvolved: ['Hematologic', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['skeletal'],
      },
      explanations: {
        level1: 'Your body has iron but can\'t use it properly because of inflammation from your other condition. Treating that condition helps.',
        level2: 'When you have a chronic illness with inflammation, your body locks away iron and doesn\'t make red blood cells as well. This causes a mild anemia.',
        level3: 'ACD results from hepcidin-mediated iron sequestration and blunted EPO response. Ferritin normal/elevated distinguishes from IDA. Treatment focuses on underlying disease.',
        level4: 'IL-6 drives hepatic hepcidin expression, which degrades ferroportin, trapping iron in macrophages and enterocytes. Diagnosis: low iron, low/normal TIBC, normal/high ferritin.',
        level5: 'Hepcidin (HAMP) is the master iron regulator. IL-6 activates JAK/STAT3 pathway increasing hepcidin transcription. Hepcidin binds ferroportin causing internalization and degradation, blocking iron export. Concomitant IDA common and challenging to diagnose (consider sTfR, ferritin/sTfR ratio).',
      },
      relatedConditions: ['iron-deficiency-anemia', 'rheumatoid-arthritis', 'inflammatory-bowel-disease', 'chronic-kidney-disease'],
      clinicalPearls: [
        'Ferritin is the key: low = IDA; normal/high with low iron = ACD',
        'Can coexist with IDA - sTfR or bone marrow biopsy may help',
        'ESAs used in CKD and cancer but have thrombosis risk',
        'Treating underlying disease is most important intervention',
      ],
      patientEducation: [
        'This anemia is caused by your other health condition',
        'Treating your underlying disease is the best way to improve the anemia',
        'Iron pills may not help because the problem is your body not using iron, not lacking it',
        'This type of anemia is usually mild and rarely needs blood transfusions',
      ],
      emergencyWarnings: [
        'Severe shortness of breath at rest',
        'Chest pain',
        'Confusion or dizziness',
        'Very pale skin with rapid heartbeat',
      ],
    },
  ],

  // ============================================
  // Hepatitis B
  // ============================================
    [
      'hepatitis-b',
      {
        conditionId: 'hepatitis-b',
      name: 'Hepatitis B',
      aliases: ['HBV Infection', 'Serum Hepatitis'],
      icdCode: 'B18.1',
      category: 'infectious',
      subcategory: 'viral hepatitis',
      description:
        'Viral infection of the liver caused by hepatitis B virus that can become chronic and lead to cirrhosis and liver cancer.',

      pathophysiology: {
        summary:
          'HBV infects hepatocytes and replicates within them. Liver damage results primarily from the immune response attacking infected cells rather than direct viral cytopathic effects.',
        mechanisms: [
          {
            name: 'Viral Replication',
            description:
              'HBV enters hepatocytes via NTCP receptor, replicates using reverse transcriptase, and integrates into host DNA',
            systemsInvolved: ['Hepatic', 'Immune'],
            keyMediators: ['cccDNA', 'HBV polymerase', 'Surface antigens'],
            contribution:
              'Establishes persistent infection and viral reservoir in hepatocytes',
          },
          {
            name: 'Immune-Mediated Hepatocyte Injury',
            description:
              'Cytotoxic T lymphocytes recognize and destroy infected hepatocytes expressing viral antigens',
            systemsInvolved: ['Immune', 'Hepatic'],
            keyMediators: ['CD8+ T cells', 'TNF-alpha', 'IFN-gamma'],
            contribution:
              'Causes hepatocyte necrosis and inflammation leading to elevated liver enzymes',
          },
        ],
        riskFactors: [
          {
            name: 'Perinatal Transmission',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Mother-to-child transmission at birth has 90% chronic infection rate',
          },
          {
            name: 'Unprotected Sexual Contact',
            type: 'modifiable',
            impact: 'major',
            description: 'Sexual transmission is a major route in adults',
            intervention: 'Use barrier protection, vaccination of partners',
          },
          {
            name: 'IV Drug Use',
            type: 'modifiable',
            impact: 'major',
            description: 'Sharing needles transmits HBV efficiently',
            intervention: 'Needle exchange programs, substance abuse treatment',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Fatigue',
            prevalence: 'very-common',
            description: 'Profound tiredness and weakness',
            timing: 'Throughout infection',
          },
          {
            name: 'Jaundice',
            prevalence: 'common',
            description: 'Yellow discoloration of skin and eyes',
            timing: 'Acute phase, may recur in chronic flares',
          },
          {
            name: 'Right Upper Quadrant Pain',
            prevalence: 'common',
            description: 'Discomfort in liver area',
            location: 'Right upper abdomen',
          },
        ],
        associatedSymptoms: [
          {
            name: 'Nausea and Anorexia',
            prevalence: 'common',
            description: 'Loss of appetite and nausea',
          },
          {
            name: 'Dark Urine',
            prevalence: 'common',
            description: 'Tea-colored urine from bilirubin',
          },
        ],
        labFindings: [
          {
            testName: 'HBsAg',
            abnormality: 'Positive',
            significance: 'Indicates active infection',
          },
          {
            testName: 'HBV DNA',
            abnormality: 'Detectable',
            significance: 'Measures viral replication',
          },
          {
            testName: 'ALT/AST',
            abnormality: 'Elevated',
            normalRange: 'ALT 7-56 U/L',
            significance: 'Indicates liver inflammation',
          },
        ],
      },

      progression: {
        naturalHistory:
          'Acute infection resolves in 95% of adults but only 5-10% of infants. Chronic infection can progress to cirrhosis over decades.',
        typicalOnsetToDiagnosis: '2-6 months incubation, often diagnosed incidentally',
        timelineSteps: [
          {
            phaseId: 'hbv-acute',
            phase: 'acute',
            displayName: 'Acute Infection',
            timeframe: 'First 6 months',
            description: 'Initial infection with immune response',
            symptoms: ['Fatigue', 'Jaundice', 'Nausea', 'Abdominal pain'],
            anatomicalChanges: [
              {
                structureId: 'liver',
                structureName: 'Liver',
                changeType: 'inflammation',
                description: 'Acute hepatitis with hepatocyte necrosis',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Supportive care', 'Monitoring'],
            goalsOfCare: ['Monitor for fulminant hepatitis', 'Allow immune clearance'],
          },
          {
            phaseId: 'hbv-chronic-active',
            phase: 'chronic',
            displayName: 'Chronic Active Hepatitis',
            timeframe: 'Years 1-10+',
            description: 'Persistent infection with ongoing liver inflammation',
            symptoms: ['Fatigue', 'Intermittent jaundice', 'RUQ discomfort'],
            anatomicalChanges: [
              {
                structureId: 'liver',
                structureName: 'Liver',
                changeType: 'inflammation',
                description: 'Chronic hepatitis with progressive fibrosis',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: true, opacity: 0.7 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Tenofovir', 'Entecavir', 'Pegylated interferon'],
            goalsOfCare: ['Suppress viral replication', 'Prevent fibrosis progression'],
          },
          {
            phaseId: 'hbv-cirrhosis',
            phase: 'end-stage',
            displayName: 'Cirrhosis',
            timeframe: 'Years 10-30',
            description: 'End-stage liver disease with risk of HCC',
            symptoms: ['Ascites', 'Variceal bleeding', 'Encephalopathy'],
            anatomicalChanges: [
              {
                structureId: 'liver',
                structureName: 'Liver',
                changeType: 'fibrosis',
                description: 'Cirrhotic liver with nodular regeneration',
                severity: 'severe',
                visualIndicator: { color: '#78716c', pulse: false, opacity: 0.8 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Continued antivirals', 'HCC surveillance', 'Transplant evaluation'],
            goalsOfCare: ['Prevent decompensation', 'Screen for HCC'],
          },
        ],
        prognosis:
          'Adults with acute HBV have excellent prognosis. Chronic carriers have 15-40% lifetime risk of cirrhosis or HCC.',
      },

      complications: [
        {
          complicationId: 'hbv-hcc',
          name: 'Hepatocellular Carcinoma',
          category: 'chronic',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Primary liver cancer developing from chronic infection',
          mechanism: 'Chronic inflammation and viral DNA integration cause oncogenic mutations',
          affectedStructures: [
            {
              structureId: 'liver',
              structureName: 'Liver',
              effect: 'Malignant transformation',
              highlightColor: '#7f1d1d',
            },
          ],
          warningSymptoms: ['Weight loss', 'RUQ mass', 'Worsening liver function'],
          prevention: ['Antiviral therapy', 'Regular surveillance ultrasound'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'hbv-tenofovir',
          name: 'Tenofovir',
          modality: 'pharmacological',
          description: 'Nucleotide analog that inhibits HBV reverse transcriptase',
          mechanism: 'Inhibits viral DNA synthesis',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['chronic'],
          goals: ['Suppress viral replication', 'Prevent progression'],
          medicationIds: ['tenofovir'],
          explanations: {
            level1: 'A pill that stops the virus from making copies of itself.',
            level2: 'An antiviral medication taken daily to control the hepatitis B virus.',
            level3:
              'Nucleotide analog that inhibits HBV reverse transcriptase with high barrier to resistance.',
            level4:
              'First-line therapy achieving viral suppression in >95% with minimal resistance development.',
            level5:
              'Acyclic nucleotide phosphonate analog incorporated into viral DNA causing chain termination. Renal monitoring required.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'liver',
            structureName: 'Liver',
            role: 'primary-site',
            involvement: 'Site of viral replication and immune-mediated injury',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
        ],
        systemsInvolved: ['Hepatic', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['organs', 'vascular'],
      },

      explanations: {
        level1: 'A virus that infects the liver and can cause long-term damage if not treated.',
        level2:
          'Hepatitis B is a viral infection that attacks the liver. It can be prevented by vaccine and treated with antiviral medicines.',
        level3:
          'HBV is transmitted through blood and body fluids. Chronic infection leads to progressive liver disease requiring antiviral therapy.',
        level4:
          'Blood-borne virus infecting hepatocytes. Immune-mediated liver damage can progress to cirrhosis and HCC. Treatment suppresses but rarely cures.',
        level5:
          'HBV establishes persistent infection through cccDNA reservoir. Liver damage results from CTL-mediated hepatocyte destruction. Functional cure (HBsAg loss) remains rare with current therapies.',
      },

      clinicalPearls: [
        'Perinatal transmission has 90% chronic infection rate vs 5% in adults',
        'HBsAg positive >6 months defines chronic infection',
        'All chronic HBV patients need HCC surveillance every 6 months',
        'Tenofovir and entecavir have high barrier to resistance',
      ],
      patientEducation: [
        'Take antiviral medication exactly as prescribed every day',
        'Avoid alcohol which accelerates liver damage',
        'All household members and sexual partners should be vaccinated',
        'You will need regular blood tests and liver imaging',
      ],
      emergencyWarnings: [
        'Severe abdominal swelling',
        'Vomiting blood or black stools',
        'Confusion or personality changes',
        'Severe jaundice with dark urine',
      ],
      },
    ],

    // ============================================
    // Hepatitis C
    // ============================================
    [
      'hepatitis-c',
      {
        conditionId: 'hepatitis-c',
      name: 'Hepatitis C',
      aliases: ['HCV Infection', 'Non-A Non-B Hepatitis'],
      icdCode: 'B18.2',
      category: 'infectious',
      subcategory: 'viral hepatitis',
      description:
        'Chronic viral infection of the liver caused by hepatitis C virus, now curable with direct-acting antiviral therapy.',

      pathophysiology: {
        summary:
          'HCV is an RNA virus that infects hepatocytes, causing chronic inflammation. Unlike HBV, it does not integrate into host DNA but establishes persistent infection through immune evasion.',
        mechanisms: [
          {
            name: 'Viral Replication and Immune Evasion',
            description:
              'HCV rapidly mutates creating quasispecies that evade immune recognition',
            systemsInvolved: ['Hepatic', 'Immune'],
            keyMediators: ['NS3/4A protease', 'NS5B polymerase', 'Quasispecies'],
            contribution:
              'Establishes chronic infection in 75-85% of cases due to immune escape',
          },
          {
            name: 'Chronic Hepatic Inflammation',
            description:
              'Ongoing immune response causes hepatocyte damage and stellate cell activation',
            systemsInvolved: ['Hepatic', 'Immune'],
            keyMediators: ['TNF-alpha', 'TGF-beta', 'Hepatic stellate cells'],
            contribution: 'Progressive fibrosis leading to cirrhosis over 20-30 years',
          },
        ],
        riskFactors: [
          {
            name: 'IV Drug Use',
            type: 'modifiable',
            impact: 'major',
            description: 'Sharing needles is the most common transmission route',
            intervention: 'Needle exchange, substance abuse treatment',
          },
          {
            name: 'Blood Transfusion Before 1992',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Blood supply screening began in 1992',
          },
          {
            name: 'HIV Coinfection',
            type: 'partially-modifiable',
            impact: 'moderate',
            description: 'Accelerates HCV progression and affects treatment',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Asymptomatic',
            prevalence: 'very-common',
            description: 'Most patients have no symptoms for decades',
            timing: 'Throughout chronic phase',
          },
          {
            name: 'Fatigue',
            prevalence: 'common',
            description: 'Chronic tiredness often attributed to other causes',
          },
          {
            name: 'Cognitive Dysfunction',
            prevalence: 'common',
            description: 'Brain fog independent of liver disease severity',
          },
        ],
        labFindings: [
          {
            testName: 'HCV Antibody',
            abnormality: 'Positive',
            significance: 'Indicates exposure (current or past)',
          },
          {
            testName: 'HCV RNA',
            abnormality: 'Detectable',
            significance: 'Confirms active infection',
          },
          {
            testName: 'HCV Genotype',
            abnormality: 'Genotypes 1-6',
            significance: 'Guides treatment selection',
          },
        ],
      },

      progression: {
        naturalHistory:
          'Acute infection becomes chronic in 75-85%. Cirrhosis develops in 15-30% over 20-30 years. Now curable with 8-12 weeks of oral therapy.',
        timelineSteps: [
          {
            phaseId: 'hcv-acute',
            phase: 'acute',
            displayName: 'Acute Infection',
            timeframe: 'First 6 months',
            description: 'Initial infection, usually asymptomatic',
            symptoms: ['Usually none', 'Occasionally jaundice', 'Fatigue'],
            anatomicalChanges: [
              {
                structureId: 'liver',
                structureName: 'Liver',
                changeType: 'inflammation',
                description: 'Mild acute hepatitis',
                severity: 'mild',
                visualIndicator: { color: '#fbbf24', pulse: true, opacity: 0.6 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            goalsOfCare: ['15-25% spontaneously clear', 'Monitor for chronicity'],
          },
          {
            phaseId: 'hcv-chronic',
            phase: 'chronic',
            displayName: 'Chronic Infection',
            timeframe: 'Years to decades',
            description: 'Persistent infection with slow fibrosis progression',
            symptoms: ['Fatigue', 'Often asymptomatic', 'Brain fog'],
            anatomicalChanges: [
              {
                structureId: 'liver',
                structureName: 'Liver',
                changeType: 'fibrosis',
                description: 'Progressive hepatic fibrosis',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.7 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Direct-acting antivirals'],
            goalsOfCare: ['Cure with DAA therapy', 'Prevent cirrhosis'],
          },
          {
            phaseId: 'hcv-cirrhosis',
            phase: 'end-stage',
            displayName: 'Cirrhosis',
            timeframe: '20-30 years untreated',
            description: 'End-stage liver disease',
            symptoms: ['Ascites', 'Variceal bleeding', 'HCC risk'],
            anatomicalChanges: [
              {
                structureId: 'liver',
                structureName: 'Liver',
                changeType: 'fibrosis',
                description: 'Cirrhotic liver',
                severity: 'severe',
                visualIndicator: { color: '#78716c', pulse: false, opacity: 0.8 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['DAAs still indicated', 'HCC surveillance'],
            goalsOfCare: ['SVR still beneficial', 'Fibrosis may regress after cure'],
          },
        ],
        prognosis:
          'With DAA therapy, >95% achieve sustained virologic response (cure). Even cirrhotic patients benefit from treatment.',
      },

      complications: [
        {
          complicationId: 'hcv-hcc',
          name: 'Hepatocellular Carcinoma',
          category: 'chronic',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Liver cancer, risk persists even after cure in cirrhotic patients',
          mechanism: 'Chronic inflammation and cirrhosis create carcinogenic environment',
          affectedStructures: [
            {
              structureId: 'liver',
              structureName: 'Liver',
              effect: 'Malignant tumor development',
              highlightColor: '#7f1d1d',
            },
          ],
          warningSymptoms: ['Weight loss', 'New liver mass', 'Elevated AFP'],
          prevention: ['HCV cure', 'Ongoing surveillance if cirrhotic'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'hcv-daa',
          name: 'Direct-Acting Antivirals',
          modality: 'pharmacological',
          description: 'Oral medications that target HCV proteins to achieve cure',
          mechanism: 'Inhibit NS3/4A protease, NS5A, or NS5B polymerase',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute', 'chronic', 'end-stage'],
          goals: ['Achieve SVR (cure)', 'Prevent progression'],
          expectedOutcomes: ['>95% cure rate'],
          timeToEffect: '8-12 weeks treatment',
          explanations: {
            level1: 'Pills taken for 2-3 months that cure hepatitis C.',
            level2:
              'New antiviral medications that eliminate the hepatitis C virus from your body permanently.',
            level3:
              'Direct-acting antivirals target viral proteins, achieving sustained virologic response (cure) in >95%.',
            level4:
              'Pan-genotypic DAA regimens combining NS5A and NS5B inhibitors cure most patients regardless of genotype or fibrosis stage.',
            level5:
              'Combination therapy with sofosbuvir-based regimens achieves SVR12 in >95%. Post-SVR HCC surveillance required in cirrhotics.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'liver',
            structureName: 'Liver',
            role: 'primary-site',
            involvement: 'Site of viral replication and progressive fibrosis',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
        ],
        systemsInvolved: ['Hepatic', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['organs'],
      },

      explanations: {
        level1: 'A liver infection that can now be cured with pills.',
        level2:
          'Hepatitis C is a virus that damages the liver over many years but can be cured with 2-3 months of medication.',
        level3:
          'Blood-borne RNA virus causing chronic hepatitis. DAA therapy achieves cure in >95% regardless of disease stage.',
        level4:
          'Chronic HCV establishes persistent infection through quasispecies evolution. DAAs targeting NS proteins achieve SVR with minimal side effects.',
        level5:
          'HCV NS5B polymerase lacks proofreading, generating quasispecies. DAA combinations with high barrier to resistance achieve pan-genotypic cure rates >95%.',
      },

      clinicalPearls: [
        'HCV antibody positive only shows exposure - confirm with HCV RNA',
        'DAAs cure >95% regardless of genotype or cirrhosis status',
        'Continue HCC surveillance after cure in cirrhotic patients',
        'Screen all people born 1945-1965 (baby boomers)',
      ],
      patientEducation: [
        'Hepatitis C can now be cured with pills taken for 2-3 months',
        'The cure rate is over 95% with modern treatments',
        'After cure, you cannot spread the virus but can be reinfected',
        'If you have scarring, you still need liver cancer screening after cure',
      ],
      emergencyWarnings: [
        'Vomiting blood',
        'Black tarry stools',
        'Confusion or drowsiness',
        'Severe abdominal swelling',
      ],
      },
    ],

    // ============================================
    // Osteoporosis
    // ============================================
    [
      'osteoporosis',
      {
        conditionId: 'osteoporosis',
      name: 'Osteoporosis',
      aliases: ['Bone Loss', 'Brittle Bones'],
      icdCode: 'M81.0',
      category: 'musculoskeletal',
      subcategory: 'metabolic bone disease',
      description:
        'Systemic skeletal disease characterized by low bone mass and microarchitectural deterioration leading to increased fracture risk.',

      pathophysiology: {
        summary:
          'Imbalance between bone resorption (osteoclasts) and bone formation (osteoblasts) leads to progressive bone loss and structural deterioration.',
        mechanisms: [
          {
            name: 'Increased Osteoclast Activity',
            description:
              'Enhanced bone resorption due to hormonal changes, inflammation, or aging',
            systemsInvolved: ['Skeletal', 'Endocrine'],
            keyMediators: ['RANKL', 'Osteoclasts', 'Estrogen deficiency'],
            contribution: 'Accelerated bone loss exceeding formation capacity',
          },
          {
            name: 'Decreased Osteoblast Function',
            description:
              'Reduced bone formation due to aging, medications, or metabolic factors',
            systemsInvolved: ['Skeletal'],
            keyMediators: ['Osteoblasts', 'Wnt signaling', 'Sclerostin'],
            contribution: 'Inability to replace resorbed bone adequately',
          },
        ],
        riskFactors: [
          {
            name: 'Postmenopausal Status',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Estrogen loss accelerates bone resorption',
          },
          {
            name: 'Advanced Age',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Bone loss increases with age in both sexes',
          },
          {
            name: 'Low Calcium/Vitamin D Intake',
            type: 'modifiable',
            impact: 'moderate',
            description: 'Inadequate nutrients for bone maintenance',
            intervention: 'Supplementation and dietary modification',
          },
          {
            name: 'Sedentary Lifestyle',
            type: 'modifiable',
            impact: 'moderate',
            description: 'Lack of weight-bearing exercise reduces bone stimulus',
            intervention: 'Regular weight-bearing and resistance exercise',
          },
          {
            name: 'Glucocorticoid Use',
            type: 'partially-modifiable',
            impact: 'major',
            description: 'Steroids inhibit bone formation and increase resorption',
            intervention: 'Use lowest effective dose, consider prophylaxis',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Asymptomatic',
            prevalence: 'very-common',
            description: 'No symptoms until fracture occurs',
            timing: 'Throughout disease until fracture',
          },
          {
            name: 'Fragility Fracture',
            prevalence: 'common',
            description: 'Fracture from minimal trauma',
            location: 'Spine, hip, wrist most common',
          },
          {
            name: 'Height Loss',
            prevalence: 'common',
            description: 'Progressive loss of height from vertebral compression',
          },
        ],
        associatedSymptoms: [
          {
            name: 'Kyphosis',
            prevalence: 'common',
            description: 'Dowager hump from multiple vertebral fractures',
          },
          {
            name: 'Back Pain',
            prevalence: 'common',
            description: 'Acute pain with vertebral fractures',
          },
        ],
        imagingFindings: [
          {
            modality: 'DEXA Scan',
            finding: 'T-score ≤ -2.5',
            significance: 'Diagnostic criterion for osteoporosis',
            structures: ['Spine', 'Hip'],
          },
          {
            modality: 'X-ray',
            finding: 'Vertebral compression fractures',
            significance: 'Often found incidentally',
            structures: ['Thoracic and lumbar spine'],
          },
        ],
      },

      progression: {
        naturalHistory:
          'Bone mass peaks in late 20s then gradually declines. Accelerated loss occurs after menopause or with risk factors.',
        timelineSteps: [
          {
            phaseId: 'osteo-low-bone-mass',
            phase: 'preclinical',
            displayName: 'Osteopenia',
            timeframe: 'Years before osteoporosis',
            description: 'Low bone mass without meeting osteoporosis criteria',
            symptoms: ['None'],
            anatomicalChanges: [
              {
                structureId: 'lumbar-vertebrae',
                structureName: 'Lumbar Vertebrae',
                changeType: 'atrophy',
                description: 'Early trabecular bone loss',
                severity: 'mild',
                visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Lifestyle modification', 'Calcium and vitamin D'],
            goalsOfCare: ['Prevent progression to osteoporosis'],
          },
          {
            phaseId: 'osteo-established',
            phase: 'established',
            displayName: 'Osteoporosis',
            timeframe: 'Varies',
            description: 'T-score ≤ -2.5 or fragility fracture',
            symptoms: ['Usually asymptomatic', 'May have fracture'],
            anatomicalChanges: [
              {
                structureId: 'lumbar-vertebrae',
                structureName: 'Lumbar Vertebrae',
                changeType: 'atrophy',
                description: 'Significant trabecular and cortical bone loss',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 },
                isNewAtPhase: false,
              },
              {
                structureId: 'femoral-neck',
                structureName: 'Femoral Neck',
                changeType: 'atrophy',
                description: 'Cortical thinning and trabecular deterioration',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Bisphosphonates', 'Denosumab', 'Anabolic agents'],
            goalsOfCare: ['Prevent fractures', 'Maintain bone mass'],
          },
          {
            phaseId: 'osteo-severe',
            phase: 'severe',
            displayName: 'Severe Osteoporosis',
            timeframe: 'After fracture',
            description: 'Osteoporosis with one or more fragility fractures',
            symptoms: ['Fracture pain', 'Disability', 'Height loss'],
            anatomicalChanges: [
              {
                structureId: 'thoracic-vertebrae',
                structureName: 'Thoracic Vertebrae',
                changeType: 'structural-damage',
                description: 'Vertebral compression fractures',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Anabolic therapy', 'Vertebroplasty if indicated'],
            goalsOfCare: ['Prevent subsequent fractures', 'Pain management'],
          },
        ],
        prognosis:
          'Hip fractures have 20% one-year mortality. Vertebral fractures increase risk of subsequent fractures 5-fold.',
      },

      complications: [
        {
          complicationId: 'osteo-hip-fracture',
          name: 'Hip Fracture',
          category: 'acute',
          severity: 'major',
          riskLevel: 'high',
          description: 'Fracture of proximal femur with high morbidity and mortality',
          mechanism: 'Weakened bone fails under minimal stress',
          affectedStructures: [
            {
              structureId: 'proximal-femur',
              structureName: 'Proximal Femur',
              effect: 'Fracture',
              highlightColor: '#dc2626',
            },
          ],
          warningSymptoms: ['Sudden hip pain', 'Inability to bear weight', 'Leg shortening'],
          prevention: ['Osteoporosis treatment', 'Fall prevention'],
          treatment: 'Surgical fixation or replacement',
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'osteo-bisphosphonate',
          name: 'Bisphosphonates',
          modality: 'pharmacological',
          description: 'Anti-resorptive medications that inhibit osteoclast activity',
          mechanism: 'Bind to bone and inhibit osteoclast-mediated resorption',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['established', 'severe'],
          goals: ['Reduce fracture risk', 'Maintain BMD'],
          expectedOutcomes: ['50-70% reduction in vertebral fractures'],
          medicationIds: ['alendronate', 'zoledronic-acid'],
          sideEffects: ['GI upset (oral)', 'Osteonecrosis of jaw (rare)', 'Atypical femur fracture (rare)'],
          explanations: {
            level1: 'Medications that slow down bone loss to prevent broken bones.',
            level2: 'Pills or injections that strengthen bones by slowing the process that removes bone.',
            level3:
              'Anti-resorptive agents that reduce osteoclast activity, decreasing bone turnover and fracture risk.',
            level4:
              'Bisphosphonates bind hydroxyapatite and are internalized by osteoclasts, inhibiting farnesyl pyrophosphate synthase.',
            level5:
              'Nitrogen-containing bisphosphonates inhibit FPP synthase in mevalonate pathway, causing osteoclast apoptosis. Long skeletal half-life allows drug holidays after 5 years.',
          },
        },
        {
          treatmentId: 'osteo-denosumab',
          name: 'Denosumab',
          modality: 'pharmacological',
          description: 'Monoclonal antibody against RANKL',
          mechanism: 'Blocks RANKL preventing osteoclast formation and activation',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['established', 'severe'],
          goals: ['Reduce fracture risk', 'Increase BMD'],
          explanations: {
            level1: 'An injection every 6 months that prevents bone loss.',
            level2: 'A biologic medication that blocks the signal telling your body to remove bone.',
            level3: 'RANKL inhibitor given subcutaneously every 6 months with potent anti-resorptive effects.',
            level4:
              'Humanized monoclonal antibody binding RANKL, preventing osteoclast differentiation and activation.',
            level5:
              'Denosumab mimics osteoprotegerin, neutralizing RANKL to prevent RANK-mediated osteoclastogenesis. Rebound bone loss occurs if discontinued.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'lumbar-vertebrae',
            structureName: 'Lumbar Spine',
            role: 'primary-site',
            involvement: 'Common site of compression fractures',
            highlightColor: '#f97316',
            showByDefault: true,
          },
          {
            structureId: 'proximal-femur',
            structureName: 'Proximal Femur',
            role: 'primary-site',
            involvement: 'Hip fracture site with highest morbidity',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'distal-radius',
            structureName: 'Distal Radius',
            role: 'secondary-site',
            involvement: 'Colles fracture site',
            highlightColor: '#f97316',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Skeletal', 'Endocrine'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['skeletal'],
      },

      explanations: {
        level1: 'A condition where bones become weak and break easily.',
        level2:
          'Osteoporosis means your bones have lost density and strength, making them more likely to break from minor falls.',
        level3:
          'Metabolic bone disease with low bone mass and structural deterioration. Diagnosed by DEXA scan, treated to prevent fractures.',
        level4:
          'Characterized by T-score ≤ -2.5 or fragility fracture. Treatment targets RANK-RANKL pathway or stimulates formation.',
        level5:
          'Results from uncoupled bone remodeling with resorption exceeding formation. Trabecular microarchitecture deteriorates before cortical bone.',
      },

      clinicalPearls: [
        'FRAX calculator helps determine treatment threshold',
        'Vertebral fractures often asymptomatic - check height annually',
        'Bisphosphonate holiday after 5 years oral or 3 years IV in low-risk patients',
        'Transition to another agent when stopping denosumab to prevent rebound loss',
      ],
      patientEducation: [
        'Take calcium (1200mg) and vitamin D (800-1000 IU) daily',
        'Do weight-bearing exercise regularly to stimulate bone',
        'Remove fall hazards at home - rugs, cords, poor lighting',
        'Take bisphosphonates on empty stomach with full glass of water, stay upright 30 minutes',
      ],
      emergencyWarnings: [
        'Sudden severe back pain (possible vertebral fracture)',
        'Hip pain after a fall',
        'Jaw pain or loose teeth (rare medication side effect)',
        'Thigh pain (possible atypical fracture)',
      ],
      },
    ],

    // ============================================
    // Generalized Anxiety Disorder
    // ============================================
    [
      'generalized-anxiety-disorder',
      {
        conditionId: 'generalized-anxiety-disorder',
      name: 'Generalized Anxiety Disorder',
      aliases: ['GAD', 'Chronic Anxiety'],
      icdCode: 'F41.1',
      category: 'psychiatric',
      subcategory: 'anxiety disorders',
      description:
        'Persistent and excessive worry about various aspects of life, difficult to control, causing significant distress and functional impairment.',

      pathophysiology: {
        summary:
          'GAD involves dysregulation of fear circuitry including amygdala hyperactivity, prefrontal cortex dysfunction, and neurotransmitter imbalances.',
        mechanisms: [
          {
            name: 'Amygdala Hyperactivity',
            description: 'Exaggerated amygdala response to perceived threats',
            systemsInvolved: ['Neurologic', 'Endocrine'],
            keyMediators: ['Amygdala', 'HPA axis', 'Cortisol'],
            contribution: 'Heightened fear response to non-threatening stimuli',
          },
          {
            name: 'Prefrontal Cortex Dysfunction',
            description: 'Reduced top-down regulation of emotional responses',
            systemsInvolved: ['Neurologic'],
            keyMediators: ['Prefrontal cortex', 'GABA', 'Glutamate'],
            contribution: 'Impaired ability to suppress worry and anxiety',
          },
          {
            name: 'Neurotransmitter Imbalance',
            description: 'Altered serotonin, GABA, and norepinephrine signaling',
            systemsInvolved: ['Neurologic'],
            keyMediators: ['Serotonin', 'GABA', 'Norepinephrine'],
            contribution: 'Sustained anxious state and physical symptoms',
          },
        ],
        riskFactors: [
          {
            name: 'Family History',
            type: 'non-modifiable',
            impact: 'moderate',
            description: 'Genetic predisposition to anxiety disorders',
          },
          {
            name: 'Childhood Adversity',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Early trauma shapes anxiety vulnerability',
          },
          {
            name: 'Chronic Stress',
            type: 'modifiable',
            impact: 'major',
            description: 'Ongoing life stressors maintain anxiety',
            intervention: 'Stress management, lifestyle changes',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Excessive Worry',
            prevalence: 'very-common',
            description: 'Persistent, difficult to control worry about multiple domains',
            timing: 'More days than not for ≥6 months',
          },
          {
            name: 'Restlessness',
            prevalence: 'very-common',
            description: 'Feeling keyed up or on edge',
          },
          {
            name: 'Fatigue',
            prevalence: 'very-common',
            description: 'Easily fatigued despite adequate rest',
          },
          {
            name: 'Difficulty Concentrating',
            prevalence: 'common',
            description: 'Mind going blank, trouble focusing',
          },
        ],
        associatedSymptoms: [
          {
            name: 'Muscle Tension',
            prevalence: 'very-common',
            description: 'Chronic muscle tightness, especially neck and shoulders',
          },
          {
            name: 'Sleep Disturbance',
            prevalence: 'very-common',
            description: 'Difficulty falling or staying asleep',
          },
          {
            name: 'Irritability',
            prevalence: 'common',
            description: 'Increased irritability and frustration',
          },
        ],
        physicalFindings: [
          {
            name: 'Elevated Heart Rate',
            examType: 'Vital signs',
            description: 'Mild tachycardia during anxious episodes',
            diagnosticValue: 'Supportive but not diagnostic',
          },
          {
            name: 'Muscle Tension',
            examType: 'Musculoskeletal',
            description: 'Palpable tension in trapezius and neck muscles',
            diagnosticValue: 'Common finding',
          },
        ],
      },

      progression: {
        naturalHistory:
          'Chronic condition with waxing and waning course. Often begins in childhood/adolescence and persists into adulthood if untreated.',
        timelineSteps: [
          {
            phaseId: 'gad-mild',
            phase: 'early',
            displayName: 'Mild GAD',
            timeframe: 'Initial presentation',
            description: 'Worry present but functional impairment is limited',
            symptoms: ['Excessive worry', 'Some physical symptoms', 'Manageable distress'],
            anatomicalChanges: [
              {
                structureId: 'brain-amygdala',
                structureName: 'Amygdala',
                changeType: 'dysfunction',
                description: 'Hyperactive fear circuitry',
                severity: 'mild',
                visualIndicator: { color: '#fbbf24', pulse: true, opacity: 0.6 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['CBT', 'Relaxation techniques'],
            goalsOfCare: ['Reduce worry', 'Prevent escalation'],
          },
          {
            phaseId: 'gad-moderate',
            phase: 'established',
            displayName: 'Moderate GAD',
            timeframe: 'Established illness',
            description: 'Significant distress and functional impairment',
            symptoms: ['Persistent worry', 'Physical symptoms daily', 'Work/social impairment'],
            anatomicalChanges: [
              {
                structureId: 'brain-amygdala',
                structureName: 'Amygdala',
                changeType: 'dysfunction',
                description: 'Persistent hyperactivity',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: true, opacity: 0.7 },
                isNewAtPhase: false,
              },
              {
                structureId: 'brain-prefrontal',
                structureName: 'Prefrontal Cortex',
                changeType: 'dysfunction',
                description: 'Reduced regulatory function',
                severity: 'moderate',
                visualIndicator: { color: '#3b82f6', pulse: false, opacity: 0.6 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['SSRIs', 'SNRIs', 'CBT'],
            goalsOfCare: ['Achieve remission', 'Restore function'],
          },
          {
            phaseId: 'gad-severe',
            phase: 'severe',
            displayName: 'Severe GAD',
            timeframe: 'Refractory or complicated',
            description: 'Severe impairment, often with comorbidities',
            symptoms: ['Debilitating worry', 'Severe physical symptoms', 'Unable to function'],
            anatomicalChanges: [
              {
                structureId: 'brain-amygdala',
                structureName: 'Amygdala',
                changeType: 'dysfunction',
                description: 'Severe dysregulation',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Combination therapy', 'Augmentation strategies'],
            goalsOfCare: ['Symptom reduction', 'Functional improvement'],
          },
        ],
        prognosis:
          'With treatment, most patients achieve significant improvement. Relapse common if treatment stopped prematurely.',
      },

      complications: [
        {
          complicationId: 'gad-depression',
          name: 'Major Depression',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'high',
          description: 'Comorbid depression develops in majority of GAD patients',
          mechanism: 'Shared neurobiology and chronic distress precipitate depression',
          affectedStructures: [
            {
              structureId: 'brain',
              structureName: 'Brain',
              effect: 'Mood dysregulation',
              highlightColor: '#6366f1',
            },
          ],
          warningSymptoms: ['Persistent sadness', 'Loss of interest', 'Suicidal thoughts'],
          prevention: ['Early and adequate treatment of GAD'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'gad-ssri',
          name: 'SSRIs',
          modality: 'pharmacological',
          description: 'First-line medication for GAD',
          mechanism: 'Increase serotonin availability in synaptic cleft',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'severe'],
          goals: ['Reduce anxiety symptoms', 'Improve function'],
          timeToEffect: '4-6 weeks for full effect',
          medicationIds: ['sertraline', 'escitalopram'],
          sideEffects: ['Nausea', 'Sexual dysfunction', 'Initial anxiety increase'],
          explanations: {
            level1: 'A type of antidepressant that also helps with anxiety.',
            level2: 'Medications that increase serotonin in the brain to reduce anxiety and worry.',
            level3:
              'SSRIs are first-line pharmacotherapy for GAD, effective for both psychological and somatic symptoms.',
            level4:
              'Selective serotonin reuptake inhibitors gradually downregulate post-synaptic receptors, reducing anxiety.',
            level5:
              'SSRIs enhance serotonergic transmission leading to adaptive changes in 5-HT1A autoreceptor sensitivity and downstream effects on amygdala reactivity.',
          },
        },
        {
          treatmentId: 'gad-cbt',
          name: 'Cognitive Behavioral Therapy',
          modality: 'rehabilitative',
          description: 'Evidence-based psychotherapy targeting maladaptive thoughts and behaviors',
          mechanism: 'Restructures catastrophic thinking and develops coping skills',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'severe'],
          goals: ['Change thought patterns', 'Develop coping strategies'],
          timeToEffect: '8-12 sessions typically',
          explanations: {
            level1: 'Talking therapy that helps you think about worries differently.',
            level2: 'Working with a therapist to identify anxious thoughts and learn to manage them better.',
            level3:
              'Structured therapy addressing cognitive distortions and avoidance behaviors maintaining anxiety.',
            level4:
              'Evidence-based protocol targeting worry, cognitive restructuring, and exposure to uncertainty.',
            level5:
              'CBT for GAD targets intolerance of uncertainty and metacognitive beliefs about worry through cognitive restructuring and behavioral experiments.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'brain-amygdala',
            structureName: 'Amygdala',
            role: 'primary-site',
            involvement: 'Hyperactive fear processing center',
            highlightColor: '#ef4444',
            showByDefault: true,
          },
          {
            structureId: 'brain-prefrontal',
            structureName: 'Prefrontal Cortex',
            role: 'secondary-site',
            involvement: 'Impaired emotion regulation',
            highlightColor: '#3b82f6',
            showByDefault: true,
          },
        ],
        systemsInvolved: ['Neurologic', 'Endocrine'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
      },

      explanations: {
        level1: 'Feeling very worried most of the time about many different things.',
        level2:
          'A condition where you have excessive, hard-to-control worry that affects your daily life and causes physical symptoms.',
        level3:
          'Chronic anxiety disorder characterized by persistent worry, physical symptoms, and functional impairment. Treatable with medication and therapy.',
        level4:
          'GAD involves amygdala hyperactivity and prefrontal hypofunction. First-line treatment includes SSRIs/SNRIs and CBT.',
        level5:
          'Neuroimaging shows increased amygdala reactivity and reduced vmPFC regulation. GABAergic deficits and HPA axis dysregulation contribute to sustained anxious state.',
      },

      clinicalPearls: [
        'GAD commonly comorbid with depression - screen for both',
        'SSRIs may initially worsen anxiety - start low and go slow',
        'CBT and medication combination often more effective than either alone',
        'Benzodiazepines not recommended for long-term use',
      ],
      patientEducation: [
        'Anxiety is a medical condition, not a character flaw',
        'Medication takes 4-6 weeks to work fully - dont give up early',
        'Caffeine and alcohol can worsen anxiety',
        'Regular exercise, sleep, and relaxation techniques help manage symptoms',
      ],
      emergencyWarnings: [
        'Thoughts of self-harm or suicide',
        'Panic attacks that feel like heart attacks',
        'Inability to function at work or home',
        'Substance use to cope with anxiety',
      ],
      },
    ],

    // ============================================
    // Bipolar Disorder
    // ============================================
    [
      'bipolar-disorder',
      {
        conditionId: 'bipolar-disorder',
      name: 'Bipolar Disorder',
      aliases: ['Manic Depression', 'Bipolar Affective Disorder'],
      icdCode: 'F31',
      category: 'psychiatric',
      subcategory: 'mood disorders',
      description:
        'Chronic mood disorder characterized by episodes of mania or hypomania alternating with depressive episodes.',

      pathophysiology: {
        summary:
          'Bipolar disorder involves complex dysregulation of mood circuits, neurotransmitter systems, and circadian rhythms with strong genetic component.',
        mechanisms: [
          {
            name: 'Monoamine Dysregulation',
            description:
              'Altered dopamine, norepinephrine, and serotonin signaling during mood episodes',
            systemsInvolved: ['Neurologic'],
            keyMediators: ['Dopamine', 'Norepinephrine', 'Serotonin'],
            contribution: 'Elevated catecholamines in mania, reduced in depression',
          },
          {
            name: 'Circadian Rhythm Disruption',
            description: 'Dysregulated sleep-wake cycles trigger and maintain episodes',
            systemsInvolved: ['Neurologic', 'Endocrine'],
            keyMediators: ['Melatonin', 'Clock genes', 'SCN'],
            contribution: 'Sleep deprivation can trigger mania, hypersomnia in depression',
          },
          {
            name: 'Prefrontal-Limbic Imbalance',
            description: 'Disrupted connectivity between emotion and regulation centers',
            systemsInvolved: ['Neurologic'],
            keyMediators: ['Prefrontal cortex', 'Amygdala', 'Striatum'],
            contribution: 'Poor emotional regulation and reward processing abnormalities',
          },
        ],
        riskFactors: [
          {
            name: 'Family History',
            type: 'non-modifiable',
            impact: 'major',
            description: 'First-degree relatives have 10x increased risk',
          },
          {
            name: 'Sleep Deprivation',
            type: 'modifiable',
            impact: 'major',
            description: 'Potent trigger for manic episodes',
            intervention: 'Sleep hygiene, consistent schedule',
          },
          {
            name: 'Substance Use',
            type: 'modifiable',
            impact: 'major',
            description: 'Stimulants and alcohol destabilize mood',
            intervention: 'Abstinence, substance abuse treatment',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Manic Episode',
            prevalence: 'very-common',
            description:
              'Period of abnormally elevated, expansive, or irritable mood with increased energy',
            timing: 'Lasts at least 1 week',
          },
          {
            name: 'Depressive Episode',
            prevalence: 'very-common',
            description: 'Period of depressed mood or loss of interest with neurovegetative symptoms',
            timing: 'Lasts at least 2 weeks',
          },
          {
            name: 'Decreased Need for Sleep',
            prevalence: 'very-common',
            description: 'Feels rested after only 3 hours of sleep during mania',
            timing: 'During manic/hypomanic episodes',
          },
        ],
        associatedSymptoms: [
          {
            name: 'Grandiosity',
            prevalence: 'common',
            description: 'Inflated self-esteem or grandiose beliefs during mania',
          },
          {
            name: 'Racing Thoughts',
            prevalence: 'very-common',
            description: 'Flight of ideas, subjective feeling thoughts are racing',
          },
          {
            name: 'Impulsivity',
            prevalence: 'common',
            description: 'Risky behaviors - spending sprees, sexual indiscretion',
          },
        ],
      },

      progression: {
        naturalHistory:
          'Chronic relapsing condition. Without treatment, episodes become more frequent and severe over time (kindling phenomenon).',
        timelineSteps: [
          {
            phaseId: 'bipolar-manic',
            phase: 'acute',
            displayName: 'Manic Episode',
            timeframe: 'Days to weeks',
            description: 'Acute mania with significant functional impairment',
            symptoms: [
              'Elevated or irritable mood',
              'Decreased sleep',
              'Grandiosity',
              'Impulsive behavior',
            ],
            anatomicalChanges: [
              {
                structureId: 'brain-prefrontal',
                structureName: 'Prefrontal Cortex',
                changeType: 'dysfunction',
                description: 'Reduced prefrontal inhibition',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: true, opacity: 0.7 },
                isNewAtPhase: true,
              },
              {
                structureId: 'brain-striatum',
                structureName: 'Striatum',
                changeType: 'dysfunction',
                description: 'Hyperactive reward circuitry',
                severity: 'moderate',
                visualIndicator: { color: '#eab308', pulse: true, opacity: 0.7 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Mood stabilizers', 'Antipsychotics', 'Hospitalization if severe'],
            goalsOfCare: ['Terminate manic episode', 'Ensure safety'],
          },
          {
            phaseId: 'bipolar-depressive',
            phase: 'acute',
            displayName: 'Depressive Episode',
            timeframe: 'Weeks to months',
            description: 'Major depressive episode in context of bipolar disorder',
            symptoms: ['Depressed mood', 'Anhedonia', 'Hypersomnia', 'Psychomotor changes'],
            anatomicalChanges: [
              {
                structureId: 'brain-prefrontal',
                structureName: 'Prefrontal Cortex',
                changeType: 'dysfunction',
                description: 'Hypoactive prefrontal function',
                severity: 'moderate',
                visualIndicator: { color: '#6366f1', pulse: false, opacity: 0.7 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Mood stabilizers', 'Quetiapine', 'Lurasidone', 'Lamotrigine'],
            goalsOfCare: ['Treat depression', 'Avoid triggering mania'],
          },
          {
            phaseId: 'bipolar-maintenance',
            phase: 'chronic',
            displayName: 'Maintenance/Euthymia',
            timeframe: 'Between episodes',
            description: 'Stable mood requiring ongoing treatment',
            symptoms: ['Normal or near-normal mood', 'May have subsyndromal symptoms'],
            anatomicalChanges: [
              {
                structureId: 'brain',
                structureName: 'Brain',
                changeType: 'dysfunction',
                description: 'Underlying vulnerability persists',
                severity: 'mild',
                visualIndicator: { color: '#94a3b8', pulse: false, opacity: 0.5 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Lithium', 'Valproate', 'Lamotrigine', 'Atypical antipsychotics'],
            goalsOfCare: ['Prevent relapse', 'Maintain function'],
          },
        ],
        prognosis:
          'Lifelong condition requiring maintenance treatment. With adherence, many achieve good quality of life.',
      },

      complications: [
        {
          complicationId: 'bipolar-suicide',
          name: 'Suicide',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'high',
          description: '15-20% lifetime suicide attempt rate',
          mechanism: 'Depression, mixed states, and impulsivity increase risk',
          affectedStructures: [
            {
              structureId: 'brain',
              structureName: 'Brain',
              effect: 'Suicidal ideation and behavior',
              highlightColor: '#7f1d1d',
            },
          ],
          warningSymptoms: ['Suicidal thoughts', 'Hopelessness', 'Giving away possessions'],
          prevention: ['Lithium (antisuicidal properties)', 'Close monitoring', 'Safety planning'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'bipolar-lithium',
          name: 'Lithium',
          modality: 'pharmacological',
          description: 'Gold standard mood stabilizer',
          mechanism: 'Multiple mechanisms including GSK-3 inhibition and neuroprotection',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute', 'chronic'],
          goals: ['Stabilize mood', 'Prevent relapse', 'Reduce suicide risk'],
          medicationIds: ['lithium'],
          monitoring: ['Lithium levels', 'Renal function', 'Thyroid function'],
          sideEffects: ['Tremor', 'Polyuria', 'Weight gain', 'Thyroid dysfunction'],
          explanations: {
            level1: 'A mineral salt that helps stabilize mood swings.',
            level2:
              'The oldest and most proven medication for bipolar disorder, preventing both manic and depressive episodes.',
            level3:
              'First-line mood stabilizer with best evidence for suicide prevention. Requires blood level monitoring.',
            level4:
              'Inhibits GSK-3beta and modulates neurotransmission. Narrow therapeutic index requires level monitoring.',
            level5:
              'Lithium affects multiple intracellular signaling cascades including inositol depletion, GSK-3 inhibition, and BDNF upregulation, conferring mood stabilization and neuroprotection.',
          },
        },
        {
          treatmentId: 'bipolar-valproate',
          name: 'Valproate',
          modality: 'pharmacological',
          description: 'Anticonvulsant mood stabilizer effective for acute mania',
          mechanism: 'Enhances GABAergic transmission and modulates ion channels',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute', 'chronic'],
          goals: ['Treat acute mania', 'Prevent recurrence'],
          medicationIds: ['valproate'],
          contraindications: ['Pregnancy', 'Liver disease'],
          explanations: {
            level1: 'A medication that calms brain activity to stabilize mood.',
            level2: 'An anticonvulsant that also works well to control manic episodes and prevent mood swings.',
            level3:
              'Mood stabilizer particularly effective for acute mania and mixed episodes. Avoid in women of childbearing potential.',
            level4:
              'Enhances GABA, inhibits histone deacetylase, and modulates sodium channels. Teratogenic - contraindicated in pregnancy.',
            level5:
              'Valproate increases GABA synthesis and turnover, inhibits HDAC affecting gene expression, and modulates voltage-gated sodium channels contributing to antimanic effects.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'brain-prefrontal',
            structureName: 'Prefrontal Cortex',
            role: 'primary-site',
            involvement: 'Dysregulated executive function and emotion regulation',
            highlightColor: '#3b82f6',
            showByDefault: true,
          },
          {
            structureId: 'brain-amygdala',
            structureName: 'Amygdala',
            role: 'primary-site',
            involvement: 'Hyperactive emotional processing',
            highlightColor: '#ef4444',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'brain-striatum',
            structureName: 'Striatum',
            role: 'secondary-site',
            involvement: 'Reward circuitry abnormalities',
            highlightColor: '#eab308',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Neurologic'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
      },

      explanations: {
        level1: 'A condition where your mood swings between very high (mania) and very low (depression).',
        level2:
          'Bipolar disorder causes extreme mood episodes - periods of unusually high energy and activity, and periods of depression.',
        level3:
          'Chronic mood disorder with manic/hypomanic and depressive episodes. Requires lifelong mood stabilizer treatment.',
        level4:
          'Characterized by discrete mood episodes with interepisode recovery. Lithium, valproate, and atypical antipsychotics are first-line.',
        level5:
          'Involves prefrontal-limbic dysconnectivity, catecholamine dysregulation, and circadian dysfunction. Kindling model suggests progressive sensitization without treatment.',
      },

      clinicalPearls: [
        'Antidepressants alone can trigger mania - always use with mood stabilizer',
        'Lithium is the only medication proven to reduce suicide risk',
        'Sleep deprivation is a potent trigger for mania',
        'Patients often miss hypomania and only present in depression',
      ],
      patientEducation: [
        'This is a lifelong condition requiring ongoing medication even when feeling well',
        'Maintain regular sleep schedule - sleep loss can trigger episodes',
        'Avoid alcohol and recreational drugs',
        'Learn to recognize early warning signs of episodes',
      ],
      emergencyWarnings: [
        'Suicidal thoughts or plans',
        'Severe mania with psychosis or dangerous behavior',
        'Not sleeping for multiple days',
        'Inability to care for yourself',
      ],
      },
    ],

  // ============================================
  // Schizophrenia
  // ============================================
  [
    'schizophrenia',
    {
      conditionId: 'schizophrenia',
      name: 'Schizophrenia',
      aliases: ['Schizophrenic Disorder'],
      icdCode: 'F20',
      category: 'psychiatric',
      subcategory: 'psychotic disorders',
      description:
        'Chronic psychiatric disorder characterized by positive symptoms (hallucinations, delusions), negative symptoms (flat affect, avolition), and cognitive impairment.',

      pathophysiology: {
        summary:
          'Complex neurodevelopmental disorder involving dopamine dysregulation, glutamate dysfunction, and structural brain changes.',
        mechanisms: [
          {
            name: 'Dopamine Dysregulation',
            description: 'Mesolimbic dopamine hyperactivity and mesocortical hypoactivity',
            systemsInvolved: ['Neurologic'],
            keyMediators: ['Dopamine', 'D2 receptors'],
            contribution: 'Positive symptoms from mesolimbic excess, negative symptoms from prefrontal deficit',
          },
          {
            name: 'Glutamate Hypofunction',
            description: 'NMDA receptor hypofunction disrupts cortical signaling',
            systemsInvolved: ['Neurologic'],
            keyMediators: ['Glutamate', 'NMDA receptors'],
            contribution: 'Cognitive deficits and negative symptoms',
          },
        ],
        riskFactors: [
          {
            name: 'Family History',
            type: 'non-modifiable',
            impact: 'major',
            description: 'First-degree relatives have 10% risk vs 1% general population',
          },
          {
            name: 'Cannabis Use in Adolescence',
            type: 'modifiable',
            impact: 'moderate',
            description: 'Increases risk in genetically vulnerable individuals',
            intervention: 'Avoidance of cannabis',
          },
          {
            name: 'Obstetric Complications',
            type: 'non-modifiable',
            impact: 'moderate',
            description: 'Hypoxia, infection, malnutrition in pregnancy',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Hallucinations',
            prevalence: 'very-common',
            description: 'Auditory hallucinations most common - hearing voices',
          },
          {
            name: 'Delusions',
            prevalence: 'very-common',
            description: 'Paranoid, grandiose, or bizarre fixed false beliefs',
          },
          {
            name: 'Disorganized Thinking',
            prevalence: 'common',
            description: 'Tangential speech, loose associations, word salad',
          },
        ],
        associatedSymptoms: [
          {
            name: 'Negative Symptoms',
            prevalence: 'very-common',
            description: 'Flat affect, avolition, alogia, anhedonia, asociality',
          },
          {
            name: 'Cognitive Impairment',
            prevalence: 'very-common',
            description: 'Working memory, attention, and executive function deficits',
          },
        ],
      },

      progression: {
        naturalHistory:
          'Typically presents in late adolescence/early adulthood. Chronic course with acute exacerbations. Progressive decline without treatment.',
        timelineSteps: [
          {
            phaseId: 'sz-prodrome',
            phase: 'preclinical',
            displayName: 'Prodromal Phase',
            timeframe: 'Months to years before onset',
            description: 'Subtle symptoms and functional decline before psychosis',
            symptoms: ['Social withdrawal', 'Declining function', 'Unusual beliefs'],
            anatomicalChanges: [
              {
                structureId: 'brain-prefrontal',
                structureName: 'Prefrontal Cortex',
                changeType: 'dysfunction',
                description: 'Early cortical changes',
                severity: 'mild',
                visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            goalsOfCare: ['Early identification', 'Prevent conversion'],
          },
          {
            phaseId: 'sz-acute',
            phase: 'acute',
            displayName: 'Acute Psychosis',
            timeframe: 'First episode or relapse',
            description: 'Active psychotic symptoms requiring treatment',
            symptoms: ['Hallucinations', 'Delusions', 'Disorganization', 'Agitation'],
            anatomicalChanges: [
              {
                structureId: 'brain-limbic',
                structureName: 'Limbic System',
                changeType: 'dysfunction',
                description: 'Mesolimbic dopamine hyperactivity',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Antipsychotics', 'Hospitalization if needed'],
            goalsOfCare: ['Symptom control', 'Safety', 'Rapid stabilization'],
          },
          {
            phaseId: 'sz-chronic',
            phase: 'chronic',
            displayName: 'Chronic/Residual Phase',
            timeframe: 'Ongoing',
            description: 'Stable but often with residual symptoms',
            symptoms: ['Negative symptoms predominate', 'Cognitive deficits', 'Some positive symptoms'],
            anatomicalChanges: [
              {
                structureId: 'brain-prefrontal',
                structureName: 'Prefrontal Cortex',
                changeType: 'atrophy',
                description: 'Gray matter loss',
                severity: 'moderate',
                visualIndicator: { color: '#71717a', pulse: false, opacity: 0.7 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Maintenance antipsychotics', 'Psychosocial rehabilitation'],
            goalsOfCare: ['Prevent relapse', 'Maximize function', 'Quality of life'],
          },
        ],
        prognosis:
          'Variable course. 20% recover, 20% remain severely impaired, majority have intermediate outcome. Early treatment improves prognosis.',
      },

      complications: [
        {
          complicationId: 'sz-suicide',
          name: 'Suicide',
          category: 'chronic',
          severity: 'life-threatening',
          riskLevel: 'high',
          description: '5-10% lifetime suicide mortality',
          mechanism: 'Depression, hopelessness, command hallucinations',
          affectedStructures: [
            {
              structureId: 'brain',
              structureName: 'Brain',
              effect: 'Suicidal ideation',
              highlightColor: '#7f1d1d',
            },
          ],
          warningSymptoms: ['Suicidal thoughts', 'Hopelessness', 'Command hallucinations'],
          prevention: ['Clozapine (reduces suicide)', 'Close monitoring', 'Depression treatment'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'sz-antipsychotic',
          name: 'Antipsychotic Medications',
          modality: 'pharmacological',
          description: 'D2 receptor antagonists that reduce positive symptoms',
          mechanism: 'Block mesolimbic dopamine transmission',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute', 'chronic'],
          goals: ['Reduce positive symptoms', 'Prevent relapse'],
          sideEffects: ['Weight gain', 'Metabolic syndrome', 'EPS', 'Tardive dyskinesia'],
          explanations: {
            level1: 'Medications that help reduce hearing voices and unusual beliefs.',
            level2: 'Antipsychotic medications block dopamine to reduce hallucinations and delusions.',
            level3: 'First and second generation antipsychotics target D2 receptors. SGAs have better side effect profile.',
            level4: 'D2 antagonism in mesolimbic pathway treats positive symptoms. 5-HT2A antagonism of SGAs may help negative symptoms.',
            level5: 'Antipsychotic efficacy correlates with D2 occupancy 60-80%. SGAs have rapid D2 dissociation and 5-HT2A antagonism reducing EPS.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'brain-prefrontal',
            structureName: 'Prefrontal Cortex',
            role: 'primary-site',
            involvement: 'Hypofrontality underlying negative and cognitive symptoms',
            highlightColor: '#3b82f6',
            showByDefault: true,
          },
          {
            structureId: 'brain-limbic',
            structureName: 'Limbic System',
            role: 'primary-site',
            involvement: 'Mesolimbic dopamine excess causing positive symptoms',
            highlightColor: '#ef4444',
            showByDefault: true,
          },
        ],
        systemsInvolved: ['Neurologic'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
      },

      explanations: {
        level1: 'A brain condition that causes hearing voices and believing things that arent real.',
        level2: 'Schizophrenia affects how the brain processes information, causing hallucinations, delusions, and difficulty thinking clearly.',
        level3: 'Psychotic disorder with positive symptoms (hallucinations, delusions), negative symptoms (flat affect), and cognitive deficits. Requires lifelong antipsychotic treatment.',
        level4: 'Neurodevelopmental disorder involving dopamine and glutamate dysregulation. First-episode psychosis is a critical treatment window.',
        level5: 'Dopamine hypothesis (mesolimbic hyperactivity, mesocortical hypoactivity) and glutamate hypothesis (NMDA hypofunction) explain symptom domains. Progressive gray matter loss correlates with duration of untreated psychosis.',
      },

      clinicalPearls: [
        'Duration of untreated psychosis predicts outcome - treat early',
        'Clozapine is most effective but reserved for treatment-resistant cases',
        'Negative symptoms respond poorly to current medications',
        'Metabolic monitoring essential with second-generation antipsychotics',
      ],
      patientEducation: [
        'This is a medical brain condition, not a character flaw',
        'Medication must be taken continuously, even when feeling well',
        'Avoid alcohol and recreational drugs which worsen symptoms',
        'Recovery is possible with treatment and support',
      ],
      emergencyWarnings: [
        'Thoughts of harming yourself or others',
        'Command hallucinations telling you to do dangerous things',
        'Severe agitation or aggression',
        'Unable to care for basic needs',
      ],
    },
  ],

  // ============================================
  // Community-Acquired Pneumonia
  // ============================================
  [
    'pneumonia',
    {
      conditionId: 'pneumonia',
      name: 'Community-Acquired Pneumonia',
      aliases: ['CAP', 'Pneumonia', 'Lung Infection'],
      icdCode: 'J18.9',
      category: 'respiratory',
      subcategory: 'infectious',
      description:
        'Acute infection of the lung parenchyma acquired outside of healthcare settings, commonly caused by bacteria or viruses.',

      pathophysiology: {
        summary:
          'Pathogens reach the alveoli via aspiration or inhalation, triggering inflammatory response that fills airspaces with exudate.',
        mechanisms: [
          {
            name: 'Alveolar Invasion',
            description: 'Pathogens overcome mucociliary clearance and reach alveoli',
            systemsInvolved: ['Respiratory', 'Immune'],
            keyMediators: ['Streptococcus pneumoniae', 'Viral pathogens', 'Atypicals'],
            contribution: 'Establishes infection in lung parenchyma',
          },
          {
            name: 'Inflammatory Response',
            description: 'Neutrophils and inflammatory mediators fill alveoli',
            systemsInvolved: ['Respiratory', 'Immune'],
            keyMediators: ['Neutrophils', 'Cytokines', 'Complement'],
            contribution: 'Consolidation and impaired gas exchange',
          },
        ],
        riskFactors: [
          {
            name: 'Age >65',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Immunosenescence and comorbidities increase risk',
          },
          {
            name: 'Smoking',
            type: 'modifiable',
            impact: 'major',
            description: 'Impairs mucociliary clearance and immune function',
            intervention: 'Smoking cessation',
          },
          {
            name: 'Chronic Lung Disease',
            type: 'partially-modifiable',
            impact: 'major',
            description: 'COPD, asthma increase susceptibility',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Cough',
            prevalence: 'very-common',
            description: 'Productive cough with purulent sputum',
          },
          {
            name: 'Fever',
            prevalence: 'very-common',
            description: 'Temperature >38°C, may be absent in elderly',
          },
          {
            name: 'Dyspnea',
            prevalence: 'common',
            description: 'Shortness of breath with exertion or at rest',
          },
          {
            name: 'Pleuritic Chest Pain',
            prevalence: 'common',
            description: 'Sharp pain worsening with breathing',
            location: 'Affected lung area',
          },
        ],
        physicalFindings: [
          {
            name: 'Crackles',
            examType: 'Auscultation',
            description: 'Inspiratory crackles over affected area',
            diagnosticValue: 'Suggestive of consolidation',
          },
          {
            name: 'Bronchial Breath Sounds',
            examType: 'Auscultation',
            description: 'Tubular breath sounds over consolidation',
            diagnosticValue: 'Indicates dense consolidation',
          },
          {
            name: 'Dullness to Percussion',
            examType: 'Percussion',
            description: 'Dull note over affected area',
            diagnosticValue: 'Indicates consolidation or effusion',
          },
        ],
        imagingFindings: [
          {
            modality: 'Chest X-ray',
            finding: 'Lobar consolidation or infiltrate',
            significance: 'Confirms diagnosis',
            structures: ['Lung parenchyma'],
          },
        ],
      },

      progression: {
        naturalHistory:
          'Untreated, can progress to respiratory failure and sepsis. With appropriate antibiotics, most cases resolve in 1-2 weeks.',
        timelineSteps: [
          {
            phaseId: 'pna-early',
            phase: 'early',
            displayName: 'Early Infection',
            timeframe: 'Days 1-3',
            description: 'Initial infection with inflammatory response',
            symptoms: ['Cough', 'Fever', 'Malaise', 'Mild dyspnea'],
            anatomicalChanges: [
              {
                structureId: 'lung',
                structureName: 'Lung',
                changeType: 'inflammation',
                description: 'Early alveolar inflammation',
                severity: 'mild',
                visualIndicator: { color: '#fbbf24', pulse: true, opacity: 0.6 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Outpatient antibiotics'],
            goalsOfCare: ['Early treatment', 'Prevent progression'],
          },
          {
            phaseId: 'pna-established',
            phase: 'established',
            displayName: 'Established Pneumonia',
            timeframe: 'Days 3-7',
            description: 'Full consolidation with significant symptoms',
            symptoms: ['Productive cough', 'High fever', 'Dyspnea', 'Pleuritic pain'],
            anatomicalChanges: [
              {
                structureId: 'lung',
                structureName: 'Lung',
                changeType: 'infiltration',
                description: 'Lobar consolidation',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.7 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Antibiotics', 'Hospitalization if severe'],
            goalsOfCare: ['Treat infection', 'Support oxygenation'],
          },
          {
            phaseId: 'pna-resolution',
            phase: 'chronic',
            displayName: 'Resolution',
            timeframe: 'Weeks 1-4',
            description: 'Gradual clearing of infiltrate and symptoms',
            symptoms: ['Improving cough', 'Fatigue', 'Gradual recovery'],
            anatomicalChanges: [
              {
                structureId: 'lung',
                structureName: 'Lung',
                changeType: 'inflammation',
                description: 'Resolving infiltrate',
                severity: 'mild',
                visualIndicator: { color: '#22c55e', pulse: false, opacity: 0.5 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'reversible',
            goalsOfCare: ['Complete resolution', 'Prevent complications'],
          },
        ],
        prognosis:
          'Most patients recover fully. Mortality 1-5% outpatient, 5-15% hospitalized, higher in ICU patients.',
      },

      complications: [
        {
          complicationId: 'pna-sepsis',
          name: 'Sepsis',
          category: 'acute',
          severity: 'life-threatening',
          riskLevel: 'moderate',
          description: 'Systemic inflammatory response to infection',
          mechanism: 'Bacteremia and cytokine storm',
          affectedStructures: [
            {
              structureId: 'circulatory-system',
              structureName: 'Circulatory System',
              effect: 'Distributive shock',
              highlightColor: '#dc2626',
            },
          ],
          warningSymptoms: ['High fever', 'Confusion', 'Hypotension', 'Tachycardia'],
          prevention: ['Early antibiotic treatment', 'Vaccination'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'pna-antibiotics',
          name: 'Antibiotic Therapy',
          modality: 'pharmacological',
          description: 'Empiric antibiotics targeting likely pathogens',
          mechanism: 'Kill or inhibit bacterial growth',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Eradicate infection', 'Prevent complications'],
          timeToEffect: '48-72 hours for clinical improvement',
          explanations: {
            level1: 'Medicines that kill the germs causing the lung infection.',
            level2: 'Antibiotics are medications that fight the bacteria causing pneumonia.',
            level3: 'Empiric coverage for S. pneumoniae, atypicals, and H. influenzae. Adjust based on severity and risk factors.',
            level4: 'CURB-65 or PSI guides disposition. Beta-lactam plus macrolide or respiratory fluoroquinolone for inpatients.',
            level5: 'Guideline-concordant therapy reduces mortality. De-escalation based on cultures and clinical response.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'lung',
            structureName: 'Lung',
            role: 'primary-site',
            involvement: 'Alveolar infection and consolidation',
            highlightColor: '#ef4444',
            showByDefault: true,
          },
        ],
        systemsInvolved: ['Respiratory', 'Immune'],
        recommendedView: 'anterior',
        recommendedLayers: ['organs', 'respiratory'],
      },

      explanations: {
        level1: 'An infection in your lungs that makes it hard to breathe.',
        level2: 'Pneumonia is a lung infection causing cough, fever, and difficulty breathing. It is treated with antibiotics.',
        level3: 'Acute lower respiratory infection with alveolar consolidation. Severity assessment guides outpatient vs inpatient treatment.',
        level4: 'CAP commonly caused by S. pneumoniae, atypicals, and respiratory viruses. CURB-65 and PSI predict mortality.',
        level5: 'Inflammatory exudate fills alveoli causing V/Q mismatch and hypoxemia. Lobar vs bronchopneumonia patterns reflect different pathophysiology.',
      },

      clinicalPearls: [
        'Elderly may present without fever - look for confusion and tachypnea',
        'Follow-up chest X-ray in 6-8 weeks for smokers to rule out underlying malignancy',
        'Procalcitonin can help distinguish bacterial from viral',
        'CURB-65 ≥2 generally warrants hospitalization',
      ],
      patientEducation: [
        'Complete the full course of antibiotics even if feeling better',
        'Rest and drink plenty of fluids',
        'Pneumonia and flu vaccines can prevent future infections',
        'It may take several weeks to fully recover your energy',
      ],
      emergencyWarnings: [
        'Severe difficulty breathing',
        'Confusion or altered mental status',
        'Coughing up blood',
        'Chest pain that is severe or worsening',
      ],
    },
  ],

  // ============================================
  // HIV/AIDS
  // ============================================
  [
    'hiv-aids',
    {
      conditionId: 'hiv-aids',
      name: 'HIV/AIDS',
      aliases: ['Human Immunodeficiency Virus', 'Acquired Immunodeficiency Syndrome'],
      icdCode: 'B20',
      category: 'infectious',
      subcategory: 'viral',
      description:
        'Chronic viral infection that attacks the immune system, specifically CD4+ T cells, leading to progressive immunodeficiency.',

      pathophysiology: {
        summary:
          'HIV infects and destroys CD4+ T lymphocytes, gradually depleting the immune system and leading to opportunistic infections.',
        mechanisms: [
          {
            name: 'CD4+ T Cell Infection',
            description: 'HIV binds CD4 and coreceptors, integrates into host genome',
            systemsInvolved: ['Immune'],
            keyMediators: ['gp120', 'CD4 receptor', 'CCR5/CXCR4'],
            contribution: 'Establishes persistent infection in immune cells',
          },
          {
            name: 'Immune Depletion',
            description: 'Progressive CD4+ T cell destruction via direct killing and immune activation',
            systemsInvolved: ['Immune'],
            keyMediators: ['Chronic immune activation', 'Apoptosis', 'Viral cytopathy'],
            contribution: 'Progressive immunodeficiency leading to AIDS',
          },
        ],
        riskFactors: [
          {
            name: 'Unprotected Sexual Contact',
            type: 'modifiable',
            impact: 'major',
            description: 'Primary mode of transmission globally',
            intervention: 'Condom use, PrEP, treatment as prevention',
          },
          {
            name: 'Injection Drug Use',
            type: 'modifiable',
            impact: 'major',
            description: 'Sharing needles transmits HIV',
            intervention: 'Needle exchange, substance abuse treatment',
          },
          {
            name: 'Perinatal Transmission',
            type: 'partially-modifiable',
            impact: 'major',
            description: 'Mother-to-child during pregnancy, birth, or breastfeeding',
            intervention: 'Antiretroviral therapy during pregnancy',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Acute Retroviral Syndrome',
            prevalence: 'common',
            description: 'Flu-like illness 2-4 weeks after infection',
            timing: 'Early infection',
          },
          {
            name: 'Chronic Asymptomatic Phase',
            prevalence: 'very-common',
            description: 'Years without symptoms while virus replicates',
            timing: 'Clinical latency',
          },
          {
            name: 'Opportunistic Infections',
            prevalence: 'common',
            description: 'Infections occurring when CD4 <200',
            timing: 'AIDS stage',
          },
        ],
        labFindings: [
          {
            testName: 'HIV Antibody/Antigen',
            abnormality: 'Positive',
            significance: 'Confirms HIV infection',
          },
          {
            testName: 'CD4 Count',
            abnormality: 'Decreased',
            normalRange: '500-1500 cells/μL',
            significance: 'Measures immune function, <200 defines AIDS',
          },
          {
            testName: 'HIV Viral Load',
            abnormality: 'Detectable',
            significance: 'Measures viral replication, goal is undetectable',
          },
        ],
      },

      progression: {
        naturalHistory:
          'Without treatment, progression to AIDS in 8-10 years on average. With ART, near-normal life expectancy.',
        timelineSteps: [
          {
            phaseId: 'hiv-acute',
            phase: 'acute',
            displayName: 'Acute HIV Infection',
            timeframe: 'Weeks 2-4 post-exposure',
            description: 'High viral replication, flu-like illness',
            symptoms: ['Fever', 'Lymphadenopathy', 'Rash', 'Pharyngitis'],
            anatomicalChanges: [
              {
                structureId: 'lymph-nodes',
                structureName: 'Lymph Nodes',
                changeType: 'inflammation',
                description: 'Lymphadenopathy from immune response',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: true, opacity: 0.7 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Immediate ART initiation'],
            goalsOfCare: ['Viral suppression', 'Preserve immune function'],
          },
          {
            phaseId: 'hiv-chronic',
            phase: 'chronic',
            displayName: 'Clinical Latency',
            timeframe: 'Years',
            description: 'Asymptomatic phase with ongoing viral replication',
            symptoms: ['Often asymptomatic', 'Possible lymphadenopathy'],
            anatomicalChanges: [
              {
                structureId: 'immune-system',
                structureName: 'Immune System',
                changeType: 'degeneration',
                description: 'Gradual CD4 depletion',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.6 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['ART'],
            goalsOfCare: ['Maintain viral suppression', 'Preserve CD4 count'],
          },
          {
            phaseId: 'hiv-aids',
            phase: 'advanced',
            displayName: 'AIDS',
            timeframe: 'When CD4 <200 or AIDS-defining illness',
            description: 'Severe immunodeficiency with opportunistic infections',
            symptoms: ['Weight loss', 'Opportunistic infections', 'Malignancies'],
            anatomicalChanges: [
              {
                structureId: 'immune-system',
                structureName: 'Immune System',
                changeType: 'degeneration',
                description: 'Severe immune depletion',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['ART', 'OI prophylaxis', 'OI treatment'],
            goalsOfCare: ['Immune reconstitution', 'Prevent and treat OIs'],
          },
        ],
        prognosis:
          'With ART, near-normal life expectancy. U=U (Undetectable = Untransmittable) - suppressed patients do not transmit HIV.',
      },

      complications: [
        {
          complicationId: 'hiv-oi',
          name: 'Opportunistic Infections',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'high',
          description: 'Infections occurring due to immunodeficiency',
          mechanism: 'CD4 depletion allows normally controlled pathogens to cause disease',
          affectedStructures: [
            {
              structureId: 'multiple-organs',
              structureName: 'Multiple Organs',
              effect: 'Various opportunistic infections',
              highlightColor: '#dc2626',
            },
          ],
          warningSymptoms: ['Fever', 'Weight loss', 'New respiratory symptoms', 'Neurologic changes'],
          prevention: ['ART', 'Prophylaxis when CD4 <200'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'hiv-art',
          name: 'Antiretroviral Therapy',
          modality: 'pharmacological',
          description: 'Combination therapy suppressing viral replication',
          mechanism: 'Target multiple steps in HIV lifecycle',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute', 'chronic', 'advanced'],
          goals: ['Viral suppression', 'Immune preservation', 'Prevent transmission'],
          expectedOutcomes: ['Undetectable viral load', 'CD4 recovery', 'Near-normal lifespan'],
          explanations: {
            level1: 'Daily pills that control the virus and keep you healthy.',
            level2: 'Antiretroviral therapy stops HIV from multiplying, allowing your immune system to stay strong.',
            level3: 'Combination ART targets multiple viral enzymes. Adherence is critical for suppression and preventing resistance.',
            level4: 'Integrase inhibitor-based regimens are first-line. Goal is undetectable viral load within 6 months.',
            level5: 'Modern ART achieves >95% viral suppression. Integrase inhibitors have high barrier to resistance. U=U proven in PARTNER and HPTN052 studies.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'immune-system',
            structureName: 'Immune System',
            role: 'primary-site',
            involvement: 'CD4+ T cell depletion',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
          {
            structureId: 'lymph-nodes',
            structureName: 'Lymph Nodes',
            role: 'primary-site',
            involvement: 'Major site of viral replication',
            highlightColor: '#f97316',
            showByDefault: true,
          },
        ],
        systemsInvolved: ['Immune', 'Lymphatic'],
        recommendedView: 'anterior',
        recommendedLayers: ['lymphatic'],
      },

      explanations: {
        level1: 'A virus that weakens your immune system but can be controlled with daily medication.',
        level2: 'HIV attacks immune cells. With daily treatment, the virus can be controlled and you can live a normal, healthy life.',
        level3: 'HIV infects CD4+ T cells. ART suppresses replication, preventing progression to AIDS. Undetectable = Untransmittable.',
        level4: 'Retrovirus integrating into host genome. Modern ART achieves durable viral suppression and immune reconstitution.',
        level5: 'HIV establishes latent reservoirs preventing cure. ART suppresses viremia to undetectable levels. Chronic immune activation persists but is reduced.',
      },

      clinicalPearls: [
        'Test all patients aged 13-64 at least once; high-risk patients annually',
        'Start ART immediately upon diagnosis regardless of CD4 count',
        'U=U - undetectable viral load means no transmission risk',
        'Screen for HBV, HCV, TB, STIs at diagnosis',
      ],
      patientEducation: [
        'With treatment, you can live a long, healthy life',
        'Take medication every day - missing doses can cause resistance',
        'When your viral load is undetectable, you cannot transmit HIV sexually',
        'Regular monitoring with your doctor is important',
      ],
      emergencyWarnings: [
        'New fever with confusion or headache',
        'Difficulty breathing',
        'Severe diarrhea with dehydration',
        'New weakness or vision changes',
      ],
    },
  ],

  // ============================================
  // Tuberculosis
  // ============================================
  [
    'tuberculosis',
    {
      conditionId: 'tuberculosis',
      name: 'Tuberculosis',
      aliases: ['TB', 'Consumption'],
      icdCode: 'A15',
      category: 'infectious',
      subcategory: 'mycobacterial',
      description:
        'Bacterial infection caused by Mycobacterium tuberculosis, primarily affecting lungs but can involve any organ.',

      pathophysiology: {
        summary:
          'M. tuberculosis is inhaled and ingested by alveolar macrophages, forming granulomas that can contain or progress to active disease.',
        mechanisms: [
          {
            name: 'Granuloma Formation',
            description: 'Immune cells wall off bacteria in granulomas',
            systemsInvolved: ['Respiratory', 'Immune'],
            keyMediators: ['Macrophages', 'T cells', 'TNF-alpha'],
            contribution: 'Contains infection but allows persistence (latent TB)',
          },
          {
            name: 'Caseating Necrosis',
            description: 'Central necrosis of granulomas in active disease',
            systemsInvolved: ['Respiratory'],
            keyMediators: ['Cytotoxic T cells', 'Macrophages'],
            contribution: 'Tissue destruction, cavity formation, transmission',
          },
        ],
        riskFactors: [
          {
            name: 'HIV Infection',
            type: 'partially-modifiable',
            impact: 'major',
            description: 'Greatest risk factor for progression to active TB',
            intervention: 'ART, TB screening and treatment',
          },
          {
            name: 'Close Contact with Active TB',
            type: 'modifiable',
            impact: 'major',
            description: 'Household or healthcare exposure',
            intervention: 'Contact tracing, infection control',
          },
          {
            name: 'Immunosuppression',
            type: 'partially-modifiable',
            impact: 'major',
            description: 'TNF inhibitors, chemotherapy, diabetes',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Chronic Cough',
            prevalence: 'very-common',
            description: 'Cough lasting >3 weeks, may be productive or bloody',
          },
          {
            name: 'Night Sweats',
            prevalence: 'common',
            description: 'Drenching sweats at night',
          },
          {
            name: 'Weight Loss',
            prevalence: 'common',
            description: 'Unintentional weight loss, cachexia',
          },
          {
            name: 'Fever',
            prevalence: 'common',
            description: 'Low-grade fever, often evening',
          },
        ],
        physicalFindings: [
          {
            name: 'Upper Lobe Findings',
            examType: 'Auscultation',
            description: 'Crackles or bronchial breathing over upper lobes',
            diagnosticValue: 'Suggestive if in typical location',
          },
        ],
        imagingFindings: [
          {
            modality: 'Chest X-ray',
            finding: 'Upper lobe infiltrates, cavities',
            significance: 'Classic but not pathognomonic',
            structures: ['Lung apices'],
          },
        ],
        labFindings: [
          {
            testName: 'AFB Smear',
            abnormality: 'Acid-fast bacilli seen',
            significance: 'Rapid presumptive diagnosis',
          },
          {
            testName: 'TB Culture',
            abnormality: 'M. tuberculosis isolated',
            significance: 'Gold standard, allows drug susceptibility testing',
          },
        ],
      },

      progression: {
        naturalHistory:
          'Only 5-10% with latent TB progress to active disease in lifetime. Higher risk in first 2 years and with immunosuppression.',
        timelineSteps: [
          {
            phaseId: 'tb-latent',
            phase: 'preclinical',
            displayName: 'Latent TB Infection',
            timeframe: 'Years to lifetime',
            description: 'Contained infection without symptoms or transmission',
            symptoms: ['None'],
            anatomicalChanges: [
              {
                structureId: 'lung',
                structureName: 'Lung',
                changeType: 'infiltration',
                description: 'Contained granulomas',
                severity: 'mild',
                visualIndicator: { color: '#94a3b8', pulse: false, opacity: 0.4 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Isoniazid', 'Rifampin', 'Isoniazid-Rifapentine'],
            goalsOfCare: ['Prevent progression to active disease'],
          },
          {
            phaseId: 'tb-active',
            phase: 'acute',
            displayName: 'Active Pulmonary TB',
            timeframe: 'Weeks to months',
            description: 'Symptomatic disease with transmission potential',
            symptoms: ['Cough', 'Night sweats', 'Weight loss', 'Hemoptysis'],
            anatomicalChanges: [
              {
                structureId: 'lung',
                structureName: 'Lung',
                changeType: 'necrosis',
                description: 'Caseating granulomas, cavitary disease',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['RIPE therapy (Rifampin, Isoniazid, Pyrazinamide, Ethambutol)'],
            goalsOfCare: ['Cure infection', 'Prevent transmission', 'Prevent resistance'],
          },
        ],
        prognosis:
          'Drug-susceptible TB is curable with 6 months treatment. MDR-TB requires 18-24 months. HIV-TB coinfection has higher mortality.',
      },

      complications: [
        {
          complicationId: 'tb-mdr',
          name: 'Multidrug-Resistant TB',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Resistance to at least isoniazid and rifampin',
          mechanism: 'Selection pressure from incomplete treatment',
          affectedStructures: [
            {
              structureId: 'lung',
              structureName: 'Lung',
              effect: 'Difficult to treat infection',
              highlightColor: '#7f1d1d',
            },
          ],
          warningSymptoms: ['Treatment failure', 'Persistent symptoms'],
          prevention: ['Directly observed therapy', 'Complete treatment'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'tb-ripe',
          name: 'RIPE Therapy',
          modality: 'pharmacological',
          description: '4-drug regimen for drug-susceptible TB',
          mechanism: 'Multiple agents prevent resistance and target different bacterial populations',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute'],
          goals: ['Cure infection', 'Prevent resistance', 'Prevent transmission'],
          timeToEffect: '2 weeks to become non-infectious',
          sideEffects: ['Hepatotoxicity', 'Neuropathy', 'Visual changes', 'Hyperuricemia'],
          explanations: {
            level1: 'Four medicines taken together for 6 months to cure TB.',
            level2: 'TB requires multiple antibiotics taken for 6 months to fully cure and prevent resistance.',
            level3: 'RIPE: 2 months intensive phase (4 drugs), 4 months continuation (2 drugs). DOT recommended.',
            level4: 'Rifampin sterilizes bacilli, isoniazid kills actively dividing organisms. Pyrazinamide targets dormant populations. Ethambutol prevents resistance.',
            level5: 'Multi-drug therapy targets different bacterial populations (actively replicating, dormant, intracellular). Duration based on bacterial burden and sterilization.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'lung',
            structureName: 'Lung',
            role: 'primary-site',
            involvement: 'Primary infection site, especially upper lobes',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'lymph-nodes',
            structureName: 'Lymph Nodes',
            role: 'secondary-site',
            involvement: 'Hilar and mediastinal adenopathy',
            highlightColor: '#f97316',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Respiratory', 'Immune', 'Lymphatic'],
        recommendedView: 'anterior',
        recommendedLayers: ['respiratory'],
      },

      explanations: {
        level1: 'A bacterial lung infection that needs months of treatment to cure.',
        level2: 'TB is caused by bacteria that spreads through the air. It is curable with 6 months of antibiotic treatment.',
        level3: 'Mycobacterial infection forming granulomas. Latent TB is contained; active TB requires multi-drug therapy.',
        level4: 'M. tuberculosis resides in macrophages. Granulomatous response can contain or progress based on immune status.',
        level5: 'Intracellular pathogen with complex cell wall requiring prolonged multi-drug therapy. Granuloma hypoxia and caseous necrosis create distinct bacterial populations.',
      },

      clinicalPearls: [
        'Think TB with cough >3 weeks + risk factors',
        'Always test for HIV in TB patients',
        'DOT (directly observed therapy) improves outcomes',
        'Respiratory isolation until 3 negative AFB smears',
      ],
      patientEducation: [
        'You must take all medications for the full 6 months to be cured',
        'Missing doses can cause drug resistance making TB much harder to treat',
        'You will not be contagious after about 2 weeks of treatment',
        'All close contacts need to be tested for TB',
      ],
      emergencyWarnings: [
        'Coughing up large amounts of blood',
        'Severe difficulty breathing',
        'High fever with confusion',
        'Signs of medication reaction (jaundice, vision changes)',
      ],
    },
  ],

  // ============================================
  // Bacterial Meningitis
  // ============================================
  [
    'bacterial-meningitis',
    {
      conditionId: 'bacterial-meningitis',
      name: 'Bacterial Meningitis',
      aliases: ['Meningitis', 'Purulent Meningitis'],
      icdCode: 'G00',
      category: 'infectious',
      subcategory: 'central nervous system',
      description:
        'Acute bacterial infection of the meninges, a medical emergency requiring immediate antibiotic treatment.',

      pathophysiology: {
        summary:
          'Bacteria reach meninges via bloodstream or direct spread, triggering intense inflammatory response that damages the brain.',
        mechanisms: [
          {
            name: 'Meningeal Invasion',
            description: 'Bacteria cross blood-brain barrier and invade CSF',
            systemsInvolved: ['Neurologic', 'Immune'],
            keyMediators: ['S. pneumoniae', 'N. meningitidis', 'Listeria'],
            contribution: 'Establishes infection in normally sterile CSF',
          },
          {
            name: 'Inflammatory Response',
            description: 'Cytokines and neutrophils cause meningeal inflammation',
            systemsInvolved: ['Neurologic', 'Immune'],
            keyMediators: ['IL-1', 'TNF-alpha', 'Neutrophils'],
            contribution: 'Cerebral edema, increased ICP, vasculitis',
          },
        ],
        riskFactors: [
          {
            name: 'Age Extremes',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Neonates and elderly at highest risk',
          },
          {
            name: 'Immunocompromise',
            type: 'partially-modifiable',
            impact: 'major',
            description: 'Asplenia, complement deficiency, HIV',
          },
          {
            name: 'Crowded Living Conditions',
            type: 'modifiable',
            impact: 'moderate',
            description: 'College dorms, military barracks (meningococcal)',
            intervention: 'Vaccination',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Headache',
            prevalence: 'very-common',
            description: 'Severe, worst headache of life',
          },
          {
            name: 'Fever',
            prevalence: 'very-common',
            description: 'High fever, may be absent in elderly',
          },
          {
            name: 'Neck Stiffness',
            prevalence: 'very-common',
            description: 'Nuchal rigidity, resistance to flexion',
          },
          {
            name: 'Altered Mental Status',
            prevalence: 'common',
            description: 'Confusion, lethargy, obtundation',
          },
        ],
        physicalFindings: [
          {
            name: 'Kernig Sign',
            examType: 'Neurologic',
            description: 'Resistance to knee extension with hip flexed',
            diagnosticValue: 'Specific but not sensitive',
          },
          {
            name: 'Brudzinski Sign',
            examType: 'Neurologic',
            description: 'Hip flexion with passive neck flexion',
            diagnosticValue: 'Specific but not sensitive',
          },
          {
            name: 'Petechial Rash',
            examType: 'Skin',
            description: 'Non-blanching petechiae/purpura',
            diagnosticValue: 'Suggests meningococcemia',
          },
        ],
        labFindings: [
          {
            testName: 'CSF Analysis',
            abnormality: 'Elevated WBC (neutrophil predominant), low glucose, high protein',
            significance: 'Diagnostic for bacterial meningitis',
          },
          {
            testName: 'CSF Gram Stain',
            abnormality: 'Bacteria visible',
            significance: 'Rapid identification of organism',
          },
        ],
      },

      progression: {
        naturalHistory:
          'Rapid progression over hours. Without treatment, nearly 100% fatal. Even with treatment, 10-30% mortality.',
        timelineSteps: [
          {
            phaseId: 'mening-early',
            phase: 'acute',
            displayName: 'Early Meningitis',
            timeframe: 'Hours',
            description: 'Initial symptoms before full syndrome',
            symptoms: ['Fever', 'Headache', 'Malaise', 'Nausea'],
            anatomicalChanges: [
              {
                structureId: 'meninges',
                structureName: 'Meninges',
                changeType: 'inflammation',
                description: 'Early meningeal inflammation',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: true, opacity: 0.7 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Empiric antibiotics IMMEDIATELY'],
            goalsOfCare: ['Early recognition', 'Immediate treatment'],
          },
          {
            phaseId: 'mening-fulminant',
            phase: 'acute',
            displayName: 'Fulminant Meningitis',
            timeframe: 'Hours to days',
            description: 'Full meningitis syndrome with complications',
            symptoms: ['Severe headache', 'Neck stiffness', 'Confusion', 'Seizures'],
            anatomicalChanges: [
              {
                structureId: 'meninges',
                structureName: 'Meninges',
                changeType: 'inflammation',
                description: 'Purulent meningitis with cerebral edema',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 },
                isNewAtPhase: false,
              },
              {
                structureId: 'brain',
                structureName: 'Brain',
                changeType: 'edema',
                description: 'Cerebral edema from inflammation',
                severity: 'severe',
                visualIndicator: { color: '#7c3aed', pulse: true, opacity: 0.7 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['IV antibiotics', 'Dexamethasone', 'ICU care'],
            goalsOfCare: ['Infection control', 'Prevent neurologic damage'],
          },
        ],
        prognosis:
          'Mortality 10-30% even with treatment. Survivors may have permanent neurologic sequelae (hearing loss, cognitive deficits).',
      },

      complications: [
        {
          complicationId: 'mening-hearing-loss',
          name: 'Hearing Loss',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Permanent sensorineural hearing loss in 10-30%',
          mechanism: 'Cochlear damage from inflammation and ischemia',
          affectedStructures: [
            {
              structureId: 'inner-ear',
              structureName: 'Inner Ear',
              effect: 'Sensorineural hearing loss',
              highlightColor: '#f97316',
            },
          ],
          warningSymptoms: ['Difficulty hearing after recovery'],
          prevention: ['Dexamethasone with first antibiotic dose'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'mening-empiric-abx',
          name: 'Empiric Antibiotic Therapy',
          modality: 'pharmacological',
          description: 'Immediate broad-spectrum antibiotics',
          mechanism: 'Kill bacteria before culture results',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['acute'],
          goals: ['Rapid sterilization of CSF', 'Prevent death'],
          timeToEffect: 'Must be given within 30-60 minutes of presentation',
          explanations: {
            level1: 'Strong antibiotics given through an IV to kill the infection quickly.',
            level2: 'Powerful intravenous antibiotics must be started immediately to treat this serious brain infection.',
            level3: 'Empiric coverage: ceftriaxone + vancomycin ± ampicillin (if Listeria risk). Adjust based on cultures.',
            level4: 'Do not delay antibiotics for LP. Dexamethasone before or with first antibiotic dose reduces mortality.',
            level5: 'Door-to-antibiotic time correlates with mortality. Third-generation cephalosporin penetrates CSF. Dexamethasone reduces IL-1/TNF-mediated neuronal damage.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'meninges',
            structureName: 'Meninges',
            role: 'primary-site',
            involvement: 'Site of infection and inflammation',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
          {
            structureId: 'brain',
            structureName: 'Brain',
            role: 'target-organ',
            involvement: 'Cerebral edema, secondary damage',
            highlightColor: '#7c3aed',
            showByDefault: true,
          },
        ],
        systemsInvolved: ['Neurologic', 'Immune'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['nervous'],
      },

      explanations: {
        level1: 'A dangerous infection around the brain that needs emergency treatment.',
        level2: 'Bacterial meningitis is a serious infection of the covering around the brain. It needs immediate antibiotic treatment.',
        level3: 'Medical emergency with rapid progression. Empiric antibiotics must not be delayed. Dexamethasone reduces mortality.',
        level4: 'CSF findings: neutrophil pleocytosis, low glucose, high protein. Do not delay antibiotics for LP.',
        level5: 'Inflammatory cascade causes BBB breakdown, cerebral edema, and vasculitis. Adjunctive dexamethasone reduces cytokine-mediated injury.',
      },

      clinicalPearls: [
        'Never delay antibiotics for LP - give immediately if meningitis suspected',
        'Classic triad (fever, neck stiffness, altered mental status) present in <50%',
        'Dexamethasone before or with first antibiotic dose, especially for pneumococcal',
        'Chemoprophylaxis for close contacts of meningococcal meningitis',
      ],
      patientEducation: [
        'This is a medical emergency - you did the right thing coming to the hospital',
        'IV antibiotics are the main treatment and will be given for 1-2 weeks',
        'Close contacts may need preventive antibiotics',
        'You will need hearing tests after recovery',
      ],
      emergencyWarnings: [
        'Severe headache with fever and neck stiffness - go to ER immediately',
        'New rash with fever',
        'Confusion or difficulty staying awake',
        'Seizures',
      ],
    },
  ],

  // ============================================
  // GASTROINTESTINAL: Irritable Bowel Syndrome
  // ============================================
  [
    'irritable-bowel-syndrome',
    {
      conditionId: 'irritable-bowel-syndrome',
      name: 'Irritable Bowel Syndrome',
      aliases: ['IBS', 'Spastic Colon', 'Nervous Stomach'],
      icdCode: 'K58',
      category: 'gastrointestinal',
      subcategory: 'Functional GI Disorders',
      description:
        'Chronic functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits without structural abnormality.',

      pathophysiology: {
        summary:
          'Disorder of gut-brain interaction involving visceral hypersensitivity, altered motility, and dysregulated communication between the enteric and central nervous systems.',
        mechanisms: [
          {
            name: 'Visceral Hypersensitivity',
            description:
              'Heightened perception of normal gut sensations leads to pain and discomfort at lower thresholds than normal.',
            systemsInvolved: ['Gastrointestinal', 'Neurologic'],
            keyMediators: ['Serotonin (5-HT)', 'Substance P', 'CGRP'],
            contribution: 'Primary driver of abdominal pain and bloating symptoms',
          },
          {
            name: 'Altered GI Motility',
            description:
              'Dysregulated colonic contractions cause either accelerated or delayed transit.',
            systemsInvolved: ['Gastrointestinal'],
            keyMediators: ['Acetylcholine', 'Serotonin', 'Motilin'],
            contribution: 'Drives diarrhea-predominant or constipation-predominant subtypes',
          },
          {
            name: 'Gut-Brain Axis Dysfunction',
            description:
              'Bidirectional communication between CNS and enteric nervous system is disrupted, amplified by stress and anxiety.',
            systemsInvolved: ['Gastrointestinal', 'Neurologic', 'Immune'],
            keyMediators: ['Cortisol', 'CRH', 'Vagal nerve signaling'],
            contribution: 'Explains stress-related symptom exacerbation',
          },
        ],
        riskFactors: [
          {
            name: 'Female Sex',
            type: 'non-modifiable',
            impact: 'moderate',
            description: '2x more common in women, possibly due to hormonal influences',
          },
          {
            name: 'Psychological Stress',
            type: 'modifiable',
            impact: 'major',
            description: 'Anxiety, depression, and life stressors strongly exacerbate symptoms',
            intervention: 'Cognitive behavioral therapy, stress management',
          },
          {
            name: 'Post-infectious',
            type: 'non-modifiable',
            impact: 'moderate',
            description: 'Can develop after acute gastroenteritis (post-infectious IBS)',
          },
          {
            name: 'Diet',
            type: 'modifiable',
            impact: 'moderate',
            description: 'FODMAPs, gluten, lactose, and other dietary triggers',
            intervention: 'Low FODMAP diet, elimination diet',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Abdominal Pain',
            prevalence: 'very-common',
            description: 'Recurrent crampy abdominal pain related to defecation',
            quality: 'Crampy, diffuse',
            location: 'Lower abdomen',
            timing: 'Related to meals and bowel movements',
          },
          {
            name: 'Altered Bowel Habits',
            prevalence: 'very-common',
            description: 'Diarrhea, constipation, or alternating between both',
          },
          {
            name: 'Bloating',
            prevalence: 'very-common',
            description: 'Abdominal distension and sensation of fullness',
          },
        ],
        associatedSymptoms: [
          {
            name: 'Urgency',
            prevalence: 'common',
            description: 'Sudden need to defecate (IBS-D)',
          },
          {
            name: 'Incomplete Evacuation',
            prevalence: 'common',
            description: 'Feeling of incomplete bowel movement',
          },
        ],
      },

      progression: {
        naturalHistory:
          'Chronic relapsing condition with periods of exacerbation and remission. Symptoms may change subtype over time but rarely lead to structural disease.',
        timelineSteps: [
          {
            phaseId: 'ibs-onset',
            phase: 'early',
            displayName: 'Symptom Onset',
            timeframe: 'Weeks to months',
            description: 'Initial development of recurrent GI symptoms, often triggered by stress or infection.',
            symptoms: ['Intermittent abdominal pain', 'Occasional bloating', 'Irregular bowel habits'],
            anatomicalChanges: [
              {
                structureId: 'large-intestine',
                structureName: 'Large Intestine',
                changeType: 'dysfunction',
                description: 'Altered motility patterns and visceral sensitivity',
                severity: 'mild',
                visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Dietary modification', 'Fiber supplementation'],
            goalsOfCare: ['Identify triggers', 'Dietary assessment'],
          },
          {
            phaseId: 'ibs-established',
            phase: 'established',
            displayName: 'Established IBS',
            timeframe: 'Months to years',
            description: 'Recurrent symptoms meeting Rome IV criteria with identified triggers and patterns.',
            symptoms: ['Regular abdominal pain with defecation', 'Consistent bowel pattern changes', 'Bloating and distension'],
            anatomicalChanges: [
              {
                structureId: 'large-intestine',
                structureName: 'Large Intestine',
                changeType: 'dysfunction',
                description: 'Persistent motility dysregulation and visceral hypersensitivity',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 },
                isNewAtPhase: false,
              },
              {
                structureId: 'enteric-nervous-system',
                structureName: 'Enteric Nervous System',
                changeType: 'dysfunction',
                description: 'Gut-brain axis dysregulation',
                severity: 'moderate',
                visualIndicator: { color: '#8b5cf6', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Low FODMAP diet', 'Antispasmodics', 'CBT'],
            goalsOfCare: ['Symptom control', 'Quality of life improvement'],
          },
          {
            phaseId: 'ibs-chronic',
            phase: 'chronic',
            displayName: 'Chronic Management',
            timeframe: 'Years to lifelong',
            description: 'Long-term management with flares and remissions, often with comorbid anxiety or depression.',
            symptoms: ['Flare-up episodes', 'Stress-related exacerbations', 'Food-related triggers'],
            anatomicalChanges: [
              {
                structureId: 'large-intestine',
                structureName: 'Large Intestine',
                changeType: 'dysfunction',
                description: 'Chronic functional changes without structural damage',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: true, opacity: 0.7 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Combined pharmacologic and behavioral therapy', 'Ongoing dietary management'],
            goalsOfCare: ['Long-term symptom management', 'Address comorbidities'],
          },
        ],
        prognosis:
          'Chronic but not life-threatening. Does not progress to IBD or cancer. Quality of life can be significantly improved with proper management.',
      },

      complications: [
        {
          complicationId: 'ibs-quality-of-life',
          name: 'Reduced Quality of Life',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'high',
          description: 'Significant impact on daily activities, work productivity, and social functioning.',
          mechanism: 'Unpredictable symptoms cause avoidance behaviors and functional limitations',
          affectedStructures: [
            {
              structureId: 'large-intestine',
              structureName: 'Large Intestine',
              effect: 'Functional impairment',
              highlightColor: '#f97316',
            },
          ],
          warningSymptoms: ['Social isolation', 'Work absenteeism', 'Depression'],
          prevention: ['Early comprehensive treatment', 'Psychological support'],
          preventable: true,
        },
        {
          complicationId: 'ibs-psych-comorbidity',
          name: 'Psychological Comorbidity',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'High rates of comorbid anxiety and depression that worsen GI symptoms.',
          mechanism: 'Gut-brain axis dysfunction amplifies both GI and psychological symptoms',
          affectedStructures: [
            {
              structureId: 'brain',
              structureName: 'Brain',
              effect: 'Anxiety and depression',
              highlightColor: '#8b5cf6',
            },
          ],
          warningSymptoms: ['Worsening mood', 'Sleep disturbance', 'Catastrophizing about symptoms'],
          prevention: ['Integrated psychological care', 'CBT'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'ibs-low-fodmap',
          name: 'Low FODMAP Diet',
          modality: 'lifestyle',
          description: 'Structured elimination and reintroduction diet targeting fermentable carbohydrates.',
          mechanism: 'Reduces osmotic load and fermentation in the colon',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'chronic'],
          goals: ['Reduce bloating and pain', 'Identify food triggers'],
          timeToEffect: '2-6 weeks',
          explanations: {
            level1: 'A special diet that avoids foods that can upset your stomach.',
            level2: 'This diet removes foods that ferment in the gut and cause bloating and pain, then slowly adds them back.',
            level3: 'Low FODMAP diet eliminates fermentable oligo-, di-, mono-saccharides and polyols. 3-phase approach: elimination, reintroduction, personalization.',
            level4: 'Evidence-based dietary intervention with ~70% response rate. Reduces colonic fermentation and osmotic water secretion. Must be dietitian-guided.',
            level5: 'FODMAPs increase small bowel water via osmosis and colonic gas via bacterial fermentation. Response correlates with baseline microbiome composition. Long-term restriction may reduce Bifidobacteria.',
          },
        },
        {
          treatmentId: 'ibs-antispasmodic',
          name: 'Antispasmodic Medications',
          modality: 'pharmacological',
          description: 'Medications that reduce intestinal smooth muscle spasm.',
          mechanism: 'Anticholinergic or direct smooth muscle relaxant action',
          efficacy: 'moderately-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['established', 'chronic'],
          goals: ['Reduce abdominal pain and cramping'],
          timeToEffect: '30-60 minutes (as needed)',
          medicationIds: ['hyoscine', 'dicyclomine'],
          explanations: {
            level1: 'Medicine that relaxes your gut to reduce cramps.',
            level2: 'These medications calm the muscles in your intestines to reduce painful cramping.',
            level3: 'Antispasmodics (e.g., hyoscine, dicyclomine) reduce smooth muscle spasm. Best used PRN before meals.',
            level4: 'NNT ~5 for global IBS symptom improvement. Anticholinergic side effects limit use. Peppermint oil (enteric-coated) is an alternative.',
            level5: 'Muscarinic receptor antagonism or direct smooth muscle relaxation reduces high-amplitude propagated contractions. Peppermint oil acts via L-menthol calcium channel blockade.',
          },
        },
        {
          treatmentId: 'ibs-cbt',
          name: 'Cognitive Behavioral Therapy',
          modality: 'supportive',
          description: 'Psychological therapy targeting the gut-brain connection.',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established', 'chronic'],
          goals: ['Address catastrophizing', 'Reduce stress-related flares', 'Improve coping'],
          timeToEffect: '8-12 weeks',
          explanations: {
            level1: 'Talking therapy that helps you manage stress that makes your stomach worse.',
            level2: 'A type of therapy that helps change thought patterns and behaviors that worsen your IBS symptoms.',
            level3: 'GI-focused CBT addresses illness-specific cognitions, visceral anxiety, and avoidance behaviors. Durable effects beyond treatment period.',
            level4: 'Gut-directed CBT has NNT ~4. Digital CBT platforms showing equivalent efficacy. Also consider gut-directed hypnotherapy.',
            level5: 'CBT modulates central pain processing via prefrontal-amygdala pathways. Neuroimaging shows reduced activation in pain matrix areas post-treatment.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'large-intestine',
            structureName: 'Large Intestine',
            role: 'primary-site',
            involvement: 'Altered motility and visceral hypersensitivity',
            highlightColor: '#f97316',
            showByDefault: true,
          },
          {
            structureId: 'small-intestine',
            structureName: 'Small Intestine',
            role: 'secondary-site',
            involvement: 'Osmotic effects and transit changes',
            highlightColor: '#fbbf24',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'brain',
            structureName: 'Brain',
            role: 'secondary-site',
            involvement: 'Gut-brain axis central processing',
            highlightColor: '#8b5cf6',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Gastrointestinal', 'Neurologic'],
        recommendedView: 'anterior',
        recommendedLayers: ['digestive'],
      },

      explanations: {
        level1: 'A stomach condition that causes pain, bloating, and changes in bathroom habits.',
        level2: 'IBS is a common condition where the gut is extra sensitive and the muscles do not work smoothly, causing pain and bowel changes.',
        level3: 'Functional GI disorder involving visceral hypersensitivity and dysmotility. Diagnosis by Rome IV criteria. No structural abnormalities.',
        level4: 'Disorder of gut-brain interaction with altered serotonin signaling, mast cell activation, and microbiome changes. Subtyped as IBS-D, IBS-C, IBS-M.',
        level5: 'Complex pathophysiology involving peripheral sensitization of visceral afferents, central pain amplification, altered 5-HT metabolism, increased intestinal permeability, and post-infectious immune activation.',
      },

      relatedConditions: ['gerd', 'anxiety-disorder', 'major-depression', 'celiac-disease'],
      comorbidities: ['anxiety-disorder', 'major-depression', 'fibromyalgia'],
      epidemiology: {
        prevalence: '10-15% globally',
        demographics: '2x more common in women, typically onset before age 50',
      },
      clinicalPearls: [
        'IBS is a diagnosis of inclusion (Rome IV), not exclusion',
        'Red flags (weight loss, blood in stool, nocturnal symptoms, age >50 new onset) require further workup',
        'Low FODMAP diet should be guided by a dietitian',
        'Psychological comorbidity should always be addressed',
      ],
      patientEducation: [
        'IBS is a real medical condition, not imaginary',
        'It does not cause cancer or damage your intestines',
        'Stress management is an important part of treatment',
        'Keeping a food and symptom diary can help identify triggers',
      ],
      emergencyWarnings: [
        'Blood in stool',
        'Unexplained weight loss',
        'Severe pain that does not improve',
        'Fever with GI symptoms',
      ],
    },
  ],

  // ============================================
  // MUSCULOSKELETAL: Carpal Tunnel Syndrome
  // ============================================
  [
    'carpal-tunnel-syndrome',
    {
      conditionId: 'carpal-tunnel-syndrome',
      name: 'Carpal Tunnel Syndrome',
      aliases: ['CTS', 'Median Nerve Entrapment', 'Carpal Tunnel'],
      icdCode: 'G56.0',
      category: 'musculoskeletal',
      subcategory: 'Entrapment Neuropathy',
      description:
        'Compression of the median nerve as it passes through the carpal tunnel in the wrist, causing pain, numbness, and weakness in the hand.',

      pathophysiology: {
        summary:
          'Increased pressure within the carpal tunnel compresses the median nerve, causing demyelination and eventually axonal damage.',
        mechanisms: [
          {
            name: 'Median Nerve Compression',
            description:
              'Swelling of flexor tendons or thickening of the transverse carpal ligament increases pressure on the median nerve.',
            systemsInvolved: ['Musculoskeletal', 'Neurologic'],
            keyMediators: ['Prostaglandins', 'VEGF', 'TGF-beta'],
            contribution: 'Primary mechanism causing nerve dysfunction',
          },
          {
            name: 'Nerve Ischemia',
            description:
              'Elevated carpal tunnel pressure impairs epineural blood flow, causing ischemic damage to nerve fibers.',
            systemsInvolved: ['Neurologic', 'Cardiovascular'],
            keyMediators: ['Nitric oxide', 'Endothelin'],
            contribution: 'Contributes to demyelination and conduction slowing',
          },
        ],
        riskFactors: [
          {
            name: 'Repetitive Hand Use',
            type: 'modifiable',
            impact: 'major',
            description: 'Repetitive wrist flexion/extension, gripping, and vibrating tools',
            intervention: 'Ergonomic modifications, activity modification',
          },
          {
            name: 'Female Sex',
            type: 'non-modifiable',
            impact: 'moderate',
            description: '3x more common in women, possibly due to smaller carpal tunnel',
          },
          {
            name: 'Obesity',
            type: 'modifiable',
            impact: 'moderate',
            description: 'Increased adipose tissue within the carpal tunnel',
            intervention: 'Weight management',
          },
          {
            name: 'Pregnancy',
            type: 'non-modifiable',
            impact: 'moderate',
            description: 'Fluid retention increases carpal tunnel pressure, usually resolves postpartum',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Numbness and Tingling',
            prevalence: 'very-common',
            description: 'Numbness in thumb, index, middle, and radial half of ring finger',
            location: 'Median nerve distribution',
            timing: 'Worse at night and with sustained grip',
          },
          {
            name: 'Hand Pain',
            prevalence: 'very-common',
            description: 'Aching pain in wrist and hand, may radiate to forearm',
            quality: 'Burning, aching',
          },
          {
            name: 'Weakness',
            prevalence: 'common',
            description: 'Grip weakness and difficulty with fine motor tasks',
            timing: 'Develops later in disease course',
          },
        ],
        physicalFindings: [
          {
            name: 'Tinel Sign',
            examType: 'Musculoskeletal',
            description: 'Tingling with tapping over the carpal tunnel',
            diagnosticValue: 'Sensitivity ~50%, specificity ~77%',
          },
          {
            name: 'Phalen Test',
            examType: 'Musculoskeletal',
            description: 'Wrist flexion for 60 seconds reproduces symptoms',
            diagnosticValue: 'Sensitivity ~68%, specificity ~73%',
          },
          {
            name: 'Thenar Atrophy',
            examType: 'Musculoskeletal',
            description: 'Wasting of thenar eminence muscles (late finding)',
            diagnosticValue: 'Highly specific for severe CTS',
          },
        ],
      },

      progression: {
        naturalHistory:
          'Gradual progression from intermittent nocturnal symptoms to constant numbness and weakness. Without treatment, permanent nerve damage can occur.',
        timelineSteps: [
          {
            phaseId: 'cts-early',
            phase: 'early',
            displayName: 'Early/Intermittent',
            timeframe: 'Weeks to months',
            description: 'Intermittent numbness and tingling, especially at night or with prolonged hand use.',
            symptoms: ['Nocturnal numbness', 'Tingling with activity', 'Shaking hand to relieve symptoms'],
            anatomicalChanges: [
              {
                structureId: 'median-nerve',
                structureName: 'Median Nerve',
                changeType: 'edema',
                description: 'Early nerve compression with reversible conduction changes',
                severity: 'mild',
                visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
              {
                structureId: 'carpal-tunnel',
                structureName: 'Carpal Tunnel',
                changeType: 'inflammation',
                description: 'Tenosynovitis of flexor tendons within the tunnel',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.4 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Wrist splinting at night', 'Activity modification'],
            goalsOfCare: ['Symptom relief', 'Prevent progression'],
          },
          {
            phaseId: 'cts-moderate',
            phase: 'established',
            displayName: 'Moderate/Persistent',
            timeframe: 'Months to years',
            description: 'Constant numbness with daytime symptoms and early weakness.',
            symptoms: ['Constant numbness in fingers', 'Daytime symptoms', 'Dropping objects', 'Difficulty with buttons'],
            anatomicalChanges: [
              {
                structureId: 'median-nerve',
                structureName: 'Median Nerve',
                changeType: 'degeneration',
                description: 'Segmental demyelination of median nerve fibers',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 },
                isNewAtPhase: false,
              },
              {
                structureId: 'thenar-muscles',
                structureName: 'Thenar Muscles',
                changeType: 'atrophy',
                description: 'Early thenar muscle weakening',
                severity: 'mild',
                visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.4 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Corticosteroid injection', 'Splinting', 'Consider surgery'],
            goalsOfCare: ['Prevent permanent nerve damage', 'Restore hand function'],
          },
          {
            phaseId: 'cts-severe',
            phase: 'severe',
            displayName: 'Severe/Advanced',
            timeframe: 'Years',
            description: 'Permanent nerve damage with thenar atrophy and loss of sensation.',
            symptoms: ['Thenar atrophy', 'Constant numbness', 'Severe grip weakness', 'Loss of fine motor control'],
            anatomicalChanges: [
              {
                structureId: 'median-nerve',
                structureName: 'Median Nerve',
                changeType: 'degeneration',
                description: 'Axonal degeneration with Wallerian degeneration',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.8 },
                isNewAtPhase: false,
              },
              {
                structureId: 'thenar-muscles',
                structureName: 'Thenar Muscles',
                changeType: 'atrophy',
                description: 'Visible thenar muscle wasting',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.7 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'irreversible',
            typicalTreatments: ['Carpal tunnel release surgery'],
            goalsOfCare: ['Prevent further damage', 'Maximize remaining function'],
          },
        ],
        prognosis:
          'Excellent with early treatment. Surgery has >90% success rate. Delayed treatment may result in permanent weakness and sensory loss.',
      },

      complications: [
        {
          complicationId: 'cts-thenar-atrophy',
          name: 'Permanent Thenar Atrophy',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Irreversible wasting of thenar muscles from prolonged nerve compression.',
          mechanism: 'Axonal degeneration of motor fibers to thenar muscles',
          affectedStructures: [
            {
              structureId: 'thenar-muscles',
              structureName: 'Thenar Muscles',
              effect: 'Muscle atrophy and weakness',
              highlightColor: '#dc2626',
            },
          ],
          warningSymptoms: ['Visible flattening of thumb base', 'Inability to oppose thumb'],
          prevention: ['Early surgical intervention when conservative measures fail'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'cts-splinting',
          name: 'Wrist Splinting',
          modality: 'supportive',
          description: 'Night-time neutral wrist splint to reduce carpal tunnel pressure.',
          efficacy: 'moderately-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Reduce nocturnal symptoms', 'Prevent wrist flexion during sleep'],
          timeToEffect: '2-4 weeks',
          explanations: {
            level1: 'A wrist brace worn at night to take pressure off the nerve.',
            level2: 'Wearing a wrist splint at night keeps your wrist straight, reducing pressure on the nerve.',
            level3: 'Neutral wrist splint maintains tunnel volume. Most effective for mild-moderate CTS with primarily nocturnal symptoms.',
            level4: 'Randomized trials show NNT ~3 at 4 weeks. Neutral position minimizes carpal tunnel pressure (lowest at 0-2 degrees extension).',
            level5: 'Splinting reduces intra-tunnel pressure from ~30mmHg (flexion) to ~2mmHg (neutral). Allows resolution of nerve edema and restoration of epineural blood flow.',
          },
        },
        {
          treatmentId: 'cts-surgery',
          name: 'Carpal Tunnel Release',
          modality: 'surgical',
          description: 'Surgical division of the transverse carpal ligament to decompress the median nerve.',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established', 'severe'],
          goals: ['Permanent decompression of median nerve', 'Restore hand function'],
          timeToEffect: 'Days to weeks for symptom relief, months for full recovery',
          explanations: {
            level1: 'A small surgery to release pressure on the nerve in your wrist.',
            level2: 'Surgery cuts the ligament pressing on your nerve. It is very effective and recovery takes a few weeks.',
            level3: 'Open or endoscopic release of transverse carpal ligament. >90% success rate. Indicated when conservative treatment fails or for moderate-severe CTS.',
            level4: 'Meta-analyses show surgical superiority over splinting at 6-12 months. Endoscopic approach has faster return to work but similar long-term outcomes.',
            level5: 'Division of flexor retinaculum increases carpal tunnel volume by ~24%. Nerve recovery depends on degree of pre-operative axonal loss. NCS improvement lags clinical improvement.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'median-nerve',
            structureName: 'Median Nerve',
            role: 'primary-site',
            involvement: 'Compressed at the carpal tunnel',
            highlightColor: '#f97316',
            showByDefault: true,
          },
          {
            structureId: 'carpal-tunnel',
            structureName: 'Carpal Tunnel',
            role: 'primary-site',
            involvement: 'Site of nerve compression',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'thenar-muscles',
            structureName: 'Thenar Muscles',
            role: 'target-organ',
            involvement: 'Denervation from motor fiber damage',
            highlightColor: '#ef4444',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Musculoskeletal', 'Neurologic'],
        recommendedView: 'anterior',
        recommendedLayers: ['musculoskeletal', 'nervous'],
      },

      explanations: {
        level1: 'A pinched nerve in the wrist that causes numbness and tingling in the hand.',
        level2: 'The median nerve gets squeezed in a tight tunnel in the wrist, causing numbness, pain, and weakness in the hand.',
        level3: 'Compressive neuropathy of the median nerve at the carpal tunnel. Diagnosed by history, exam (Phalen/Tinel), and nerve conduction studies.',
        level4: 'Most common entrapment neuropathy. Elevated carpal tunnel pressure causes segmental demyelination, then axonal loss. EMG/NCS grades severity.',
        level5: 'Carpal tunnel pressure >30mmHg causes nerve ischemia. Chronic compression leads to subperineurial edema, demyelination, and fibrosis. Severe cases show Wallerian degeneration with incomplete recovery post-release.',
      },

      relatedConditions: ['rheumatoid-arthritis', 'hypothyroidism', 'type-2-diabetes'],
      comorbidities: ['hypothyroidism', 'type-2-diabetes', 'obesity'],
      epidemiology: {
        prevalence: '3-6% of adults',
        demographics: '3x more common in women, peak age 40-60',
      },
      clinicalPearls: [
        'Nocturnal symptoms are the hallmark of early CTS',
        'Consider bilateral NCS even if symptoms are unilateral',
        'Pregnancy-related CTS usually resolves postpartum',
        'Thenar atrophy is a late sign indicating severe, potentially irreversible damage',
      ],
      patientEducation: [
        'Wear your wrist splint every night',
        'Take breaks from repetitive hand activities',
        'Ergonomic modifications at work can help prevent worsening',
        'Surgery is very effective if needed - do not wait until muscles waste',
      ],
      emergencyWarnings: [
        'Sudden complete numbness in the hand',
        'Rapid loss of hand strength',
        'Symptoms after wrist trauma (may indicate fracture)',
      ],
    },
  ],

  // allergic-rhinitis entry removed: duplicate of seasonal-allergies

  // ============================================
  // MUSCULOSKELETAL: Plantar Fasciitis
  // ============================================
  [
    'plantar-fasciitis',
    {
      conditionId: 'plantar-fasciitis',
      name: 'Plantar Fasciitis',
      aliases: ['Heel Pain', 'Plantar Heel Pain', 'Plantar Fasciopathy'],
      icdCode: 'M72.2',
      category: 'musculoskeletal',
      subcategory: 'Foot and Ankle',
      description:
        'Degenerative condition of the plantar fascia at its calcaneal insertion, causing heel pain that is characteristically worst with first steps in the morning.',

      pathophysiology: {
        summary:
          'Repetitive microtrauma to the plantar fascia causes collagen degeneration rather than true inflammation, leading to pain and thickening at the calcaneal origin.',
        mechanisms: [
          {
            name: 'Plantar Fascia Degeneration',
            description:
              'Repetitive tensile loading causes microtears, collagen disorganization, and angiofibroblastic degeneration.',
            systemsInvolved: ['Musculoskeletal'],
            keyMediators: ['VEGF', 'Substance P', 'Matrix metalloproteinases'],
            contribution: 'Primary mechanism of chronic heel pain',
          },
          {
            name: 'Biomechanical Overload',
            description:
              'Excessive pronation, tight Achilles tendon, or high BMI increases tensile stress on the plantar fascia.',
            systemsInvolved: ['Musculoskeletal'],
            contribution: 'Predisposes to repetitive injury',
          },
        ],
        riskFactors: [
          {
            name: 'Obesity',
            type: 'modifiable',
            impact: 'major',
            description: 'Increased load on the plantar fascia with each step',
            intervention: 'Weight management',
          },
          {
            name: 'Prolonged Standing',
            type: 'modifiable',
            impact: 'major',
            description: 'Occupations requiring prolonged standing on hard surfaces',
            intervention: 'Supportive footwear, anti-fatigue mats',
          },
          {
            name: 'Tight Achilles Tendon',
            type: 'modifiable',
            impact: 'moderate',
            description: 'Reduced ankle dorsiflexion increases plantar fascia strain',
            intervention: 'Stretching exercises',
          },
          {
            name: 'Running/Athletics',
            type: 'modifiable',
            impact: 'moderate',
            description: 'High-impact activities and sudden increase in training load',
            intervention: 'Gradual training progression, proper footwear',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'First-Step Pain',
            prevalence: 'very-common',
            description: 'Sharp heel pain with first steps in the morning or after prolonged sitting',
            quality: 'Sharp, stabbing',
            location: 'Medial calcaneal tubercle',
            timing: 'Worst in morning, improves then worsens with prolonged activity',
          },
          {
            name: 'Heel Pain with Activity',
            prevalence: 'very-common',
            description: 'Pain after prolonged standing or walking',
          },
        ],
        physicalFindings: [
          {
            name: 'Point Tenderness',
            examType: 'Musculoskeletal',
            description: 'Tenderness at the medial calcaneal tubercle',
            diagnosticValue: 'Most specific clinical finding',
          },
          {
            name: 'Windlass Test',
            examType: 'Musculoskeletal',
            description: 'Pain with passive dorsiflexion of great toe',
            diagnosticValue: 'Sensitivity ~32%, specificity ~100%',
          },
        ],
      },

      progression: {
        naturalHistory:
          'Self-limiting in most cases (80-90% resolve within 12 months). However, can become chronic and debilitating without proper treatment.',
        timelineSteps: [
          {
            phaseId: 'pf-acute',
            phase: 'acute',
            displayName: 'Acute Phase',
            timeframe: '0-6 weeks',
            description: 'Initial onset of heel pain, often after change in activity or footwear.',
            symptoms: ['Morning heel pain', 'Pain after rest', 'Tenderness at heel'],
            anatomicalChanges: [
              {
                structureId: 'plantar-fascia',
                structureName: 'Plantar Fascia',
                changeType: 'inflammation',
                description: 'Acute inflammatory response at calcaneal insertion',
                severity: 'mild',
                visualIndicator: { color: '#fbbf24', pulse: true, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Rest', 'Ice', 'Stretching', 'NSAIDs', 'Supportive shoes'],
            goalsOfCare: ['Pain relief', 'Activity modification'],
          },
          {
            phaseId: 'pf-subacute',
            phase: 'subacute',
            displayName: 'Subacute/Degenerative',
            timeframe: '6 weeks to 6 months',
            description: 'Transition from inflammation to degeneration if symptoms persist.',
            symptoms: ['Persistent morning pain', 'Pain with prolonged standing', 'Heel stiffness'],
            anatomicalChanges: [
              {
                structureId: 'plantar-fascia',
                structureName: 'Plantar Fascia',
                changeType: 'degeneration',
                description: 'Collagen degeneration and thickening of plantar fascia',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: true, opacity: 0.6 },
                isNewAtPhase: false,
              },
              {
                structureId: 'calcaneus',
                structureName: 'Calcaneus',
                changeType: 'calcification',
                description: 'Heel spur formation at fascia attachment',
                severity: 'mild',
                visualIndicator: { color: '#78716c', pulse: false, opacity: 0.4 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Physical therapy', 'Orthotic insoles', 'Night splints'],
            goalsOfCare: ['Restore function', 'Prevent chronicity'],
          },
          {
            phaseId: 'pf-chronic',
            phase: 'chronic',
            displayName: 'Chronic Plantar Fasciopathy',
            timeframe: '6+ months',
            description: 'Persistent symptoms despite conservative treatment. Degenerative changes predominate.',
            symptoms: ['Chronic heel pain', 'Altered gait', 'Activity limitation', 'Pain affecting daily life'],
            anatomicalChanges: [
              {
                structureId: 'plantar-fascia',
                structureName: 'Plantar Fascia',
                changeType: 'degeneration',
                description: 'Chronic degenerative changes with marked thickening',
                severity: 'severe',
                visualIndicator: { color: '#dc2626', pulse: true, opacity: 0.7 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Shockwave therapy', 'PRP injection', 'Consider surgery'],
            goalsOfCare: ['Pain management', 'Restore mobility'],
          },
        ],
        prognosis:
          '80-90% resolve within 12 months with conservative treatment. Refractory cases may benefit from extracorporeal shockwave therapy or surgical release.',
      },

      complications: [
        {
          complicationId: 'pf-chronic-pain',
          name: 'Chronic Heel Pain',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Persistent pain lasting beyond 12 months despite treatment.',
          mechanism: 'Ongoing fascial degeneration and central pain sensitization',
          affectedStructures: [
            {
              structureId: 'plantar-fascia',
              structureName: 'Plantar Fascia',
              effect: 'Chronic degeneration',
              highlightColor: '#dc2626',
            },
          ],
          warningSymptoms: ['Pain lasting >12 months', 'Inability to walk normally'],
          prevention: ['Early aggressive conservative treatment', 'Address biomechanical factors'],
          preventable: true,
        },
        {
          complicationId: 'pf-compensatory',
          name: 'Compensatory Injuries',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Altered gait from heel pain leads to knee, hip, or back problems.',
          mechanism: 'Compensatory gait changes redistribute forces abnormally',
          affectedStructures: [
            {
              structureId: 'knee-joint',
              structureName: 'Knee Joint',
              effect: 'Altered loading from compensatory gait',
              highlightColor: '#f97316',
            },
          ],
          warningSymptoms: ['New knee or hip pain', 'Back pain', 'Limping'],
          prevention: ['Address biomechanics', 'Physical therapy for gait correction'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'pf-stretching',
          name: 'Stretching and Physical Therapy',
          modality: 'rehabilitative',
          description: 'Plantar fascia-specific stretching and calf stretching program.',
          efficacy: 'effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['acute', 'subacute', 'chronic'],
          goals: ['Reduce fascial tension', 'Improve flexibility', 'Reduce pain'],
          timeToEffect: '2-8 weeks',
          explanations: {
            level1: 'Stretching exercises for your foot and calf to reduce heel pain.',
            level2: 'Specific stretches for the bottom of your foot and calf muscles help relieve tension on the painful area.',
            level3: 'Plantar fascia-specific stretching (dorsiflexion of toes) superior to Achilles stretching alone. High-load strength training also effective.',
            level4: 'RCTs show plantar fascia-specific stretching superior to calf stretching. Eccentric loading protocols may promote tissue remodeling.',
            level5: 'Mechanical loading stimulates tenocyte activity and collagen synthesis. Windlass mechanism-based stretching targets the degenerated enthesis directly.',
          },
        },
        {
          treatmentId: 'pf-orthotics',
          name: 'Orthotic Insoles',
          modality: 'supportive',
          description: 'Arch-supporting insoles to redistribute plantar pressure.',
          efficacy: 'moderately-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: true,
          appropriatePhases: ['acute', 'subacute', 'chronic'],
          goals: ['Reduce plantar fascia strain', 'Improve foot biomechanics'],
          timeToEffect: '2-4 weeks',
          explanations: {
            level1: 'Special shoe inserts that support your foot and reduce heel pain.',
            level2: 'Insoles that support your arch and cushion your heel to take pressure off the painful area.',
            level3: 'Prefabricated orthotics equally effective as custom in most studies. Key feature is arch support, not just heel cushioning.',
            level4: 'Systematic reviews show orthotics provide short-term benefit. No significant difference between custom and prefabricated in most trials.',
            level5: 'Orthotics reduce peak plantar pressure by ~12% and decrease fascial strain by supporting the medial longitudinal arch during mid-stance.',
          },
        },
        {
          treatmentId: 'pf-shockwave',
          name: 'Extracorporeal Shockwave Therapy',
          modality: 'interventional',
          description: 'Acoustic waves applied to the heel to promote tissue healing.',
          efficacy: 'moderately-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['subacute', 'chronic'],
          goals: ['Stimulate tissue repair', 'Reduce chronic pain'],
          timeToEffect: '4-12 weeks',
          explanations: {
            level1: 'A treatment that uses sound waves to help your heel heal.',
            level2: 'Shockwave therapy sends energy pulses to your heel to stimulate healing of the damaged tissue.',
            level3: 'ESWT recommended for chronic plantar fasciitis (>6 months) refractory to conservative treatment. Both focused and radial modalities used.',
            level4: 'Meta-analyses show ESWT superior to placebo for chronic PF. Mechanism involves neovascularization, growth factor release, and pain gate modulation.',
            level5: 'Mechanotransduction stimulates TGF-beta1, VEGF, and eNOS expression. Cavitation effects disrupt calcified tissue. Hyperstimulation analgesia via A-beta fiber activation.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'plantar-fascia',
            structureName: 'Plantar Fascia',
            role: 'primary-site',
            involvement: 'Degeneration at calcaneal insertion',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
          {
            structureId: 'calcaneus',
            structureName: 'Calcaneus',
            role: 'primary-site',
            involvement: 'Attachment point of plantar fascia',
            highlightColor: '#f97316',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'achilles-tendon',
            structureName: 'Achilles Tendon',
            role: 'collateral',
            involvement: 'Tight Achilles contributes to fascial strain',
            highlightColor: '#fbbf24',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Musculoskeletal'],
        recommendedView: 'lateral-left',
        recommendedLayers: ['musculoskeletal'],
      },

      explanations: {
        level1: 'A common cause of heel pain from strain on the bottom of the foot.',
        level2: 'The thick band of tissue on the bottom of the foot becomes damaged and painful, especially in the morning.',
        level3: 'Degenerative fasciopathy (not true fasciitis) at the calcaneal enthesis. Diagnosis is clinical. Imaging rarely needed.',
        level4: 'Histopathology shows angiofibroblastic degeneration, not inflammation. Risk factors include BMI >30, limited dorsiflexion, and prolonged standing.',
        level5: 'Chronic degenerative tendinopathy with collagen disarray, ground substance mucoid change, and neovascularization. Enthesopathy model with failed healing response.',
      },

      relatedConditions: ['achilles-tendinopathy', 'tarsal-tunnel-syndrome'],
      comorbidities: ['obesity', 'type-2-diabetes'],
      epidemiology: {
        prevalence: '~10% lifetime risk',
        demographics: 'Peak age 40-60, more common in runners and obese individuals',
      },
      clinicalPearls: [
        'First-step pain is the hallmark symptom',
        'Heel spurs are present in 50% but are not the cause of pain',
        'Night splints can be very effective for morning pain',
        'Most cases resolve with conservative treatment within 12 months',
      ],
      patientEducation: [
        'Stretch your foot before getting out of bed',
        'Wear supportive shoes - avoid flat shoes and going barefoot',
        'Ice the bottom of your foot for 15 minutes after activity',
        'Be patient - recovery takes weeks to months',
      ],
      emergencyWarnings: [
        'Sudden pop in the heel with acute severe pain (possible plantar fascia rupture)',
        'Heel pain with fever or redness (possible infection)',
      ],
    },
  ],

  // ============================================
  // NEUROLOGIC: Tension Headache
  // ============================================
  [
    'tension-headache',
    {
      conditionId: 'tension-headache',
      name: 'Tension Headache',
      aliases: ['Tension-Type Headache', 'TTH', 'Stress Headache', 'Muscle Contraction Headache'],
      icdCode: 'G44.2',
      category: 'neurologic',
      subcategory: 'Primary Headache Disorders',
      description:
        'Most common primary headache disorder, characterized by bilateral, pressing/tightening pain of mild-to-moderate intensity without associated nausea or photophobia.',

      pathophysiology: {
        summary:
          'Complex interplay of peripheral myofascial mechanisms and central pain sensitization, with pericranial muscle tenderness being a hallmark finding.',
        mechanisms: [
          {
            name: 'Peripheral Myofascial Mechanism',
            description:
              'Increased pericranial muscle tension and tenderness from sustained contraction, stress, or poor posture.',
            systemsInvolved: ['Neurologic', 'Musculoskeletal'],
            keyMediators: ['Substance P', 'CGRP', 'Nitric oxide'],
            contribution: 'Primary mechanism in episodic TTH',
          },
          {
            name: 'Central Sensitization',
            description:
              'Repeated peripheral nociceptive input leads to sensitization of second-order neurons in the trigeminal nucleus caudalis.',
            systemsInvolved: ['Neurologic'],
            keyMediators: ['NMDA receptors', 'Serotonin', 'Nitric oxide'],
            contribution: 'Drives transformation to chronic TTH',
          },
        ],
        riskFactors: [
          {
            name: 'Psychological Stress',
            type: 'modifiable',
            impact: 'major',
            description: 'Most common trigger, causing muscle tension and central sensitization',
            intervention: 'Stress management, CBT, relaxation techniques',
          },
          {
            name: 'Poor Posture',
            type: 'modifiable',
            impact: 'moderate',
            description: 'Forward head posture and prolonged screen use',
            intervention: 'Ergonomic corrections, posture exercises',
          },
          {
            name: 'Sleep Disturbance',
            type: 'modifiable',
            impact: 'moderate',
            description: 'Insomnia and irregular sleep patterns',
            intervention: 'Sleep hygiene, consistent schedule',
          },
          {
            name: 'Medication Overuse',
            type: 'modifiable',
            impact: 'major',
            description: 'Frequent analgesic use (>15 days/month) can worsen chronic TTH',
            intervention: 'Analgesic restriction, preventive therapy',
          },
        ],
      },

      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Bilateral Pressing Headache',
            prevalence: 'very-common',
            description: 'Band-like pressure or tightness around the head',
            quality: 'Pressing, tightening (non-pulsating)',
            location: 'Bilateral, frontal-occipital',
          },
          {
            name: 'Mild-Moderate Intensity',
            prevalence: 'very-common',
            description: 'Pain does not prohibit activities (unlike migraine)',
          },
        ],
        associatedSymptoms: [
          {
            name: 'Pericranial Tenderness',
            prevalence: 'common',
            description: 'Tenderness of scalp, neck, and shoulder muscles on palpation',
          },
        ],
        physicalFindings: [
          {
            name: 'Pericranial Muscle Tenderness',
            examType: 'Neurologic',
            description: 'Increased tenderness on manual palpation of pericranial muscles',
            diagnosticValue: 'Most significant abnormal finding in TTH',
          },
        ],
      },

      progression: {
        naturalHistory:
          'Episodic TTH is common and self-limiting. Can progress to chronic TTH (>15 days/month) with central sensitization. Chronic TTH is one of the most disabling headache disorders.',
        timelineSteps: [
          {
            phaseId: 'tth-episodic-infrequent',
            phase: 'early',
            displayName: 'Infrequent Episodic',
            timeframe: '<1 day per month',
            description: 'Rare episodes triggered by identifiable stressors. Minimal impact on daily life.',
            symptoms: ['Occasional band-like headache', 'Mild pain', 'Resolves with rest or OTC analgesics'],
            anatomicalChanges: [
              {
                structureId: 'pericranial-muscles',
                structureName: 'Pericranial Muscles',
                changeType: 'dysfunction',
                description: 'Intermittent increased muscle tension',
                severity: 'mild',
                visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.4 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Simple analgesics PRN', 'Stress management'],
            goalsOfCare: ['Acute symptom relief', 'Identify triggers'],
          },
          {
            phaseId: 'tth-episodic-frequent',
            phase: 'established',
            displayName: 'Frequent Episodic',
            timeframe: '1-14 days per month',
            description: 'More frequent episodes, beginning to affect quality of life. Risk of progression with analgesic overuse.',
            symptoms: ['Regular headache episodes', 'Moderate impact on activities', 'Pericranial tenderness'],
            anatomicalChanges: [
              {
                structureId: 'pericranial-muscles',
                structureName: 'Pericranial Muscles',
                changeType: 'dysfunction',
                description: 'Persistent increased muscle tension and tenderness',
                severity: 'moderate',
                visualIndicator: { color: '#f97316', pulse: true, opacity: 0.5 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Analgesics (limit frequency)', 'Consider preventive therapy', 'Physical therapy'],
            goalsOfCare: ['Reduce frequency', 'Prevent chronification', 'Avoid medication overuse'],
          },
          {
            phaseId: 'tth-chronic',
            phase: 'chronic',
            displayName: 'Chronic TTH',
            timeframe: '>15 days per month for >3 months',
            description: 'Near-daily headache with central sensitization. Major impact on quality of life and function.',
            symptoms: ['Near-daily headache', 'Constant tightness', 'Significant functional impairment', 'Often comorbid depression'],
            anatomicalChanges: [
              {
                structureId: 'pericranial-muscles',
                structureName: 'Pericranial Muscles',
                changeType: 'dysfunction',
                description: 'Chronic muscle tension with pain sensitization',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 },
                isNewAtPhase: false,
              },
              {
                structureId: 'trigeminal-nucleus',
                structureName: 'Trigeminal Nucleus Caudalis',
                changeType: 'dysfunction',
                description: 'Central sensitization of pain processing pathways',
                severity: 'moderate',
                visualIndicator: { color: '#8b5cf6', pulse: true, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Amitriptyline', 'CBT', 'Physical therapy', 'Withdraw analgesics if overused'],
            goalsOfCare: ['Reduce headache frequency', 'Address central sensitization', 'Treat comorbidities'],
          },
        ],
        prognosis:
          'Episodic TTH has excellent prognosis. Chronic TTH is challenging but can improve with multimodal treatment. Medication overuse must be addressed.',
      },

      complications: [
        {
          complicationId: 'tth-medication-overuse',
          name: 'Medication Overuse Headache',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'high',
          description: 'Paradoxical worsening of headaches from frequent analgesic use.',
          mechanism: 'Downregulation of endogenous pain modulation from chronic analgesic exposure',
          affectedStructures: [
            {
              structureId: 'brain',
              structureName: 'Brain',
              effect: 'Altered pain processing',
              highlightColor: '#dc2626',
            },
          ],
          warningSymptoms: ['Needing pain medication >2-3 days per week', 'Headaches worsening despite treatment', 'Rebound headaches when medication wears off'],
          prevention: ['Limit acute analgesic use to <10-15 days/month', 'Start preventive therapy early'],
          treatment: 'Analgesic withdrawal with bridge therapy',
          preventable: true,
        },
        {
          complicationId: 'tth-chronification',
          name: 'Chronification',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Transformation from episodic to chronic TTH with daily or near-daily headaches.',
          mechanism: 'Central sensitization from repeated peripheral nociceptive input',
          affectedStructures: [
            {
              structureId: 'trigeminal-nucleus',
              structureName: 'Trigeminal Nucleus',
              effect: 'Central pain sensitization',
              highlightColor: '#8b5cf6',
            },
          ],
          warningSymptoms: ['Increasing headache frequency', 'Headaches becoming harder to treat', 'Need for more frequent medication'],
          prevention: ['Early preventive treatment', 'Stress management', 'Avoid analgesic overuse'],
          preventable: true,
        },
      ],

      treatmentOptions: [
        {
          treatmentId: 'tth-simple-analgesics',
          name: 'Simple Analgesics',
          modality: 'pharmacological',
          description: 'Over-the-counter pain medications for acute episodes.',
          mechanism: 'COX inhibition (NSAIDs) or central analgesic action (acetaminophen)',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established'],
          goals: ['Acute pain relief'],
          timeToEffect: '30-60 minutes',
          medicationIds: ['ibuprofen', 'acetaminophen', 'aspirin'],
          explanations: {
            level1: 'Common pain medicines like ibuprofen or acetaminophen to treat headache.',
            level2: 'Over-the-counter pain relievers are the first choice for tension headaches. Use only as needed, not daily.',
            level3: 'NSAIDs (ibuprofen 400mg, aspirin 1000mg) more effective than acetaminophen. Limit to <15 days/month to avoid MOH.',
            level4: 'NNT ~3 for ibuprofen 400mg. Combination analgesics (aspirin + acetaminophen + caffeine) superior to single agents. Monitor for MOH.',
            level5: 'Peripheral COX-2 inhibition reduces prostaglandin-mediated sensitization of myofascial nociceptors. Central analgesic action via descending pain modulation.',
          },
        },
        {
          treatmentId: 'tth-amitriptyline',
          name: 'Amitriptyline (Preventive)',
          modality: 'pharmacological',
          description: 'Low-dose tricyclic antidepressant for prevention of chronic TTH.',
          mechanism: 'Inhibits serotonin and norepinephrine reuptake, modulates central pain processing',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['established', 'chronic'],
          goals: ['Reduce headache frequency', 'Address central sensitization'],
          timeToEffect: '4-8 weeks',
          medicationIds: ['amitriptyline'],
          explanations: {
            level1: 'A daily medicine to prevent headaches from happening.',
            level2: 'A low-dose antidepressant that prevents headaches by calming the nerves in your head.',
            level3: 'Amitriptyline 10-75mg at bedtime is first-line preventive for chronic TTH. Analgesic effect independent of antidepressant action.',
            level4: 'NNT ~3 for chronic TTH. Start 10-25mg, titrate to effect. Alternatives: venlafaxine, mirtazapine. Combine with non-pharmacologic approaches.',
            level5: 'Modulates descending serotonergic and noradrenergic pain inhibition. May also block NMDA receptors and sodium channels. Reduces central sensitization over weeks.',
          },
        },
        {
          treatmentId: 'tth-physical-therapy',
          name: 'Physical Therapy and Manual Therapy',
          modality: 'rehabilitative',
          description: 'Exercises and manual techniques targeting pericranial muscle tension.',
          efficacy: 'moderately-effective',
          evidenceLevel: 'level-1b',
          isFirstLine: false,
          appropriatePhases: ['established', 'chronic'],
          goals: ['Reduce muscle tension', 'Improve posture', 'Decrease headache frequency'],
          timeToEffect: '4-8 weeks',
          explanations: {
            level1: 'Exercises and massage to relax the tight muscles causing headaches.',
            level2: 'Physical therapy uses exercises, stretches, and hands-on techniques to relieve muscle tension that causes headaches.',
            level3: 'Manual therapy, cervical exercises, and postural correction. EMG biofeedback also effective. Combination with medication superior to either alone.',
            level4: 'Meta-analyses support multimodal physical therapy. Myofascial trigger point therapy may reduce pericranial tenderness. Exercise reduces headache days by ~2/month.',
            level5: 'Manual therapy likely modulates segmental spinal cord inhibition and descending pain control. Exercise increases endogenous opioid release and modulates conditioned pain modulation.',
          },
        },
      ],

      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'pericranial-muscles',
            structureName: 'Pericranial Muscles',
            role: 'primary-site',
            involvement: 'Increased tension and tenderness',
            highlightColor: '#f97316',
            showByDefault: true,
          },
          {
            structureId: 'trapezius',
            structureName: 'Trapezius Muscle',
            role: 'primary-site',
            involvement: 'Neck and shoulder tension contributing to headache',
            highlightColor: '#ef4444',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'trigeminal-nucleus',
            structureName: 'Trigeminal Nucleus Caudalis',
            role: 'secondary-site',
            involvement: 'Central pain processing and sensitization',
            highlightColor: '#8b5cf6',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Neurologic', 'Musculoskeletal'],
        recommendedView: 'posterior',
        recommendedLayers: ['musculoskeletal', 'nervous'],
      },

      explanations: {
        level1: 'The most common type of headache, feeling like a tight band around your head.',
        level2: 'Tension headaches cause a pressing, tightening pain on both sides of the head, often from muscle tension and stress.',
        level3: 'Primary headache disorder with bilateral pressing quality. Classified as infrequent episodic, frequent episodic, or chronic by ICHD-3 criteria.',
        level4: 'Most prevalent primary headache. Peripheral myofascial and central sensitization mechanisms. Chronic TTH (>15 days/month) is distinct entity requiring preventive treatment.',
        level5: 'Peripheral sensitization of myofascial nociceptors drives episodic TTH. Chronic TTH involves NMDA-mediated central sensitization, impaired supraspinal pain modulation, and reduced conditioned pain modulation.',
      },

      relatedConditions: ['migraine', 'medication-overuse-headache', 'cervicogenic-headache'],
      comorbidities: ['major-depression', 'anxiety-disorder', 'insomnia'],
      epidemiology: {
        prevalence: '~40% annual prevalence',
        demographics: 'Most common headache type, affects all ages and demographics',
      },
      clinicalPearls: [
        'Distinguish from migraine: TTH is bilateral, pressing, mild-moderate, no nausea/aura',
        'Pericranial muscle tenderness is the most consistent exam finding',
        'Always screen for medication overuse in frequent TTH',
        'Amitriptyline is the best-evidenced preventive for chronic TTH',
      ],
      patientEducation: [
        'Limit pain medication to no more than 2-3 days per week',
        'Regular exercise helps prevent headaches',
        'Stress management and good sleep habits are important',
        'Track your headache diary to identify triggers and patterns',
      ],
      emergencyWarnings: [
        'Thunderclap headache (worst headache of life)',
        'Headache with fever, stiff neck, or confusion',
        'New headache after age 50',
        'Headache with neurological symptoms (weakness, vision changes, speech difficulty)',
      ],
    },
  ],

  // ============================================
  // IMMUNOLOGIC: Seasonal Allergies (Allergic Rhinitis)
  // ============================================
  [
    'seasonal-allergies',
    {
      conditionId: 'seasonal-allergies',
      name: 'Seasonal Allergies (Allergic Rhinitis)',
      aliases: ['Allergic Rhinitis', 'Hay Fever', 'Seasonal Allergic Rhinitis', 'SAR'],
      icdCode: 'J30.1',
      category: 'immunologic',
      subcategory: 'Allergic Disorders',
      description:
        'IgE-mediated hypersensitivity reaction of the nasal mucosa to seasonal aeroallergens such as pollen, causing sneezing, rhinorrhea, nasal congestion, and ocular symptoms',
      pathophysiology: {
        summary:
          'Type I (immediate) hypersensitivity reaction where inhaled allergens bind IgE on mast cells in the nasal mucosa, triggering histamine release, inflammation, and both early and late-phase allergic responses',
        mechanisms: [
          {
            name: 'IgE-Mediated Mast Cell Degranulation',
            description:
              'Allergen cross-links surface IgE on mast cells, triggering degranulation with release of preformed mediators (histamine, tryptase) causing immediate symptoms',
            systemsInvolved: ['Immune', 'Respiratory'],
            keyMediators: ['Histamine', 'Tryptase', 'Heparin', 'TNF-alpha'],
            contribution: 'Drives the early-phase response (minutes) with sneezing, rhinorrhea, and itching',
          },
          {
            name: 'Late-Phase Allergic Response',
            description:
              'Recruitment of eosinophils, basophils, and T-helper 2 cells to the nasal mucosa 4-8 hours after exposure, causing sustained inflammation and nasal congestion',
            systemsInvolved: ['Immune', 'Respiratory'],
            keyMediators: ['Leukotrienes', 'IL-4', 'IL-5', 'IL-13', 'Eosinophil cationic protein'],
            contribution: 'Causes persistent nasal congestion and mucosal remodeling with chronic exposure',
          },
        ],
        riskFactors: [
          {
            name: 'Family History of Atopy',
            type: 'non-modifiable',
            impact: 'major',
            description: 'Genetic predisposition to produce IgE against environmental allergens (atopic triad: rhinitis, asthma, eczema)',
          },
          {
            name: 'Environmental Allergen Exposure',
            type: 'partially-modifiable',
            impact: 'major',
            description: 'Exposure to tree, grass, and weed pollens during their respective seasons',
            intervention: 'Pollen avoidance strategies, keeping windows closed, using HEPA filters',
          },
          {
            name: 'Air Pollution',
            type: 'partially-modifiable',
            impact: 'moderate',
            description: 'Particulate matter and diesel exhaust enhance allergic sensitization and symptom severity',
            intervention: 'Air quality monitoring, indoor air filtration',
          },
          {
            name: 'Early Childhood Infections/Hygiene',
            type: 'non-modifiable',
            impact: 'moderate',
            description: 'Hygiene hypothesis: reduced early microbial exposure may promote Th2 immune skewing and allergy development',
          },
        ],
      },
      clinicalPresentation: {
        primarySymptoms: [
          {
            name: 'Sneezing',
            prevalence: 'very-common',
            description: 'Paroxysmal sneezing, often in rapid succession, triggered by allergen exposure',
            timing: 'Seasonal pattern corresponding to pollen season',
          },
          {
            name: 'Rhinorrhea',
            prevalence: 'very-common',
            description: 'Clear, watery nasal discharge (anterior rhinorrhea)',
            quality: 'Clear, thin, watery',
            timing: 'Coincides with allergen exposure',
          },
          {
            name: 'Nasal Congestion',
            prevalence: 'very-common',
            description: 'Bilateral nasal obstruction from mucosal edema and secretions',
            timing: 'Often worse at night; predominant in late-phase response',
          },
          {
            name: 'Nasal and Ocular Itching',
            prevalence: 'very-common',
            description: 'Intense itching of the nose, palate, eyes, and ears',
            quality: 'Itching, tickling',
            location: 'Nose, palate, eyes, ears',
          },
        ],
        physicalFindings: [
          {
            name: 'Pale, Boggy Nasal Turbinates',
            examType: 'ENT',
            description: 'Swollen, pale-bluish nasal turbinates with clear secretions on anterior rhinoscopy',
            diagnosticValue: 'Characteristic of allergic rhinitis; distinguishes from infectious rhinitis (erythematous turbinates)',
          },
          {
            name: 'Allergic Shiners',
            examType: 'General',
            description: 'Dark circles under the eyes from venous congestion due to chronic nasal obstruction',
            diagnosticValue: 'Suggestive but not specific for allergic rhinitis',
          },
          {
            name: 'Allergic Salute',
            examType: 'General',
            description: 'Upward rubbing of the nose with the palm, especially in children, causing a transverse nasal crease',
            diagnosticValue: 'Classic sign in pediatric allergic rhinitis',
          },
        ],
      },
      progression: {
        naturalHistory:
          'Chronic condition with seasonal exacerbations. Onset typically in childhood or young adulthood. Symptoms may decrease with age but rarely resolve completely. Untreated, it increases risk of asthma, sinusitis, and otitis media.',
        timelineSteps: [
          {
            phaseId: 'ar-sensitization',
            phase: 'preclinical',
            displayName: 'Allergic Sensitization',
            timeframe: 'Months to years before symptoms',
            description: 'Immune system develops IgE antibodies against specific allergens without clinical symptoms',
            symptoms: ['No symptoms'],
            anatomicalChanges: [
              {
                structureId: 'nasal-mucosa',
                structureName: 'Nasal Mucosa',
                changeType: 'dysfunction',
                description: 'IgE-sensitized mast cells accumulate in nasal mucosa',
                severity: 'mild',
                visualIndicator: { color: '#fbbf24', pulse: false, opacity: 0.3 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['None needed'],
            goalsOfCare: ['Prevention in high-risk individuals'],
          },
          {
            phaseId: 'ar-early',
            phase: 'early',
            displayName: 'Early Symptomatic Phase',
            timeframe: 'First allergic seasons',
            description: 'Initial allergic symptoms during pollen season; symptoms may be mild and dismissed',
            symptoms: ['Occasional sneezing', 'Mild rhinorrhea', 'Itchy eyes', 'Nasal itching'],
            anatomicalChanges: [
              {
                structureId: 'nasal-mucosa',
                structureName: 'Nasal Mucosa',
                changeType: 'inflammation',
                description: 'Seasonal mucosal edema and eosinophilic infiltration',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 },
                isNewAtPhase: false,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Oral antihistamines as needed', 'Allergen avoidance'],
            goalsOfCare: ['Symptom relief', 'Identify triggers'],
          },
          {
            phaseId: 'ar-established',
            phase: 'established',
            displayName: 'Established Allergic Rhinitis',
            timeframe: 'Subsequent seasons',
            duration: 'Recurring annually',
            description: 'Predictable seasonal symptoms with nasal priming effect leading to increased sensitivity throughout the season',
            symptoms: ['Frequent sneezing', 'Profuse rhinorrhea', 'Nasal congestion', 'Itchy watery eyes', 'Fatigue'],
            anatomicalChanges: [
              {
                structureId: 'nasal-mucosa',
                structureName: 'Nasal Mucosa',
                changeType: 'inflammation',
                description: 'Recurrent eosinophilic inflammation with goblet cell hyperplasia',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: true, opacity: 0.6 },
                isNewAtPhase: false,
              },
              {
                structureId: 'nasal-turbinates',
                structureName: 'Nasal Turbinates',
                changeType: 'hypertrophy',
                description: 'Inferior turbinate hypertrophy from chronic inflammation',
                severity: 'moderate',
                visualIndicator: { color: '#ef4444', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'reversible',
            typicalTreatments: ['Intranasal corticosteroids', 'Second-generation antihistamines', 'Allergen avoidance'],
            goalsOfCare: ['Symptom control', 'Prevent complications', 'Maintain quality of life'],
          },
          {
            phaseId: 'ar-chronic',
            phase: 'chronic',
            displayName: 'Chronic with Complications',
            timeframe: 'Years',
            description: 'Longstanding allergic rhinitis with development of comorbid conditions and possible nasal remodeling',
            symptoms: ['Year-round nasal congestion', 'Reduced smell', 'Postnasal drip', 'Mouth breathing', 'Sleep disruption'],
            anatomicalChanges: [
              {
                structureId: 'nasal-mucosa',
                structureName: 'Nasal Mucosa',
                changeType: 'hypertrophy',
                description: 'Chronic mucosal remodeling with basement membrane thickening and subepithelial fibrosis',
                severity: 'moderate',
                visualIndicator: { color: '#dc2626', pulse: false, opacity: 0.7 },
                isNewAtPhase: false,
              },
              {
                structureId: 'sinuses',
                structureName: 'Paranasal Sinuses',
                changeType: 'inflammation',
                description: 'Mucosal thickening in sinuses, predisposing to chronic sinusitis',
                severity: 'mild',
                visualIndicator: { color: '#f97316', pulse: false, opacity: 0.5 },
                isNewAtPhase: true,
              },
            ],
            reversibility: 'partially-reversible',
            typicalTreatments: ['Allergen immunotherapy', 'Combination intranasal therapy', 'Treat comorbidities'],
            goalsOfCare: ['Disease modification', 'Address complications', 'Consider immunotherapy'],
          },
        ],
        progressionFactors: [
          'Continued allergen exposure',
          'Lack of treatment',
          'Comorbid asthma',
          'Polysensitization (multiple allergens)',
          'Environmental pollution',
        ],
        prognosis:
          'Chronic but manageable. Symptoms well-controlled with intranasal corticosteroids in most patients. Allergen immunotherapy can achieve long-term remission in 60-80% of patients.',
      },
      complications: [
        {
          complicationId: 'ar-sinusitis',
          name: 'Chronic Sinusitis',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'moderate',
          description: 'Chronic inflammation of the paranasal sinuses due to impaired drainage and mucosal inflammation',
          mechanism: 'Allergic nasal mucosal edema obstructs sinus ostia, trapping secretions and promoting bacterial colonization',
          affectedStructures: [
            {
              structureId: 'sinuses',
              structureName: 'Paranasal Sinuses',
              effect: 'Chronic mucosal inflammation and impaired drainage',
              highlightColor: '#f97316',
            },
          ],
          warningSymptoms: ['Facial pressure/pain', 'Purulent nasal discharge', 'Postnasal drip', 'Anosmia'],
          prevention: ['Intranasal corticosteroids', 'Nasal saline irrigation', 'Prompt treatment of rhinitis'],
          preventable: true,
        },
        {
          complicationId: 'ar-asthma',
          name: 'Allergic Asthma Development',
          category: 'chronic',
          severity: 'major',
          riskLevel: 'moderate',
          description: 'Development of allergic asthma in patients with allergic rhinitis (unified airway concept)',
          mechanism: 'Systemic Th2 inflammation and nasobronchial reflex contribute to lower airway hyperreactivity',
          affectedStructures: [
            {
              structureId: 'bronchi',
              structureName: 'Bronchial Airways',
              effect: 'Airway hyperresponsiveness and inflammation',
              highlightColor: '#ef4444',
            },
          ],
          warningSymptoms: ['Wheezing', 'Cough (especially at night)', 'Chest tightness', 'Exercise intolerance'],
          prevention: ['Optimal rhinitis treatment', 'Allergen immunotherapy'],
          preventable: true,
        },
        {
          complicationId: 'ar-quality-of-life',
          name: 'Sleep and Cognitive Impairment',
          category: 'chronic',
          severity: 'moderate',
          riskLevel: 'high',
          description: 'Nasal congestion disrupts sleep quality, causing daytime fatigue, poor concentration, and decreased productivity',
          mechanism: 'Nasal obstruction causes mouth breathing, sleep fragmentation, and reduced oxygen delivery during sleep',
          affectedStructures: [
            {
              structureId: 'nasal-passages',
              structureName: 'Nasal Passages',
              effect: 'Obstruction leading to mouth breathing and sleep disruption',
              highlightColor: '#f97316',
            },
          ],
          warningSymptoms: ['Daytime sleepiness', 'Poor concentration', 'Irritability', 'Impaired school/work performance'],
          prevention: ['Effective symptom control', 'Intranasal corticosteroids at bedtime'],
          preventable: true,
        },
      ],
      treatmentOptions: [
        {
          treatmentId: 'ar-intranasal-corticosteroid',
          name: 'Intranasal Corticosteroids',
          modality: 'pharmacological',
          description: 'Daily intranasal corticosteroid spray for comprehensive symptom control',
          mechanism: 'Reduces nasal mucosal inflammation by inhibiting multiple inflammatory pathways, decreasing eosinophil infiltration and mediator release',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'chronic'],
          goals: ['Control all nasal symptoms', 'Reduce nasal congestion', 'Prevent late-phase response'],
          expectedOutcomes: ['Significant improvement in all symptom domains within 1-2 weeks'],
          timeToEffect: 'Hours to days; peak effect at 1-2 weeks',
          sideEffects: ['Nasal dryness', 'Epistaxis (5-10%)', 'Rare septal perforation'],
          explanations: {
            level1: 'A nose spray you use daily that reduces swelling and inflammation inside your nose to stop allergy symptoms.',
            level2: 'Intranasal corticosteroid sprays like fluticasone are the most effective single treatment for allergic rhinitis. They reduce swelling, sneezing, runny nose, and congestion when used daily.',
            level3: 'First-line treatment for moderate-severe allergic rhinitis per all guidelines. Superior to antihistamines for nasal congestion. Begin 1-2 weeks before expected pollen season for best results. Safe for long-term use.',
            level4: 'Intranasal corticosteroids suppress multiple inflammatory pathways: reduce eosinophil recruitment, inhibit cytokine expression (IL-4, IL-5, IL-13), decrease mast cell numbers, and reduce vascular permeability. Superior to all other monotherapies across all symptom domains.',
            level5: 'Mechanism involves glucocorticoid receptor-mediated transrepression of NF-kB and AP-1, reducing transcription of pro-inflammatory genes. Topical bioavailability is high with minimal systemic absorption (fluticasone propionate <2%). No clinically significant HPA axis suppression at recommended doses.',
          },
        },
        {
          treatmentId: 'ar-antihistamine',
          name: 'Second-Generation Oral Antihistamines',
          modality: 'pharmacological',
          description: 'Non-sedating oral antihistamines for symptom relief',
          mechanism: 'Selective H1 receptor inverse agonists that block histamine-mediated symptoms without significant CNS sedation',
          efficacy: 'effective',
          evidenceLevel: 'level-1a',
          isFirstLine: true,
          appropriatePhases: ['early', 'established', 'chronic'],
          goals: ['Reduce sneezing and rhinorrhea', 'Relieve itching', 'Improve eye symptoms'],
          expectedOutcomes: ['Rapid relief of sneezing, rhinorrhea, itching; less effective for congestion'],
          timeToEffect: '1-3 hours',
          sideEffects: ['Minimal sedation', 'Rare headache'],
          costLevel: 'low',
          explanations: {
            level1: 'Allergy pills like cetirizine that stop sneezing and itching without making you very sleepy.',
            level2: 'Modern antihistamines (loratadine, cetirizine, fexofenadine) block histamine to reduce sneezing, itching, and runny nose with minimal drowsiness. Less effective for nasal stuffiness.',
            level3: 'First-line for mild allergic rhinitis and as add-on for moderate-severe. Effective for sneezing, rhinorrhea, itching, and ocular symptoms. Less effective for nasal congestion. Cetirizine most potent but slightly more sedating.',
            level4: 'Second-generation antihistamines are selective peripheral H1 inverse agonists with minimal blood-brain barrier penetration. Onset within 1 hour, duration 24 hours. Additional anti-inflammatory properties: reduce ICAM-1, eosinophil chemotaxis, and LTC4 release.',
            level5: 'H1 receptor inverse agonism stabilizes the receptor in inactive conformation. Second-generation agents have higher H1 affinity and additional anti-allergic effects including inhibition of NF-kB, reduced mast cell tryptase release, and decreased eotaxin expression.',
          },
        },
        {
          treatmentId: 'ar-immunotherapy',
          name: 'Allergen Immunotherapy',
          modality: 'preventive',
          description: 'Graduated exposure to specific allergens to achieve immune tolerance and disease modification',
          mechanism: 'Shifts immune response from Th2 to Th1/Treg phenotype, inducing blocking IgG4 antibodies and reducing IgE-mediated reactivity',
          efficacy: 'highly-effective',
          evidenceLevel: 'level-1a',
          isFirstLine: false,
          appropriatePhases: ['established', 'chronic'],
          goals: ['Long-term disease modification', 'Reduce medication need', 'Prevent asthma development'],
          expectedOutcomes: ['60-80% sustained improvement', 'Benefits persist years after completion'],
          timeToEffect: '3-6 months for clinical benefit; full course 3-5 years',
          sideEffects: ['Local reactions (common)', 'Systemic allergic reaction (rare)', 'Anaphylaxis (very rare with SCIT)'],
          costLevel: 'moderate',
          explanations: {
            level1: 'A treatment where you receive tiny amounts of what you are allergic to, so your body learns to tolerate it over time.',
            level2: 'Allergy shots or under-the-tongue tablets gradually expose you to small increasing doses of your allergens. Over 3-5 years, this retrains your immune system to stop overreacting.',
            level3: 'Disease-modifying therapy available as subcutaneous (SCIT) or sublingual (SLIT). Indicated for moderate-severe rhinitis inadequately controlled by medications. Prevents new sensitizations and asthma development. 3-5 year treatment course.',
            level4: 'Immunotherapy induces allergen-specific Treg cells producing IL-10 and TGF-beta, switching B cells from IgE to IgG4 production. SCIT requires in-office administration with observation; SLIT can be home-administered.',
            level5: 'Mechanism involves immune deviation from Th2 to Th1/Treg with increased IL-10 and IFN-gamma, decreased IL-4/IL-5. Blocking IgG4 antibodies compete with IgE for allergen binding. Mast cell and basophil desensitization reduces mediator release. SCIT risk of systemic reaction ~0.1% per injection. SLIT has superior safety profile.',
          },
        },
      ],
      anatomyMapping: {
        primaryStructures: [
          {
            structureId: 'nasal-mucosa',
            structureName: 'Nasal Mucosa',
            role: 'primary-site',
            involvement: 'Site of allergen deposition, IgE-mediated inflammation, and symptom generation',
            highlightColor: '#dc2626',
            showByDefault: true,
          },
          {
            structureId: 'nasal-turbinates',
            structureName: 'Nasal Turbinates',
            role: 'primary-site',
            involvement: 'Mucosal swelling causes nasal obstruction and congestion',
            highlightColor: '#ef4444',
            showByDefault: true,
          },
        ],
        secondaryStructures: [
          {
            structureId: 'sinuses',
            structureName: 'Paranasal Sinuses',
            role: 'secondary-site',
            involvement: 'Sinus ostia obstruction from mucosal edema',
            highlightColor: '#f97316',
            showByDefault: false,
          },
          {
            structureId: 'eyes',
            structureName: 'Conjunctivae',
            role: 'secondary-site',
            involvement: 'Allergic conjunctivitis with itching and tearing',
            highlightColor: '#eab308',
            showByDefault: false,
          },
        ],
        systemsInvolved: ['Immune', 'Respiratory', 'ENT'],
        recommendedView: 'anterior',
        recommendedLayers: ['respiratory'],
        focusRegion: 'head-sinuses',
      },
      explanations: {
        level1: 'Your body overreacts to pollen and other outdoor particles, causing sneezing, runny nose, and itchy eyes during certain times of year.',
        level2: 'Seasonal allergies happen when your immune system mistakes harmless pollen for a threat and releases histamine, causing inflammation in your nose and eyes. Nasal sprays and antihistamines are very effective.',
        level3: 'IgE-mediated Type I hypersensitivity to seasonal aeroallergens. ARIA classification: intermittent vs. persistent, mild vs. moderate-severe. First-line: intranasal corticosteroids. Consider immunotherapy for moderate-severe refractory disease.',
        level4: 'Allergic rhinitis involves both early-phase (mast cell, histamine) and late-phase (eosinophil, Th2 cytokine) responses. Nasal priming effect lowers threshold for symptoms throughout the season. Unified airway: treat rhinitis to improve asthma control.',
        level5: 'Allergen presentation by DCs to Th2 cells produces IL-4 (IgE class switching), IL-5 (eosinophil recruitment), IL-13 (mucus hypersecretion). IgE cross-linking on FceRI triggers mast cell degranulation via Syk kinase cascade. Late-phase infiltrate includes Th2 cells, eosinophils, and basophils. Epithelial-derived TSLP, IL-25, and IL-33 are key upstream activators of the Th2 cascade.',
      },
      relatedConditions: ['asthma', 'eczema', 'food-allergies'],
      comorbidities: ['asthma', 'atopic-dermatitis', 'allergic-conjunctivitis', 'chronic-sinusitis'],
      epidemiology: {
        prevalence: '10-30% of adults globally, up to 40% of children',
        demographics: 'Onset typically in childhood/adolescence, slight male predominance in children',
      },
      clinicalPearls: [
        'Intranasal corticosteroids are superior to oral antihistamines for all symptoms, especially congestion',
        'Start intranasal steroids 1-2 weeks before expected pollen season for best efficacy',
        'Allergic rhinitis increases asthma risk 3-fold — always assess for lower airway symptoms',
        'The allergic salute and transverse nasal crease are classic pediatric signs',
      ],
      patientEducation: [
        'Use your nasal spray daily during allergy season, even when you feel fine',
        'Check pollen counts and stay indoors when levels are high',
        'Shower and change clothes after being outdoors during pollen season',
        'Allergy shots can provide long-term relief if medications are not enough',
      ],
      emergencyWarnings: [
        'Severe difficulty breathing or throat swelling (possible anaphylaxis)',
        'Wheezing or chest tightness (possible asthma exacerbation)',
      ],
    },
  ],
]);

// ============================================
// Store Access Functions
// ============================================

/**
 * Get a condition by ID
 */
export function getCondition(conditionId: string): ConditionSimulation | undefined {
  return conditionDatabase.get(conditionId.toLowerCase());
}

/**
 * Get all conditions
 */
export function getAllConditions(): ConditionSimulation[] {
  return Array.from(conditionDatabase.values());
}

/**
 * Get condition summaries for list display
 */
export function getConditionSummaries(): ConditionSummary[] {
  return Array.from(conditionDatabase.values()).map((condition) => ({
    conditionId: condition.conditionId,
    name: condition.name,
    category: condition.category,
    icdCode: condition.icdCode,
    description: condition.description,
    primarySymptoms: condition.clinicalPresentation.primarySymptoms
      .slice(0, 3)
      .map((s) => s.name),
    numberOfPhases: condition.progression.timelineSteps.length,
    numberOfTreatments: condition.treatmentOptions.length,
  }));
}

/**
 * Get conditions by category
 */
export function getConditionsByCategory(
  category: ConditionCategory
): ConditionSimulation[] {
  return Array.from(conditionDatabase.values()).filter(
    (c) => c.category === category
  );
}

/**
 * Search conditions by query
 */
export function searchConditions(query: string): ConditionSearchResult[] {
  const normalizedQuery = query.toLowerCase().trim();
  const results: ConditionSearchResult[] = [];

  for (const condition of conditionDatabase.values()) {
    let matchType: ConditionSearchResult['matchType'] | null = null;
    let relevanceScore = 0;

    // Check exact name match
    if (condition.name.toLowerCase() === normalizedQuery) {
      matchType = 'exact';
      relevanceScore = 100;
    }
    // Check alias match
    else if (
      condition.aliases?.some((a) => a.toLowerCase() === normalizedQuery)
    ) {
      matchType = 'alias';
      relevanceScore = 90;
    }
    // Check name contains
    else if (condition.name.toLowerCase().includes(normalizedQuery)) {
      matchType = 'partial';
      relevanceScore = 70;
    }
    // Check alias contains
    else if (
      condition.aliases?.some((a) => a.toLowerCase().includes(normalizedQuery))
    ) {
      matchType = 'partial';
      relevanceScore = 60;
    }
    // Check category
    else if (condition.category.toLowerCase().includes(normalizedQuery)) {
      matchType = 'category';
      relevanceScore = 40;
    }
    // Check symptoms
    else if (
      condition.clinicalPresentation.primarySymptoms.some((s) =>
        s.name.toLowerCase().includes(normalizedQuery)
      )
    ) {
      matchType = 'symptom';
      relevanceScore = 30;
    }

    if (matchType) {
      results.push({
        conditionId: condition.conditionId,
        name: condition.name,
        aliases: condition.aliases,
        category: condition.category,
        matchType,
        relevanceScore,
      });
    }
  }

  return results.sort((a, b) => b.relevanceScore - a.relevanceScore);
}

/**
 * Get anatomy highlights for a condition at a specific phase
 */
export function getConditionAnatomyHighlights(
  conditionId: string,
  phaseId?: string
): Array<{
  structureId: string;
  color: string;
  pulse: boolean;
  opacity: number;
  label: string;
}> {
  const condition = getCondition(conditionId);
  if (!condition) return [];

  const highlights: Array<{
    structureId: string;
    color: string;
    pulse: boolean;
    opacity: number;
    label: string;
  }> = [];

  // If a specific phase is requested, get changes for that phase
  if (phaseId) {
    const phase = condition.progression.timelineSteps.find(
      (s) => s.phaseId === phaseId
    );
    if (phase) {
      for (const change of phase.anatomicalChanges) {
        highlights.push({
          structureId: change.structureId,
          color: change.visualIndicator.color,
          pulse: change.visualIndicator.pulse,
          opacity: change.visualIndicator.opacity,
          label: change.description,
        });
      }
    }
  } else {
    // Otherwise, return highlights from anatomy mapping
    for (const structure of condition.anatomyMapping.primaryStructures) {
      if (structure.showByDefault) {
        highlights.push({
          structureId: structure.structureId,
          color: structure.highlightColor,
          pulse: true,
          opacity: 0.7,
          label: structure.involvement,
        });
      }
    }
    for (const structure of condition.anatomyMapping.secondaryStructures || []) {
      if (structure.showByDefault) {
        highlights.push({
          structureId: structure.structureId,
          color: structure.highlightColor,
          pulse: false,
          opacity: 0.5,
          label: structure.involvement,
        });
      }
    }
  }

  return highlights;
}

// ============================================
// ICD-11 Integration (390+ conditions)
// ============================================

/** Cache for generated condition templates from ICD-11 entries */
const generatedConditionCache: Map<string, ConditionSimulation> = new Map();

/**
 * Get a condition by ID, checking the detailed store first,
 * then falling back to auto-generated templates from ICD-11 entries.
 */
export function getConditionWithFallback(conditionId: string): ConditionSimulation | undefined {
  // First, check the detailed database
  const detailed = conditionDatabase.get(conditionId.toLowerCase());
  if (detailed) return detailed;

  // Check cache of generated templates
  const cached = generatedConditionCache.get(conditionId.toLowerCase());
  if (cached) return cached;

  // Generate from ICD-11 entry
  const icd11Entry = ICD11_CONDITIONS.find(
    (e) => e.id === conditionId.toLowerCase()
  );
  if (icd11Entry) {
    const generated = generateConditionTemplate({
      conditionId: icd11Entry.id,
      name: icd11Entry.name,
      icdCode: icd11Entry.icd,
      category: icd11Entry.cat,
      description: icd11Entry.desc,
      systems: icd11Entry.sys,
    });
    generatedConditionCache.set(conditionId.toLowerCase(), generated);
    return generated;
  }

  return undefined;
}

/**
 * Get all conditions: detailed database + ICD-11 entries that aren't already in the store.
 * Returns all ~425 conditions, preferring detailed versions when available.
 */
export function getAllConditionsWithICD11(): ConditionSimulation[] {
  const result: Map<string, ConditionSimulation> = new Map();

  // Add all detailed conditions first
  for (const [key, value] of conditionDatabase) {
    result.set(key, value);
  }

  // Add ICD-11 conditions that don't have detailed entries
  for (const entry of ICD11_CONDITIONS) {
    if (!result.has(entry.id)) {
      const generated = getConditionWithFallback(entry.id);
      if (generated) {
        result.set(entry.id, generated);
      }
    }
  }

  return Array.from(result.values());
}

/**
 * Get all ICD-11 condition entries (lightweight, no full simulation data).
 * Useful for browse/search without loading full simulation templates.
 */
export function getICD11Entries(): ICD11ConditionEntry[] {
  return ICD11_CONDITIONS;
}

/**
 * Check whether a condition has detailed simulation data in the store
 * vs. a generated template from ICD-11 index.
 */
export function hasDetailedConditionData(conditionId: string): boolean {
  return conditionDatabase.has(conditionId.toLowerCase());
}

/**
 * Search across ALL conditions (detailed + ICD-11).
 * Returns results sorted by relevance with match type information.
 */
export function searchAllConditions(query: string): ConditionSearchResult[] {
  const normalizedQuery = query.toLowerCase().trim();
  if (!normalizedQuery) return [];

  const results: ConditionSearchResult[] = [];
  const seenIds = new Set<string>();

  // First search the detailed database (higher relevance)
  for (const condition of conditionDatabase.values()) {
    let matchType: ConditionSearchResult['matchType'] | null = null;
    let relevanceScore = 0;

    if (condition.name.toLowerCase() === normalizedQuery) {
      matchType = 'exact';
      relevanceScore = 100;
    } else if (
      condition.aliases?.some((a) => a.toLowerCase() === normalizedQuery)
    ) {
      matchType = 'alias';
      relevanceScore = 95;
    } else if (condition.icdCode.toLowerCase() === normalizedQuery) {
      matchType = 'exact';
      relevanceScore = 90;
    } else if (condition.name.toLowerCase().includes(normalizedQuery)) {
      matchType = 'partial';
      relevanceScore = 75;
    } else if (
      condition.aliases?.some((a) => a.toLowerCase().includes(normalizedQuery))
    ) {
      matchType = 'partial';
      relevanceScore = 65;
    } else if (condition.category.toLowerCase().includes(normalizedQuery)) {
      matchType = 'category';
      relevanceScore = 45;
    } else if (
      condition.clinicalPresentation.primarySymptoms.some((s) =>
        s.name.toLowerCase().includes(normalizedQuery)
      )
    ) {
      matchType = 'symptom';
      relevanceScore = 35;
    } else if (condition.description.toLowerCase().includes(normalizedQuery)) {
      matchType = 'partial';
      relevanceScore = 25;
    }

    if (matchType) {
      seenIds.add(condition.conditionId);
      results.push({
        conditionId: condition.conditionId,
        name: condition.name,
        aliases: condition.aliases,
        category: condition.category,
        matchType,
        relevanceScore,
      });
    }
  }

  // Then search ICD-11 entries not already found
  for (const entry of ICD11_CONDITIONS) {
    if (seenIds.has(entry.id)) continue;

    let matchType: ConditionSearchResult['matchType'] | null = null;
    let relevanceScore = 0;

    if (entry.name.toLowerCase() === normalizedQuery) {
      matchType = 'exact';
      relevanceScore = 95;
    } else if (entry.icd.toLowerCase() === normalizedQuery) {
      matchType = 'exact';
      relevanceScore = 85;
    } else if (entry.name.toLowerCase().includes(normalizedQuery)) {
      matchType = 'partial';
      relevanceScore = 60;
    } else if (entry.cat.toLowerCase().includes(normalizedQuery)) {
      matchType = 'category';
      relevanceScore = 35;
    } else if (entry.desc.toLowerCase().includes(normalizedQuery)) {
      matchType = 'partial';
      relevanceScore = 20;
    } else if (
      entry.sys.some((s) => s.toLowerCase().includes(normalizedQuery))
    ) {
      matchType = 'partial';
      relevanceScore = 15;
    }

    if (matchType) {
      seenIds.add(entry.id);
      results.push({
        conditionId: entry.id,
        name: entry.name,
        category: entry.cat,
        matchType,
        relevanceScore,
      });
    }
  }

  return results.sort((a, b) => b.relevanceScore - a.relevanceScore);
}

/**
 * Get ICD-11 conditions filtered by category.
 * Returns ICD11ConditionEntry[] for lightweight browsing.
 */
export function getICD11ByCategory(category: ConditionCategory): ICD11ConditionEntry[] {
  return ICD11_CONDITIONS.filter((e) => e.cat === category);
}

/**
 * Get count of conditions per category across all ICD-11 entries.
 */
export function getConditionCountByCategory(): Record<ConditionCategory, number> {
  const counts = {} as Record<ConditionCategory, number>;
  for (const entry of ICD11_CONDITIONS) {
    counts[entry.cat] = (counts[entry.cat] || 0) + 1;
  }
  return counts;
}

/**
 * Get all unique body systems mentioned across ICD-11 conditions.
 */
export function getAllBodySystems(): string[] {
  const systems = new Set<string>();
  for (const entry of ICD11_CONDITIONS) {
    for (const sys of entry.sys) {
      systems.add(sys);
    }
  }
  return Array.from(systems).sort();
}

/**
 * Get conditions that affect a specific body system.
 */
export function getConditionsBySystem(system: string): ICD11ConditionEntry[] {
  const normalizedSystem = system.toLowerCase();
  return ICD11_CONDITIONS.filter((e) =>
    e.sys.some((s) => s.toLowerCase() === normalizedSystem)
  );
}
